<SEC-DOCUMENT>0001062822-18-000008.txt : 20180301
<SEC-HEADER>0001062822-18-000008.hdr.sgml : 20180301
<ACCEPTANCE-DATETIME>20180228203828
ACCESSION NUMBER:		0001062822-18-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180301
DATE AS OF CHANGE:		20180228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		18654226

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k12312017.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s38C0D8E30CA8D8985D83BC7761F9820A"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.78544061302682%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Mark One)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Fiscal Year Ended December 31, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">or</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Transition Period from _____________ to _____________</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File Number:&#160;&#160;000-30111</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:2%;"></td><td style="width:45%;"></td><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">76-0474169</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(State or Other Jurisdiction of Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(I.R.S. Employer Identification Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:2%;"></td><td style="width:45%;"></td><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">8800 Technology Forest Place</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">The Woodlands, Texas 77381</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Address of Principal Executive Offices and Zip Code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(281) 863-3000</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Registrant&#8217;s Telephone Number,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Including Area Code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.46743295019157%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:8%;"></td><td style="width:38%;"></td><td style="width:7%;"></td><td style="width:38%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Name of Each Exchange on which Registered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Common Stock, par value $0.001 per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Nasdaq Global Select Market</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act:</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;None</font></div><div style="line-height:100%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act of 1933.&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;No </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div><div style="line-height:100%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;No </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.&#160;&#160;(check one):&#160;&#160;Large accelerated filer </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;Accelerated filer&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:Wingdings 2;font-size:9pt;">&#32;</font><font style="font-family:inherit;font-size:9pt;">Non-accelerated filer </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;Smaller reporting company </font><font style="font-family:Wingdings;font-size:9pt;">o </font><font style="font-family:inherit;font-size:9pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934. </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#32;No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The aggregate market value of voting stock held by non-affiliates of the registrant as of the last day of the registrant&#8217;s most recently completed second quarter was approximately </font><font style="font-family:inherit;font-size:9pt;">$715.3 million</font><font style="font-family:inherit;font-size:9pt;">, based on the closing price of the common stock on the Nasdaq Global Select Market on </font><font style="font-family:inherit;font-size:9pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:9pt;">&#32;of </font><font style="font-family:inherit;font-size:9pt;">$16.45</font><font style="font-family:inherit;font-size:9pt;">&#32;per share.&#160;&#160;For purposes of the preceding sentence only, our directors, executive officers and controlling stockholders are assumed to be affiliates.&#160;&#160;As of </font><font style="font-family:inherit;font-size:9pt;">February 26, 2018</font><font style="font-family:inherit;font-size:9pt;">, </font><font style="font-family:inherit;font-size:9pt;">105,591,828</font><font style="font-family:inherit;font-size:9pt;">&#32;shares of common stock were outstanding.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Documents Incorporated by Reference</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s </font><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:9pt;">&#32;annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended </font><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:9pt;">, are incorporated by reference into Part III of this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.78544061302682%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sA49DF2FBF10D11241896BC776257FAC2"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:89%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Item</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF5418D1A53A097BD1863BC7762A59B3B"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF5418D1A53A097BD1863BC7762A59B3B"> 1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE58F086D0A23E67C0962BC77647A490C"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE58F086D0A23E67C0962BC77647A490C"> 17</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1B.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC352BEBF31661F982237BC776499379B"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC352BEBF31661F982237BC776499379B"> 34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBE1AFBC631DEEE490F68BC7764C8D84F"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBE1AFBC631DEEE490F68BC7764C8D84F"> 34</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68E46D2C1BF374BB26F7BC7764E7C8BE"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68E46D2C1BF374BB26F7BC7764E7C8BE"> 35</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2AC67AF7355E1AE95DECBC7765263E4F"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2AC67AF7355E1AE95DECBC7765263E4F"> 35</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC17292EBDB0121B91AFDBC776574DF05"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC17292EBDB0121B91AFDBC776574DF05"> 36</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s475B15398927532E0EA1BC7754D9A6C1"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s475B15398927532E0EA1BC7754D9A6C1"> 38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s903E8CECB323152D5491BC7754AA9DB3"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s903E8CECB323152D5491BC7754AA9DB3"> 39</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7A.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s952BFC93499CF85F0E5CBC7765E14D46"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s952BFC93499CF85F0E5CBC7765E14D46"> 50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C03D45C6C2C54F0E5ABBC776620457E"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C03D45C6C2C54F0E5ABBC776620457E"> 50</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s931CD457D87C0C954DB5BC77663F8B0C"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s931CD457D87C0C954DB5BC77663F8B0C"> 50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s619ABF8068254A9C2F30BC77666E38FC"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s619ABF8068254A9C2F30BC77666E38FC"> 50</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9B.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s281A258F01049BEB9070BC77668DD963"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s281A258F01049BEB9070BC77668DD963"> 51</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0335E9E6F99DFD660296BC7766DBAF1F"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0335E9E6F99DFD660296BC7766DBAF1F"> 52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s31BD471ED8FB17AFB182BC77671ABB5B"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s31BD471ED8FB17AFB182BC77671ABB5B"> 52</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3419C2BC887F532DF0E9BC776739CC2B"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3419C2BC887F532DF0E9BC776739CC2B"> 52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCA1AA3E5557E34555EAFBC7767683FA3"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCA1AA3E5557E34555EAFBC7767683FA3"> 52</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2234C406CCCF6653E193BC776787721D"><font style="font-family:inherit;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2234C406CCCF6653E193BC776787721D"> 52</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7E9A3A78BBB7B5EA4FA3BC7767D5E1F2"><font style="font-family:inherit;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7E9A3A78BBB7B5EA4FA3BC7767D5E1F2"> 53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8763D1ECB5E0CEC00A8FBC776814215D"><font style="font-family:inherit;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8763D1ECB5E0CEC00A8FBC776814215D"> 55</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3773E35BF04A8825801BC7768338244"><font style="font-family:inherit;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3773E35BF04A8825801BC7768338244"> 56</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Lexicon name and logo and XERMELO</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;are registered trademarks of Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_____________________________________________________</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this annual report on Form 10-K, &#8220;Lexicon Pharmaceuticals,&#8221; &#8220;Lexicon,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Lexicon Pharmaceuticals, Inc. and its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_____________________________________________________</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This annual report on Form 10-K contains forward-looking statements.&#160;&#160;These statements relate to future events or our future financial performance.&#160;&#160;We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Item 1A.&#160;&#160;Risk Factors,&#8221; that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this annual report on Form 10-K to conform these statements to actual results, unless required by law.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sAB39AD5336D57A09F254BC7762863C71"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF5418D1A53A097BD1863BC7762A59B3B"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s007BD68491FC16179911BC7762D477C2"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of breakthrough treatments for human disease.&#160;&#160;We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have obtained approval from the U.S. Food and Drug Administration, or FDA, to sell our first commercial product, XERMELO</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy.  We have commenced sales and marketing of XERMELO, and it is commercially available to patients in the United States.  We have granted Ipsen Pharma SAS, or Ipsen, an exclusive, royalty-bearing right to commercialize XERMELO outside of the United States and Japan, and Ipsen has obtained approval from the European Commission to market XERMELO in the member states of the European Union, Norway and Iceland.  Ipsen has commenced sales and marketing of XERMELO, and it is commercially available to patients in the United Kingdom, Germany and certain other European Union member states.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 and type&#160;2 diabetes.  We have reported positive top-line data from two pivotal Phase 3 clinical trials and a third Phase 3 clinical trial of sotagliflozin in type 1 diabetes patients.  We have granted Sanofi-Aventis Deutschland GmbH, or Sanofi, an exclusive, worldwide (excluding Japan), royalty-bearing right to develop, manufacture and commercialize sotagliflozin.  We and Sanofi are presently preparing applications for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and the European Union, and Sanofi is presently conducting Phase 3 development of sotagliflozin in type 2 diabetes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing LX2761, an orally-delivered small molecule drug candidate, as a treatment for diabetes.  We are presently conducting Phase 1 clinical development of LX2761.  We have granted Sanofi certain rights of first negotiation with respect to the future development and commercialization of LX2761.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We are presently conducting Phase 1 clinical development of LX9211.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies, such as Ipsen and Sanofi, with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States, commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals was incorporated in Delaware in July 1995, and commenced operations in September 1995.&#160;&#160;Our corporate headquarters are located at 8800 Technology Forest Place, The Woodlands, Texas 77381, and our telephone number is (281) 863-3000.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are made available free of charge on our corporate website located at www.lexpharma.com as soon as reasonably practicable after the filing of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">those reports with the Securities and Exchange Commission.&#160;&#160;Information found on our website should not be considered part of this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0097FE46FB6E5F1526ECBC7762F33084"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Drug Programs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs:  XERMELO (telotristat ethyl) for carcinoid syndrome diarrhea, sotagliflozin for type 1 and type 2 diabetes, LX2761 for diabetes and LX9211 for neuropathic pain.  We have also advanced a number of additional compounds into various stages of clinical and preclinical development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">XERMELO (telotristat ethyl</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commercially launched XERMELO, an orally-delivered small molecule compound, following regulatory approval in the United States in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy.  XERMELO was internally generated by our scientists and inhibits tryptophan hydroxylase, or TPH, the rate-limiting enzyme for serotonin production found primarily in enterochromaffin cells of the gastrointestinal tract.  Carcinoid syndrome is characterized by frequent and debilitating diarrhea and can result when these cells become cancerous and metastisize to the liver or other organs, where they overproduce serotonin.  The recommended dose of XERMELO is 250mg three times daily, and the full prescribing information for XERMELO includes certain warnings and precautions relating to constipation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into a license and collaboration agreement under which we granted Ipsen an exclusive, royalty-bearing right and license to commercialize XERMELO outside of the United States and Japan.  In September 2017, Ipsen received approval from the European Commission for the marketing of telotristat ethyl for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy in all member states of the European Union, Norway and Iceland.  Ipsen has commenced sales and marketing of XERMELO, and it is now commercially available to patients in the United Kingdom, Germany and certain other European Union member states.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our pivotal TELESTAR Phase 3 clinical trial assessed the safety and efficacy of XERMELO and served as the primary basis for the regulatory approval of XERMELO in the United States and the European Union.  Data from the study showed that patients who added XERMELO to SSA therapy experienced a statistically significant reduction from baseline compared to placebo in the average number of daily bowel movements over the 12-week study period (p&lt;0.001), meeting the study&#8217;s primary endpoint.  Thirty three percent of patients who added XERMELO to SSA therapy at the approved 250mg dose experienced a reduction in overall bowel movements from baseline of at least two per day, as compared to four percent with placebo.  The proportion of patients with treatment-emergent adverse events, serious adverse events and discontinuation due to adverse events were generally similar in all three treatment arms, with the tolerability profile of the approved 250mg dose appearing similar to placebo and somewhat better than the 500mg dose with respect to gastrointestinal discomfort and mood.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are presently preparing to submit Investigational New Drug applications, or INDs, and commence clinical development of XERMELO in cholangiocarcinoma and neuroendocrine tumors as part of our life cycle management of the program.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sotagliflozin</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sotagliflozin is an orally-delivered small molecule compound that we and Sanofi are developing for the treatment of type&#160;1 and type 2 diabetes mellitus.  Sotagliflozin was internally generated by our scientists and inhibits both sodium-glucose cotransporter type&#160;2, or SGLT2, a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type&#160;1, or SGLT1, a transporter responsible for glucose and galactose absorption in the gastrointestinal tract.  Our scientists identified mice lacking SGLT1, SGLT2 or both as having potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism, and found that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into a collaboration and license agreement with Sanofi under which we granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license to develop, manufacture and commercialize sotagliflozin.  Under the alliance, we are responsible for conducting all clinical development activities relating to type 1 diabetes and Sanofi is responsible for conducting all clinical development activities relating to type 2 diabetes.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Type 1 Diabetes</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reported top-line primary efficacy endpoint data in September 2016 and additional data in May 2017 from our pivotal inTandem1 Phase 3 clinical trial evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type&#160;1 diabetes.  The trial enrolled 793 patients with type 1 diabetes in the United States and Canada in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  The primary efficacy endpoint under evaluation in the trial was the reduction of hemoglobin A1c, or A1C, versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing an event of severe hypoglycemia or diabetic ketoacidosis, or DKA, change in meal-time, or bolus, insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.43% for the 200mg dose (p&lt;0.001) and 0.48% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.07% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Benefits in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo, with statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm and in the percentage of patients achieving A1C levels of less than 7% without any severe hypoglycemia or DKA events and weight loss observed in the 200mg dose arm and statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 80.6%, 81.7% and 79.8%, respectively; the incidences of serious adverse events were 7.5%, 10.3% and 11.1%, respectively; and the incidences of discontinuation due to adverse events were 4.1%, 4.9% and 6.5%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 26 (9.7%), 17 (6.5%) and 17 (6.5%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 1 (0.4%), 9 (3.4%) and 11 (4.2%) in the placebo, 200mg and 400mg dose arms, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;We reported top-line primary efficacy endpoint data in December 2016 and additional data in August 2017 from our pivotal inTandem2 Phase 3 clinical trial evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type&#160;1 diabetes.  The trial enrolled 782 patients with type 1 diabetes in Europe and Israel in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  As with inTandem1, the primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemia or DKA event, change in bolus insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.39% for the 200mg dose (p&lt;0.001) and 0.37% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.02% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Statistically significant improvements in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 61.2%, 68.2% and 68.8%, respectively; the incidences of serious adverse events were 6.6%, 10.0% and 8.0%, respectively; and the incidences of discontinuation due to adverse events were 3.5%, 3.8% and 6.8%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 13 (5.0%), 13 (5.0%) and 6 (2.3%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 0 (0.0%), 6 (2.3%) and 9 (3.4%) in the placebo, 200mg and 400mg dose arms, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reported pooled continuous glucose monitoring, or CGM, data in September 2017 from the inTandem1 and inTandem2 clinical trials.  The percentage of time during the initial 24-week treatment period spent inside the target range for CGM glucose (70-180 mg/dL) increased from 52.2% to 57.8% in patients treated with 200mg of sotagliflozin and from 50.7% to 64.1% in patients treated with 400mg of sotagliflozin, with no relevant change observed in patients receiving placebo.  The differences from placebo were clinically significant for both the 200mg and 400mg dose groups (p=0.026 and p&lt;0.001, respectively).  The increase in time spent in range by both sotagliflozin dose groups was a result of significantly reduced time spent above 180 mg/dL, while the time spent below 70 mg/dL was not increased.  These results translate into an additional 1.41 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">hours and 3.02 hours that a patient would spend within the 70-180 mg/dL target range in a 24-hour period, for the 200mg and 400mg dose groups respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reported top-line data in June 2017 from our inTandem3 Phase 3 clinical trial evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 1 diabetes.  The trial enrolled 1,405 patients with type 1 diabetes in the United States and Europe in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin over a 24-week treatment period.  Insulin therapy was not optimized in patients and eligibility criteria included any background insulin therapy.  The primary efficacy endpoint under evaluation in the trial was the proportion of patients achieving A1C levels of less than 7% at 24 weeks without experiencing a severe hypoglycemic or DKA event, with secondary endpoints including the change from baseline in A1C, body weight, systolic blood pressure and bolus insulin use.  Data from the study showed statistically significant superiority of sotagliflozin (28.6%) compared to placebo (15.2%) in the proportion of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemic or DKA event (p&lt;0.001), meeting the study&#8217;s primary endpoint.  Patients treated with sotagliflozin also experienced statistically significant improvements in all secondary efficacy endpoints compared to placebo.  The incidences of treatment-emergent adverse events in the placebo and 400mg dose arms were 52.5% and 55.1%, respectively; the incidences of serious adverse events were 3.3% and 6.9%, respectively; and the incidences of discontinuation due to adverse events were 2.3% and 6.3%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the 24-week treatment period was 17 (2.4%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the 24-week treatment period was 4 (0.6%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  Results from the inTandem3 trial were published in the New England Journal of Medicine in September 2017.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Sanofi are presently preparing for the submission of applications for regulatory approval to market sotagliflozin for the treatment of type 1 diabetes in the United States and the European Union. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Type 2 Diabetes.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sanofi is presently conducting a comprehensive Phase 3 development program for sotagliflozin in type 2 diabetes patients, including the following randomized, double-blind, placebo-controlled studies:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin as monotherapy in approximately 400 patients over a 26-week treatment period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400mg once daily dose of sotagliflozin in approximately 500 patients on background metformin therapy over a 26-week treatment period, followed by a 52-week extension;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400mg once daily dose of sotagliflozin in approximately 500 patients added to sulfonylurea alone or in combination with metformin over a 26-week treatment period, followed by a 52-week extension;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg or 400mg once daily dose of sotagliflozin in approximately 10,500 patients with cardiovascular risk factors and moderately impaired renal function over a treatment period to be determined by cardiovascular outcome events, currently expected to be approximately four years;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin in approximately 780 patients with moderate renal impairment over a 52-week treatment period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin in approximately 276 patients with severe renal impairment over a 52-week treatment period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin in approximately 560 patients on background basal insulin alone or in addition to other oral antidiabetic drug therapies over an 18-week treatment period, followed by a 34-week extension;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin in approximately 700 patients on dipeptidyl peptidase-4, or DPP-4, inhibitors, with or without metformin, compared to 25mg dose of empagliflozin over a 26-week treatment period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin in approximately 930 patients on background metformin therapy compared to 2-6mg dose of glimepiride over a 52-week treatment period; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200mg and 400mg once daily doses of sotagliflozin in approximately 360 patients aged 55 years or older, with or without any stable anti-diabetes therapy, evaluating efficacy and bone safety over a 26-week treatment period, followed by a 78-week extension.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We previously completed two Phase 2 clinical trials evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 2 diabetes.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Phase 2b clinical trial enrolled 299 patients with type 2 diabetes who were not adequately controlled on metformin monotherapy in a double-blind, randomized, placebo-controlled study of 75mg once daily, 200mg once daily, 200mg twice daily and 400mg once daily doses of sotagliflozin, each administered in combination with standard metformin therapy over a 12&#8209;week treatment period.  The primary efficacy endpoint under evaluation in the trial was the change in A1C from baseline to week&#160;12.  Secondary efficacy endpoints included percentage of patients achieving A1C levels of less than 7%, as well as changes in fasting plasma glucose levels, weight, blood pressure and triglyceride levels.  Data from the study showed that treatment with sotagliflozin demonstrated statistically significant benefits in the primary and multiple secondary endpoints.  Patients in each of the 75mg once daily, 200mg once daily, 200mg twice daily and 400mg once daily sotagliflozin treatment arms had mean A1C reductions from baseline of 0.43, 0.52, 0.79 and 0.92 percent, respectively (p&lt;0.001 for all treatment arms), while in patients randomized to placebo, A1C decreased by 0.09 percent.  We also observed that patients treated with sotagliflozin showed significant reductions in body weight and blood pressure.  Sotagliflozin was well tolerated and adverse events were generally mild to moderate, with the overall incidence of adverse events with sotagliflozin being similar to placebo.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Phase 2a clinical trial enrolled 36 patients with non-insulin dependent type 2 diabetes in a double-blind, randomized, placebo-controlled study of 150mg and 300mg doses of sotagliflozin, each administered once daily over a four-week treatment period.  The efficacy endpoints under evaluation in the trial included urinary glucose excretion, fasting plasma glucose, response to oral glucose tolerance testing, and change in A1C.  Data from the study showed that treatment with 150mg and 300mg of sotagliflozin provided improvements in glycemic control and demonstrated statistically significant benefits in the primary and multiple secondary efficacy endpoints.  A marked and statistically significant decrease in fasting plasma glucose was observed at each measurement point throughout the treatment period in both treatment arms relative to placebo.  After four weeks of dosing, patients in both dose groups exhibited statistically significant reductions in A1C as compared to patients receiving placebo (p=0.001 and p&lt;0.001 for the 150mg and 300mg treatment arms, respectively).  Patients in both treatment arms also exhibited statistically significant improvements in glucose tolerance in response to oral glucose tolerance testing (p&lt;0.001 for both treatment arms).  Consistent with the mechanism of action of sotgliflozin, there was also a significant, dose-dependent increase in 24-hour urinary glucose excretion in both treatment arms at each measurement point throughout the study period relative to placebo (p&lt;0.001 at all time points measured).  Patients in both treatment arms also showed positive trends in broader metabolic and cardiovascular parameters, including weight reduction, decreased blood pressure and lower triglyceride levels.  Sotagliflozin was well tolerated in the trial, with no dose-limiting toxicities observed and adverse events being generally mild and equally distributed across all treatment groups, including the placebo group.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">LX2761</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LX2761 is an orally-delivered small molecule compound that we are developing for the treatment of diabetes.  LX2761 was internally generated by our scientists and is designed to inhibit SGLT1 locally in the gastrointestinal tract without any significant inhibition of SGLT2 in the kidney.  We are presently conducting Phase 1 clinical development of LX2761. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have granted Sanofi certain rights of first negotiation with respect to the future development and commercialization of LX2761.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">LX9211</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LX9211 is an orally-delivered small molecule compound that we are developing for the treatment of neuropathic pain.  LX9211 was jointly generated by our and Bristol-Myers Squibb&#8217;s scientists as part of our drug discovery alliance with Bristol-Myers Squibb and inhibits adaptor associated kinase 1, or AAK1, in the central nervous system.  Our scientists identified mice lacking AAK1 as having increased resistance to induced neuropathic pain in preclinical models.  We are presently conducting Phase 1 clinical development of LX9211.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have obtained exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1 from Bristol-Myers Squibb.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Drug Target Discoveries</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our internal drug discovery efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4D2A04051CD8B61252DFBC776332D888"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians, as we have with XERMELO in the United States.  We seek to collaborate with other pharmaceutical and biotechnology companies, such as Ipsen and Sanofi, with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States, commercialization in the United States for indications treated by primary care physicians, or when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.  We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Collaborations</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sanofi</font><font style="font-family:inherit;font-size:10pt;">. We entered into a collaboration and license agreement with Sanofi in November 2015 under which we granted Sanofi an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize sotagliflozin.  In December 2016, Sanofi terminated its rights under the agreement with respect to Japan.  We received a $300 million upfront payment under the agreement and we are eligible to receive up to $210 million upon the achievement of specified clinical development milestones, up to $220 million upon the achievement of specified regulatory milestones and up to $990 million upon the achievement of specified commercial milestones.  We are also entitled to tiered, escalating royalties ranging from low double digit percentages to 40 percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are responsible for all clinical development activities relating to type 1 diabetes and have exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States.  Under the terms of the exercised co-promotion option, we will fund 40 percent of the commercialization costs relating to such co-promotion activities.  Sanofi is responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and is solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States.  We share in the funding of a portion of the planned type 2 diabetes development costs over the first three years of the collaboration, up to an aggregate of $100 million.  Sanofi will book sales worldwide in all indications.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ipsen</font><font style="font-family:inherit;font-size:10pt;">.  We entered into a license and collaboration agreement with Ipsen in October 2014 under which we granted Ipsen an exclusive, royalty-bearing right and license to commercialize telotristat ethyl outside of the United States, Canada and Japan.  The collaboration was expanded in March 2015 to include Canada.  We have received $24.5&#160;million in upfront payments and $19.2 million in regulatory and commercial launch milestones under the agreement.  In addition, we are eligible to receive up to an additional $13.1&#160;million upon the achievement of additional specified regulatory and commercial launch milestones and up to &#8364;72&#160;million upon the achievement of specified sales milestones.  We are also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of telotristat ethyl in the licensed territory, subject to a credit for Ipsen&#8217;s payments to us for the manufacture and supply of such units of telotristat ethyl and customary royalty reduction provisions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bristol-Myers Squibb</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We established a drug discovery alliance with Bristol-Myers Squibb Company in December 2003 to discover, develop and commercialize small molecule drugs in the neuroscience field.&#160;&#160;Bristol-Myers Squibb extended the target discovery term of the alliance in May 2006.&#160;&#160;We initiated the alliance with a number of neuroscience drug discovery programs at various stages of development and used our gene knockout technologies to identify additional drug targets with promise in the neuroscience field.&#160;&#160;For those targets that were selected for the alliance, we and Bristol-Myers Squibb worked together, on an exclusive basis, to identify, characterize and carry out the preclinical development of small molecule drugs.  Bristol-Myers Squibb has the first option to assume full responsibility for clinical development and commercialization of any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">drugs resulting from the alliance which enter clinical trials, other than LX9211 and additional compounds acting through AAK1.  We received $86&#160;million in upfront payments and research funding under the agreement during the target discovery portion of the alliance, which expired in October 2009. &#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76&#160;million for each drug developed by Bristol-Myers Squibb under the alliance.&#160;&#160;We will also earn royalties on sales of drugs commercialized by Bristol-Myers Squibb under the alliance.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We jointly developed LX9211 with Bristol-Myers Squibb as part of the alliance, and separately obtained from Bristol-Myers Squibb exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1.  We have agreed to pay Bristol-Myers Squibb up to $34.5 million in clinical and regulatory milestones for the first indication and up to $16 million in clinical and regulatory milestones for each of the second and third indications, if applicable.  We have also agreed to pay single digit royalties on worldwide net sales and up to $40 million in commercial milestones.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We established a drug discovery alliance with Genentech, Inc. in December 2002 to discover novel therapeutic proteins and antibody targets.&#160;&#160;We and Genentech expanded the alliance in November 2005 for the advanced research, development and commercialization of new biotherapeutic drugs.&#160;&#160;Under the original alliance agreement, we used our target validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech&#8217;s internal drug discovery research.&#160;&#160;In the expanded alliance, we conducted additional, advanced research on a broad subset of those proteins and targets.&#160;&#160;We have exclusive rights to develop and commercialize biotherapeutic drugs for two of these targets, while Genentech has exclusive rights to develop and commercialize biotherapeutic drugs for the other targets.&#160;&#160;We retain certain other rights to discoveries made in the alliance, including non-exclusive rights, along with Genentech, for the development and commercialization of small molecule drugs addressing the targets included in the alliance.  We received $58&#160;million in upfront payments, research funding and research milestone payments under the agreement during the research collaboration term, which expired in November 2008.&#160;&#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the extent of our efforts in the alliance, up to $25&#160;million for each drug target for which Genentech develops a biotherapeutic drug under the alliance.&#160;&#160;We will also earn royalties on sales of biotherapeutic drugs commercialized by Genentech under the alliance.&#160;&#160;Genentech is entitled to receive milestone payments and royalties on sales of biotherapeutic drugs which we develop or commercialize under the alliance.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have established collaborations with a number of pharmaceutical and biotechnology companies, research institutes and academic institutions under which we have received fees in exchange for generating knockout mice for genes requested by the collaborator, providing phenotypic data with respect to such knockout mice or otherwise granting access to some of our technologies and discoveries.&#160;&#160;In some cases, we remain eligible to receive milestone or royalty payments on the sale of mice and phenotypic data or on products that our collaborators discover or develop using our technology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s622B707116FFAE562AD0BC7763806B67"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing and Product Supply</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not own or operate manufacturing or distribution facilities or resources for clinical or commercial production and distribution of XERMELO or any of our drug candidates.  Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations, or CMOs, who, on our behalf, manufacture&#160;clinical and commercial supplies of XERMELO and clinical supplies of our drug candidates, and will continue to do so for the foreseeable future.  Sanofi is responsible for the manufacture of all clinical and commercial supplies of sotagliflozin under the terms of our collaboration.  We have selected well-established and reputable global CMOs for our active pharmaceutical ingredient, or API, and drug product manufacturing that have good regulatory standing, large manufacturing capacities, and multiple manufacturing sites within their business footprint.  We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our CMOs.  Our quality department audits these suppliers on a periodic basis.  Our commercial suppliers are subject to routine inspections by regulatory agencies.  We work closely with our third-party manufacturers to ensure compliance with current good manufacturing practices, or cGMP, and other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies in other territories, as applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials that are used to manufacture our API are sourced from multiple third-party suppliers in Asia and Europe.  Third-party API contract manufacturers in Asia and Europe stock sufficient quantities of these materials to ensure they can manufacture adequate API quantities per our requirements, for both clinical and commercial purposes.  We store API at third-party facilities, and provide appropriate amounts to third-party drug product contract manufacturers in Asia and North America who then manufacture, package and label our specified quantities of finished goods for XERMELO and our drug candidates.  We rely on sole source third-party drug product contract manufacturers in the United States to manufacture, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">package and label finished drug product for commercial distribution of XERMELO.  We also rely on a single third-party logistics provider, with two distribution locations, to provide shipping and warehousing services for our commercial supply of XERMELO in the United States.  Our third-party contract manufacturers also need to obtain materials such as excipients, components and reagents to manufacture our API and finished drug products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Within our supply chain, we have established safety stock amounts for both our API and drug products, and store those quantities for XERMELO in multiple locations.  The quantities that we store are based on our business needs and take into account scenarios for market and clinical demand, production lead times, potential supply interruptions and shelf life for our API and drug products.  In parallel, for business continuity reasons, we are in the process of evaluating and expect to establish additional or backup suppliers for our API and drug product manufacturers in the near future.  We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of XERMELO for both our and Ipsen&#8217;s commercialization efforts in support of the current approved indication of carcinoid syndrome diarrhea, as well as potential indications of cholangiocarcinoma and neuroendocrine tumors, if those indications prove to be successful and gain regulatory approval in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sfc9d0937720a402b89aa3bde82e85a7d"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketing, Sales and Distribution</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions.  Our specialized sales team promotes XERMELO in the United States, concentrating their efforts on oncologists, oncology nurses and pharmacists.  We have also built an internal medical affairs function with responsibility for responding to external inquiries regarding the appropriate use of XERMELO with regularly updated and well-substantiated scientific and medical information.&#160; We have contracted with two independent specialty pharmacies to dispense XERMELO and provide specialty pharmacy services in fulfillment of prescriptions in the United States, allowing for efficient delivery of XERMELO by mail directly to patients.  We rely on Ipsen for the commercialization and distribution of XERMELO in territories outside of the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To help ensure that all eligible patients in the United States have appropriate access to XERMELO, we have established a comprehensive reimbursement and support program called LexCares.  Through LexCares, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria.  In addition, LexCares is designed to provide comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2F29B9E0DEA0C05B4105BC7763CE5072"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change.&#160;&#160;We face significant competition in each of the aspects of our business from other pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and governmental agencies that are pursuing research or development activities similar to ours.  Many of our competitors have substantially greater research, development and commercialization capabilities and financial, scientific, marketing and human resources than we do.&#160;&#160;As a result, our competitors may succeed in developing products earlier than we do, obtaining approvals from the FDA or other regulatory agencies for those products more rapidly than we do, developing products that are more effective than those we develop or commercializing products more effectively and profitably than we do.&#160;&#160;Similarly, our collaborators face similar competition from other competitors who may succeed in developing products more quickly, developing products that are more effective than those developed by our collaborators or commercialize products more effectively and profitably than our collaborators.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The competition for our products and drug candidates includes both marketed products and drug candidates that are being developed by others, including pharmaceutical products that are currently in a more advanced stage of clinical development or commercialization than are our own drug candidates.&#160;&#160;These competitive marketed products and drug candidates include compounds that employ different mechanisms of action in addressing diseases and conditions for which we are developing our own drug candidates and, in some cases such as sotagliflozin, that employ the same or similar mechanisms of action.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our ability to successfully compete with these potentially competitive drug candidates and other competitive products currently on the market will depend on, among other things:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the efficacy, safety and reliability of our products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, and the ability of our collaborators, to complete preclinical and clinical development and obtain regulatory approvals for our drug candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and scope of regulatory approvals of our products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, and the ability of our collaborators, to obtain product acceptance by physicians and other health care providers and secure coverage and adequate reimbursement for product use in approved indications;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, and the ability of our collaborators, to manufacture and sell commercial quantities of our products;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the skills of our employees and our ability to recruit and retain skilled employees;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">protection of our intellectual property; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of substantial capital resources to fund development and commercialization activities.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal competition for XERMELO includes the use, above their maximum labeled dose, of the established SSA therapies octreotide and lanreotide, injectable products currently marketed by Novartis and Ipsen, respectively.  In addition, we also expect that XERMELO will experience competition from lutetium Lu 177 dotatate, a radiopharmaceutical product currently marketed for the treatment of gastroenteropancreatic neuroendocrine tumors by Advanced Accelerator Applications (a subsidiary of Novartis).</font></div><div style="line-height:120%;padding-left:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If approved for the treatment of type 1 diabetes, we expect that our principal competition for sotagliflozin will include established insulin therapies, as well as selective SGLT2 inhibitors which may gain regulatory approval for the treatment of type 1 diabetes, such as dapagliflozin, empagliflozin and canagliflozin, currently marketed for the treatment of type 2 diabetes by AstraZeneca, Boehringer Ingelheim and Eli Lilly, and Janssen (a subsidiary of Johnson &amp; Johnson), respectively.  If approved for the treatment of type 2 diabetes, we expect that our principal competition for sotagliflozin will include such selective SGLT2 inhibitors, as well as DPP-4 inhibitors such as sitagliptin, currently marketed for the treatment of type 2 diabetes by Merck.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sE32DADAE7220F2630C64BC7763ED47C8"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development, manufacture and sale of pharmaceutical products are subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.&#160;&#160;In the United States, new drugs are subject to regulation under the Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the FDC Act.&#160;&#160;The FDA and comparable governmental authorities regulate, among other things, research and development activities and the testing, manufacture, quality control, safety, efficacy, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, export and import of pharmaceutical products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The standard process required by the FDA before a drug candidate may be marketed in the United States generally includes the following:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preclinical laboratory and animal tests performed under current good laboratory practices, or cGLP;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission of an IND, which must become effective before human clinical trials may commence;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for its intended use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission of a New Drug Application, or NDA, for approval of commercial marketing and sale, or of an NDA supplement, or sNDA, for approval of a new indication if the product is already approved for another indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and current good clinical practices, or cGCP;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA approval of the NDA or sNDA.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;This process for the testing and approval of drug candidates requires substantial time, effort and financial resources.&#160;&#160;Preclinical development of a drug candidate can take from one to several years to complete, with no guarantee that an IND based on those studies will become effective to even permit clinical testing to begin.&#160;&#160;Before commencing the first clinical trial of a drug candidate in the United States, we must submit an IND to the FDA.&#160;&#160;The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial.&#160;&#160;In such a case, we and the FDA must resolve any outstanding concerns before the clinical trial may begin.&#160;&#160;Submission of an IND may not result in FDA authorization to commence a clinical trial.  A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, and the FDA must grant permission for each clinical trial to start and continue.&#160;&#160;Further, an independent institutional review board for each medical center proposing to participate in the clinical trial must review and approve the plan for any clinical trial before it commences at that center.&#160;&#160;Regulatory authorities or an institutional review board or we may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 1 clinical trials are conducted in a limited number of healthy human volunteers or, in some cases, patients, to evaluate the safety, dosage tolerance, absorption, metabolism, distribution and excretion of the drug candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 clinical trials are conducted in groups of patients afflicted with a specified disease or condition to obtain preliminary data regarding efficacy as well as to further evaluate safety and optimize dosing of the drug candidate.  Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 clinical trials are conducted in larger patient populations at multiple clinical trial sites to obtain statistically significant evidence of the efficacy of the drug candidate for its intended use and to further test for safety in an expanded patient population.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the FDA may require, or companies may pursue, additional clinical trials after a product is approved.&#160;&#160;These so-called Phase&#160;4 studies may be made a condition to be satisfied after a drug receives approval.  Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up and to including withdrawal of NDA approval.  The results of phase 4 studies can confirm the effectiveness of a drug candidate and can provide important safety information to augment the FDA&#8217;s adverse drug reaction reporting system.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After completion of clinical trials, FDA approval of an NDA must be obtained before a new drug may be marketed in the United States.&#160;&#160;The submission of an NDA requires payment of a substantial user fee to the FDA.  An NDA must contain, among other things, information on chemistry, manufacturing controls and potency and purity, non-clinical pharmacology and toxicology, human pharmacokinetics and bioavailability and clinical data.&#160;&#160;There can be no assurance that the FDA will accept an NDA for filing and, even if accepted for filing, that approval will be granted.&#160;&#160;The FDA may convene an advisory committee to provide clinical insight on NDA review questions.  Although the FDA is not required to follow the recommendations of an advisory committee, the agency typically does so.  Among other things, the FDA reviews an NDA to determine whether a product is safe and effective for its intended use and whether the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.&#160;&#160;The FDA may deny approval of an NDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase 3 clinical trial.&#160;&#160;Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.&#160;&#160;An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy or otherwise that could restrict the commercial applications of a product or impose costly procedures in connection with the commercialization or use of the product.  Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market.&#160;&#160;In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to obtaining FDA approval for each product, each drug manufacturing establishment must be inspected and approved by the FDA.&#160;&#160;All manufacturing establishments are subject to inspections by the FDA and by other federal, state and local agencies and must comply with current Good Manufacturing Practices requirements.&#160;&#160;Non-compliance with these requirements can result in, among other things, total or partial suspension of production, failure of the government to grant approval for marketing and withdrawal, suspension or revocation of marketing approvals.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Satisfaction of FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes many years, with the actual time required varying substantially based on, among other things, the nature, novelty and complexity of the drug candidate and of the disease or condition.&#160;&#160;Government regulation may delay or prevent marketing of drug candidates or new diseases for a considerable period of time and impose costly procedures upon our activities.  The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all.  Success in earlier-stage clinical trials does not ensure success in later-stage clinical trials.&#160;&#160;Targets and pathways identified in vitro may be determined to be less relevant in clinical studies and results in animal model studies may not be predictive of human clinical results.  Furthermore, data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.  Even if a drug candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages.  Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the FDA approves a product, a manufacturer must provide certain updated safety and efficacy information.&#160;&#160;Product changes as well as certain changes in a manufacturing process or facility would necessitate additional FDA review and approval.&#160;&#160;Other post-approval changes may also necessitate further FDA review and approval.&#160;&#160;Additionally, a manufacturer must meet other requirements including those related to adverse event reporting and record keeping.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug.  Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA closely regulates the marketing and promotion of drugs, including restricting the promotion of uses for which a drug is not approved by the agency.&#160;&#160;Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA&#8217;s current interpretation of relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which FDA has approved the drug and are otherwise consistent with the FDA-approved label for the drug.&#160;&#160;Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.  Physicians may, in their independent medical judgment, prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA.  Such off-label uses are common across medical specialties.  Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances.  The FDA does not regulate the behavior of physicians in their choice of treatments.  The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use.  Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various United States federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various United States federal and state laws and regulations, including claims asserting antitrust violations, violations of the FDC Act, false claims laws, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States Orphan Drug Act is intended to incentivize the development of products for rare diseases or conditions that affect fewer than 200,000 people in the United States.  If a drug is being developed for a rare disease or condition, to be eligible for designation as an orphan drug, the FDA must not have previously approved a drug considered the &#8220;same drug&#8221; for the same orphan indication.  If the FDA has previously approved another same drug for the same indication, the sponsor of the subsequent drug would be required to provide a plausible hypotheses of clinical superiority over the previously approved drug to obtain an orphan designation.  Upon FDA receipt of orphan drug designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses, the ability to apply for annual grant funding and waiver of PDUFA application fee.  In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity for the approved orphan-designated indication.  Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication.  Moreover, a subsequent same drug could break a previously approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint.  Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments.  For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">treat serious or life-threatening diseases or conditions and fill unmet medical needs.  Priority review is designed to give drugs that treat serious conditions and offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months of NDA filing as compared to a standard review time of 10 months from NDA filing.  Certain other types of drug applications are also eligible for priority review.  Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track-designated drug and expedite review of the application for a drug designated for priority review.  Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint.  As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial.  In addition to the Fast Track, accelerated approval and priority review programs, the FDA also designates Breakthrough Therapy status to drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.  Drugs designated as breakthrough therapies are also eligible for accelerated approval.  The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional programs intended to expedite the development of drug products were included in the 21st Century Cures Act, or the Cures Act.  The Cures Act includes various provisions to accelerate the development and delivery of new treatments, such as those intended to expand the types of evidence manufacturers may bring to the FDA to support drug approval, to encourage patient-centered drug development, to liberalize the communication of healthcare economic information to payers, and to create greater transparency with regard to manufacturer expanded access programs.  Central to the Cures Act are provisions that enhance and accelerate the FDA&#8217;s processes for reviewing and approving new drugs and supplements to approved NDAs, including provisions that:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require the FDA to establish a program to evaluate the potential use of real world evidence to help support the approval of a new indication for an approved drug and to help support or satisfy post-approval study requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide that the FDA may rely upon qualified data summaries to support the approval of a supplemental application with respect to a qualified indication for an already approved drug;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require the FDA to issue guidance for purposes of assisting sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require the FDA to establish a process for the qualification of drug development tools for use in supporting or obtaining FDA approval for or investigational use of a drug.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Cures Act amends Section 114 of the Food and Drug Administration Modernization Act of 1997 to help clarify and facilitate the dissemination of healthcare economic information, including by broadening the definition of healthcare economic information, expressly extending the dissemination of healthcare economic information to payors, and clarifying that healthcare economic information must only relate to an FDA-approved indication rather than directly relate to the indication.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulation Outside of the United States</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to regulations in the United States, we are subject to the regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the United States.  Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas.  The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under European Union regulatory systems, a company may submit marketing authorization applications, or MAAs, either under a centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the European Medicines Agency, or EMA, whose Committee for Medicinal Products for Human Use reviews the application and issues an opinion on it.  The opinion is considered by the European Commission which is responsible for deciding applications.  If the application is approved, the European Commission grants a single marketing authorization that is valid for all European Union member states as well as Iceland, Liechtenstein and Norway, or the EEA.  The national authorization procedures, the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decentralized and mutual recognition procedures, as well as national applications, are available for products for which the centralized procedure is not compulsory.  The mutual recognition procedure provides for the European Union member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State, or RMS.  The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state.  Under this procedure the applicant can select the member state that will act as the RMS.  In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States or CMS.  Within 90 days of receiving the application and assessment report, each CMS must decide whether to recognize the RMS assessment.  If a member state does not agree with the assessment, and the disputed points cannot be resolved the matter is eventually referred to the European Commission, whose decision is binding on all member states.  If the application is successful national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conditional marketing authorizations may be granted for a limited number of medicinal products for human use referenced in European Union law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if the risk-benefit balance of the product is positive, it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, unmet medical needs will be fulfilled and the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.  Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As in the United States, we may apply for designation of a product as an Orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. In the European Union, orphan designation is available for products in development which are either intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union, or intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the community and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.  Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product.  The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare Regulation</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business.  If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.  The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute, which prohibits. among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent.  Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information.  Other countries also have, or are developing, laws governing the collection, use and transmission of personal information.  In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA.  The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business. International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the PPACA, created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services, or CMS, annually certain payments and other transfers of value provided to physicians and teaching hospitals made in the previous calendar year.  In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information.  These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us.  In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For those marketed products which are covered in the United States by the Medicaid program, we have various obligations, including government price reporting and rebate requirements, which generally require products be offered at substantial rebates/discounts to Medicaid and certain purchasers.  We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply.  These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear.  Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or rebates could subject us to substantial penalties.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, our business is subject to regulation under various state and federal environmental laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act.&#160;&#160;These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in and wastes generated by our operations.&#160;&#160;We believe that we are in material compliance with applicable environmental laws and that our continued compliance with these laws will not have a material adverse effect on our business.&#160;&#160;We cannot predict, however, whether new regulatory restrictions will be imposed by state or federal regulators and agencies or whether existing laws and regulations will adversely affect us in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s9E410BC4BCF0E83FE345BC77639F2B15"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents and Proprietary Rights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are able to protect our proprietary rights from unauthorized use by third parties only to the extent that those rights are covered by valid and enforceable patents or are effectively maintained as trade secrets.  Accordingly, patents and other proprietary rights are an essential element of our business.&#160;&#160;We own or exclusively license patents and/or patent applications throughout the world that claim our approved drug, XERMELO, and our drug candidates, including:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim telotristat ethyl and associated crystalline forms, pharmaceutical compositions comprising telotristat ethyl, and methods of its manufacture and use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim sotagliflozin and associated crystalline forms, pharmaceutical compositions comprising sotagliflozin, and methods of its manufacture and use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that disclose and/or claim LX2761, pharmaceutical compositions comprising LX2761, and methods of its use; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that disclose and/or claim LX9211, pharmaceutical compositions comprising LX9211, and methods of its use.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we hold rights to a number of patents and patent applications under license agreements with third parties.&#160;&#160;Many of these licenses are nonexclusive, although some are exclusive in specified fields.&#160;&#160;Most of the licenses have terms that extend for the life of the licensed patents.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.&#160;&#160;We have filed patent applications and hold issued patents covering our approved drug, XERMELO, and each of our drug candidates.&#160;&#160;None of our United States patents that claim XERMELO or one of our drug candidates has a normal expiration date earlier than 2026.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our employees, consultants and advisors are required to execute a proprietary information agreement upon the commencement of employment or consultation. In general, the agreement provides that all inventions conceived by the employee or consultant, and all confidential information developed or made known to the individual during the term of the agreement, shall be our exclusive property and shall be kept confidential, with disclosure to third parties allowed only in specified circumstances. We cannot assure you, however, that these agreements will provide useful protection of our proprietary information in the event of unauthorized use or disclosure of such information.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our patent and intellectual property rights are subject to certain rights and uncertainties.  See &#8220;Risks Related to Our Intellectual Property&#8221; under &#8220;Item 1A.&#160;Risk Factors.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sEE24B03BC8628A715256BC7752684FEA"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Officers</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our executive officers and their ages and positions are listed below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:28%;"></td><td style="width:7%;"></td><td style="width:65%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Age</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Position with the Company</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pablo Lapuerta, M.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Medical Officer</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alan J. Main, Ph.D.</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Commercial Supply Operations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alexander A. Santini</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Commercial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Praveen Tyle, Ph.D.</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Research and Development</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James F. Tessmer</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Finance and Accounting</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lonnel Coats</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our president and chief executive officer and a director since July 2014.  Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining our company, most recently as chief executive officer from 2010 to 2014 and president and chief operating officer from 2004 to 2010.  Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson &amp; Johnson, where he held a variety of management and sales positions.  Mr. Coats serves as a director of Blueprint Medicines Corporation and holds a B.S. from Oakland University.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pablo Lapuerta, M.D.</font><font style="font-family:inherit;font-size:10pt;">&#160;has been our executive vice president and chief medical officer since February 2015 and previously served in a series of medical and clinical leadership positions since joining our company in 2011.  Dr. Lapuerta was formerly vice president at Bristol-Myers Squibb Company with responsibility for global development of an Alzheimer&#8217;s disease drug candidate, and prior to that served as senior vice president, clinical strategy and chief medical officer of Cogentus Pharmaceuticals, Inc. and in a variety of clinical development leadership roles at Bristol-Myers Squibb, where he worked for 11&#160;years before joining Cogentus. He holds a B.A. in biology from Harvard College and an M.D. from Harvard Medical School.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Alan J. Main, Ph.D</font><font style="font-family:inherit;font-size:10pt;">. has been our executive vice president, commercial supply operations since May 2017 and previously served in a series of manufacturing and scientific leadership positions since joining our company in 2001.&#160;&#160;Dr.&#160;Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">rapidly discover new chemical entities for drug development, until our acquisition of Coelacanth in 2001.&#160;&#160;Dr.&#160;Main was formerly senior vice president, U.S.&#160;Research at Novartis Pharmaceuticals Corporation, where he worked for 20&#160;years before joining Coelacanth.&#160;&#160;Dr.&#160;Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Alexander A. Santini</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our executive vice president and chief commercial officer since November 2016 and previously served in a series of commercial leadership positions since joining our company in April 2015.  Mr. Santini was formerly vice president of market access and an executive member at Bayer Healthcare Pharmaceuticals, where he had executive responsibility for market access, pricing, trade and channel management and payer account management, and prior to that served in a variety of commercial leadership roles of increasing responsibility during eight years of service at Bayer and 22 years of service at Berlex Laboratories.  Mr. Santini served as a non-commissioned officer in the United States Air Force, where he completed the Radiologic Technology Program at the United States Air Force School of Health Care Science and an AAS in business marketing from Westchester Community College.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Praveen Tyle, Ph.D.</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our executive vice president of research and development since May 2016.  Dr. Tyle was previously a member of the executive management team at Osmotica Pharmaceutical Corp., serving as president and chief executive officer from January 2013 through April 2016 and prior to that as executive vice president and chief scientific officer.  Prior to his service at Osmotica, Dr. Tyle held a series of scientific leadership positions within the pharmaceutical industry, including executive vice president and chief science officer for the United States Pharmacopeia, senior vice president and global head of research and development and business development and licensing at Novartis OTC, corporate senior vice president of global research and development and chief scientific officer at Bausch &amp; Lomb Incorporated and vice president and global head of pharmaceutical sciences at Pharmacia Corporation.  Dr. Tyle serves as director of Eyegate Pharmaceuticals, Inc. and Orient Europharma Ltd.  Dr. Tyle received his B.Pharm. from the Indian Institute of Technology, Banaras Hindu University and his Ph.D. in pharmaceutics and pharmaceutical chemistry from the Ohio State University.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jeffrey L. Wade</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our executive vice president, corporate and administrative affairs and chief financial officer since February 2015 and previously served in a series of finance and legal leadership positions since joining our company in 1999.&#160;&#160;Mr.&#160;Wade was previously a corporate securities and finance attorney for ten years with the law firm of Andrews&#160;&amp; Kurth&#160;L.L.P., where he represented companies in the biotechnology, information technology and energy industries.&#160;&#160;Mr.&#160;Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute.&#160;&#160;He received his B.A. and J.D. from the University of Texas.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">James F. Tessmer</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our vice president, finance and accounting since November 2007 and previously served in a series of finance and accounting leadership positions since joining our company in 2001.&#160;&#160;Mr. Tessmer was previously assistant controller for Mariner Health Network, Inc. and prior to that served in a variety of financial and accounting management positions for HWC Distribution Corp. and American General Corporation.&#160;&#160;Mr. Tessmer is a certified public accountant and received his B.B.A. from the University of Wisconsin &#8211; Milwaukee and his M.B.A. from the University of Houston.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sA0A44B9EE0EAE724C410BC77644B3CFE"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February&#160;26, 2018</font><font style="font-family:inherit;font-size:10pt;">, we employed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">174</font><font style="font-family:inherit;font-size:10pt;">&#32;persons, of whom </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33</font><font style="font-family:inherit;font-size:10pt;">&#32;hold M.D. or Ph.D. degrees and another </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">41</font><font style="font-family:inherit;font-size:10pt;">&#32;hold other advanced degrees.&#160;&#160;All of our employees are located in the United States.  None of our employees are represented by a labor union and we believe that our relationship with our employees is good.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDC62B5A96CC542303D3BBC77642CD1A6"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, we incurred expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$156.8&#160;million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$178.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$95.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in company-sponsored as well as collaborative research and development activities, including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;of stock-based compensation expense in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;16</font></div></div><hr style="page-break-after:always"><div><a name="sE58F086D0A23E67C0962BC77647A490C"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risk Factors </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.&#160;&#160;The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We depend heavily on the commercial success of XERMELO.  If we do not achieve commercial success with XERMELO, our business will suffer and our stock price will likely decline.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that a significant portion of our total revenues for the next several years will be attributable to sales of XERMELO in the United States, but we cannot be certain that XERMELO will be commercially successful.  Our future sales of XERMELO will depend on numerous factors, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of patients with carcinoid syndrome diarrhea who are inadequately controlled by SSA therapy, as well as the number of newly diagnosed carcinoid syndrome diarrhea patients;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition from SSA therapies, radiopharmaceutical products and any additional products for the treatment of carcinoid syndrome diarrhea that may be approved by the FDA in the future;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the safety profile of XERMELO, including whether previously unknown side effects or increased incidence or severity of known side effects as compared to those seen during development are identified with the increased use of XERMELO after approval;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness of our commercial strategy for marketing XERMELO and our execution of that strategy, including our pricing strategy and the effectiveness of our efforts to obtain adequate third-party reimbursement;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the acceptance of XERMELO by patients, the medical community and third-party payers; and</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to meet the demand for commercial supplies of XERMELO and to maintain and successfully monitor commercial manufacturing arrangements for XERMELO with third-party manufacturers to ensure they meet our standards and those of the FDA, which extensively regulates and monitors pharmaceutical manufacturing facilities.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we believe that XERMELO has a competitive commercial profile, our current estimates of the revenues that XERMELO could generate in future periods may change based upon the above factors, and could prove to be incorrect.  If our revenues, market share or other indicators of market acceptance of XERMELO fail to meet the expectations of investors or public market analysts, the market price of our common stock could decline.  In addition, if one or more of the factors above negatively affects XERMELO sales, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We depend heavily on our and Sanofi&#8217;s ability to obtain regulatory approval in the United States and the European Union for sotagliflozin in type 1 diabetes.  If we and Sanofi fail to obtain such regulatory approval or fail to successfully commercialize sotagliflozin for type 1 diabetes upon regulatory approval, our business will suffer and our stock price will likely decline.&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Sanofi are presently preparing for the submission of applications for regulatory approval to market sotagliflozin for the treatment of type 1 diabetes in the United States and the European Union.  We cannot offer any assurances or predict with any certainty that the FDA and/or EMA will accept such applications for filing or grant marketing approval for sotagliflozin, in either case on the expected timelines.  Furthermore, regulatory approvals for sotagliflozin, even if obtained, may limit the type of patients in which sotagliflozin may be used or otherwise require specific warning or labeling language, each of which may reduce the commercial potential of sotagliflozin.  Even if approved, we and Sanofi might not be successful in commercializing sotagliflozin for type 1 diabetes.  Should we and Sanofi fail to obtain regulatory approval for sotagliflozin in type 1 diabetes or fail to successfully commercialize sotagliflozin upon such regulatory approval, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to obtain regulatory approvals for the commercial sale of any products that we or our collaborators may develop in addition to XERMELO, we or our collaborators are required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of our drug candidates.&#160;&#160;We or our collaborators may not be able to obtain authority from the FDA, or other equivalent foreign regulatory agencies to initiate or complete any clinical trials.&#160;&#160;In addition, we have limited internal resources for making regulatory filings and interacting with regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials are inherently risky and the results from nonclinical testing of a drug candidate that is under development may not be predictive of results that will be obtained in human clinical trials.&#160;&#160;In addition, the results of early human clinical trials may not be predictive of results that will be obtained in larger-scale, advanced stage clinical trials.&#160;&#160;A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after achieving positive results in earlier trials.&#160;&#160;Although Phase&#160;2 proof-of-concept clinical trials of sotagliflozin in type 2 diabetes patients were positive, we cannot assure you that the Phase&#160;3 clinical development program for sotagliflozin being conducted by Sanofi in type 2 diabetes patients will yield positive results.  Negative or inconclusive results from a nonclinical study or a clinical trial could cause us, our collaborators or the FDA or other equivalent foreign regulatory agencies to terminate a nonclinical study or clinical trial or require that we or our collaborators repeat or modify it.&#160;&#160;Furthermore, we, one of our collaborators or a regulatory agency with jurisdiction over the trials may suspend clinical trials at any time if the subjects or patients participating in such trials are being exposed to unacceptable health risks or for other reasons.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any nonclinical or clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities.&#160;&#160;Nonclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval.  The FDA or institutional review boards at the medical institutions and healthcare facilities where we or our collaborators sponsor clinical trials may suspend any trial indefinitely if they find deficiencies in the conduct of these trials.&#160;&#160;Clinical trials must be conducted in accordance with the FDA&#8217;s current Good Clinical Practices.&#160;&#160;The FDA and these institutional review boards have authority to oversee our and our collaborators&#8217; clinical trials, and the FDA may require large numbers of subjects or patients.&#160;&#160;In addition, we or our collaborators must manufacture, or contract for the manufacture of, the drug candidates that we use in our clinical trials under the FDA&#8217;s current Good Manufacturing Practices.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rate of completion of clinical trials is dependent, in part, upon the rate of enrollment of patients.&#160;&#160;Patient accrual is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the nature of the study, the existence of competitive clinical trials and the availability of alternative treatments.&#160;&#160;Delays in planned patient enrollment may result in increased costs and prolonged clinical development, which in turn could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or potential products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our collaborators may not be able to successfully complete any clinical trial of a drug candidate within any specified time period.&#160;&#160;In some cases, we or our collaborators may not be able to complete the trial at all. Moreover, clinical trials may not show our drug candidates to be both safe and effective.&#160;&#160;Thus, the FDA and other regulatory authorities may not approve any additional drug candidates that we develop for any indication or may limit the approved indications or impose other conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our drug candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries.&#160;&#160;Failure to obtain regulatory approval for any drug candidate would prevent us from commercializing that drug candidate.&#160;&#160;Other than XERMELO, we and our collaborators have not received regulatory approval to market any of our drug candidates in any jurisdiction.&#160;&#160;The process of obtaining regulatory approvals is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the drug candidates involved.&#160;&#160;Before a new drug application can be filed with the FDA, the drug candidate must undergo extensive clinical trials, which can take many years and may require substantial expenditures.&#160;&#160;Any clinical trial may fail to produce results satisfactory to the FDA.&#160;&#160;For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results.&#160;&#160;Furthermore, prior to approving a new drug, the FDA typically requires that the efficacy of the drug be demonstrated in two double-blind, controlled studies.  The regulatory process also requires nonclinical testing, and data obtained from nonclinical and clinical activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.&#160;&#160;In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">during the period of product development and regulatory agency review.&#160;&#160;Changes in regulatory approval policy, regulations or statutes or the process for regulatory review during the development or approval periods of our drug candidates may cause delays in the approval or rejection of an application.  Even if the FDA or a comparable authority in another country approves a drug candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials.&#160;&#160;These agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The commercial success of XERMELO and any other products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to commercialize XERMELO and our or our collaborators&#8217; ability to commercialize any other products that we or they may develop will be highly dependent upon the extent to which XERMELO and such other products gain market acceptance among physicians, patients, health care payers, such as commercial health insurers, Medicare and Medicaid, and the medical community.&#160;&#160;If XERMELO and such other products do not achieve an adequate level of acceptance, we may not generate adequate product revenues and we may not become profitable.&#160;&#160;The degree of market acceptance of XERMELO and such other products will depend upon a number of factors, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness, or perceived effectiveness, of our products in comparison to competing products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the existence of any significant side effects, as well as their severity in comparison to any competing products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential advantages or disadvantages in relation to alternative treatments;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">current and future indications for which our products may be approved;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to offer our products for sale at competitive prices;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the strength of marketing and distribution support; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sufficient third-party coverage or reimbursement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to implement and maintain an effective and specialized sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize XERMELO or any other products that we or our collaborators may develop.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to successfully commercialize XERMELO, we have built a marketing organization and a specialized sales force for XERMELO and established distribution capabilities in the United States.  However, we had no prior experience in building and maintaining such a commercialization infrastructure.  Factors that may hinder our efforts to effectively manage and maintain such infrastructure for XERMELO or establish, manage and maintain such infrastructure for other products that we or our collaborators may develop include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to recruit, retain and effectively manage adequate numbers of effective sales and marketing personnel;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to maintain relationships with third-party logistics providers, specialty pharmacies, third-party manufacturers and other third parties instrumental in the commercial manufacture and distribution of XERMELO and any other products;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to establish or implement internal controls and procedures required in connection with sales of pharmaceutical products;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability of sales personnel to obtain access to or convince adequate numbers of physicians to prescribe XERMELO or any other products; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of complementary products to be offered by our sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to implement and sustain our sales force, marketing infrastructure and distribution capability for XERMELO or any other products, we may not be able to generate any product revenue, may generate increased expenses and may never become profitable.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to continue to expend significant time and resources to train our XERMELO sales force to be credible, persuasive and compliant in discussing XERMELO with the specialists treating the patients indicated under the label.  We will also need to continue to train our sales force to ensure that a consistent and appropriate message about XERMELO is being delivered to our potential customers.  If we are unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of XERMELO and its proper administration, our ability to successfully commercialize XERMELO could be diminished, which could have a material adverse effect on our financial condition, stock price and operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to obtain adequate coverage and reimbursement from third-party payers for XERMELO and any other products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to successfully commercialize XERMELO and any other products that we or our collaborators may develop will be highly dependent on the extent to which coverage and reimbursement for such products will be available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers, including managed care organizations and group purchasing organizations.&#160;&#160;Many patients will not be capable of paying themselves for XERMELO and some or all of the other products that we or our collaborators may develop, and will rely on third-party payers to pay for, or subsidize, their medical needs.&#160;&#160;If third-party payers do not provide coverage or reimbursement for XERMELO or any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.&#160;&#160;In addition, even if third-party payers provide some coverage or reimbursement for such products, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans often varies based on the type of contract or plan purchased.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in some foreign countries, particularly the countries in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control.&#160;&#160;In these countries, price negotiations with governmental authorities can take six to 12&#160;months or longer after the receipt of regulatory marketing approval for a product.&#160;&#160;To obtain reimbursement and/or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost effectiveness of our drug candidates or products to other available therapies.&#160;&#160;The conduct of such a clinical trial could be expensive and result in delays in the commercialization of our drug candidates.&#160;&#160;Third-party payers are challenging the prices charged for medical products and services, and many third-party payers limit reimbursement for newly approved health care products.&#160;&#160;In particular, third-party payers may limit the indications for which they will reimburse patients who use any products that we or our collaborators may develop.&#160;&#160;Cost-control initiatives could decrease prices we or our collaborators might establish for products that may be developed, which would result in lower product revenues to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may not be able to manufacture XERMELO and any other products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than XERMELO, our drug candidates have been manufactured in relatively small quantities for nonclinical and clinical trials.&#160;&#160;If any of these drug candidates are approved by the FDA or other regulatory agencies for commercial sale, we or our collaborators will need to manufacture them in larger quantities.  We may not be able to successfully increase the manufacturing capacity, whether in collaboration with third-party manufacturers or on our own, for any of such drug candidates in a timely or economic manner, or at all.&#160;&#160;Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.&#160;&#160;If we or our collaborators are unable to successfully increase the manufacturing capacity for a drug candidate, the regulatory approval or commercial launch of that drug candidate may be delayed or there may be a shortage in supply.&#160;&#160;Our drug candidates require precise, high-quality manufacturing.&#160;&#160;The failure to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to XERMELO and any other products that we or our collaborators may develop.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to extensive and rigorous ongoing domestic and foreign government regulation of, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of XERMELO and any other products which receive regulatory approvals from the FDA or foreign regulatory authorities.&#160;&#160;The failure to comply with these requirements or the identification of safety problems during commercial marketing could lead to the need </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for product marketing restrictions, product withdrawal or recall or other voluntary or regulatory action, which could delay further marketing until the product is brought into compliance.&#160;&#160;The failure to comply with these requirements may also subject us or our collaborators to stringent penalties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, without limitation:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Law, which constrains our business activities, which includes our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state and federal government price reporting laws that require us to calculate and report complex pricing metrics to government programs, where such reported price may be used in the calculation of reimbursement and/or discounts on our marketed drugs (participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and potentially limit our ability to offer certain marketplace discounts); and</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state and federal marketing expenditure tracking and reporting laws, which generally require certain types of expenditures in the United States to be tracked and reported.  Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, certain marketing practices, including off-label promotion, may also violate certain federal and state health regulatory fraud and abuse laws as well as false claims laws, including the civil False Claims Act.  Suits filed under the civil False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement.  The filing of&#160;qui tam&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to defend a civil False Claims Act action.  When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, withdrawal of regulatory approval, the curtailment or restructuring of our operations, the exclusion </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from participation in Medicare, Medicaid and other federal and state healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to sell our products or operate our business and also adversely affect our financial results.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who may be expected to prescribe our products and from whom we may obtain patient health information are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business.  International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within Europe and between European countries and the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A primary trend in the United States and some foreign countries is toward reform and cost containment in the health care industry.&#160;&#160;The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals that may have the effect of reducing the prices that we are able to charge for XERMELO and other products we or our collaborators may develop.  Healthcare reform measures which may be adopted in the future in the United States and foreign jurisdictions may result in more rigorous coverage criteria and significant downward pressure on the prices drug manufacturers may charge.  As a result, our revenues and prospects for profitability could be significantly harmed.</font></div><div style="line-height:120%;padding-left:4px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the United States, third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. They may use tiered reimbursement and may adversely affect demand for XERMELO and other products we or our collaborators may develop by placing them in an expensive tier.  They may also refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted market approvals.  As a result, significant uncertainty exists as to whether and how much third-party payers will reimburse for newly approved drugs, which in turn will put pressure on the pricing of drugs.  Further, we do not have experience in ensuring approval by applicable third-party payers outside of the United States for coverage and reimbursement of pharmaceutical products.  We also anticipate pricing pressures in connection with the sale of XERMELO and other products we or our collaborators may develop due to the increasing influence of health maintenance organizations and additional legislative proposals.</font></div><div style="line-height:120%;padding-left:4px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many companies in our industry have received a governmental request for documents and information relating to drug pricing and patient support programs.  We may become subject to similar requests, which would require us to incur significant expense and result in distraction for our management team.  Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of our company, such findings could further harm our business, reputation and/or prospects.  It is possible that such inquiries could result in negative publicity or other negative actions that could harm our reputation, changes in our product pricing and distribution strategies, reduced demand for our approved products and/or reduced reimbursement of approved products, including by federal health care programs such as Medicare and Medicaid and state health care programs.</font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our competitors may develop products that impair the value of XERMELO or any other products that we or our collaborators may develop.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical and biotechnology industries are highly diversified and are characterized by rapid technological change.&#160;&#160;We and our collaborators face, and will continue to face, intense competition from biotechnology and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research and development activities similar to ours.&#160;&#160;In addition, significant delays in the development of our drug candidates could allow our competitors to bring products to market before us, which would impair our or our collaborators&#8217; ability to commercialize our drug candidates.&#160;&#160;XERMELO and any other products that we or our collaborators develop will compete in highly competitive markets.&#160;&#160;Further, our competitors may be more effective at using their technologies to develop commercial products.&#160;&#160;Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and marketing capabilities.&#160;&#160;As a result, our competitors may be able to more easily develop products that would render XERMELO and any other products that we or our collaborators develop obsolete and noncompetitive.&#160;&#160;For example, dapagliflozin, empagliflozin and canagliflozin are currently being marketed by AstraZeneca, Boehringer Ingelheim and Eli Lilly, and Janssen (a subsidiary of Johnson &amp; Johnson), respectively, for the treatment of type 2 diabetes.  Each of those products act through SGLT2, one of the targets of sotagliflozin. &#160;In addition, there may be drug candidates of which we are not aware at an earlier stage of development that may compete with our drug candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Capital Requirements and Financial Results</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our commercialization efforts or product development programs.&#160;&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$310.8&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and investments.&#160;&#160;We anticipate that our existing capital resources and the cash and revenues we expect to derive from product revenues, collaborations and other sources will enable us to fund our currently planned operations for at least the next 12 months.  However, we caution you that we may generate less cash and revenues or incur expenses more rapidly than we currently anticipate.  Our currently planned operations for the next twelve months include the continued commercialization of XERMELO in the United States; preparations with Sanofi for the submission of regulatory applications to market sotagliflozin for type 1 diabetes in the United States and the European Union; preparations for the commercial launch of sotagliflozin for type 1 diabetes in the United States, if approved; the initiation of clinical development of XERMELO for cholangiocarcinoma and neuroendocrine tumors; the continued clinical development of LX2761 for diabetes; and the continued clinical development of LX9211 for neuropathic pain.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although difficult to accurately predict, the amount of our future capital requirements will be substantial and will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of our sales, marketing, distribution and other commercialization activities for XERMELO in the United States and the revenues we generate from that approved product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of Ipsen&#8217;s sales, marketing, distribution and other commercialization activities for XERMELO outside of the United States and Japan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our and Sanofi&#8217;s ability to obtain regulatory approval for the marketing and sale of sotagliflozin for type 1 diabetes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if approved, our and Sanofi&#8217;s ability to successfully commercialize sotagliflozin for type 1 diabetes in the United States and Sanofi&#8217;s ability to successfully commercialize sotagliflozin for type 1 diabetes outside of the United States and Japan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the progress and scope of Sanofi&#8217;s development activities with respect to sotagliflozin in type 2 diabetes patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing, progress and results of our clinical trials of XERMELO, LX2761 and LX9211;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of payments, if any, under our existing collaboration agreements with Sanofi, Ipsen and other entities and any future collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of our research, development and commercialization expenditures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">future results from clinical trials of our other drug candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of regulatory approvals and commercialization of additional drug candidates that we successfully develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the market acceptance and commercial success of additional products that we successfully develop and commercially launch;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing programs and products, and of technological and market developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of establishing or contracting for commercialization capabilities of any other approved drug candidate.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our capital requirements have and will continue to be substantial as we market XERMELO in the United States, prepare for the submission of regulatory applications to market sotagliflozin for type 1 diabetes in the United States and the European Union, prepare for the commercial launch of sotagliflozin for type 1 diabetes in the United States, continue to share in the funding of the type 2 diabetes development costs for sotagliflozin; initiate clinical trials of XERMELO for cholangiocarcinoma and neuroendocrine tumors, continue to conduct early stage clinical trials of LX2761 and LX9211 and advance new drug candidates into clinical development.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary products and technologies.&#160;&#160;For all of these reasons, our future capital requirements cannot easily be quantified.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our capital resources are insufficient to meet future capital requirements, we will need to raise additional funds to continue our currently planned operations.&#160;&#160;Our ability to raise additional capital is dependent on a number of factors, including the market demand for our securities, which itself is subject to a number of pharmaceutical development and business risks and uncertainties, as well as uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.  If we raise additional capital by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preferences over our common stock.&#160;&#160;The affirmative and restrictive covenants and the pledge of substantially all of our assets as collateral under our existing term loan with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP, or the BioPharma Term Loan, restrict our ability to raise additional capital by issuing debt securities.  We cannot be certain that additional financing, whether debt or equity, will be available in amounts or on terms acceptable to us, if at all.&#160;&#160;We may be unable to raise sufficient additional capital on reasonable terms, and if so, we will be forced to delay, reduce or eliminate our clinical development programs or commercialization efforts or obtain funds, if at all, by entering into financing agreements on unattractive terms.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception, including net losses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$129.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$141.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.4&#160;billion</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Because of the numerous risks and uncertainties associated with successfully developing and commercializing drugs, we are unable to predict the extent of any future losses or whether or when we will become profitable, if at all.&#160;&#160;The size of our net losses will depend, in part, on the rate of decline or growth in our revenues and on the amount of our expenses.  We expect to continue to incur significant expenses over the next several years as we expect to make significant investments in the commercialization of XERMELO in the United States, the commercialization of sotagliflozin for type 1 diabetes in the United States, if approved, and the ongoing clinical development of XERMELO, sotagliflozin and our other drug candidates.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commercially launched XERMELO following regulatory approval in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy in the United States.  Prior to the launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future revenues from our commercialization of XERMELO are uncertain because they depend on a number of factors, including market acceptance of XERMELO, the success of our sales, marketing, distribution and other commercialization activities and the cost and availability of reimbursement for XERMELO.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any future products developed under the collaborations.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, including XERMELO in the United States and Japan, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to spend significant amounts to fund our commercialization activities with respect to XERMELO in the United States, our preparations for the commercial launch of sotagliflozin for type 1 diabetes in the United States and our nonclinical and clinical development activities, including the conduct of ongoing and planned clinical trials for XERMELO, sotagliflozin, LX2761 and LX9211.  As a result, we will need to generate substantial additional revenues to achieve profitability.&#160;&#160;Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating results have fluctuated in the past and are likely to fluctuate in the future.  A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our and Sanofi&#8217;s ability to obtain regulatory approval for the marketing and sale of sotagliflozin for type 1 diabetes;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of payments, if any, under our existing collaboration agreements with Sanofi, Ipsen and other entities;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of our ongoing preclinical and clinical development efforts;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and amount of expenses incurred with respect to our preclinical and clinical development and commercialization efforts;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our success in establishing new collaborations and technology licenses, and the timing of such arrangements;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success rate of our development efforts leading to opportunities for new collaborations and licenses, as well as milestone payments and royalties;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and willingness of our collaborators to commercialize pharmaceutical products that would result in milestone payments and royalties;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products and technologies;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general and industry-specific economic conditions, which may affect our and our collaborators&#8217; research and development expenditures.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of these and other factors, including the risks and uncertainties described in this section, our operating results have fluctuated in the past and are likely to do so in the future.&#160;&#160;Due to the likelihood of fluctuations in our revenues and expenses, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred </font><font style="font-family:inherit;font-size:10pt;">$245.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of indebtedness.  Although the affirmative and restrictive covenants and the pledge of substantially all of our assets as collateral under the BioPharma Term Loan restrict our ability to obtain additional debt financing, we could in the future incur additional indebtedness beyond such amount.  Our substantial debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requiring us to dedicate a substantial portion of cash flow from operations to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product commercialization and development efforts and other general corporate purposes;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents and marketable securities and funds from external sources.  However, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt.  Funds from external sources may not be available on acceptable terms, if at all.  In addition, a failure to comply with the covenants under our existing debt instruments could result in an event of default under those instruments.  In the event of an acceleration of amounts due under our debt instruments as a result of an event of default, including upon the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, properties, assets or condition or a failure to pay any amount due, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and the lenders could seek to enforce their security interests in the collateral securing such indebtedness.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we do not effectively manage our affirmative and restrictive covenants under the BioPharma Term Loan, our financial condition and results of operations could be adversely affected.  In addition, we may not achieve the amount of XERMELO net sales required for us to access the second tranche available under the BioPharma Term Loan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of our assets.  In addition, the BioPharma Term Loan requires that we comply with certain affirmative and restrictive covenants, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us.  Our failure to comply with any of these covenants could result in a default under the BioPharma Term Loan, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable.  If we are unable to repay those amounts, the lenders could enforce the security interest granted to them to secure that debt, which would seriously harm our business.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, the second $50.0 million tranche is only available for draw by March 2019 if XERMELO net sales are greater than $25 million in the preceding quarter.  We may be unable to achieve such amount of XERMELO net sales, in which case our liquidity could be negatively affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Relationships with Third Parties</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We are significantly dependent upon our collaborations with Ipsen, Sanofi and other pharmaceutical and biotechnology companies.&#160;&#160;If pharmaceutical products are not successfully and timely developed and commercialized under our collaborations, our opportunities to generate revenues from milestones and royalties will be greatly reduced.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into collaboration agreements with Ipsen for the commercialization of XERMELO outside of the United States and Japan and with Sanofi for the worldwide (excluding Japan) development and commercialization of sotagliflozin.  We have also established collaborative arrangements with other pharmaceutical and biotechnology companies with respect to the research, development and commercialization of drug candidates from other programs.  We have derived a substantial majority of our revenues to date from these strategic collaborations and other research and development collaborations and technology licenses.  Future revenues from our existing collaborations depend upon the achievement of milestones and payment of royalties we earn from any future products developed under the collaborations.&#160;&#160;If our relationship terminates with any of our collaborators, particularly Ipsen and Sanofi, our reputation in the business and scientific community may suffer and revenues will be negatively impacted to the extent such losses are not offset by additional collaboration agreements.&#160;&#160;If milestones are not achieved under our collaborations or our collaborators are unable to successfully develop and commercialize products from which milestones and royalties are payable, we will not earn the revenues contemplated by those collaborations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have limited or no control over the resources that any collaborator may devote to the development and commercialization of products under our alliances.&#160;&#160;For example, Sanofi is responsible for all clinical development activities relating to sotagliflozin for the treatment of type 2 diabetes and we have limited influence on the manner in which Sanofi may conduct such clinical development.  Any of our present or future collaborators may not perform their obligations as expected.&#160;These collaborators may breach or terminate their agreements with us or otherwise fail to conduct research, development or commercialization activities successfully or in a timely manner.&#160;&#160;Further, our collaborators may elect not to develop pharmaceutical products arising out of our collaborative arrangements or may not devote sufficient resources to the development, regulatory approval, manufacture, marketing or sale of these products.&#160;&#160;If any of these events occurs, we may not receive collaboration revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts may be delayed and our business, operating results and financial condition could be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may pursue opportunities in specific disease and therapeutic modality fields that could result in conflicts with our collaborators, if any of our collaborators takes the position that our internal activities overlap with those activities that are exclusive to our collaboration.&#160;&#160;Moreover, disagreements could arise with our collaborators over rights to our intellectual property or our rights to share in any of the future revenues of compounds or therapeutic approaches developed by our collaborators.&#160;&#160;Any conflict with or among our collaborators could result in the termination of our collaborative agreements, delay collaborative research or development activities, impair our ability to renew or obtain future collaborative agreements or lead to costly and time consuming litigation.&#160;&#160;Conflicts with our collaborators could also have a negative impact on our relationship with existing collaborators, materially impairing our business and revenues.&#160;&#160;Some of our collaborators are also potential competitors or may become competitors in the future.&#160;&#160;Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors or terminate their agreements with us prematurely.&#160;&#160;Any of these events could harm our product development efforts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We depend on third-party manufacturers, including sole source suppliers, to manufacture commercial quantities of XERMELO.  We may not be able to maintain these relationships and could experience supply disruptions outside of our control.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on a network of third-party manufacturers to manufacture and supply XERMELO for commercial sale.  As a result of our reliance on these third-party manufacturers and suppliers, including sole source suppliers for certain steps in the manufacture of XERMELO, we could be subject to significant supply disruptions.  Our supply chain for sourcing raw materials and manufacturing drug product ready for distribution is a multi-step endeavor.  Third-party contract manufacturers procure raw materials, convert these raw materials into API, and then convert the API into final dosage form. Establishing and managing this supply chain requires a significant financial commitment and the creation and maintenance of numerous third party contractual relationships.  Although we attempt to effectively manage the business relationships with companies in our supply chain, we do not have control over their operations.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We require our own commercial supply of XERMELO for sale in the United States, and are required under our collaboration agreement to supply Ipsen&#8217;s commercial requirements of XERMELO in the European Union and other territories outside of the United States and Japan once approved in such jurisdictions.  We currently rely, and expect to continue to rely, on sole source third-party manufacturers to produce final drug product and package and label XERMELO.  While we have identified and expect to qualify and engage back-up third-party manufacturers as additional or alternative suppliers for the production of final drug product and packaging and labeling of XERMELO, we currently do not have such arrangements in place.  Moreover, some of these alternative manufacturers will need to be approved by the FDA before we can use them for manufacturing XERMELO.  It is also possible that supplies of materials that cannot be second-sourced can be managed with inventory planning.  There can be no assurance, however, that failure of any of our sole source third-party manufacturers to meet our and Ipsen&#8217;s commercial demands for XERMELO in a timely manner, or our failure to engage qualified additional or back-up suppliers for the production of final drug product and packaging and labeling of XERMELO, would not have a material adverse effect on commercialization of XERMELO and our business.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supply disruptions may result from a number of factors, including shortages in product raw materials, labor or technical difficulties, regulatory inspections or restrictions, shipping or customs delays or any other performance failure by any third-party manufacturer on which we rely.  Any supply disruptions could disrupt sales of XERMELO, which could have a material adverse impact on our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We rely on a single third-party logistics provider and two independent specialty pharmacies for distribution of XERMELO in the United States, and their failure to distribute XERMELO effectively would adversely affect sales of XERMELO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on a single third-party logistics provider for shipping and warehousing of our commercial supply of XERMELO and two independent specialty pharmacies for dispensation of XERMELO to patients in fulfillment of prescriptions in the United States.  Although our third-party logistics provider stores our commercial supply of XERMELO at two separate warehouses, the use of a single third-party logistics provider increases the risk that a fire or damage from another type of disaster at either of the warehouses may result in a disruption of our commercialization efforts.  A specialty pharmacy is a pharmacy that specializes in the dispensing of medications for complex or chronic conditions, which often require a high level of patient education and ongoing management.  The use of specialty pharmacies involves certain additional risks, including, but not limited to, risks that these specialty pharmacies will:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not provide us accurate or timely information regarding their inventories, the number of patients who are using XERMELO or complaints about XERMELO;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce or discontinue their efforts to sell or support or otherwise not effectively sell or support XERMELO;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not devote the resources necessary to sell XERMELO in the volumes and within the time frames that we expect;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be unable to satisfy their financial obligations to us; or</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cease operations.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our third-party logistics provider or either or both of our specialty pharmacies do not fulfill their contractual obligations to us, or refuse or fail to adequately distribute XERMELO and serve patients, or the agreements are terminated without adequate notice, shipments of XERMELO, and associated revenues, would be adversely affected.  In addition, we expect that it may take a significant amount of time if we were required to change our third-party logistics provider or either of our specialty pharmacies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We rely on third parties to carry out drug development activities.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on clinical research organizations and other third-party contractors to carry out many of our drug development activities, including the performance of nonclinical laboratory and animal tests under the FDA&#8217;s current Good Laboratory Practices regulations and the conduct of clinical trials of our drug candidates in accordance with protocols we establish.&#160;&#160;If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, our drug development activities may be delayed, suspended or terminated.&#160;&#160;Such a failure by these third parties could significantly impair our ability to develop and commercialize the affected drug candidates.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We lack the capability to manufacture materials for nonclinical studies, clinical trials or commercial sales and rely on third parties to manufacture our drug candidates, which may harm or delay our product development and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not have the manufacturing capabilities or experience necessary to produce materials for nonclinical studies, clinical trials or commercial sales and intend in the future to continue to rely on collaborators and third-party contractors to produce such materials.&#160;&#160;We will rely on selected manufacturers to deliver materials on a timely basis and to comply with applicable regulatory requirements, including the current Good Manufacturing Practices of the FDA, which relate to manufacturing and quality control activities.&#160;&#160;These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development timelines and applicable regulatory requirements.&#160;&#160;In addition, there are a limited number of manufacturers that operate under the FDA&#8217;s current Good Manufacturing Practices and that are capable of producing such materials, and we may experience difficulty finding manufacturers with adequate capacity for our needs.&#160;&#160;If we are unable to contract for the production of sufficient quantity and quality of materials on acceptable terms, our product development and commercialization efforts may be delayed.&#160;&#160;Moreover, noncompliance with the FDA&#8217;s current Good Manufacturing Practices can result in, among other things, fines, injunctions, civil and criminal penalties, product recalls or seizures, suspension of production, failure to obtain marketing approval and withdrawal, suspension or revocation of marketing approvals.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our products and technologies.&#160;&#160;The patent positions of biotechnology and pharmaceutical companies, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">including our patent position, are generally uncertain and involve complex legal and factual questions.&#160;&#160;We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our products and technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.&#160;&#160;We will continue to apply for patents covering our products and technologies as, where and when we deem appropriate.  However, pending patent applications do not provide protection against competitors because they are not enforceable until they issue as patents.&#160;&#160;Further, the disclosures contained in our current and future patent applications may not be sufficient to meet statutory requirements for patentability and our applications may fail to result in issued patents.&#160;&#160;Once issued, patents still may not provide commercially meaningful protection.&#160;&#160;Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from developing competing products and technologies.&#160;&#160;Furthermore, others may independently develop similar or alternative products or technologies or design around our patents.&#160;&#160;If anyone infringes upon our or our collaborators&#8217; patent rights, enforcing these rights may be difficult, costly and time-consuming and, as a result, it may not be cost-effective or otherwise expedient to pursue litigation to enforce those patent rights.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our patents may be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties.  As a result, we may be involved in the defense and enforcement of our patent or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the United States and elsewhere.  The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation may be substantial and the outcome can be uncertain.  An adverse outcome may allow third parties to use our intellectual property without a license and negatively impact our business.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our products and drug candidates.&#160;&#160;&#160;If any such patents are issued to other entities, we will be unable to obtain patent protection for the same or similar discoveries that we make relating to our products and drug candidates.&#160;&#160;Moreover, we may be blocked from using our drug targets or drug candidates or developing or commercializing our products and other drug candidates, or may be required to obtain a license that may not be available on reasonable terms, if at all.&#160;&#160;Further, others may discover uses for our drug targets and drug candidates other than those covered in our issued or pending patents, and these other uses may be separately patentable.&#160;&#160;Even if we have a patent claim on a particular technology or product, the holder of a patent covering the use of that technology or product could exclude us from selling a product that is based on the same use of that product.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions.&#160;&#160;Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, if the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements).&#160;&#160;In addition, many countries limit the enforceability of patents against government agencies or government contractors.&#160;&#160;In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.&#160;&#160;Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives.&#160;&#160;Such compulsory licenses could be extended to include some of our products and drug candidates, which could limit our potential revenue opportunities.&#160;&#160;Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on trade secret protection for some of our confidential and proprietary information.&#160;&#160;We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection.&#160;&#160;While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets.&#160;&#160;In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products and those of our collaborators, as well as our nonclinical and clinical development efforts, may give rise to claims that they infringe the patents of others.&#160;&#160;We are aware that other companies and institutions are developing products acting through the same drug targets through which some of our drug candidates currently in clinical development act, have conducted research on many of the same targets that we have identified and have filed patent applications potentially covering drug targets that we have identified and certain therapeutic products addressing such targets.&#160;&#160;In some cases, patents have issued from these applications.&#160;&#160;In addition, many companies and institutions have well-established patent portfolios directed to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common techniques, methods and means of developing, producing and manufacturing pharmaceutical products.&#160;&#160;These or other companies or institutions could bring legal actions against us or our collaborators for damages or to stop us or our collaborators from engaging in certain nonclinical or clinical development activities or from manufacturing and marketing therapeutic products that allegedly infringe their patent rights.&#160;&#160;If any of these actions are successful, in addition to our potential liability for damages, these entities would likely require us or our collaborators to obtain a license in order to continue engaging in the infringing activities or to manufacture or market the infringing therapeutic products or may force us to terminate such activities or manufacturing and marketing efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may deem it advisable to pursue litigation against others to enforce our patents and intellectual property rights and may be the subject of litigation brought by third parties to enforce their patent and intellectual property rights.&#160;&#160;In addition, we may become involved in litigation based on intellectual property indemnification undertakings that we have given to certain of our collaborators.&#160;&#160;Patent litigation is expensive and requires substantial amounts of management attention.&#160;&#160;The eventual outcome of any such litigation is uncertain and involves substantial risks.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that there will continue to be significant litigation in our industry regarding patent and other intellectual property rights.&#160;&#160;We have expended and many of our competitors have expended and are continuing to expend significant amounts of time, money and management resources on intellectual property litigation.&#160;&#160;If we become involved in future intellectual property litigation, it could consume a substantial portion of our resources and could negatively affect our results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners.  We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information.  The secure maintenance of this information is critical to our business and reputation.  We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access.  These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage).  Cyber threats may be generic, or they may be custom-crafted against our information systems.  Our network and storage applications and those of our vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions.  It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents.  These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information.  A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others.  Cyber-attacks could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.  Our network security and data recovery measures and those of our vendors may not be adequate to protect against such security breaches and disruptions.  These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our employees and independent contractors were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.&#160;&#160;We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.&#160;&#160;Litigation may be necessary to defend against these claims.&#160;&#160;Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention.&#160;&#160;If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel.&#160;&#160;A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain drug candidates, which could severely harm our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Employees and Facilities Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations.  This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth.  To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies.  We expect that we may need to increase our medical, clinical, commercial and other personnel, and recruiting and retaining qualified individuals is difficult.  If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified personnel when advisable, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are highly dependent upon the principal members of our management, as well as medical, clinical and commercial staff, the loss of whose services might adversely impact the achievement of our objectives.&#160;&#160;Retaining and, where advisable, recruiting qualified medical, clinical and commercial personnel will be critical to support activities related to successfully executing on our commercial plan for XERMELO and advancing our nonclinical and clinical development programs for sotagliflozin and our other drug programs.&#160;&#160;Competition is intense for experienced medical, clinical and commercial personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products.&#160;&#160;Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any break-in or trespass of our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our equipment and assets could subject us to liability and have a material adverse impact on our business, operating results and financial condition.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our facilities are located in The Woodlands, Texas and Basking Ridge, New Jersey, and therefore our facilities are vulnerable to damage from hurricanes.  We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events and any insurance we may maintain may not be adequate to cover our losses.  If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Environmental and Product Liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have used hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development processes have historically involved the controlled use of hazardous materials, including chemicals and radioactive and biological materials.&#160;&#160;Our operations have produced hazardous waste products.&#160;&#160;We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials.&#160;&#160;Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials.&#160;&#160;We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets.&#160;&#160;Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, these hazardous materials used by these parties.&#160;&#160;Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be held liable if XERMELO or any other product that we or our collaborators develop or commercialize, or any product that is made with the use or incorporation of any of our technologies, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale.&#160;&#160;Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop.  These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products.  We have obtained limited product liability insurance coverage for our clinical trials and commercial activities.  However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer.  Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.  On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects.  In addition, the pharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation.  A successful product liability claim or series of claims brought against us could harm our reputation and business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invus, L.P. and Invus C.V., which we collectively refer to as Invus, and their affiliates currently own approximately 59.3% of the outstanding shares of our common stock and are thereby able to control the election and removal of our directors and determine our corporate and management policies, including potential mergers or acquisitions, asset sales, the amendment of our articles of incorporation or bylaws and other significant corporate transactions.  This concentration of ownership may delay or deter possible changes in control of our company, which may reduce the value of an investment in our common stock.  The interests of Invus and its affiliates may not be aligned with the interests of other holders of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Invus has additional rights under our stockholders</font><font style="font-family:inherit;font-size:10pt;">&#8217;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;agreement with Invus, L.P. relating to the membership of our board of directors, which provides Invus with substantial influence over significant corporate matters. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our stockholders&#8217; agreement with Invus, L.P., Invus has the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates, rounded up to the nearest whole number of directors.  Invus has designated three of the nine current members of our board of directors.  While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion.  To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary steps in accordance with our obligations under the stockholders&#8217; agreement to (1) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the stockholders&#8217; agreement) and (2) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions.  Invus-designated directors currently serve as one of the three members of each of the compensation committee and the corporate governance committee of our board of directors.  No Invus-designated directors currently serve on the audit committee of our board of directors.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the stockholders&#8217; agreement relating to Invus&#8217; rights to designate members of our board of directors and its audit, compensation and corporate governance committees will terminate if the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates falls below 10%.  Invus also has the right to terminate these provisions at any time in its discretion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our stock price may be extremely volatile.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commercial success of XERMELO and the revenues we generate from sales of XERMELO;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse results or delays in our or our collaborators&#8217; clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and achievement of milestones under our collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the announcement of FDA approval or non-approval, or delays in the FDA review process, of our or our collaborators&#8217; drug candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators&#8217; or our competitors&#8217; clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actions taken by regulatory agencies with respect to XERMELO, sotagliflozin and our other drug candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the announcement of new products by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments in our relationships with our collaborators, including conflicts, litigation or the termination or modification of our agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the announcement of an in-licensed drug candidate or strategic acquisition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to achieve operating results projected by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the satisfaction of outstanding debt obligations or entry into new financing arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments in the biotechnology or pharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">departures of key personnel or board members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA or international regulatory actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party coverage and reimbursement policies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disposition of any of our drug programs or other technologies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors, including general market, economic and political conditions and other factors unrelated to our operating performance or the operatin</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">g</font><font style="font-family:inherit;font-size:10pt;">&#32;performance of our competitors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These factors may materially adversely affect the market price of our common stock.  In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies.  For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks.  Likewise, the broader financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks.  These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock.  Excessive volatility may continue for an extended period of time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted.&#160;&#160;A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Future sales of our common stock, or the perception that such sales may occur, may depress our stock price.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A substantial number of shares of our common stock is reserved for issuance upon conversion of notes evidencing our current indebtedness, upon the exercise of stock options and upon vesting of restricted stock units.  If our stockholders sell substantial amounts of our common stock (including shares issued upon the conversion of notes, exercise of stock options or vesting of restricted stock units) in the public market, or if the market perceives that such sales may occur, the market price of our common stock could fall and it may become more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.&#160;&#160;For example, following an acquisition, a significant number of shares of our common stock held by new stockholders may become freely tradable or holders of registration rights could cause us to register their shares for resale.&#160;&#160;Sales of these shares of common stock held by existing stockholders could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of our 5.25% Convertible Senior Notes due 2021 may dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes, or may otherwise depress the price of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The conversion of some or all of our 5.25% Convertible Senior Notes due 2021 will dilute the ownership interests of existing stockholders to the extent we deliver shares upon conversion of any of the notes.  Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock.  In addition, the existence of the notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, or anticipated conversion of the notes into shares of our common stock could depress the price of our common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.&#160;&#160;If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline.&#160;&#160;If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may acquire additional businesses, technologies and products if we determine that these businesses, technologies and products complement our existing technology or otherwise serve our strategic goals.&#160;&#160;If we do undertake any transactions of this sort, the process of integrating an acquired business, technology or product may result in operating difficulties and expenditures and may not be achieved in a timely and non-disruptive manner, if at all, and may absorb significant management attention that would otherwise be available for ongoing development of our business.&#160;&#160;If we fail to integrate acquired businesses, technologies or products effectively or if key employees of an acquired business leave, the anticipated benefits of the acquisition would be jeopardized.&#160;&#160;Moreover, we may never realize the anticipated benefits of any acquisition, such as increased revenues and earnings or enhanced business synergies.&#160;&#160;Future acquisitions could result in potentially dilutive issuances of our equity securities, the incurrence of debt and contingent liabilities and amortization expenses related to intangible assets, which could materially impair our results of operations and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="sC352BEBF31661F982237BC776499379B"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1B. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unresolved Staff Comments</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div><a name="sBE1AFBC631DEEE490F68BC7764C8D84F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Properties</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently own approximately 260,000 square feet of space for our corporate offices and laboratories in buildings located in The Woodlands, Texas, a suburb of Houston, Texas, and lease approximately 25,000 square feet of office space in Basking Ridge, New Jersey.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2004, we obtained a $34.0&#160;million mortgage on our facilities in The Woodlands, Texas.&#160;&#160;The mortgage loan originally had a ten-year term with a  20-year amortization and a fixed rate of 8.23%.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017 and again in April 2017 to extend the maturity date to April 2018, in each case with the mortgage loan&#8217;s monthly payment amount and fixed interest rate remaining unchanged.  The mortgage had a principal balance outstanding of </font><font style="font-family:inherit;font-size:10pt;">$14.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The entire principal balance is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recorded as current portion of long-term debt in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as there is a balloon payment due in April 2018.  We intend to refinance the mortgage prior to the balloon payment becoming due. </font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our facilities are well-maintained, in good operating condition and acceptable for our current operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s68E46D2C1BF374BB26F7BC7764E7C8BE"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="s2AC67AF7355E1AE95DECBC7765263E4F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Mine Safety Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s171522E53EBB0C3241E8BC7765455BDC"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sC17292EBDB0121B91AFDBC776574DF05"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is quoted on The Nasdaq Global Select Market under the symbol &#8220;LXRX.&#8221;&#160;&#160;The following table sets forth, for the periods indicated, the high and low sales prices for our common stock as reported on The Nasdaq Global Select Market.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February&#160;26, 2018</font><font style="font-family:inherit;font-size:10pt;">, there were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">224</font><font style="font-family:inherit;font-size:10pt;">&#32;holders of record of our common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never paid cash dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our business and do not anticipate paying cash dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following performance graph compares the performance of our common stock to the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period beginning </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">&#32;and ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The graph assumes that the value of the investment in our common stock and each index was $100 at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, and that all dividends were reinvested.</font></div><div style="line-height:120%;text-align:left;"><img src="image27.jpg" alt="image27.jpg" style="height:226px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Composite Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Biotechnology Index</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing stock price performance comparisons shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this annual report on Form 10-K into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate such comparisons by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;37</font></div></div><hr style="page-break-after:always"><div><a name="s475B15398927532E0EA1BC7754D9A6C1"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selected Financial Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The statements of comprehensive loss data for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and the balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited financial statements included elsewhere in this annual report on Form&#160;10-K.&#160;&#160;The statements of comprehensive loss data for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, and the balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited financial statements not included in this annual report on Form 10-K.&#160;&#160;Our historical results are not necessarily indicative of results to be expected for any future period.&#160;&#160;The data presented below has been derived from financial statements that have been prepared in accordance with accounting principles generally accepted in the United States and should be read with our financial statements, including the notes, and with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this annual report on Form 10-K.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of Comprehensive Loss Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share data)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,337</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,222</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cost of sales (including finite-lived intangible asset amortization)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,899</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#000000;">Research and development, including stock-based compensation of $4,905 in 2017, $3,938 in 2016, $3,693 in 2015, $4,020 in 2014 and $4,376 in 2013 </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">156,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">95,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(703</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,927</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,428</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#000000;">Selling, general and administrative, including stock-based compensation of $4,567 in 2017, $3,514 in 2016, $3,150 in 2015, $3,061 in 2014 and $3,045 in 2013 </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Impairment loss on buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">227,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">220,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">128,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">123,220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(136,681</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(137,155</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,468</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100,366</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest and other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,274</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,755</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consolidated net loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(141,711</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(141,429</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,682</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100,364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(104,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(129,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(141,429</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(104,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">105,237</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,863</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,591</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76,347</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,302</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and short-term investments, including restricted cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">310,788</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">346,504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">521,352</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">339,339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129,128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Working capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">193,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">324,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">436,539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">471,376</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">274,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Long-term debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">231,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,381,404</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,250,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,108,934</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,104,252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,003,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lexicon Pharmaceuticals, Inc. stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">157,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">285,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">170,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;38</font></div></div><hr style="page-break-after:always"><div><a name="s903E8CECB323152D5491BC7754AA9DB3"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis should be read with &#8220;Selected Financial Data&#8221; and our financial statements and notes included elsewhere in this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company focused on the development and commercialization of breakthrough treatments for human disease.&#160;&#160;We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have obtained approval from the FDA to sell our first commercial product, XERMELO (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy.  We have commenced sales and marketing of XERMELO, and it is now commercially available to patients in the United States.  We have granted Ipsen an exclusive, royalty-bearing right to commercialize XERMELO outside of the United States and Japan, and Ipsen has obtained approval from the European Commission to market XERMELO in the member states of the European Union, Norway and Iceland.  Ipsen has commenced sales and marketing of XERMELO, and it is commercially available to patients in the United Kingdom, Germany and certain other European Union member states.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 and type&#160;2 diabetes.  We have reported positive top-line data from two pivotal Phase 3 clinical trials and a third Phase 3 clinical trial of sotagliflozin in type 1 diabetes patients.  We have granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right to develop, manufacture and commercialize sotagliflozin.  We and Sanofi are presently preparing applications for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and the European Union, and Sanofi is presently conducting Phase 3 development of sotagliflozin in type 2 diabetes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing LX2761, an orally-delivered small molecule drug candidate, as a treatment for diabetes.  We are presently conducting Phase 1 clinical development of LX2761.  We have granted Sanofi certain rights of first negotiation with respect to the future development and commercialization of LX2761.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We are presently conducting Phase 1 clinical development of LX9211.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies, such as Ipsen and Sanofi, with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States, commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commercially launched XERMELO following regulatory approval in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy in the United States.  Prior to the launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  To date, we have generated a substantial portion of our revenues from a limited number of sources.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; our and Sanofi&#8217;s ability to obtain regulatory approval for the marketing and sale of sotagliflozin for type 1 diabetes; the amount and timing of payments, if any, under our existing collaboration agreements with Sanofi, Ipsen and other entities; the success of our ongoing preclinical and clinical development efforts and ability to obtain necessary regulatory approvals; our success in establishing new collaborations and licenses; the timing and willingness of such new collaborators to commercialize products that would result in milestone payments and royalties and their success in such efforts; and general and industry-specific economic conditions which may affect research and development expenditures.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future revenues from our commercialization of XERMELO are uncertain because they depend on a number of factors, including market acceptance of XERMELO, the success of our sales, marketing, medical affairs, distribution and other commercialization activities and the cost and availability of reimbursement for XERMELO.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any future products developed under the collaborations.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, including XERMELO in the United States and Japan, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have incurred significant losses and, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.4 billion</font><font style="font-family:inherit;font-size:10pt;">. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock granted to employees and consultants.&#160;&#160;Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.&#160;&#160;We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates.  As a result, we will need to generate significantly higher revenues to achieve profitability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized once we meet all four revenue recognition criteria described above.  In March 2017, we began shipping XERMELO to our customers in the United States.  We recognize revenue for product sales of XERMELO at the time product is received by our specialty pharmacy customers, net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States.  Product shipping and handling costs are included in cost of sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer Credits:  Our specialty pharmacy customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  We expect that the specialty pharmacies will earn prompt payment discounts.  As a result, we deduct the full amount of those discounts from total product sales when revenues are recognized. Service fees are also deducted from product sales as they are earned.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  Our estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy.  Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacies, in turn, charge back us the difference between the price initially paid by the specialty pharmacies and the discounted price paid to the specialty pharmacies by the customer.  The allowance for chargebacks is based on known sales to contracted customers.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  Our estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  We identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting.  We account for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within our control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, we allocate the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration payable to us is commensurate with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone relates solely to our past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone is reasonable relative to all of the other deliverables and payments within the arrangement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial milestones will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Subscription and license fees are recognized as other revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in our revenue recognition policy or changes in the terms of contracts under which we recognize revenues could have an impact on the amount and timing of our recognition of revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs incurred for research and development activities solely sponsored by us as well as collaborative research and development activities.&#160;&#160;These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XERMELO, an orally-delivered small molecule drug approved by the FDA for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sotagliflozin, an orally-delivered small molecule drug candidate that we are developing as a treatment for type&#160;1 and type&#160;2 diabetes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LX2761, an orally-delivered small molecule drug candidate, that we are developing as a treatment for diabetes; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LX9211, an orally-delivered small molecule drug candidate, that we are developing as a treatment for neuropathic pain.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The drug development process takes many years to complete.&#160;&#160;The cost and length of time varies due to many factors including the type, complexity and intended use of the drug candidate.&#160;&#160;We estimate that drug development activities are typically completed over the following periods:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:62%;"></td><td style="width:4%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Phase</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Completion Period</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical development</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-2 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 1 clinical trials</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-2 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 clinical trials</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-2 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 clinical trials</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2-4 years</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect research and development costs to remain substantial in the future as we continue to fund our share of type 2 diabetes development expenses for sotagliflozin and our clinical trials of XERMELO, LX2761 and LX9211 and advance new drug candidates into clinical development.&#160;&#160;Due to the variability in the length of time necessary for drug development, the uncertainties related to the cost of these activities and ultimate ability to obtain governmental approval for commercialization, accurate and meaningful estimates of the ultimate costs to bring our potential drug candidates to market are not available. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record significant accrued liabilities related to unbilled expenses for products or services that we have received from service providers, specifically related to ongoing nonclinical studies and clinical trials.&#160;&#160;These costs primarily relate to clinical study management, monitoring, laboratory and analysis costs, drug supplies, toxicology studies and investigator grants.&#160;&#160;We have multiple drugs in concurrent nonclinical studies and clinical trials at clinical sites throughout the world.&#160;&#160;In order to ensure that we have adequately provided for ongoing nonclinical and clinical development costs during the period in which we incur such costs, we maintain accruals to cover these expenses.&#160;&#160;Substantial portions of our nonclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For nonclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the vendors and clinical site visits.  Our estimates depend on the timeliness and accuracy of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data provided by our vendors regarding the status of each program and total program spending.  We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&#160;&#160;Although we use consistent milestones or subject or patient enrollment to drive expense recognition, the assessment of these costs is a subjective process that requires judgment.&#160;&#160;Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record our research and development costs by type or category, rather than by project.&#160;&#160;Significant categories of costs include personnel, facilities and equipment costs and third-party and other services.&#160;&#160;In addition, a significant portion of our research and development expenses is not tracked by project as it benefits multiple projects. Consequently, fully-loaded research and development cost summaries by project are not available.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense in our statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;We had stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.09</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average vesting period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes option-pricing model.&#160;&#160;For purposes of determining the fair value of stock options, we segregate our options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in our stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long-lived assets include property, plant and equipment, intangible assets and goodwill.  We regularly review long-lived assets for impairment.  The recoverability of long-lived assets, other than goodwill, is measured by comparing the assets carrying amount to the expected undiscounted future cash flows that the asset is expected to generate.  Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount, and the asset's residual value, if any.  We use internal cash flow estimates, quoted market prices when available and independent appraisals as appropriate to determine fair value.  We derive the required cash flow estimates from our historical experience and our internal business plans and apply an appropriate discount rate.  During 2015, we determined that our buildings were impaired and therefore recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in impairment loss on buildings in the accompanying consolidated statements of comprehensive loss.  There were no significant impairments of long-lived assets in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets, composed primarily of in-process research and development, or IPR&amp;D, projects acquired in business combinations which have not reached technological feasibility, are reviewed annually for impairment and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.  Estimating future cash flows of an IPR&amp;D product candidate for purposes of an impairment analysis requires us to make significant estimates and assumptions regarding the amount and timing of costs to complete the project and the amount, timing and probability of achieving revenues from the completed product similar to how the acquisition date fair value of the project was determined.    </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;We have determined that the reporting unit is the single operating segment disclosed in our current financial statements.&#160;&#160;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;We determined that the market capitalization approach is the most appropriate method of measuring fair value of the reporting unit.&#160;&#160;Under this approach, fair value is calculated as the average closing price of our common stock for the 30 days preceding the date that the annual impairment test is performed, multiplied by the number of outstanding shares on that date.&#160;&#160;A control premium, which is representative of premiums paid in the marketplace to acquire a controlling interest in a company, is then added to the market capitalization to determine the fair value of the reporting unit.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if we encounter events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date.  The purchase price allocation process requires management to make significant estimates and assumptions, especially at acquisition date with respect to intangible assets and in-process research and development.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These assumptions are based in part on historical experience and are inherently uncertain.  Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to: the feasibility and timing of achievement of development, regulatory and commercial milestones; expected costs to develop the in-process research and development into commercially viable products; and future expected cash flows from product sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the purchase price allocations for acquisitions, we estimate the fair value of the contingent payments.  The estimated fair value of any contingent payments is determined utilizing a probability-based income approach inclusive of an estimated discount rate.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 3, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of new accounting standards on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations &#8211; Comparison of Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar increase&#160;(decrease)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage increase (decrease)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net product revenues </font><font style="font-family:inherit;font-size:10pt;">&#8211; Net product revenue was </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, representing revenues recognized from the sale of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.  Revenue recognition policies require estimates of the aforementioned sales allowances each period.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative agreements </font><font style="font-family:inherit;font-size:10pt;">&#8211; Revenue from collaborative agreements decreased </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$74.3 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to a decrease in revenues recognized from the collaboration and license agreement with Sanofi, partially offset by increases in milestone revenues recognized in 2017 from the license and collaboration agreement with Ipsen.  Revenues under the Sanofi agreement in 2017 and 2016 were primarily attributable to the development activities we performed relating to type 1 diabetes, together with funding of our share of type 2 diabetes development expenses. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties and other revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenues from royalties and other revenue increased 15% in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to $0.2 million.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">2015</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative agreements </font><font style="font-family:inherit;font-size:10pt;">&#8211; Revenue from collaborative agreements decreased 36% in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$83.2 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to a decrease in revenues recognized from the collaboration and license agreement with Sanofi.  Revenues under the Sanofi agreement in 2016 were primarily attributable to the development activities we performed relating to type 1 diabetes, together with funding of our share of type 2 diabetes development expenses.  Revenues under the Sanofi agreement in 2015 were primarily attributable to the license portion of the upfront payment made by Sanofi in connection with the agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties and other revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenues from royalties and other revenue decreased 46% in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to $0.2 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Sanofi</font><font style="font-family:inherit;font-size:10pt;">&#32;and Ipsen represented </font><font style="font-family:inherit;font-size:10pt;">64%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">Sanofi</font><font style="font-family:inherit;font-size:10pt;">&#32;and Ipsen represented </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Ipsen represented </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Sales</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales for </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">.  We began capitalizing inventory in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;following FDA approval of XERMELO, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to FDA approval were recorded as research and development expenses in the consolidated statements of comprehensive loss.  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The pre-commercialized inventory is expected to be sold over approximately the next two years.  As a result, cost of sales will reflect a lower average per unit cost of materials.  Cost of sales in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;includes </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of amortization of intangible assets related to XERMELO.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar increase (decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage increase (decrease)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs and stock-based compensation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Third-party and other services &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Third-party and other services </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">17%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$121.0 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to decreases in our external clinical development costs relating to sotagliflozin.  Third-party and other services </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.&#160;</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Personnel costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$22.2 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in personnel.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Stock-based compensation expense </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Facilities and equipment costs </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Third-party and other services &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Third-party and other services </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$146.5 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in our external clinical development costs relating to sotagliflozin.  Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Personnel costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">27%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$18.8 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in personnel, including increases in medical affairs personnel, in preparation for commercialization of XERMELO.  </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Stock-based compensation expense </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Facilities and equipment costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in travel and sponsorships.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Increase (Decrease) in Fair Value of Symphony Icon Liability</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Symphony Icon purchase liability increased by </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;by $0.7 million in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively (see Note 10, Arrangements with Symphony Icon, Inc., of the Notes to Consolidated Financial Statements, for more information). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total selling, general and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar increase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage increase</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses consist primarily of personnel costs to support the commercialization of XERMELO and our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Personnel costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">86%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$30.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in personnel, including increases in sales and marketing personnel, in connection with commercialization of XERMELO.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional and consulting fees</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Professional and consulting fees </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">13%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in legal and patent fees, as well as marketing and consulting costs in connection with commercialization of XERMELO.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Stock-based compensation expense </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to awards granted to sales and marketing personnel.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Facilities and equipment costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">28%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">161%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in travel and contributions to charitable foundations.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional and consulting fees</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Professional and consulting fees </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">149%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$18.5 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increased consulting costs in preparation for commercialization of XERMELO.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Personnel costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">58%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in personnel, including increases in sales and marketing personnel, in preparation for commercialization of XERMELO. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Stock-based compensation expense </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Facilities and equipment costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">59%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in depreciation expense and property taxes. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">65%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to travel and training expenses.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment Loss on Buildings</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized an impairment loss on our buildings of </font><font style="font-family:inherit;font-size:10pt;">$3.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, as a result of writing down the buildings to the estimated net selling price.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense and Interest and Other Income (Expense), Net</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Interest expense </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, due to a new loan agreement completed in December 2017.  Interest expense </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest and Other Income (Expense), Net.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Interest and other income, net was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Tax Benefit</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax benefit for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(see Note 7, Income Taxes of the Notes to Consolidated Financial Statements, for more information).  There was no income tax expense or benefit in 2016 or 2015.  </font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Net Loss and Consolidated Net Loss&#160;per Common Share</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$129.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$141.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Net loss per common share was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.23</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.36</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.05</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements.&#160;&#160;We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc.&#160;&#160;From our inception through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had received net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.4 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;from issuances of common and preferred stock and convertible debt.&#160;&#160;In December 2017, we received $145.9 million in net proceeds from the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">first tranche of a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP, as discussed below.  In addition, from our inception through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we received </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$828.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash payments from strategic and other collaborations, target validation, database subscription and technology license agreements, sales of compound libraries and reagents, product sales, and government grants and contracts, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$771.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;had been recognized as revenues through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$310.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and short-term investments. &#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$346.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and short-term investments.&#160;&#160;We used cash of </font><font style="font-family:inherit;font-size:10pt;">$185.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in operations in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. This consisted primarily of the consolidated net loss for the year of </font><font style="font-family:inherit;font-size:10pt;">$129.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a net decrease in other operating liabilities net of assets of </font><font style="font-family:inherit;font-size:10pt;">$59.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the deferred tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">, partially offset by non-cash charges of </font><font style="font-family:inherit;font-size:10pt;">$9.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to stock-based compensation expense, </font><font style="font-family:inherit;font-size:10pt;">$3.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to depreciation and amortization expense and </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the increase in fair value of the Symphony Icon purchase liability.&#160;&#160;Investing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;">$50.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, primarily due to net maturities of investments of </font><font style="font-family:inherit;font-size:10pt;">$50.8&#160;million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Financing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;">$149.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$145.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from a new loan agreement completed in December 2017 and </font><font style="font-family:inherit;font-size:10pt;">$8.0&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;from issuance of common stock, partially offset by repayment of debt borrowings of $2.3 million and repurchases of common stock of $1.7 million.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Symphony Drug Development Financing Agreements.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In June 2007, we entered into a series of related agreements providing for the financing of the clinical development of certain drug programs, including XERMELO, along with any other pharmaceutical compositions modulating the same targets as those drug candidates.&#160;&#160;Under the financing arrangement, we licensed to Symphony Icon, Inc., a then wholly-owned subsidiary of Symphony Icon Holdings LLC, our intellectual property rights related to the programs and Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the programs.&#160;&#160;We also issued and sold to Holdings shares of our common stock in exchange for $15&#160;million and received an exclusive option to acquire all of the equity of Symphony Icon, thereby allowing us to reacquire the programs.&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the recommendation of Symphony Icon&#8217;s development committee, which was comprised of an equal number of representatives from us and Symphony Icon, Symphony Icon&#8217;s board of directors had the right to require us to pay Symphony Icon up to $15 million for Symphony Icon&#8217;s use in the development of the programs in accordance with a specified development plan and related development budget.&#160;&#160;Symphony Icon&#8217;s board of directors requested that we pay Symphony Icon $9.3&#160;million under the agreement, all of which was paid prior to the exercise of the purchase option in July 2010.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2010, we entered into an amended and restated purchase option agreement with Symphony Icon and Holdings and simultaneously exercised our purchase option. Pursuant to the amended terms of the purchase option, we paid Holdings $10&#160;million in July 2010 and issued 1,891,074 shares of common stock to designees of Holdings in July 2012 in satisfaction of an additional $35 million base payment obligation.  We also agreed to make up to $45 million in additional contingent payments upon the occurrence of certain specified events.  In December 2014, we paid </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and issued </font><font style="font-family:inherit;font-size:10pt;">666,111</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings in satisfaction of a </font><font style="font-family:inherit;font-size:10pt;">$11.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;contingent payment obligation as a result of receiving an upfront payment pursuant to our license and collaboration agreement with Ipsen.  In April 2015, we paid $0.75 million in cash to Holdings in satisfaction of our contingent payment obligation as a result of receiving an additional upfront payment from Ipsen in March 2015.  In September 2016, we paid $3.2 million in cash to Holdings in satisfaction of our contingent payment obligation as a result of receiving a milestone payment from Ipsen in August 2016 (see Note 15, Collaboration and License Agreements, of the Notes to Consolidated Financial Statements, for more information).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, we entered into an amendment to the amended and restated purchase option agreement pursuant to which we agreed to pay Holdings $21.0 million upon our receipt of regulatory approval in the United States for the marketing and sale of XERMELO, such buyout amount to be in lieu of any remaining payments due to Holdings under the amended and restated purchase option agreement. In March 2017, we paid $10.5 million in cash and issued 659,905 shares of common stock to designees of Holdings in satisfaction of our remaining contingent payment obligation as a result of receiving regulatory approval in the United States for the marketing and sale of XERMELO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loan Agreement. </font><font style="font-family:inherit;font-size:10pt;">In December 2017, we entered into a loan agreement that provides up to $200.0 million in borrowing capacity available in two tranches, each maturing in December 2022 and bearing interest at 9.0% per year.  The first $150.0 million tranche was funded in December 2017 and we plan to use the net proceeds of $145.9 million to fund working capital and other general corporate purposes.  The second $50.0 million tranche is available for draw at our discretion by March 2019 if net sales of XERMELO are greater than $25 million in the preceding quarter. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Texas Institute for Genomic Medicine.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In July 2005, we received an award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine, or TIGM, using our proprietary gene trapping technology, which we completed in 2007.&#160;&#160;We also equipped TIGM </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">with the bioinformatics software required for the management and analysis of data relating to the library.&#160;&#160;The Texas Enterprise Fund made an additional award to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of our award, we are responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of 1,616 new jobs in Texas by December 31, 2016.  We will receive credits against those job obligations based on funding received by TIGM and certain related parties from sources other than the State of Texas.&#160;&#160;We will also receive credits against those job obligations for any surplus jobs we create.  Subject to these credits, the State may require us to repay $2,415 for each job we fall short beginning in 2013.&#160;&#160;Our maximum aggregate exposure for such payments, if we fail to create any new jobs, is approximately $14.2&#160;million, without giving effect to any credits to which we may be entitled. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In April 2004, we obtained a $34.0 million mortgage on our facilities in The Woodlands, Texas.&#160;&#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of 8.23%.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  In April 2017, the mortgage was amended to extend the maturity date to April 2018, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance outstanding of </font><font style="font-family:inherit;font-size:10pt;">$14.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The entire principal balance is recorded as current portion of long-term debt in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as there is a balloon payment due in April 2018.  We intend to refinance the mortgage prior to the balloon payment becoming due. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Including the lease and debt obligations described above, we had incurred the following contractual obligations as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments due by period (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2-3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4-5 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">251.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">237.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest payment obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">341.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">269.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future capital requirements will be substantial and will depend on many factors, including the success of our sales, marketing, distribution and other commercialization activities for XERMELO in the United States and the revenues we generate from that approved product; the success of Ipsen&#8217;s sales, marketing, distribution and other commercialization activities for XERMELO outside of the United States and Japan; our and Sanofi&#8217;s ability to obtain regulatory approval for the marketing and sale of sotagliflozin for type 1 diabetes; if approved, our and Sanofi&#8217;s ability to successfully commercialize sotagliflozin for type 1 diabetes in the United States and Sanofi&#8217;s ability to successfully commercialize sotagliflozin for type 1 diabetes outside of the United States and Japan; the progress and scope of Sanofi&#8217;s development activities with respect to sotagliflozin in type 2 diabetes patients; the timing, progress and results of clinical trials of XERMELO, LX2761 and LX9211; the amount and timing of payments, if any, under our existing collaboration agreements with Sanofi, Ipsen and other entities; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to devote substantial capital resources to commercialize XERMELO; to seek regulatory approval and prepare for commercialization in the United States for sotagliflozin in type 1 diabetes; to our clinical development efforts with respect to XERMELO, LX2761 and LX9211; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure about Market Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase.&#160;&#160;We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk.&#160;&#160;We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$310.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and cash equivalents and short-term investments as of&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which included $145.9 million in net proceeds from Tranche A borrowings.&#160; We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div><div><a name="s952BFC93499CF85F0E5CBC7765E14D46"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 7. Management&#8217;s Discussion and Analysis</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s4C03D45C6C2C54F0E5ABBC776620457E"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statements and Supplementary Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements required by this Item are incorporated under Item 15 in Part IV of this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s931CD457D87C0C954DB5BC77663F8B0C"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s619ABF8068254A9C2F30BC77666E38FC"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9A.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to our evaluation, there were no significant changes in internal controls or other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control-Integrated Framework </font><font style="font-family:inherit;font-size:10pt;">(2013 Framework)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on such assessment using those criteria, management believes that, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our internal control over financial reporting is effective.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our independent auditors have also audited our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as stated in the audit report which appears on page F-2 and is incorporated under Item&#160;15 in Part&#160;IV of this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;50</font></div></div><hr style="page-break-after:always"><div><a name="s281A258F01049BEB9070BC77668DD963"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B.&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Information</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;51</font></div></div><hr style="page-break-after:always"><div><a name="sF004B82A1B94810F829FBC7766BCB0F1"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s0335E9E6F99DFD660296BC7766DBAF1F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10.&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from (a) the information appearing under the captions &#8220;Election of Directors,&#8221; &#8220;Stock Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and (b)&#160;the information appearing under Item&#160;1 in Part&#160;I</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s31BD471ED8FB17AFB182BC77671ABB5B"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Executive Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding the foregoing, in accordance with the instructions to Item 407(e)(5) of Regulation S-K, the information contained in our proxy statement under the sub-heading &#8220;Compensation Committee Report&#8221; shall not be deemed to be filed as part of or incorporated by reference into this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s3419C2BC887F532DF0E9BC776739CC2B"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Stock Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sCA1AA3E5557E34555EAFBC7767683FA3"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Transactions with Related Persons&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s2234C406CCCF6653E193BC776787721D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14.&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principal Accounting Fees and Services</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item as to the fees we pay our principal accountant is hereby incorporated by reference from the information appearing under the caption &#8220;Ratification and Approval of Independent Auditors&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;52</font></div></div><hr style="page-break-after:always"><div><a name="s54D6AB42810EE828F9DEBC7767B6ED78"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7E9A3A78BBB7B5EA4FA3BC7767D5E1F2"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exhibits and Financial Statement Schedules</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Documents filed as a part of this report:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:636px;"></td><td style="width:46px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s092758A916B3B3DD9944BC776881789B"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s092758A916B3B3DD9944BC776881789B"><font style="font-family:inherit;font-size:10pt;">F-1</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA84367A864E6146EB9D8BC7752680A52"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA84367A864E6146EB9D8BC7752680A52"><font style="font-family:inherit;font-size:10pt;">F-2</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37A44D38B47E738AB316BC7751BC4510"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37A44D38B47E738AB316BC7751BC4510"><font style="font-family:inherit;font-size:10pt;">F-3</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA014A0B9E6479DC6E25EBC77523999F1"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA014A0B9E6479DC6E25EBC77523999F1"><font style="font-family:inherit;font-size:10pt;">F-4</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE306B46257A3740468FBC7752396507"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE306B46257A3740468FBC7752396507"><font style="font-family:inherit;font-size:10pt;">F-5</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4E61DBD6B923766C4DB2BC77520AA1B0"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4E61DBD6B923766C4DB2BC77520AA1B0"><font style="font-family:inherit;font-size:10pt;">F-6</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB183059AAC856DBB4826BC7769C9DC5D"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB183059AAC856DBB4826BC7769C9DC5D"><font style="font-family:inherit;font-size:10pt;">F-7</font></a></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other financial statement schedules are omitted because they are not applicable or not required, or because the required information is included in the financial statements or notes thereto.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000016/exh31amendedandrestatedcer.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Certificate of Incorporation</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000027/exh31-01.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Amendment to Amended and Restated Certificate of Incorporation</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form&#160;8-K dated May 20, 2015 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000016/exh32secondamendedandresta.htm"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Bylaws </font></a><font style="font-family:inherit;font-size:10pt;">(filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form&#160;8&#8209;K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w1.htm"><font style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000118/exh10_1.htm"><font style="font-family:inherit;font-size:10pt;">Amendment</font></a><font style="font-family:inherit;font-size:10pt;">, dated October 7, 2009, to Securities Purchase Agreement, dated June&#160;17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated October 7, 2009 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w3.htm"><font style="font-family:inherit;font-size:10pt;">Registration Rights Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w4.htm"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012310024973/h70210exv10w1.htm"><font style="font-family:inherit;font-size:10pt;">Supplement to Transaction Agreements</font></a><font style="font-family:inherit;font-size:10pt;">, dated March 15, 2010, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated March 15, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000005/exhibit101.htm"><font style="font-family:inherit;font-size:10pt;">Supplement No. 2 to Transaction Agreements</font></a><font style="font-family:inherit;font-size:10pt;">, dated February 23, 2012, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated February 23, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000119312514428223/d825616dex41.htm"><font style="font-family:inherit;font-size:10pt;">Indenture</font></a><font style="font-family:inherit;font-size:10pt;">&#160;related to the 5.25% Convertible Senior Notes due 2021, dated as of November&#160;26, 2014, with Wells Fargo Bank, N.A. (filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K dated November 26, 2014 and incorporated by reference herein).</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000119312514428223/d825616dex41.htm"><font style="font-family:inherit;font-size:10pt;">Form of 5.25% Convertible Senior Notes due 2021</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit A to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K dated November 26, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282214000026/exh103offerletter.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter</font></a><font style="font-family:inherit;font-size:10pt;">, dated July 1, 2014, with Lonnel Coats (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated July 7, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000010/exh105-xlapuertaofferletter.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter</font></a><font style="font-family:inherit;font-size:10pt;">, dated March 10, 2011, with Pablo Lapuerta, M.D. (filed as Exhibit 10.5 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2011 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000013/exh104tyleofferletter.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter</font></a><font style="font-family:inherit;font-size:10pt;">, dated March 23, 2016, with Praveen Tyle, Ph.D. (filed as Exhibit 10.4 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2016 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Jeffrey L. Wade, J.D.</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282210000053/exh10_1.htm"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement</font></a><font style="font-family:inherit;font-size:10pt;">&#160;with Alan S. Nies, M.D. dated February 19, 2003, as amended (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September&#160;30, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012903002588/h05669exv10w1.txt"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement</font></a><font style="font-family:inherit;font-size:10pt;">&#160;with Robert J. Lefkowitz, M.D. dated March 31, 2003 (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2003 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement with Officers and Directors</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000028/exhibit103-summaryofnonxem.htm"><font style="font-family:inherit;font-size:10pt;">Summary of Non-Employee Director Compensation</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated April 27, 2017 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000028/exhibit101-2017equityincen.htm"><font style="font-family:inherit;font-size:10pt;">2017 Equity Incentive Plan</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 27, 2017 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000028/exhibit102-2017nonxemploye.htm"><font style="font-family:inherit;font-size:10pt;">2017 Non-Employee Directors&#8217; Equity Incentive Plan</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K dated April 27, 2017 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*10.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh1011officerstockoptiona.htm"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement with Officers</font></a><font style="font-family:inherit;font-size:10pt;">&#160;under the 2017 Equity Incentive Plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*10.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh1012officerrestrictedst.htm"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Unit Agreement with Officers</font></a><font style="font-family:inherit;font-size:10pt;">&#160;under the 2017 Equity Incentive Plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*10.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh1013stockoptionnoticeto.htm"><font style="font-family:inherit;font-size:10pt;">Form of Notice of Stock Option Grant to Directors</font></a><font style="font-family:inherit;font-size:10pt;">&#160;under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282216000068/exh1014collaborationandlic.htm"><font style="font-family:inherit;font-size:10pt;">Collaboration and License Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated November 5, 2015, with Sanofi (filed as Exhibit 10.14 to the Company&#8217;s Annual Report on Form 10-K/A for the period ended December 31, 2015 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000054/exhibit101-amendment1tolic.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1</font></a><font style="font-family:inherit;font-size:10pt;">, dated July 1, 2017, to Collaboration and License Agreement, dated November 5, 2015, with Sanofi (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2017 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282214000066/exh101licenseandcollaborat.htm"><font style="font-family:inherit;font-size:10pt;">License and Collaboration Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated October 21, 2014, with Ipsen Pharma SAS (filed as Exhibit 10.1 to the amendment to the Company&#8217;s Quarterly Report on Form 10-Q/A for the period ended September 30, 2014, as filed on December 23, 2014, and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh101ipsenagreement.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment</font></a><font style="font-family:inherit;font-size:10pt;">, dated March 17, 2015, to License and Collaboration Agreement, dated October 21, 2014, with Ipsen Pharma SAS (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh102bmsagreement.htm"><font style="font-family:inherit;font-size:10pt;">Collaboration and License Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:3%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh103bmsagreeementamendme.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment</font></a><font style="font-family:inherit;font-size:10pt;">, dated May 30, 2006, to Collaboration and License Agreement, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.20</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282216000081/secondamendmenttocollabora.htm"><font style="font-family:inherit;font-size:10pt;">Second Amendment,</font></a><font style="font-family:inherit;font-size:10pt;">&#160;dated November 2, 2016, to Collaboration and License Agreement, dated December 17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated November 2, 2016 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.21</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012906002238/h33572exv10w22.txt"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Collaboration and License Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.22 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2005 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.22</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000109/exh10_1.htm"><font style="font-family:inherit;font-size:10pt;">Amendment</font></a><font style="font-family:inherit;font-size:10pt;">, dated June 8, 2009, to Second Amended and Restated Collaboration and License Agreement, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A dated June 8, 2009 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.23</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000045/exh101commercialsupplyagr.htm"><font style="font-family:inherit;font-size:10pt;">Commercial Supply Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated June 6, 2016, with Catalent CTS, LLC (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q/A for the period ended March 31, 2017 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012905010385/h29775exv10w1.txt"><font style="font-family:inherit;font-size:10pt;">Economic Development Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated July 15, 2005, with the State of Texas and the Texas A&amp;M University System (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2005 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282208000050/exh10_1.htm"><font style="font-family:inherit;font-size:10pt;">Amendment</font></a><font style="font-family:inherit;font-size:10pt;">, dated April 30, 2008, to Economic Development Agreement, dated July 15, 2005, with the State of Texas and the Texas A&amp;M University System (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 30, 2008 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;*10.26</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh1026loanandsecurityagre.htm"><font style="font-family:inherit;font-size:10pt;">Loan and Security Agreement, dated April 21, 2004, between Lex-Gen Woodlands, L.P. and iStar Financial Inc., as amended.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.27</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000056/loanagrredacted12-04x2017.htm"><font style="font-family:inherit;font-size:10pt;">Loan Agreement</font></a><font style="font-family:inherit;font-size:10pt;">, dated December 4, 2017, with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated December 4, 2017 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282211000021/exh211subsidiaries.htm"><font style="font-family:inherit;font-size:10pt;">Subsidiaries </font></a><font style="font-family:inherit;font-size:10pt;">(filed as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*23.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh231ernst_youngconsent10.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*24.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3773E35BF04A8825801BC7768338244"><font style="font-family:inherit;font-size:10pt;">Power of Attorney</font></a><font style="font-family:inherit;font-size:10pt;">&#160;(contained in signature page).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*31.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh311certificationofprinc.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*31.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh312certificationofprinc.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*32.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exh321certificationofprinc.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.INS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.SCH</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.CAL</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.DEF</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.LAB</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.PRE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_____________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been requested for a portion of this exhibit.&#160;&#160;The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8763D1ECB5E0CEC00A8FBC776814215D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 16.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Form 10-K Summary</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;55</font></div></div><hr style="page-break-after:always"><div><a name="sF3773E35BF04A8825801BC7768338244"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signatures</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:6%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">LONNEL COATS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">JEFFREY L. WADE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Power of Attorney</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lonnel Coats and Jeffrey L. Wade, or either of them, each with the power of substitution, his or her attorney-in-fact, to sign any amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, here ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:3%;"></td><td style="width:39%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ LONNEL COATS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">President, Chief Executive Officer and Director</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Lonnel Coats</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ JEFFREY L. WADE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer (Principal Financial Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Jeffrey L. Wade</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ JAMES F. TESSMER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Vice President, Finance and Accounting</font></div><div style="font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(Principal Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">James F. Tessmer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ RAYMOND DEBBANE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Raymond Debbane</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ PHILIPPE J. AMOUYAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Philippe J. Amouyal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ SAMUEL L. BARKER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Samuel L. Barker, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ ROBERT J. LEFKOWITZ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Robert J. Lefkowitz, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ ALAN S. NIES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Alan S. Nies, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ FRANK P. PALANTONI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Frank P. Palantoni</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ CHRISTOPHER J. SOBECKI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Christopher J. Sobecki</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">/s/ JUDITH L. SWAIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">March&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Judith L. Swain, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;56</font></div></div><hr style="page-break-after:always"><div><a name="s55D9E79E660D5AEAE329BC77686244B9"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s092758A916B3B3DD9944BC776881789B"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Lexicon Pharmaceuticals, Inc. as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the related consolidated statements of comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and the consolidated results of its operations and its cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Opinion</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 2002.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Houston, Texas</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="sA84367A864E6146EB9D8BC7752680A52"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited Lexicon Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Lexicon Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on the COSO criteria. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the accompanying consolidated balance sheets of Lexicon Pharmaceuticals, Inc. as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the related consolidated statements of comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;financial statements&#8221;) of the Company and our report dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Houston, Texas</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s37A44D38B47E738AB316BC7751BC4510"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except par value)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable, net of allowances of $4</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357,874</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment, net of accumulated depreciation and amortization of $58,623 and $59,875, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436,539</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,625</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, net of deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,094</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">318,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Common stock, $.001 par value; 225,000 shares authorized; 105,711 and 104,582 shares issued, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,435,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,411,222</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,381,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,250,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, at cost, 122 and 306 shares, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,102</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,401</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436,539</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,625</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="sA014A0B9E6479DC6E25EBC77523999F1"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except per share amounts)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties and other revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales (including finite-lived intangible asset amortization)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development, including stock-based compensation of $4,905, $3,938 and $3,693, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178,151</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Selling, general and administrative, including stock-based compensation of $4,567, $3,514 and $3,150, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,835</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment loss on buildings</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(136,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,984</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,722</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,954</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,711</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,429</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,682</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,429</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.23</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.36</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,237</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="sCE306B46257A3740468FBC7752396507"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:32%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-In</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Par Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">103,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,390,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,104,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">284,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under Equity Incentive Plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(357</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(357</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(156</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(156</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">103,860</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,397,646</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,108,934</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">285,850</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under Equity Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">722</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(141,429</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(141,429</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104,582</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">105</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,411,222</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,250,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,368</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">157,401</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cumulative effect of change in accounting principle</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock to designees of Symphony Icon Holdings LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under Equity Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">469</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,485</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of treasury stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(129,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(129,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">105,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,435,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,381,404</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="s4E61DBD6B923766C4DB2BC77520AA1B0"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,429</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,682</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,056</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(703</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,927</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Gain) loss on disposal of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,661</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Increase) decrease in accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,080</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,948</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Increase) decrease in prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,259</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,373</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Increase) decrease in other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in accounts payable and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in deferred revenue&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185,394</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175,628</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,776</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(228</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(910</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from disposal of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(267,873</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(425,673</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(326,446</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of investments&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">318,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">444,156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,522</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,252</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net of fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from debt borrowings, net of fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of debt borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,933</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,032</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(156,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,723</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,989</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of noncash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued in satisfaction of Symphony Icon payment obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,499</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain(loss) on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="sB183059AAC856DBB4826BC7769C9DC5D"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sEAFFB84F5D9DD132EB3ABC77520A3D9B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, its ability to successfully commercialize XERMELO (telotristat ethyl) and any other products which gain regulatory approval, develop and obtain regulatory approval for its other drug candidates, achieve milestones under its collaboration agreements, establish new collaboration and license agreements, obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF1F89B4D046FCAEBE7E5BC7751ACF465"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation:</font><font style="font-family:inherit;font-size:10pt;">&#32;The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;">&#32;The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash, Cash Equivalents and Short-Term Investments:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory: </font><font style="font-family:inherit;font-size:10pt;">&#32;Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.  The Company began capitalizing inventory during 2017 after the approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO were recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.   Inventory consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:580px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:434px;"></td><td style="width:13px;"></td><td style="width:9px;"></td><td style="width:119px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;In 2017, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">82%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue, respectively.  In 2016, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2015, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue, respectively.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, management believes that the Company has no significant concentrations of credit risk.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information and Significant Customers:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2017, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Sanofi</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">Ipsen Pharma SAS</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;Ipsen&#8221;) represented </font><font style="font-family:inherit;font-size:10pt;">64%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">Sanofi</font><font style="font-family:inherit;font-size:10pt;">&#32;and Ipsen represented </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Sanofi represented </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangible Assets:</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Other intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, intangible assets relating to XERMELO of </font><font style="font-family:inherit;font-size:10pt;">$24.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the FDA.  The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in amortization expense related to this asset, which is recorded as cost of sales in the accompanying consolidated statements of comprehensive loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,247</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment:</font><font style="font-family:inherit;font-size:10pt;">&#32;Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During 2015, the Company determined that its buildings were impaired and therefore recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in impairment loss on buildings in the accompanying consolidated statements of comprehensive loss.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairments of long-lived assets, including finite-lived intangible assets, in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairments of indefinite lived intangible assets in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment of goodwill in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;">&#32;Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Product Revenues</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized once the Company meets all four revenue recognition criteria described above.  In March 2017, Lexicon began shipping XERMELO to its customers in the United States.  The Company recognizes revenue for product sales of XERMELO at the time the product is received by its specialty pharmacy customers, net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States.  Product shipping and handling costs are included in cost of sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer Credits:  The Company&#8217;s specialty pharmacy customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. The Company expects the specialty pharmacies will earn prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from product sales as they are earned.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company&#8217;s estimates for expected utilization of rebates are based in part on third party market research data, and data received from the specialty pharmacies. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarter&#8217;s unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy, in turn, charges back to Lexicon the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on known sales to contracted customers.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. The Company&#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Collaborative Agreements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration payable to the Company is commensurate with the Company&#8217;s performance necessary to achieve the milestone or the increase in value to the collaboration resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone relates solely to the Company&#8217;s past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone is reasonable relative to all of the other deliverables and payments within the arrangement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial milestones will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Subscription and license fees are recognized as other revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Sales: </font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;following approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:49%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016:</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Common Share:</font><font style="font-family:inherit;font-size:10pt;">&#32;Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s863ADBB9901CBF0409EBBC7751CCD462"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221;, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or services.  In August 2015, the FASB issued ASU No. 2015-14, &#8220;Revenue from Contracts with Customers: Deferral of Effective Date&#8221;, which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual periods after December 15, 2017 including interim periods within that reporting period. Early application is permitted only for annual periods beginning after December 15, 2016, including interim periods within that reporting period. In 2016, the FASB issued four additional ASUs related to Topic 606: ASU Nos. 2016-08, 2016-10, 2016-12 and 2016-20.  These ASUs clarify various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations and licensing, and they include other improvements and practical expedients.  Two adoption methods are permitted; retrospectively to all prior reporting periods presented, with certain practical expedients; or the modified retrospective method with the cumulative effect of initially adopting the ASU recognized at the date of initial application.  The Company has elected to adopt this new standard effective January 1, 2018, using the modified retrospective transition method.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company has assessed that ASU 2014-09 will not have a material impact on revenue recognition from product revenue.  The Company&#8217;s only source of product revenue has been sales of XERMELO, which the Company received FDA approval for in February 2017, and subsequently, entered into a limited number of arrangements with specialty pharmacies (&#8220;SPs&#8221;) in the U.S. (collectively, the &#8220;customers&#8221;), under which the Company began shipping to its customers in March 2017.  Under current GAAP, the Company recognizes revenue on its product sales when the customer obtains control of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the product, which occurs upon delivery.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.  Under ASU 2014-09, the Company expects to be able to utilize a process and controls approach consistent with its historical process and based on the nature of its current contracts with customers, does not anticipate a significant amount of variable consideration subject to constraint.  As a result, the Company does not believe that the adoption of this ASU will have a material impact on the timing or amount of revenues recognized related to its contracts with customers for the sale of product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects the accounting for contingent milestone payments to be the most significant change in the accounting for its license and collaboration agreements.  Topic 605 provides guidance specific to the accounting for milestone payments, including the ability to defer the recognition of any milestones until received and, if certain criteria are met, the ability to recognize milestone payments as revenue when received.  Under the Company&#8217;s current accounting policy, Lexicon recognizes contingent or milestone payments as revenue in the period that the payment-triggering event occurs or is achieved.  However, under the new revenue standard, it is possible to recognize contingent or milestone payments before the payment-triggering event is completely achieved, subject to management&#8217;s assessment of the probability of achievement of the milestone and the likelihood of a significant reversal of such milestone revenue at each reporting date.  This assessment may result in recognizing milestone revenue before the milestone event has been achieved. The Company expects to evaluate estimates and timing of milestone achievement and related variable consideration based on the most likely amount method in its application of this ASU to collaborative agreements.  Estimating variable consideration and the related constraint will require the use of significant management judgment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company&#8217;s primary sources of collaboration revenue have been license and collaboration agreements with three separate third-party licensees: Texas Institute for Genomic Medicine (&#8220;TIGM&#8221;), Sanofi and Ipsen.  The Company has performed an evaluation of the expected effect of adoption in its accounting for license and collaboration agreements as discussed further below.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to its contract with TIGM, the Company evaluated the variable consideration related to the remaining milestone in the adoption of this ASU and determined based on the most likely amount method that it was not probable that a significant reversal would occur and therefore, no constraint was required.  As a result, under the modified retrospective method, the Company will record a </font><font style="font-family:inherit;font-size:10pt;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;cumulative-effect adjustment to its accumulated deficit on the date of adoption.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to its collaboration agreements with Sanofi and Ipsen, the Company evaluated the variable consideration relating to future milestone payments and determined, based on the most likely amount method, that the estimated amounts could be considered as part of the transaction price. The Company then evaluated the variable constraint and determined that the variable consideration amounts are constrained, primarily by future events that are not within the control of the Company. The future events primarily related to receipt of positive results from studies, approval from regulatory agencies, and upon achieving sales in certain locations.  As a result, the Company has determined that there is no cumulative adjustment necessary for these agreements on the date of adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption of the ASU will have no significant impact to the provision for income taxes and will have no impact to the net cash provided by or used in operating, investing or financing activities on the Company&#8217;s consolidated statements of cash flows.  Estimated impacts from adoption of this ASU may differ upon the final adoption and implementation in the first quarter of 2018.  As the Company completes its analysis of the accounting for the collaboration agreements under the new revenue standard, management is assessing the required changes to its accounting policies, systems and internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, &#8220;Recognition and Measurement of Financial Assets and Financial Liabilities.&#8221; ASU 2016-01 requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is not permitted. The adoption of this ASU on January 1, 2018 is not expected to have a material impact on Lexicon&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases.&#8221; ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement will also require additional disclosures about the amount, timing and uncertainty of cash flows </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">arising from leases. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. This ASU is required to be adopted using a modified retrospective approach.  Management plans to adopt ASU 2016-02 on January 1, 2019, and anticipates that most of its operating leases will result in the recognition of additional assets and corresponding liabilities on the consolidated balance sheet.  The Company does not expect that the implementation of the ASU will have a material impact on its financial position.  The actual impact will depend on the Company&#8217;s lease portfolio at the time of adoption.  The Company continues to assess all implications of the standard and related financial disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, &#8220;Stock Compensation,&#8221; which is intended to simplify several aspects of the accounting for share-based payment award transactions. The Company adopted this pronouncement effective January 1, 2017.  Upon adoption, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance is applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of deferred tax assets, the recognition of this provision of ASU 2016-09 had no impact to the Company&#8217;s accumulated deficit as of January 1, 2017.  Additionally, the Company recorded an adjustment to accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of making an entity-wide accounting policy election to account for forfeitures of share-based payment awards as they occur instead of estimating the number of awards that are expected to vest.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7D4859C594B556995736BC7751EB925C"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents and Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of cash and cash equivalents and investments held at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,148</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,911</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,699</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,504</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">$7,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in realized losses for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  There were no realized gains or losses for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE215139769F71AE01CA3BC7751DB8B22"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; significant unobservable inputs (including the Company&#8217;s own assumptions in determining the fair value of the Symphony Icon purchase consideration liability)</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,809</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,788</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,093</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,898</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,606</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,504</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s Level&#160;3 liabilities represented the contingent purchase consideration payable to Symphony Icon, and was estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon (&#8220;Symphony Icon&#8221;) purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.  The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,927</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of base payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,815</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s14FEA375C4A21F6BD8F9BC7751ACF6BB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:57%;"></td><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Lives</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">In Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,605</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5-7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7-10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15-40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,265</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,687</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,390</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><a name="s48458B856BC2F3D40670BC7751EBCCC4"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including reducing the U.S. corporate income tax rate from 35 percent to 21 percent beginning in 2018.  At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, Lexicon has not completed the accounting for the tax effects of the 2017 Tax Act; however, an estimate of the effects on the existing deferred tax balances has been made, as further discussed below.     </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Accordingly, Lexicon remeasured certain deferred tax assets and liabilities based on the newly enacted U.S. corporate income tax rate, which resulted in a decrease of </font><font style="font-family:inherit;font-size:10pt;">$171.4 million</font><font style="font-family:inherit;font-size:10pt;">.  Lexicon will continue to make and refine calculations and estimates, which could potentially affect the measurement of the deferred tax balances or give rise to new deferred tax amounts.  Where the Company has not yet been able to make reasonable estimates of the impact of certain elements, the Company has not recorded any amounts related to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">those elements and has continued accounting for them in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the 2017 Tax Act.  Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of Lexicon&#8217;s deferred tax assets (liabilities) at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,561</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,845</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,307</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability related to acquisition of Symphony Icon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,896</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(347,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(468,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,014</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  During 2017, after XERMELO was approved by the FDA, the intangible asset related to XERMELO became finite-lived and as a result </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the related deferred tax liability could be considered as a source of taxable income. Lexicon does not believe it can estimate the reversal of the temporary difference related to the remaining assets acquired with sufficient certainty such that </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the deferred tax liability is not considered as a source of taxable income in assessing the Company&#8217;s need for a valuation allowance in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the 2017 Tax Act.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, Lexicon had both federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$851.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$382.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The federal and state NOL carryforwards will begin to expire in 2018.&#160;&#160;The Company&#8217;s R&amp;D tax credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$46.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;began to expire in 2018.  The orphan drug credit relates to a credit that is calculated as a percentage of expenditures for development of XERMELO, which has received Orphan Drug designation from the FDA.&#160;&#160;Utilization of the NOL, R&amp;D credit and orphan drug credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets, excluding the deferred tax liability relating to the XERMELO finite-lived asset, until an appropriate level of profitability is sustained.&#160;&#160;During the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the valuation allowance decreased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$121.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to the effect of the new U.S. federal corporate tax rate.&#160;&#160;Lexicon recorded income tax benefits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  Of the </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;tax benefits, </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is the release of a valuation allowance as a result of the ability to estimate the reversal of the deferred tax liability related to the intangible associated with XERMELO, as discussed above.  The remaining </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded to remeasure the deferred tax liability associated with the remaining indefinite-lived intangible asset associated with Symphony Icon at the newly enacted U.S. corporate income tax rate.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;income tax benefits in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company did not have any unrecognized tax benefits.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had no accruals for interest or penalties related to income tax matters.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s13C0D995E01D3C4AF03ABC7751EB4D49"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$25.8 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the excess of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 30, 2010, Lexicon exercised its Purchase Option (as defined in Note 10) and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s81AB69F4D918FB7D47F3BC7751BC1550"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Obligations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Notes.</font><font style="font-family:inherit;font-size:10pt;">&#32;In November 2014, Lexicon completed an offering of </font><font style="font-family:inherit;font-size:10pt;">$87.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially </font><font style="font-family:inherit;font-size:10pt;">118.4553</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$8.442</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of the Convertible Notes, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of debt issuance costs, which offsets long-term debt on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the balance of unamortized debt issuance costs was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">, which offsets long-term debt on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Convertible Notes was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$127.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mortgage Loan. </font><font style="font-family:inherit;font-size:10pt;">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;third-party mortgage financing and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash.&#160;&#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.23%</font><font style="font-family:inherit;font-size:10pt;">.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payment amount and fixed interest rate each remaining unchanged.  In April 2017, the mortgage was amended to extend the maturity date to April 2018, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance of </font><font style="font-family:inherit;font-size:10pt;">$14.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#160;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  This entire balance is recorded as current portion of long-term debt in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as there is a balloon payment due in April 2018.  Lexicon intends to refinance this debt prior to paying the balloon payment.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at </font><font style="font-family:inherit;font-size:10pt;">$59.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, before accumulated depreciation, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BioPharma Term Loan.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP that provides up to </font><font style="font-family:inherit;font-size:10pt;">$200 million</font><font style="font-family:inherit;font-size:10pt;">&#32;borrowing capacity (the &#8220;BioPharma Term Loan&#8221;) available in two tranches, each maturing in December 2022.  The BioPharma Term Loan bears interest at </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly.  The first </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;">&#32;tranche was funded in December 2017.  The second </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">&#32;tranche is available for draw by March 2019 at Lexicon&#8217;s option if net XERMELO sales are greater than </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the preceding quarter.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the BioPharma Term Loan, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of debt issuance costs, which offsets long-term debt on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan.  The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes the aggregate scheduled future principal payments of the Company&#8217;s long-term debt as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,094</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,576</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><a name="sD04D1505F9114351B4CEBC7751FABE0C"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arrangements with Symphony Icon, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including XERMELO, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &#8220;Programs&#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&#8220;Holdings&#8221;), the Company&#8217;s intellectual property rights related to the Programs. Holdings contributed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Symphony Icon in order to fund the clinical development of the Programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,092,946</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock on June&#160;15, 2007 in exchange for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an exclusive purchase option (the &#8220;Purchase Option&#8221;) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.  On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;">&#32;on July&#160;30, 2010 and issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,891,074</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings on July&#160;30, 2012 in satisfaction of an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35 million</font><font style="font-family:inherit;font-size:10pt;">&#32;base payment obligation.   </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon also agreed to make up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional contingent payments, which would consist of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of any consideration Lexicon received pursuant to any licensing transaction (a &#8220;Licensing Transaction&#8221;) under which Lexicon grants a third party rights to commercialize XERMELO or other pharmaceutical compositions modulating the same target as XERMELO (the &#8220;LG103 Programs&#8221;), subject to certain exceptions. The contingent payments would be due if and when Lexicon received such consideration from a Licensing Transaction. In the event Lexicon received regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon would pay Holdings the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which were attributable to the development of such product, reduced by up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon made any such payment upon United States regulatory approval, Lexicon would have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the payment made as a result of such United States regulatory approval.  The contingent payments were payable in cash or a combination of cash and common stock, in Lexicon&#8217;s discretion, provided that no more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of any contingent payment would be paid in common stock.  In December 2014, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and issued </font><font style="font-family:inherit;font-size:10pt;">666,111</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings in satisfaction of a </font><font style="font-family:inherit;font-size:10pt;">$11.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;contingent payment obligation as a result of receiving an upfront payment pursuant to Lexicon&#8217;s license and collaboration agreement with Ipsen.  In April 2015, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$0.75 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash to Holdings in satisfaction of its contingent payment obligation as a result of receiving an additional upfront payment from Ipsen in March 2015.  In September 2016, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash to Holdings in satisfaction of its contingent payment obligation as a result of receiving a milestone payment from Ipsen in August 2016 (see Note 15, Collaboration and License Agreements).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, Lexicon entered into an amendment (the &#8220;Amendment&#8221;) to the Purchase Option Agreement with Holdings and Symphony Icon pursuant to which Lexicon agreed to pay Holdings </font><font style="font-family:inherit;font-size:10pt;">$21.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon Lexicon&#8217;s receipt of regulatory approval in the United States for the marketing and sale of XERMELO, such buyout amount to be in lieu of any remaining payments which may be or become payable to Holdings under the Purchase Option Agreement. In March 2017, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and issued </font><font style="font-family:inherit;font-size:10pt;">659,905</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings in satisfaction of its remaining contingent payment obligation as a result of receiving regulatory approval in the United states for the marketing and sale of XERMELO. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Key assumptions include: (1)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the base payments; (2)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">18%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the contingent payments; and (3)&#160;a probability adjusted contingency.  No discount rate was used in the valuation of the contingent consideration liability as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as the expected buyout was short-term in nature.  Subsequent changes in the fair value of the Symphony Icon purchase consideration liability were recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss.  The fair value </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC3C244E51CFCC0801505BC7751ACB728"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Lease Obligations</font><font style="font-family:inherit;font-size:10pt;">:&#160;&#160;A Lexicon subsidiary leases office space in Basking Ridge, New Jersey under a lease agreement, the term of which began in June 2015 and terminates in December 2022.  Rent expense is recognized on a straight-line basis over the lease term.&#160;&#160;Additionally, Lexicon leases certain equipment under operating leases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for all operating leases was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The following table includes non-cancelable, escalating future lease payments for the facility in New Jersey:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">614</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Arrangements:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either six or 12 months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF828316131E46173D0E3BC7751AC5676"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Capital Stock Agreements </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse Stock Split</font><font style="font-family:inherit;font-size:10pt;">:  Effective May 20, 2015, Lexicon completed a one-for-seven reverse split of its common stock.  All references to shares of common stock and per-share data for all periods presented in this report have been adjusted to give effect to this reverse stock split. Proportional adjustments were also made to all shares of common stock issuable under Lexicon&#8217;s equity incentive plans and upon conversion of Lexicon&#8217;s Notes. Concurrent with the reverse stock split, the authorized shares of common stock were reduced from </font><font style="font-family:inherit;font-size:10pt;">900 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(prior to the reverse stock split) to </font><font style="font-family:inherit;font-size:10pt;">225 million</font><font style="font-family:inherit;font-size:10pt;">. As no change was made to the par value of the common shares, common stock and additional paid-in capital were adjusted on a retroactive basis to give effect to the reverse stock split. No fractional shares were issued in connection with the reverse stock split. Any fractional share of common stock that would otherwise have resulted from the reverse stock split were converted into cash payments equal to such fraction multiplied by the closing sales price of the common stock as last reported on the last trading day immediately preceding the effective date of the reverse stock split.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><a name="sF44C5154A6016DB2B6BABC7751AC2E55"></a></div><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Incentive Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Plans</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and restated in February 2000, April 2009, April 2012, April 2015 and April 2017 and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock had been reserved for issuance, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4,773,915</font><font style="font-family:inherit;font-size:10pt;">&#32;shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">945,723</font><font style="font-family:inherit;font-size:10pt;">&#32;restricted stock units were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,812,584</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued upon the exercise of stock options, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,118,151</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued pursuant to restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">113,940</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and restated in April 2009, April 2012, April 2015 and April 2017 and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of more than </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;during any calender year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calender year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">600,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">600,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock had been reserved for issuance, stock options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">187,119</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">none</font><font style="font-family:inherit;font-size:10pt;">&#32;had been issued upon the exercise of stock options and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">82,696</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued pursuant to restricted stock awards granted under the Directors&#8217; Plan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Activity:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except exercise price data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,370</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(157</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,961</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,834</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at end of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,077</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,727</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,686</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average estimated grant date fair value of stock options granted during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.59</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.43</font><font style="font-family:inherit;font-size:10pt;">&#32;and&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.58</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The weighted average remaining contractual term of stock options outstanding and exercisable was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#32;years, respectively, as of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of the outstanding stock options and the exercisable stock options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Bonus and Restricted Stock Unit Activity:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Lexicon granted its non-employee directors </font><font style="font-family:inherit;font-size:10pt;">10,248</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">11,456</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">21,360</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, respectively, of restricted stock awards.  The restricted stock awards had weighted average grant date fair values of </font><font style="font-family:inherit;font-size:10pt;">$15.61</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.96</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.49</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively, and vested immediately.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aggregate Shares Reserved for Issuance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,906,757</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6,565,872</font><font style="font-family:inherit;font-size:10pt;">&#32;additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sADB2A4DC8F440D9A94EABC7751EB8901"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Benefit Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,033,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$733,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$332,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after four years of service.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB3F40A69217A4CDD55B6BC7751ACD6EB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sanofi.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Sanofi Agreement, Lexicon has granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.  Subject to specified exceptions, neither party may (a) perform clinical development activities relating to any other compound which inhibits sodium-glucose cotransporters type 1 or type 2 or (b) commercialize any such compounds in the United States, countries of the European Union and certain other specified countries, in each case during the royalty terms applicable in such </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">countries.  Among the specified exceptions is a right Lexicon retained to pursue the development of its LX2761 drug candidate, with respect to which Lexicon granted Sanofi certain rights of first negotiation specified in the Sanofi Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;">.  In addition, Lexicon is eligible to receive from Sanofi (a) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$110 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of four development milestones relating to the results of certain Phase 3 clinical trials of sotagliflozin in type 2 diabetes patients, (b) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$220 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of four regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes, respectively, in each of the United States and Europe, of which two milestones representing the substantial majority of such aggregate amount relate to type 2 diabetes and the remaining two milestones relate to type 1 diabetes, (c) </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of a milestone based on the results of either of two outcomes studies in type 2 diabetes patients, the completion of which would likely occur after initial regulatory approval of sotagliflozin in type 2 diabetes, and (d) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$990 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of six commercial milestones that will be achieved upon reaching specified levels of sales.  The Company believes that each of the development and regulatory milestones under the Sanofi Agreement is substantive.  Due to the uncertainty surrounding the achievement of the future development and regulatory milestones, these payments will not be recognized as revenue unless and until they are earned, as the Company is not able to reasonably predict if and when the milestones will be achieved.  Commercial milestones, which are not encompassed within the definition of milestones under generally accepted accounting principles, will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Lexicon is also entitled to tiered, escalating royalties ranging from low double digit percentages to </font><font style="font-family:inherit;font-size:10pt;">forty</font><font style="font-family:inherit;font-size:10pt;">&#32;percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon will continue to be responsible for all clinical development activities relating to type 1 diabetes and has exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States. Under the terms of its co-promotion option, Lexicon will fund forty percent of the commercialization costs relating to such co-promotion activities. Sanofi will be responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and will be solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States. Lexicon will share in the funding of a portion of the planned type 2 diabetes development costs over the first three years of the collaboration, up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">. Sanofi will book sales worldwide in all indications.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The parties are responsible for using commercially reasonable efforts to perform their development and commercialization obligations pursuant to mutually approved development and commercialization plans.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The parties&#8217; activities under the Sanofi Agreement are governed by a joint steering committee and certain other governance committees which reflect equal or other appropriate representation from both parties. If the applicable governance committee is not able to make a decision by consensus and the parties are not able to resolve the issue through escalation to specified senior executive officers of the parties, then Sanofi will have final decision-making authority, subject to limitations specified in the Sanofi Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Sanofi Agreement will expire upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country is the period commencing on the effective date of the Sanofi Agreement and ending on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity and 10 years following the first commercial sale in the applicable country. Either party may terminate the Sanofi Agreement in the event of an uncured material breach by the other party. Prior to completion of the core development activities for type 2 diabetes specified in the development plan, Sanofi may terminate the Sanofi Agreement on a country-by-country and licensed product-by-licensed product basis, in the event of (a) notification of a material safety issue relating to the licensed product or the class of sodium-glucose cotransporters type 1 or type 2 inhibitors resulting in a recommendation or requirement that Lexicon or Sanofi cease development, (b) failure to achieve positive results with respect to certain clinical trial results, (c) the occurrence of specified fundamental adverse events or (d) the exploitation of the licensed product infringing third party intellectual property rights in specified major markets and Sanofi is unable to obtain a license to such third party intellectual property rights.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considered the following deliverables with respect to the revenue recognition of the </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The exclusive worldwide license granted to Sanofi to develop and commercialize sotagliflozin;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The development services Lexicon is performing for sotagliflozin relating to type 1 diabetes; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The funding Lexicon will provide for development relating to type 2 diabetes.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the license had stand-alone value because it is an exclusive license that gives Sanofi the right to develop and commercialize sotagliflozin or to sublicense its rights.  In addition, sotagliflozin is currently in development and it is possible that Sanofi or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Sanofi Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services for type 1 diabetes and the obligation to provide funding for development services for type 2 diabetes over the period of time Lexicon performs services or provides funding, currently expected to be through 2020.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the initial allocable arrangement consideration was the </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments or royalty payments.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: exercising the option to co-promote, estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services for type 1 diabetes by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the obligation to provide funding for type 2 diabetes by using internal estimates of the expected cash flows and timing for </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in funding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the allocation, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$126.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment for the license in 2015.  The Company is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$113.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;allocated to the development services deliverable and the </font><font style="font-family:inherit;font-size:10pt;">$59.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;allocated to the funding deliverable over the estimated period of performance as the development and funding occurs.  Revenue recognized under the Sanofi Agreement was </font><font style="font-family:inherit;font-size:10pt;">$56.3 million</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;">$75.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$126.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  Revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of sales of clinical trial materials to Sanofi. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ipsen.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$43.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in upfront payments, a </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a </font><font style="font-family:inherit;font-size:10pt;">$3.84 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone upon Ipsen&#8217;s first commercial sale in Germany, and a </font><font style="font-family:inherit;font-size:10pt;">$3.84 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8364;72&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified sales milestones.  Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned as the Company is not able to reasonably predict if and when the milestones will be achieved.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon supplies Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considered the following deliverables with respect to the revenue recognition of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Territory;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The development services Lexicon is performing for XERMELO;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to participate in committees which govern the development of XERMELO</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">until commercialization; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the license had stand-alone value because it is an exclusive license that grants Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, currently expected to be through mid-2018.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company has determined the commercial supply agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the initial allocable arrangement consideration was the </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As a result of the allocation, the Company recognized </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$21.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">of the</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment for the license in 2014, and an additional </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2015 upon entering into the amendment.  The Company is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;allocated to the development services deliverable over the estimated period of performance as development occurs, and is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;allocated to the committee participation deliverable ratably over the estimated period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  Revenue recognized under the Agreement was </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  Revenue for the year ended December 31, 2017 includes </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from sales of bulk tablets of XERMELO to Ipsen.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Texas Institute for Genomic Medicine</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;In July 2005, Lexicon received a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing </font><font style="font-family:inherit;font-size:10pt;">350,000</font><font style="font-family:inherit;font-size:10pt;">&#32;cell lines for the Texas Institute for Genomic Medicine (&#8220;TIGM&#8221;) using Lexicon&#8217;s proprietary gene trapping technology, which Lexicon completed in 2007.&#160;&#160;Lexicon also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&#160;&#160;The Texas Enterprise Fund made an additional award of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the award, Lexicon is responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,616</font><font style="font-family:inherit;font-size:10pt;">&#32;new jobs in Texas by December 31, 2016.&#160;&#160;Lexicon will receive credits against those job obligations based on funding received by TIGM and certain related parties from sources other than the State of Texas.  Lexicon will also receive credits against those job obligations for any surplus jobs that Lexicon created.  Subject to these credits, the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sA49DF2FBF10D11241896BC776257FAC2"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state may require Lexicon to repay </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,415</font><font style="font-family:inherit;font-size:10pt;">&#32;for each job Lexicon falls short beginning in 2013.&#160;&#160;Lexicon&#8217;s maximum aggregate exposure for such payments, if Lexicon fails to create any new jobs, is approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">, without giving effect to any credits to which Lexicon may be entitled.&#160;&#160;Lexicon has recorded this obligation as deferred revenue in the accompanying consolidated balance sheets.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF2C45FE3EF9F38F88055BC77520AF0F8"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,518</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,785</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,871</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all periods presented, the weighted average number of shares outstanding are the same for both basic and diluted consolidated net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-26</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>exh1011officerstockoptiona.htm
<DESCRIPTION>OFFICER STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0625B0DED303AB78B75E9B52F997285F"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.11</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK OPTION AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(Officer Incentive Stock Option)</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THIS STOCK OPTION AGREEMENT (this &#8220;Agreement&#8221;), effective as of __________ (the &#8220;Grant Date&#8221;), is by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation (the &#8220;Company&#8221;), and _____________ (&#8220;Optionee&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To carry out the purposes of the Lexicon Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the &#8220;Plan&#8221;), by providing Optionee the opportunity to purchase shares of Common Stock, par value $0.001 per share, of the Company (&#8220;Stock&#8221;), and in consideration of the mutual agreements and other matters set forth herein and in the Plan, the Company and Optionee hereby agree as follows:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Grant of Option</font><font style="font-family:inherit;font-size:11pt;">.  The Company hereby grants to Optionee the right and option (the &#8220;Option&#8221;) to purchase all or any part of an aggregate of ___________ shares of Stock, on the terms and conditions set forth in this Agreement and in the Plan.  The Option shall be treated as an &#8220;incentive stock option&#8221; within the meaning of section 422(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), to the maximum extent permitted under the Code, and as a non-statutory stock option to the extent it exceeds the limitations imposed by the Code for incentive stock options.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercise Price</font><font style="font-family:inherit;font-size:11pt;">.  The price at which Optionee may purchase Stock upon exercise of the Option (the &#8220;Exercise Price&#8221;) shall be $_______ per share, which has been determined to be the Fair Market Value (as defined in the Plan) of the Stock on the Grant Date.  The Exercise Price is subject to adjustment under certain circumstances as provided in the Plan.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11pt;">.  The Option shall expire on the 10th anniversary of the Grant Date, subject to earlier termination under the circumstances specified in Section 8 of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercisability and Vesting</font><font style="font-family:inherit;font-size:11pt;">.  (a) Subject to the terms and conditions set forth in this Agreement and the Plan, the Option may be exercised, in whole or in part, at any time and from time to time during the term of the Option, to purchase the number of shares of Stock that have vested and become exercisable in accordance with this Agreement.  The Option shall vest and become exercisable with respect to (i) 25% of the total number of shares of Stock subject to the Option on __________ and (ii) an additional 1/48 of the total number of shares subject to the Option each month thereafter; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that such options shall become vested with respect to all remaining unvested shares in the event of a Change in Control (as defined below); and </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided further</font><font style="font-family:inherit;font-size:11pt;">, that, upon the termination of Optionee&#8217;s Continuous Service (as defined in the Plan), the Option shall cease to vest and shall terminate with respect to all shares of Stock that have not vested and become exercisable prior to such time.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;A &#8220;Change in Control&#8221; shall be deemed to have occurred if any of the following shall have taken place: (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Act of 1934 (the &#8220;Exchange Act&#8221;)) other than Invus, L.P. and its affiliates (collectively, &#8220;Invus&#8221;) is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities; (ii) Invus becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities; (iii) the approval by the stockholders of the Company of a reorganization, merger, or consolidation, in each case with respect to which persons who were stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the reorganized, merged or consolidated Company&#8217;s then-outstanding securities entitled to vote generally in the election of directors in substantially the same proportions as their ownership of the Company&#8217;s outstanding voting securities prior to such reorganization, merger or consolidation; (iv) a liquidation or dissolution of the Company or the sale of all or substantially all of the Company&#8217;s assets; (v) in the event any person is elected by the stockholders of the Company to the Company&#8217;s board of directors (the &#8220;Board&#8221;) who has not been nominated for election by a majority of the Board or any duly appointed committee thereof; or (vi) following the election or removal of directors, a majority of the Board consists of individuals who were not members of the Board two years before such election or removal, unless the election of each director who is not a director at the beginning of such two-year period has been approved in advance by directors representing at least a majority of the directors then in office who were directors at the beginning of the two-year period;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;provided</font><font style="font-family:inherit;font-size:11pt;">, that notwithstanding the foregoing, neither the execution by the Company of the Securities Purchase Agreement and Stockholders&#8217; Agreement with Invus, L.P., each dated June 15, 2007 (as amended, supplemented or otherwise modified, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Invus Transaction Agreements</font><font style="font-family:inherit;font-size:11pt;">&#8221;), nor the consummation of the transactions contemplated in the Invus Transaction Agreements, including, without limitation, the acquisition by Invus of the Initial Shares and the Rights Shares (as defined in the Invus Transaction Agreements), the election of any representatives of Invus to the board of directors of the Company, or the acquisition by Invus of additional shares of Stock, as permitted or contemplated under the Invus Transaction Agreements, will constitute a &#8220;Change in Control.&#8221;  The Compensation Committee of the Board, in its discretion, may deem any other corporate event affecting the Company to be a &#8220;Change in Control&#8221; hereunder.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Procedures for Exercise</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the terms and conditions set forth in this Agreement and the Plan, the Option may be exercised by delivery to the Company at its principal executive office of (i) written notice addressed to the Secretary of the Company specifying the number of shares of Stock as to which the Option is being exercised and (ii) payment in full of the Exercise Price for such shares.  The Exercise Price shall be paid in cash or in such other manner as may be authorized by the administrator of the Plan in accordance with the terms of the Plan.  If the offering, sale and delivery of the shares of Stock issuable upon exercise of the Option have not been registered under the Securities Act of 1933 (the &#8220;Securities Act&#8221;), the Company may require Optionee, as a condition to Optionee&#8217;s exercise of the Option, to enter into a stock purchase agreement containing such representations and warranties as the Company may deem necessary to permit the issuance of the Stock purchased upon exercise of the Option in compliance with the Securities Act and applicable state securities laws.  </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Rights of Ownership in Stock Before Issuance</font><font style="font-family:inherit;font-size:11pt;">.  No person shall be entitled to the rights and privileges of stock ownership with respect to any shares of Stock issuable upon exercise of the Option until such shares have been issued in accordance with the terms of this Agreement and the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Transferability</font><font style="font-family:inherit;font-size:11pt;">.  The Option may not be transferred by Optionee otherwise than by will or the laws of descent and distribution or pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination of Option</font><font style="font-family:inherit;font-size:11pt;">.   If Optionee&#8217;s Continuous Service is terminated for any reason other than (i) the Disability (as defined in the Plan) or death of Optionee or (ii) the Company&#8217;s termination of Optionee&#8217;s employment without cause, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Agreement before the date of such termination, for a period of 90 days after the date of such termination (but in no event later than the expiration date of the Option specified in Section 3 of this Agreement), following which 90&#8209;day period this Agreement and Optionee&#8217;s right to exercise the Option shall terminate.  If Optionee&#8217;s Continuous Service is terminated because of (i) the Disability or death of Optionee or (ii) the Company&#8217;s termination of Optionee&#8217;s employment without cause, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Agreement before the date of such termination, for a period of one year after the date of such termination (but in no event later than the expiration date of the Option specified in Section 3 of this Agreement), following which one-year period this Agreement and Optionee&#8217;s right to exercise the Option shall terminate; provided that the Option shall not be treated as an &#8220;incentive stock option&#8221; within the meaning of the Code if the Option is exercised more than 90 days following the termination of Optionee&#8217;s Continuous Service as a result of the Company&#8217;s termination of Optionee&#8217;s employment without cause.  Notwithstanding the foregoing, if the employment of Optionee by the Company is terminated for cause, this Agreement and Optionee&#8217;s right to exercise any portion of the Option, whether or not vested, shall terminate at the commencement of business on the date of such termination.  For purposes of this Agreement, &#8220;cause&#8221; shall mean (x) the breach of a material obligation of Optionee under any agreement between Optionee and the Company, (y) gross negligence or willful or intentional wrongdoing or misconduct on the part of Optionee, or (z) Optionee&#8217;s conviction of a felony offense or a crime involving moral turpitude.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Withholding of Tax</font><font style="font-family:inherit;font-size:11pt;">.   To the extent that the Company is required under applicable federal or state income tax laws to withhold any amount on account of any present or future tax imposed as a result of the exercise of the Option, Optionee shall pay the Company, at the time of such exercise, funds in an amount sufficient to permit the Company to satisfy such withholding obligations in full.  If Optionee fails to pay such amount, the Company shall be authorized (i) to withhold from any cash remuneration then or thereafter payable to Optionee any tax required to be withheld or (ii) to refuse to issue or transfer any shares otherwise required to be issued pursuant to the terms of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Status of Stock</font><font style="font-family:inherit;font-size:11pt;">.  (a)  Unless the offering, sale and delivery of the shares of Stock issuable upon exercise of the Option have been registered under the Securities Act, Optionee agrees that any shares of Stock purchased upon exercise of the Option shall be acquired for investment without a view to distribution, </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">within the meaning of the Securities Act, and shall not be sold, transferred, assigned, pledged or hypothecated in the absence of an effective registration statement under the Securities Act and applicable state securities laws or an applicable exemption from the registration requirements of the Act and any applicable state securities laws.  Optionee further agrees that the shares of Stock which Optionee may acquire by exercising the Option will not be sold or disposed of in any manner which would constitute a violation of any other applicable federal or state securities laws.  In addition, Optionee agrees (i) that the certificates representing the shares of Stock issued under this Agreement may bear such legend or legends as the administrator of the Plan deems appropriate in order to assure compliance with applicable securities laws, and (ii) that the Company may give instruction to its transfer agent, if any, to stop transfer of the shares of Stock issued under this Agreement on the stock transfer records of the Company, if such proposed transfer would, in the opinion of counsel to the Company, constitute a violation of any applicable securities law or any such agreements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;Optionee further agrees that the Option granted herein shall be subject to the requirement that if at any time the administrator of the Plan shall determine, in its discretion, that the listing, registration or qualification of the shares of Stock subject to such Option upon any securities exchange or market or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the purchase or issuance of shares of Stock hereunder, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not reasonably acceptable to the  administrator of the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017 Equity Incentive Plan</font><font style="font-family:inherit;font-size:11pt;">.  The Plan, a copy of which is available for inspection by Optionee or other persons entitled to exercise this Option at the Company&#8217;s principal executive office during business hours, is incorporated by reference in this Agreement.  The Option is subject to, and the Company and Optionee agree to be bound by, all of the terms and conditions of the Plan. In the event of a conflict between this Agreement and the Plan, the terms of the Plan shall control.  Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Agreement, and the determinations of the administrator of the Plan shall be final and binding on Optionee and the Company.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under Optionee. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement and all actions taken hereunder shall be governed by and construed in accordance with the laws of the State of Delaware. </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed and Optionee has executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lonnel Coats</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OPTIONEE</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>exh1012officerrestrictedst.htm
<DESCRIPTION>OFFICER RESTRICTED STOCK UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3D365862230047D669129B70A275F5A2"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.12</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(Officer Restricted Stock Unit)</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THIS RESTRICTED STOCK UNIT AGREEMENT (this &#8220;Agreement&#8221;), effective as of _____&#160;___, 20___ (the &#8220;Grant Date&#8221;), is by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation (the &#8220;Company&#8221;), and _____________ (&#8220;Employee&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To carry out the purposes of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;Plan&#8221;) and the determination of the compensation committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s board of directors (the &#8220;Board&#8221;) to grant Employee a Restricted Stock Unit Award (as defined in the Plan) under the Plan, subject to the terms and conditions of this Agreement, of shares of the Company&#8217;s Common Stock, par value $0.001 per share (&#8220;Stock&#8221;), in order to provide Employee with incentives to exert maximum efforts for the Company&#8217;s success by providing Employee the opportunity to benefit from increases in the value of the Stock, and in consideration of the mutual agreements and other matters set forth herein and in the Plan, the Company and Employee hereby agree as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Grant of Restricted Stock Unit Award</font><font style="font-family:inherit;font-size:11pt;">.  The Company hereby grants to Employee a Restricted Stock Unit Award, on the terms and conditions set forth in this Agreement and in the Plan, consisting of the right to receive an aggregate of ___________ shares of Stock (the &#8220;Shares&#8221;).  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Vesting</font><font style="font-family:inherit;font-size:11pt;">.  (a) Subject to the terms and conditions set forth in this Agreement and the Plan, the right of Employee to receive the Shares shall vest with respect to (i) [25%][one third] of the total number of Shares on February 28, 20__ and (ii) an additional [25%][one third] of the total number of Shares on February 28 of each of the [three][two] succeeding years thereafter; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that, if not already vested in accordance with the foregoing, the right of Employee to receive the Shares shall become vested upon (i) a termination of Employee&#8217;s Continuous Service (as defined in the Plan) by the Company without Cause (as defined below) or by Employee for Good Reason (as defined below) that occurs after the occurrence of a Change in Control (as defined below) or (ii) the termination of Employee&#8217;s Continuous Service as a result of Employee&#8217;s death or Disability (as defined in the Plan).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;For purposes of the foregoing:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">A &#8220;Change in Control&#8221; shall be deemed to have occurred if any of the following shall have taken place: (A) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)) other than Invus, L.P. and its affiliates (collectively, &#8220;Invus&#8221;) is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities; (B) Invus becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities; (C) the consummation of a reorganization, merger, or consolidation, in each case with respect to which persons who were stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the reorganized, merged or consolidated Company&#8217;s then-outstanding securities entitled to vote generally in the election of directors in substantially the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">same proportions as their ownership of the Company&#8217;s outstanding voting securities prior to such reorganization, merger or consolidation; (D) a liquidation or dissolution of the Company or the sale of all or substantially all of the Company&#8217;s assets; or (E) following the election or removal of directors, a majority of the Board consists of individuals who were not members of the Board two years before such election or removal, unless the election of each director who is not a director at the beginning of such two-year period has been approved in advance by directors representing at least a majority of the directors then in office who were directors at the beginning of the two-year period; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:11pt;">, that notwithstanding the foregoing, neither the execution by the Company of the Securities Purchase Agreement and Stockholders&#8217; Agreement with Invus, L.P., each dated June 15, 2007 (as amended, supplemented or otherwise modified, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Invus Transaction Agreements</font><font style="font-family:inherit;font-size:11pt;">&#8221;), nor the consummation of the transactions contemplated in the Invus Transaction Agreements, including, without limitation, the acquisition by Invus of the Initial Shares and the Rights Shares (as defined in the Invus Transaction Agreements), the election of any representatives of Invus to the board of directors of the Company, or the acquisition by Invus of additional shares of Stock, as permitted or contemplated under the Invus Transaction Agreements, will constitute a &#8220;Change in Control.&#8221;  The Compensation Committee, in its discretion, may deem any other corporate event affecting the Company to be a &#8220;Change in Control&#8221; hereunder.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">&#8220;Cause&#8221; means a termination of Employee&#8217;s employment directly resulting from (A)&#160;Employee having engaged in intentional misconduct causing a material violation by the Company of any state or federal laws, (B) Employee having engaged in a theft of Company funds or Company assets or in a material act of fraud upon the Company, (C)&#160;an act of personal dishonesty taken by Employee that was intended to result in personal enrichment of Employee at the expense of the Company, (D) Employee&#8217;s final conviction (or the entry of any plea other than not guilty) in a court of competent jurisdiction of a felony, or (E)&#160;a breach by Employee of any contractual or fiduciary obligation to the Company, if such breach results in a material injury to the Company.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">&#8220;Good Reason&#8221; means the occurrence of any of the following events without Employee&#8217;s express written consent: (A) a material diminution in Employee&#8217;s base salary, (B) a material diminution in Employee&#8217;s authority, duties, or responsibilities, or (C) any other action or inaction that constitutes a material breach by the Company of any contractual obligation to Employee.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Forfeiture upon Termination of Service</font><font style="font-family:inherit;font-size:11pt;">.  Simultaneously with termination of Employee&#8217;s Continuous Service for any reason other than as a result of Employee&#8217;s death or Disability (as defined in the Plan) prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, Employee shall automatically forfeit all rights to receive the Shares, unless and except to the extent otherwise agreed by the Company, in its sole discretion.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Issuance of Shares upon Vesting</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the provisions of Sections 3 and 6 of this Agreement, upon vesting of the Shares in accordance with Section 2 of this Agreement, the Company shall (a) provide Employee with prompt notice of such vesting event and (b) issue the Shares to Employee for no additional consideration.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Transferability</font><font style="font-family:inherit;font-size:11pt;">.  Employee&#8217;s rights under this Agreement, including with respect to any Shares as to which the interest of Employee has not vested in accordance with Section 2 of this Agreement, may not be transferred by Employee otherwise than by will or the laws of descent and distribution or pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Withholding of Tax</font><font style="font-family:inherit;font-size:11pt;">.   Employee shall be liable for any and all federal, state or local taxes, including withholding taxes, arising out of the grant or vesting of Shares hereunder.  Unless Employee elects otherwise as provided below, Employee shall satisfy such withholding tax obligation by forfeiting to the Company that number of Shares having a Fair Market Value (as defined in the Plan) equal to the Company&#8217;s withholding obligation relating to such grant or vesting of Shares hereunder.  Employee may alternatively elect to satisfy such withholding tax obligation by making a cash payment to the Company equal to the Company&#8217;s minimum withholding obligation, in which case Employee shall (a) provide the Company with written notice of such election and (b) pay to the Company in immediately available funds an amount equal to the Company&#8217;s minimum withholding obligation, in each case by no later than the date giving rise to such withholding tax obligation.  No Shares shall be issued to Employee unless and until Employee shall have paid or otherwise satisfied the withholding tax obligations with respect thereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Dividend Equivalents; Voting</font><font style="font-family:inherit;font-size:11pt;">.  If the Board declares any dividends with respect to the Stock prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, dividend equivalents shall be credited to Employee in respect of the Shares and shall be converted into additional shares of Stock covered by this Agreement and such additional shares shall be subject to all of the terms and conditions of the underlying Shares.  Employee shall have no voting rights with respect to the Restricted Stock Unit Award or the Shares subject thereto until such time as the Shares are issued to Employee pursuant to Section 4 of this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Right to Continued Employment</font><font style="font-family:inherit;font-size:11pt;">. Nothing in this Agreement or the Plan shall confer upon Employee any right to continue in the employ of the Company or shall interfere with or restrict in any way the right of the Company, which is hereby expressly reserved, to terminate Employee&#8217;s employment at any time for any reason whatsoever, with or without cause and with or without advance notice.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017 Equity Incentive Plan</font><font style="font-family:inherit;font-size:11pt;">.  The Plan, a copy of which is available for inspection by Employee at the Company&#8217;s principal executive office during business hours, is incorporated by reference in this Agreement.  This Agreement is subject to, and the Company and Employee agree to be bound by, all of the terms and conditions of the Plan. In the event of a conflict between this Agreement and the Plan, the terms of the Plan shall control.  Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Agreement, and the determinations of the administrator of the Plan shall be final and binding on Employee and the Company.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under Employee. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement and all actions taken hereunder shall be governed by and construed in accordance with the laws of the State of Delaware. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed and Employee has executed this Agreement effective for all purposes as of the Grant Date.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lonnel Coats</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMPLOYEE</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>exh1013stockoptionnoticeto.htm
<DESCRIPTION>STOCK OPTION NOTICE TO DIRECTORS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s360F8079575B341F3CFC9B7C19D87406"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.13</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOTICE OF STOCK OPTION GRANT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(Non-Employee Director Stock Option)</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To carry out the purposes of the Lexicon Pharmaceuticals, Inc. 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Plan&#8221;), by providing ____________ (&#8220;Director&#8221;) the opportunity to purchase shares of Common Stock, par value $0.001 per share (&#8220;Stock&#8221;), of LEXICON PHARMACEUTICALS, INC. (the &#8220;Company&#8221;) in accordance with the Plan, the Company hereby provides notice to Director as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Grant of Option</font><font style="font-family:inherit;font-size:11pt;">.  Effective as of __________, 20__ (the &#8220;Grant Date&#8221;), the Company has granted Director the right and option (the &#8220;Option&#8221;) to purchase all or any part of an aggregate of ________ shares of Stock, on the terms and conditions set forth in this Notice and in the Plan.  The Option shall be treated as a non-statutory stock option and not as an &#8220;incentive stock option&#8221; within the meaning of section 422(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercise Price</font><font style="font-family:inherit;font-size:11pt;">.  The price at which Director may purchase Stock upon exercise of the Option (the &#8220;Exercise Price&#8221;) shall be $______ per share, which has been determined to be the Fair Market Value (as defined in the Plan) of the Stock on the Grant Date.  The Exercise Price is subject to adjustment under certain circumstances as provided in the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11pt;">.  The Option shall expire on the 10th anniversary of the Grant Date, subject to earlier termination under the circumstances specified in Section 8 of this Notice.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercisability and Vesting</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the terms and conditions set forth in this Notice and the Plan, the Option may be exercised, in whole or in part, at any time and from time to time during the term of the Option, to purchase the number of shares of Stock that have vested and become exercisable in accordance with this Notice.  The Option shall vest and become exercisable with respect to [1/12 of the total number of shares of Stock subject to the Option each month after grant for 12 months after the Grant Date]; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that, such vesting schedule may be accelerated upon a change in control of the Company pursuant to the provisions of the Plan and; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided further</font><font style="font-family:inherit;font-size:11pt;">, that, upon the termination of Director&#8217;s Continuous Service (as defined in the Plan), the Option shall cease to vest and shall terminate with respect to all shares of Stock that have not vested and become exercisable prior to such time.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Procedures for Exercise</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the terms and conditions set forth in this Notice and the Plan, the Option may be exercised by delivery to the Company at its principal executive office of (i) written notice addressed to the Secretary of the Company specifying the number of shares of Stock as to which the Option is being exercised and (ii) payment in full of the Exercise Price for such shares.  The Exercise Price shall be paid in cash or in such other manner as may be authorized by the administrator of the Plan in accordance with the terms of the Plan.  If the offering, sale and delivery of the shares of Stock issuable upon exercise of the Option have not been registered under the Securities Act of 1933 (the &#8220;Securities Act&#8221;), the Company may require Director, as a condition to Director&#8217;s exercise of the Option, to enter into a stock purchase agreement containing such representations and warranties as the Company may deem necessary to permit the issuance of the Stock purchased upon exercise of the Option in compliance with the Securities Act and applicable state securities laws.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Rights of Ownership in Stock Before Issuance</font><font style="font-family:inherit;font-size:11pt;">.  No person shall be entitled to the rights and privileges of stock ownership with respect to any shares of Stock issuable upon exercise of the Option until such shares have been issued in accordance with the terms of this Notice and the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Transferability</font><font style="font-family:inherit;font-size:11pt;">.  The Option may not be transferred by Director otherwise than (i) by will or the laws of descent and distribution, by instrument to an inter vivos or testamentary trust or by gift to a member of Director&#8217;s immediate family, in each case in accordance with the terms of the Plan, or (ii) pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination of Option</font><font style="font-family:inherit;font-size:11pt;">.  If Director&#8217;s Continuous Service is terminated for any reason other than the Disability (as defined in the Plan) or death of Director, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Notice before the date of such termination, for a period of six months after the date of such termination (subject to extension as provided in the Plan, but in no event later than the expiration date of the Option specified in Section 3 of this Notice), following which six-month period this Notice and Director&#8217;s right to exercise the Option shall terminate.  If Director&#8217;s Continuous Service is terminated because of Disability of Director, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Notice before the date of such termination, for a period of 12 months after the date of such termination (but in no event later than the expiration date of the Option specified in Section 3 of this Notice), following which 12-month period this Notice and Director&#8217;s right to exercise the Option shall terminate.  If (i) Director&#8217;s Continuous Service is terminated because of death of Director or (ii) Director dies within the three-month period after the termination of Director&#8217;s Continuous Service for a reason other than death, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Notice before the date of death, for a period of 18 months after the date of such termination (but in no event later than the expiration date of the Option specified in Section 3 of this Notice), following which 18-month period this Notice and the right to exercise the Option shall terminate.  Notwithstanding the foregoing, if the Director is removed from the Company&#8217;s Board of Directors for cause in accordance with the Company&#8217;s Bylaws, this Notice and Director&#8217;s right to exercise any portion of the Option, whether or not vested, shall terminate at the commencement of business on the date of such removal.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Withholding of Tax</font><font style="font-family:inherit;font-size:11pt;">.   To the extent that the Company is required under applicable federal or state income tax laws to withhold any amount on account of any present or future tax imposed as a result of the exercise of the Option, Director shall pay the Company, at the time of such exercise, funds in an amount sufficient to permit the Company to satisfy such withholding obligations in full.  If Director fails to pay such amount, the Company shall be authorized (i) to withhold from any cash remuneration then or thereafter payable to Director any tax required to be withheld or (ii) to refuse to issue or transfer any shares otherwise required to be issued pursuant to the terms of this Notice.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Status of Stock</font><font style="font-family:inherit;font-size:11pt;">.  (a)  Unless the offering, sale and delivery of the shares of Stock issuable upon exercise of the Option have been registered under the Securities Act, Director agrees that any shares of Stock purchased upon exercise of the Option shall be acquired for investment without a view to distribution, within the meaning of the Securities Act, and shall not be sold, transferred, assigned, pledged or hypothecated in the absence of an effective registration statement under the Securities Act and applicable state securities laws or an applicable exemption from the registration requirements of the Act and any applicable state securities laws.  Director further agrees that the shares of Stock which Director may acquire by exercising the Option will not be sold or disposed of in any manner which would constitute a violation of any other applicable federal or state securities laws.  In addition, Director agrees (i) that the certificates representing </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the shares of Stock issued under this Notice may bear such legend or legends as the administrator of the Plan deems appropriate in order to assure compliance with applicable securities laws, and (ii) that the Company may give instruction to its transfer agent, if any, to stop transfer of the shares of Stock issued under this Notice on the stock transfer records of the Company, if such proposed transfer would, in the opinion of counsel to the Company, constitute a violation of any applicable securities law or any such agreements.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;Director further agrees that the Option granted herein shall be subject to the requirement that if at any time the administrator of the Plan shall determine, in its discretion, that the listing, registration or qualification of the shares of Stock subject to such Option upon any securities exchange or market or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the purchase or issuance of shares of Stock hereunder, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not reasonably acceptable to the  administrator of the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017 Non-Employee Directors&#8217; Equity Incentive Plan</font><font style="font-family:inherit;font-size:11pt;">.  The Plan, a copy of which is available for inspection by Director or other persons entitled to exercise this Option at the Company&#8217;s principal executive office during business hours, is incorporated by reference in this Notice.  The Option is subject to, and the Company and Director agree to be bound by, all of the terms and conditions of the Plan.  In the event of a conflict between this Notice and the Plan, the terms of the Plan shall control.  Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Notice, and the determinations of the administrator of the Plan shall be final and binding on Director and the Company.  This Notice shall constitute a Stock Award Agreement (as defined in the Plan) evidencing the terms and conditions of the Option grant for all purposes under the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>exh1026loanandsecurityagre.htm
<DESCRIPTION>LOAN AND SECURITY AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA96D71E96F068B0E2DE79B673F03EB82"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.23</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:32px;padding-top:40px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">$34,000,000</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:40px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LOAN AND SECURITY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:40px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">between</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.,</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">a Delaware limited partnership</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">as Borrower</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">and</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iSTAR FINANCIAL INC.,</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">as Lender</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dated as of April&#160;21, 2004</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s897842B5517B785C576A9B673F360798"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LOAN AND SECURITY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS LOAN AND SECURITY AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) dated as of April&#160;21, 2004, by LEX&#8209;GEN WOODLANDS, L.P., a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), having an address at&#160;c/o&#160;Lexicon Genetics Incorporated, 8800 Technology Forest Place, The&#160;Woodlands, Texas 77381&#8209;1160 and iSTAR FINANCIAL INC., a Maryland corporation (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at 1114 Avenue of the Americas, 27</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New&#160;York, New&#160;York 10036.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">R E C I T A L S</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">The Mortgaged Property</font><font style="font-family:inherit;font-size:12pt;">.  Borrower is the fee owner of the Land and Improvements (as such terms are defined herein).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">The Loan</font><font style="font-family:inherit;font-size:12pt;">.  Borrower desires to borrow from Lender and Lender desires to lend to Borrower, a loan in the amount of $34,000,000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the foregoing and of the covenants, conditions and agreements contained herein, Borrower and Lender agree as follows:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">General Definitions</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition to any other terms defined in this Agreement, the following terms shall have the following meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Acceptable Financial Institution</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a depository institution or trust company incorporated under the laws of the United States of America or any state thereof and subject to supervision and examination by federal or state banking authorities, so long as (a)&#160;at all times the short-term commercial paper, certificates of deposit or other debt obligations of such depository institution or trust company are rated at least A&#8209;1 by S&amp;P and P&#8209;1 by Moody&#8217;s and the long-term unsecured debt obligations of which are rated at least A by S&amp;P and the equivalent thereof by Moody&#8217;s or (b)&#160;such depository institution or trust company has otherwise been approved by Lender, such approval not to be unreasonably withheld.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Accounting Changes</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a)&#160;changes in accounting principles required by GAAP consistently applied and implemented by Borrower; and (b)&#160;changes in accounting principles recommended or approved by Borrower&#8217;s certified public accountant, with the approval of Lender, which approval shall not be unreasonably withheld; provided that Lender&#8217;s approval shall not be required so long as (i) Borrower&#8217;s financial statements are prepared on a consolidated basis with the financial statements of Guarantor, (ii) Guarantor is a reporting company under the Exchange Act, and (iii) Guarantor&#8217;s financial statements are audited by a so&#8209;called &#8220;Big&#8209;4&#8221; accounting firm.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Accounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Borrower&#8217;s present and future rights to payment of money, accounts and accounts receivable including (a) rights to payment of money, accounts and accounts receivable arising from or relating to the construction, use, leasing, occupancy or operation of the  Mortgaged Property, the rental of, or payment for, space, goods sold or leased or services rendered, whether or not yet earned by performance, and all other &#8220;accounts&#8221; (as defined in the UCC), (b) rights to payment, accounts, and accounts receivable arising from any consumer credit, charge, entertainment or travel card or service organization or entity, (c) all reserves, deferred payments, refunds, cost savings payments and deposits no matter how evidenced and whether now </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or later to be received from third parties (including all earnest money sales deposits) or deposited with, or by, Borrower by, or with, third parties (including all utility deposits), (d) all chattel paper, instruments, documents, notes, drafts and letters of credit (other than any letters of credit in favor of Lender), (e) the Reserve Accounts and any and all other accounts held by or on behalf of Lender and/or Borrower pursuant to this Agreement, (f) all &#8220;deposit accounts&#8221; (as defined in the UCC), (g) all &#8220;securities accounts&#8221; (as defined in the UCC), and (h) all contracts and agreements which relate to any of the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person:  (A)&#160;directly or indirectly controlling, controlled by, or under common control with, another Person; (B)&#160;directly or indirectly owning or holding ten percent (10%) or more of any equity interest in another Person; or (C)&#160;ten percent (10%) or more of whose voting stock or other equity interest is directly or indirectly owned or held by such other Person.  When used with respect to Borrower, the term &#8220;Affiliate&#8221; shall also include the spouse, ancestors, descendants and siblings of an Affiliate of Borrower (such Persons being sometimes referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Family Members</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Affiliates of such Family Members and trusts for the benefit of another Affiliate of Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means this Loan and Security Agreement (including all schedules, exhibits, annexes and appendices hereto), as amended, modified or supplemented from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Alteration</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;7.14.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Budget</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 5.1(D) hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved Budget</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Budget and Capital Plan approved by Lender from time to time as described in Section 5.1(D) hereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved Capital Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Capital Plan approved by Lender as part of the Approved Budget.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved Operating Expenses</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Expenses set forth in an Approved Budget.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Assignment(s)</font><font style="font-family:inherit;font-size:12pt;">&#8221; means individually and collectively, the assignment of leases and rents, assignments of contracts, agreements and equipment leases, the assignments of licenses, permits and approvals, the assignments of management agreement, if any, the assignment of trademarks, tradenames and copyrights, if any, and such other assignments of even date herewith from Borrower to or for the benefit of Lender, each granting a security interest in collateral for the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Bankruptcy Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Title 11 of the United States Code entitled &#8220;Bankruptcy,&#8221; as amended from time to time and all rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Bank(s)</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Acceptable Financial Institution at which the Reserve Accounts are maintained.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Base Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a fixed rate per annum equal to eight and 23/100ths percent (8.23%).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower Account</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means a demand, time or deposit account maintained by the Borrower at the Bank or other financial institution selected by the Borrower, as required under the Loan Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower Representative</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Lex&#8209;Gen Woodlands GP, LLC, a Delaware limited liability company, the sole general partner in Borrower.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Budget</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a budget setting forth the projected revenues and budgeted costs and expenses for the ownership, operation and management for the Mortgaged Property for each calendar year commencing with calendar year 2004.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any day excluding Saturday, Sunday and any day which is a legal holiday under the laws of the State of New&#160;York or is a day on which banking institutions located in such state is closed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Lease</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any lease of any property (whether real, personal or mixed) that, in conformity with GAAP, should be accounted for as a capital lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Borrower&#8217;s budget for capital improvements and equipment for the Mortgaged Property for each calendar year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cash Management Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the Cash Management Agreement dated as of the date hereof, among Borrower, Lender and Bank.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Change in Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of any one or more of the following: (i)&#160;a&#160;sale of all or substantially all of the assets of Guarantor, in a single transaction or series of transactions, (ii)&#160;a&#160;Person or Group shall have acquired, in one or more transactions, ownership or control of forty-nine percent (49%) or more of the voting Securities of Guarantor, (iii)&#160;Guarantor shall cease to directly or indirectly Control the business and affairs of the Borrower or (iv) Guarantor shall cease to directly or indirectly own fifty-one percent (51%) or more of the voting Securities of Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Claims</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 5.3(A).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Closing</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that all conditions for disbursement of the proceeds of the Loan to or for the benefit of Borrower have been satisfied or waived in writing by Lender and the disbursement of the proceeds of the Loan shall have been made to, or upon the order of, Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Closing Checklist</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the closing checklist attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;F</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Closing Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the date on which the Closing occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the United States Internal Revenue Code of 1986, and any rule or regulation promulgated thereunder from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collateral</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Mortgaged Property, the Reserve&#160;Account Collateral and all other real and personal property of Borrower or any other Person pledged or mortgaged to Lender as collateral security for repayment of the Loan, if any.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;11.12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Construction</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Restoration, the Alterations, the construction, equipping and fixturing of the Required Capital Improvements or any other construction, equipping, fixturing and furnishing, approved (or deemed approved) by Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Construction Legal Compliance</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Borrower&#8217;s satisfaction of all of the following:  (A)  (i)&#160;the applicable Construction through the applicable date of determination, has been constructed substantially in accordance with the applicable Plans and Specifications (other than deviations therefrom that are immaterial individually and in the aggregate); and (ii) the applicable Construction has been, or will be, constructed in </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">substantial compliance with all Legal Requirements; (B) all material entitlements, approvals, allocations, certificates, authorizations, permits and licenses required through the then-current stage of construction have been obtained from all appropriate Governmental Authorities and have been validly and irrevocably obtained without qualification, appeal or existence of unexpired appeal periods; (C) all conditions to the issuance of, and the requirements under, all permits, conditional use permits and licenses required through the current stage of construction have been satisfied in all material respects; and (D) no appeals, suits or other actions are pending or threatened in writing by any Governmental Authority which, if determined adversely to the interests of Borrower or the Mortgaged Property, would result in the revocation, suspension or qualification of any of such permits or approvals.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contingent Obligation</font><font style="font-family:inherit;font-size:12pt;">,&#8221; as applied to any Person, means any direct or indirect liability, contingent or otherwise, of that Person:  (A)&#160;with respect to any indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto; (B)&#160;with respect to any letter of credit issued for the account of that Person or as to which that Person is otherwise liable for reimbursement of drawings; (C)&#160;under any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement or other similar agreement or arrangement designed to protect the applicable Person against fluctuations in interest rates; or (D)&#160;under any foreign exchange contract, currency swap agreement or other similar agreement or arrangement designed to protect that Person against fluctuations in currency values.  Contingent Obligations shall include (1)&#160;the direct or indirect guaranty, endorsement (other than for collection or deposit in the ordinary course of business), co&#8209;making, discounting with recourse or sale with recourse by such Person of the obligation of another, (2)&#160;the obligation to make take-or-pay or similar payments if required regardless of nonperformance by any other party or parties to an agreement, and (3)&#160;any liability of such Person for the obligations of another through any agreement to purchase, repurchase or otherwise acquire such obligation or any property constituting security therefor, to provide funds for the payment or discharge of such obligation or to maintain the solvency, financial condition or any balance sheet item or level of income of another.  The amount of any Contingent Obligation shall be equal to the amount of the obligation so guaranteed or otherwise supported or, if not a fixed and determined amount, the maximum amount so guaranteed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contractor</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the contractor(s) or construction manager(s) for the Construction as Lender may, from time to time approve, which approval shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contracts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all contracts, agreements, warranties and representations relating to or governing the use, occupancy, design, construction, operation, management, repair and service of any other component of the Mortgaged Property, as amended, modified or supplemented from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contractual Obligation</font><font style="font-family:inherit;font-size:12pt;">,&#8221; as applied to any Person, means any indenture, mortgage, deed of trust, contract, undertaking, agreement or other instrument to which that Person is a party or by which it or any of its properties is bound or to which it or any of its properties is subject including the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; (including with correlative meanings, the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession directly or indirectly of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Credit Rating</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the senior unsecured debt rating issued by S&amp;P and Moody&#8217;s or if either or both no longer exist or no longer issue ratings then, for either or both as so applicable, another Rating Agency.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All references to specific levels of a Credit Rating mean such rating with a &#8220;stable&#8221; or &#8220;positive&#8221; outlook, but not a &#8220;negative&#8221; outlook or &#8220;on watch&#8221; associated with such rating.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Default</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a condition or event that, after notice or lapse of time or both, would constitute an Event of Default if that condition or event were not cured or removed within any applicable grace or cure period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Default Interest</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 2.2(A). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Default Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a rate per annum equal to the Base Rate plus five percent (5%).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Distribution</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 7.12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dollars</font><font style="font-family:inherit;font-size:12pt;">&#8221; and the sign &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">$</font><font style="font-family:inherit;font-size:12pt;">&#8221; mean the lawful money of the United States of America.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EBITDA Interest Coverage</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, at any reporting date, for a Person, the ratio calculated by dividing (A) the earnings from continuing operations (including interest income and equity earnings, but excluding nonrecurring items) before interest, taxes, depreciation and amortization for such Person by (B) gross interest incurred by such Person before subtracting (i) capitalized interest and (ii) interest income.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Eligible Account</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a segregated account maintained at an Acceptable Financial Institution.  An Eligible Account will not be evidenced by a certificate of deposit, passbook or other instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Employee Benefit Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an employee pension benefit plan which is covered by Title IV of ERISA or subject to the minimum funding standards under Part 3 of Title I of ERISA or Section 412 of the Code and is either (a) maintained by any Person or any ERISA Affiliate for employees of such Person or any ERISA Affiliate or (b) maintained pursuant to a collective bargaining agreement or any other arrangement under which more than one employer makes contributions and to which such Person or any ERISA Affiliate is then making or has any obligation to make contributions or, within the preceding five (5) plan years, has made or has had any obligation to make contributions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Environmental Claims</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 4.13.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Environmental Indemnity Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Environmental Indemnity Agreement, dated of even date herewith, executed by Borrower and Guarantor in favor of Lender, together with all amendments, modifications, renewals, substitutions and extensions thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Environmental Laws</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all present and future federal, state and/or local laws, statutes, ordinances, codes, rules, regulations, orders, decrees, licenses, decisions, orders, injunctions, requirements and/or directives of Governmental Authorities, as well as common law, imposing liability, standards of conduct or otherwise pertains or relates to, or for, for the environment, industrial hygiene, the regulation of Hazardous Substances, natural resources, pollution or waste management.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Environmental Reports</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those reports and audits itemized on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;1.1(B)</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Equipment, Fixtures and Personalty</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all fixtures and all of the equipment and personalty listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto, together with all accessions, replacements and substitutions thereto and the proceeds thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ERISA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Employee Retirement Income Security Act of 1974, and all rules and regulations promulgated thereunder.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ERISA Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person who is a member of a group which is under common control with another Person, who together with such other Person is treated as a single employer within the meaning of Sections 414(b), (c), (m) and (o) of the IRC or Sections&#160;4001 of ERISA. Guarantor shall be deemed to be an ERISA Affiliate of Borrower for purposes of this Agreement, irrespective of whether it and Borrower would be treated as a single employer.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Event of Default</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 9.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess Interest</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;2.2(C).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exchange Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Existing Indebtedness</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the synthetic lease</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">encumbering the Mortgaged Property immediately prior to the Closing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Expenses</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the costs and expenditures accrued or incurred by Borrower, without duplication, in connection with the ownership, operation and management of the Mortgaged Property, specifically including in Expenses (1) periodic deposits required to be made into the Reserves; (2) capital expenditures incurred pursuant to an Approved Budget to the extent not paid from any Reserves or the proceeds of the Loan; and (3) management fees and specifically excluding from Expenses, however, (i)&#160;all expenditures to the extent funded from any Reserves, (ii)&#160;principal, interest and all other payments made by Borrower to Lender under the Loan Documents, (iii)&#160;federal or state income taxes, and (iv)&#160;depreciation and other non&#8209;cash expenses of the Mortgaged Property.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financing Statements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the UCC&#8209;1 Financing Statements naming Borrower, as debtor, and Lender, as secured party, and filed with such filing offices as Lender may require.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FIRREA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means The Financial Institutions Reform, Recovery and Enforcement Act of 1989, Pub.&#160;L. No. 101&#8209;73 Stat. 183 (1989) and the regulations adopted pursuant thereto, as the same may be amended from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GAAP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means generally accepted accounting principles in the United States of America, consistently applied, as of the date in question.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">General Intangibles</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all of the items listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;C</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">hereto.  In addition, the General Intangibles also include all of Borrower&#8217;s right, title and interest in and to all Contracts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Governmental Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the United States of America, any state, any foreign governments and any political subdivision or regional division of the foregoing, and any agency, department, court, regulatory body, commission, board, bureau or instrumentality of any of them.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Gross Revenues</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, for the applicable period, all Rents and all other income, rents, revenues, issues, profits, deposits, proceeds of rent loss insurance, lease termination or similar payments and all other payments actually received by or for the benefit of Borrower in cash or current funds or other consideration from any source whatsoever from or with respect to the Mortgaged Property; provided, however, that Gross Revenues shall exclude Proceeds (other than insurance proceeds in respect of rent loss insurance), litigation proceeds, sale or refinancing proceeds and any other non-recurring income from extraordinary events.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person or Persons acting together which would constitute a &#8220;group&#8221; for purposes of Section 13(d) of the Exchange Act, as in effect on the date hereof, together with all affiliates and associates (as defined in Rule 12b&#8209;2 under the Exchange Act, as in effect on the date hereof) thereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guarantor</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Lexicon Genetics Incorporated, a Delaware corporation and its successors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guarantor Lease</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means that Lease Agreement dated as of even date herewith, by and between Borrower and Guarantor for the Lease by Guarantor of the Improvements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain Guaranty of Guarantor in favor of Lender of even date herewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Hazardous Materials</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) any pollutants, toxic pollutants, oil, gasoline, petroleum products, asbestos, materials or substances containing asbestos, explosives, chemical liquids or solids, radioactive materials, polychlorinated biphenyls or related or similar materials, or any other solid, liquid or other emission, substance, material, product or by&#8209;product, in each case defined, listed or regulated as a hazardous, noxious, toxic or solid substance, material or waste or defined, listed or regulated as causing cancer or reproductive toxicity, or otherwise defined, listed or regulated as hazardous or toxic in, pursuant to, or by any federal, state or local law, ordinance, rule, or regulation, now or hereafter enacted, amended or modified, in each case to the extent applicable to the Mortgaged Property including the Comprehensive Environmental Response, Compensation, and Liability Act (42 U.S.C. Section 9601, et&#160;seq.); the Hazardous Materials Transportation Act (49 U.S.C. Section 1801, et&#160;seq.); the Resource Conservation and Recovery Act (42 U.S.C. Section 6901, et&#160;seq.); any so&#8209;called &#8220;Superfund&#8221; or &#8220;Superlien&#8221; law; the Toxic Substance Control Act of 1976 (15 U.S.C. Section 2601 et&#160;seq.); the Clean Water Act (33 U.S.C. Section 1251 et&#160;seq.); and the Clean Air Act (42 U.S.C. Section 7901 et&#160;seq.); (b) any substance which is or contains asbestos, radon, polychlorinated biphenyl, urea formaldehyde foam insulation, explosive or radioactive material, lead paint, motor fuel or other petroleum hydrocarbons, and/or (c)&#160;fungus, mold, mildew, or other biological agents the presence of which may adversely affect the health of individuals or other animals or materially adversely affect the value or utility of the Mortgaged Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Impositions</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all real estate and personal property taxes, and vault charges and all other taxes, levies, assessments and other similar charges, general and special, ordinary and extraordinary, foreseen and unforeseen, of every kind and nature whatsoever, which at any time prior to, at or after the execution hereof may be assessed, levied or imposed by, in each case, (i)&#160;a&#160;Governmental Authority or (ii)&#160;The&#160;Woodlands Community Association or The&#160;Woodlands Commercial Owners Association (or their respective successor entities) upon the Mortgaged Property or upon the ownership, use, occupancy or enjoyment thereof, and any interest, cost or penalties imposed by such entity with respect to any of the foregoing.  Impositions shall not include any sales or use taxes or any income taxes payable by Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Improvements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all buildings, improvements, alterations or appurtenances now, or at any time hereafter, located upon, in, under or above the Land or any part thereof.  The term &#8220;Improvements&#8221; also includes all buildings, improvements, alterations or appurtenances not located on, in, under or above the land to the extent of Borrower&#8217;s right, title and interest therein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indebtedness</font><font style="font-family:inherit;font-size:12pt;">&#8221; means with respect to any Person, without duplication, (a)&#160;any indebtedness of such Person for borrowed money (whether by loan, the issuance and sale of debt securities or the sale of any property or asset of such Person to another Person subject to an understanding or agreement, contingent or otherwise, to repurchase such property from such Person), (b)&#160;any obligations of such Person for the deferred purchase price of property or services, (c)&#160;any obligations of such Person evidenced by notes, bonds, debentures or other similar instruments, (d)&#160;any obligations of such Person created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property), (e)&#160;any obligations of such Person as lessee under leases that have been or should be, in accordance with GAAP, recorded as capital leases, (f)&#160;any obligations of such Person as a result of any final judgment rendered against such Person or any settlement agreement entered into by </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such Person with respect to any litigation unless such obligations are stayed upon appeal (for so long as such appeal shall be maintained) or are fully discharged or bonded within thirty (30) days after the entry of such judgment or execution of such settlement agreement, (g) any obligations, contingent or otherwise, of such Person in respect of acceptances, letters of credit or similar extensions of credit, (h) any Contingent Obligations, (i) any Indebtedness of others referred to in clauses&#160;(a) through (h) above or clause&#160;(j) below guaranteed directly or indirectly in any manner by such Person, or in effect guaranteed directly or indirectly by such Person through an agreement (1)&#160;to pay or purchase such Indebtedness or to advance or supply funds for the payment or purchase of such Indebtedness, (2)&#160;to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling the debtor to make payment of such Indebtedness or to assure the holder of such Indebtedness against loss, (3)&#160;to supply funds to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether such property is received or such services are rendered) or (4)&#160;otherwise to assure a creditor against loss, and (j) any Indebtedness referred to in clauses&#160;(a) through (i) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property (including accounts and contract rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such Indebtedness.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnified Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 11.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 11.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Independent Architect</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 7.14.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Independent Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning ascribed to it in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;7.13</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inspection Certificate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a certificate from an architect or other design professional approved by Lender in form and substance reasonably acceptable to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insurance Reserve</font><font style="font-family:inherit;font-size:12pt;">&#8221; is the reserve for insurance premiums established pursuant to Section 5.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insurance Reserve Account</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 6.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Interest Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the period of time beginning on the 10</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of a Loan Month and ending on the 9</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of the following Loan Month, provided, however, the first Interest Period shall commence on the date the Loan commences to bear interest and continues to and includes May&#160;9, 2004.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Interest Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the applicable of the Base Rate or the Default Rate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; means &#8220;inventory&#8221; (as defined in the UCC), including any and all goods, merchandise and other personal property, whether tangible or intangible, now owned or hereafter acquired by Borrower which is held for sale, lease or license to customers, furnished to customers under any contract or service or held as raw materials, work in process, or supplies or materials used or consumed in Borrower&#8217;s business, if any.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (A)&#160;any direct or indirect purchase or other acquisition by Borrower  of any beneficial interest in, including stock, partnership interest or other Securities of, any other Person or (B)&#160;any direct or indirect loan, advance or capital contribution by Borrower to any other Person, including all indebtedness and accounts receivable from that other Person that are not current assets or did not arise from sales to that other Person in the ordinary course of business.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Land</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the real estate comprising the Mortgaged Property, as more specifically described in the Mortgage, including all of Borrower&#8217;s right, title and interest in and to all oil, gas and mineral rights, oil, gas and minerals (whether before or after extraction), easements, appurtenances, water rights, water stock, rights in and to streets, roads and highways (whether before or after vacation thereof), hereditaments and privilege relating, in any manner whatsoever, to the Land.  The Land is legally described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Late Charge</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 2.2(D).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Leases</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all leases, subleases, occupancy agreements or grants of other possessory interests, whereby Borrower acts as the lessor, sublessor, licensor, grantor or in another similar capacity, now or hereafter in force, oral or written, covering or affecting the Land or Improvements, or any part thereof, together with all rights, powers, privileges, options and other benefits of Borrower thereunder and any and all guaranties of the obligations of the lessees, sublessees, occupants, and grantees thereunder, as such leases, subleases, occupancy agreements or grants may be extended, renewed, modified or replaced from time to time (exclusive of any ground lease having Borrower as ground lessee).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Legal Requirements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all applicable laws, statutes, ordinances, rulings, regulations, codes, decrees, orders, judgments, covenants, conditions, restrictions, approvals, permits and requirements under any Permitted Encumbrances or of, from or by any Governmental Authority, including zoning, subdivision, land use, environmental, building, safety, health, wetlands and landmark preservation, housing and fire laws and the Americans with Disabilities Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender&#8217;s Representative</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an independent consulting architect, inspector and/or engineering designated by Lender in Lender&#8217;s sole discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lien</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a)&#160;any lien, mortgage, pledge, security interest, charge or monetary encumbrance of any kind, whether voluntary or involuntary (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any agreement to give any security interest) and (b) any negative pledge or analogous agreement including any agreement not to directly or indirectly convey, assign, sell, mortgage, pledge, hypothecate, grant a security interest in, grant options with respect to, transfer or otherwise dispose of, voluntarily or involuntarily, by operation of law or otherwise, any direct or indirect interest in an asset or direct or indirect interest in the ownership of an asset.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the loan in the aggregate amount of $34,000,000 from Lender to Borrower as evidenced by the Note.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Documents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means this Agreement, the Note, the Mortgage, the Assignments, the Environmental Indemnity Agreement, the Cash Management Agreement, the Financing Statements, the Guaranty and all other documents, instruments, certificates and other deliveries made by Borrower or Guarantor to Lender in accordance herewith or which otherwise evidence, secure and/or govern the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Month</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a calendar month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Quarter</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a calendar quarter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lockout Expiration Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the third anniversary of the Closing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Management Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the property management agreement for the Mortgaged Property between Borrower and Manager, if any. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Person which is the manager of the Mortgaged Property from time to time, which Person must be a Qualified Manager.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Material Adverse Effect</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (A)&#160;a material adverse effect upon the business, operations, properties, assets or condition (financial or otherwise) of Borrower, Guarantor or the Mortgaged Property taken as a whole, or (B)&#160;the impairment, in any material respect, of the ability of Borrower or Guarantor to perform its respective obligations under any of the Loan Documents or of Lender to enforce any of the Obligations.  In determining whether any individual event would result in a Material Adverse Effect, notwithstanding that such event does not of itself have such effect, a Material Adverse Effect shall be deemed to have occurred if the cumulative effect of such event and all other then existing events would result in a Material Adverse Effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Material Contracts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a)&#160;the Permitted Encumbrances (not otherwise referred to in this definition of Material Contracts), and (b) those (i)&#160;Contracts set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;4.6(C)</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and (ii) other Contracts which, if not complied with by Borrower, could reasonably be expected to have a Material Adverse Effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Maturity Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Maturity Date, as defined in Section 2.4(B),</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or such earlier date as the Loan is prepaid in full or accelerated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Maximum Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 2.2(C).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Moody&#8217;s</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Moody&#8217;s Investors Services, Inc. and its successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Deed of Trust, Assignment of Leases and Rents, Security Agreement and Fixture Filing of even date herewith from Borrower to or for the benefit of Lender, constituting a first Lien on the Mortgaged Property as collateral for the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgaged Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Land, the Improvements and the Equipment, Fixtures and Personalty, and all of Borrower&#8217;s now and/or hereafter existing right, title and interest in and to the Inventory, the Accounts, the General Intangibles, the Leases, the Rents and other Gross Revenues, the Proceeds, the Plans and Specifications and all other property of every kind and description used or useful in connection with the ownership, occupancy, operation and maintenance of the other components of the Mortgaged Property and all substitutions therefor, replacements and accessions thereto, and proceeds including &#8220;proceeds&#8221; (as defined in the UCC) derived therefrom, all as more specifically described in the Mortgage.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Multiemployer Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a &#8220;multiemployer plan&#8221; as defined in Section 4001(a)(3) of ERISA to which Borrower or any ERISA Affiliate is making, or is accruing an obligation to make, contributions or has made, or been obligated to make, contributions within the preceding six (6) years, or for which Borrower or any ERISA Affiliate has any liability, including contingent liability.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Net Worth</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, at any reporting date, for a Person, which shall include such Person&#8217;s subsidiaries, if any, on either a combined or consolidated basis pursuant to and determined in accordance with GAAP (such combined or consolidated entities are collectively herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Subject Person</font><font style="font-family:inherit;font-size:12pt;">&#8221;) the total assets of the Subject Person less (i) intangible assets of such Subject Person (including, goodwill, anticipated future benefits of tax loss carry forwards, and organization or developmental expenses and specifically excluding from the definition of intangible assets solely for purposes of this definition, patents, trademarks, service marks, trade names and copyrights) otherwise determined in accordance with GAAP, and less (ii) the total liabilities of such Subject Person, all on either a combined or consolidated basis, as applicable, determined in accordance with GAAP, in each case without duplication.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Promissory Note, together with the Substitute Notes and all future advances, extensions, renewals, substitutions, modifications and amendments of the Promissory Note and Substitute Notes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Obligations</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, in the aggregate, all obligations, liabilities and indebtedness of every nature of Borrower from time to time owed to Lender under the Loan Documents, including the principal amount of all debts, claims and indebtedness, accrued and unpaid interest and all fees, costs and expenses, whether primary, secondary, direct, contingent, fixed or otherwise, heretofore, now and/or from time to time hereafter owing, due or payable to Lender under the Loan Documents whether before or after the filing of a proceeding under the Bankruptcy Code by or against Borrower.  The term &#8220;Obligations&#8221; shall also include any judgment against Borrower or the Mortgaged Property with respect to such obligations, liabilities and indebtedness of Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OFAC</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 4.9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Officer&#8217;s Certificate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the certificate of a president, vice president, or other officer or representative with knowledge of the matters addressed in such certificate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Organizational Documents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as applicable, for any Person, such Person&#8217;s articles or certificate of incorporation, by&#8209;laws, partnership agreement, trust agreement, certificate of limited partnership, articles of organization, certificate of formation, shareholder agreement, voting trust agreement, operating agreement, limited liability company agreement and/or analogous documents, as amended, modified or supplemented from time to time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Origination Fee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an amount of money equal to $510,000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the 10</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of each calendar month commencing on June 10, 2004.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Contest</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 5.3(B).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Encumbrances</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the matters identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;D&#160;</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Indebtedness</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) ordinary and customary trade payables incurred in the ordinary course of business of ownership and operation of the Mortgaged Property which are payable not later than thirty (30) days after receipt of the original invoice which are in fact not more than sixty (60) days overdue, and do not at any one time exceed $500,000 in the aggregate (not including any payables for Impositions or insurance premiums for which amounts have been deposited by Borrower in the Reserve Accounts) and (b) the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Investments</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the investments identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 6.4</font><font style="font-family:inherit;font-size:12pt;">, and any other investments that are approved by Lender in its sole discretion, provided that at all times Lender has a perfected first priority security interest in such investment, and Borrower has provided evidence of such, in form and substance satisfactory to Lender, and provided further that the Lender has approved the maturity of such investments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means and includes natural persons, corporations, limited liability companies, limited partnerships, general partnerships, joint stock companies, joint ventures, associations, companies, trusts, banks, trust companies, land trusts, business trusts or other organizations, whether or not legal entities, and governments and agencies and political subdivisions thereof and their respective permitted successors and assigns (or in the case of a governmental person, the successor functional equivalent of such Person).</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Physical Condition Report</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the report(s) regarding the physical inspection of the Land and Improvements listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(C)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Plans and Specifications</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the final drawings and specifications for the development and construction of each component part of the applicable Construction (as the same may be amended in accordance with the provisions permitted by this Agreement), as applicable, which plans and specifications and all amendments thereto shall be (i) subject to Lender&#8217;s approval, which approval shall not be unreasonably withheld or delayed, and (ii) in accordance with all applicable Legal Requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Prepayment Premium</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Yield Maintenance Amount.  However, if an Event of Default occurs on or before the Lockout Expiration Date and the Loan is accelerated to a date on or before the Lockout Expiration Date, the Prepayment Premium shall be equal to the sum of (a)&#160;the Yield Maintenance Amount and (b)&#160;five percent (5%) of the principal balance of the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proceeds</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;8.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Promissory Note</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Promissory Note dated of even date herewith made by Borrower to the order of Lender in the original principal amount of $34,000,000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proprietary Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;4.11.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Punch-List Items</font><font style="font-family:inherit;font-size:12pt;">&#8221; means details of construction, decoration and mechanical and electrical adjustment which in the aggregate are minor in character and do not materially interfere with the intended use and operation of the applicable Construction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Qualified Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any property manager reasonably acceptable to Lender that, as of the date of such designation, is a nationally recognized management firm engaged in the business, operation and management of office buildings, laboratories, vivariums, life service facilities or facilities for other similar uses containing in the aggregate at least 1,000,000 square feet of gross leaseable office space which are located in the United States and which is approved by Lender and with respect to which a Rating Agency Confirmation is provided.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rating Agency Confirmation</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, collectively, an affirmation from each of the Rating Agencies that the credit rating by such Rating Agency of the securities issued in connection with a securitization of the Loan or otherwise secured by a pledge of the Note immediately prior to the occurrence of the event with respect to which such Rating Agency Confirmation is sought will not be qualified, downgraded or withdrawn as a result of the occurrence of such event, which affirmation may be granted or withheld in such Rating Agency&#8217;s sole and absolute discretion provided, however if the Loan has not been securitized in connection with a Securitization in which some or all of the securities have been rated by one or more of the Rating Agencies, Rating Agency Confirmation means Lender&#8217;s approval, which approval is not to be unreasonably withheld or delayed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rating Agencies</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean S&amp;P and Moody&#8217;s or, if any of such firms shall for any reason no longer perform the functions of a securities rating agency, any other nationally recognized statistical rating agency reasonably designated by Lender; provided, however, that at any time during which the Loan is an asset of a securitization, &#8220;Rating Agencies&#8221; shall mean the rating agencies that from time to time rate the securities issued in connection with such securitization.  If the Loan is not an asset in a securitization, Rating Agency shall mean those rating agencies designated by Lender from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rents</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean all of Borrower&#8217;s right, title and interest in and to rents, income, receipts, royalties, profits, issues, service reimbursements, fees, termination payments receivables, accounts receivable and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">payments from or related to the Land and/or Improvements from time to time accruing from the operation of the Land and/or Improvements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Request for Release</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a request from Borrower to Lender in connection with a request for disbursement from the applicable Reserve accompanied by the following items, which request and items are subject to the approval of Lender not to be unreasonably withheld, conditioned or delayed: (a) currently dated certificate approved by Borrower from a Contractor, the Independent Architect, if any, and Lender&#8217;s Representative, if any, on a form to be reasonably approved by Lender; (b) the Required Lien Waivers in form and substance reasonably satisfactory to Lender; (c) if requested by Lender, from time to time, the requisitions for payment then the subject of such Request for Release from subcontractors and material suppliers engaged in the construction of the applicable Construction in form and content reasonably satisfactory to Lender; (d) an Inspection Certificate of an architect approved by Lender based upon an on&#8209;site inspection of the applicable Construction made by the Independent Architect and confirmed by Lender&#8217;s Representative, if any, which shall certify to all work for which such Request for Release has been completed; (e) evidence reasonably satisfactory to Lender of Construction Legal Compliance in the form of (i) a certificate of an Independent Architect as to items (a), (b) and (c) of the definition of Construction Legal Compliance (together with copies of the applicable entitlements, approvals, allocations, permits, licenses and conditional use permits), (ii) a certificate from the Borrower Representative as to item (d) of the definition of Construction Legal Compliance (which certificate may, as to &#8220;threatened&#8221; matters, be qualified to &#8220;such Person&#8217;s knowledge following due inquiry&#8221;) and (iii) such other showings, certificates, reports and items as Lender or Lender&#8217;s Representative, if any, may reasonably request to confirm Construction Legal Compliance; (f) a date&#8209;down endorsement to the Title Policy dating the Title Policy down to the date and time of the requested disbursement; and (g) such other information and documents as may be reasonably requested or required by Lender or Lender&#8217;s Representative, if any, including, but not limited to, certificates, inspections, date&#8209;down and other title policy endorsements, invoices, receipts, estoppel certificates, permits, licenses and certificates of occupancy, affidavits and other documents, appropriate for the applicable stage of Construction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Capital Improvements</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">is defined in Section 5.12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Completion Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means with respect to the Required Capital Improvements the applicable date for the applicable component of the Required Capital Improvements identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;E</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Lien Waivers</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, waivers of liens executed by (a) for each Request for Release, Contractor and each design professional with whom Borrower has a direct agreement, respectively, waiving their respective rights, if any, and any right of a subcontractor claiming through or under any of them, to file or maintain any construction liens or claims, all in such form containing such provisions as may be reasonably required by Lender and in accordance with applicable law and (b) for each Request for Release that includes a request for final payment to any subcontractor, such subcontractor, waiving its right to file or maintain any construction liens or claims, all in such form and containing such provisions as may be reasonably required by Lender executed with respect to and applicable to the extent such subcontractor has received payment.  Such waivers may be conditioned upon payment for work performed and materials supplied; provided, that the Request for Release that includes the request described in clause (b) above shall include (and in the case of the final Request for Release, within ten (10) days after the funding of such final Request for Release, Borrower shall deliver to Lender) a duly executed, unconditional waiver for each Person described in clauses (a) or (b) above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Restoration Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;8.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserve Account Collateral</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 6.5.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserve Accounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Insurance Reserve Account, the Tax Reserve Account and any other securities or deposit accounts required to be maintained pursuant to this Agreement or the other Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserves</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Tax Reserve and the Insurance Reserve.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Restoration</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;8.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">S&amp;P</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Standard &amp; Poor&#8217;s Rating Service and its successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Secure Areas</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the restricted access areas located within (i) that certain building containing approximately 29,600 square feet of rentable area, commonly referred to as the &#8220;Original Vivarium&#8221; and (ii) that certain building containing approximately 60,000 square feet of rentable area, commonly referred to as the &#8220;New Vivarium&#8221; in which access to such areas is restricted in order to provide a specific pathogen free environment, such restricted access areas being commonly referred to as the &#8220;area behind the barrier.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any stock, shares, voting trust certificates, bonds, debentures, options, warrants, notes, or other evidences of indebtedness, secured or unsecured, convertible, subordinated or otherwise, or in general any instruments commonly known as &#8220;securities&#8221; or any certificates of interest, shares or participations in temporary or interim certificates for the purchase or acquisition of, or any right to subscribe to, purchase or acquire, any of the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securitization</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section&#160;10.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Servicer</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 10.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Special Purpose Bankruptcy Remote Entity</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;7.13</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Subsidiary</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Person (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parent</font><font style="font-family:inherit;font-size:12pt;">&#8221;) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent&#8217;s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity (a)&#160;of which securities or other ownership interests representing more than fifty percent (50%) of the equity or more than fifty percent (50%) of the ordinary voting power or, in the case of a partnership, more than fifty percent (50%) of the general partnership interests are, as of such date, owned, controlled or held, or (b)&#160;that is, as of such date, otherwise Controlled, by the parent or one or more Subsidiaries of the parent or by the parent and one or more Subsidiaries of the parent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Substantial Completion and Substantially Completed</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the satisfaction of all of the following conditions: (a) the date when the applicable Construction shall have been completed (except for Punch List Items and minor items which can be fully completed without material interference with the use and operation of the Mortgaged Property) in accordance with the applicable Plans and Specifications as certified by the Independent Architect on standard AIA&#8209;G702 forms and approved by Lender&#8217;s Representative, if any, and Lender, such approval not to be unreasonably withheld or delayed; (b) all material permits and approvals required for the normal use and occupancy of the applicable Construction (including a certificate of occupancy if required for occupancy under applicable Legal Requirements) shall have been issued by the appropriate Governmental Authority and shall be in full force and effect; and (c) the applicable Construction shall have been equipped with all fixtures and equipment required for the intended use and operation of the Required Capital Improvements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Substitute Note</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all notes given in substitution or exchange for the Promissory Note or another Substitute Note.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Abatement Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, the Tax Abatement Agreement dated as of December 1, 2000, by and among Wells Fargo Bank Northwest, National Association (formerly First Security Bank, National Association), not in its individual capacity but solely as the Owner Trustee under the LEXI TRUST 2000&#8209;1, Guarantor and Montgomery County, Texas, as amended, and  that certain Assessment Abatement Agreement  dated as of December 4, 2000, by and between Wells Fargo Bank Northwest, National Association (formerly First Security Bank, National Association), not in its individual capacity but solely as the Owner Trustee under the LEXI TRUST 2000&#8209;1, Guarantor and The&#160;Woodlands Commercial Owners Association, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Reserve</font><font style="font-family:inherit;font-size:12pt;">&#8221; is the reserve for Impositions established pursuant to Section 5.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Reserve Account</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning provided in Section&#160;6.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tenant Impairment Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any one or more of the following has occurred: (a) the tenant under the Guarantor Lease has commenced or is the subject of a proceeding under the Bankruptcy Code; or (b) a default by the tenant under the Guarantor Lease shall have occurred which is not cured prior to the expiration of the applicable grace or curative period, if any, in such Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Title Company</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Commonwealth Land Title Insurance Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Title Policy</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a the mortgagee&#8217;s policy of title insurance issued on the standard Texas form by the Title Company, together with such reinsurance and direct access agreements as Lender may require, insuring that the Mortgage is a valid first and prior enforceable lien on Borrower&#8217;s fee simple interest in the Mortgaged Property (including any easements appurtenant thereto but excluding any non-real estate property interests included in the definition of Mortgaged Property) subject only to the Permitted Encumbrances.  The Title Policy shall contain such endorsements as Lender may require.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Total Debt/Capitalization</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, at any reporting date, for a Person, the percentage equal to (A) the sum of the long term debt (including any amounts for operating lease debt equivalents) of such Person plus the amount of any current maturities, commercial paper and other short-term borrowings (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Total Debt</font><font style="font-family:inherit;font-size:12pt;">&#8221;) divided by (B) the sum of the Total Debt plus the amount of shareholder&#8217;s equity (including any preferred stock) plus minority interests.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Total Loss</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i)&#160;a casualty, damage or destruction of the Mortgaged Property, the cost of restoration of which (as reasonably determined by Lender) would exceed $40,000,000,  (ii)&#160;a permanent taking of fifty percent (50%) or more of the gross leasable area of the Land or Improvements, (iii)&#160;a permanent taking of fifty percent (50%) or more of the automobile parking spaces located on the Land or such number of parking spaces as would cause the Borrower or the Mortgaged Property to cease to comply with applicable Legal Requirements or Material Contracts, or (iv)&#160;a permanent taking of so much of the Land or Improvements, in either case, such that it would be impracticable, in Lender&#8217;s reasonable discretion, even after restoration, to operate the Mortgaged Property as an economically viable whole.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, (a)&#160;when used as a verb, to, directly or indirectly, lease, sell, assign, convey, give, exchange, devise, mortgage, encumber, pledge, hypothecate, alienate, grant a security interest, or otherwise create or suffer to exist any Lien, transfer or otherwise dispose, or to contract or agreement to do any of the foregoing, whether by operation of law, voluntarily, involuntarily or otherwise as well as any other action or omission which has the practical effect of initiating or completing the foregoing and (b)&#160;when used as a noun, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a direct or indirect, lease, sale, assignment, conveyance, gift, exchange, devise, mortgage, encumbrance, pledge, hypothecation, alienation, grant of a security interest or other creation or sufferance of a Lien, transfer of other disposition, or contract or agreement by which any of the foregoing may be effected, whether by operation of law, voluntary or involuntary and any other action or omission which has the practical effect of initiating or completing the foregoing. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Treasury Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the annualized yield on securities issued by the United States Treasury having a maturity corresponding to the remaining term to the originally scheduled Maturity Date, as quoted in Federal Reserve Statistical Release H. 15(519) under the heading &#8220;U.S. Government Securities&#160;- Treasury Constant Maturities&#8221; for the Treasury Rate Determination Date (as defined below), converted to a monthly equivalent yield.  If yields for such securities of such maturity are not shown in such publication, then the Treasury Rate shall be determined by Lender by linear interpolation between the yields of securities of the next longer and next shorter maturities.  If said Federal Reserve Statistical Release or any other information necessary for determination of the Treasury Rate in accordance with the foregoing is no longer published or is otherwise unavailable, then the Treasury Rate shall be reasonably determined by Lender based on comparable data. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Treasury Rate Determination Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the date which is five (5) Business Days prior to the scheduled prepayment date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UCC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Uniform Commercial Code as in effect in the State of New&#160;York.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UCC Collateral</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 2.9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">U.S. Government Obligations</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any direct obligations of, or obligations guaranteed as to principal and interest by, the United States Government or any agency or instrumentality thereof, provided that such obligations are backed by the full faith and credit of the United States.  Any such obligation must be limited to instruments that have a predetermined fixed dollar amount of principal due at maturity that cannot vary or change.  If any such obligation is rated by S&amp;P, it shall not have an &#8220;r&#8221; highlighter affixed to its rating.  Interest must be fixed or tied to a single interest rate index plus a single fixed spread (if any), and move proportionately with said index.  U.S. Government Obligations include, but are not limited to:  U.S. Treasury direct or fully guaranteed obligations, Farmers Home Administration certificates of beneficial ownership, General Services Administration participation certificates, U.S. Maritime Administration guaranteed Title XI financing, Small Business Administration guaranteed participation certificates or guaranteed pool certificates, U.S. Department of Housing and Urban Development local authority bonds, and Washington Metropolitan Area Transit Authority guaranteed transit bonds.  In no event shall any such obligation have a maturity in excess of one hundred eighty (180) days.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Yield Maintenance Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means (A) the net present value of all future payments of principal and interest due for the remainder of the Term, discounted, each from the date such payments are due to the date of the prepayment, at the result of the Treasury Rate divided by 12, less (B) the then outstanding principal balance of the Loan; such Yield Maintenance Amount can never be less than zero; provided, however, for purposes of any partial prepayment, all references to the remaining outstanding principal balance of the Loan shall instead refer to the amount of such partial prepayment.  For purposes of computing the Yield Maintenance Amount with regard to Section 2.4(C)(iii), the date of prepayment shall be deemed the date the Loan is accelerated.   </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Terms; Utilization of GAAP for Purposes of Financial Statements Under Agreement</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes of this Agreement, all accounting terms not otherwise defined herein shall have the meanings assigned to such terms in conformity with GAAP.  Financial statements and other information </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">furnished to Lender pursuant to subsection 5.1 shall be prepared in accordance with GAAP as in effect at the time of such preparation.  No Accounting Changes shall affect financial covenants, standards or terms in this Agreement; provided, that Borrower shall prepare footnotes to the financial statements required to be delivered hereunder that show the differences between the financial statements delivered (which reflect such Accounting Changes) and the basis for calculating financial covenant compliance (without reflecting such Accounting Changes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Definitional Provisions</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">References to &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sections</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibits</font><font style="font-family:inherit;font-size:12pt;">&#8221; and &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Schedules</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall be to Sections, Exhibits and Schedules, respectively, of this Agreement unless otherwise specifically provided.  Any of the terms defined in Section&#160;1.1 may, unless the context otherwise requires, be used in the singular or the plural depending on the reference.  In this Agreement, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">hereof</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">herein</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">hereto</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">hereunde</font><font style="font-family:inherit;font-size:12pt;">r&#8221; and the like mean and refer to this Agreement as a whole and not merely to the specific section, paragraph or clause in which the respective word appears; words importing any gender include the other genders; references to &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">writing</font><font style="font-family:inherit;font-size:12pt;">&#8221; include printing, typing, lithography and other means of reproducing words in a tangible visible form; the words &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">including</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">includes</font><font style="font-family:inherit;font-size:12pt;">&#8221; and &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">include</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall be deemed to be followed by the words &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">without limitation</font><font style="font-family:inherit;font-size:12pt;">&#8221;; the phrase &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">and/or</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that either &#8220;and&#8221; or &#8220;or&#8221; may apply; the phrases &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">attorneys&#8217; fees</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">legal fees</font><font style="font-family:inherit;font-size:12pt;">&#8221; and &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">counsel fees</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall include any and all attorneys&#8217;, paralegal and law clerk fees and disbursements, including court costs, fees and disbursements at the pre-trial, trial and appellate levels incurred or paid by Lender in protecting its interest in the Mortgaged Property and the Collateral and enforcing its rights hereunder and/or the other Loan Documents; references to agreements and other contractual instruments shall be deemed to include subsequent amendments, assignments, and other modifications thereto, but only to the extent such amendments, assignments and other modifications are not prohibited by the terms of this Agreement or any other Loan Document; references to Persons include their respective permitted successors and assigns or, in the case of governmental Persons, Persons succeeding to the relevant functions of such Persons; references to a Person&#8217;s &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">knowledge</font><font style="font-family:inherit;font-size:12pt;">&#8221; in this Agreement or the other Loan Documents refers to the actual knowledge of the Person in question and such knowledge as a reasonably prudent Person would have acquired by virtue of such inquiry and due diligence as a reasonably prudent Person would have undertaken and all references to statutes and related regulations shall include any amendments of same and any successor statutes and regulations.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AMOUNTS AND TERMS OF THE LOAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Loan Disbursement and Note</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and conditions of this Agreement, Lender shall lend the Loan to Borrower on the Closing Date.  The proceeds of the Loan shall be used to (i) satisfy the Existing Indebtedness encumbering the Mortgaged Property; and (ii)&#160;satisfy actual, documented closing costs related to the Loan and approved by Lender.  The disbursement of the Loan in accordance with the foregoing shall be made on the Closing Date.  The Loan shall be evidenced by the Note.  The Obligations of Borrower under this Agreement, the Note and the other Loan Documents are secured by, among other things, the Mortgage and the Liens created or arising under the other Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Interest</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Interest Rate</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the provisions of Section&#160;2.2(C) hereof, the outstanding principal balance of the Loan shall bear interest at the Base Rate.  However, (a)&#160;during the existence of any Event of Default, or (b)&#160;after the Maturity Date or earlier upon acceleration of the Loan, the principal amount of the Loan shall bear interest (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Default Interest</font><font style="font-family:inherit;font-size:12pt;">&#8221;) at the Default Rate.  With respect to any scheduled payments of principal and interest (excluding the payment due on the Maturity Date), Borrower will be entitled to a </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">grace period of five (5) days from such date before Default Interest is imposed by reason of such late payment; provided, however, such grace period will not be available more than once in any twelve (12) Loan Month period and if Borrower fails to make the required payment within said five (5) day period, Default Interest will be calculated from the original due date.  Except as set forth in the preceding sentence, the Default Interest shall commence, without notice, immediately upon and from the occurrence of (a) or (b) above, as the case may be, and shall continue until all Events of Default are cured and all sums then due and payable under the Loan Documents are paid in full; provided that in the event of any monetary Event of Default, Default Interest shall be calculated from the date the applicable Default actually occurred.  Default Interest shall be payable upon demand, and, to the extent unpaid, shall be compounded monthly at the Default Rate.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Computation and Payment of Interest</font><font style="font-family:inherit;font-size:12pt;">.  Interest on the Loan and all other Obligations owing to Lender shall be computed on the daily principal balance of the Note on the basis of actual days elapsed and a three hundred sixty (360)&#8209;day year.  Interest on the Loan is payable in arrears.  Payments of interest shall be paid to Lender as specified in Section&#160;2.3.  In addition, all accrued and unpaid interest shall be paid to Lender on the earlier of the date of prepayment (to the extent prepayment is permitted under Section&#160;2.4) and maturity, whether by acceleration or otherwise.  The Loan shall commence to bear interest on the date the proceeds of the Loan are to be disbursed to or for the order of Borrower, provided, however, if the proceeds are disbursed to an escrowee, the Loan shall commence to bear interest from and including the date of disbursement to such escrowee regardless of the date such proceeds are disbursed from escrow.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Interest Laws</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any provision to the contrary contained in this Agreement or the other Loan Documents, Borrower shall not be required to pay, and Lender shall not be permitted to collect, any amount of interest in excess of the maximum amount of interest permitted by law (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess Interest</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  If any Excess Interest is provided for or determined by a court of competent jurisdiction to have been provided for in this Agreement or in any of the other Loan Documents, then in such event: (1)&#160;the provisions of this Section shall govern and control; (2)&#160;Borrower shall not be obligated to pay any Excess Interest; (3)&#160;any Excess Interest that Lender may have received hereunder shall be, at Lender&#8217;s option, (a)&#160;applied as a credit against the outstanding principal balance of the Obligations due and owing to Lender (without any prepayment penalty or premium therefor) or for accrued and unpaid interest thereunder (not to exceed the maximum amount permitted by law), (b)&#160;refunded to the payor thereof, or (c)&#160;any combination of the foregoing; (4)&#160;the interest rate(s) provided for herein shall be automatically reduced to the maximum lawful rate allowed from time to time under applicable law (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Maximum Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and this Agreement and the other Loan Documents shall be deemed to have been and shall be, reformed and modified to reflect such reduction; and (5)&#160;Borrower shall not have any action against Lender for any damages arising out of the payment or collection of any Excess Interest.  Notwithstanding the foregoing, if for any period of time interest on any Obligation due and owing to Lender is calculated at the Maximum Rate rather than the applicable rate under this Agreement, and thereafter such applicable rate becomes less than the Maximum Rate, the rate of interest payable on such Obligations due and owing to Lender shall, to the extent permitted by law, remain at the Maximum Rate until Lender shall have received or accrued the amount of interest which Lender would have received or accrued during such period on Obligations due and owing to Lender had the rate of interest not been limited to the Maximum Rate during such period.  All sums paid or agreed to be paid to Lender  for the use, forbearance or detention of the Obligations of Borrower to Lender shall, to the extent permitted by applicable law, (i) be amortized, prorated, allocated and spread throughout the full term of such Obligations until payment in full so that the actual rate of interest on account of such Obligations does not exceed the Maximum Rate throughout the term thereof, (ii) be characterized as a fee, expense or other charge other than interest, and/or (iii) exclude any voluntary prepayments and the effects thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Late Charges</font><font style="font-family:inherit;font-size:12pt;">.  If any scheduled payment of principal and/or interest or other amount owing pursuant to this Agreement or the other Loan Documents (excluding the payment due on the Maturity Date) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is not paid when due, Borrower shall pay to Lender, in addition to all sums otherwise due and payable, a late charge (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Late Charge</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in an amount equal to five percent (5%) of the unpaid amount.  With respect to regular monthly payments of principal and/or interest, Borrower will be entitled to a grace period of five (5) days (five (5) Business Days with respect to any non-scheduled payment due pursuant to this Agreement or the other Loan Documents) from the date due before a late charge is imposed by reason of such late payment; provided, however, such grace period will not be available more than once in any consecutive twelve (12) month period.  Any unpaid late charge shall bear interest at the Default Rate until paid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payments</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interest for the period commencing on the date of disbursement of the Loan and ending on May 9, 2004 shall be paid on the Closing Date.  On each Payment Date thereafter commencing with the Payment Date occurring on June 10, 2004, Borrower shall pay to Lender interest on the outstanding principal of the Loan accrued from and including the immediately preceding Payment Date, to, but not including, the Payment Date on which such payment is to be made.  Commencing on June 10, 2004, and on each Payment Date thereafter, principal of the Loan evidenced by the Note shall be paid to Lender in monthly installments of principal and interest in an amount equal to Two Hundred Eighty-Nine Thousand Two Hundred Seventy-Five and 64/100 Dollars ($289,275.64) per month, which amount shall be sufficient to amortize the full principal amount outstanding as of the date of disbursement of the Loan over a twenty (20) year term (such amortization schedule is attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.3</font><font style="font-family:inherit;font-size:12pt;">).  A balloon payment will be required on the Maturity Date as set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.3</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payments and Prepayments on the Loan</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Manner and Time of Payment</font><font style="font-family:inherit;font-size:12pt;">.  Borrower agrees to pay all of the Obligations relating to the Loan as such amounts become due or are declared due pursuant to the terms of this Agreement and the other Loan Documents.  All payments shall be made without deduction, defense, setoff or counterclaim by the wire transfer of good immediately available wire transferred federal funds to Lender&#8217;s account at JP Morgan Chase Bank for the account of Lender, Reference:  The Lexicon Campus, or at such other place as Lender may direct from time to time by five (5) days&#8217; advance written notice to Borrower.  Borrower shall receive credit for such funds on the date received if such funds are received by Lender by 1:00 P.M. (New&#160;York time) on such day.  In the absence of timely receipt, such funds shall be deemed to have been paid by Borrower on the following Business Day.  Whenever any payment to be made under the Loan Documents shall be stated to be due on a day that is not a Business Day, or any time period relating to a payment to be made hereunder is stated to expire on a day that is not a Business Day, the payment may be made on the following Business Day and the period will not expire until the following Business Day.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Maturity</font><font style="font-family:inherit;font-size:12pt;">.  The outstanding principal balance of the Loan, all accrued and unpaid interest thereon and all other sums owing to Lender pursuant to the Loan Documents, shall be due and payable on April 21, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Maturity Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Prepayments</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise provided in Section 5.3(C), Section 8.1 or Section 11.17 herein, no prepayment of the Loan shall be allowed in whole or in part, on or prior to the Lockout Expiration Date other than principal payments required pursuant to Section 2.3.  Thereafter, the Loan may be prepaid, in whole, but not in part, upon not less than thirty (30) days&#8217; prior notice to Lender.  Any prepayments on the principal balance of the Loan evidenced by the Note whether voluntary or involuntary, shall be accompanied by payment of interest accrued to the date of prepayment, together with the applicable Prepayment Premium.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event of (a) the payment of any principal of any Loan other than on the last day of an Interest Period applicable thereto (including as a result of an Event of Default) or (b)&#160;the failure to borrow or prepay the Loan on the date specified in any notice delivered pursuant to this Agreement or the other Loan Documents (regardless of whether such notice was revoked by Borrower prior to such prepayment), then, in any such event and, in addition to the payments to be made to Lender pursuant to 2.4(C)(i), Borrower agrees to compensate Lender for all out-of-pocket losses, costs, expenses and damages Lender may incur attributable to such event.  A certificate of Lender setting forth any amount or amounts that Lender is entitled to receive pursuant to this Section shall be delivered to Borrower and shall be conclusive absent manifest error.  Borrower shall pay Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If, following an Event of Default, payment of all or any part of the Loan is tendered by Borrower or otherwise recovered by Lender, such tender or recovery shall be deemed a voluntary prepayment by Borrower in violation of the prohibition against prepayment set forth in Section 2.4(C)(i) and Borrower shall pay to Lender, in addition to the other Obligations, the Prepayment Premium.  If the Maturity Date is accelerated, due to an Event of Default or otherwise, or if any prepayment of all or any portion of the Loan hereunder occurs, whether in connection with Lender&#8217;s acceleration of the Loan or otherwise, or if the Mortgage is satisfied or released by foreclosure (whether by power of sale or judicial proceeding), deed in lieu of foreclosure or by any other means, then the Prepayment Premium shall become immediately due and owing and Borrower shall immediately pay the Prepayment Premium to Lender.  Nothing contained in this Section 2.4(C)(iii) shall create any right of prepayment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lender&#8217;s Records; Mutilated, Destroyed or Lost Notes</font><font style="font-family:inherit;font-size:12pt;">.  The balance on Lender&#8217;s books and records shall be presumptive evidence (absent manifest error) of the amounts due and owing to Lender by Borrower; provided that any failure to so record or any error in so recording shall not limit or otherwise affect Borrower&#8217;s obligation to pay the Obligations.  In case any Note shall become mutilated or defaced, or be destroyed, lost or stolen, Borrower shall, upon request from Lender, execute and deliver a new Note of like principal amount in exchange and substitution for the mutilated or defaced Note, or in lieu of and in substitution for the destroyed, lost or stolen Note.  In the case of a mutilated or defaced Note, the mutilated or defaced Note shall be surrendered to Borrower upon delivery to Lender of the new Note.  In the case of any destroyed, lost or stolen Note, Lender shall furnish to Borrower, upon delivery to Lender of the new Note (i) certification of the destruction, loss or theft of such Note and (ii) such security or indemnity as may be reasonably required by Borrower to hold Borrower harmless.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:12pt;">.  Any and all payments or reimbursements made under the Agreement, the Note or the other Loan Documents shall be made free and clear of and without deduction for any and all taxes, levies, imposts, deductions, charges or withholdings, and all liabilities with respect thereto arising out of or in connection with the transactions contemplated by the Loan Documents; excluding, however, the following:  taxes imposed on the income of Lender by any jurisdiction or any political subdivision thereof; taxes that are not directly attributable to the Loan; and any &#8220;doing business&#8221; taxes, however denominated, charged by any state or other jurisdiction (all such taxes, levies, imposts, deductions, charges or withholdings and all liabilities with respect thereto, excluding such taxes imposed on income, taxes not directly attributable to the Loan and any &#8220;doing business&#8221; taxes, herein &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  If Borrower shall be required by law to deduct any such amounts from or in respect of any sum payable hereunder to Lender, then the sum payable hereunder shall be increased as may be necessary so that, after making all required deductions, Lender receives an amount equal to the sum it would have received had no such deductions been made.  In the event that, subsequent to the Closing Date, (1) any changes in any existing law, regulation, treaty or directive or in the interpretation or application thereof, (2) any new law, regulation, treaty or directive enacted or any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">interpretation or application thereof, or (3) compliance by Lender with any new request or directive (whether or not having the force of law) from any governmental authority, agency or instrumentality does or shall subject Lender to any tax of any kind whatsoever with respect to this Agreement, the other Loan Documents or the Loan, or change the basis of taxation of payments to Lender of principal, fees, interest or any other amount payable hereunder (except for income taxes, or franchise taxes imposed in lieu of income taxes, imposed generally by federal, state or local taxing authorities with respect to interest or commitment or other fees payable hereunder or changes in the rate of interest or tax on the overall income of Lender, taxes that are not directly attributable to the Loan and any &#8220;doing business&#8221; taxes, however denominated, charged by any state or other jurisdiction) and the result of any of the foregoing is to increase the cost to Lender of making or continuing its Loan hereunder, as the case may be, or to reduce any amount receivable hereunder, then, in any such case, Borrower shall promptly pay to Lender, within thirty (30) days after its demand, any additional amounts necessary to compensate Lender, on an after-tax basis, for such additional cost or reduced amount receivable, as determined by Lender with respect to this Agreement or the other Loan Documents.  If Lender becomes entitled to claim any additional amounts pursuant to this Section 2.6, it shall promptly notify Borrower of the event by reason of which Lender has become so entitled.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Application of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Except as otherwise expressly provided in the last sentence of this Section&#160;2.7, all payments made hereunder shall be applied first, to the payment of any Late Charges and other sums (other than principal and interest) due from Borrower to Lender under the Loan Documents, second, to any interest then due at the Default Rate, third to interest then due at the Base Rate, and last to the principal amount.  Following and during the continuance of an Event of Default, all sums collected by Lender shall be applied in such order of priority to such items set forth below as Lender shall determine in its sole discretion:  (i) to the costs and expenses, including reasonable attorneys&#8217; and paralegals&#8217; fees and costs of appeal, incurred in the collection of any or all of the Loan due or the realization of any collateral securing any or all of the Loan; and (ii) to any or all unpaid amounts owing pursuant to the Loan Documents in any order of application as Lender, in its sole discretion, shall determine.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Origination Fee</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall pay the Origination Fee to Lender on the Closing Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Security Agreement</font><font style="font-family:inherit;font-size:12pt;">.  To secure the payment, performance and discharge of the Obligations, Borrower hereby grants, assigns, transfers, conveys and sets over unto Lender, and hereby grants to Lender a continuing first priority, perfected security interest in all of Borrower&#8217;s right, title and interest in, to and under any and all of the following, whether now and/or existing and/or now owned and/or hereafter acquired and/or arising:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Accounts;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Contracts;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Reserve Accounts and other Reserve Account Collateral;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Equipment, Fixtures and Personalty;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the General Intangibles;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Leases;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(7)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Inventory;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(8)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Management Agreement(s);</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(9)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Rents and other Gross Revenues;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(10)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Proceeds; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(11)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">together with all accessions to, substitutions for, and replacements of, any of the foregoing and any and all products and cash and non-cash proceeds of any of the foregoing (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UCC Collateral</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to all UCC Collateral constituting a part of the Mortgaged Property, including, without limitation, the Accounts, this Agreement shall constitute a &#8220;security agreement&#8221; within the meaning of, and shall create a security interest under, the UCC.    Borrower hereby acknowledges and agrees that Lender shall be permitted to file one or more financing statements naming Borrower as debtor and Lender as secured party identifying &#8220;the Accounts, the Contracts, the Reserve Accounts and other Reserve Account Collateral, the Equipment, Fixtures and Personalty, the General Intangibles, the Leases, the Inventory, the Management Agreements, the Rents and other Gross Revenues and the Proceeds&#8221; of Borrower in the collateral description thereon.  As to the UCC Collateral, the grant, transfer, and assignment provisions of this Section 2.9 shall control over the grant provision of Section 2.1 of the Mortgage.  Borrower represents and warrants that, except for any financing statement filed by Lender, no presently effective financing statement covering the Collateral or any part thereof has been filed with any filing officer, and no other security interest has attached to or has been perfected in the Collateral or any part thereof.  Borrower shall from time to time within fifteen (15) days after request by Lender, execute, acknowledge and deliver, or authorize the filing of any financing statement, renewal, affidavit, certificate, continuation statement or other document as Lender may reasonably request in order to evidence, perfect, preserve, continue, extend or maintain this security agreement and the security interest created hereby as a first priority Lien on the UCC Collateral, subject only to the Permitted Encumbrances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Certain Secured Party Remedies</font><font style="font-family:inherit;font-size:12pt;">.  If an Event of Default shall have occurred and be continuing, Lender shall have all the remedies of a secured party under the UCC and all other rights and remedies now or hereafter provided or permitted by law, including, without limitation, the right to take immediate and exclusive possession of the UCC Collateral, or any part thereof, and for that purpose Lender may, as far as Borrower can give authority therefor, with or without judicial process, enter (if this can be done without breach of the peace) upon any premises on which any of the Collateral or any part thereof may be situated.  Without limitation of the foregoing, Lender shall be entitled to hold, maintain, preserve and prepare all of the Collateral for sale and to dispose of said Collateral, if Lender so chooses, from the Mortgaged Property provided that Lender may require Borrower to assemble such UCC Collateral and make it available to Lender for disposition at a place to be designated by Lender from which the UCC Collateral would be sold or disposed of, and provided further that, for a reasonable period of time prior to the disposition of such UCC Collateral, Lender shall have the right to use same in the operation of the Mortgaged Property.  Borrower will execute and deliver to Lender any and all forms, documents, certificates and registrations as may be necessary or appropriate to enable Lender to sell and deliver good and clear title to the UCC Collateral to the buyer at the sale as herein provided.  Unless the UCC Collateral is of the type customarily sold on a recognized market, Lender will give Borrower at least ten (10) days&#8217; written notice of the time and place of any public sale of such UCC Collateral or of the time after which any private sale or any other intended disposition thereof is to be made.  The requirements of reasonable notice shall be met if such notice is given to Borrower in writing at least ten (10) days before the time of the sale or disposition.  Lender may buy at any public sale and, if the UCC Collateral is of a type customarily sold in a recognized market or is a type which is the subject of widely distributed standard price quotations, it may buy at private sale.  Unless Lender shall otherwise elect, any sale of the UCC Collateral shall be solely as a unit and not in separate lots or parcels, it being expressly agreed, however, that Lender shall have the absolute right to dispose of such UCC Collateral in separate lots or parcels.  Lender shall further have the absolute right to elect to sell the UCC Collateral as a unit with, and not separately from, the Land and Improvements constituting a portion of the Mortgaged Property.  The net proceeds realized upon any disposition of the UCC Collateral, after deduction for the expenses of retaining, holding, preparing for sale, selling and the like and the attorneys&#8217; fees and legal expenses incurred by Lender shall be applied towards satisfaction of such of the Obligations secured hereby, and in such order of application, as Lender may elect.  If all of the Obligations are satisfied, Lender will account to Borrower for any surplus realized on such disposition.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONDITIONS TO LOAN</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions to Funding of the Loan on the Closing Date</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The obligation of Lender to disburse the Loan is subject to the prior or concurrent satisfaction of the conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Performance of Agreements; Truth of Representations and Warranties; No Injunction</font><font style="font-family:inherit;font-size:12pt;">.  Borrower, Guarantor and all other Persons executing any Loan Document on behalf of Borrower and Guarantor shall have performed in all material respects all agreements which any of the Loan Documents provide shall be performed on or before the Closing Date.  The representations and warranties contained in the Loan Documents shall be true, correct and complete in all material respects on and as of the Closing Date to the same extent as though made on and as of that date.  No Legal Requirements shall have been adopted, no order, judgment or decree of any Governmental Authority shall have been issued or entered, and no litigation shall be pending or threatened, which in the reasonable judgment of Lender would enjoin, prohibit or restrain, or impose or result in an adverse effect upon the making, borrowing or repayment of the Loan or the execution, delivery or performance of the Loan Documents.  No Default or Event of Default shall have occurred and then be continuing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Opinion of Counsel</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved written opinions of counsel for Borrower, Guarantor and Borrower Representative, in form and substance reasonably satisfactory to Lender and its counsel, dated as of the Closing Date.  By execution of this Agreement, Borrower  authorizes and directs its counsel to render and deliver such opinions to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  On or before the Closing Date, Borrower shall execute and deliver and cause to be executed and delivered, to Lender all of the Loan Documents, each, unless otherwise noted, dated the Closing Date, duly executed, in form and substance satisfactory to Lender and in quantities designated by Lender (except for the Promissory Note, of which only the original shall be executed).  Borrower hereby authorizes Lender to file the financing statements in such filing offices as Lender elects.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Intentionally Omitted.</font><font style="font-family:inherit;font-size:12pt;">]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(E)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insurance Policies and Endorsements</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved the original policies of insurance required to be maintained under this Agreement and the other Loan Documents, together with endorsements satisfactory to Lender naming Lender as additional insured under such policies.  If such policies are not delivered to Lender, Lender must receive and approve a copy of the insurance policies in question and evidence of such insurance required to be maintained in connection with this Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(F)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Organizational and Authorization Documents</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received all documents reasonably requested by Lender, including all Organizational Documents, with regard to the due organization, existence, internal governance, power and authority, due authorization, execution and delivery, authorization to do business and good standing of Borrower, Guarantor and the Borrower Representative, the validity and binding effect of the Loan Documents and other matters relating thereto, in form and substance reasonably satisfactory to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(G)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Closing Statement</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved a closing and disbursement statement executed by Borrower with respect to the disbursement of the proceeds of the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(H)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Financial Statements</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received financial statements of Guarantor as of December 31, 2003.  Lender shall have received (a)&#160;audited historical operating statements for the Mortgaged </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Property (such statements may be unaudited, to the extent audited statements are not available), for the calendar years 2002 and 2003, and unaudited financial statements for 2004 (to date); (b)&#160;audited financial statements for Guarantor for the calendar years 2002 and 2003, and unaudited financial statements for the calendar year 2004 (to&#160;date); and (c) a pro forma balance sheet of Borrower dated the Closing Date giving effect to the making of the Loan and the transactions occurring on the Closing Date, each accompanied by an Officer&#8217;s Certificate of the Borrower Representative.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(I)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Budget and Capital Plan</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved the initial Budget and initial Capital Plan for Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(J)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Appointment of Agent for Service of Process</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved a letter appointing (and accepted by) CT&#160;Corporation System as Borrower&#8217;s and Guarantor&#8217;s agent for service of process.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(K)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Material Contracts and Other Agreements</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved true, correct and complete certified copies of each Material Contract, all other operating agreements, service contracts and equipment leases and all permits, licenses and documents pertaining to the Proprietary Rights relating to the Mortgaged Property. Lender shall have received executed estoppel certificates from all Parties to the Material Contracts designated by Lender (and not otherwise addressed in this Section 3.1).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(L)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Environmental Assessments, Physical Condition Reports and Lender&#8217;s Inspection and Plans and Specifications</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved the Environmental Reports and Physical Condition Reports relating to the Mortgaged Property, together with letters from the preparer(s) thereof permitting Lender to rely upon the Environmental Reports and Physical Condition Reports.  To the extent in the possession of, or reasonably obtainable by, the Borrower, a true, correct and complete copy of &#8220;as&#8209;built&#8221; plans and specifications for  the Improvements.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(M)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Title Policy, Survey, Searches, Perfection and Priority</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved (i) the Title Policy and (ii) a plat of survey of the Land, Improvements and other components of the Mortgaged Property constituting real estate certified to such Persons as Lender may designate and prepared in accordance with Lender&#8217;s requirements.  Lender shall have received and approved copies of Uniform Commercial Code financing statement, judgment, tax lien, bankruptcy and litigation search reports of such jurisdictions and offices as Lender may reasonably designate with respect to Borrower, Guarantor, Borrower Representative and such other Persons as Lender may reasonably require.  Lender shall have received such other evidence as Lender may require confirming that Lender has a perfected first priority security interests and Lien upon the Collateral.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(N)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Licenses, Permits and Approvals, Zoning and Land Use Compliance</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received and approved (i)&#160;a copy of the certificate of compliance issued by The Community Standards Committee of The&#160;Woodlands Commercial Owners Association and The Woodlands Community Association issued with respect to the Mortgaged Property and all other applicable licenses, permits and approvals required to own, use, occupy, operate and maintain the Mortgaged Property, including all necessary licenses and permits relating to wetlands compliance, and use of water; (ii)&#160;evidence satisfactory to Lender of the existence, ownership and status of all Proprietary Rights and Material Contracts; and (iii)&#160;evidence satisfactory to Lender as to the compliance of the Mortgaged Property with all applicable Legal Requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(O)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Reserve Accounts and Deposits</font><font style="font-family:inherit;font-size:12pt;">.  The Reserve Accounts shall have been established in a manner satisfactory to Lender.  The initial deposits into the Reserves on the Closing Date, shall have been made (which amounts may, with Lender&#8217;s approval, be made from the proceeds of the Loan).</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(P)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Origination Fee</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received its Origination Fee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Q)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Leases</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have received (a) an estoppel certificate and subordination, nondisturbance and attornment agreement executed by each tenant of the Mortgaged Property and (b) true, correct and complete certified copies of each of the Leases.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(R)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Documents and Deliveries</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall have delivered such other documents and deliveries as are set forth on the Closing Checklist attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(A)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(S)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Legal Fees; Closing Expenses</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall have paid any and all legal fees and expenses of counsel to Lender, together with all recording fees and taxes, title insurance premiums, and other costs and expenses related to the Loan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(T)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">.  Guarantor shall have executed and delivered the Guaranty. </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 4</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">REPRESENTATIONS AND WARRANTIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower represents and warrants to Lender that, after giving effect to the Loan, as of the Closing Date:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Organization, Powers, Qualification and Organization Chart</font><font style="font-family:inherit;font-size:12pt;">.  Borrower is a limited partnership duly formed, validly existing and in good standing under the laws of its state of formation.  Each of Borrower and Borrower Representative has all requisite power and authority to own and operate its properties, to carry on its business as now conducted and proposed to be conducted, and to enter into each Loan Document to which it is a party and to perform the terms thereof.  Guarantor is a corporation, duly organized, validly existing and in good standing under the laws of its state of formation and has all requisite power and authority to own and operate its properties, to carry on its business as now conducted, and to enter into each Loan Document to which it is a party and to perform the terms thereof.  Borrower&#8217;s U.S. taxpayer identification number is set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.1(A)&#8209;1</font><font style="font-family:inherit;font-size:12pt;">.  Borrower and Guarantor are each duly qualified and in good standing wherever necessary to carry on its present business and operations.  Borrower Representative is a limited liability company, duly organized and validly existing under the laws of the State of Delaware and is the sole general partner in Borrower.  Guarantor owns one hundred percent (100%) of the ownership interests in Borrower Representative.  Guarantor owns, indirectly, one hundred percent (100%) of the ownership interests in Borrower.  The organization chart attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;4.1(A)&#8209;2</font><font style="font-family:inherit;font-size:12pt;">&#32;correctly identifies each Subsidiary of Borrower and each Person directly owning (and/or indirectly owning five percent (5%) or more of) the ownership interests in Borrower and Borrower Representative; provided that such organizational chart shall not identify any Person owning, directly or in directly, any ownership interests of Guarantor.  The principal place of business and chief executive office of Borrower is set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.1(A)&#8209;3</font><font style="font-family:inherit;font-size:12pt;">.  Borrower has filed in a timely manner all reports, documents and other materials required to be filed by it with any Governmental Authorities and the information contained in each of such filings is true, correct and complete in all respects).  Borrower has retained all records and documents required to be retained by it pursuant to any law, ordinance, rule, regulation, order, policy, guideline or other requirement of any Governmental Authority.  Borrower has no Subsidiaries and has not made an Investment in any Person.  Borrower  Representative&#8217;s sole asset is its interest in Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Authorization of Borrowing; No Conflicts; Governmental Consents; Binding Obli-gations and License and Security Interests of Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  Borrower has the power and authority to incur the Obligations evidenced by the Note and other Loan Documents to which it is a party, to execute and deliver the Loan Documents to which it is a party and to perform its Obligations, to own the Mortgaged Property </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and to continue its businesses and affairs as presently conducted.  Guarantor has the power and authority to execute and deliver the Guaranty, the Environmental Indemnification Agreement and the other Loan Documents to which it is a party.  The incurring of the Obligations and the execution, delivery and performance by Borrower and Guarantor of each of the Loan Documents to which either is a party and the consummation of the transactions contemplated thereby have been duly authorized by all necessary partnership, corporate or limited liability company action, as the case may be.  The incurring of the Obligations and the execution, delivery and performance by Borrower and Guarantor of the Loan Documents to which either is a party and the consummation of the transactions contemplated thereby do not and will not:  (1)&#160;violate any provision of law applicable to Borrower, Guarantor or the Mortgaged Property, the respective other Organizational Documents of, or applicable to, Borrower or Guarantor, as the case may be, or any order, judgment or decree of any court or other agency of government binding on Borrower or Guarantor or their respective properties including the Mortgaged Property; (2)&#160;conflict with, result in a breach of, or constitute (with due notice or lapse of time or both) a default under any Material Contracts or any other agreement or document to which such Person is a party or by which such Person or its property may be bound; (3)&#160;result in or require the creation or imposition of any Lien upon the Mortgaged Property or assets of Borrower or Guarantor (other than the Liens of Lender); or (4)&#160;require any approval or consent of any Person under any Material Contracts or any other agreement or document to which such Person is a party or by which such Person or its property may be bound (except to the extent such approvals or consents have been unconditionally obtained on or before the Closing Date).  The incurring of the Obligations, the execution, delivery and performance by Borrower and Guarantor of the Loan Documents and the consummation of the transactions contemplated thereby do not and will not require any registration with, consent or approval of, or notice to, or other action to, with or by, any federal, state or other Governmental Authority or regulatory body (except to the extent unconditionally obtained on or before the Closing Date).  The Loan Documents, when executed and delivered by Borrower and Guarantor, as applicable, will be the legally valid and binding obligations of Borrower and Guarantor, as applicable, enforceable against Borrower and Guarantor, subject to bankruptcy, insolvency, moratorium, reorganization and other similar laws affecting creditors&#8217; rights generally and to the application of general equitable principles in connection with the enforcement thereof.  The Mortgage, together with the Financing Statements to be filed in connection therewith, create a valid, enforceable and perfected first priority lien and security interest in the Mortgaged Property subject to no other interests, Liens or encumbrances, other than the Permitted Encumbrances.  Article 6 of this Agreement creates a valid, enforceable and perfected first priority security interest in the Reserve Account Collateral.  Borrower is a &#8220;registered organization&#8221; (as defined in the UCC) organized under the laws of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Financial Statements</font><font style="font-family:inherit;font-size:12pt;">.  All financial statements concerning Borrower and Guarantor which have been or will hereafter be furnished by Borrower and Guarantor to Lender pursuant to this Agreement have been or will be prepared in accordance with GAAP consistently applied (except as disclosed therein, to the extent Lender approves such disclosure) and do or will, in all material respects, present fairly the financial condition of the Persons covered thereby as at the dates thereof and the results of their operations for the periods then ended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness</font><font style="font-family:inherit;font-size:12pt;">.  As of the Closing Date, after giving effect to the transactions contemplated hereby, Borrower does not have any Indebtedness except for Permitted Indebtedness.  Other than ordinary operating expenses pertaining to the Mortgaged Property, all Expenses owing or accrued as of the Closing Date, have been paid in full or have been reserved for by deposit into the Reserves.  No claim of any creditor of Borrower exists which would have a Material Adverse Effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">No Material Adverse Change</font><font style="font-family:inherit;font-size:12pt;">.  Since December 31, 2003, no event or change has occurred that has caused or evidences, either individually or together with such other events or changes, a Material Adverse Effect.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Title to Property; Liens; Zoning; Contracts; Condition of the Mortgaged Property</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower has good and indefeasible fee simple title to the Land, the Improvements and the other components of the Mortgaged Property, subject only to the Permitted Encumbrances.  Borrower owns all real and personal property necessary for the operation of the Mortgaged Property subject only to the Permitted Encumbrances.  Except for the Permitted Encumbrances, the Mortgaged Property is free and clear of Liens and other encumbrances.  Except as otherwise identified on Schedule 4.6(a), there are no outstanding Claims and all work, services or materials the provision of which might ripen into a Claim have been fully paid for.  There are no assessments for improvements or other similar outstanding charges or Impositions affecting the Mortgaged Property.  Except as otherwise identified on the survey provided to Lender, no Improvements lie outside the boundaries and building restriction lines of the Land or encroach onto any easements to any extent (unless affirmatively insured by the Title Policy), and no improvements on adjoining properties encroach upon the Land to any extent which would materially impair the Mortgaged Property.  The Title Policy premium has been fully paid.  Except for the affidavit as to debts, liens and possession provided by Borrower to the Title Company at Closing, neither Borrower, nor, to Borrower&#8217;s knowledge, any other Person, has provided any title indemnities (or analogous documentation) or deposits of cash or other security to the title insurer to obtain the Title Policy.  The Permitted Encumbrances do not and will not materially interfere with the security intended to be provided by the Mortgage, the use or operation of the Mortgaged Property or the marketability or value of the Mortgaged Property.  Borrower will preserve its right, title and interest in and to the  Mortgaged Property for so long as the Obligations remain outstanding and will warrant and defend same and the validity and priority of the Mortgage and the Liens arising pursuant to the Loan Documents from and against any and all claims whatsoever other than the Permitted Encumbrances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Mortgaged Property is restricted for use as an office, laboratory, vivarium, research, marketing, sales, storage, experimentation and production of laboratory animals, which restriction is in full force and effect, and is beyond all applicable appeal periods.  Borrower is not in violation of, and, the Mortgaged Property is in full compliance with all applicable zoning, subdivision, land use and other Legal Requirements.  No legal proceedings are pending or, to Borrower&#8217;s knowledge threatened, with respect to the compliance of the Mortgaged Property  with Legal Requirements.  Neither the zoning nor any other right to construct, use or operate the Mortgaged Property is in any way dependent upon or related to any real estate other than the Mortgaged Property and validly created, existing appurtenant perpetual easements insured in the Title Policy or use of public rights of way.  In the event that all or any part of the Improvements are destroyed or damaged, said Improvements can be legally reconstructed to their condition prior to such damage or destruction, and thereafter exist for the same use without violating any zoning or other Legal Requirements applicable thereto and without the necessity of obtaining any variances or special permits.  The Mortgaged Property contains not less than 468 parking spaces, which is enough permanent parking spaces to satisfy all requirements imposed by applicable Legal Requirements with respect to parking.  All licenses, permits and other Proprietary Rights necessary to operate the Mortgaged Property as it is currently operated are in full force and effect including all water permits and approvals.  Borrower has not received any written notice of any violation of any such licenses, permits, authorizations, registrations or approvals that materially impair the value of the Mortgaged Property for which such notice was given or which would affect the use or operation of the Mortgaged Property in any material respect, which noticed violation remains uncured.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower has provided Lender with true and complete copies of all Material Contracts, all of which are specifically listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.6(C)</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof, other than the Permitted Encumbrances.  Except for the Loan Documents and as set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.6(C)</font><font style="font-family:inherit;font-size:12pt;">, Borrower is not a party to and neither it nor the Mortgaged Property is bound by any material agreement, document or instrument which is binding upon the Mortgaged Property other than the Loan Documents, the Permitted Encumbrances, the other Material </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contracts, if any, and such party&#8217;s organizational documents, true, correct and complete copies of which have been delivered to Lender.  Except for the Loan Documents and the Material Contracts, none of Borrower, Borrower Representative and Guarantor are parties to or bound by, nor is any of their respective property subject to or bound by, any contract or other agreement which restricts its ability to conduct its business at the Mortgaged Property in the ordinary course or, either individually or in the aggregate, has a Material Adverse Effect or could reasonably be expected to have a Material Adverse Effect.  Borrower, Borrower Representative and Guarantor are not in default in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in any Material Contract of any such Person which could have a Material Adverse Effect.  No Default or Event of Default exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All of the Improvements are in good condition and repair except with respect to the Required Capital Improvements.  To Borrower&#8217;s knowledge, except as disclosed in the Physical Condition Report, there are no latent or patent structural or other significant defects or deficiencies in the Improvements or Equipment, Fixtures and Personalty. Municipal or private water supply, storm and sanitary sewers, and electrical, gas and telephone facilities are available to the Mortgaged Property to the boundary lines of the Mortgaged Property through publicly dedicated streets or highways or perpetual appurtenant easements insured on the Title Policy as appurtenant easements, are sufficient to meet the reasonable needs of the Mortgaged Property as now used or as otherwise presently contemplated to be used, and are connected to, and is in full unimpaired operation with respect to the Improvements and no other utility facilities are necessary to meet the reasonable needs of the Mortgaged Property as now used.  The design and as&#8209;built conditions of the Mortgaged Property are such that surface and storm water does not accumulate on the Mortgaged Property and does not drain from the Mortgaged Property across land of adjacent property owners or others in any manner which would have a Material Adverse Effect or which require any approvals or easements not already obtained.  Except as set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.6(D)</font><font style="font-family:inherit;font-size:12pt;">&#32;or on the plat of survey delivered to Lender, no part of the Mortgaged Property is within a flood plain or in a flood hazard area as currently shown on the most recent Flood Hazard Boundary Maps prepared by the Department of Housing and Urban Development and (except to the extent validly created and existing perpetual appurtenant easements insured in the Title Policy have been created therefor) none of the Improvements create encroachments over, across or upon any of the Mortgaged Property&#8217;s boundary lines, rights of way or easements, and no building or other improvements on adjoining land create such an encroachment.  All irrigation lines servicing the Mortgaged Property are entirely located on the Mortgaged Property or are located on adjacent property pursuant to validly created and existing perpetual appurtenant easements insured as appurtenant easements in the Title Policy.  The Land and Improvements have legally adequate contiguous rights of access to public ways.  All roads necessary for the full utilization of the Land and Improvements for their current purpose have been completed and dedicated to public use and accepted by all Governmental Authorities.  No offsite improvements are necessary or used for the ownership, use or operation of the Mortgaged Property, other than public utilities.  The Improvements, the Land, the Equipment, Fixtures and Personalty and the Inventory located on the Land constitutes all of the real property, equipment, fixtures and other tangible property currently owned or leased by Borrower or used in the operation of the Mortgaged Property and the Equipment, Fixtures and Personalty owned by the Borrower are sufficient to own, operate and use the Land and Improvements as currently operated.  Except as identified in the Permitted Encumbrances, Borrower has not entered into any agreement or option, and is not otherwise bound, to sell the Mortgaged Property (or any part thereof). Borrower has not entered into any agreement or option, and is not otherwise bound, to acquire any additional real estate or Investments.  As of the date hereof, no portion of the Improvements constituting part of the Mortgaged Property or on the Land has been materially damaged, destroyed or injured by fire or other casualty which has not been fully restored.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Litigation</font><font style="font-family:inherit;font-size:12pt;">.  Except as set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.7</font><font style="font-family:inherit;font-size:12pt;">, there are no judgments outstanding against Borrower or Guarantor or are binding upon the Mortgaged Property or any property of, Borrower Representative or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Guarantor, nor is there any litigation, governmental investigation or arbitration pending or, to Borrower&#8217;s knowledge, threatened against Borrower, Borrower Representative or Guarantor.  The judgments, litigation, investigations and arbitrations set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;4.7</font><font style="font-family:inherit;font-size:12pt;">&#32;will not result, if adversely determined, and could not reasonably be expected to result, either individually or in the aggregate, in any Material Adverse Effect and do not relate to and will not affect the consummation of the transactions contemplated hereby.  No petition in bankruptcy, whether voluntary or involuntary, or assignment for the benefit of creditors, or any other action involving debtors&#8217; and creditors&#8217; rights has ever been filed under the laws of the United States of America or any state thereof, or threatened, by or against, Borrower, Guarantor or Borrower Representative.  Except as set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.7</font><font style="font-family:inherit;font-size:12pt;">, there are no mechanics&#8217; or materialmen&#8217;s liens, alienable bills or other claims constituting or that may constitute a Lien on the Mortgaged Property or any part thereof, and no work for which any such Lien could be asserted has been performed which has not been fully paid for.  Borrower has not received any notice from any governmental or quasi-governmental body or agency or from any person or entity with respect to (and Borrower does not know of) any actual or threatened taking of the Land or Improvements, or any portion thereof, for any public or quasi-public propose or of any moratorium which may affect the use, operation or ownership of the Mortgaged Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payment of Taxes</font><font style="font-family:inherit;font-size:12pt;">.  All tax returns and reports of Borrower, Borrower Representative and Guarantor required to be filed by such Persons have been timely filed, and all taxes, assessments, fees and other governmental charges upon such Person and upon the Mortgaged Property, assets, income and franchises which are due and payable have been paid in full.  To Borrower&#8217;s knowledge, no tax returns of Borrower, Borrower Representative or Guarantor is under audit.  No tax liens have been filed and, to Borrower&#8217;s knowledge no claims are being asserted with respect to any such taxes.  The charges, accruals and reserves on the books of Borrower, Borrower Representative and Guarantor in respect of any taxes or other governmental charges are in accordance with GAAP.  Except as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.8</font><font style="font-family:inherit;font-size:12pt;">, none of Borrower, Guarantor and Borrower Representative has given or been requested to give waivers or extensions (or is or would be subject to a waiver or extension given by any other Person) of any statute of limitations relating to the payment of taxes of Borrower, Guarantor and Borrower Representative or for which Borrower, Guarantor and Borrower Representative may be liable.  All taxes that Borrower, Guarantor and Borrower Representative is or was required by Legal Requirements to withhold or collect have been duly withheld or collected and, to the extent required, have been paid to the applicable Governmental Authority.  All tax returns filed by (or that include on a consolidated basis) Borrower, Guarantor and Borrower Representative are true, correct and complete.  There is no tax sharing agreement that will require any payment by Borrower, Guarantor and Borrower Representative after the date of this Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governmental Regulation; Margin Loan</font><font style="font-family:inherit;font-size:12pt;">.  Borrower, Borrower Representative and Guarantor are not, nor after giving effect to the Loan, will be, subject to regulation under the Public Utility Holding Company Act of 1935, the Federal Power Act or the Investment Company Act of 1940 or to any federal or state statute or regulation limiting its ability to incur indebtedness for borrowed money.  Borrower shall use the proceeds of the Loan only for the purposes set forth in this Agreement and consistent with all applicable laws, statutes, rules and regulations.  No portion of the proceeds of the Loan shall be used by Borrower in any manner that might cause the borrowing or the application of such proceeds to violate Regulation&#160;U, Regulation&#160;T or Regulation&#160;X or any other regulation of the Board of Governors of the Federal Reserve System or to violate the Exchange Act or any other Legal Requirements.  The Loan is an exempt transaction under the Truth-in-Lending Act (15 U.S.C.A. &#167;&#167;&#160;1601 et&#160;seq.).  Borrower is not a non-resident alien for purposes of U.S. income taxation and neither Borrower nor Borrower Representative is a foreign corporation, partnership, foreign trust or foreign estate (as said terms are defined in the United States Internal Revenue Code).  Borrower, Borrower Representative, Guarantor or any of their respective Subsidiaries are not, and shall not become, a Person with whom Lender is restricted from doing business with under regulations of the Office of Foreign Asset Control </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OFAC</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">)</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Department of the Treasury (including, but not limited to, those named on </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OFAC&#8217;s Specially Designated and Blocked Persons list) or under any statute, executive order (including, but not limited to, the September 24, 2001 Executive Order Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism) or other governmental action relating to terrorism financing, terrorism support and/or otherwise relating to terrorism and are not and shall not engage in any dealings or transaction or otherwise be associated with Persons named on OFAC&#8217;s Specially Designated and Blocked Persons list.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Employee Benefit Plans; ERISA; Employees</font><font style="font-family:inherit;font-size:12pt;">.  Except for the Employee Benefit Plans set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.10</font><font style="font-family:inherit;font-size:12pt;">, neither Borrower nor any ERISA Affiliate of Borrower maintains or contributes to, or has any obligation under, any Employee Benefit Plans.  Borrower is not an &#8220;employee benefit plan&#8221; (within the meaning of section 3(3) of ERISA) to which ERISA applies and the Mortgaged Property and Borrower&#8217;s assets do not constitute plan assets.  No actions, suits or claims under any laws and regulations promulgated pursuant to ERISA are pending or, to Borrower&#8217;s knowledge, threatened against Borrower.  Borrower has no knowledge of any material liability incurred by Borrower which remains unsatisfied for any taxes or penalties with respect to any Employee Benefit Plan or any Multiemployer Plan, or of any lien which has been imposed on Borrower&#8217;s assets pursuant to section 412 of the Code or section 302 or 4068 of ERISA.  The Loan, the execution, delivery and performance of the Loan Documents and the transactions contemplated by this Agreement do not constitute a non-exempt prohibited transaction under ERISA.  Borrower is not a party to any collective bargaining or other employment agreement other than the agreements identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.10</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.11</font><font style="font-family:inherit;font-size:12pt;">&#32;sets forth a true, correct and complete list of all of the patents, trademarks, tradenames, technology, other intellectual property rights and other Proprietary Rights owned by Borrower and used in connection with the ownership, operation and management of the Mortgaged Property.  Borrower possesses, owns or has valid licenses, permits, certificates of public convenience, service marks, authorizations, licenses, patents, patent rights or licenses, trademarks, trademark rights, trade name rights, trade styles, trade dress, logos and other source or business affiliation identifiers, and copyrights, certificates, consents, orders, approvals and other authorizations from, and have made all declarations and filings with, all federal, state, local and other Governmental Authority, all self-regulatory organizations and all courts and other tribunals (collectively, together with the goodwill associated therewith, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proprietary Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221;) presently required or necessary to own or lease, as the case may be, and to operate, the Mortgaged Property and to carry on its business as now conducted in accordance with the Approved Budget and Approved Capital Plan, except where the failure to obtain same would not, individually or in the aggregate, have a Material Adverse Effect.  Borrower has fulfilled and performed all of its obligations with respect to such permits, and no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or could result in any other material impairment of the rights of the holder of any such permit; and Borrower has not received any notice of any proceeding relating to unenforceability, invalidity, revocation or modification of any Proprietary Rights, except where such revocation, unenforceability, invalidity, or modification would not, individually or in the aggregate, have a Material Adverse Effect.  Borrower has not received any notice that any Proprietary Rights have been declared unenforceable or otherwise invalid by any court or Governmental Authority other than notices relating to Proprietary Rights the loss of which would not, individually or in the aggregate, have a Material Adverse Effect.  Borrower has not received any notice of infringement of, or conflict with, and Borrower does not know of any such infringement of or conflict with, asserted rights of others with respect to any Proprietary Rights which, if such assertion of infringement or conflict were sustained, would have a Material Adverse Effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Broker&#8217;s Fees</font><font style="font-family:inherit;font-size:12pt;">.  No broker&#8217;s or finder&#8217;s fee, commission or similar compensation will be payable with respect to the Loan, the issuance of the Note or any of the other transactions contemplated hereby or by any of the Loan Documents based upon any broker or lender engaged by Borrower, Guarantor or any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">affiliate of Borrower.  Borrower shall indemnify and hold Lender harmless from and against any and all claims of all brokers or finders claiming by, through or under Borrower and in any way related to the Loan or any of the transactions contemplated hereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Environmental Compliance</font><font style="font-family:inherit;font-size:12pt;">.  There are no claims, liabilities, investigations, litigation, administrative proceedings, whether pending or, to Borrower&#8217;s knowledge threatened, or judgments or orders relating to any Hazardous Materials (collectively called &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Environmental Claims</font><font style="font-family:inherit;font-size:12pt;">&#8221;) asserted or threatened against Borrower, any predecessor owner, tenant or operator or relating to any real property currently or formerly owned, leased or operated by Borrower  including the Mortgaged Property.  Except as disclosed in the Environmental Reports, to Borrower&#8217;s knowledge, neither Borrower nor any other Person has caused or permitted any Hazardous Material to be used, generated, reclaimed, transported, released, treated, stored or disposed of in a manner which could form the basis for an Environmental Claim against Borrower.  Except as disclosed in the Environmental Reports, to Borrower&#8217;s knowledge, no Hazardous Materials in violation of applicable Environmental Laws are or were stored or otherwise located, and no underground storage tanks or surface impoundments are or were located, on real property currently or formerly owned, leased or operated by Borrower, including the Mortgaged Property, or to the knowledge of Borrower, on adjacent parcels of real property, and no part of such real property or, to the knowledge of Borrower no part of such adjacent parcels of real property, including the groundwater located thereon, is presently contaminated by Hazardous Materials in violation of applicable Environmental Laws or to any extent which has, or might reasonably be expected to have, a Material Adverse Effect.  Except as disclosed in the Environmental Reports, to Borrower&#8217;s knowledge, Borrower and the Mortgaged Property has been and is currently in compliance with all applicable Environmental Laws, including obtaining and maintaining in effect all permits, licenses or other authorizations required by applicable Environmental Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Solvency</font><font style="font-family:inherit;font-size:12pt;">.  As of the date of this Agreement and after giving effect to the consummation of the transactions contemplated by the Loan Documents, Borrower:  (A)&#160;owns and will own assets the fair saleable value of which are (1)&#160;greater than the total amount of liabilities (including Contingent Obligations) of Borrower, and (2)&#160;greater than the amount that will be required to pay the probable liabilities of Borrower&#8217;s then existing debts as they become absolute and matured considering all financing alternatives and potential asset sales reasonably available to Borrower; (B)&#160;has capital that is not insufficient in relation to its business as presently conducted or any contemplated or undertaken transaction; and (C)&#160;does not intend to incur and does not believe that it will incur debts beyond its ability to pay such debts as they become due.  Borrower has not entered into the Loan Documents or the transactions contemplated under the Loan Documents with the actual intent to hinder, delay, or defraud any creditor.  After giving effect to the Loan and the transactions occurring on the Closing Date, Borrower&#8217;s net unreimbursed investment in the Mortgaged Property is not less than $21,000,000.  After giving effect to the transactions occurring on the Closing Date, no Default or Event of Default exists.  No material adverse change in the financial conditions or operation of the business of Borrower and Guarantor has occurred since the applicable dates of the financial statements of the applicable Person provided on or before the Closing Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Disclosure</font><font style="font-family:inherit;font-size:12pt;">.  The representations and warranties of Borrower and Guarantor contained in the Loan Documents, the financial statements referred to in Section 5.1(A), and any other documents, certificates or written statements furnished to Lender by or on behalf of Borrower or Guarantor for use in connection with the Loan do not contain any untrue statement of a material fact or omit or will omit to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances in which the same were made. There is no material fact known to Borrower that has had or will have a Material Adverse Effect that has not been disclosed in this Agreement or in such other documents, certificates and statements furnished to Lender by or, on behalf of, Borrower for use in connection with the Loan.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.16</font><font style="font-family:inherit;font-size:12pt;">&#32;sets forth a complete and accurate description of all policies of insurance that will be in effect as of the Closing Date for Borrower and such policies of insurance satisfy all of the requirements of Section 5.4.  All premiums thereon have been paid in full through December 1, 2004, no notice of cancellation has been received with respect to such policies and Borrower is in compliance, in all material respects, with all conditions contained in such policies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Budget</font><font style="font-family:inherit;font-size:12pt;">.  The Approved Budget submitted to Lender for the Mortgaged Property is a true, correct and complete copy of the Budget and Capital Plan in effect on and as of the Closing Date.  A true, correct and complete copy of the initial Approved Budget for the period ending December&#160;31, 2004 is attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;4.17</font><font style="font-family:inherit;font-size:12pt;">.  The Approved Budget and all of the amounts set forth therein, present a true, full and complete line itemization (by category for the fiscal year to which such Annual Budget applies) of all reasonably estimated Gross Revenues and all reasonably estimated Expenses which Borrower expects to pay or anticipates becoming obligated to pay relating to the Mortgaged Property. No material capital expenditures with respect to the Mortgaged Property are being incurred, contemplated or are reasonably necessary, except as specified in the Approved Budget.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Accounts</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.18</font><font style="font-family:inherit;font-size:12pt;">&#32;sets forth a complete and accurate itemization of all of Borrower&#8217;s time, demand, securities or similar Accounts that are in existence as of the Closing Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Management Agreement</font><font style="font-family:inherit;font-size:12pt;">.  Borrower is not party to any Management Agreement nor has it otherwise contracted with any managing agent to assist Borrower in the management and operation of the Mortgaged Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.20</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Special Assessments; Taxes</font><font style="font-family:inherit;font-size:12pt;">.  There are no pending or, to the knowledge of Borrower proposed, special or other assessments for public improvements or otherwise affecting the Mortgaged Property, nor, to Borrower&#8217;s knowledge, are there any contemplated improvements to the Mortgaged Property that may result in such special or other assessments.  Borrower has provided Lender with true, correct and complete copies of all bills and invoices for Impositions which have been levied or assessed against or are outstanding with respect to the Mortgaged Property.  Borrower has provided Lender with a true, correct and complete schedule of the assessment of the Mortgaged Property in effect as of the Closing Date.  Borrower has not received any notice that any portion of the Mortgaged Property has been re&#8209;assessed or is currently the subject of a reassessment.  Except for abatements pursuant to the Tax Abatement Agreements, no portion of the Mortgaged Property is exempt from taxation or constitutes an &#8220;omitted&#8221; tax parcel.  No Impositions are currently delinquent or outstanding with respect to the Mortgaged Property.  The conveyance of the Mortgaged Property to Borrower did not, in and of itself, constitute the basis for any reassessment of all or any part of the Mortgaged Property or the basis for any increase in any currently outstanding or previously satisfied Impositions which has not already been imposed and disclosed in writing to Lender by Borrower.  No tax contests of any Impositions or assessments are currently pending.  The Land and Improvements constitute a separate tax lot or lots, with a separate tax assessment or assessments, independent of any other land or improvements not constituting a part of the Mortgaged Property and no other land or improvements is assessed and taxed together with any portion of the Mortgaged Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.21</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Leases</font><font style="font-family:inherit;font-size:12pt;">.  Except for the Guarantor Lease, there are no Leases or other arrangements for occupancy of space within the Mortgaged Property that are currently in effect.  Borrower has provided Lender with a true, complete and correct copy of the Guarantor Lease, including any amendments or modifications thereto.  The Mortgaged Property is occupied solely by Guarantor.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.22</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations Remade</font><font style="font-family:inherit;font-size:12pt;">.  Borrower warrants and covenants that the foregoing representations and warranties will be true and shall be deemed remade as of the date of the Closing.  All representations and warranties made in the other Loan Document or in any certificate or other document delivered to Lender by </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or on behalf of Borrower pursuant to the Loan Documents shall be deemed to have been relied upon by Lender, notwithstanding any investigation made by or on behalf of Lender.  All such representations and warranties shall survive the making of the Loan and shall continue in full force and effect until such time as the Loan has been paid in full.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 5</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AFFIRMATIVE COVENANTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower covenants and agrees that so long as this Agreement shall remain in effect or the Note shall remain outstanding, Borrower shall perform and comply with all covenants in this Section&#160;5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Financial Statements and Other Reports</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will maintain a system of accounting in accordance with sound business practices to permit preparation of financial statements in conformity with GAAP and proper and accurate books, records and accounts reflecting all of the financial affairs of Borrower with respect to all items of income and expense in connection with the operation of the Mortgaged Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Financial Statements</font><font style="font-family:inherit;font-size:12pt;">.  Within one hundred twenty (120) days after the end of each calendar year, Borrower shall provide to Lender true and complete annual audited consolidated financial statements for Guarantor and true and complete annual unaudited financial statements for Borrower and the operation of the Mortgaged Property, all prepared in accordance with GAAP.  All audited financial statements shall be audited by a so&#8209;called &#8220;Big&#8209;4&#8221; accounting firm or another independent certified public accounting firm reasonably satisfactory to Lender.  All financial statements (whether or not audited) shall include a balance sheet as of the end of such year, profit and loss statements for such year and a statement of cash flow for such year, with such detailed supporting schedules covering the operation of the Mortgaged Property as Lender shall reasonably require including a reconciliation to the monthly reports and statements delivered to Lender and include an itemized accounting of all Gross Revenues and Expenses for the Mortgaged Property.  As soon as reasonably practicable (but in any event within forty-five (45) days) after the end of each calendar quarter, Borrower shall provide to Lender a true and complete quarterly cash flow, balance sheet, and operating statement for Borrower, Guarantor and the Mortgaged Property (none of which are required to be audited) certified by the president or vice president of Borrower Representative and Guarantor which quarterly statements shall be in form and substance acceptable to Lender.  Such quarterly statements shall be compared to the prior year&#8217;s quarter and year-to-date and to the then applicable Approved Budget.  Borrower shall also provide (and cause Guarantor to provide), such other financial information as Lender may, from time to time, reasonably request certified (if requested by Lender) by the applicable chief financial officer (or similar position).  Borrower will deliver, concurrently with the annual and quarterly statements, a certificate of its chief financial officer (or analogous position) certifying that no Default or Event of Default has occurred.  In the event Borrower enters into a Management Agreement subsequent to the date hereof, as soon as available, and in any event within twenty (20) days after the end of each Loan Month, Borrower will deliver to Lender a copy of the periodic reporting package required to be delivered to Borrower by a Manager pursuant to such Management Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Accountants&#8217; Certification</font><font style="font-family:inherit;font-size:12pt;">.  Together with each delivery of annual financial statements of Borrower and Guarantor pursuant to subsection 5.1(A), Borrower shall request as part of the engagement of its independent certified public accountant, and shall use best efforts</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to obtain, a written statement by such independent certified public accountant (1)&#160;stating that the examination has included a review of the terms of this Agreement as such terms relate to accounting matters, (2)&#160;stating whether, in connection with the examination, any condition or event that constitutes a Default or an Event of Default (of which said accountants may be aware from said review, and without obligation to review other aspects of this Agreement or to review any of the other Loan Documents) has come to their attention, and (3)&#160;if such a condition or event has come to their attention, specifying the nature and period of existence thereof; provided that the requirements set </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">forth in this subsection (B) shall be waived for so long as (i) Borrower&#8217;s financial statements are prepared on a consolidated basis with the financial statements of Guarantor and (ii) Guarantor is a reporting company under the Exchange Act, and provided further that, for purposes of the foregoing, &#8220;best&#160;efforts&#8221; shall not require a change in Borrower&#8217;s independent certified public accountant.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Accountants&#8217; Reports</font><font style="font-family:inherit;font-size:12pt;">.  Promptly upon receipt thereof, Borrower will deliver copies of all significant reports submitted to Borrower or Guarantor, as applicable, by independent public accountants in connection with each annual, interim or special audit of the financial statements of Borrower or Guarantor, as applicable, made by such accountants, including the comment letter submitted by such accountants to management in connection with their annual audit; provided that the requirements set forth in this subsection (C) shall be waived for so long as (i) Borrower&#8217;s financial statements are prepared on a consolidated basis with the financial statements of Guarantor and (ii) Guarantor is a reporting company under the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Annual Budgets and Capital Plans</font><font style="font-family:inherit;font-size:12pt;">.  Not later than November 30</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;of each calendar year, Borrower shall deliver a Budget and a Capital Plan for the following calendar year for the Mortgaged Property to Lender for its review and approval (the Budget and Capital Plan are collectively referred to as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Budget</font><font style="font-family:inherit;font-size:12pt;">&#8221; and the Annual Budget approved by Lender is referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved Budget</font><font style="font-family:inherit;font-size:12pt;">&#8221;), which approval shall not be unreasonably withheld, conditioned or delayed.  Lender shall have fifteen (15) Business Days to approve or reject each proposed Annual Budget.  Concurrently, Borrower shall deliver an annual business plan for the Mortgaged Property.  If Lender disapproves the Annual Budget, which disapproval shall specify the respects in which it is unacceptable, Borrower shall resubmit same to Lender for its review until such time as the Annual Budget is approved by Lender.  Borrower shall not modify any Approved Budget without Lender&#8217;s approval, which approval shall not be unreasonably withheld, conditioned or delayed.  Borrower shall not incur any Expenses which are not set forth in the Approved Budget except as otherwise approved by Lender, which approval shall not be unreasonably withheld, conditioned or delayed.  Borrower shall, within one hundred twenty (120) days after the end of each calendar year during the term of the Loan, deliver to Lender an annual summary of any and all capital expenditures made at the Mortgaged Property during the prior twelve (12)&#8209;month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(E)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices, Events of Default and Litigation</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall promptly deliver, or cause to be delivered, copies of all notices, demands, reports or requests given to, or received by Borrower from, any Governmental Authorities or with respect to any Indebtedness of Borrower or any Material Contracts, and shall notify Lender within two (2) Business Days after Borrower receives notice or acquires knowledge of, any violation of Legal Requirements, investigation, subpoena or audit by any Governmental Authority or default with respect to the Mortgaged Property or any Indebtedness or Material Contracts.  Promptly upon Borrower obtaining knowledge of any of the following events or conditions, Borrower shall deliver to Lender a written notice specifying the nature and period of existence of such condition or event and what action Borrower has taken, is taking and proposes to take with respect thereto:  (1)&#160;any condition or event that constitutes an Event of Default or Default; and/or (2) or any fact, circumstance, event or condition which has, or would reasonably be expected to have, a Material Adverse Effect.  Promptly upon Borrower obtaining knowledge of (i)&#160;the institution of any action, suit, proceeding, governmental investigation or arbitration against or affecting Borrower or Guarantor or the Mortgaged Property, or any other property of Borrower that would reasonably be expected to have a Material Adverse Effect or (ii)&#160;any material development in any  action, suit, proceeding, governmental investigation or arbitration at any time pending against or affecting Borrower or Guarantor or the Mortgaged Property or any other property of Borrower that would reasonably be expected to have a Material Adverse Effect, Borrower will give notice thereof to Lender and provide such other information as may be available to it to enable Lender and its counsel to evaluate such matters.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(F)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">ERISA</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall deliver to Lender such certifications or other evidence from time to time throughout the term of the Loan, as Lender, in its sole discretion, may reasonably request, that (A)&#160; Borrower is not and does not maintain an &#8220;employee benefit plan&#8221; as defined in Section&#160;3(3) of ERISA, which is subject to Title I of ERISA, or a &#8220;governmental plan&#8221; within the meaning of Section&#160;3(32) of ERISA; (B)&#160; Borrower is not subject to state statutes regulating investments and fiduciary obligations with respect to governmental plans; and (C)&#160;one or more of the following circumstances is true:  (i) equity interests in Borrower are publicly offered securities, within the meaning of 29 C.F.R. &#167;2510.3&#8209;101(b)(2); (ii) less than twenty-five percent (25%) of each outstanding class of equity interests in Borrower is held by &#8220;benefit plan investors&#8221; within the meaning of 29 C.F.R. &#167;2510.3&#8209;101(f)(2); or (iii) Borrower qualifies as an &#8220;operating company&#8221; or a &#8220;real estate operating company&#8221; within the meaning of 29 C.F.R. &#167;2510.3&#8209;101(c)&#160;or (e).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(G)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tax Returns</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will deliver to Lender copies of all federal and state income and other tax returns, schedules, statements and reports to its owners within ten (10) Business Days after the earlier of filing or delivery of such tax returns or other items with the Internal Revenue Service or the applicable Governmental Authority or delivery to its owners.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(H)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Estoppel Certificates</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">Within ten (10) Business Days following a request by Lender, Borrower shall provide to Lender, a duly acknowledged written statement confirming the amount of the outstanding Obligations, the terms of payment and maturity date of the Note, the date to which interest has been paid, and whether, to Borrower&#8217;s knowledge, any offsets or defenses exist against the Obligations, and if any such offsets or defenses are alleged to exist, the nature thereof shall be set forth in detail.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(I)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other</font><font style="font-family:inherit;font-size:12pt;">.  With reasonable promptness, Borrower will deliver such other infor-mation and data with respect to Borrower as from time to time may be reasonably requested by Lender.  Borrower shall also provide Lender with a copy of each 8K, 10Q and 10K (each as defined in the Exchange Act) or their successor forms under the Exchange Act, filed by Guarantor from time to time with the United States Securities and Exchange Commission not later than five (5) Business Days after the filing thereof.  Borrower shall deliver, or cause to be delivered, to Lender annually, concurrently with the renewal of the insurance policies required hereunder, an Officer&#8217;s Certificate stating that the insurance policies required to be delivered to Lender pursuant to Section 5.4 are maintained with insurers who comply with the terms of Section 5.4, setting forth a schedule describing all premiums required to be paid by Borrower to maintain the policies of insurance required under Section 5.4, and confirming full payment of all such premiums.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(J)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Electronic Format</font><font style="font-family:inherit;font-size:12pt;">.  To the extent then available, Borrower will provide to Lender a copy of any reports, notices, statements or other deliveries required pursuant to this Section 5.1 in an electronic format reasonably satisfactory to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Existence; Qualification</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will be, and will cause Guarantor to be, and continue to be, qualified in the jurisdiction in which the Mortgaged Property is located and keep in full force and effect its existence in the jurisdiction in which the Mortgaged Property is located.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payment of Impositions and Lien Claims; Permitted Contests</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to Section 5.3(B), Borrower will pay, or cause payment of, (i)&#160;all Impositions before in each instance any penalty or fine is incurred with respect thereto, (ii)&#160;all claims (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Claims</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (including claims for labor, services, materials and supplies) for sums that have become due and payable and that by law have or may become a Lien upon the Mortgaged Property or Borrower, before in each instance any penalty or fine is incurred with respect thereto, and (iii)&#160;all federal, state and local income taxes, sales taxes, excise taxes and all other taxes and assessments levied, imposed, confirmed or assessed against Borrower, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">its business, income, liabilities or assets or the Mortgaged Property, before in each instance any penalty or fine is incurred with respect thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With prior notice to Lender, Borrower shall have the right to pay Impositions, in full, under &#8220;protest.&#8221; Notwithstanding Section&#160;5.3(A), Borrower shall not be required to pay, discharge or remove or cause payment, discharge or removal of any Imposition or Claims pertaining to labor, services, materials and supplies supplied to the Land and Improvements so long as Borrower contests (each such contest, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Contest</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in good faith such Imposition or Claims or the validity, applicability or amount thereof by an appropriate legal proceeding which operates to prevent the collection of such amounts and the sale of the Mortgaged Property or any portion thereof so long as: (a)&#160;at least thirty (30) days prior to the date on which such Imposition or Claims would otherwise have become delinquent, Borrower shall have given Lender notice of its intent to contest said Imposition, (b)&#160;at least thirty (30) days prior to the date on which such Imposition would otherwise have become delinquent, Borrower shall have deposited with Lender (or with a court of competent jurisdiction or other appropriate Person approved by Lender) such additional amounts or other security as are necessary to keep on deposit at all times, an amount equal to at least one hundred twenty-five percent (125%) (or such higher amount as may be required by applicable law) of the total of (x)&#160;the balance of such Imposition or Claims then remaining unpaid, and (y)&#160;all interest, penalties, costs and charges accrued or accumulated thereon, (c)&#160;no risk of sale, forfeiture or loss of any interest in the Mortgaged Property or any part thereof arises, in Lender&#8217;s reasonable judgment, during the pendency of such contest, (d)&#160;such contest does not, in Lender&#8217;s reasonable discretion, have a Material Adverse Effect and (e) in the case of Claims, the liens, if any, securing the Claims in question have been defeased or bonded against in a manner satisfactory to Lender.  Each Permitted Contest shall be prosecuted, at Borrower&#8217;s sole cost and expense, with reasonable diligence, and Borrower shall promptly pay, or cause payment of, the amount of such Imposition or Claims as finally determined, together with all interest and penalties payable in connection with such Permitted Contest.  Lender, in its sole discretion, may apply any amount or other security deposited with Lender under this subsection or otherwise to the payment of any unpaid Imposition or Claims to prevent the sale, loss or forfeiture of the Mortgaged Property or any portion thereof.  Lender shall not be liable for any failure to so apply any amount or other security deposited.  Any surplus retained by Lender after payment of the Imposition or Claims for which a deposit was made shall be repaid to Borrower unless an Event of Default exists, in which case the surplus may be applied by Lender to the Obligations.  Notwithstanding any provision of this Section 5.3 to the contrary, Borrower shall promptly pay any Imposition or Claims which it might otherwise be entitled to contest if, in reasonable determination of Lender, the Mortgaged Property or any portion thereof is in jeopardy or in danger of being forfeited or foreclosed.  If Borrower refuses to pay any such Imposition or Claims, Lender may (but shall not be obligated to) make such payment and Borrower shall reimburse Lender within five (5) Business Days of written notice by Lender for all such advances which advances will bear interest at the Default Rate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to Section 2.6, Borrower shall pay any and all taxes, charges, filing, registration and recording fees, excises and levies imposed upon Lender by reason of its interests in, or measured by amounts payable under, the Note, this Agreement, the Mortgage or any other Loan Document (other than income, franchise and doing business taxes), and shall pay all stamp taxes and other taxes required to be paid on the Note or any of the other Loan Documents.  If Borrower fails to make such payment within five (5) days after notice thereof from Lender, Lender may (but shall not be obligated to) pay the amount due, and Borrower shall reimburse Lender within five (5) Business Days of written notice by Lender for all such advances which will bear interest at the Default Rate.  If applicable law prohibits Borrower from paying such taxes, charges, filing, registration and recording fees, excises, levies, stamp taxes or other taxes, then Lender may declare Borrower&#8217;s Obligations to be immediately due and payable, upon ninety (90) days&#8217; prior written notice.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall at all times provide, maintain and keep in force or cause to be provided, maintained and kept in force, at no expense to Lender, the following policies of insurance with respect to the Mortgaged Property and Borrower, as applicable:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Property insurance on an &#8220;all risk&#8221; and &#8220;special perils&#8221; basis (special form cause of loss) for one hundred percent (100%) of the replacement value of the Mortgaged Property with customary deductibles as approved by Lender.  The policy should contain the following endorsements: (a) Replacement Cost (without any deduction made for depreciation), (b) Agreed Amount (waiving co&#8209;insurance penalties), (c) Building Ordin-ance and Law coverage and (d) a standard mortgagee clause acceptable to Lender.  Such policy will also include the following coverage: (i) comprehensive boiler and machinery coverage in amounts as reasonably determined by Lender; (ii) earthquake and earth movement coverage with a $2,500,000 limit; however if in Lender&#8217;s reasonable judgment, the risks associated with such coverage have increased whereby additional coverage would be maintained by a prudent operator of property similar in use and locale, in sufficient amount as reasonably determined by Lender; and (iii) flood insurance coverage with a $2,500,000 limit; however, if the Improvements are located in a special flood hazard area as designated by the Director of the Federal Emergency Management Agency, in sufficient amount as reasonably determined by Lender.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Insurance against rent loss for not less than eighteen months gross rent or gross income from the Mortgaged Property including stabilized management fees and applicable reserve deposits plus debt service.  The perils covered by this policy shall be the same as those accepted on the Mortgaged Property including flood, earthquake and earth movement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Commercial general liability insurance covering bodily injury and property damage occurring on, in or about the Mortgaged Property and any adjoining streets, sidewalks, and passageways arising out of or connected with the possession, use, leasing, operation, or condition of the Mortgaged Property.  Policy limits will be not less than $1,000,000 per occurrence, $2,000,000 per location in the aggregate with respect to the Mortgaged Property and $1,000,000 per occurrence, $2,000,000 per location in the aggregate with respect to Borrower.  Such coverage shall include but not be limited to premises/ operations, personal injury and liquor liability (if applicable).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Umbrella excess liability insurance for not less than $10,000,000 in the aggregate with respect to the Mortgaged Property and Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the course of construction of Improvements, Borrower will obtain (1) commercial general liability insurance including contractual liability, in the amount of $1,000,000 primary and $10,000,000 excess liability in the aggregate (the policy shall provide coverage on an occurrence basis against claims for personal injury, bodily injury and death or property damage occurring on, in or about the Mortgaged Property and the adjoining streets, sidewalks and passageways).  In addition, Borrower shall require all contractors and subcontractors, architects and engineers to provide appropriate insurance coverage); and (2) Builder&#8217;s risk completed value form insurance against &#8220;all risks&#8221; of physical loss, including collapse, water damage, flood, earthquake and transit coverage (coverage should be on a non-reporting form, covering the total value of work performed and equipment, supplies and materials furnished (with an appropriate limit for soft costs in the case of construction) with deductibles approved by Lender).  Borrower agrees to consult with Lender prior to commencing the construction of any Improvements and to comply with all reasonable special insurance requirements of Lender pertaining to any construction.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No policies shall contain any exclusion for terrorism, terrorist activities or similar activities defined under the Terrorism Risk Insurance Act of 2002 (&#8220;TRIA&#8221;) and will be endorsed to insure such risks.  Notwithstanding the foregoing, should the cost of TRIA coverage and/or endorsements for the full replacement cost of the Mortgaged Property be greater than 10% of the premium for the applicable all risk property policy, then Borrower shall purchase the maximum terrorism insurance available for 10% of the then applicable all risk property insurance premium.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All insurance policies required pursuant to this Agreement shall be endorsed to provide that:  (i) Lender, its successors, and/or assigns, is named as mortgagee with respect to the all risk property; as a loss payee with respect to all rent loss coverage; as additional named insured on all liability coverage, with the understanding that any obligation imposed upon the insureds (including the liability to pay premiums) shall be the sole obligation of Borrower and not of any other insured; (ii) the interests of Lender shall not be invalidated by any action or inaction of Borrower or any other Person, and such policies shall insure Lender regardless of any breach or violation by Borrower or any other Person of any warranties, declaration or conditions in such policies; (iii) the insurer under each such policy shall waive all rights of subrogation against Lender, any right to set&#8209;off and counterclaim and any other right to deduction, whether by attachment or otherwise; (iv) such insurance shall be primary and without right of contribution of any other insurance carried by or on behalf of Lender with respect to its interest in the Mortgaged Property; (v) if such insurance is canceled for any reason whatsoever, including nonpayment of premium or, if any substantial modification, change or reduction is made in the coverage which affects the interests of Lender, such cancellation, modification, change or reduction in coverage shall not be effective as to Lender until thirty (30) days after receipt by Lender of written notice sent by registered mail from such insurer; (vi) any such  insurance shall be endorsed to provide in as much as the policy is written to cover more than one insured, all terms, conditions, insuring agreements and endorsements with the exception of limits of liability, shall operate in the same manner as if there were a separate policy covering each insured; and (vii) if required by Lender, such insurance shall contain &#8220;cut&#8209;through&#8221; endorsements providing Lender with direct access to any re&#8209;insurers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall deliver to Lender a copy of each insurance policy with further evidence of such insurance acceptable to Lender, together with a copy of the declaration page for each such policy.  Renewal certificates should be provided no later than five (5) days prior to the expiration of each policy.  Upon request of Lender, Borrower shall deliver a renewed policy or policies, or duplicate original or originals thereof, marked &#8220;premium paid,&#8221; or accompanied by such other evidence of payment satisfactory to Lender with standard non-contributory mortgagee clause in favor of and acceptable to Lender.  Borrower shall comply promptly with and conform to (i)&#160;all provisions of each such insurance policy and (ii)&#160;all requirements of the insurers applicable to Borrower as respects use, occupancy, possession, operation, maintenance, alteration or repair of the Mortgaged Property.  Borrower shall not use or permit the use of the Mortgaged Property in any manner that would permit any insurer to cancel any insurance policy or void coverage required to be maintained by this Agreement.  No insurance policy may provide for assessments to be made against Lender or Lender&#8217;s servicer, if any.  The insurance coverage required under this Section 5.4 may be effected under a blanket policy or policies covering the Mortgaged Property and other properties and assets not constituting a part of the Mortgaged Property; provided that any such blanket policy shall specify the portion of the total coverage of such policy that is allocated to the Mortgaged Property, and any sublimits in such blanket policy applicable to the Mortgaged Property, which amounts shall not be less than the amounts required pursuant to this Section 5.4 and which shall in any case comply in all other respects with all of the requirements of this Section 5.4.  Borrower shall comply with all insurance requirements and shall not bring or keep or permit to be brought or kept any article upon the Mortgaged Property or cause or permit any condition to exist thereon which would be prohibited by any insurance requirement, or would invalidate insurance coverage required hereunder to be maintained by Borrower on or with respect to any part of the Mortgaged Property pursuant to this Section&#160;5.4.  Notwithstanding anything to the contrary contained herein, it is expressly </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">understood and agreed that any insurance which Borrower shall cause any tenant to provide that shall otherwise be in compliance with all of the terms and conditions of this Section 5.4 shall satisfy Borrower&#8217;s obligations with respect thereto hereunder.  Borrower shall cause each tenant to provide business interruption, products/completed operations and workers compensation coverage in amounts reasonably acceptable to Borrower to insure risks of each tenant&#8217;s business.  Borrower will not take out separate insurance contributing in the event of loss with that required to be maintained pursuant to this Section 5.4 unless such insurance complies with this Section 5.4.  All insurance policies shall be in form, with endorsements, risk coverage, deductibles and amounts and maintained with companies approved by Lender, such approval not to be unreasonably withheld, conditioned or delayed.  Without limiting Lender&#8217;s ability to approve the aforementioned, an insurance company shall not be reasonably satisfactory unless such insurance company (a) has a rating of a least A with financial size of Class X or better as specified in Best&#8217;s Key Rating Guide,  (b) is licensed or authorized to do business, as required under applicable law, in the State where the Mortgaged Property is located and (c) a claims-paying ability rating by S&amp;P of not less than &#8220;A&#8221; and an equivalent rating by another Rating Agency.  All insurance policies insuring against casualty, rent loss and other appropriate policies shall provide that no claims be paid thereunder without twenty (20) days&#8217; advance written notice to Lender.  Such notice  may be given by Borrower. Lender shall not, by the fact of approving, disapproving, accepting, preventing, obtaining or failing to obtain any insurance, incur any liability for or with respect to the amount of insurance carried, the form or legal sufficiency of insurance contracts, solvency of insurance companies, or payment or defense of lawsuits, and Borrower hereby expressly assumes full responsibility therefore and all liability, if any, with respect thereto.  If Borrower fails to provide to Lender the policies of insurance required by this Section 5.4 or any other Loan Documents, Lender may (but shall have no obligation to) procure such insurance or single-interest insurance for such risks covering Lender&#8217;s interest and Borrower will pay all premiums thereon within five (5) Business Days of written notice by Lender, and until such payment is made by Borrower, the amount of all such premiums shall bear interest at the Default Rate and shall constitute additions to the Obligations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tax Reserve and Insurance Reserve</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall deposit (or cause to be deposited) with Lender (or such agent of Lender as Lender may designate in writing to Borrower from time to time), monthly, on each Payment Date, 1/12th of the annual charges (as estimated by Lender) for all Impositions relating to the Mortgaged Property and all insurance premiums with respect to the insurance required pursuant to Section 5.4(A)(i)&#8209;(iv).  Borrower shall also deposit with Lender, simultaneously with such monthly deposits and/or on the Closing Date, a sum of money which, together with such monthly deposits, will be sufficient to make the payment of each such charge at least thirty (30) days prior to the date finally delinquent.  Should such charges not be ascertainable at the time any deposit is required to be made, the deposit shall be made on the basis of Lender&#8217;s reasonable estimate.  When the charges are fixed for the then current year or period, Borrower shall deposit any deficiency within fifteen (15) days following Lender&#8217;s written demand.  Should an Event of Default occur and be continuing, the funds so deposited may be applied in payment of the charges for which such funds shall have been deposited or to the payment of the Obligations or any other charges affecting the Mortgaged Property as Lender in its sole and absolute discretion may determine, but no such application shall be deemed to have been made by operation of law or otherwise until actually made by Lender as herein provided.  Borrower shall provide Lender with bills and all other documents necessary for the payment of the foregoing charges at least ten (10) days prior to the date on which each payment thereof shall first become delinquent.  So long as (i)&#160;no Event of Default exists, (ii)&#160;Borrower has provided Lender with the foregoing bills and other documents in a timely manner, and (iii)&#160;sufficient funds are held by Lender for the payment of the Impositions and insurance premiums relating to the Mortgaged Property, as applicable, Lender shall pay said items or allow such funds to be used to pay said items or to reimburse Borrower for such items upon Lender&#8217;s receipt of reasonable evidence documenting Borrower&#8217;s payment of such items.  All refunds of Impositions and insurance premiums shall be deposited into the applicable of the Tax Reserve Account or the Insurance Reserve Account.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Maintenance of Mortgaged Property</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will maintain or cause the Mortgaged Property to be maintained in compliance with all Legal Requirements and in good repair, working order and condition and will make or cause to be made all appropriate repairs, renewals and replacements thereof.  Without regard as to whether Proceeds are made available to Borrower for such purposes, Borrower will promptly restore and repair all loss or damage occasioned by (i) any casualty which has occurred to at least the condition existing prior to any such casualty or (ii) any condemnation to an economically and structurally integrated unit.  Borrower will prevent any act or thing which might materially impair the value or usefulness of the Mortgaged Property.  Borrower will not commit or permit any waste of the Mortgaged Property or any part thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Inspection; Lender Meeting</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall, upon request from Lender, permit (and cause to be permitted) Lender&#8217;s designated representatives to (a)&#160;visit, examine, audit, and inspect the Mortgaged Property, (b)&#160;examine, audit, inspect, copy, duplicate and abstract Borrower&#8217;s financial, accounting and other books and records, and (c)&#160;discuss Borrower&#8217;s and the Mortgaged Property&#8217;s affairs, finances and business with Borrower Representative&#8217;s officers, representatives, independent public accountants and agents (including the Manager).  Lender acknowledges and agrees that any inspection or entry to the Mortgaged Property by Lender or Lender&#8217;s designated representatives shall be conducted (i) during Borrower&#8217;s normal business hours, (ii) in accordance with Borrower&#8217;s safety and security procedures then applicable to the Mortgaged Property in general and to the Secure Areas in particular that are, in each instance, in effect from time to time, (iii) at Borrower&#8217;s option, accompanied by an employee or representative of Borrower and/or Guarantor, (iv) in accordance with the confidentiality requirements of Section 11.12 and (v) in such a manner so as to minimize any disruption or interference with Borrower&#8217;s use or operation of the Mortgaged Property.  Borrower shall cause its books and records to be maintained at Borrower&#8217;s principal offices located at c/o Lexicon Genetics Incorporated, 8800 Technology Forest Place, The&#160;Woodlands, Texas 77381&#8209;1160.  Borrower will not change its principal offices or the location where its books and records are kept without giving at least thirty (30) days&#8217; advance notice to Lender.  Borrower shall pay Lender&#8217;s costs and expenses incurred in connection with such audit if an Event of Default has occurred and is continuing or if any audit reveals any material discrepancy, in Lender&#8217;s reasonable judgment, in the financial information provided by Borrower.  All audits, inspections and reports shall be made for the sole benefit of Lender.  Neither Lender nor Lender&#8217;s auditors, inspectors, representatives, agents or contractors assumes any responsibility or liability (except to Lender) by reason of such audits, inspections or reports.  Borrower will not rely upon any of such audits, inspections or reports.  The performance of such audits, inspections and reports will not constitute a waiver of any of the provisions of the Loan Documents.  Neither Lender nor any other of Lender&#8217;s inspectors, representatives, agents or contractors, shall be responsible for any matters related to design or construction of the Improvements or any Construction.  Borrower shall cooperate, from time to time, with Lender and use reasonable efforts to assist Lender in obtaining an appraisal of the Mortgaged Property.  Such cooperation and assistance from Borrower shall include reasonable access to the Mortgaged Property and books and records pertaining to the Mortgaged Property for Lender and its appraiser.  The appraiser performing any such appraisal shall be engaged by Lender.  Borrower shall not be responsible for the expenses of any such appraisal, provided, however, Borrower shall pay the fees of such appraiser in connection with one appraisal of the Mortgaged Property during the term of the Loan and any such appraisal when conducted following the occurrence and during the continuation of an Event of Default.  Borrower shall cooperate with Lender with respect to any proceedings before any Governmental Authority which may in any way affect the rights of Lender under any of the Loan Documents and, in connection therewith, not prohibit Lender, at its election, from participating in any such proceedings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Environmental Compliance</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall:  (a)&#160; comply (or cause compliance) at all times with all applicable Environmental Laws, and (b)&#160;promptly take, or cause to be taken, any and all necessary remedial actions upon obtaining knowledge of the presence, storage, use, disposal, transportation, release or discharge </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of any Hazardous Materials on, under or about the Mortgaged Property which has a Material Adverse Effect or is in violation of any Environmental Laws.  Borrower shall cause all remedial action with respect to Hazardous Material on, under or about the Mortgaged Property, to comply with all applicable Environmental Laws and the applicable policies, orders and directives of all federal, state and local Governmental Authorities.  If Lender at any time has a reasonable basis to believe that there may be a violation of any Environmental Law by, or any liability arising thereunder of, Borrower or related to the Mortgaged Property, Borrower shall, upon request from Lender, provide Lender with such reports, certificates, engineering studies and other written material or data as Lender may reasonably require to confirm compliance by Borrower and the Mortgaged Property with all applicable Environmental Laws.  Borrower shall permit Lender, its authorized representatives, consultants or other Persons retained by Lender to enter upon, examine, test and inspect the Mortgaged Property with regard to compliance with Environmental Laws, the presence of Hazardous Materials and the environmental condition of the Mortgaged Property and properties adjacent to the Land.  Such entry, examination, testing and inspecting and reporting shall be at the expense of Borrower if (x)&#160;an Event of Default has occurred or (y)&#160;Lender has reasonably determined that there may be a violation of Environmental Law or any liability arising under Environmental Law, which expense shall be paid by Borrower to Lender within five (5) Business Days of written notice by Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Environmental Disclosure</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall immediately upon becoming aware thereof advise Lender in writing and in reasonable detail of:  (1) any release, disposal or discharge of any Hazardous Material at the Mortgaged Property required to be reported to any federal, state or local governmental or regulatory agency under all applicable Environmental Laws; (2) any and all written communications sent or received by Borrower or its agents with respect to any Environmental Claims or any release, disposal or discharge of Hazardous Material required to be reported to any federal, state or local governmental or regulatory agency; (3) any remedial action taken by Borrower or any other Person in response to any Hazardous Material on, under or about any real property owned, leased or operated by Borrower or the Mortgaged Property or its agents, the existence of which could result in an Environmental Claim; (4) the discovery by Borrower or its agents of any occurrence or condition on any real property adjoining or in the vicinity of the Mortgaged Property that could cause such real property or any part thereof to be classified as &#8220;border-zone property&#8221; or to be otherwise subject to any restrictions on the ownership, occupancy, transferability or use thereof under any Environmental Laws; and (5) any request for information from any Governmental Authority that indicates such Governmental Authority is investigating whether Borrower or another present or former occupant of the Mortgaged Property may be potentially responsible for a release, disposal or discharge of Hazardous Materials from any of the Mortgaged Property.  Borrower shall promptly notify Lender of any proposed action to be taken by Borrower to commence any operations that could reasonably be expected to subject Borrower to additional laws, rules or regulations, including laws, rules and regulations requiring additional or amended environmental permits or licenses.  Borrower shall, at its own expense, provide copies of such documents or information as Lender may reasonably request in relation to any matters disclosed pursuant to this Section 5.9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compliance with Laws, Employee Benefit Plans and Contractual Obligations</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will promptly and faithfully (A) comply and cause the Mortgaged Property to comply, in all material respects, with the requirements of all Legal Requirements and the orders and requirements of any Governmental Authority in all jurisdictions in which it is now doing business or may hereafter be doing business and of every board of fire underwriters or similar body exercising similar functions, (B) maintain all licenses, certificates of occupancy, permits and Proprietary Rights now held or hereafter acquired by it or with respect to which a Material Adverse Effect will result if same are not existing and held by Borrower and (C) perform, observe, comply and fulfill all of its obligations, covenants and conditions contained in the Loan Documents and the Material Contracts.  Borrower shall: (i) promptly notify Lender of any claim made against Borrower that Borrower is in default under any Material Contract or that any other party is in default under any Material </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contract; (ii) not terminate, or permit termination of, any Material Contract, and (iii) not enter into, amend or modify any Material Contract without first obtaining the prior written approval of Lender.  Except for the plans described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.10</font><font style="font-family:inherit;font-size:12pt;">, Borrower is not a party to, and will not establish, any Employee Benefit Plan.  Except for the plans described in Schedule 4.10, Borrower will not commence making contributions to (or obligate itself to make contributions to) any Employee Benefit Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall, from time to time, at its sole cost and expense, execute and/or deliver, or cause execution and/or delivery of, such documents, agreements and reports, and perform such acts as Lender at any time may reasonably request to carry out the purposes and otherwise implement the terms and provisions provided for in the Loan Documents.  Borrower shall execute any documents and take any other actions necessary to provide Lender with a first priority, perfected security interest in the Reserves and the other Collateral.  Borrower shall, at Borrower&#8217;s sole cost and expense: (i) upon Lender&#8217;s request therefore given from time to time (but not more frequently than once per calendar year unless an Event of Default then exists) pay for (a) current reports of Uniform Commercial Code, federal tax lien, state tax lien, judgment and pending litigation searches with respect to Borrower and Borrower Representative, (b) current good standing and existence certificates with respect to Borrower and Borrower Representative and (c) current searches of title to the Mortgaged Property, each such search to be conducted by search firms reasonably designated by Lender in each of the locations reasonably designated by Lender; and (ii) execute and deliver to Lender such documents, instruments, certificates, assignments and other writings, and do such other acts necessary, to evidence, preserve and/or protect the Reserve Account Collateral and the other Collateral at any time securing or intended to secure the Obligations, as Lender may require in Lender&#8217;s reasonable discretion.  Borrower shall promptly execute, acknowledge, deliver, file or do, at its sole cost and expense, all acts, assignments, notices, agreements or other instruments as Lender may require in order to effectuate, assure, convey, secure, assign, transfer and convey unto Lender any of the rights granted by this Agreement and to more fully perfect and protect any assignment, pledge, lien and security interest confirmed or purported to be created under the Loan Documents or to enable Lender to exercise and enforce their rights and remedies hereunder, in respect of the Collateral.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Required Capital Improvements</font><font style="font-family:inherit;font-size:12pt;">.  Each of the capital improvement items listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;E</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Capital Improvements</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be completed by the applicable Required Completion Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[Intentionally Omitted.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[Intentionally Omitted.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[Intentionally Omitted.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[Intentionally Omitted.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[Intentionally Omitted.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Management</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall provide competent, responsible management for the Mortgaged Property, which management, Lender acknowledges, is currently being provided, at no expense or cost to Borrower, by employees of Guarantor.  In the event Borrower enters into a Management Agreement subsequent to the date hereof, the Manager and such Management Agreement must contain subordination and termination provisions and must be otherwise satisfactory to Lender.  Borrower shall not enter into any management agreement or arrangement with any Person with respect to the management of the Mortgaged Property without Lender&#8217;s prior written consent.  Borrower shall cause management subordination agreements in form and substance satisfactory to Lender to be executed by the Manager.  Borrower shall not modify, amend or terminate any approved management agreement without Lender&#8217;s prior written consent.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower shall provide Lender with written notice of the occurrence of any event of default or condition which with the giving of notice or passage of time, or both, would constitute an event of default under any Management Agreement or which would entitle the Manager to terminate the Management Agreement. Any Management Agreement entered into by Borrower shall be terminated by Borrower, at Lender&#8217;s request, upon thirty (30) days&#8217; prior notice to Borrower (i) upon the occurrence of an Event of Default or (ii) if such Manager commits any act which would permit termination by Borrower under such Management Agreement.  If a Manager is terminated pursuant hereto, Borrower shall immediately seek to appoint a replacement manager which is a Qualified Manager, and Borrower&#8217;s failure to appoint an acceptable Manager within thirty (30) days after Lender&#8217;s request of such Borrower to terminate the Management Agreement shall constitute an immediate Event of Default.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Construction Matters</font><font style="font-family:inherit;font-size:12pt;">.  Without limitation of Lender&#8217;s rights and Borrower&#8217;s Obliga-tions set forth elsewhere in the Loan Documents, Borrower shall:  (1) cause the Restoration and all other Construction to proceed with reasonable diligence and continuously, with sufficient workers employed and sufficient materials supplied for that purpose so that the applicable Construction is substantially completed by the applicable Required Completion Date, or, if no Required Completion Date is applicable, as promptly as reasonably practicable or, in the case of Restoration, the Restoration is Substantially Completed prior to the Required Restoration Date; (2) cause all Construction to be performed in accordance with the applicable Plans and Specifications or plans and specifications for the work in question, in substantial conformity with the Legal Requirements, the requirements of all insurers and fire underwriters, and with the requirements set forth herein and in the other Loan Documents, in compliance with the Material Contracts and in a good, safe and workmanlike manner; (3) cause all materials acquired or furnished in connection with the Construction and Restoration to be new and stored under adequate safeguards to minimize the possibility of loss, theft, damage or commingling with other materials or projects; (4) utilize, or permit utilization of, only contractors approved by Lender (such approval not to be unreasonably withheld, conditioned or delayed); (5) not permit the revision of Plans and Specifications without consent of Lender (not to be unreasonably withheld, conditioned or delayed); and (6) from time to time upon the reasonable request of Lender deliver to Lender such certificates and other documentation confirming the matters set forth in the preceding clauses (1) through (5).  Promptly upon the giving or receipt of such notice, Borrower shall forward to Lender copies of all material written notices given or received by, or on behalf of, Borrower with respect to the Construction to or from:  (x) Contractor or any subcontractor or material supplier, or any of the design professionals (including notices relating to any nonconforming construction, any refusal or inability to pay or perform pursuant to the terms of any contract or other agreement or any delay, default or change order) or (y) any claim of default, or relating to any work stoppage, notice of violation or cease and desist order, stop order, construction liens, strike, claim, litigation, damage, loss or any other materially adverse condition, circumstance or event.  Borrower shall pay and discharge or cause to be paid and discharged promptly all payments due for labor, materials and supplies unless the same shall be contested by Borrower in accordance with Section 5.3(B).  Borrower shall make available for inspection at all times by Lender and its representatives copies of all contracts for Construction and, to the extent available to or reasonably obtained by Borrower, entered into by Contractor and design professionals relating to the Construction.  Within ninety (90) days after Substantial Completion of applicable Construction activities, Borrower shall (i) complete, or cause to be completed, all Punch-List Items, (ii) deliver to Lender two (2) copies of the as&#8209;built Plans and Specifications and such other as&#8209;built surveys and plans and specifications as Lender may reasonably require and (iii) obtain all final permits and approvals required for the normal use and occupancy of the Improvements in question (including a permanent certificate of occupancy if required for occupancy under applicable laws or its equivalent for the Improvements in question, to the extent available) provided, however, to the extent that applicable Legal Requirements require satisfaction of items (i), (ii) or (iii) prior to the expiration of such ninety (90)-day period, the date such items must be satisfied prior to the date satisfaction is required pursuant to the applicable Legal Requirements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 6</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">ACCOUNTS/CASH MANAGEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Establishment of Accounts</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Borrower and Lender confirm that Lender has established, and agrees that Borrower and Lender shall maintain at Bank, the following segregated securities accounts (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserve Account</font><font style="font-family:inherit;font-size:12pt;">&#8221; and, collective the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserve Accounts</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be maintained by Borrower with Bank:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Account No. _____, captioned &#8220;Lex-Gen Woodlands, L.P./iStar Financial Inc./Tax Reserve&#8221; for the retention of collateral in respect of insurance premiums for the Mortgaged Property as provided in Section 5.5 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insurance Reserve Account</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Account No. ____, captioned &#8220;Lex-Gen Woodlands, L.P./iStar Financial Inc./Tax Reserve&#8221; for the retention of collateral for the payment of Impositions for the Mortgaged Property as provided in Section 5.5 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Reserve Account</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Type and Control of Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Borrower represents, warrants, covenants and agrees that (A) each of the Reserve Accounts are and shall be maintained as a &#8220;securities account&#8221; (as in Section 8&#8209;501(a) of the UCC); (B) Lender is entitled to exercise the rights that comprise any financial asset credited to such Reserve Accounts; (C) Borrower shall have no right to give entitlement orders with respect to such Reserve Accounts and, except as provided in this Agreement, no Reserve Account Collateral shall be released to Borrower from such Reserve Accounts; and (D) all securities or other property underlying any financial assets credited to the Reserve Accounts shall be registered in the name of Bank or indorsed to Bank or in blank and in no case will any financial asset credited to the Reserve Accounts be registered in the name of Borrower, payable to the order of Borrower or specially indorsed to Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Eligible Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Each of the Reserve Accounts shall be an Eligible Account.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cash Management Agreement</font><font style="font-family:inherit;font-size:12pt;">.  Borrower agrees that: (i) the Reserve Accounts shall be maintained in accordance with the terms hereof and of the Cash Management Agreement; and (ii) prior to the indefeasible re&#8209;payment in full of the Loan and indefeasible satisfaction of the Obligations, the Cash Management Agreement shall not be amended, supplemented or modified without the prior written consent of Lender, which consent Lender may grant or withhold in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(E)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Other Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Borrower represents and warrants that there are no deposit, securities or similar Accounts other than the Reserve Accounts maintained by Borrower or any other Person with respect to the collection of Gross Revenues.  Borrower agrees that, until the Loan is indefeasibly re&#8209;paid in full and the indefeasible satisfaction of the Obligations neither Borrower nor any other Person shall open any Accounts for the collection or holding of Gross Revenues, except for the Reserve Accounts.  The foregoing shall not prohibit Borrower from (i) utilizing one or more separate accounts for the disbursement or retention of funds that have been transferred to Borrower pursuant to Section 6.3 of this Agreement or (ii) maintaining a separate bank account for the collection of Rents under the Guarantor Lease.  Borrower covenants and agrees that it will not pledge, or create or permit to exist any security interest in, the foregoing accounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(F)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Miscellaneous Account Provisions</font><font style="font-family:inherit;font-size:12pt;">.  The Reserve Accounts shall be subject to such applicable laws, and such applicable regulations of the Board of Governors of the Federal Reserve System and of any other banking or governmental authority, as may now or hereafter be in effect.  Interest accruing on the Reserve Accounts, if any, shall be periodically added to the principal amount of the applicable Reserve Account and shall be held, disbursed and applied in accordance with the provisions of this Agreement.  All statements relating to the Reserve Accounts shall be issued simultaneously by Bank to Lender and Borrower.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower shall be the beneficial owner of the Reserve Accounts for federal and state income tax purposes and shall report all income on the Reserve Accounts.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Deposits into Accounts</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Initial Deposits</font><font style="font-family:inherit;font-size:12pt;">.  On the Closing Date, Borrower agrees, represents and warrants that it has deposited or caused to be deposited the following amounts into the Accounts:  (i)&#160;$156,000 into the Insurance Reserve Account; and (ii)&#160;$590,000.00 into the Tax Reserve Account.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Continuing Deposits</font><font style="font-family:inherit;font-size:12pt;">.  Borrower agrees to deposit on each Payment Date funds in the following amounts:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">funds in an amount equal to the deposit for insurance premiums due under Section&#160;5.5 on the applicable Payment Date shall be deposited into the Insurance Reserve Account; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">funds in an amount equal to the deposit for Impositions due under Section&#160;5.5 on the applicable Payment Date shall be deposited into the Tax Reserve Account.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payments from Reserve Accounts</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Event of Default</font><font style="font-family:inherit;font-size:12pt;">.  Borrower hereby irrevocably authorizes Lender to withdraw, and, Lender shall withdraw or re&#8209;allocate, the following payments or allocations, as applicable, from the applicable Reserve Accounts to the extent of the monies on deposit in the applicable Reserve Account if no Event of Default exists:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">funds from the Tax Reserve Account and Insurance Reserve Account sufficient to pay (A)&#160;Impositions and (B)&#160;insurance premiums for the insurance required to be maintained pursuant to the terms of the Agreement, on the due date therefore, and pay such funds to the Governmental Authority or insurance company having the right to receive such funds, provided, that Lender shall only be required to make such payments if Borrower has delivered to Lender an Officer&#8217;s Certificate identifying (1)&#160;the amount of such required payments, (2)&#160;the due date of such payments and (3)&#160;the person entitled to receive such payments, at least five (5) Business Days prior to the due date thereof, provided further, if Borrower shall have paid Impositions or insurance proceeds directly, the funds will be paid to Borrower in reimbursement thereof provided no Event of Default exists and Borrower provides evidence reasonably satisfactory to Lender of payment of the item in question.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Event of Default Exists</font><font style="font-family:inherit;font-size:12pt;">.  If an Event of Default exists, Borrower hereby irrevocably authorizes Lender to make any and all withdrawals from and transfers between any Reserve Account, as Lender shall determine in Lender&#8217;s sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall not, without the prior written consent of Lender, change the account location of any Reserve Account and, as a condition precedent to any such change, the bank to which Borrower proposes to relocate such Reserve Account shall have executed an appropriate acknowledgment letter, in accordance with the provisions set forth above.  With respect to the Reserve Account Collateral, Lender shall not be liable for any acts, omissions, errors in judgment or mistakes of fact or law, except for those arising as a result of Lender&#8217;s investment of such Reserve Account Collateral in other than Permitted Investments or from gross negligence or willful misconduct.  Funds in the Borrower Account shall (a) be used only to pay Expenses related to the Mortgaged Property prior to any distributions by Borrower and (b) not be disbursed in violation of any provision of this Agreement.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Creation of Security Interest in Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Borrower hereby pledges, transfers and assigns to Lender, and grants to Lender, as additional security for the Obligations, a continuing perfected first priority security interest in and to, and a first lien upon:  (i) the Reserve Accounts and all amounts which may from time to time be on deposit in each of the Reserve Accounts; (ii) all of Borrower&#8217;s right, title and interest in and to all cash, property or rights transferred to or deposited in each of the Reserve Accounts from time to time; (iii) all certificates and instruments, if any, from time to time representing or evidencing any such Reserve Account or any amount on deposit in any thereof, or any value received as a consequence of possession thereof, including all interest, dividends, cash, instruments and other property from time to time received, receivable or otherwise distributed in respect of, or in exchange for, any or all of the Reserve Accounts; (iv) all monies, chattel paper, checks, notes, bills of exchange, negotiable instruments, documents of title, money orders, commercial paper, and other security instruments, documents, deposits and credits from time to time in the possession of Lender representing or evidencing such Reserve Accounts; (v) all other property, held in, credited to, or constituting part of any of the Reserve Accounts; (vi) all earnings and investments held in any Reserve Account in accordance with this Agreement; and (vii) to the extent not described above, any and all proceeds of the foregoing, (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserve Account Collateral</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  This Agreement and the pledge, assignment and grant of security interest made hereby secures payment of all Obligations in accordance with the provisions set forth herein. This Agreement shall be deemed a security agreement within the meaning of the Uniform Commercial Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Certain Matters Regarding Lender following an Event of Default</font><font style="font-family:inherit;font-size:12pt;">.  Borrower agrees that the Bank shall pay over to Lender all amounts deposited in the Reserve Accounts on demand, without notice to Borrower, if, in making such demand, Lender shall give notice, in writing, signed by Lender or an authorized agent thereof, that an Event of Default exists.  Lender may exercise in respect of the Reserve Account Collateral all rights and remedies available to Lender hereunder or under the other Loan Documents, or otherwise available at law or in equity.  If an Event of Default exists, Lender may exercise in respect of the Reserve Account Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all of the rights and remedies of a secured party upon default under the Uniform Commercial Code then in effect in the applicable jurisdiction.  Without limiting the generality of the foregoing, Borrower agree(s) that, upon the occurrence and during the continuance of an Event of Default, it will have no further right to request or otherwise require Lender to disburse funds from any Account in accordance with the terms of this Agreement, it being agreed that Lender may, at its option, (i)&#160;direct the Bank to continue to hold the funds in the Reserve Accounts, (ii)&#160;continue, from time to time, to apply all or any portion of the funds held in the Reserve Accounts to any payment(s) which such funds could have been applied to prior to such Event of Default (or to pay Expenses directly), to the extent and in such order and manner as Lender in its sole discretion may determine, and/or (iii)&#160;direct the Bank to disburse all or any portion of the funds held in the Reserve Accounts or other Reserve Account Collateral then or thereafter held by the Bank to Lender, in which event Lender may apply the funds held in the Reserve Accounts or other Reserve Account Collateral to the Obligations, in any order and in such manner as Lender may determine in its sole discretion.  If an Event of Default exists, Lender may, at any time or from time to time:  (1) collect, appropriate, redeem, realize upon or otherwise enforce its rights with respect to the Reserve Account Collateral, or any part thereof, without notice to any Borrower and without the need to institute any legal action, make demand to or upon any Borrower or any other Person, exhaust any other remedies or otherwise proceed to enforce its rights; (2) execute (in the name, place and stead of Borrower) any endorsements, assignments or other instruments of conveyance which may be required for the withdrawal and negotiation of the Reserve Account Collateral; and/or (3) exercise all other rights and remedies available to Lender hereunder and under any of the other Loan Documents.  Notwithstanding anything to the contrary contained herein:  (w) Borrower shall remain liable under the Loan Documents to the extent set forth herein and therein to perform all of its respective obligations thereunder, to the same extent as if this Agreement had not been executed; (x) the exercise by Lender of any of its rights hereunder shall not release Borrower from its obligations under any of the Loan </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Documents, nor shall it constitute an election of remedies by Lender or a waiver by Lender of any of its rights and remedies under the Loan Documents; (y) except as expressly set forth in this Agreement or in any of the other Loan Documents, Lender shall not have any obligation or liability by reason of this Agreement, nor shall Lender be obligated to perform any of the obligations or duties of Borrower hereunder or to take any action, in each case, to collect or enforce any claim for payment assigned hereunder; and (z) Lender shall not have to resort to using the Reserve Account Collateral before making demand upon or bringing an action against Borrower under any Loan Document under any guaranty given in connection with the Loan.  No failure on the part of Lender to exercise, and no delay in exercising, any right under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right under this Agreement or the other Loan Documents.  The remedies provided in this Agreement, the Note and the other Loan Documents are cumulative and not exclusive of any remedies provided at law or in equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties Regarding Reserve Account Collateral</font><font style="font-family:inherit;font-size:12pt;">.  In addition to any representations or warranties contained in this Agreement, Borrower represents and warrants as follows:  (a) Borrower is the legal and beneficial owner of the Reserve Account Collateral, respectively, free and clear of any Liens, except for the Liens in favor of Lender created by this Agreement and the other Loan Documents; (b) upon execution by Borrower of this Agreement, the pledge and assignment of the Reserve Account Collateral pursuant to this Agreement will create a valid, first priority security interest in the such Reserve Account Collateral, securing the payment and performance of the Obligations; and (c) Borrower is not a party to any credit agreement or other borrowing facility including, but not limited to, a line of credit or overdraft line, with the Bank.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covenants Regarding Reserve Account Collateral</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will not, without the prior consent of Lender, (a)&#160;sell, assign (by operation of law or otherwise), pledge, or grant any option with respect to, any of the Gross Revenues or any interest in the Reserve Account Collateral or (b)&#160;create or permit to exist any assignment, lien, security interest, option or other charge or encumbrance upon or with respect to any Gross Revenues or any Reserve Account Collateral, except for the Liens in favor of Lender under this Agreement and the other Loan Documents.  Borrower will give Lender not less than thirty (30) days&#8217; prior written notice of any change in the address of its chief executive office or its principal office.  Borrower agrees that all records of Borrower with respect to the Reserve Account Collateral will be kept at Borrower&#8217;s principal office and will not be removed from such addresses without the prior written consent of Lender.  Borrower will not make or consent to any amendment or other modification or waiver with respect to any Reserve Account Collateral, or enter into any agreement, or permit to exist any restriction, with respect to any Reserve Account Collateral.  Borrower will, at its expense, defend Lender&#8217;s right, title and security interest in and to the Reserve Account Collateral against the claims of any Person.  Borrower will not take any action which would in any manner impair the enforceability of this Agreement or the security interests created hereby.  Borrower will not enter into any credit agreement or other borrowing facility including a line of credit or overdraft line, with Bank.  Nothing contained in this Section 6 shall impair or otherwise limit Borrower&#8217;s obligations to timely make the payments (including interest and principal) required by the Note and the other Loan Documents, it being understood that such payments shall be so timely made in accordance with the Loan Documents, regardless of the amounts on deposit in any Account.  Lender may, from time to time, at its sole option, perform any act which Borrower agrees hereunder to perform which Borrower shall fail to perform after being requested in writing to so perform and Lender may from time to time take any other action which Lender deems necessary for the maintenance, preservation or protection of any of the rights granted to Lender hereunder.  With respect to the powers conferred on Lender hereunder, Lender shall not have any duty as to the Accounts or the other Reserve Account Collateral, or any responsibility for (i)&#160;ascertaining or taking action with respect to any matters relative to the Accounts or the other Reserve Account Collateral, whether or not Lender has or is deemed to have knowledge of such matters or (ii)&#160;taking </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any necessary steps to preserve rights against prior parties or any other rights pertaining to the Accounts or the other Reserve Account Collateral.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Cash Management Fees</font><font style="font-family:inherit;font-size:12pt;">.  All fees, costs and expenses associated with the Cash Management Agreement and Reserve Account Collateral shall be paid by Borrower when due.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 7</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">NEGATIVE COVENANTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower covenants and agrees that from the date hereof and so long as this Agreement shall remain in effect or the Note remains outstanding, Borrower shall comply with all covenants and agreements in this Section&#160;7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will not directly or indirectly create, incur, assume, guaranty, or otherwise become or remain directly or indirectly liable with respect to any Indebtedness except Permitted Indebtedness.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Liens and Related Matters</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will not directly or indirectly create, incur, assume or permit to exist any Lien on or with respect to the Mortgaged Property or other Collateral whether now owned or hereafter acquired, or any income or profits therefrom, except the Liens in favor of Lender under this Agreement and the Permitted Encumbrances.  Borrower shall have the right to contest any such Lien securing Claims in accordance with Section 5.3(B), except by their own terms or in accordance with a specific termination right granted thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Material Rights</font><font style="font-family:inherit;font-size:12pt;">.  Without Lender&#8217;s consent, which consent shall not be unreasonably withheld, conditioned or delayed, Borrower shall not (a) amend, modify or waive the performance of material obligations with regard to the Material Contracts or Proprietary Rights, (b) request a waiver or consent from, any party to, or issuer of any of the Material Contracts or Proprietary Rights or (c) terminate or permit termination of any Material Contracts or Proprietary Rights.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Restriction on Fundamental Changes</font><font style="font-family:inherit;font-size:12pt;">.  Neither Borrower nor Borrower Representative will: (1)&#160;amend, modify or waive in any material respect any term or provision of its Organizational Documents, (2)&#160;liquidate, wind&#8209;up or dissolve itself (or suffer any liquidation or dissolution); or (3)&#160;acquire by purchase or otherwise all or any part of the business or assets of, or stock or other evidence of beneficial ownership of, any Person.  Neither Borrower nor Borrower Representative will issue, sell, assign, pledge, convey, dispose or otherwise encumber any partnership, stock, membership, beneficial or other ownership interests or grant any options, warrants, purchase rights or other similar agreements or understandings with respect thereto.  Borrower will not establish any Subsidiaries.  Borrower will not make any Investments in any other Person.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Restriction on Leases</font><font style="font-family:inherit;font-size:12pt;">.  Except for the Guarantor Lease and as set forth below, Borrower shall not hereafter enter into any Lease or other rental or occupancy arrangement or concession agreement with respect to the Mortgaged Property or any portion thereof or otherwise permit any occupancy of the Mortgaged Property other than by Guarantor.  Borrower shall not modify, amend or terminate any Lease, give any consents, waive any obligations under any leases or release any tenant of any Lease, without, in each instance, Lender&#8217;s consent, such consent not to be unreasonably withheld, conditioned or delayed.  Borrower shall perform and comply, in all material respects, with all of the landlord&#8217;s obligations under each Lease and shall not suffer or permit any material breach or default on the part of the landlord to occur thereunder.  In addition to the Guarantor Lease, Guarantor shall have the right to enter into subleases with third parties for occupancy of the Improvements without Lender&#8217;s consent, provided that (i) any such sublease shall be subject and subordinate to the Liens in favor of Lender under this Agreement and (ii) all subleases, in the aggregate, shall </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">be for (1)&#160;less than 50% of the leasable space of any single building and (2) less than 30% of the aggregate leasable improved space for the Mortgaged Property.  Borrower shall provide Lender with written notice of any such permitted sublease prior to Guarantor entering into any such sublease.  In no event will Borrower enter into any Capital Leases.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Transactions with Affiliates</font><font style="font-family:inherit;font-size:12pt;">.  Except for the Guarantor Lease, Borrower shall not directly or indirectly enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property or the rendering of any service) with any director, officer, employee or Affiliate of Borrower, Borrower Representative or Guarantor, except transactions in the ordinary course of and pursuant to the reasonable requirements of the business of Borrower and upon fair and reasonable terms which are fully disclosed to Lender and are no less favorable to Borrower than would be obtained in a comparable arm&#8217;s length transaction with a Person that is not an Affiliate, director, officer or employee of Borrower.  Each such agreement with any Affiliate, director, officer or employee of Borrower shall provide that the same may be terminated by Lender at its option if an Event of Default exists.  Other than pursuant to the Management Agreement approved by Lender, Borrower shall not pay any management, consulting, director or similar fees to any director, officer, employee or Affiliate of Borrower or Guarantor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Management Fees and Compensation; Contracts</font><font style="font-family:inherit;font-size:12pt;">.  Borrower will not enter into or become obligated under any management (property and asset), brokerage or other such similar agreement, whether with an Affiliate or any other Person, with respect to the Mortgaged Property, without Lender&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, and unless the same may be terminated, without cause and without payment of a penalty or fee, on not more than thirty (30) days&#8217; prior written notice.  In no event will Borrower pay a management fee in excess of the then prevailing market rates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conduct of Business</font><font style="font-family:inherit;font-size:12pt;">.  From and after the Closing Date, Borrower will not engage in any business other than the ownership and operation of  the Mortgaged Property.  Borrower shall not use the Mortgaged Property or any part thereof, or allow the same to be used or occupied, for any purpose other than for the purposes of an office, laboratory, vivarium or other facility for similar use and related amenities, or for any unlawful purpose, or in violation of any Legal Requirement.  Borrower will not suffer any act to be done or any condition to exist on the Mortgaged Property or any part thereof or any article to be brought thereon, which may be dangerous (unless safeguarded as required by Legal Requirement) or which may constitute a nuisance, public or private, or which may void or make voidable any insurance then in force with respect thereto.  No tract map, parcel map, condominium plan, condominium declaration, or plat of subdivision (or analogous document) will be recorded with respect to the Mortgaged Property without Lender&#8217;s consent, which consent shall not be unreasonably withheld, conditioned or delayed.  The Mortgaged Property shall not be converted to the condominium or &#8220;cooperative&#8221; form of ownership.  Borrower will not initiate or consent to any change in the zoning of the Mortgaged Property.  Borrower shall at all times maintain good and indefeasible fee title to the Mortgaged Property free and clear of any encumbrances other than the Liens in favor of Lender under the Loan Documents and the Permitted Encumbrances.  Borrower shall not change its fiscal year without giving advance notice thereof to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Use of Lender&#8217;s Name</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall not use the names of Lender or any of Lender&#8217;s Subsidiaries or Affiliates in connection with the development, marketing, leasing, use and operation of the Mortgaged Property.  Borrower shall not disclose or permit any Subsidiary of Guarantor or Borrower, or any officer, director, partner, manager, member or employee of Borrower to disclose any of the terms and conditions of the Loan to any Person except (a) to the extent disclosed in the Mortgage and the Financing Statements, (b) to the extent such disclosure is required pursuant to the Loan Documents or applicable legal process, (c) to the extent, and only to the extent, such disclosure is required pursuant to Guarantor&#8217;s reporting requirements </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under the Exchange Act, (d)&#160;to the extent the content of such disclosure is already generally available to the public, or (e) to the extent Lender consents to such disclosure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compliance with ERISA</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall not adopt, modify or terminate any Employee Benefit Plans except as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 4.10</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall not fail to maintain and operate each existing Employee Benefit Plan in compliance in all material respects with the provisions of ERISA, the Code and all other applicable laws and the regulations and interpretations thereof.  Borrower shall not engage in any transaction which would cause the Obligations or any action taken or to be taken under this Agreement or the other Loan Documents or otherwise (or the exercise by Lender of any of its rights under the Loan Documents) to be a non-exempt prohibited transaction under ERISA.  Borrower shall not become an &#8220;employee benefit plan&#8221; (within the meaning of Section&#160;3(3) of ERISA) to which ERISA applies and Borrower shall not permit its assets to be plan assets.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Due on Sale or Encumbrance</font><font style="font-family:inherit;font-size:12pt;">.  Without Lender&#8217;s consent, which consent may be given or withheld in the sole discretion of Lender, neither Borrower nor any other Person directly or indirectly holding any direct or indirect legal, beneficial, equitable or other interest in Borrower (at each and every tier or level of ownership) shall, or permit other Persons to, Transfer (whether or not for consideration or of record) all or any portion of the Mortgaged Property or any direct or indirect legal, equitable, beneficial or other interest (1)&#160;in all or any portion of the Mortgaged Property; (2)&#160;in Borrower; or (3)&#160;at each and every tier or level of ownership, in Borrower&#8217;s direct or indirect partners, members, shareholders, beneficial or constituent owners including Guarantor, Borrower Representative, any owners of Borrower Representative (or the direct or indirect owners of any direct or indirect interests in any such constituent owners), including (a) an installment sales agreement for a price to be paid in installments; (b)&#160;except as otherwise permitted pursuant to Section 7.5, any Leases or a sale, assignment or other transfer of, or the grant of a security interest in, Borrower&#8217;s right, title and interest in and to any Leases or any Rents; (c)&#160;any direct or indirect voluntary or involuntary sale of any ownership interest in Borrower or other Person directly or indirectly owning any direct or indirect interest in Borrower; (d) the creation, issuance or redemption of direct or indirect ownership interests by Borrower or any Person owning a direct or indirect interest in Borrower (at each every tier or level of ownership); (e) any merger, consolidation, dissolution or liquidation; and (f) without limitation of any of the foregoing, any direct or indirect voluntary or involuntary Transfer by any Person which indirectly controls Borrower (by operation of law or otherwise) of its direct or indirect controlling interests in Borrower.  Notwithstanding the foregoing, the following shall not be deemed to be prohibited under this Section 7.11:  (i)&#160;a Transfer of an indirect ownership interest in Borrower, by the current owner thereof to a wholly-owned subsidiary of Guarantor and (ii)&#160;Transfers of ownership interests in a Person whose stock is publicly traded, so long as (x)&#160;no such transfers described in parts (i) and (ii) of this sentence result in any Person or Group acquiring, directly or indirectly, more than a forty-nine percent (49%) direct or indirect interest in Borrower (if such Person or Group did not prior to the Transfer, own at least forty-nine percent (49%) of the direct or indirect ownership interests in Borrower), unless such Person or Group acquiring, directly or indirectly, more than a forty-nine percent (49%) direct or indirect interest in Borrower has a Credit Rating of &#8220;Baa2&#8221; or higher from Moody&#8217;s or &#8220;BBB&#8221; or higher from S&amp;P, or, as applicable, an equivalent rating from another Rating Agency, or, if such Person or Group is not rated by a Rating Agency, has (A) a Net Worth of $1,000,000,000 or more, (B) an EBITDA Interest Coverage of 6.0 or greater and (C)&#160;a&#160;Total Debt/Capitalization no greater than 40%, and (y) no Change in Control occurs by virtue of such Transfers (other than pursuant to clause (ii) of the definition of &#8220;Change of Control&#8221;).  Notwithstanding the foregoing, Borrower may sell Inventory in the ordinary course of business and transfer or dispose of tangible personal property to Persons that are not Borrower&#8217;s Affiliates, which tangible personal property is immediately replaced by an article of equivalent suitability and value or which is no longer necessary in connection with the operation of the Mortgaged Property provided that such transfer or disposal will (i) not have a Material Adverse Effect; (ii) not materially impair the utility of the Mortgaged Property, and (iii) not result in a reduction or abatement of, or right of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">offset against, the Gross Revenues payable under any Lease or otherwise, and provided that any tangible personal property acquired by Borrower (and not so disposed of) shall be subject to the Lien of the Mortgage.  Borrower acknowledges that Lender has examined and relied on the experience of Borrower and Guarantor in owning and operating properties such as the Mortgaged Property in agreeing to make the Loan and will continue to rely on such ownership of the Mortgaged Property and Borrower and Guarantor as a means of maintaining the value of the Mortgaged Property as security for repayment of the Loan and the performance of the other Obligations.  Borrower acknowledges that Lender has a valid interest in maintaining the value of the Mortgaged Property so as to ensure that, should Borrower default in the repayment of the Loan or the performance of the other Obligations, Lender can recover the Loan by a sale of the Mortgaged Property.  Lender shall not be required to demonstrate any actual impairment of its security or any increased risk of default hereunder in order to declare the Loan immediately due and payable upon any Default under this Section 7.11.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payments; Distributions</font><font style="font-family:inherit;font-size:12pt;">.  Except for payments of management fees otherwise permitted to be paid to Manager under this Agreement pursuant to a Management Agreement approved by Lender at a time when no Event of Default exists, Borrower shall not pay any distributions, dividends or other payments or return any capital to any of its respective partners, members, owners or shareholders or any other Affiliate or make any distribution of assets, rights, options, obligations or securities to any of its respective partners, members, shareholders or owners or any other Affiliate (individually, or collectively, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Distribution</font><font style="font-family:inherit;font-size:12pt;">&#8221;) unless (a) on the date of the proposed Distribution, and after giving effect to the subsequent Distribution, no Default or Event of Default exists; (b) funds are not then required to be deposited into any Reserves; (c) Borrower is not &#8220;insolvent&#8221; (as defined in the Bankruptcy Code) and will not be rendered insolvent by virtue of such Distribution; (d) Borrower shall deliver, at least ten (10) days in advance of the proposed Distribution, to Lender, an Officer&#8217;s Certificate executed by the chief financial officer or similar officer of Borrower, stating that the foregoing conditions (a), (b) and (c) have been satisfied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Single Purpose Bankruptcy Remote Entities</font><font style="font-family:inherit;font-size:12pt;">. </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Borrower hereby represents, warrants, agrees and covenants that Borrower and Borrower Representative have, at all times, from their formation, been, and, at all times will be, a Special Purpose Bankruptcy Remote Entity.  Neither Borrower nor Borrower Representative will, directly or indirectly, make any change, amendment or modification to its Organizational Documents or otherwise take any action which could result in Borrower or Borrower Representative not being a Special Purpose Bankruptcy Remote Entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Alterations</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall not alter, remove or demolish or permit the alteration, removal or demolition of, any Improvement except as the same may be necessary in connection with (i) a Restoration in connection with a taking or casualty in accordance with the terms and conditions of the Agreement, (ii) Required Capital Improvements in accordance with the terms and conditions of the Agreement and (iii) other Alterations permitted in accordance with the terms and conditions of this Section 7.14.  If no Event of Default exists, Borrower may undertake any alteration, improvement, demolition or removal of Improvements or any portion thereof (any such alteration, improvement, demolition or removal, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Alteration</font><font style="font-family:inherit;font-size:12pt;">&#8221;) so long as (1) Borrower provides Lender with at least thirty (30) days&#8217; prior notice of any such Alteration, (2) such Alteration is undertaken in accordance with the applicable provisions of this Agreement, is not prohibited by, and is in full compliance with, and does not violate, any Material Contracts or Legal Requirements and does not, during Construction and upon completion, have a Material Adverse Effect, (3) Borrower provides Lender with evidence, satisfactory to Lender, that Borrower has sufficient funds to complete and pay all of the costs of the Alterations, (4) such Alteration does not eliminate or materially modify any amenity (e.g., health club) available to tenants and their employees or customers, (5) such Alteration is in the nature of (x) Required Capital Improvements permitted under this Agreement, (y) a Restoration required or permitted under the Agreement or (z) if not in the nature of the Alterations contemplated by (x) or (y), such Alteration </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">has been consented to by Lender (such consent will not be unreasonably withheld, conditioned or delayed in the case of Alterations the cost of which, as estimated by Lender, does not exceed $50,000) and (6) prior to commencement and from time to time upon request from Lender, Borrower delivers an Officer&#8217;s Certificate certifying that conditions (1)-(5), inclusive, have been satisfied.  Any Alteration shall, unless Lender otherwise approves or the Agreement otherwise provides, be conducted under the supervision of an independent architect approved by Lender (an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Independent Architect</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  No Alteration shall be undertaken until Lender has approved plans and specifications and cost estimates for the Alterations, prepared by such Independent Architect or another Person approved by Lender, such approvals not to be unreasonably withheld, conditioned or delayed.  Notwithstanding anything contained in this Section 7.14 to the contrary, Borrower shall have the right to make non-structural Alterations to the Improvements, the cost of which does not exceed $500,000 per Alteration, without Lender&#8217;s consent and without complying with clauses (3)-(5) set forth above; provided, however, that Borrower shall provide Lender with prior written notice at least ten (10) days prior to commencing such Alteration and prior to commencing any permitted Alteration, Borrower shall have delivered to Lender a copy of the proposed plans and specifications for such Alteration.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 8</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CASUALTY AND CONDEMNATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Restoration Following Casualty or Condemnation</font><font style="font-family:inherit;font-size:12pt;">.  After the happening of any casualty or condemnation to the Mortgaged Property or any part thereof, Borrower shall give prompt notice thereof to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event of any damage or destruction of all or any part of the Mortgaged Property, all Proceeds shall be payable to Lender.  Borrower hereby authorizes and directs any affected insurance company or condemning Governmental Authority or other Persons to make payment of such proceeds directly to Lender.  Borrower shall obtain Lender&#8217;s approval prior to any settlement, adjustment or compromise of any claims for loss, damage or destruction under any policy or policies of insurance or with respect to any condemnation, and Lender shall have the right to participate with Borrower in negotiation of any such settlement, adjustment or compromise provided, however, Borrower shall be permitted, so long as no Event of Default exists, to settle insurance claims of $250,000 or less without Lender&#8217;s approval (but with reasonable advance notice to Lender) and utilize any such funds for Restoration.  Lender shall also have the right to appear with Borrower in any action against an insurer based on a claim for loss, damage or destruction under any policy or policies of insurance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All compensation, proceeds, damages, claims, insurance recoveries, rights of action and payments which Borrower may receive or to which Borrower may become entitled with respect to the Mortgaged Property or any part thereof as a result of any casualty or condemnation, except as set forth below in this Section 8.1 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proceeds</font><font style="font-family:inherit;font-size:12pt;">&#8221;), shall be paid over to Lender and shall be held in an escrow account with an Acceptable Financial Institution.  The Proceeds shall be applied first toward reimbursement of all costs and expenses of Lender in connection with recovery of the same, and then, except as set forth below in this Section 8.1, shall be applied in the sole and absolute discretion of Lender, without regard to the adequacy of Lender&#8217;s security hereunder, to the payment or prepayment of the Obligations in such order as Lender may determine, and any amounts so applied shall reduce the Obligations </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">pro&#160;tanto</font><font style="font-family:inherit;font-size:12pt;">&#32;(without any Prepayment Premium due in connection therewith).  Any application of the Proceeds or any portion thereof to the Obligations shall not be construed to cure or waive any Default or Event of Default or invalidate any act done pursuant to any such Default or Event of Default.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to the other provisions of this Section 8.1, and provided that (i) all Proceeds have been deposited with an Acceptable Financial Institution; (ii) no Event of Default shall exist; (iii) a Total Loss with respect to the Property shall not have occurred; (iv) the Restoration is capable, as reasonably determined by Lender, of being completed before the earlier (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Restoration Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to occur of (x)&#160;the date which is six (6) months prior to the Maturity Date, (y)&#160;the date on which the insurance carried by Borrower pursuant to Section 5.4(a)(ii), with respect to the Mortgaged Property shall expire and (z)&#160;eighteen (18) months after the occurrence of the casualty or condemnation in question; (v) Lender shall have been furnished with an estimate of the cost of restoration accompanied by an architect&#8217;s certificate as to such costs and appropriate final plans and specifications for reconstruction of the Improvements, all of which shall be approved by Lender, which approval shall not be unreasonably withheld, conditioned or delayed; (vi) the Improvements so restored or rebuilt shall be of at least equal value and substantially the same character as prior to the damage or destruction and appropriate for the purposes for which they were originally erected (and, if requested by Lender, Borrower will furnish, at its expense, an appraisal confirming such valuation); (vii) Borrower shall have furnished Lender with evidence reasonably satisfactory to Lender that all Improvements so restored and/or reconstructed and their use fully comply with all applicable zoning, building laws, ordinances and regulations and other Legal Requirements and that all required licenses and approvals required for use, operation and occupancy of the Improvements can be obtained, to the extent available; (viii) if the estimated cost of restoration exceeds the Proceeds available, Borrower shall have deposited with Lender such sums or other security as may be necessary, in Lender&#8217;s reasonable judgment, to pay such excess costs and (ix) Lender shall have received notice within thirty (30) days of the fire or other hazard or of the condemnation proceedings specifying the date of such fire or other hazard or the date the notice of condemnation proceedings was received and the request to Lender to make said Proceeds available to Borrower; then the Proceeds, less the actual costs, fees and expenses, if any, incurred in connection with adjustment of loss and Lender&#8217;s reasonable administrative expenses relating to such loss and the disbursement of the Proceeds shall be made available by Lender to the payment of all the costs of the aforesaid restoration, repairs, replacement, rebuilding or alterations, including the cost of temporary repairs or for the protection of property pending the completion of permanent restoration, repairs, replacements, rebuilding or alterations (all of which temporary repairs, protection of property and permanent restoration, repairs, replacement, rebuilding or alterations are hereinafter collectively referred to as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Restoration</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and shall be paid out from time to time as such Restoration progresses upon the request of Borrower if the work for which payment is requested has been done in a good and workmanlike manner, in compliance with applicable Legal Requirements and substantially in accordance with the plans and specifications therefor.  Each request by Borrower for disbursement of Proceeds shall (unless Lender otherwise elects, in its sole discretion, with respect to a Restoration estimated by Lender to cost $100,000 or less to complete, to waive any of the following requirements) be accompanied by the required Lien Waivers, a Request for Release, and, to the extent not subsumed within a Request for Release, the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A certificate signed by Borrower, dated not more than thirty (30) days prior to such request, setting forth the following:  (A) That the sum then requested either has been paid, or is justly due to contractors, subcontractors, materialmen, engineers, architects or other persons who have rendered services or furnished materials for the restoration therein specified or have paid for the same, the names and addresses of such persons, a brief description of such services and materials, the several amounts so paid or due to each of said persons in respect thereof (together with supporting statements and invoices for the same), that no part of such expenditures has been or is being made the basis of any previous or then pending request for the withdrawal of Proceeds or has been made out of any of the Proceeds received </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">by Borrower, and that the sum then requested does not exceed the value of the services and materials described in the certificate; and (B) That the costs, as estimated by the persons signing such certificate, of the Restoration required to be done subsequent to the date of such certificate in order to complete and pay for the same, do not exceed the Proceeds, plus any amount or security approved by Lender and deposited with such Acceptable Financial Institution by Borrower to defray such costs and remaining in the hands of Lender after payment of the sum requested in such certificate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A title insurance report or other evidence satisfactory to Lender to the effect that there has not been filed with respect to the Mortgaged Property, or any part thereof, any vendor&#8217;s, contractor&#8217;s, mechanics&#8217;, laborer&#8217;s, materialmen&#8217;s or other Lien which has not been discharged of record or bonded or insured over, except such as will be disbursed by payment of the amount then requested.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A certificate signed by the Independent Architect and/or engineer in charge of the Restoration, who shall be selected by Borrower and approved in writing by Lender, certifying that the Restoration is proceeding in accordance with the plans and specifications approved by Lender and in accordance with all zoning, subdivision and other Legal Requirements.  Upon compliance with the foregoing provisions, Lender shall, out of Proceeds (and the amount of security approved by Lender, if any, deposited by Borrower to defray the costs of the Restoration), pay or cause to be paid to Borrower or the Persons named (pursuant to clause (1)(A) above) in such certificate the respective amounts stated therein to have been paid by Borrower or to be due to them, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Proceeds at the time held by the Acceptable Financial Institution, less the actual costs, fees and expenses, if any, incurred in connection with the adjustment of the loss and Lender&#8217;s administrative expenses relating to such loss and the disbursement of the Proceeds, shall be, in Lender&#8217;s reasonable judgment, insufficient to pay the entire cost of the Restoration, Borrower shall deposit with such Acceptable Financial Institution any such deficiency prior to disbursement of any additional portion of the Proceeds.  Lender shall at all times have a perfected security interest on all Proceeds and other amounts held by such Acceptable Financial Institution pursuant to this Section&#160;8.  No payment made prior to the final completion of the Restoration shall exceed ninety percent (90%) of the value of the work performed from time to time (provided that, notwithstanding the foregoing, subcontractors who have completed their work may be paid in full), and at all times the undisbursed balance of said Proceeds remaining in the hands of Lender shall be at least sufficient to pay for the cost of completion of the Restoration free and clear of liens.  In addition to the requirements and conditions set forth in Section 5.19, final payment shall be upon an architect&#8217;s certificate of completion in accordance with the final plans and specifications and compliance with all applicable zoning, building, subdivision and other governmental laws, ordinances, rules, and regulations, the filing of a notice of completion and the expiration of the period provided under applicable law for the filing of mechanic&#8217;s and materialmen&#8217;s liens and delivery to Lender of a certified copy of a final unconditional permanent (i) certificate of occupancy regarding the Restoration, to the extent available, and (ii) certificate of compliance from The&#160;Woodlands Community Association and The Woodlands Community Owners Association (or their successor entities).  To the extent available, Lender may, at its option, require an endorsement to the Title Policy insuring the continued priority of the lien of the Mortgage as to all sums advanced hereunder, such endorsement to be paid for by Borrower.  Upon completion of the Restoration in a good and workmanlike manner in accordance herewith, and provided that Lender has received satisfactory evidence that the Restoration has been paid for in full and the Mortgaged Property is free and clear of all Liens, other than the Liens created in favor of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lender by the Loan Documents and the Permitted Encumbrances (including signed lien waivers from all contractors and subcontractors conditioned only on payment of amounts specified therein), any balance of the Proceeds at the time held by Lender (after reimbursement to Lender of all costs and expenses of Lender, including administrative expenses, in connection with recovery of the same and disbursement of such Proceeds for the Restoration), if any, shall be applied as follows:  (i) to the extent that such balance of the Proceeds is equal to or less than the amount, if any, by which the value of the Mortgaged Property prior to such damage or destruction exceeds the value of the Mortgaged Property after such Restoration (for these purposes, the value of the Mortgaged Property shall be determined by Lender in its discretion), then the portion of the balance of the Proceeds equal to such excess amount shall be applied to the payment or prepayment of the principal balance of the Obligations in such order as Lender may determine, and any amounts so applied shall reduce the Obligations </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">pro tanto</font><font style="font-family:inherit;font-size:12pt;">&#32;(without any Prepayment Premium due in connection therewith); and (ii) to the extent that the balance of the Proceeds exceeds such excess amount, such portion of the balance of the Proceeds shall be paid to Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Nothing herein contained shall be deemed to excuse Borrower from repairing or maintaining the Mortgaged Property as provided in the Agreement hereof or restoring all damage or destruction to the Mortgaged Property, regardless of whether or not there are insurance proceeds available or whether any such Proceeds are sufficient in amount, and the application or release by Lender of any Proceeds shall not cure or waive any Default or Event of Default or invalidate any other act done by Lender to exercise its remedies under this Agreement or the other Loan Documents; provided, however, if, prior to the last two (2) years of the term of the Loan, Lender elects not to make such Proceeds available to Borrower for restoration, then Borrower may prepay the Loan without payment of the Prepayment Premium, so long as an Event of Default is not then in existence.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 9</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">DEFAULT, RIGHTS AND REMEDIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Event of Default</font><font style="font-family:inherit;font-size:12pt;">.  &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Event of Default</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence or existence of any one or more of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payment</font><font style="font-family:inherit;font-size:12pt;">.  Failure of Borrower to pay (i) on the Maturity Date, the outstanding principal of, accrued interest in, and other Indebtedness owing pursuant to the Agreement, the Note and the other Loan Documents, (ii) within five (5) days after the due date, any installment of principal or interest due under the Note; provided, however, the aforesaid five (5) day grace period may be utilized by Borrower no more than once in any consecutive twelve (12) Loan Month period, or (iii) within five (5) days after the respective due date, any other amount due under the other Loan Documents, provided, however, the aforesaid five (5)&#8209;day grace period may be utilized by Borrower no more than once in any consecutive twelve (12) Loan Month period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Breach of Certain Provisions</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Failure of Borrower to perform or comply with any term, agreement, covenant, representation, warranty or condition contained in Sections 5.1(E), 5.1(F), 5.1(G), 5.1(H), 5.13, 6.2, 7.2, 7.5, 7.9, 7.12, 7.13, 7.14, 8.1(a), 8.1(b) or 10  and such failure is not remedied or waived within five (5) Business Days after receipt by Borrower of notice from Lender of such failure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Failure of Borrower to perform or comply with any term, agreement, covenant, representation, warranty or condition contained in Sections 5.4 (except any such failure which does </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">not result in any insurance coverage required by Section 5.4 not in fact being in place), 7.1, 7.3, 7.4, 7.10 or 7.11.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Breach of Representation and Warranty</font><font style="font-family:inherit;font-size:12pt;">.  Any representation, warranty, certification or other statement made by Borrower or Guarantor in any Loan Document or in any statement or certificate at any time given in writing pursuant or in connection with any Loan Document (other than occurrences described in other provisions of this Section 9.1 for which a different grace or cure period is specified or which constitute immediate Events of Default) is false in any material respect on the date made which remains uncured for five (5) Business Days after notice, but no grace or curative period will apply if the representation, warranty, certification or other statement was known by Borrower or Guarantor to be false when made or deemed made.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Defaults Under Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  A&#160;default by Borrower shall occur in the performance of or compliance with any term contained in this Agreement or the other Loan Documents and such default is not remedied or waived within thirty (30) days after receipt by Borrower of notice from Lender of such default (other than occurrences described in other provisions of this Section 9.1 for which a different grace or cure period is specified or which constitute immediate Events of Default); provided, however, that (i)&#160;if such default cannot be remedied with reasonably diligent effort within a period of thirty (30) days, but is susceptible to cure within a period of one hundred twenty (120) days and (ii) the continued default in performance will not have a Material Adverse Effect, such longer period, not to exceed ninety (90) additional days, as Borrower may need to remedy such default, if Borrower is proceeding with diligent effort to remedy such default throughout said one hundred twenty (120)-day period; provided, further, however, that (A) if Borrower has been, and will continue to be, diligent in its efforts to cure such default, and (B) the continued default has not, and will not, have a Material Adverse Effect, Borrower shall have such longer period, not to exceed an additional sixty (60) days (for a total of one hundred eighty (180) days), as Borrower may need to remedy such default.  The rights to notice and cure periods granted herein shall not be cumulative with any other rights to notice or a cure period in any other Loan Document and the giving of notice or a cure period pursuant to this section shall satisfy any and all obligations of Lender to grant any such notice or cure period pursuant to any of the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(E)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Involuntary Bankruptcy; Appointment of Receiver, etc.</font><font style="font-family:inherit;font-size:12pt;">&#32;(1)&#160; A&#160;court enters a decree or order for relief with respect to Borrower, Guarantor or Borrower Representative in an involuntary case under the Bankruptcy Code or any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, which decree or order is not stayed or other similar relief is not granted under any applicable federal or state law; or (2)&#160;the continuance of any of the following events for ninety (90) days unless dismissed, bonded or discharged:  (a)&#160;an involuntary case is commenced against any Borrower, Borrower Representative or Guarantor under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect; or (b)&#160;a decree or order of a court for the appointment of a receiver, liquidator, sequestrator, trustee, custodian or other officer having similar powers over Borrower, Borrower Representative or Guarantor or over all or a substantial part of its property, is entered; or (c)&#160;an interim receiver, trustee or other custodian is appointed without the consent of Borrower, Borrower Representative or Guarantor for all or a substantial part of the property of Borrower, Borrower Representative or Guarantor; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(F)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Bankruptcy; Appointment of Receiver, etc.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;(1)&#160;An order for relief is entered with respect to Borrower, Borrower Representative or Guarantor or Borrower, Borrower Representative or Guarantor commences a voluntary case under the Bankruptcy Code or any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or consents to the entry of an order for relief in an involuntary case or to the conversion of an involuntary case to a voluntary case under any such law or consents to the appointment of or taking possession by a receiver, trustee or other custodian for all or a substantial part of its property; or (2)&#160;Borrower, Borrower Representative or Guarantor makes any assignment for the benefit </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of creditors; or (3)&#160;partners, shareholders, or members in Borrower, Borrower Representative or Guarantor adopts any resolution or otherwise authorizes action to approve any of the actions referred to in this Section&#160;9.1(F); or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(G)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governmental Liens</font><font style="font-family:inherit;font-size:12pt;">.  Any lien, levy or assessment is filed or recorded with respect to or otherwise imposed upon all or any part of the Mortgaged Property by the United&#160;States or any department or instrumentality thereof or by any state, county, municipality or other governmental agency (other than Permitted Encumbrances) and such lien, levy or assessment is not stayed, vacated, paid, discharged or insured or bonded over within thirty (30) days;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(H)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Judgment and Attachments</font><font style="font-family:inherit;font-size:12pt;">.  Any money judgment, writ or warrant of attachment, or similar process (other than those described in Section 9.1(G)) involving (1)&#160;an amount in any individual case in excess of $100,000 or (2)&#160;an amount in the aggregate at any time in excess of $250,000 (in either case not adequately covered by insurance as to which the insurance company has acknowledged coverage) is entered or filed against Borrower, Borrower Representative or Guarantor and remains undischarged, unvacated, unbonded, uninsured or unstayed for a period of thirty (30) days or in any event later than five (5) days prior to the date of any proposed sale thereunder;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(I)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Dissolution</font><font style="font-family:inherit;font-size:12pt;">.  Any order, judgment or decree is entered against Borrower, Borrower Representative or Guarantor decreeing the dissolution or split up of Borrower, Borrower Representative or Guarantor and such order remains undischarged or unstayed for a period in excess of twenty (20) days; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(J)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Injunction</font><font style="font-family:inherit;font-size:12pt;">.  Either (i) Borrower, Borrower Representative or any Guarantor is enjoined, restrained or in any way prevented by the order of any court or any administrative or regulatory agency from conducting all or any material part of its business relating to the any Mortgaged Property and such order continues for more than thirty (30) days; or (ii) any order or decree is entered by any court of competent jurisdiction directly or indirectly enjoining or prohibiting Lender, Borrower, Borrower Representative or Guarantor from performing any of their obligations under this Agreement or any of the other Loan Documents; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(K)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Invalidity of Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  Any of the Loan Documents for any reason, other than a partial or full release in accordance with the terms of the Loan Documents, ceases to be in full force and effect or is declared to be null and void by a court of competent jurisdiction, or any of Borrower, Borrower Representative or Guarantor denies that it has any further liability under any Loan Documents to which it is party, or gives notice to such effect; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(L)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Event of Default</font><font style="font-family:inherit;font-size:12pt;">.  The occurrence of an Event of Default specified elsewhere in this Agreement or in any of the other Loan Documents or the occurrence of an Event of Default by Guarantor under the Guaranty; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(M)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Cross-Default</font><font style="font-family:inherit;font-size:12pt;">.  The occurrence of any of the following with respect to Guarantor:  (i) the acceleration of any Indebtedness in the aggregate amount of $10,000,000 or more; (ii) the occurrence of a default under any Indebtedness in the aggregate amount of $10,000,000 or more not cured within the grace or curative period applicable to such Indebtedness, (iii) the occurrence of a default or breach under any Material Contracts not cured within any applicable grace period or notice and cure period, which, in Lender&#8217;s reasonable judgment, could have a Material Adverse Effect, or (iv) the loss or termination of any Proprietary Rights which, in Lender&#8217;s reasonable judgment, could have a Material Adverse Effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(N)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Death, etc.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Dissolution, cessation of existence or felony or other criminal conviction or indictment of Borrower, Borrower Representative and/or Guarantor, a punishment for which could result in </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">forfeiture of any assets of the Borrower, Guarantor or any direct or indirect equity interest to Borrower or loss of eligibility for any material Proprietary Rights, which in Lender&#8217;s reasonable judgment could have a Material Adverse Effect; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(O)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Independent Person</font><font style="font-family:inherit;font-size:12pt;">. Borrower or Borrower Representative shall at any time cease to have at least one (1) Independent Person or, if requested by Lender in writing in connection with a contemplated Securitization, two (2) Independent Persons for more than ten (10) consecutive Business Days; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(P)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Zoning</font><font style="font-family:inherit;font-size:12pt;">.  The Land and Improvements or any portion thereof are zoned either voluntarily or involuntarily, such that the zoning or other applicable land use restriction prohibits the Borrower from operating the Land and Improvements or any portion thereof as an office, laboratory, vivarium, life sciences facility or other facility for similar use; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Q)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tenant Impairment Event</font><font style="font-family:inherit;font-size:12pt;">.  The occurrence of a Tenant Impairment Event; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(R)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Change in Control</font><font style="font-family:inherit;font-size:12pt;">.  The occurrence of any direct or indirect Change in Control with respect to Borrower or Guarantor, except as permitted pursuant to Section 7.11; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(S)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:12pt;">.  The occurrence of any default by Borrower in any of its obligations under the Guarantor Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Acceleration and Remedies</font><font style="font-family:inherit;font-size:12pt;">.  Upon the occurrence of any Event of Default specified in Sections 9.1(E) and 9.1(F), payment of all Obligations shall be accelerated without notice, presentment, demand, protest or notice of protest and shall be immediately due and payable and, in addition, Lender may in addition to any other rights and remedies available to Lender at law or in equity or under any other Loan Documents, exercise one of more of the following rights and remedies as it, in its sole discretion, deems necessary or advisable.  Upon the occurrence of any Event of Default (other than Events of Default specified in Sections 9.1(E) and 9.1(F)), Lender, in addition to any other rights or remedies available to Lender at law or in equity, or under any of the other Loan Documents, may exercise any one or more of the following rights and remedies as it, in its sole discretion, deems necessary or desirable:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Acceleration</font><font style="font-family:inherit;font-size:12pt;">.  Declare immediately due and payable, without further notice, protest, presentment, notice of protest or demand, all Obligations including all monies advanced under this Agreement, the Note, the Mortgage and/or any of the Loan Documents which are then unpaid, together with all interest then accrued thereon and all other amounts then owing (including any Default Interest, or prepayment premium owed as a result of such acceleration).  If payment of the Obligations is accelerated, Lender may, in its sole discretion, exercise all rights and remedies hereunder and under the Note, the Mortgage and/or any of the other Loan Documents at law, in equity or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Possession</font><font style="font-family:inherit;font-size:12pt;">.  Enter upon and take possession of the Mortgaged Property and proceed in the name of Lender or Borrower as the attorney-in-fact of Borrower (which authority, to the extent permitted by law, is hereby granted by Borrower, is coupled with an interest, and is irrevocable), as Lender shall elect.  If Lender elects to so enter upon and take possession of the Mortgaged Property, Lender (i) may enforce or cancel all contracts entered into by Borrower or make other contracts which are in Lender&#8217;s sole opinion advisable, and (iii) shall be reimbursed by Borrower upon demand any reasonable amount or amounts expended by Lender for such performance together with any reasonable costs, charges, or expenses incident thereto or otherwise incurred or expended by Lender or its representatives (including an appraisal) on behalf of Borrower in connection with the Mortgaged Property, and the amounts so expended shall be considered part of the Loan evidenced by the Note and secured by the Loan Documents and shall bear interest at the Default Rate.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Injunctive Relief</font><font style="font-family:inherit;font-size:12pt;">.  Institute appropriate proceedings for injunctive relief (including specific performance of the obligations of Borrower).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Release all funds contained in the Reserve Accounts to be applied to Borrower&#8217;s Obligations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Remedies Cumulative; Waivers; Reasonable Charges</font><font style="font-family:inherit;font-size:12pt;">.  All of the remedies given to Lender in the Loan Documents or otherwise available at law or in equity to Lender shall be cumulative and may be exercised separately, successively or concurrently.  Failure to exercise any one of the remedies herein provided shall not constitute a waiver thereof by Lender, nor shall the use of any such remedies prevent the subsequent or concurrent resort to any other remedy or remedies vested in Lender by the Loan Documents or at law or in equity.  To be effective, any waiver by Lender must be in writing and such waiver shall be limited in its effect to the condition or default specified therein, and no such waiver shall extend to any subsequent condition or default.  It is agreed that (i) the actual costs and damages that Lender would suffer by reason of an Event of Default (exclusive of the attorneys&#8217; fees and other costs incurred in connection with enforcement of Lender&#8217;s rights under the Loan Documents) or a prepayment would be difficult and needlessly expensive to calculate and establish, and (ii) the amounts of the Default Rate, the Late Charge, payments to be made pursuant to Section 2.4(c)(ii) and the Prepayment Premium are reasonable, taking into consideration the circumstances known to the parties at this time, and (iii) the Default Rate, the Late Charges and Lender&#8217;s reasonable attorneys&#8217; fees and other costs and expenses incurred in connection with enforcement of Lender&#8217;s rights under the Loan Documents shall be due and payable as provided herein, and (iv) the Default Rate, Late Charges, Prepayment Premium, the payments to be made pursuant to Section 2.4(c)(ii) and the obligation to pay Lender&#8217;s reasonable attorneys&#8217; fees and other enforcement costs do not, individually or collectively, constitute a penalty.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SECONDARY MARKET TRANSACTION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Secondary Market Transaction</font><font style="font-family:inherit;font-size:12pt;">.  Borrower agrees that Lender has the absolute right to securitize, syndicate, grant participations in, or otherwise Transfer all or any portion of the Loan (each such transaction, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securitization</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Lender may determine to Transfer some or all of the Loan or retain title to some or all of the Loan as part of a Securitization.  Borrower further agrees that Lender may delegate any or all of Lender&#8217;s rights, powers and privileges to a servicer (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Servicer</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Borrower shall, upon notice from Lender, recognize the Servicer as the agent of Lender.  In the event this Loan becomes or is designated by Lender to become an asset of a Securitization, upon Lender&#8217;s request, Borrower shall meet, from time to time, with representatives of the Rating Agencies in connection with such a Securitization to discuss the business and operations of the Mortgaged Property and, in that regard, agrees to cooperate with the reasonable requests of the Rating Agencies.  Lender may retain the Rating Agencies to provide rating surveillance services on any certificates issued in a Securitization.  In no event shall Borrower be required to pay any servicer fees, Securitization trustee fees or other Securitization administrative expenses except as may be expressly provided in this Agreement.  Borrower shall, upon request from Lender, from time to time, cooperate, and Borrower shall, cause Guarantor and Borrower&#8217;s partners and/or members to cooperate, in all reasonable respects in connection with a Securitization.  Such cooperation may, in Lender&#8217;s discretion, include documentation changes, changes in organizational documents, changes in Accounts, Reserves, Payment Dates, Interest Periods, insurance endorsement changes, tenant payment direction changes, site inspections, updated appraisals, preparation and delivery of financial information or other diligence requested by Lender and/or any Rating Agency; provided, however, any third party costs incurred by Borrower related to such changes shall be reimbursed by Lender and such changes shall not materially and adversely diminish Borrower&#8217;s rights under the Loan Documents nor increase Borrower&#8217;s burdens and obligations under the Loan Documents.  Such cooperation may include, in Lender&#8217;s discretion, execution of one or more promissory notes and the creation of Liens securing such notes of differing priority and/or the creation of mezzanine </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">debt secured by pledges of all of the membership interests in the Borrower so long as the principal amount, interest rate, payment terms and other monetary terms of the Loan do not, in the aggregate change.  Borrower will not be required to incur any expenses or costs pursuant to this Section&#160;10.1.  Borrower will, upon request from Lender, in connection with a Securitization, enter into such acknowledgments and confirmations of the applicable assignments as Lender may request.  Borrower shall, subject to the terms and provisions of this Section 10.1, use reasonable efforts to satisfy the market standards which Lender determines are reasonably required in the marketplace or by the Rating Agencies in connection with a Securitization.  Notwithstanding anything else contained to the contrary herein, Borrower will not, pursuant to any of the provisions of this Section&#160;10.1, incur, suffer or accept (i) any lesser rights or greater obligations as are currently set forth in the Loan Documents or Borrower&#8217;s Organizational Documents (unless Borrower is made whole by the holder of the Note) or (ii) subject to Section 11.13 hereof, any personal liability other than as set forth in the Loan Documents.  Borrower will also, if requested by Lender, cause independent counsel to render opinions customary in securitization transactions with respect to the Mortgaged Property and Borrower and Borrower&#8217;s and Guarantor&#8217;s Subsidiaries (but not a true sale, 10b&#8209;5 opinion or nonconsolidation opinion), which counsel and opinions shall be reasonably satisfactory to Lender and the Rating Agencies and which shall be addressed to such Persons as shall be reasonably designated by the holder of the Note.  Borrower&#8217;s failure to deliver the opinions required hereby within ten (10) Business Days after written request therefore shall constitute an Event of Default hereunder.  If requested by Lender, Borrower&#8217;s cooperation will also include (but subject to Section 11.3) certifications and agreements pursuant to which Borrower will certify that it has examined the portion of applicable preliminary and final private placement memorandum or preliminary, final and supplement or prospectus specified by Lender as pertaining to Borrower, the Loan, Guarantor, the Mortgaged Property and the Manager, and that each such designated portion, as it relates to Borrower, Guarantor, the Mortgaged Property, Manager and all other aspects of the Loan, does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading.  All reasonable costs of Borrower&#8217;s cooperation as described in this Section 10.1 shall be at the expense of Lender, except (a) any costs and expenses for the appointment of a second Independent Person for Borrower and Borrower Representative, which costs shall be paid by Borrower, and (b) any reasonable fees and expenses of the Servicer which Borrower may be obligated to pay based upon actions, consents or waivers requested by Borrower.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECTION 11</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MISCELLANEOUS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Expenses and Attorneys&#8217; Fees</font><font style="font-family:inherit;font-size:12pt;">.  Whether or not the transactions contemplated hereby shall be consummated, Borrower agrees to promptly pay all fees, costs and expenses (including reasonable attorneys&#8217; fees, court costs, cost of appeal and the reasonable fees, costs and expenses of other professionals retained by Lender) incurred by Lender in connection with the following, and all such fees, costs and expenses shall be part of the Obligations, payable on five (5) Business Days written notice: (A) the examination, review, due diligence investigation, documentation and closing of the financing arrangements evidenced by the Loan Documents; (B) the giving or withholding of any consents, approvals, or permissions, administration of the Loan, disbursements of the Loan and disbursements from the Accounts and in connection with any amendments, modifications and waivers relating to the Loan Documents requested by Borrower; (C) the review, documentation, negotiation and closing of any subordination or intercreditor agreements, Lease reviews, and subordination, nondisturbance and attornment agreements; (D) Lender&#8217;s Representative; and (E) enforcement of this Agreement or the other Loan Documents, the collection of any payments due from Borrower or Guarantor under the Loan Documents or any refinancing or restructuring of the credit arrangements provided under the Loan Document, whether in the nature of a &#8220;workout&#8221; or in connection with any insolvency or bankruptcy proceedings or otherwise; provided, however, in no event shall Borrower be liable for any fees incurred by Lender in connection with a Securitization.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Certain Lender Matters</font><font style="font-family:inherit;font-size:12pt;">.  Lender may, in accordance with Lender&#8217; customary practices, destroy or otherwise dispose of all documents, schedules, invoices or other papers, delivered by Borrower to Lender unless Borrower requests, at the time of delivery, in writing that same be returned.  Borrower and Lender intend that the relationships created hereunder and under the other Loan Documents be solely that of borrower and lender.  Nothing herein or therein is intended to create a joint venture, partnership, tenancy-in-common, or joint tenancy relationship between Borrower and Lender nor to grant Lender any interest in the Mortgaged Property other than that of mortgagee, beneficiary or lender.  No provision in this Agreement or in any of the other Loan Documents and no course of dealing between the parties shall be deemed to create any fiduciary duty by Lender to Borrower or any other Person.  All attorneys, accountants, appraisers, and other professional Persons and consultants retained by Lender shall have the right to act exclusively in the interest of Lender and shall have no duty of loyalty, duty of care or any other duty to Borrower or any of Borrower&#8217;s partners, shareholders, members, managers, Affiliates or any other Person.  By accepting or approving anything required to be observed, performed or fulfilled or to be given to Lender pursuant to the Loan Documents, Lender shall not be deemed to have warranted or represented the sufficiency, legality, effectiveness or legal effect of the same, or of any term, provision or condition thereof, and such acceptance or approval thereof shall not be or constitute any warranty or representation with respect hereto or thereto by Lender.  Borrower shall rely solely on its own judgment and advisors in entering into the Loan without relying in any manner on any statements, representations or recommendations of Lender or any parent, subsidiary or Affiliate of Lender or their respective attorneys, advisors, accountants, officers, representatives, directors, employees, partners, shareholders, trustees, members or managers.  Lender shall not be subject to any limitation whatsoever in the exercise of any rights or remedies available to it under any of the Loan Documents or any other agreements or instruments which govern the Loan by virtue of the ownership by it or any parent, subsidiary or Affiliate of Lender of any equity interest any of them may acquire in Borrower, and Borrower hereby irrevocably waives the right to raise any defense or take any action, in either case, on the basis of the foregoing with respect to Lender&#8217;s exercise of any such rights or remedies.  Borrower acknowledges that Lender engages in the business of real estate financings and other real estate transactions and investments which may be viewed as adverse to or competitive with the business of Borrower or its Affiliates.  LENDER SHALL HAVE NO LIABILITY HEREUNDER FOR ANY CONSEQUENTIAL, SPECIAL, PUNITIVE OR INDIRECT DAMAGES.  In the case of any receivership, insolvency, bankruptcy, reorganization, arrangement, adjustment, composition or other proceedings affecting Borrower or Borrower Representative or Guarantor, or their respective creditors or property, Lender, to the extent permitted by law, shall be entitled to file such proofs of claim and other documents as may be necessary or advisable in order to have the claims of Lender allowed in such proceedings for the entire secured Obligations at the date of the institution of such proceedings and for any additional amount which may become due and payable by Borrower after such date.  Lender shall have the right from time to time to designate, appoint and replace one or more servicers and to allow servicer to exercise any and all rights of Lender under the Loan Documents.  All documents and other matters required by any of the provisions of this Agreement to be submitted or provided to Lender shall be in form and substance satisfactory to Lender.  Borrower shall not be entitled to (and does hereby waive any and all rights to receive) any notices of any nature whatsoever from Lender except with respect to matters for which the Loan Documents expressly provide for the giving of notice by Lender to Borrower.  In any action or proceeding brought by Borrower against Lender claiming or based upon an allegation that Lender unreasonably withheld its consent to or approval of a proposed act by Borrower which requires Lender&#8217;s consent hereunder, Borrower&#8217;s sole and exclusive remedy in said action or proceeding shall be injunctive relief or specific performance requiring Lender to grant such consent or approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indemnity</font><font style="font-family:inherit;font-size:12pt;">.  In addition to the payment of expenses pursuant to Section&#160;11.1 and the indemnification obligations set forth in other portions of this Agreement, the Environmental Indemnification Agreement or the other Loan Documents, whether or not the transactions contemplated hereby shall be consummated, Borrower agrees to indemnify, pay, defend and hold Lender, its officers, directors, members, partners, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shareholders, participants, beneficiaries, trustees, employees, agents, successors and assigns, any subsequent holder of the Note, any trustee, fiscal agent, servicer, underwriter and placement agent, (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221;) harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, causes of action, suits, claims, tax liabilities, broker&#8217;s or finders fees, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnitees in connection with any investigative, administrative or judicial proceeding commenced or threatened, whether or not such Indemnitee shall be designated a party thereto) that may be imposed on, incurred by, or asserted against that Indemnitee, based upon any third party claims against such Indemnitees in any manner related to or arising out of (A)&#160;any breach by Borrower or Guarantor of any representation, warranty, covenant, or other agreement contained in any of the Loan Documents, (B)&#160;the actual or threatened presence, release, disposal, spill, escape, leakage, transportation, migration, seepage, discharge, removal, or cleanup of any  Hazardous Material located on, about, within, under, affecting, from or onto the Mortgaged Property or any violation of any applicable Environmental Law by Borrower or the Mortgaged Property, or (C)&#160;the use or intended use of the proceeds of any of the Loan (the foregoing liabilities herein collectively referred to as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnified Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221;); provided that Borrower shall have no obligation to an Indemnitee hereunder with respect to Indemnified Liabilities arising from the gross negligence or willful misconduct of that Indemnitee as determined in a final order by a court of competent jurisdiction.  Borrower shall be relieved of its obligation under clause (B) of this Section 11.3 with respect to Hazardous Materials first introduced to the Land and Improvements after either (1) the foreclosure of the Mortgage or (2) the delivery by Borrower to, and acceptance by, Lender or its designee of a deed-in-lieu of foreclosure with respect to the Mortgaged Property.  To the extent that the undertaking to indemnify, pay, defend and hold harmless set forth in the preceding sentence may be unenforceable because it is violative of any law or public policy, Borrower shall contribute the maximum portion that it is permitted to pay and satisfy under applicable law to the payment and satisfaction of all Indemnified Liabilities incurred by the Indemnitees or any of them.  If any such action or other proceeding shall be brought against Lender, upon written notice from Borrower to Lender (given reasonably promptly following Lender&#8217;s notice to Borrower of such action or proceeding), Borrower shall be entitled to assume the defense thereof, at Borrower&#8217;s expense, with counsel reasonably acceptable to Lender; provided, however, Lender may, at its own expense, retain separate counsel to participate in such defense, but such participation shall not be deemed to give Lender a right to control such defense, which right Borrower expressly retains.  Notwithstanding the foregoing, each Indemnitee shall, following notice to and consultation with Borrower, have the right to employ separate counsel at Borrower&#8217;s expense if, in the reasonable opinion of legal counsel, a conflict or potential conflict exists between the Indemnitee and Borrower that would make such separate representation advisable.  Borrower shall have no obligation to indemnify an Indemnitee for damage or loss resulting from such Indemnitee&#8217;s gross negligence or willful misconduct.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments and Waivers</font><font style="font-family:inherit;font-size:12pt;">.  Except as otherwise provided herein, no amendment, modification, termination or waiver of any provision of this Agreement, the Note or any other Loan Document, or consent to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by Lender (and, with respect to any amendment or modification, unless also signed by Borrower).  Each amendment, modification, termination or waiver shall be effective only in the specific instance and for the specific purpose for which it was given.  No notice to or demand on Borrower in any case shall entitle Borrower, or any other Person to any other or further notice or demand in similar or other circumstances.  To the fullest extent permitted by law, Borrower, for itself and its successors and assigns, waives all rights to a marshalling of the assets of Borrower, Borrower&#8217;s partners or members and others with interests in Borrower, and of the Mortgaged Property, or to a sale in inverse order of alienation in the event of foreclosure of all or any of the Mortgage, and agrees not to assert any right under any laws pertaining to the marshalling of assets, the sale in inverse order of alienation, homestead exemption, the administration of estates of decedents, or any other matters whatsoever to defeat, reduce or affect the right of Lender under the Loan </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Documents to a sale of the Mortgaged Property for the collection of the obligations without any prior or different resort for collection or of the right of Lender to the payment of the obligations owing Lender on account of the Loan Documents out of the net proceeds of the Mortgaged Property in preference to every other claimant whatsoever.  In addition, Borrower, for itself and its successors and assigns, waives in the event of foreclosure of the Mortgage, any equitable right otherwise available to Borrower which would require the separate sale of any of any portion of the Mortgaged Property or require Lender to exhaust its remedies against any portion of the Mortgaged Property or any combination of the Mortgaged Property before proceeding against any other portion; and further in the event of such foreclosure, Borrower expressly consents to and authorizes, at the option of Lender, the foreclosure and sale either separately of all or any portion of the Mortgaged Property.  Borrower hereby waives the right to assert a counterclaim, other than a compulsory counterclaim or defense of performance, in any action or proceeding brought against it by Lender or its agents.  Subject to the remaining terms of the Loan Documents, Borrower shall have the right to bring a separate action against Lender for breaches of Lender&#8217;s obligations under the Loan Documents.  No failure or delay on the part of Lender or any holder of any Note in the exercise of any power, right or privilege hereunder or under the Note or any other Loan Document shall impair such power, right or privilege or be construed to be a waiver of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.  All rights and remedies existing under this Agreement, the Note and the other Loan Documents are cumulative to, and not exclusive of, any rights or remedies otherwise available.  Lender shall not be under any obligation to marshal any assets in favor of any Person or against or in payment of any or all of the Obligations.  To the extent that any Person makes a payment or payments to Lender, or Lender enforces its remedies or exercise its rights of setoff, and such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, state or federal law, common law or equitable cause, then to the extent of such recovery, the Obligations or part thereof originally intended to be satisfied, and all Liens, if any, rights and remedies therefore, shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.  Borrower agrees (to the extent that it may lawfully do so) that it will not at any time insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay or extension law or any usury or other law wherever enacted, now or at any time hereafter in force, which would prohibit or forgive Borrower from paying all or any portion of the principal of, premium, if any, or interest on Loan contemplated herein or in any of the other Loan Documents or which may affect the covenants or the performance of this Agreement; and Borrower (to the extent that it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it will not hinder, delay or impede the execution of any power herein granted to the holders, but will suffer and permit the execution of every such power as though no such law had been enacted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise specifically provided herein, any notice or other communica-tion required or permitted to be given shall be in writing addressed to the respective party as set forth below and may be personally served, telecopied (with request for confirmation) or sent by overnight courier service or United States registered mail return receipt requested, postage prepaid.  Any notice so given shall be deemed effective upon delivery or on refusal or failure of delivery during normal business hours.  Notices shall be addressed to the parties at the addresses specified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 11.5</font><font style="font-family:inherit;font-size:12pt;">&#32;or to such other address as the party addressed shall have previously designated by written notice to the serving party, given in accordance with this Section 11.5. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Survival of Warranties and Certain Agreements</font><font style="font-family:inherit;font-size:12pt;">.  All agreements, representations and warranties made herein shall survive the execution and delivery of this Agreement, the making of the Loan hereunder and the execution and delivery of the Notes.  Notwithstanding anything in this Agreement or implied by law to the contrary, the provisions of Sections 2.6, 5.8, 11.1, 11.2, 11.3, 11.12, 11.13 and 11.15 shall survive the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">payment of the Loan and the termination of this Agreement. Subject to this Section 11.6, all other representations, warranties and agreements of Borrower and Lender set forth in this Agreement shall terminate upon indefeasible payment in full of the Loan and the termination of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;">.  Section headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose or be given any substantive effect.  All covenants and agreements hereunder shall be given in any jurisdiction independent effect so that if a particular action or condition is not permitted by any of such covenants, the fact that it would be permitted by an exception to, or be otherwise within the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists.  The invalidity, illegality or unenforceability in any jurisdiction of any provision in or obligation under this Agreement, the Note or other Loan Documents shall not affect or impair the validity, legality or enforceability of the remaining provisions or obligations under this Agreement, the Note or other Loan Documents or of such provision or obligation in any other jurisdiction.  This Agreement is made for the sole benefit of Borrower and Lender, and no other Person shall be deemed to have any privity of contract hereunder nor any right to rely hereon to any extent or for any purpose whatsoever, nor shall any other person have any right of action of any kind hereon or be deemed to be a third party beneficiary hereunder.  This Agreement, the Note, and the other Loan Documents referred to herein embody the final, entire agreement among the parties hereto and supersede any and all prior commitments, agreements, representations, and understandings, whether written or oral, relating to the subject matter hereof and may not be contradicted or varied by evidence of prior, contemporaneous, or subsequent oral agreements or discussions of the parties hereto.  There are no oral agreements among the parties hereto.  Borrower and Lender acknowledge that each of them has had the benefit of legal counsel of its own choice and has been afforded an opportunity to review this Agreement and the other Loan Documents with its legal counsel and that this Agreement and the other Loan Documents shall be construed as if jointly drafted by Borrower and Lender.  If any term, condition or provision of this Agreement shall be inconsistent with any term, condition or provision of any other Loan Document, this Agreement shall control.  This Agreement and any amendments, waivers, consents, or supplements may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all of which counterparts together shall constitute but one and the same instrument. This Agreement shall become effective upon the execution of a counterpart hereof by each of the parties hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">APPLICABLE LAW</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  THE PARTIES ACKNOWLEDGE AND AGREE THAT THE LOAN AND LOAN DOCUMENTS HAVE A SUBSTANTIAL NEXUS TO THE STATE OF NEW YORK AND AGREE THAT THIS AGREEMENT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW&#160;YORK.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns except that Borrower may not assign its rights or obligations hereunder or under any of the other Loan Documents without the written consent of Lender.  Any assignee of Lender&#8217;s interest in the Loan Documents shall take the same free and clear of all offsets, counterclaims or defenses which are unrelated to the Loan Documents which Borrower may otherwise have against any assignor of the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONSENT TO JURISDICTION AND SERVICE OF PROCESS</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  BORROWER HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE COUNTY OF NEW&#160;YORK, STATE OF NEW&#160;YORK AND IRREVOCABLY AGREES THAT, SUBJECT TO LENDER&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS SHALL BE </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LITIGATED IN SUCH COURTS.  BORROWER ACCEPTS FOR ITSELF AND IN CONNECTION WITH ITS MORTGAGED PROPERTY, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF </font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">FORUM NON CONVENIENS,</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT, THE NOTE, SUCH OTHER LOAN DOCUMENTS OR SUCH OBLIGATION.  BORROWER DESIGNATES AND APPOINTS CT&#160;CORPORATION SYSTEM AND SUCH OTHER PERSONS AS MAY HEREAFTER BE SELECTED BY BORROWER WITH LENDER&#8217;S APPROVAL WHICH IRREVOCABLY AGREE IN WRITING TO SO SERVE AS ITS AGENT TO RECEIVE ON ITS BEHALF SERVICE OF ALL PROCESS IN ANY SUCH PROCEEDINGS IN ANY SUCH COURT, SUCH SERVICE BEING HEREBY ACKNOWLEDGED BY BORROWER TO BE EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT.  A COPY OF ANY SUCH PROCESS SO SERVED SHALL BE MAILED BY REGISTERED MAIL TO BORROWER AT ITS ADDRESS PROVIDED IN SUBSECTION 11.5 EXCEPT THAT UNLESS OTHERWISE PROVIDED BY APPLIC-ABLE LAW, ANY FAILURE TO MAIL SUCH COPY SHALL NOT AFFECT THE VALIDITY OF SERVICE OF PROCESS.  IF ANY AGENT APPOINTED BY BORROWER AS ITS AGENT FOR SERVICE OF PROCESS REFUSES TO ACCEPT SERVICE OF PROCESS, BORROWER HEREBY AGREES THAT SERVICE UPON IT BY MAIL SHALL CONSTITUTE SUFFICIENT SERVICE.  NOTHING HEREIN SHALL AFFECT THE RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR SHALL LIMIT THE RIGHT OF LENDER TO BRING PROCEEDINGS AGAINST BORROWER IN THE COURTS OF ANY OTHER JURISDICTION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">WAIVER OF JURY TRIAL</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  BORROWER AND LENDER HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, ANY OF THE LOAN DOCUMENTS, OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER OF THIS LOAN TRANSACTION AND LENDER/BORROWER RELATIONSHIP THAT IS BEING ESTABLISHED.  BORROWER AND LENDER ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF BORROWER OR LENDER.  THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL&#8209;ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.  BORROWER AND LENDER ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS.  BORROWER AND LENDER FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.  THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT, THE LOAN DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOAN.  IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Publicity</font><font style="font-family:inherit;font-size:12pt;">.  Lender (and Lender&#8217;s Affiliates) may, subject to the applicable limitations on distribution of Confidential Information set forth in this Section 11.12 and subject to the approval of Guarantor, such </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">approval not to be unreasonably withheld, and Borrower does hereby authorize Lender (and its Affiliates) to, refer, in its sole discretion, to the Loan in tombstone advertisements,  offering memoranda in connection with Securitizations and reports to investors, which references, may include use of photographs, drawings and other depictions, images of the Land and Improvements (provided that such photographs, drawings and other depictions, and/or images shall not include floor plans of the area behind the barrier or other trade secrets), a description of the Loan, use of Borrower&#8217;s name, the address of the Mortgaged Property and the logo of Borrower and/or Guarantor.  Borrower shall cause the owner of such &#8220;logo&#8221; rights to consent to such use upon request from Lender at the Closing. Lender hereby agrees that (i) any written information, data, documents, etc. delivered in connection with the making of the Loan which has been expressly designated as such by notice to Lender from Borrower, (ii) any information contained in the books and records of Borrower, Guarantor or Borrower Representative which is either confidential, proprietary, or otherwise not generally available to the public (but excluding information Lender has obtained independently from third-party sources without Lender&#8217;s knowledge that the source has violated any fiduciary or other duty not to disclose such information) and which has been expressly designated as such by notice to Lender from Borrower, (iii) any financial statements of Borrower provided pursuant to this Agreement which are not publicly available and which has been expressly designated as confidential by notice to Lender from Borrower, and (iv) any other information, data, documents, etc. which are delivered to or received by Lender and which are conspicuously stamped or marked &#8220;CONFIDENTIAL&#8221;, or, if delivered or received pursuant to an oral communication, such communication is subsequently referred to in a writing memorializing such communication delivered to Lender within thirty (30) days of such communication and marked as &#8220;CONFIDENTIAL&#8221; (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;), will be kept confidential by Lender, using the same standard of care in safeguarding the Confidential Information as Lender employs in protecting its own proprietary information which Lender desires not to disseminate or publish. Notwithstanding the foregoing, Confidential Information may be disseminated (a) pursuant to the requirements of applicable law, (b) pursuant to judicial process, administrative agency process or order of Governmental Authority, (c) in connection with litigation, arbitration proceedings or administrative proceedings before or by any Governmental Authority or stock exchange, (d) to Lender&#8217;s attorneys, accountants, advisors and actual or prospective financing sources who will be instructed to comply with this Section&#160;11.12, (e) to the Rating Agencies, (f) to actual or prospective trustees, assignees, pledgees, participants, agents, servicers, or securities holders in a Securitization, and (g) pursuant to the requirements or rules of a stock exchange or stock trading system on which the Securities of Lender or its Affiliates may be listed or traded.  In addition, notwithstanding any other provision, any party (and its employee, representative or other agent) may disclose to any and all persons, without limitation of any kind, any information with respect to the tax treatment and tax structure of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses) that are provided to such party relating to such tax treatment and tax structure, if required by applicable law.  For purposes of this Section 11.12, Confidential Information will not be deemed to include the Loan amount and the other terms, conditions and provisions of the Loan Documents, the street address and common name, if any, of the Land and Improvements and the name of Borrower and Guarantor, the logo of Borrower and /or Guarantor and photographs or other depictions of the Mortgaged Property (provided that such photographs or other depictions shall not include floor plans of the area behind the barrier or other trade secrets).  Notwithstanding the foregoing, in the event Borrower or Guarantor conspicuously marks specific information, data, documents, etc. or with respect to an oral communication, in a subsequent writing memorializing such communication delivered to Lender within thirty (30) days of such communication marked as, &#8220;CONFIDENTIAL: FOR LENDER&#8217;S INTERNAL USE ONLY; NOT FOR DISTRIBUTION,&#8221; then Lender may only disseminate such information, data, documents, etc. pursuant to the requirements of applicable law (including pursuant to an order of a Governmental Authority) or pursuant to the written consent of Borrower or Guarantor.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Recourse Loan</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall have full personal recourse liability for the Obligations incurred under this Agreement, this Note or any of the other Loan Documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Performance by Lender/Attorney-in-Fact</font><font style="font-family:inherit;font-size:12pt;">.  In the event that Borrower shall at any time fail to duly and punctually pay, perform, observe or comply with any of its covenants and agreements hereunder or under the other Loan Documents or if any Event of Default hereunder shall exist, then Lender may (but shall in no event be required to) make any such payment or perform any such term, provision, condition, covenant or agreement or cure any such Event of Default.  Lender shall not take action under this Section 11.14 prior to the occurrence of an Event of Default unless in Lender&#8217;s good faith judgment reasonably exercised, such action is necessary or appropriate in order to preserve the value of the Collateral, to protect Persons or property, or Borrower has abandoned the Mortgaged Property or any portion thereof.  Lender shall not be obligated to continue any such action having commenced the same and may cease the same without notice to Borrower.  Any amounts expended by Lender in connection with such action shall constitute additional advances hereunder, the payment of which is additional Indebtedness, secured by the Loan Documents and shall become due and payable within five (5) Business Days of written notice by Lender upon demand by Lender, with interest at the Default Rate from the date of disbursement thereof until fully paid.  No further direction or authorization from Borrower shall be necessary for such disbursements.  The execution of this Agreement by Borrower shall and hereby does constitute an irrevocable direction and authorization to Lender to so disburse such funds.  To the extent permitted by law, Borrower hereby irrevocably appoints Lender, as its attorney-in-fact, coupled with an interest, with full authority in the place and stead of Borrower and in the name of Borrower or otherwise (A) during the existence of an Event of Default in the discretion of Lender, to take any action and to execute any instrument which Lender may deem necessary to accomplish the purpose of this Agreement or any other Loan Document, including the following: (i) to ask, demand, collect, sue for, recover, compromise, receive and give acquittance and receipts for monies due and to become due under or in respect of the Accounts and/or any of the Reserve Account Collateral; (ii) to receive, endorse, and collect (x) any Gross Revenues, (y) any instruments made payable to any Borrower representing any dividend, payment of principal, interest, redemption price, purchase price or other distribution or payment in respect of any Reserve Account Collateral, or (z) any other instruments, documents and chattel paper received in connection with this Agreement or any other Loan Document; and (iii) to file any claims, or take any action or institute any proceedings which Lender shall deem necessary or desirable for the collection of any Gross Revenues in the event Borrower shall fail to do so, or to otherwise enforce the rights of Lender with respect to this Agreement; (B) to execute and/or file, without the signature of Borrower any Uniform Commercial Code financing statements, continuation statements, or other filing, and any amendment thereof, relating to the Reserve Account Collateral; (C) to give notice to any third parties which may be required to perfect Lender&#8217;s security interest in the Reserve Account Collateral; and (D) during the existence of an Event of Default, to register, purchase, sell, assign, transfer, pledge or take any other action with respect to any Reserve Account Collateral in accordance with this Agreement or any Loan Document.  Lender shall notify Borrower of Lender&#8217;s taking of any action as attorney-in-fact, or otherwise in Borrower&#8217;s name, pursuant to the provisions of this Section. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Brokerage Claims</font><font style="font-family:inherit;font-size:12pt;">.  Borrower shall protect, defend, indemnify and hold Lender harmless from and against all loss, cost, liability and expense incurred as a result of any claim for a broker&#8217;s or finder&#8217;s fee against Lender or any Person, in connection with the transaction herein contemplated, provided such claim is made by or arises through or under Borrower or is based in whole or in part upon alleged acts or omissions of Borrower.  Lender shall protect, defend, indemnify and hold Borrower harmless from and against all loss, cost, liability and expense incurred as a result of any claim for a broker&#8217;s or finder&#8217;s fee against Borrower or any other Person in connection with the transaction herein contemplated, provided such claim is made by or arises through or under Lender or is based in whole or in part upon alleged acts or omissions of Lender.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  THE RIGHTS AND OBLIGATIONS OF BORROWER AND LENDER SHALL BE DETERMINED SOLELY FROM THIS WRITTEN LOAN AGREEMENT AND THE OTHER LOAN DOCUMENTS, AND ANY PRIOR ORAL OR WRITTEN AGREEMENTS BETWEEN LENDER AND BORROWER CONCERNING THE SUBJECT MATTER HEREOF AND OF THE OTHER LOAN DOCUMENTS ARE SUPERSEDED BY AND MERGED INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.  THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS MAY NOT BE VARIED BY ANY ORAL AGREEMENTS OR DISCUSSIONS THAT OCCUR BEFORE, CONTEMPORANEOUSLY WITH, OR SUBSEQUENT TO THE EXECUTION OF THIS LOAN AGREEMENT OR THE LOAN DOCUMENTS.  THIS WRITTEN AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENTS BETWEEN THE PARTIES AND MAY NOT BE CONTRA-DICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES.  THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Release of Excess Land</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:12pt;">In the event that Borrower wishes to develop an additional building on a portion of the Excess Land containing not more than 91,000 rentable square feet (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Additional Development</font><font style="font-family:inherit;font-size:12pt;">&#8221;) at any time prior to the Maturity Date, then Borrower shall deliver written notice (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Additional Development Notice</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to Lender which shall include the following: (i) a statement of Borrower&#8217;s intent to construct the Additional Development,  (ii) a statement of Borrower&#8217;s belief that the Release Conditions (defined below) have been satisfied, and (iii) a copy of the Appraisal (defined below).  During the thirty (30)&#8209;day period following Lender&#8217;s receipt of the Additional Development Notice, Lender and Borrower shall negotiate in good faith to arrange construction and/or permanent financing with respect to the Additional Development.  During such thirty (30)&#8209;day period, Borrower shall negotiate exclusively and in good faith with Lender with respect to said financing.  If Borrower and Lender are unable to agree upon terms with respect to such construction and/or permanent financing within the aforementioned thirty (30)&#8209;day period, then upon written notice to Lender, Borrower may pursue the arrangement of construction and/or permanent financing with respect to the Additional Development from a third party lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Simultaneously with the closing for the construction and/or permanent financing with respect to the Additional Development, provided that the Release Conditions have been satisfied and Lender has received the Excess Land Principal Reduction Amount (defined below), Lender shall release the Excess Land from the Liens created in favor of Lender pursuant to the Loan Documents and amend the Loan Documents to exclude the Excess Land from the Mortgaged Property.  Simultaneously with, and in consideration of, Lender&#8217;s release of the Excess Land from the Liens created in favor of Lender pursuant to the Loan Documents, Borrower shall pay to Lender an amount equal to the sum of (A) the Fair Market Value (as defined below) of the Excess Land (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess Land Principal Reduction Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221;), which payment shall be used to reduce the then outstanding principal balance of the Loan, and (B) the Prepayment Premium payable as a result of the partial prepayment of the Loan by Borrower&#8217;s delivery of the Excess Land Principal Reduction Amount to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In connection with the Additional Development, Lender hereby agrees that if same is required by Borrower or Borrower&#8217;s Mortgagee (defined below), Lender shall enter into reciprocal easement agreements, temporary construction easements, and/or other easement agreements reasonably acceptable to Borrower, Lender and Borrower&#8217;s mortgagee with respect to the Excess Land (if such mortgagee is other than Lender (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower&#8217;s Mortgagee</font><font style="font-family:inherit;font-size:12pt;">&#8221;)), providing for (1) mutual restrictive covenants regarding the use of each of the Excess Land and the remaining Mortgaged Property in a manner that does not adversely affect the operation of the remaining Mortgaged Property and that does not violate any Permitted Encumbrance; and (2) appropriate rights with respect to access, egress, utilities and parking, and for the maintenance of access </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">roads, curb cuts, utilities and common facilities (including parking facilities) to be shared by each of the Excess Land and the remaining Mortgaged Property. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lender hereby acknowledges and agrees that Section 2.4(C) of the Loan Agreement pertaining to the restriction imposed against Borrower making non-scheduled principal payments prior to the Lockout Expiration Date shall not apply to the payment of the Excess Land Principal Reduction Amount by Borrower prior to said Lockout Expiration Date, nor shall the restriction set forth in Section 2.4(C) of the Loan Agreement pertaining to partial prepayments of the Loan apply to the payment of the Excess Land Principal Reduction Amount by Borrower to Lender.  Any and all reasonable costs and expenses approved in advance by Borrower that are incurred by, or on behalf of Lender in connection with releasing the Excess Land from the Liens created in favor of Lender under the Loan Documents or the attempt by Lender to arrange financing with respect to the Additional Development, shall be reimbursed by Borrower within ten (10) Business Days following Lender&#8217;s written request therefore.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes hereof, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess Land</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the portion of the Land marked as &#8220;Excess Land&#8221; on Exhibit&#160;G hereto.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes hereof, the following shall constitute the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Release Conditions</font><font style="font-family:inherit;font-size:12pt;">&#8221; that must be satisfied prior to Borrower having the right to cause Lender to release the Excess Land from the Liens created in favor of Lender pursuant to the Loan Documents: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">at the time of Borrower&#8217;s request for the release of the Excess Land, no Event of Default must then exist or be continuing;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">at the time of Borrower&#8217;s request for release of the Excess Land, Borrower shall have obtained an appraisal of the Excess Land performed by an MAI certified appraiser selected by Borrower, and approved by Lender, said approval not to be unreasonably withheld, conditioned or delayed, which appraisal shall be in a form reasonably acceptable to Lender (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Appraisal</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">neither the release of the Excess Land from the Liens created by the Loan Documents nor Borrower&#8217;s development of the Additional Development shall result in a Material Adverse Effect.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes hereof, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Fair Market Value</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall be the fair market value of the Excess Land as agreed upon by the Borrower and Lender; provided that if Borrower and Lender are unable to reach an agreement on the fair market value after reasonable negotiations, the fair market value of the Excess Land shall be determined by the agreement of two (2) appraisers (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Initial Appraiser</font><font style="font-family:inherit;font-size:12pt;">&#8221;), one of which shall be selected by Borrower and the other of which shall be selected by Lender.  Each of Borrower and Lender shall direct, in writing with a copy to the other party, its Initial Appraiser to work with the other party&#8217;s Initial Appraiser to endeavor to determine and reach agreement upon the fair market value of the Excess Land, and thereafter to deliver in writing to Borrower and Landlord within thirty (30) days (such thirty (30)-day period, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Valuation Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;) the agreed-upon fair market value (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Valuation Notice</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The costs and expenses of each Initial Appraiser shall be paid by Borrower.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the Initial Appraisers are not able to reach agreement upon the fair market value within the Valuation Period, within ten (10) days after the end of the Valuation Period each Initial Appraiser shall deliver a written notice to Borrower, Lender, and the other Initial Appraiser setting forth (i) such Initial Appraiser&#8217;s valuation of the fair market value (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Initial Valuation</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and (ii) the name, address and qualifications of a third appraiser selected jointly by the Initial Appraisers (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Appraiser</font><font style="font-family:inherit;font-size:12pt;">&#8221;); provided that if the higher of the valuations of the two Initial Appraisers is within ten percent (10%) of the lower valuation, then the arithmetic average of the valuations of the Initial Appraisers shall be the &#8220;Fair Market Value&#8221; for the Excess </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Land and the parties shall not be required to engage the Third Appraiser.  The Initial Appraisers shall, in writing with a copy to Borrower and Lender, direct the Third Appraiser (or substitute Third Appraiser) to determine a valuation of the fair market value of the Excess Land, and to deliver in writing to Borrower, Lender and the Initial Appraisers such valuation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Valuation</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within twenty (20) days of the date of the written direction retaining such Third Appraiser.  The fair market value shall be the arithmetic mean of (A) the Third Valuation and (B) the Initial Valuation closer to the Third Valuation.  If the Third Valuation is exactly between the two Initial Valuations, then the fair market value shall be the Third Valuation.  If the Initial Appraisers are unable to agree upon the designation of a Third Appraiser within the requisite time period or if the Third Appraiser selected does not make a valuation of the fair market value within twenty (20) calendar days after being directed by the Initial Appraisers, then such Third Appraiser or a substitute Third Appraiser, as applicable, shall, at the request of Lender, be appointed by the President or Chairman of the American Arbitration Association in the area in which the Excess Land is located.  The costs and expenses of the Third Appraiser (and substitute Third Appraiser and the American Arbitration Association, if applicable) shall be paid by Borrower. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">All appraisers selected or appointed pursuant to this Section 11.17 shall be independent qualified appraisers.  Such appraisers shall have no right, power or authority to alter or modify the provisions of this Agreement, and such appraisers shall determine the fair market value of the Excess Land.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Witness the due execution hereof by the undersigned as of the date first written above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">:</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LEX&#8209;GEN WOODLANDS, L.P.,</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Delaware limited partnership</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:336px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:288px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex&#8209;Gen Woodlands GP, LLC,</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Delaware limited liability company,</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">its sole general partner</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Julia P. Gregory, Vice President</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iSTAR FINANCIAL INC.,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Maryland corporation</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Its:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><a name="s391A0F8A71347C149D559B673FB0718F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-1</font></div></div><hr style="page-break-after:always"><div><a name="s92C7C70B79470646915B9B673FB52DF6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">List of Equipment and Personalty</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fisher Hamilton modular lab casework and lab furniture</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Teknion Altos modular wall system</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Environmental cold and warm rooms</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Getinge Castle tunnel cage washers</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Getinge Castle cage rack washers</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Getinge Castle bedding disposal and dispensing/filling systems</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Getinge Castle bulk steam sterilizers/autoclaves</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AVAYA Definity phone switch</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Voice and data patch bays</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dumpster containers, to the extent owned by Borrower</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CO</font><font style="font-family:inherit;font-size:12pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:8pt">2 </sub></font><font style="font-family:inherit;font-size:12pt;">distribution piping and regulators at the source</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reverse osmosis / de-ionized water systems</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All fixed mechanical, electrical and plumbing systems, active or redundant, including emergency generators, server room AC and UPS units and air compressors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Kitchen and food service equipment, to the extent owned by Borrower and affixed to the Improvements, whose removal would require material repairs to be made</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CCTV monitors, multiplexers, recorders, security badge station with printer, camera, etc., to the extent required to operate the security software system</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A workstation or server with all peripherals, if and to the extent necessary to operate the software systems listed in Exhibit C.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All red-line, and/or as-built system and facility drawings</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All facility and equipment installation and operation and maintenance books, drawings, special tools and materials</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biological materials digester and Bio-hazard dumpster disposal unit</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B-1</font></div></div><hr style="page-break-after:always"><div><a name="s5468C7AE010824DF456B9B673FC44560"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit C</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">List of General Intangibles</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Edstrom vivarium environmental monitoring software and installed database</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Teletrol HVAC controls software and installed database</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CCure 800 security software, including ID, NETVUE, etc (if installed) and installed database</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Micromain work order software and installed database</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C-1</font></div></div><hr style="page-break-after:always"><div><a name="sBE5295C9B4BA9E932BCD9B673FDBA3C5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit D</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Permitted Encumbrances</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Restrictions as set out under File Nos. 8624668, 8647645, 2000-084612, 9353446, 9886434, 2000-090175, 9357930, 2000-090176 and 2000-090177 in the Official Public Records of Real Property of Montgomery County, Texas, and Cabinet O, Sheet 180, Cabinet E, Sheet 193A and Cabinet G, Sheet 68B of the Map Records of Montgomery County, Texas</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Restrictions as set out under File Nos 8610313, 8620448, 9429755, 9445768 and 2000-104003 of the Real Property of Montgomery County, Texas, and in Cabinet E, Sheet 163B and 164A of the Map Records of Montgomery County, Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Restrictions as set out under File Nos 8807519, 9429754, 9445769 and 9445792 of the real Property of Montgomery County, Texas, and in Cabinet F, Sheet 24 of the Map Records of Montgomery County, Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Deleting from each of a, b and c above any covenant or restriction based on race, color, religion, sex, handicap, familial status, or national origin. </font></div><div style="line-height:120%;text-align:left;padding-left:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easements and Building lines as shown on maps filed of record in Cabinet E, Sheet 193, Cabinet&#160;O, Sheet 180 and Cabinet G, Sheet 68B all of the Map Records of Montgomery County, Texas.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easement 10 feet wide along the front and rear property line and 5 feet wide along the side property lines of the property as reserved by instrument recorded under County Clerk's File No. 8624668 of the Real Property Records of Montgomery County, Texas.  Partial Release as to strip 10 feet wide along the northeast boundary line of subject property recorded under Clerk's File No. 2000-086442 of the Real Property Records of Montgomery County, Texas. (Applies to 6.1797 acres of Tract I) </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Forest preserves and Pathway easements as imposed by instrument recorded under Clerk's File Nos. 2000-090175 and 2000-09177 of the Real Property Records of Montgomery County, Texas.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easement 10 feet wide along the front and rear property lines and 5 feet wide along the side property lines of the subject property as reserved for public utilities by instrument recorded under Clerk's File No. 9357930, annexed by File No. 2000-090176 of the Real Property Records of Montgomery County, Texas.  Partial Release as to strip of land 10 feet wide running along and adjacent to the southwest boundary line of subject property as recorded under Clerk's File No. 2000-090190 of the Real Property Records of Montgomery County, Texas.  (As to 5.5921 acres of Tract I)</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">h.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easement 5 feet wide along the southeast property line of the property, as reserved for public utilities by instrument recorded under County Clerk's File No. 9353446 and annexed by County Clerk's File No. 9886434 of the Real Property Records of Montgomery County, Texas.  Partial release as to 10 foot wide strip along the southwest and northeast boundary lines of subject property and 5 foot wide strip along the northwest boundary line of subject property as recorded under Clerk's File No. 2000-086441 of the Real Property Records of Montgomery County, Texas.  (As to a 0.588 acre portion of Tract I) </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D-1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Utility easement Ten (10) feet in width along the Southeasterly property line granted to Entergy Gulf States, Inc. recorded under Montgomery County Clerk's File No. 2001-081155.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">j.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">An undivided 8.74098% interest of the oil, gas and other minerals, as conveyed to Gloria Harris and Faye M. Monroe by Mineral Deed recorded under Clerk's File No. 8011718 of the Real Property Records of Montgomery County, Texas.  Title to said interest has not been investigated subsequent to the date of the aforesaid instrument.  (As to that portion of the property lying in the Henry Applewhite Survey, A-51) </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">k.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All of the oil, gas and other minerals, the royalties, bonuses, rentals and all other rights in connection with same, and all subterranean waters including without limitation all percolating waters and underground reservoirs are expressly excepted here from as the same are reserved by The Woodlands Commercial Properties Company, L.P., by instrument recorded under File Nos. 2000-090175 and 2000-090177 of the Real Property Records of Montgomery County, Texas.  Surface rights waived therein.  Title to said interests have not been investigated subsequent to the execution date of cited instrument. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">l.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Annual Maintenance Charge payable to The Woodlands Community Association, Inc., secured by a Vendor's Lien retained in instrument(s) filed for record under Montgomery County Clerk's File No(s) 8624668 and 9353446, annexed under Clerk's File No. 9886434.  Said maintenance assessments are subordinated to first liens and improvement liens.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">m.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms, conditions and stipulations in that certain Non-Exclusive Reciprocal Access Easement., as described by instrument filed for record under Montgomery County Clerk's File No(s). 8647647, amended under Clerk's File No. 8713940. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">n.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easement for utility purposes 10 feet wide adjacent to, parallel with, and extending the full length of the northwest, southeast, northeast and southwest boundary lines of the property as imposed by instrument recorded under Clerk's File No. 2000-090177 of the Real Property Records of Montgomery County, Texas. (As to 5.5921 acres of Tract I)</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">o.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms, conditions and stipulations in that certain Non-Exclusive Reciprocal Access Easement., as described by instrument filed for record under Montgomery County Clerk's File No(s). 8647647, amended under Clerk's File No. 8713940.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">p.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms, conditions and stipulations in that certain Reciprocal Easement Agreement dated December 8, 2000, recorded under Clerk's File No. 2000-104008 of the Real Property Records of Montgomery County, Texas, by and between Woodlands Office Equities-'95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1.   </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">q.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All of the oil, gas and other minerals, the royalties, bonuses, rentals and all other rights in connection with same, and all subterranean waters including without limitation all percolating waters and underground reservoirs are expressly excepted here from as the same are reserved  by instrument recorded under File Nos. 9445792 and 2000-104003 of the Real Property Records of Montgomery County, Texas.  Surface rights waived therein.  Title to said interests have not been investigated subsequent to the execution date of cited instruments.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">r.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Building lines and easements as shown on map recorded in  Cabinet E, Sheet 164-A of the Map Records of Montgomery County, Texas. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D-2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">s.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Forest preserves and Pathway easement as reserved by instrument recorded under County Clerk's File No. 9445792 and 2000-104003 of the Real Property Records of Montgomery County, Texas.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">t.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easement 10 feet wide along the front and rear property lines and 5 feet wide along the side property lines as reserved for public utilities by instruments recorded under County Clerk's File Nos. 8610313 and 8620448 of the Real Property Records of Montgomery County, Texas. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">u.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Utility Easement 10 feet wide adjacent to, parallel with, and extending the full length of each boundary line as reserved by instrument recorded under County Clerk's File Nos. 9445792 and 2000-104003 of the Real Property Records of Montgomery County, Texas. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">v.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Annual Maintenance Charge payable to The Woodlands Community Association, Inc., secured by a Vendor's Lien retained in instrument(s) filed for record under Montgomery County Clerk's File No. 8610313.  Said maintenance assessments are subordinated to first liens and improvement liens.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">w.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms, conditions and stipulations in that certain Reciprocal Easement Agreement dated December 8, 2000, recorded under Clerk's File No. 2000-104008 of the Real Property Records of Montgomery County, Texas, by and between Woodlands Office Equities-'95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">x.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Building set-back lines as reflected by Cabinet F, Sheet 24A of the Map Records of Montgomery County, Texas.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">y.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Forest preserve and Pathway easement as reserved by instrument recorded under County Clerk's File No. 9445792 of the Real Property Records of Montgomery County, Texas.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">z.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Easement 10 feet wide along the southwesterly property line and 5 feet wide along the side property lines as reserved for public utilities by instruments recorded under County Clerk's File No. 8807519 of the Real Property Records of Montgomery County, Texas.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">aa.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Utility Easement 10 feet wide adjacent to, parallel with, and extending the full length of each boundary line as reserved by instrument recorded under County Clerk's File No. 9445792 of the Real Property Records of Montgomery County, Texas. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">bb.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All oil, gas and other minerals, the royalties, bonuses, rentals and all other rights in connection with same and all subterranean waters including without limitation all percolating waters and underground reservoirs and all other rights in connection with same are reserved by The Woodlands Corporation by instrument filed for record under Montgomery County Clerk's File No.9445792.  Surface rights waived therein.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">cc.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Maintenance assessment payable to the Woodlands Community Association, Inc. as set forth in instrument recorded under County Clerk's File No. 8807519 of the Real Property Records of Montgomery County, Texas.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D-3</font></div></div><hr style="page-break-after:always"><div><a name="sE4B1259E2A1C7893B72B9B673FFDF51B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Required Capital Improvements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Required Capital Improvement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Required Completion Date</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Replace Roof at Building 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 21, 2009</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Replace HVAC units at Building 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 21, 2009</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E-1</font></div></div><hr style="page-break-after:always"><div><a name="sD1673553A519806D26D29B67402FB9E4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AMENDMENT TO LOAN AND SECURITY AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AND TO OTHER LOAN DOCUMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS AMENDMENT TO LOAN AND SECURITY AGREEMENT AND TO OTHER LOAN DOCUMENTS (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made as of September ___, 2009, by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iSTAR FINANCIAL INC.</font><font style="font-family:inherit;font-size:12pt;">, a Maryland corporation (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at c/o iStar Financial Inc., 1114 Avenue of the Americas, 38</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower and Lender entered into a Loan and Security Agreement dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan  Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Lender agreed to make a loan to Borrower in the principal amount of Thirty-Four Million Dollars ($34,000,000) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221;) upon the terms and conditions set forth in the Loan Agreement.  Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.  The Loan is evidenced by that certain Promissory Note of even date with the Loan Agreement in the principal amount of the Loan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and is secured by, among other things, that certain Deed of Trust with Security Agreement, Assignment of Leases and Rents and Fixture Filing of even date with the Loan Agreement,, recorded in the Official Records of Montgomery County, Texas, as Document No. 2004-042420 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221;), covering the Property more particularly described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.12</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement provides that Borrower must complete the Required Capital Improvements by April 21, 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Completion Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower has requested that Lender extend the Required Completion Date to permit additional time to perform the Required Capital Improvements, and Lender is willing to do so upon the establishment of a Capital Improvements Reserve and the pledge of a Capital Improvements Account (each as defined hereafter), all upon the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incorporation of Recitals</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The foregoing Recitals are incorporated herein and expressly made a part hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Loan Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The following terms and related definition are hereby added to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement immediately after the defined term &#8220;Business Day&#8221; and immediately before the defined term &#8220;Capital Lease,&#8221; and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Improvements Account</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 6.1.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Improvements Reserve</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the reserve for Required Capital Improvements established pursuant to Section 5.12.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Improvements Reserve Statement</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 5.12.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The following term and related definition is hereby added to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement immediately after the defined term &#8220;Collateral&#8221; and immediately before the defined term &#8220;Confidential Information,&#8221; and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Completion Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; is defined in Section 5.12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Required Completion Date&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is hereby amended and restated in its entirety and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Completion Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the date that is sixty (60) days following (i) the date that Borrower receives written notice from Lender that a Required Capital Improvement item requires replacement or repair, or (ii) such earlier date specified in a notification from Borrower to Lender that such replacement or repair is necessary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Reserve Accounts&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is hereby amended and restated in its entirety and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserve Accounts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Insurance Reserve Account, the Tax Reserve Account, the Capital Improvements Reserve Account and any other securities or deposit accounts required to be maintained pursuant to this Agreement or the other Loan Documents.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Reserves&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is hereby  amended and restated in its entirety and shall read as follows:</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Reserves</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Tax Reserve, the Insurance Reserve and the Capital Improvements Reserve.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.12</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is amended and restated in its entirety as follows:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">5.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Required Capital Improvements and Capital Improvements Reserve.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Required Capital Improvements</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to Section 5.12(C), each of the capital improvement items listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Capital Improvements</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be completed by the Required Completion Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Capital Improvements Reserve</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">On or before September __, 2009, Borrower shall deposit $282,000 into the Capital Improvements Account for the purpose of establishing and maintaining a reserve (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Improvements Reserve</font><font style="font-family:inherit;font-size:12pt;">&#8221;) for the completion of the Required Capital Improvements as required by this Agreement.  Subject to Section 5.12(C), the funds contained in the Capital Improvements Reserve shall be utilized by Borrower solely for the Required Capital Improvements.  So long as no Default or Event of Default exists at the time of any requested distribution of funds from the Capital Improvements Reserve, Lender shall make funds in the Capital Improvements Reserve available to Borrower subject to satisfaction of each of the following terms and conditions: (a) all Capital Improvements Reserve funds released by Lender to Borrower shall be used to pay for or reimburse Borrower for the reasonable expenses actually incurred and paid by Borrower for Required Capital Improvements; (b) Borrower shall have given Lender a Request for Release satisfactory to Lender; (c) disbursements from the Capital Improvements Reserve shall not be made more frequently than once per Loan Month; (d) each request for a disbursement shall be in an amount of not less than $10,000.00; and (e) upon </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">request of Lender, Borrower shall also provide Lender with additional evidence reasonably satisfactory to Lender that Borrower is the owner or lessee of any capital improvements or equipment for which reimbursement is sought, free of any Liens (other than the first priority security interest in favor of Lender).  Lender shall make each disbursement of the Capital Improvements Reserve funds within fifteen (15) days after satisfaction of all the conditions to that disbursement.  If an Event of Default exists, Lender may apply the Capital Improvements Reserve funds, together with any interest accrued thereon, to Borrower&#8217;s Obligations in such order and priority as Lender may determine.  Lender shall not make any disbursements from the Capital Expenditure Reserve to or for the benefit of Borrower until (i)&#160;Lender has approved the expenditures proposed by Borrower, (ii) all conditions to such disbursement have been satisfied and (iii)&#160;Borrower has provided Lender with all invoices, receipts, lien waivers and other documentation reasonably requested by Lender.  If at any time Lender determines, in its reasonable discretion, that the amount in the Capital Improvements Reserve is insufficient for Borrower to complete the requested Required Capital Improvements, then Borrower shall deposit any deficiency, based on Lender&#8217;s reasonable estimate, within fifteen (15) days following Lender&#8217;s written demand.  If there are any funds remaining in the Capital Improvements Reserve on the date on which the Required Capital Improvements have been completed to Lender&#8217;s satisfaction (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Completion Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then Lender shall promptly return such remaining funds to Borrower.  If Borrower has prepaid the Loan pursuant to Section 2.4(C) before the Completion Date, then Lender shall promptly return any amount remaining in the Capital Improvements Reserve to Borrower.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Transfer of Mortgaged Property Relating to Required Capital Improvements.  </font><font style="font-family:inherit;font-size:12pt;">If Borrower Transfers any portion of the Mortgaged Property to which the Required Capital Improvements relate, and Lender consents in writing to such Transfer, in each case prior to the Required Completion Date with respect to such Required Capital Improvements, (a) Lender shall promptly return to Borrower the funds in the Capital Improvements Reserve which would otherwise have been made available to Borrower hereunder to pay for or reimburse Borrower for such Required Capital Improvements and (b) Borrower shall be under no further obligation to complete such Required Capital Improvements.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is amended by adding the following </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(A)(iii)</font><font style="font-family:inherit;font-size:12pt;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Account No. 293-0798992, captioned &#8220;Lex-Gen Woodlands, L.P./iStar Tara LLC/Upgrades and Improvements Account&#8221; for the retention of collateral in respect of the Required Capital Contributions as provided in Section 5.12 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Capital Improvements Account</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:240px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">&#32;attached to the Loan Agreement is amended by deleting the column entitled &#8220;Required Completion Date.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Other Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  All references in each Loan Document to the Loan Agreement shall refer to the Loan Agreement as amended hereby, as such Loan Agreement may be further amended from time to time.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower agrees that it shall be a condition precedent to the effectiveness of this Amendment that, among other things, all of the following shall have been satisfied on or prior to the date of this Amendment:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have paid the actual out-of-pocket fees and expenses of Lender reasonably incurred in connection with this Amendment, including reasonable fees and disbursements of Lender&#8217;s attorneys fees; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have furnished to Lender an affidavit stating the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there have been no modifications to Borrower&#8217;s Articles of Organization; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there has been no change to the status of Borrower&#8217;s good standing in the State of Delaware; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there has been no change to the status of Borrower&#8217;s qualification to do business in the State of Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have deposited or caused to be deposited $282,000 into the Capital Improvements Account.  </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lender hereby acknowledges and agrees that its execution and delivery of this Amendment shall constitute the satisfaction and/or waiver of the above conditions.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In order to induce Lender to execute this Amendment, Borrower represents and warrants as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment, and any other documents and instruments required to be executed and delivered by Borrower in connection herewith, when executed and delivered, will constitute the duly authorized, valid and legally binding obligations of Borrower, and will be enforceable in accordance with their respective terms, subject only to bankruptcy and insolvency laws of general applicability and the application of general principles of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Amendment will not: (i) violate any laws or (ii) conflict with, be inconsistent with, or result in any breach or default of any of the terms, covenants, conditions, or provisions of any indenture, mortgage, deed of trust, corporate charter or bylaws, instrument, document, agreement or contract of any kind to which Borrower is a party or by which Borrower may be bound.  Borrower is not in default (beyond applicable grace or cure periods) under any contract or agreement to which each is a party, the effect of which default will materially adversely affect the performance by Borrower its representative obligations pursuant to and as contemplated by the terms and provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower hereby represents and warrants that as of the date hereof, Borrower has no defenses, claims, offsets or setoffs with regard to the enforcement of the Loan Documents as modified hereby.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower agrees that the Loan Agreement, the Note and each other Loan Document, as amended by this Amendment, remain in full force and effect in accordance with the previously existing terms thereof, as amended by this Amendment, and such documents and instruments are hereby ratified and confirmed.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment shall be construed in accordance with and governed by the internal laws of the State of New York, except that the creation, perfection and enforcement of the Liens and security interests created pursuant to the Mortgage shall be governed and construed according to the law of the state of Texas, it being understood that to the fullest extent permitted by the laws of Texas, the law of the State of New York shall govern the Loan Agreement, the Notes and the other Loan Documents as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.8</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The parties hereto expressly acknowledge and agree that this Amendment shall not be construed as a novation of the Note, the Mortgage or any other Loan Document.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All of the Mortgaged Property (as defined in the Mortgage) shall remain in all respects subject to the lien, charge and encumbrance of the Mortgage, as herein modified, and nothing herein contained and nothing done pursuant hereto, shall affect the lien, charge or encumbrance of the Mortgage, as herein modified, or the priority thereof with respect to other liens, charges, encumbrances or conveyances, or release or affect the liability of any part or parties whomsoever, who may now or hereafter be liable under, or on account of, the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution and delivery of this Amendment does not constitute a waiver of any default under the Note, Mortgage or any of the other Loan Documents (other than Lender waiving Borrower&#8217;s obligation to complete the Required Capital Improvements by the Required Completion Date as originally contemplated by the Loan Agreement); provided, however, that Lender hereby acknowledges that it is not aware of any defaults under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Time is hereby declared to be of the essence of this Amendment and of every part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signatures Follow on the Next Page]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iSTAR FINANCIAL INC.</font><font style="font-family:inherit;font-size:12pt;">, a Maryland corporation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF GUARANTOR</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The undersigned, being the &#8220;Guarantor&#8221; under that certain Guaranty dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221;), made by the undersigned for the benefit of iStar Financial Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), hereby consents to the foregoing Amendment to Loan and Security Agreement and to Other Loan Documents.  The undersigned agrees that the Guaranty is and shall remain in full force and effect, that the Guaranty is ratified and confirmed hereby, that no defenses or offsets exist to the enforcement thereof, and that Guarantor has no Claims against Lender with respect thereto.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(formerly known as Lexicon Genetics</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incorporated), a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">`</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.359 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HENRY APPLEWHITE SURVEY, ABSTRACT NUMBER 51</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 12.359 acres of land situated in the Henry Applewhite Survey, Abstract Number 51 and the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 12.359 acres), The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 12.359 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set marking the south end of a 25-foot cut-back line at the intersection of the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.) with the southeasterly R.O.W. line of Technology Forest Place (width varies), said iron rod marking the most southerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 01&#176;27'36" West, along said southeasterly R.O.W. line of Technology Forest Place, along said cut-back line and along the west line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the north end of said 25-foot cut-back line and marking the most northerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, continuing along said southeasterly R.O.W. line of Technology Forest Place and along the northwesterly line of said Restricted Reserve "A", a distance of 1,060.00 feet to a 5/8-inch iron rod with cap found marking the west end of a 25-foot cut-back line and marking the most westerly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 88&#176;32'24" East, continuing along said southeasterly R.O.W. line, along said cutback line and along the north line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the east end of said cut-back line and marking the intersection of said southeasterly R.O.W. line of Technology Forest Place with the southwesterly R.O.W. line of New Trails Drive (80-foot wide R.O.W.), said iron rod marking the most easterly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along said southwesterly R.O.W. line of New Trails Drive and along the northeasterly line of said Restricted Reserve "A", a distance of 460.59 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A, M.C.M.R., said iron rod marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, departing said southwesterly R.O.W. line of New Trails Drive, along the northwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4, and along the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, at a distance of 742.00 feet passing a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A M.C.M.R. and marking the most westerly corner of said Section 4, continuing along southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, in all, a distance of 1,110.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", a distance of 460.59 feet to the POINT OF BEGINNING and containing 12.359 acres (538,380 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 2</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.590 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 3.590 acres of land situated in the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 3.5905 acres), The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 3.590 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.), marking most southerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 M.C.M.R. and marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, departing the northeasterly R.O.W. line of said Research Forest Drive, along the southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 368.00 feet to a 5/8-inch iron rod with cap found marking the most westerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A M.C.M.R. and marking the most northerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along the southwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4 and along the northeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 425.00 feet to a 5/8-inch iron rod with cap found marking </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 2, a subdivision plat recorded in Cabinet F, Sheet 24 M.C.M.R. and marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 2 and along the southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 368.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 2 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 425.00 feet to the POINT OF BEGINNING and containing 3.590 acres (156,400 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April, 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 3</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A non-exclusive easement for vehicular and pedestrian ingress and egress created under the Reciprocal Easement Agreement by and between Woodlands Office Equities-&#8217;95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1 dated as of December 8, 2000, and recorded under the County Clerk&#8217;s File No. 2000-104008 and the Real Property Records of Montgomery County, Texas. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s41C54F55B293458587879B6740518700"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AND TO OTHER LOAN DOCUMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT AND TO OTHER LOAN DOCUMENTS (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made as of June ___, 2011, by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability company (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at c/o iStar Financial Inc., 1114 Avenue of the Americas, 38</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower and iStar Financial Inc., a Maryland corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;) entered into a Loan and Security Agreement dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Loan  Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as amended by that certain Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 28, 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;; the Original Loan Agreement, as amended by such First Amendment, is herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Lender agreed to make a loan to Borrower in the principal amount of Thirty-Four Million Dollars ($34,000,000) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221;) upon the terms and conditions set forth in the Loan Agreement.  Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.  The Loan is evidenced by that certain Promissory Note of even date with the Loan Agreement in the principal amount of the Loan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and is secured by, among other things, (i) that certain Deed of Trust with Security Agreement, Assignment of Leases and Rents and Fixture Filing of even date with the Loan Agreement, recorded in the Official Records of Montgomery County, Texas (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Official Records</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as Document No. 2004-042420 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221;), covering the Property more particularly described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, and (ii) that certain Guaranty of even date with the Loan Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in favor of Original Lender made by Lexicon Genetics Incorporated, which is now known as Lexicon Pharmaceuticals, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Loan Documents were assigned by Original Lender to iSTAR TARA LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iStar Tara</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to that certain Assignment and Assumption of Note, Mortgage, and Other Loan Documents made as of March 1, 2009, recorded in the Official Records as Document No. 2009-022702 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Assignment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and then subsequently assigned by iStar Tara to Lender pursuant to that certain Assignment and Assumption of Note, Deed of Trust and Other Loan Documents made as of March 16, 2011 and recorded in the Official Records as Document No. 2011039443-1. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.11</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement prohibits, among other things, the sale of all or any portion of the Mortgaged Property without Lender&#8217;s consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower desires to sell the portion of the Mortgaged Property which constitutes that portion of the Land (and the Improvement located thereupon) identified as &#8220;TRACT 2&#8221; on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto (herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tract 2 Release Parcel</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with Borrower retaining both &#8220;TRACT 1&#8221; and &#8220;TRACT 3&#8221; on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, pursuant to that certain Purchase and Sale Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tract 2 Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) between Borrower and Tridan II, LLC, a Texas limited liability company, as successor by assignment to Tridan, LLC, a Texas limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tract 2 Purchaser</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and has requested Lender&#8217;s consent to such sale and Lender to release the lien of the Mortgage on the Tract 2 Release Parcel, and Lender is willing to do so solely upon the terms and subject to the conditions set forth herein.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incorporation of Recitals</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The foregoing Recitals are incorporated herein and expressly made a part hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lender Consent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:12pt;">Lender hereby consents to the sale of the Tract 2 Release Parcel to the Tract 2 Purchaser (or its permitted assigns) pursuant to the Tract 2 Agreement and agrees to authorize the Title Company (as defined in the Tract 2 Agreement) to record an executed and acknowledged counterpart of the partial release attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;(&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Partial Release</font><font style="font-family:inherit;font-size:12pt;">&#8221;) only upon satisfaction of all of the following conditions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower and Lender execute and deliver this Amendment and Guarantor executes and delivers the Consent of Guarantor attached hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The gross purchase price paid by Tract 2 Purchaser to Borrower (that is, prior to deducting commissions, pro rated taxes and other expenses, costs associated with the title policy to be acquired for the benefit of Tract 2 Purchaser, any other closing costs to be paid by Borrower, as contemplated by the Tract 2 Agreement, and Borrower&#8217;s expenses related to such sale, including reasonable attorneys fees (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tract 2 Closing Costs</font><font style="font-family:inherit;font-size:12pt;">&#8221;)), remains at least $2,500,000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Prior to the closing of the sale of the Tract 2 Release Parcel to Tract 2 Purchaser (herein, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tract 2 Closing</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Borrower&#8217;s executing and delivering the final settlement statement for the Tract 2 Closing, Borrower obtains Lender&#8217;s prior consent thereto (which consent shall not be unreasonably withheld, conditioned or delayed, but may be withheld by Lender if the requirements in item (d) below is not satisfied).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The final closing statement for the Tract 2 Closing reflects that all of the net proceeds (i.e., gross purchase price reduced by the Tract 2 Closing Costs) shall be paid directly to Lender.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Contemporaneously with or prior to the Tract 2 Closing, Borrower pays (or delivers sufficient funds to the Title Company to pay) Lender an amount equal to $210,000, which amount Borrower and Lender agree is the Prepayment Premium attributable to the partial principal repayment being made in item (d) above. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Lender agrees to deliver the Partial Release to the Title Company on or prior to the scheduled date of the Tract 2 Closing, whereupon Borrower agrees that it shall cause each of the foregoing conditions to be satisfied and completed within two (2) business days of such Tract 2 Closing, or alternatively, Borrower shall cause the Partial Release to be returned to Lender within two (2) business days following the scheduled date of the Tract 2 Closing.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Application of Payments</font><font style="font-family:inherit;font-size:12pt;">.  Lender agrees that all amounts Lender receives pursuant to item (d) of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:12pt;">&#32;above shall be applied to reduce the outstanding principal of the Loan.  Borrower understands and agrees that none of the yield maintenance premium paid to Lender pursuant to item (e) of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:12pt;">&#32;above shall be applied to any principal or interest due under the Loan.  Additionally, Lender and Borrower recognize and agree that regular monthly installments of principal and interest following the Tract 2 Closing shall continue (so long as interest is not charged at the Default Rate as required by the Loan Documents) to be in an amount of Two Hundred Eighty-Nine Thousand Two Hundred Seventy-Five and 64/100 Dollars ($289,275.64).  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Partial Termination of Guarantor Lease</font><font style="font-family:inherit;font-size:12pt;">.  Subject to Borrower&#8217;s satisfaction of the conditions set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:12pt;">&#32;above, Lender consents to the termination of the Guarantor Lease with respect to Tract 2 simultaneously with, and as part of, the Tract 2 Closing.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Capital Improvements</font><font style="font-family:inherit;font-size:12pt;">.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sale Modification Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the first day when all of the following have occurred:  (A) the Tract 2 Closing has occurred, (B) Lender has received the payments required by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sections 2(d)</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(e)</font><font style="font-family:inherit;font-size:12pt;">&#32;above, and (C) Lender has authorized the Title Company to record the Partial Release.  Promptly following the Sale Modification Date, Lender shall deliver or cause to be delivered to Borrower, One Hundred Thirty-Eight Thousand and No/100 Dollars ($138,000.00) from the Capital Improvements Reserve.  Effective as of the Sale Modification Date, and only if such date occurs, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">&#32;attached to the Loan Agreement shall be amended by deleting the row stating &#8220;Replace HVAC units at Building 3&#8221;, without further action by any party.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Other Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  All references in each of the Loan Documents to the Loan Agreement shall refer to the Loan Agreement, as amended hereby, as such Loan Agreement may be further amended from time to time.  From and after such time, if ever, when Lender delivers and releases the Partial Release for recording, all references to the Mortgaged Property shall not include the portion of the Mortgaged Property released from Lender&#8217;s liens as set forth in the Partial Release.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower agrees that it shall be a condition precedent to the effectiveness of this Amendment that, among other things, all of the following shall have been satisfied on or prior to the date Lender authorizes the Title Company to record the Partial Release:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have paid (or have delivered sufficient funds to the Title Company to pay) the actual out-of-pocket fees and expenses of Lender reasonably incurred in connection with this Amendment, including reasonable fees and disbursements of Lender&#8217;s attorneys; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have furnished to Lender an affidavit stating the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there have been no modifications to Borrower&#8217;s Articles of Organization that have not been previously delivered to Lender; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is in good standing in the State of Delaware; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is qualified to conduct business in the State of Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In order to induce Lender to execute this Amendment, Borrower represents and warrants as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment, and any other documents and instruments required to be executed and delivered by Borrower in connection herewith, when executed and delivered, will constitute the duly authorized, valid and legally binding obligations of Borrower, and will be enforceable in accordance with their respective terms, subject only to bankruptcy and insolvency laws of general applicability and the application of general principles of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Amendment will not: (i) violate any laws or (ii) conflict with, be inconsistent with, or result in any breach or default of any of the terms, covenants, conditions, or provisions of any indenture, mortgage, deed of trust, corporate charter or bylaws, instrument, document, agreement or contract of any kind to which Borrower is a party or by which Borrower may be bound.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To Borrower&#8217;s knowledge, Borrower is not in default (beyond applicable grace or cure periods) under any contract or agreement to which Borrower is a party, the effect of which default will materially </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">adversely affect the performance by Borrower of its representative obligations pursuant to and as contemplated by the terms and provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower hereby represents and warrants that as of the date hereof, Borrower has no defenses, claims, offsets or setoffs with regard to the enforcement of the Loan Documents as modified hereby.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower agrees that the Loan Agreement, the Note and each other Loan Document, as amended by this Amendment, remain in full force and effect in accordance with the previously existing terms thereof, as amended by this Amendment, and such documents and instruments are hereby ratified and confirmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment shall be construed in accordance with and governed by the internal laws of the State of New York, except that the creation, perfection and enforcement of the Liens and security interests created pursuant to the Mortgage shall be governed and construed according to the law of the state of Texas, it being understood that to the fullest extent permitted by the laws of Texas, the law of the State of New York shall govern the Loan Agreement, the Notes and the other Loan Documents as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.8</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The parties hereto expressly acknowledge and agree that this Amendment shall not be construed as a novation of the Note, the Mortgage or any other Loan Document.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All of the Mortgaged Property (other than the portion of the Mortgaged Property released from Lender&#8217;s liens as set forth in the Partial Release, upon the execution and recording of same) shall remain in all respects subject to the lien, charge and encumbrance of the Mortgage, as herein modified, and nothing herein contained and nothing done pursuant hereto, shall affect the lien, charge or encumbrance of the Mortgage, as herein modified, or the priority thereof with respect to other liens, charges, encumbrances or conveyances, or release or affect the liability of any part or parties whomsoever, who may now or hereafter be liable under, or on account of, the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution and delivery of this Amendment does not constitute a waiver of any default under the Note, Mortgage or any of the other Loan Documents (other than Lender waiving Borrower&#8217;s obligation to complete the Required Capital Improvements by the Required Completion Date as originally contemplated by the Loan Agreement); provided, however, that Lender hereby acknowledges that it is not aware of any defaults under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Time is hereby declared to be of the essence of this Amendment and of every part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signatures Follow on the Next Page]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">company</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF GUARANTOR</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The undersigned, being the &#8220;Guarantor&#8221; under the Guaranty, hereby consents to the foregoing Amendment to Loan and Security Agreement and to Other Loan Documents.  The undersigned agrees that the Guaranty is and shall remain in full force and effect, that as of the date hereof (i) the Guaranty is ratified and confirmed hereby, (ii) no defenses or offsets exist to the enforcement thereof, and (iii) Guarantor has no Claims against Lender with respect thereto.  All capitalized terms used in this Consent of Guarantor shall have the meaning ascribed to such terms in the Amendment to which this Consent of Guarantor is attached.  Further, Guarantor, as tenant under the Guarantor Lease, agrees for the benefit of Lender and Borrower that following the Tract 2 Closing, the Premises under and as defined in the Guarantor Lease shall not include the property sold by Borrower to Tract 2 Purchaser and released from Lender&#8217;s liens by the Partial Release, and that such reduction in the Premises does not and shall not change the rent payable under such Guarantor Lease or Guarantor&#8217;s obligations and liabilities for the remaining portions of such Premises.  Guarantor agrees, upon request of either Lender or Borrower, to enter into an amendment to the Guarantor Lease, to reflect such change in the Premises and other items above.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(formerly known as Lexicon Genetics</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incorporated), a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.359 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HENRY APPLEWHITE SURVEY, ABSTRACT NUMBER 51</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 12.359 acres of land situated in the Henry Applewhite Survey, Abstract Number 51 and the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 12.359 acres), The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 12.359 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set marking the south end of a 25-foot cut-back line at the intersection of the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.) with the southeasterly R.O.W. line of Technology Forest Place (width varies), said iron rod marking the most southerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 01&#176;27'36" West, along said southeasterly R.O.W. line of Technology Forest Place, along said cut-back line and along the west line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the north end of said 25-foot cut-back line and marking the most northerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, continuing along said southeasterly R.O.W. line of Technology Forest Place and along the northwesterly line of said Restricted Reserve "A", a distance of 1,060.00 feet to a 5/8-inch iron rod with cap found marking the west end of a 25-foot cut-back line and marking the most westerly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 88&#176;32'24" East, continuing along said southeasterly R.O.W. line, along said cutback line and along the north line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the east end of said cut-back line and marking the intersection of said southeasterly R.O.W. line of Technology Forest Place with the southwesterly R.O.W. line of New Trails Drive (80-foot wide R.O.W.), said iron rod marking the most easterly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along said southwesterly R.O.W. line of New Trails Drive and along the northeasterly line of said Restricted Reserve "A", a distance of 460.59 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A, M.C.M.R., said iron rod marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, departing said southwesterly R.O.W. line of New Trails Drive, along the northwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4, and along the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, at a distance of 742.00 feet passing a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A M.C.M.R. and marking the most westerly corner of said Section 4, continuing along southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, in all, a distance of 1,110.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", a distance of 460.59 feet to the POINT OF BEGINNING and containing 12.359 acres (538,380 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 2</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.590 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 3.590 acres of land situated in the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 3.5905 acres), The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 3.590 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.), marking most southerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 M.C.M.R. and marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, departing the northeasterly R.O.W. line of said Research Forest Drive, along the southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 368.00 feet to a 5/8-inch iron rod with cap found marking the most westerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A M.C.M.R. and marking the most northerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along the southwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4 and along the northeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 425.00 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 2, a </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">subdivision plat recorded in Cabinet F, Sheet 24 M.C.M.R. and marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 2 and along the southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 368.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 2 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a distance of 425.00 feet to the POINT OF BEGINNING and containing 3.590 acres (156,400 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April, 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 3</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A non-exclusive easement for vehicular and pedestrian ingress and egress created under the Reciprocal Easement Agreement by and between Woodlands Office Equities-&#8217;95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1 dated as of December 8, 2000, and recorded under the County Clerk&#8217;s File No. 2000-104008 and the Real Property Records of Montgomery County, Texas. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit B</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Partial Release</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="sEE19AD372878AA00AA129B67408246EA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AND TO OTHER LOAN DOCUMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT AND TO OTHER LOAN DOCUMENTS (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made as of August 30, 2011, by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability company (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at c/o iStar Financial Inc., 1114 Avenue of the Americas, 38</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower and iStar Financial Inc., a Maryland corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;) entered into a Loan and Security Agreement dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Loan  Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as amended by that certain Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 28, 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and that certain Second Amendment to Loan and Security Agreement and to other Loan Documents dated as of June 17, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Second Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;; the Original Loan Agreement, as amended by such First Amendment and Second Amendment, is herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Lender agreed to make a loan to Borrower in the principal amount of Thirty-Four Million Dollars ($34,000,000) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221;) upon the terms and conditions set forth in the Loan Agreement.  Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.  The Loan is evidenced by that certain Promissory Note of even date with the Loan Agreement in the principal amount of the Loan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and is secured by, among other things, (i) that certain Deed of Trust with Security Agreement, Assignment of Leases and Rents and Fixture Filing of even date with the Loan Agreement, recorded in the Official Records of Montgomery County, Texas (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Official Records</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as Document No. 2004-042420 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221;), covering the Property more particularly described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, and (ii) that certain Guaranty of even date with the Loan Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in favor of Original Lender made by Lexicon Genetics Incorporated, which is now known as Lexicon Pharmaceuticals, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Loan Documents were assigned by Original Lender to iSTAR TARA LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iStar Tara</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to that certain Assignment and Assumption of Note, Mortgage, and Other Loan Documents made as of March 1, 2009, recorded in the Official Records as Document No. 2009-022702 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Assignment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and then subsequently assigned by iStar Tara to Lender pursuant to that certain Assignment and Assumption of Note, Deed of Trust and Other Loan Documents made as of March 16, 2011 and recorded in the Official Records as Document No. 2011039443.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower has requested that the definition of &#8220;Change in Control&#8221; in the Loan Agreement be modified as contemplated by this Amendment, and Lender is willing to consent to such modification, all upon the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incorporation of Recitals</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The foregoing Recitals are incorporated herein and expressly made a part hereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendment to Loan Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Change in Control&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is hereby amended and restated in its entirety and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Change in Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of any one or more of the following:  (i) a sale of all or substantially all of the assets of Guarantor, in a single transaction or series of transactions, (ii) a Person or Group, other than Invus, shall have acquired, in one or more transactions, ownership or control of forty-nine percent (49%) or more of the voting Securities of Guarantor, (iii) Guarantor shall cease to directly or indirectly Control the business and affairs of the Borrower or (iv) Guarantor shall cease to directly or indirectly own fifty-one percent (51%) or more of the voting Securities of Borrower.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">The following term and related definition is hereby added to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement immediately after the defined term &#8220;Investment&#8221; and immediately before the defined term &#8220;Land,&#8221; and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Invus</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, Invus, L.P., a Bermuda limited partnership, Invus C.V., a Netherlands limited partnership, Invus Public Equities, L.P., a Bermuda limited partnership, and any other Person who, directly or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, any of such entities.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Other Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  All references in each of the Loan Documents to the Loan Agreement shall refer to the Loan Agreement, as amended hereby, as such Loan Agreement may be further amended from time to time.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower agrees that it shall be a condition precedent to the effectiveness of this Amendment that, among other things, all of the following shall have been satisfied promptly following the date of this Amendment:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have paid the actual out-of-pocket fees and expenses of Lender reasonably incurred in connection with this Amendment, including reasonable fees and disbursements of Lender&#8217;s attorneys; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall have furnished to Lender an affidavit stating the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there have been no modifications to Borrower&#8217;s Articles of Organization that have not been previously delivered to Lender; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is in good standing in the State of Delaware; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is qualified to conduct business in the State of Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In order to induce Lender to execute this Amendment, Borrower represents and warrants as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment, and any other documents and instruments required to be executed and delivered by Borrower in connection herewith, when executed and delivered, will constitute the duly authorized, valid and legally binding obligations of Borrower, and will be enforceable in accordance with their respective terms, subject only to bankruptcy and insolvency laws of general applicability and the application of general principles of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Amendment will not: (i) violate any laws or (ii) conflict with, be inconsistent with, or result in any breach or default of any of the terms, covenants, conditions, or provisions of any indenture, mortgage, deed of trust, corporate charter or bylaws, instrument, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">document, agreement or contract of any kind to which Borrower is a party or by which Borrower may be bound.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To Borrower&#8217;s knowledge, Borrower is not in default (beyond applicable grace or cure periods) under any contract or agreement to which Borrower is a party, the effect of which default will materially adversely affect the performance by Borrower of its representative obligations pursuant to and as contemplated by the terms and provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower hereby represents and warrants that as of the date hereof, Borrower has no defenses, claims, offsets or setoffs with regard to the enforcement of the Loan Documents as modified hereby.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower agrees that the Loan Agreement, the Note and each other Loan Document, as amended by this Amendment, remain in full force and effect in accordance with the previously existing terms thereof, as amended by this Amendment, and such documents and instruments are hereby ratified and confirmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment shall be construed in accordance with and governed by the internal laws of the State of New York, except that the creation, perfection and enforcement of the Liens and security interests created pursuant to the Mortgage shall be governed and construed according to the law of the state of Texas, it being understood that to the fullest extent permitted by the laws of Texas, the law of the State of New York shall govern the Loan Agreement, the Notes and the other Loan Documents as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.8</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The parties hereto expressly acknowledge and agree that this Amendment shall not be construed as a novation of the Note, the Mortgage or any other Loan Document.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All of the Mortgaged Property shall remain in all respects subject to the lien, charge and encumbrance of the Mortgage, as herein modified, and nothing herein contained and nothing done pursuant hereto, shall affect the lien, charge or encumbrance of the Mortgage, as herein modified, or the priority thereof with respect to other liens, charges, encumbrances or conveyances, or release or affect the liability of any part or parties whomsoever, who may now or hereafter be liable under, or on account of, the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution and delivery of this Amendment does not constitute a waiver of any default under the Note, Mortgage or any of the other Loan Documents; provided, however, that Lender hereby acknowledges that it is not aware of any defaults under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Time is hereby declared to be of the essence of this Amendment and of every part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signatures Follow on the Next Page]</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">company</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF GUARANTOR</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The undersigned, being the &#8220;Guarantor&#8221; under the Guaranty, hereby consents to the foregoing Amendment to Loan and Security Agreement and to Other Loan Documents.  The undersigned agrees that the Guaranty is and shall remain in full force and effect, that as of the date hereof (i) the Guaranty is ratified and confirmed hereby, (ii) no defenses or offsets exist to the enforcement thereof, and (iii) Guarantor has no Claims against Lender with respect thereto.  All capitalized terms used in this Consent of Guarantor shall have the meaning ascribed to such terms in the Amendment to which this Consent of Guarantor is attached.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(formerly known as Lexicon Genetics</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incorporated), a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.359 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HENRY APPLEWHITE SURVEY, ABSTRACT NUMBER 51</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 12.359 acres of land situated in the Henry Applewhite Survey, Abstract Number 51 and the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 12.359 acres), The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 12.359 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set marking the south end of a 25-foot cut-back line at the intersection of the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.) with the southeasterly R.O.W. line of Technology Forest Place (width varies), said iron rod marking the most southerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 01&#176;27'36" West, along said southeasterly R.O.W. line of Technology Forest Place, along said cut-back line and along the west line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the north end of said 25-foot cut-back line and marking the most northerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, continuing along said southeasterly R.O.W. line of Technology Forest Place and along the northwesterly line of said Restricted Reserve "A", a distance of 1,060.00 feet to a 5/8-inch iron rod with cap found marking the west end of a 25-foot cut-back line and marking the most westerly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 88&#176;32'24" East, continuing along said southeasterly R.O.W. line, along said cutback line and along the north line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the east end of said cut-back line and marking the intersection of said southeasterly R.O.W. line of Technology Forest Place with the southwesterly R.O.W. line of New Trails Drive (80-foot wide R.O.W.), said iron rod marking the most easterly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along said southwesterly R.O.W. line of New Trails Drive and along the northeasterly line of said Restricted Reserve "A", a distance of 460.59 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A, M.C.M.R., said iron rod marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, departing said southwesterly R.O.W. line of New Trails Drive, along the northwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4, and along the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, at a distance of 742.00 feet passing a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A M.C.M.R. and marking the most westerly corner of said Section 4, continuing along southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, in all, a distance of 1,110.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", a distance of 460.59 feet to the POINT OF BEGINNING and containing 12.359 acres (538,380 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 2</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A non-exclusive easement for vehicular and pedestrian ingress and egress created under the Reciprocal Easement Agreement by and between Woodlands Office Equities-&#8217;95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1 dated as of December 8, 2000, and recorded under the County Clerk&#8217;s File No. 2000-104008 and the Real Property Records of Montgomery County, Texas. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s6C805595691A6BD0001F9B6740A4BCC8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AND TO OTHER LOAN DOCUMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT AND TO OTHER LOAN DOCUMENTS (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made as of September 17, 2013, by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability company (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at c/o iStar Financial Inc., 1114 Avenue of the Americas, 38</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower and iStar Financial Inc., a Maryland corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;) entered into a Loan and Security Agreement dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Loan  Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as amended by that certain Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 28, 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); that certain Second Amendment to Loan and Security Agreement and to other Loan Documents dated as of June 17, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Second Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and that certain Third Amendment to Loan and Security and to other Loan Documents dated as of August 30, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); the Original Loan Agreement, as amended by such First Amendment, Second Amendment, and Third Amendment, is herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Lender agreed to make a loan to Borrower in the principal amount of Thirty-Four Million Dollars ($34,000,000) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221;) upon the terms and conditions set forth in the Loan Agreement.  Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.  The Loan is evidenced by that certain Promissory Note of even date with the Loan Agreement in the principal amount of the Loan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and is secured by, among other things, (i) that certain Deed of Trust with Security Agreement, Assignment of Leases and Rents and Fixture Filing of even date with the Loan Agreement, recorded in the Official Records of Montgomery County, Texas (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Official Records</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as Document No. 2004-042420 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221;), covering the Property more particularly described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, and (ii) that certain Guaranty of even date with the Loan Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in favor of Original Lender made by Lexicon Genetics Incorporated, which is now known as Lexicon Pharmaceuticals, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Loan Documents were assigned by Original Lender to iSTAR TARA LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iStar Tara</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to that certain Assignment and Assumption of Note, Mortgage, and Other Loan Documents made as of March 1, 2009, recorded in the Official Records as Document No. 2009-022702 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Assignment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and then subsequently assigned by iStar Tara to Lender pursuant to that certain Assignment and Assumption of Note, Deed of Trust and Other Loan Documents made as of March 16, 2011 and recorded in the Official Records as Document No. 2011039443.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower has requested an extension of the Maturity Date of the Loan as contemplated by this Amendment, and Lender is willing to consent to such modification, all upon the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incorporation of Recitals</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The foregoing Recitals are incorporated herein and expressly made a part hereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendment to Loan Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Lockout Expiration Date&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is hereby amended and restated in its entirety and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lockout Expiration Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means January 20, 2017.&#8221;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Maturity Date&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.4(B)</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement and all references in the other Loan Documents to the Maturity Date shall mean April 21, 2017, or such earlier date as the Loan is prepaid in full or accelerated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18</font><font style="font-family:inherit;font-size:12pt;">&#32;is hereby added to the Loan Agreement immediately following </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;11.17</font><font style="font-family:inherit;font-size:12pt;">&#32;and before the sentence &#8220;witness the due execution hereof as of the date first written above&#8221;, which new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18</font><font style="font-family:inherit;font-size:12pt;">&#32;provides as follows:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">11.18  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Right of First Offer</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Borrower or any Affiliate of Borrower (herein, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) intends to seek, obtain or accept a proposal for a loan, refinancing, or sale-leaseback transaction of the Mortgaged Property, or any portion thereof, Borrower shall deliver to Lender a letter or other writing setting forth Borrower Party&#8217;s desire to undertake such a transaction and the general requirements thereof, including the requested loan amount, loan term, interest rate, purchase price, and/or lease term, as applicable, together with any special conditions (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Request for Proposal</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the period from the receipt by Lender of the initial Request for Proposal and thirty (30) days thereafter (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proposal Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Lender shall have the right and option to provide a loan, refinancing, loan extension, or a sale-leaseback proposal for such transaction for the Mortgaged Property (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender&#8217;s Proposal</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to Borrower Party setting forth the terms and conditions of such transaction from Lender, which Lender&#8217;s Proposal shall include a time period (which shall not extend more than ten (10) days beyond the Proposal Period) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Response Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within which Borrower Party must accept or reject such Lender&#8217;s Proposal by delivering written notice thereof to Lender.  To the extent Borrower Party fails to so accept or reject Lender&#8217;s Proposal on or prior to the expiration of Response Period, Borrower Party shall be deemed to have rejected Lender&#8217;s Proposal.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower Party shall have the right to request and negotiate additional proposals, term sheets, commitments, or similar items relating to any potential loan, refinancing, or sale-leaseback transactions for the Mortgaged Property or any portion thereof (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third-Party Proposal</font><font style="font-family:inherit;font-size:12pt;">&#8221;) during the Proposal Period and thereafter.  If Borrower Party receives a Third Party Proposal during the Proposal Period, and if such Third-Party Proposal is &#8220;Competitive With&#8221; (as defined below) Lender&#8217;s Proposal, then within three (3) Business Days of Borrower Party&#8217;s receipt of such Third-Party Proposal, Borrower shall furnish to Lender a copy of such Third-Party Proposal (subject to any confidentiality restrictions to which Borrower Party may be subject thereunder).  Lender agrees (i) to hold any such Third-Party Proposal in strict confidence and take reasonable precautions to protect such Third-Party Proposal, (ii) not to divulge the contents of any such Third-Party Proposal to any third party, subject to the right to disclose such information (a) to Lender&#8217;s directors, officers, employees and agents, including advisors, accountants, attorneys and parent entities, under like strictures of confidentiality, as may be reasonably required for Lender to evaluate the Third-Party Proposal, and (b) to the extent required by law or regulations or by any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">subpoena or similar legal process, and (iii) not to make any use of any such Third-Party Proposal except to evaluate whether to revise Lender&#8217;s Proposal as contemplated in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18</font><font style="font-family:inherit;font-size:12pt;">.  For clarity, Borrower shall only be obligated to furnish Lender with a copy of any Third-Party Proposal received by Borrower Party from any particular third party during the Proposal Period.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Borrower Party furnishes a copy of a Third-Party Proposal to Lender pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18(b)</font><font style="font-family:inherit;font-size:12pt;">, on or prior to the earlier of (i) five (5) Business Days of Lender&#8217;s receipt of a copy of a Third-Party Proposal or (ii) the last day of the Proposal Period (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Revised Proposal Submission Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Lender shall be permitted to (but Lender shall be under no obligation to) provide an initial Lender&#8217;s Proposal or, if Lender has already provided an initial Lender&#8217;s Proposal, revise Lender&#8217;s Proposal as Lender deems appropriate, if at all, and submit same to Borrower Party, in which event Borrower Party shall have until the later of (1) five (5) Business Days following Lender&#8217;s submission of the initial or revised Lender&#8217;s Proposal, as applicable, or (2) the last day of the Proposal Period (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Revised Proposal Response Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), to accept or reject the initial or revised Lender&#8217;s Proposal, as applicable, by delivering written notice thereof to Lender.  To the extent Borrower Party fails to so accept or reject the initial or revised Lender&#8217;s Proposal, as applicable, on or prior to the expiration of the Revised Proposal Response Period, Borrower shall be deemed to have rejected such Lender&#8217;s Proposal. For purposes of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18</font><font style="font-family:inherit;font-size:12pt;">, Lender&#8217;s Proposal shall be deemed to be &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Competitive With</font><font style="font-family:inherit;font-size:12pt;">&#8221; a Third-Party Proposal if (a) Lender&#8217;s Proposal is for a loan amount or purchase price, as applicable, of one hundred percent (100%) or more of the loan amount or purchase price, as applicable, set forth in such Third-Party Proposal and (b) if (I) a sale-leaseback transaction, Lender&#8217;s Proposal sets forth an annual rental rate as a percentage of purchase price calculated over the term of the lease which is within twenty-five (25) basis points (0.0025) of the annual rental rate as a percentage of purchase price (calculated over the term of the lease) set forth in such Third-Party Proposal or (II) a loan or refinance, the annual interest rate is within fifty (50) basis points (0.0050) of the interest rate set forth in such Third-Party Proposal</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18(g)</font><font style="font-family:inherit;font-size:12pt;">, upon the later to occur of Borrower&#8217;s rejection of Lender&#8217;s Proposal or the revised Lender&#8217;s Proposal, as applicable, this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be of no further force or effect.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower shall not and shall not permit its Affiliates to accept or commit to any loan, refinancing, or any sale-leaseback transaction set forth in any Third-Party Proposal required to be furnished to Lender hereunder until the expiration of the Proposal Period or the Revised Proposal Response Period, as applicable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Borrower Party elects to accept Lender&#8217;s Proposal or the revised Lender&#8217;s Proposal, as applicable, such parties shall negotiate in good faith for purposes of entering into documents relating thereto as the parties shall agree upon consistent with the terms of Lender&#8217;s Proposal or the revised Lender&#8217;s Proposal, as applicable; provided, however, that neither party shall be under any obligation to consummate the transaction described in the Lender&#8217;s Proposal or the revised Lender&#8217;s Proposal, as applicable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If (i) Borrower Party does not close on a loan, refinancing, or sale-leaseback transaction for the Mortgaged Property, or any portion thereof, pursuant to a Third-Party Proposal within one hundred eighty (180) days following the expiration of the Proposal Period or the Revised Proposal Response Period, as applicable, and (ii) Borrower Party intends at any time thereafter to seek, obtain or accept a proposal for a loan, refinancing or sale-leaseback transaction of the Mortgaged Property, then Borrower shall deliver to Lender a new </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Request for Proposal in connection therewith and the process set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.18</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be reinitiated.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Schedule 2.3, Amortization Schedule, to the Loan Agreement is hereby amended and restated to be Schedule 2.3, Amortization Schedule, attached to this Amendment.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Other Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  All references in each of the Loan Documents to the Loan Agreement shall refer to the Loan Agreement, as amended hereby, as such Loan Agreement may be further amended from time to time.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower agrees that it shall be a condition precedent to the effectiveness of this Amendment that, among other things, all of the following shall have been satisfied promptly and in any event within the time periods specified below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Within five (5) Business Days following Borrower&#8217;s receipt from Lender of an invoice setting forth the amounts due and payable with respect thereto, Borrower shall have paid the actual out-of-pocket fees and expenses of Lender reasonably incurred in connection with this Amendment, including reasonable fees and disbursements of Lender&#8217;s attorneys; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Within five (5) Business Days following the date of this Amendment, Borrower shall have furnished to Lender an affidavit stating the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there have been no modifications to Borrower&#8217;s Articles of Organization that have not been previously delivered to Lender; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is in good standing in the State of Delaware; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is qualified to conduct business in the State of Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Within five (5) Business Days following the date of this Amendment, Borrower shall have paid Lender a fee in the amount of $111,422 as an extension fee for the Loan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In order to induce Lender to execute this Amendment, Borrower represents and warrants as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment, and any other documents and instruments required to be executed and delivered by Borrower in connection herewith, when executed and delivered, will constitute the duly authorized, valid and legally binding obligations of Borrower, and will be enforceable in accordance with their respective terms, subject only to bankruptcy and insolvency laws of general applicability and the application of general principles of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Amendment will not: (i) violate any laws or (ii) conflict with, be inconsistent with, or result in any breach or default of any of the terms, covenants, conditions, or provisions of any indenture, mortgage, deed of trust, corporate charter or bylaws, instrument, document, agreement or contract of any kind to which Borrower is a party or by which Borrower may be bound.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To Borrower&#8217;s knowledge, Borrower is not in default (beyond applicable grace or cure periods) under any contract or agreement to which Borrower is a party, the effect of which default will materially adversely affect the performance by Borrower of its representative obligations pursuant to and as contemplated by the terms and provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower hereby represents and warrants that as of the date hereof, Borrower has no defenses, claims, offsets or setoffs with regard to the enforcement of the Loan Documents as modified hereby.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower agrees that the Loan Agreement, the Note and each other Loan Document, as amended by this Amendment, remain in full force and effect in accordance with the previously existing terms thereof, as amended by this Amendment, and such documents and instruments are hereby ratified and confirmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment shall be construed in accordance with and governed by the internal laws of the State of New York, except that the creation, perfection and enforcement of the Liens and security interests created pursuant to the Mortgage shall be governed and construed according to the law of the state of Texas, it being understood that to the fullest extent permitted by the laws of Texas, the law of the State of New York shall govern the Loan Agreement, the Notes and the other Loan Documents as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.8</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The parties hereto expressly acknowledge and agree that this Amendment shall not be construed as a novation of the Note, the Mortgage or any other Loan Document.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All of the Mortgaged Property shall remain in all respects subject to the lien, charge and encumbrance of the Mortgage, as herein modified, and nothing herein contained and nothing done pursuant hereto, shall affect the lien, charge or encumbrance of the Mortgage, as herein modified, or the priority thereof with respect to other liens, charges, encumbrances or conveyances, or release or affect the liability of any part or parties whomsoever, who may now or hereafter be liable under, or on account of, the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution and delivery of this Amendment does not constitute a waiver of any default under the Note, Mortgage or any of the other Loan Documents; provided, however, that Lender hereby acknowledges that it is not aware of any defaults under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Time is hereby declared to be of the essence of this Amendment and of every part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signatures Follow on the Next Page]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Jeffrey L. Wade</font><font style="font-family:inherit;font-size:12pt;">__________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Jeffrey L. Wade</font><font style="font-family:inherit;font-size:12pt;">_____________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EVP, Corporate Development and CFO</font><font style="font-family:inherit;font-size:12pt;">__</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">company</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Samantha K. Garbus</font><font style="font-family:inherit;font-size:12pt;">____________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Samantha K. Garbus</font><font style="font-family:inherit;font-size:12pt;">_______________________</font></div><div style="line-height:120%;text-align:justify;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Senior Vice President</font><font style="font-family:inherit;font-size:12pt;">______________________</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF GUARANTOR</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The undersigned, being the &#8220;Guarantor&#8221; under the Guaranty, hereby consents to the foregoing Amendment to Loan and Security Agreement and to Other Loan Documents.  The undersigned agrees that the Guaranty is and shall remain in full force and effect, that as of the date hereof (i) the Guaranty is ratified and confirmed hereby, (ii) no defenses or offsets exist to the enforcement thereof, and (iii) Guarantor has no Claims against Lender with respect thereto.  All capitalized terms used in this Consent of Guarantor shall have the meaning ascribed to such terms in the Amendment to which this Consent of Guarantor is attached.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(formerly known as Lexicon Genetics</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incorporated), a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Jeffrey L. Wade</font><font style="font-family:inherit;font-size:12pt;">__________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Jeffrey L. Wade</font><font style="font-family:inherit;font-size:12pt;">_____________________</font></div><div style="line-height:120%;text-align:center;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">__</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EVP, Corporate Development and CFO</font><font style="font-family:inherit;font-size:12pt;">__</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.359 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HENRY APPLEWHITE SURVEY, ABSTRACT NUMBER 51</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 12.359 acres of land situated in the Henry Applewhite Survey, Abstract Number 51 and the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 12.359 acres), The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 12.359 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set marking the south end of a 25-foot cut-back line at the intersection of the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.) with the southeasterly R.O.W. line of Technology Forest Place (width varies), said iron rod marking the most southerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 01&#176;27'36" West, along said southeasterly R.O.W. line of Technology Forest Place, along said cut-back line and along the west line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the north end of said 25-foot cut-back line and marking the most northerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, continuing along said southeasterly R.O.W. line of Technology Forest Place and along the northwesterly line of said Restricted Reserve "A", a distance of 1,060.00 feet to a 5/8-inch iron rod with cap found marking the west end of a 25-foot cut-back line and marking the most westerly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 88&#176;32'24" East, continuing along said southeasterly R.O.W. line, along said cutback line and along the north line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the east end of said cut-back line and marking the intersection of said southeasterly R.O.W. line of Technology Forest Place with the southwesterly R.O.W. line of New Trails Drive (80-foot wide R.O.W.), said iron rod marking the most easterly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along said southwesterly R.O.W. line of New Trails Drive and along the northeasterly line of said Restricted Reserve "A", a distance of 460.59 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A, M.C.M.R., said iron rod marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, departing said southwesterly R.O.W. line of New Trails Drive, along the northwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4, and along the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, at a distance of 742.00 feet passing a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A M.C.M.R. and marking the most westerly corner of said Section 4, continuing along southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, in all, a distance of 1,110.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", a distance of 460.59 feet to the POINT OF BEGINNING and containing 12.359 acres (538,380 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 3</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A non-exclusive easement for vehicular and pedestrian ingress and egress created under the Reciprocal Easement Agreement by and between Woodlands Office Equities-&#8217;95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1 dated as of December 8, 2000, and recorded under the County Clerk&#8217;s File No. 2000-104008 and the Real Property Records of Montgomery County, Texas. </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Schedule 2.3</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amortization Schedule</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">See Attached</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s3249E2B90E1FC8CBDD419B6740D53799"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AND TO OTHER LOAN DOCUMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT AND TO OTHER LOAN DOCUMENTS (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made as of October 2, 2013, by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability company (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at c/o iStar Financial Inc., 1114 Avenue of the Americas, 38</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower and iStar Financial Inc., a Maryland corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;) entered into a Loan and Security Agreement dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Loan  Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as amended by that certain Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 28, 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); that certain Second Amendment to Loan and Security Agreement and to other Loan Documents dated as of June 17, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Second Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); that certain Third Amendment to Loan and Security Agreement and to other Loan Documents dated as of August 30, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and that certain Fourth Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 17, 2013 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Fourth Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); the Original Loan Agreement, as amended by such First Amendment, Second Amendment, Third Amendment and Fourth Amendment, is herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Lender agreed to make a loan to Borrower in the principal amount of Thirty-Four Million Dollars ($34,000,000) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221;) upon the terms and conditions set forth in the Loan Agreement.  Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.  The Loan is evidenced by that certain Promissory Note of even date with the Loan Agreement in the principal amount of the Loan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and is secured by, among other things, (i) that certain Deed of Trust with Security Agreement, Assignment of Leases and Rents and Fixture Filing of even date with the Loan Agreement, recorded in the Official Records of Montgomery County, Texas (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Official Records</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as Document No. 2004-042420 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221;), covering the Property more particularly described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, and (ii) that certain Guaranty of even date with the Loan Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in favor of Original Lender made by Lexicon Genetics Incorporated, which is now known as Lexicon Pharmaceuticals, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Loan Documents were assigned by Original Lender to iSTAR TARA LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iStar Tara</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to that certain Assignment and Assumption of Note, Mortgage, and Other Loan Documents made as of March 1, 2009, recorded in the Official Records as Document No. 2009-022702 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Assignment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and then subsequently assigned by iStar Tara to Lender pursuant to that certain Assignment and Assumption of Note, Deed of Trust and Other Loan Documents made as of March 16, 2011 and recorded in the Official Records as Document No. 2011039443.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower has requested certain clarifications on Borrower&#8217;s ability to prepay the Loan as contemplated by this Amendment, and Lender is willing to consent to such modification, all upon the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incorporation of Recitals</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The foregoing Recitals are incorporated herein and expressly made a part hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendment to Loan Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Lockout Expiration Date&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement is hereby amended and restated in its entirety and shall read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lockout Expiration Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the third anniversary of the Closing.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The last sentence of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.4(c)(i)</font><font style="font-family:inherit;font-size:12pt;">&#32;is amended by deleting the word &#8220;together&#8221; and in its place adding the phrase &#8220;and if prepaid before January 20, 2017 then together&#8221;.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Other Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  All references in each of the Loan Documents to the Loan Agreement shall refer to the Loan Agreement, as amended hereby, as such Loan Agreement may be further amended from time to time.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower agrees that it shall be a condition precedent to the effectiveness of this Amendment that, among other things, all of the following shall have been satisfied promptly and in any event within the time periods specified below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Within five (5) Business Days following Borrower&#8217;s receipt from Lender of an invoice setting forth the amounts due and payable with respect thereto, Borrower shall have paid the actual out-of-pocket fees and expenses of Lender reasonably incurred in connection with this Amendment, if any, excluding any reasonable fees and disbursements of Lender&#8217;s attorneys; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Within five (5) Business Days following the date of this Amendment, Borrower shall have furnished to Lender an affidavit stating the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there have been no modifications to Borrower&#8217;s Articles of Organization that have not been previously delivered to Lender; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is in good standing in the State of Delaware; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is qualified to conduct business in the State of Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In order to induce Lender to execute this Amendment, Borrower represents and warrants as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment, and any other documents and instruments required to be executed and delivered by Borrower in connection herewith, when executed and delivered, will constitute the duly authorized, valid and legally binding obligations of Borrower, and will be enforceable in accordance with their respective terms, subject only to bankruptcy and insolvency laws of general applicability and the application of general principles of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Amendment will not: (i) violate any laws or (ii) conflict with, be inconsistent with, or result in any breach or default of any of the terms, covenants, conditions, or provisions of any indenture, mortgage, deed of trust, corporate charter or bylaws, instrument, document, agreement or contract of any kind to which Borrower is a party or by which Borrower may be bound.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To Borrower&#8217;s knowledge, Borrower is not in default (beyond applicable grace or cure periods) under any contract or agreement to which Borrower is a party, the effect of which default will materially </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">adversely affect the performance by Borrower of its representative obligations pursuant to and as contemplated by the terms and provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower hereby represents and warrants that as of the date hereof, Borrower has no defenses, claims, offsets or setoffs with regard to the enforcement of the Loan Documents as modified hereby.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower agrees that the Loan Agreement, the Note and each other Loan Document, as amended by this Amendment, remain in full force and effect in accordance with the previously existing terms thereof, as amended by this Amendment, and such documents and instruments are hereby ratified and confirmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment shall be construed in accordance with and governed by the internal laws of the State of New York, except that the creation, perfection and enforcement of the Liens and security interests created pursuant to the Mortgage shall be governed and construed according to the law of the state of Texas, it being understood that to the fullest extent permitted by the laws of Texas, the law of the State of New York shall govern the Loan Agreement, the Notes and the other Loan Documents as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.8</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The parties hereto expressly acknowledge and agree that this Amendment shall not be construed as a novation of the Note, the Mortgage or any other Loan Document.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All of the Mortgaged Property shall remain in all respects subject to the lien, charge and encumbrance of the Mortgage, as herein modified, and nothing herein contained and nothing done pursuant hereto, shall affect the lien, charge or encumbrance of the Mortgage, as herein modified, or the priority thereof with respect to other liens, charges, encumbrances or conveyances, or release or affect the liability of any part or parties whomsoever, who may now or hereafter be liable under, or on account of, the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution and delivery of this Amendment does not constitute a waiver of any default under the Note, Mortgage or any of the other Loan Documents; provided, however, that Lender hereby acknowledges that it is not aware of any defaults under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Time is hereby declared to be of the essence of this Amendment and of every part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signatures Follow on the Next Page]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI BELMONT LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">company</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF GUARANTOR</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The undersigned, being the &#8220;Guarantor&#8221; under the Guaranty, hereby consents to the foregoing Amendment to Loan and Security Agreement and to Other Loan Documents.  The undersigned agrees that the Guaranty is and shall remain in full force and effect, that as of the date hereof (i) the Guaranty is ratified and confirmed hereby, (ii) no defenses or offsets exist to the enforcement thereof, and (iii) Guarantor has no Claims against Lender with respect thereto.  All capitalized terms used in this Consent of Guarantor shall have the meaning ascribed to such terms in the Amendment to which this Consent of Guarantor is attached.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(formerly known as Lexicon Genetics</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incorporated), a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sCEDA95D8F440C897599A9B6740F7385F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">METES AND BOUNDS DESCRIPTION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.359 ACRES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HENRY APPLEWHITE SURVEY, ABSTRACT NUMBER 51</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 12.359 acres of land situated in the Henry Applewhite Survey, Abstract Number 51 and the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 12.359 acres), The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 12.359 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set marking the south end of a 25-foot cut-back line at the intersection of the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.) with the southeasterly R.O.W. line of Technology Forest Place (width varies), said iron rod marking the most southerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 01&#176;27'36" West, along said southeasterly R.O.W. line of Technology Forest Place, along said cut-back line and along the west line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the north end of said 25-foot cut-back line and marking the most northerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, continuing along said southeasterly R.O.W. line of Technology Forest Place and along the northwesterly line of said Restricted Reserve "A", a distance of 1,060.00 feet to a 5/8-inch iron rod with cap found marking the west end of a 25-foot cut-back line and marking the most westerly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 88&#176;32'24" East, continuing along said southeasterly R.O.W. line, along said cutback line and along the north line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the east end of said cut-back line and marking the intersection of said southeasterly R.O.W. line of Technology Forest Place with the southwesterly R.O.W. line of New Trails Drive (80-foot wide R.O.W.), said iron rod marking the most easterly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along said southwesterly R.O.W. line of New Trails Drive and along the northeasterly line of said Restricted Reserve "A", a distance of 460.59 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A, M.C.M.R., said iron rod marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, departing said southwesterly R.O.W. line of New Trails Drive, along the northwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4, and along the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, at a distance of 742.00 feet passing a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A M.C.M.R. and marking the most westerly corner of said Section 4, continuing along southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, in all, a distance of 1,110.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", a distance of 460.59 feet to the POINT OF BEGINNING and containing 12.359 acres (538,380 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 3</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A non-exclusive easement for vehicular and pedestrian ingress and egress created under the Reciprocal Easement Agreement by and between Woodlands Office Equities-&#8217;95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1 dated as of December 8, 2000, and recorded under the County Clerk&#8217;s File No. 2000-104008 and the Real Property Records of Montgomery County, Texas. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-2</font></div></div><hr style="page-break-after:always"><div><a name="s09a0346774f949caaee187fe5713fb54"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AND TO OTHER LOAN DOCUMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT AND TO OTHER LOAN DOCUMENTS (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made as of April 20, 2017, by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iSTAR LEX LENDER LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited liability company (together with its successors and assigns, hereinafter referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with offices at c/o iStar Inc., 1114 Avenue of the Americas, 38</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.&#160;&#160;&#160;&#160;Borrower and iStar Financial Inc., a Maryland corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;) entered into a Loan and Security Agreement dated as of April 21, 2004 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Loan  Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as amended by that certain Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 28, 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); that certain Second Amendment to Loan and Security Agreement and to other Loan Documents dated as of June 17, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Second Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); that certain Third Amendment to Loan and Security Agreement and to other Loan Documents dated as of August 30, 2011 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); that certain Fourth Amendment to Loan and Security Agreement and to other Loan Documents dated as of September 17, 2013 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Fourth Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and that certain Fifth Amendment to Loan and Security Agreement and to other Loan Documents dated as of October 2, 2013 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Fifth Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (the Original Loan Agreement, as amended by such First Amendment, Second Amendment, Third Amendment, Fourth Amendment and Fifth Amendment, is herein called the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Lender agreed to make a loan to Borrower in the principal amount of Thirty-Four Million Dollars ($34,000,000) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221;) upon the terms and conditions set forth in the Loan Agreement.  Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.  The Loan is evidenced by that certain Promissory Note of even date with the Loan Agreement in the principal amount of the Loan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and is secured by, among other things, (i) that certain Deed of Trust with Security Agreement, Assignment of Leases and Rents and Fixture Filing of even date with the Loan Agreement, recorded in the Official Records of Montgomery County, Texas (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Official Records</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as Document No. 2004-042420 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mortgage</font><font style="font-family:inherit;font-size:12pt;">&#8221;), covering the Property more particularly described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, and (ii) that certain Guaranty of even date with the Loan Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in favor of Original Lender made by Lexicon Genetics Incorporated, which is now known as Lexicon Pharmaceuticals, Inc., a Delaware corporation.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.&#160;&#160;&#160;&#160;The Loan Documents were assigned by Original Lender to iSTAR TARA LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iStar Tara</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to that certain Assignment and Assumption of Note, Mortgage, and Other Loan Documents made as of March 1, 2009, recorded in the Official Records as Document No. 2009-022702 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Assignment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and then subsequently assigned (i) by iStar Tara to SFI Belmont LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SFI Belmont</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to that certain Assignment and Assumption of Note, Deed of Trust and Other Loan Documents made as of March 16, 2011 and recorded in the Official Records as Document No. 2011039443 and (ii) by SFI Belmont to Lender pursuant to that certain Assignment and Assumption of Note, Deed of Trust and Other Loan Documents made as of March 26, 2015, and recorded in the Official Records as Document No. 2015027704.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.&#160;&#160;&#160;&#160;Borrower has requested an extension of the Maturity Date of the Loan as contemplated by this Amendment, and Lender is willing to consent to such modification, all upon the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incorporation of Recitals</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The foregoing Recitals are incorporated herein and expressly made a part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendment to Loan Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">The definition of &#8220;Maturity Date&#8221; in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.4(B)</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement and all references in the other Loan Documents to the Maturity Date shall mean April 21, 2018, or such earlier date as the Loan is prepaid in full or accelerated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;A new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.4(D)</font><font style="font-family:inherit;font-size:12pt;">&#32;is hereby added to the Loan Agreement immediately following </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.4(C)(iii)</font><font style="font-family:inherit;font-size:12pt;">&#32;and immediately before </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.5</font><font style="font-family:inherit;font-size:12pt;">, which new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.4(D)</font><font style="font-family:inherit;font-size:12pt;">&#32;provides as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:53px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)&#160;&#160;&#160;&#160;Upon the Maturity Date or such other date as the Loan is prepaid, in whole, but not in part, Borrower shall pay Lender the Exit Interest (as defined herein) in addition to, and not in limitation of, all other Obligations under the Loan Documents.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exit Interest</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an amount equal to $632,656.97, reduced by all payments of interest computed at the Base Rate, received by Lender for the period following April 20, 2017, until such Maturity Date or prepayment date, as applicable; provided, however, that Exit Interest may be reduced to but not below zero.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;A new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.20</font><font style="font-family:inherit;font-size:12pt;">&#32;is hereby added immediately after </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.19</font><font style="font-family:inherit;font-size:12pt;">&#32;and immediately before </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">, which new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.20</font><font style="font-family:inherit;font-size:12pt;">&#32;provides as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.20.  At all times from and after April 1, 2017, Borrower and Guarantor covenant and agree that either Borrower or Guarantor shall maintain Liquid Assets (as defined below) of not less than $50,000,000 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Liquid Assets Covenant</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  &#8220;Liquid Assets&#8221; shall mean the following:  (1) cash or cash equivalents held in the United States; (2) United States Treasury or governmental agency obligations backed by the full faith and credit of the United States of America; (3) commercial paper related P-1 or A1 by Moody&#8217;s or S&amp;P, respectively; (4) medium and long-term securities rated investment grate by one of the rating agencies described in (c) above; (5) Eligible Stocks (as defined below); and (6) mutual funds quoted in the Wall Street Journal which invest primarily in the assets described in (1) - (5) above.  &#8220;Eligible Stocks&#8221; shall mean any common or preferred stock which (i) is not subject to statutory or contractual restrictions and is freely saleable on the public market, or (ii) is traded on the New York Stock Exchange, American Stock Exchange, or included in the National Market tier of NASDAQ.  On a quarterly basis and as part of the delivery of quarterly financial statements as required in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.1</font><font style="font-family:inherit;font-size:12pt;">, Borrower or Guarantor, as applicable, shall provide Lender a certification on behalf of such party that such party is in compliance with the Liquid Assets Covenant set forth herein in form reasonably acceptable to Lender.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Schedule 2.3, Amortization Schedule, to the Loan Agreement is hereby amended and restated to be Schedule 2.3, Amortization Schedule, attached to this Amendment.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendments to Other Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  All references in each of the Loan Documents to the Loan Agreement shall refer to the Loan Agreement, as amended hereby, as such Loan Agreement may be further amended from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Consent</font><font style="font-family:inherit;font-size:12pt;">.  Borrower has requested and Lender hereby consents to Borrower&#8217;s demolition of 89,600 square feet of the unoccupied former animal science buildings 2 and 5 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Demolition</font><font style="font-family:inherit;font-size:12pt;">&#8221;) as an Alteration permitted under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.14</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement, except that such consent (which shall satisfy condition (5)(z) of said </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.14</font><font style="font-family:inherit;font-size:12pt;">) shall be conditioned on Borrower&#8217;s compliance with the remaining conditions set forth in conditions (1), (2), (3), (4) and (6) of said </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.14</font><font style="font-family:inherit;font-size:12pt;">.  For the avoidance of doubt, Borrower and Lender agree that the third and fourth sentences of said Section 7.14 shall not apply to the Demolition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower agrees that it shall be a condition precedent to the effectiveness of this Amendment that, among other things, all of the following shall have been satisfied promptly and in any event within the time periods specified below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Within five (5) Business Days following Borrower&#8217;s receipt from Lender of an invoice setting forth the amounts due and payable with respect thereto, Borrower shall have paid the actual out-of-pocket fees and expenses of Lender reasonably incurred in connection with this Amendment, including reasonable fees and disbursements of Lender&#8217;s attorneys; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Within five (5) Business Days following the date of this Amendment, Borrower shall have furnished to Lender an affidavit stating the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that there have been no modifications to Borrower&#8217;s Articles of Organization that have not been previously delivered to Lender; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is in good standing in the State of Delaware; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Borrower is qualified to conduct business in the State of Texas.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Within five (5) Business Days following the date of this Amendment, Borrower shall have paid Lender a fee in the amount of $78,755.00 as an extension fee for the Loan.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In order to induce Lender to execute this Amendment, Borrower represents and warrants as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;This Amendment, and any other documents and instruments required to be executed and delivered by Borrower in connection herewith, when executed and delivered, will constitute the duly authorized, valid and legally binding obligations of Borrower, and will be enforceable in accordance with their respective terms, subject only to bankruptcy and insolvency laws of general applicability and the application of general principles of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Amendment will not: (i) violate any laws or (ii) conflict with, be inconsistent with, or result in any breach or default of any of the terms, covenants, conditions, or provisions of any indenture, mortgage, deed of trust, corporate charter or bylaws, instrument, document, agreement or contract of any kind to which Borrower is a party or by which Borrower may be bound.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;To Borrower&#8217;s knowledge, Borrower is not in default (beyond applicable grace or cure periods) under any contract or agreement to which Borrower is a party, the effect of which default will materially </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">adversely affect the performance by Borrower of its representative obligations pursuant to and as contemplated by the terms and provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Borrower hereby represents and warrants that as of the date hereof, Borrower has no defenses, claims, offsets or setoffs with regard to the enforcement of the Loan Documents as modified hereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:12px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower agrees that the Loan Agreement, the Note and each other Loan Document, as amended by this Amendment, remain in full force and effect in accordance with the previously existing terms thereof, as amended by this Amendment, and such documents and instruments are hereby ratified and confirmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Amendment shall be construed in accordance with and governed by the internal laws of the State of New York, except that the creation, perfection and enforcement of the Liens and security interests created pursuant to the Mortgage shall be governed and construed according to the law of the state of Texas, it being understood that to the fullest extent permitted by the laws of Texas, the law of the State of New York shall govern the Loan Agreement, the Notes and the other Loan Documents as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 11.8</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The parties hereto expressly acknowledge and agree that this Amendment shall not be construed as a novation of the Note, the Mortgage or any other Loan Document.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;All of the Mortgaged Property shall remain in all respects subject to the lien, charge and encumbrance of the Mortgage, as herein modified, and nothing herein contained and nothing done pursuant hereto, shall affect the lien, charge or encumbrance of the Mortgage, as herein modified, or the priority thereof with respect to other liens, charges, encumbrances or conveyances, or release or affect the liability of any part or parties whomsoever, who may now or hereafter be liable under, or on account of, the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;The execution and delivery of this Amendment does not constitute a waiver of any default under the Note, Mortgage or any of the other Loan Documents; provided, however, that Lender hereby acknowledges that it is not aware of any defaults under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;Time is hereby declared to be of the essence of this Amendment and of every part hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signatures Follow on the Next Page]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">iSTAR LEX LENDER LLC</font><font style="font-family:inherit;font-size:12pt;">, a Delaware</font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">limited liability company</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:&#160;&#160;&#160;&#160;____________________________</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF GUARANTOR</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The undersigned, being the &#8220;Guarantor&#8221; under the Guaranty, hereby consents to the foregoing Sixth Amendment to Loan and Security Agreement and to Other Loan Documents and hereby agrees to be bound by the terms and requirements of the new </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.20</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Loan Agreement (added pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2(d)</font><font style="font-family:inherit;font-size:12pt;">&#32;of the foregoing Sixth Amendment to Loan and Security Agreement and to Other Loan Documents), as part of Guarantor&#8217;s Obligations under the Guaranty.  The undersigned agrees that the Guaranty, as supplemented provided above, is and shall remain in full force and effect, and that as of the date hereof (i) the Guaranty, as supplemented as provided above, is ratified and confirmed hereby, (ii) no defenses or offsets exist to the enforcement thereof, and (iii) Guarantor has no Claims against Lender with respect thereto.  All capitalized terms used in this Consent of Guarantor shall have the meaning ascribed to such terms in the Amendment to which this Consent of Guarantor is attached.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(formerly known as Lexicon Genetics</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incorporated), a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s9d5dbe94b97a4b6bbe679c9f6a3857e6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Legal Description</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 1</font><font style="font-family:inherit;font-size:12pt;">&#32;<br>METES AND BOUNDS DESCRIPTION <br>12.359 ACRES <br>HENRY APPLEWHITE SURVEY, ABSTRACT NUMBER 51 <br>JOHN TAYLOR SURVEY, ABSTRACT NUMBER 547 <br>MONTGOMERY COUNTY, TEXAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Being a tract or parcel containing 12.359 acres of land situated in the Henry Applewhite Survey, Abstract Number 51 and the John Taylor Survey, Abstract Number 547, Montgomery County, Texas; being all of Restricted Reserve "A" (called 12.359 acres), The Woodlands Medical Research Park, Section 9, a subdivision plat recorded in Cabinet O, Sheet 180 Montgomery County Map Records (M.C.M.R.), Montgomery County, Texas; said 12.359 acre tract being more particularly described as follows (bearings are referenced to the record information contained in the above described subdivision plat);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BEGINNING at a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set marking the south end of a 25-foot cut-back line at the intersection of the northeasterly right-of-way (R.O.W.) line of Research Forest Drive (160-foot wide R.O.W.) with the southeasterly R.O.W. line of Technology Forest Place (width varies), said iron rod marking the most southerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 01&#176;27'36" West, along said southeasterly R.O.W. line of Technology Forest Place, along said cut-back line and along the west line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the north end of said 25-foot cut-back line and marking the most northerly west corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 43&#176;32'24" East, continuing along said southeasterly R.O.W. line of Technology Forest Place and along the northwesterly line of said Restricted Reserve "A", a distance of 1,060.00 feet to a 5/8-inch iron rod with cap found marking the west end of a 25-foot cut-back line and marking the most westerly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 88&#176;32'24" East, continuing along said southeasterly R.O.W. line, along said cutback line and along the north line of said Restricted Reserve "A", a distance of 35.36 feet to a 5/8-inch iron rod with cap found marking the east end of said cut-back line and marking the intersection of said southeasterly R.O.W. line of Technology Forest Place with the southwesterly R.O.W. line of New Trails Drive (80-foot wide R.O.W.), said iron rod marking the most easterly north corner of said Restricted Reserve "A" and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 46&#176;27'36" East, along said southwesterly R.O.W. line of New Trails Drive and along the northeasterly line of said Restricted Reserve "A", a distance of 460.59 feet to a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", Medical Research Park, Section 4, a subdivision plat recorded in Cabinet G, Sheet 51A, M.C.M.R., said iron rod marking the most easterly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, South 43&#176;32'24" West, departing said southwesterly R.O.W. line of New Trails Drive, along the northwesterly line of said Restricted Reserve "A", Medical Research Park, Section 4, and along the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9, at a distance of 742.00 feet passing a 5/8-inch iron rod with cap found marking the most northerly corner of Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, a subdivision plat recorded in Cabinet E, Sheet 163B and 164A M.C.M.R. and marking the most westerly corner of said Section 4, continuing along southeasterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and along the northwesterly line of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1, in all, a distance of 1,110.00 feet to a 5/8-inch iron rod with plastic cap stamped "Terra Surveying" set in the aforesaid northeasterly R.O.W. line of Research Forest Drive, marking the most westerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 1 and marking the most southerly corner of said Restricted Reserve "A", The Woodlands Medical Research Park, Section 9 and the herein described tract;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THENCE, North 46&#176;27'36" West, along said northeasterly R.O.W. line of Research Forest Drive and along the southwesterly line of said Restricted Reserve "A", a distance of 460.59 feet to the POINT OF BEGINNING and containing 12.359 acres (538,380 square feet) of land. This description is based on the ALTA/ACSM Land Title Survey and plat made by Terra Surveying Co., dated April, 2003, updated April 2004, Project Number 1851-0316-S.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TRACT 3</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A non-exclusive easement for vehicular and pedestrian ingress and egress created under the Reciprocal Easement Agreement by and between Woodlands Office Equities-&#8217;95 Limited and First Security Bank, National Association, not individually, but solely as Owner Trustee under the Lexi Trust 2000-1 dated as of December 8, 2000, and recorded under the County Clerk&#8217;s File No. 2000-104008 and the Real Property Records of Montgomery County, Texas. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Schedule 2.3</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amortization Schedule</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">See Attached</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;"><img src="amendno6tolsagrimage1.gif" alt="amendno6tolsagrimage1.gif" style="height:504px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;"><img src="amendno6tolsagrimage2.gif" alt="amendno6tolsagrimage2.gif" style="height:510px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;"><img src="amendno6tolsagrimage3.gif" alt="amendno6tolsagrimage3.gif" style="height:508px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;"><img src="amendno6tolsagrimage4.gif" alt="amendno6tolsagrimage4.gif" style="height:518px;width:624px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-7</font></div></div><hr style="page-break-after:always"><div><a name="sD4409D0E01AFF5C61D299B67412A913B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PROMISSORY NOTE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$34,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">April 21, 2004</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">FOR VALUE RECEIVED, LEX-GEN WOODLANDS, L.P., a Delaware limited partnership (&#8220;Borrower&#8221;), promises to pay to iSTAR FINANCIAL, INC., a Maryland corporation (&#8220;Holder&#8221;), or order, at 1114 Avenue of the Americas, 27th&#160;Floor, New&#160;York, New&#160;York 10036, or at such other place as Holder may from time to time in writing designate, in lawful money of the United&#160;States of America, the principal sum of THIRTY FOUR MILLION AND NO/100 DOLLARS ($34,000,000.00) or such other sum as may be the total amount outstanding pursuant to this Note (the &#8220;Loan&#8221;), payable at such rates and at such times as are provided in the &#8220;Loan Agreement&#8221; (as hereinafter defined).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payments of both principal and interest are to be made in lawful money of the United&#160;States of America.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Promissory Note (this &#8220;Note&#8221;) evidences Indebtedness incurred under, and is subject to the terms and provisions of, that certain Loan and Security Agreement of even date herewith, by and among the Borrower and the Holder (herein, as the same may be further amended, modified or supplemented from time to time, called the &#8220;Loan Agreement&#8221;).  The Loan Agreement, to which reference is hereby made, sets forth said terms and provisions, including those under which this Note may or must be paid prior to its due date or may have its due date accelerated or extended.  The Loan Agreement also contains provisions for the payment of late charges and interest at the Default Rate, all as more specifically set forth therein.  Repayment of the Indebtedness evidenced by this Note is secured by the Mortgage and the other Loan Documents referred to in the Loan Agreement, and reference is made thereto for a statement of terms and provisions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms used but not otherwise defined herein are used herein as defined in the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Note may only be prepaid in whole or in part in accordance with the terms of Section 2.4 of the Loan Agreement (or as otherwise expressly provided elsewhere in the Loan Agreement or the other Loan Documents).  Any payments of the outstanding principal balance of the Loan evidenced by this Note, whether voluntary or involuntary, shall be accompanied by interest accrued to the date of prepayment and the Prepayment Premium, to the extent, if any, provided in Section 2.4 of the Loan Agreement (except to the extent any other provision of the Loan Agreement expressly provides otherwise, including, without limitation, Section 2.2(C) of the Loan Agreement).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXCEPT AS OTHERWISE EXPRESSLY PERMITTED IN THIS NOTE OR THE OTHER LOAN DOCUMENTS, BORROWER HEREBY EXPRESSLY (i)&#160;WAIVES ANY RIGHTS IT MAY HAVE UNDER LAW TO PREPAY THIS NOTE, IN WHOLE OR IN PART, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">WITHOUT PENALTY</font><font style="font-family:inherit;font-size:12pt;">, UPON ACCELERATION OF THE MATURITY DATE, AND (ii)&#160;AGREES THAT IF, FOR ANY REASON, A PREPAYMENT OF ALL OR ANY PORTION OF THE PRINCIPAL AMOUNT OF THIS NOTE IS MADE, INCLUDING, WITHOUT LIMITATION, UPON OR FOLLOWING ANY ACCELERATION OF THE MATURITY DATE BY HOLDER ON ACCOUNT OF THE OCCURRENCE OF ANY EVENT OF DEFAULT, INCLUDING, WITHOUT LIMITATION, ANY TRANSFER, DISPOSITION, OR FURTHER ENCUMBRANCE PROHIBITED OR RESTRICTED BY THE LOAN AGREEMENT, THEN BORROWER SHALL BE OBLIGATED TO PAY CONCURRENTLY WITH SUCH PREPAYMENT THE PREPAYMENT PREMIUM TO THE EXTENT REQUIRED UNDER SECTION 2.4 OF THE LOAN AGREEMENT.  BY INITIALING THIS PROVISION IN THE SPACE PROVIDED BELOW, BORROWER HEREBY DECLARES THAT (1)&#160;EACH OF THE MATTERS SET FORTH IN THIS PARAGRAPH IS TRUE AND CORRECT, (2)&#160;HOLDER&#8217;S AGREEMENT TO MAKE THE LOAN EVIDENCED BY THIS </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOTE AT THE INTEREST RATES SET FORTH IN THE LOAN AGREEMENT AND FOR THE TERM SET FORTH IN THIS NOTE CONSTITUTES ADEQUATE CONSIDERATION FOR THIS WAIVER AND AGREEMENT, AND HAS BEEN GIVEN INDIVIDUAL WEIGHT BY BORROWER AND HOLDER, (3)&#160;BORROWER IS A SOPHISTICATED AND KNOWLEDGE-ABLE REAL ESTATE INVESTOR WITH COMPETENT AND INDEPENDENT LEGAL COUNSEL, AND (4)&#160;BORROWER FULLY UNDERSTANDS THE EFFECT OF THIS WAIVER AND AGREEMENT.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On behalf of the Borrower</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The remedies of Holder, as provided in this Note, the Loan Agreement and the other Loan Documents, shall be cumulative and concurrent and may be pursued singularly, successively or together, at the sole discretion of Holder, and may be exercised as often as occasion therefor shall occur; and the failure to exercise any such right or remedy shall in no event be construed as a waiver or release thereof.  In any action, sale of collateral, or other proceedings to enforce this Note, the Loan Agreement or any other Loan Document, Holder need not file or produce the original of this Note, but only need file or produce a photocopy of this Note certified by Holder to be a true and correct copy of this Note.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event of any dispute, action or lawsuit regarding the terms hereof, subject to the provisions of the Loan Agreement, the prevailing party will have the right to recover from the other party all court costs and reasonable attorneys&#8217; fees and disbursements incurred with respect thereto, in addition to all other applicable damages and costs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BORROWER WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, DILIGENCE, PRESENTMENT FOR PAYMENT, DEMAND, NOTICE OF DEMAND, NOTICE OF PROTEST, NOTICE OF NONPAYMENT OR DISHONOR, NOTICE OF INTENTION TO ACCELERATE, NOTICE OF ACCELERATION, PROTEST AND NOTICE OF PROTEST OF THIS NOTE, AND ALL OTHER NOTICES (OTHER THAN AS EXPRESSLY PROVIDED IN THE LOAN AGREEMENT OR OTHER LOAN DOCUMENTS) IN CONNECTION WITH THE DELIVERY, ACCEPTANCE, PERFORMANCE, DEFAULT OR ENFORCEMENT OF THE PAYMENT OF THIS NOTE.  BORROWER FURTHER WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ALL VALUATION AND APPRAISEMENT PRIVILEGES, CLAIMS OF LACK OF DILIGENCE OR DELAYS IN COLLECTION OR ENFORCEMENT OF THIS NOTE, THE RELEASE OF ANY PARTY LIABLE, THE RELEASE OF ANY SECURITY FOR THE DEBT, THE TAKING OF ANY ADDITIONAL SECURITY AND ANY OTHER INDULGENCE OF FORBEARANCE.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Holder shall not be deemed, by any act of omission or commission, to have waived any of its rights or remedies hereunder unless such waiver is in writing and signed by Holder, and then only to the extent specifically set forth in the writing.  The acceptance by Holder of any payment hereunder which is less than payment in full of all amounts due and payable at the time of such payment shall not constitute a waiver of the right to exercise any of the foregoing options at that time or at any subsequent time or nullify any prior exercise of any such option without the express consent of Holder, except as and to the extent otherwise provided by law.  A waiver with reference to one event shall not be construed as continuing or as a bar to or waiver of any right or remedy as to a subsequent event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PURSUANT TO SECTION 5&#8209;1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW&#160;YORK, BORROWER AND ANY GUARANTOR OF THIS NOTE AGREE THAT THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERE-UNDER SHALL BE GOVERNED </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE UNITED&#160;STATES OF AMERICA AND THE LAWS OF THE STATE OF NEW&#160;YORK.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Whenever used, the singular number shall include the plural, the plural shall include the singular, and the words &#8220;Holder&#8221; and &#8220;Borrower&#8221; shall be deemed to include their respective heirs, executors, successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All notices which Holder or Borrower may be required or permitted to give hereunder shall be made in the same manner as set forth in Section 11.5 of the Loan Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event any one or more of the provisions hereof shall be invalid, illegal or unenforceable in any respect, the validity of the remaining provisions hereof shall be in no way affected, prejudiced or disturbed thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower acknowledges that Holder may, in its sole discretion, sell all or any part of its interest in the Loan evidenced by this Note, including, without limitation, for purposes of effecting a Securitization.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary contained in this Note or any other Loan Documents, to the fullest extent permitted by applicable law, the Holder&#8217;s rights hereunder shall be reinstated and revived, and the enforceability of this Note and the other Loan Documents shall continue, with respect to any amount at any time paid on account of the Loan which thereafter shall be required to be restored by Holder pursuant to a court order or judgment (whether or not final or non-appealable), as though such amount had not been paid.  The rights of Holder created or granted herein and the enforceability of the Loan Documents at all times shall, to the fullest extent permitted by applicable law, remain effective to cover the full amount of the Loan even though the Loan, including any part thereof or any other security or guaranty therefor, may be or hereafter may become invalid or otherwise unenforceable as against any other party and whether or not any other party shall have any personal liability with respect thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower and Holder, by acceptance of this Note, hereby agree that the Loan Documents supersede any prior oral or written agreements of the parties; without limiting the generality of the foregoing, in the event of conflict between the terms of this Note and the terms of the Loan Agreement, the terms of the Loan Agreement shall prevail.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Time is of the essence for the performance of each and every covenant of the parties hereunder or under the other Loan Documents.  No excuse, delay, act of God, or other reason, whether or not within the control of Borrower or Holder (as the case may be), shall operate to defer, reduce or waive Borrower&#8217;s or Holder&#8217;s (as the case may be) performance of any such covenant or obligation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;(END OF PAGE)</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, Borrower, intending to be legally bound hereby, has duly executed this Note the day and year first above written.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">BORROWER</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEX-GEN WOODLANDS, L.P.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware limited partnership</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Lex-Gen Woodlands GP, LLC, a </font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Delaware limited liability company </font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">and its sole general partner</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Julia P. Gregory, Vice President</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sCD909E3BA76A10098A0D9B67414A0C02"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">GUARANTY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS GUARANTY (this </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Guaranty&#8221;</font><font style="font-family:inherit;font-size:12pt;">), dated as of April 21, 2004, is made and entered into by LEXICON GENETICS INCORPORATED, a Delaware corporation (</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Guarantor&#8221;</font><font style="font-family:inherit;font-size:12pt;">), in favor of iSTAR FINANCIAL INC., a Maryland corporation (</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Lender&#8221;</font><font style="font-family:inherit;font-size:12pt;">), with an address for notice hereunder of 1114 Avenue of the Americas, 27</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, New York, New York 10036.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, Lex-Gen Woodlands, L.P., a Delaware limited partnership (</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Borrower</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">), and Lender have entered into a certain Loan and Security Agreement of even date herewith (as the same may be amended, modified, supplemented or restated from time to time, the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Loan Agreement&#8221;</font><font style="font-family:inherit;font-size:12pt;">). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, Lender has required, as a condition to making the Loan and entering into and executing the Loan Agreement and the other Loan Documents, that Guarantor enter into this Guaranty.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, Guarantor directly or indirectly owns all of the ownership interests in the Borrower and will benefit from the making of the Loan and the financial accommodations extended to Borrower pursuant to the Loan Agreement and the other Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:inherit;font-size:12pt;">, in consideration for the extension of credit and other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, and to induce Lender to extend credit to Borrower, Guarantor does hereby unconditionally, absolutely and irrevocably guarantee to Lender, its successors and assigns, the due payment, fulfillment and performance of the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Guaranteed Obligations&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;(as hereinafter defined).  Guarantor, hereby irrevocably and unconditionally covenants and agrees that it is liable for and shall pay, the Guaranteed Obligations as primary obligor, this Guaranty being upon the following terms and conditions:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  All capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Loan Agreement.  As used herein, the term </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Guaranteed Obligations&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means the full, complete and punctual observance, performance, payment and satisfaction of all of the Borrower&#8217;s Obligations.  The failure by Guarantor to pay or perform any Guaranteed Obligations, after expiration of any applicable notice and cure periods provided to Borrower, without duplication thereof, or any other covenant, agreement or obligation of Guarantor under this Guaranty or the inaccuracy when made, or deemed made, of any representations, certifications and warranties of Guarantor in this Guaranty or in any certificate, agreement or document provided by, or on behalf of Guarantor, pursuant to this Guaranty or any of the other Loan Documents shall constitute an </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;">Event of Default</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;for purposes of this Guaranty and the Loan Agreement.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Continuing Guaranty</font><font style="font-family:inherit;font-size:12pt;">.  This is an irrevocable, absolute, continuing guaranty of payment and performance.  This Guaranty may not be revoked by Guarantor and shall continue to be effective with respect to the Guaranteed Obligations arising or created after any attempted revocation by Guarantor and after Guarantor&#8217;s dissolution (in which event this Guaranty shall be binding upon Guarantor&#8217;s successors and assigns).  It is the intent of Guarantor that the obligations and liabilities of Guarantor hereunder are absolute and unconditional under any and all circumstances and that until the Guaranteed Obligations are fully, finally and indefeasibly satisfied, such obligations and liabilities shall not be discharged or released in whole or in part, by any act or occurrence which might, but for the provisions of this Guaranty, be deemed a legal or equitable discharge or release of Guarantor.  Each and every default in payment of any amounts due or performance of any obligation required under this Guaranty shall give rise to a separate cause of action hereunder, and separate suits may be brought hereunder as each cause of action arises, or, in the discretion of Lender, may be brought as a consolidated suit or suits. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waivers</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">Guarantor hereby assents to all terms and agreements heretofore or hereafter made by Borrower with Lender, and, to the fullest extent permitted by applicable law, waives notice of:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:12pt;">Any loans or advances made by Lender to Borrower under the Loan Documents;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:12pt;">The present existence or future incurring of any of the indebtedness pursuant to the Note or any future modifications thereof or any terms or amounts thereof or any Guaranteed Obligations or any terms or amounts thereof;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:12pt;">The obtaining or release of any guaranty or surety agreement (in addition to this Guaranty), pledge, assignment, or other security for any of the indebtedness evidenced by the Note, or any Guaranteed Obligations; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:12pt;">Notice of protest, default, notice of intent to accelerate and notice of acceleration in relation to any instrument relating to the indebtedness evidenced by the Note or any Guaranteed Obligations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">Guarantor hereby waives, to the fullest extent permitted by applicable law, any rights and defenses which such Guarantor might have as a result of any representation, warranty or statement made by Lender or its agents to such Guarantor in order to induce Guarantor to execute this Guaranty.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:12pt;">Regardless of whether Guarantor may have made any payments to Lender, until the Loan is indefeasibly paid in full and except as set forth in Section 10 hereof, Guarantor hereby waives, to the fullest extent permitted by applicable law: (i) all rights of subrogation, indemnification, contribution and any other rights to collect reimbursement from Borrower or any other party for any sums paid to Lender, whether contractual or arising by operation of law (including the United States Bankruptcy Code or any successor or similar statute) or otherwise, (ii) all rights to enforce any remedy that Lender may have against Borrower, and (iii) all rights to participate in any security now or later to be held by Lender for the Loan.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:12pt;">Guarantor further waives, to the fullest extent permitted by applicable law, any defense to the recovery by Lender against Guarantor of any deficiency or otherwise to the enforcement of this Guaranty or any security for this Guaranty based upon Lender&#8217;s election of any remedy against Guarantor or Borrower, including the defense to enforcement of this Guaranty by virtue of any </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;">anti-deficiency</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;statutes and their application following a non-judicial foreclosure sale.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Events and Circumstances Not Reducing or Discharging Guarantor&#8217;s Obligations</font><font style="font-family:inherit;font-size:12pt;">.  Guarantor hereby consents and agrees to each of the following, and agrees that Guarantor&#8217;s obligations under this Guaranty shall not be released, diminished, impaired, reduced or adversely affected by any of the following, and waives, to the fullest extent permitted by applicable law, any rights and defenses (excluding the rights to notice, if any, as herein provided or as required by law) which Guarantor might have otherwise as a result of or in connection with any of the following:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">any and all extensions, modifications, adjustments, indulgences, forbearances or compromises that might be granted or given by Lender to Borrower, including, without limitation, any and all amendments, modifications, supplements, extensions or restatements of any of the Loan Documents;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">the insolvency, bankruptcy, rearrangement, adjustment, composition, liquidation, disability, dissolution or lack of power of Borrower or any other party at any time liable for the payment of all or part of the indebtedness evidenced by the Note or any Guaranteed Obligations; or any dissolution, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">consolidation or merger of Borrower or Guarantor, or any sale, lease or transfer of any or all of the assets of Borrower or Guarantor, or any changes in the ownership, partners or members of Borrower or Guarantor;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:12pt;">the invalidity, illegality or unenforceability of all or any part of the indebtedness evidenced by the Note or any Guaranteed Obligations, or any document or agreement executed in connection with the indebtedness evidenced by the Note or any Guaranteed Obligations, for any reason whatsoever, including, without limitation, the fact that the indebtedness evidenced by the Note, or any part thereof exceeds the amount permitted by law, the act of creating the indebtedness evidenced by the Note or any Guaranteed Obligations or any part thereof is </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ultra</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">vires</font><font style="font-family:inherit;font-size:12pt;">, the representatives executing the Note or the other Loan Documents or otherwise creating the indebtedness evidenced by the Note or any Guaranteed Obligations acted in excess of their authority, the indebtedness evidenced by the Note violates applicable usury laws, Borrower has valid defenses, claims or offsets (whether at law, in equity or by agreement) which render the indebtedness evidenced by the Note or any Guaranteed Obligations wholly or partially uncollectible from Borrower, the creation, performance or repayment of the indebtedness evidenced by the Note or any Guaranteed Obligations is illegal, uncollectible, legally impossible or unenforceable, or any of the other Loan Documents pertaining to the indebtedness evidenced by the Note or any Guaranteed Obligations are irregular or not genuine or authentic; provided, however, the foregoing shall not prohibit Guarantor from (i) asserting a defense of performance, (ii) asserting a compulsory counterclaim on an action brought under this Guaranty, or (iii) subject to the remaining terms of the Loan Documents, bringing a separate action against Lender for breaches of Lender&#8217;s obligations under the Loan Documents;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:12pt;">the taking or accepting of any other security, collateral or guaranty, or other assurance of the payment, for all or any of the indebtedness evidenced by the Note or any Guaranteed Obligations;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:12pt;">any release, surrender or exchange of any collateral, property or security, at any time existing in connection with, or assuring or securing payment of, all or any part of the indebtedness evidenced by the Note or the Guaranteed Obligations;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:12pt;">the failure of Lender or any other party to exercise diligence or reasonable care in the preservation, protection, enforcement, sale or other handling or treatment of all or any part of such collateral, property or security;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:12pt;">the fact that any collateral, security, security interest or lien contemplated or intended to be given, created or granted as security for the repayment of the indebtedness evidenced by the Note or Guaranteed Obligations shall not be properly perfected or created, or shall prove to be unenforceable or subordinate to any other security interest or lien, it being recognized and agreed by Guarantor that Guarantor is not entering into this Guaranty in reliance on, or in contemplation of the benefits of, the validity, enforceability, collectibility or value of any of the collateral for the indebtedness evidenced by the Note or the Guaranteed Obligations; or</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(h)</font><font style="font-family:inherit;font-size:12pt;">any payment by Borrower to Lender is held to constitute a preference under the Bankruptcy Code, or for any reason Lender is required to refund such payment or pay such amounts to such Borrower, or any other Person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">It is the unambiguous and unequivocal intention of Guarantor that Guarantor shall be obligated to pay and perform the Guaranteed Obligations when due, notwithstanding any occurrence, circumstance, event, action or omission whatsoever, whether contemplated or uncontemplated, and whether or not otherwise or particularly described herein, except for the full and final payment and satisfaction of all Guaranteed Obligations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payment by Guarantor</font><font style="font-family:inherit;font-size:12pt;">.  If the Guaranteed Obligations, or any part thereof, are not punctually paid or performed (following the expiration of any applicable notice and cure periods), as the case may be, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Guarantor shall, immediately on demand and without protest or notice of protest, pay the amount due thereon to Lender, at its address set forth above or as otherwise designated by Lender.  Such demand(s) may be made at any time coincident with or after the time for payment or performance of all or part of the Guaranteed Obligations.  Such demand shall be deemed made if given in accordance with Section 18 hereof.  It shall not be necessary for Lender, in order to enforce such payment or performance by Guarantor, first to institute suit or exhaust its remedies against Borrower, or others liable to pay or perform such Guaranteed Obligations, or to enforce its rights against any security which shall ever have been given to secure the Guaranteed Obligations.  Lender shall not be required to mitigate damages or take any other action to reduce, collect or enforce the indebtedness evidenced by the Note or Guaranteed Obligations.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indebtedness or Other Obligations of Guarantor</font><font style="font-family:inherit;font-size:12pt;">.  If Guarantor is or becomes liable for any indebtedness owed by Borrower to Lender by endorsement or otherwise than under this Guaranty, such liability shall not be in any manner impaired or affected by this Guaranty, and the rights of Lender hereunder shall be cumulative of any and all other rights that Lender may ever have against Guarantor.  The exercise by Lender of any right or remedy hereunder or under any other instrument or at law or in equity shall not preclude the concurrent or subsequent exercise of any other instrument or remedy at law or in equity and shall not preclude the concurrent or subsequent exercise of any other right or remedy.  Further, without in any way diminishing or limiting the generality of the foregoing, it is specifically understood and agreed that this Guaranty is given by Guarantor as an additional guaranty to any and all guarantees hereafter executed and delivered to Lender by Guarantor in favor of Lender relating to the indebtedness and obligations of Borrower to Lender, and nothing herein shall ever be deemed to replace or be in lieu of any other of such previous or subsequent guarantees.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Application of Payments</font><font style="font-family:inherit;font-size:12pt;">.  If, at any time, there is any indebtedness or obligations (or any portion thereof) of Borrower to Lender which is not guaranteed by Guarantor, Lender, without in any manner impairing its rights hereunder, may, at its option, apply all amounts realized by Lender from collateral or security held by Lender first to the payment of such unguaranteed indebtedness or obligations, with the remaining amounts, if any, to then be applied to the payment of the indebtedness or obligations guaranteed by Guarantor.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Suits, Releases of Settlements with Others</font><font style="font-family:inherit;font-size:12pt;">.  Guarantor agrees that Lender, in its sole discretion, may bring suit against any other guarantor without impairing the rights of Lender or its successors and assigns against Guarantor or any other guarantor of the Guaranteed Obligations; and Lender may settle or compromise with such other guarantor for such sum or sums as Lender may see fit and release such other guarantor from all further liability to Lender, all without impairing its rights against Guarantor.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warranties, Representations and Covenants</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">Guarantor warrants and represents, as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:12pt;">Guarantor has received, or will receive, direct or indirect benefit from the making of this Guaranty, the making of the Loan and the entering into and execution of the Loan Agreement and the Loan Documents in connection therewith;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:12pt;">Guarantor is familiar with, and has independently reviewed the financial condition of the Borrower and is familiar with the value of any and all collateral intended to be created as security for the payment and performance of the indebtedness evidenced by the Note and the Guaranteed Obligations, and Guarantor assumes full responsibility for keeping fully informed as to such matters in the future; however, Guarantor is not relying on such financial condition or the collateral as an inducement to enter into this Guaranty; and</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:12pt;">All financial statements concerning Guarantor which have been or will hereafter be furnished by Guarantor or Borrower to Lender pursuant to the Loan Documents, have been or will be prepared in accordance with GAAP consistently applied (except as disclosed therein, to the extent Lender approves such disclosure; provided that Lender&#8217;s approval shall not be required so long as (a) Guarantor is a reporting company under the Exchange Act, and (b) Guarantor&#8217;s financial statements are audited by a so-called &#8220;Big-4&#8221; accounting firm) and, in all material respects, present fairly the financial condition of the Persons covered thereby as at the dates thereof and the results of their operations for the periods then ended.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:12pt;">No ERISA Affiliate of Guarantor maintains or contributes to, or has any obligation under, any Employee Benefit Plans.  Guarantor is not an </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;">employee benefit plan</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;(within the meaning of section 3(3) of ERISA) to which ERISA applies and Guarantor&#8217;s assets do not constitute plan assets.  No actions, suits or claims under any laws and regulations promulgated pursuant to ERISA are pending or, to Guarantor&#8217;s knowledge, threatened against Guarantor.  Guarantor has no knowledge of any material liability incurred by Guarantor which remains unsatisfied for any taxes or penalties with respect to any employee benefit plan or any Multiemployer Plan, or of any lien which has been imposed on Guarantor&#8217;s assets pursuant to section 412 of the Code or sections 302 or 4068 of ERISA.  The Loan, the execution, delivery and performance of the Loan Documents and the transactions contemplated by this Guaranty do not constitute a non-exempt prohibited transaction under ERISA or the Code.  Guarantor is an </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;">operating company</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;as defined in ERISA.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:144px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(v)</font><font style="font-family:inherit;font-size:12pt;">As of the date hereof, and after giving effect to this Guaranty and the contingent obligations evidenced hereby, Guarantor is and expects to be solvent at all times, and has and expects to have assets at all times which, fairly valued, exceed his or its obligations, liabilities and debts, and has and expects to have property and assets at all times sufficient to satisfy and repay its obligations and liabilities.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">Guarantor covenants and agrees that, for so long as this Guaranty remains in effect, Guarantor shall not liquidate, wind-up or dissolve itself (or suffer any liquidation or dissolution).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subordination</font><font style="font-family:inherit;font-size:12pt;">.  If, for any reason Borrower is now or hereafter becomes indebted to Guarantor (such indebtedness and all interest thereon being referred to as the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Affiliated Debt&#8221;</font><font style="font-family:inherit;font-size:12pt;">), such Affiliated Debt shall, at all times, be subordinate in all respects to the full payment and performance of the obligations evidenced by the Note, and Guarantor shall not be entitled to enforce or receive payment thereof until all of the obligations evidenced by the Note have been fully paid.  Guarantor agrees that any liens, mortgages, deeds of trust, security interests, judgment liens, charges or other encumbrances upon Borrower&#8217;s assets securing payment of the Affiliated Debt shall be and remain subordinate and inferior to any liens, security interests, judgment liens, charge or other encumbrances upon Borrower&#8217;s assets securing the payment of the obligations evidenced by the Note and Guaranteed Obligations, and without the prior written consent of Lender, Guarantor shall not exercise or enforce any creditor&#8217;s rights of any nature against Borrower to collect the Affiliated Debt (other than demand payment therefor).  In the event of the receivership, bankruptcy, reorganization, arrangement, debtor&#8217;s relief or other insolvency proceedings involving Borrower as a debtor, to the fullest extent permitted by law, Lender shall have the right and authority, either in its own name or as attorney-in-fact for Guarantor, to file such proof of debt claim, petition or other documents and to take such other steps as are necessary to prove its rights hereunder.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver of Subrogation</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provision of this Guaranty to the contrary, until the Loan is indefeasibly paid in full, Guarantor hereby waives any claim or other rights which Guarantor may now have or hereafter acquire against Borrower or any other guarantor of all or any of the obligations that arise from the existence or performance of Guarantor&#8217;s obligations under this Guaranty (all such claims and rights are referred to as </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Guarantor&#8217;s Conditional Rights&#8221;</font><font style="font-family:inherit;font-size:12pt;">), including, without limitation, any right of subrogation, reimbursement, exoneration, contribution, or indemnification, any right to participate in any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">claim or remedy of Lender against Borrower or any security or collateral which Lender now has or hereafter acquires, whether or not such claim, remedy or right arises in equity or under contract, statute (including the Bankruptcy Code or any successor or similar statute) or common law, by any payment made hereunder or otherwise, including without limitation, the right to take or receive from Borrower, directly or indirectly, in cash or other property or by setoff or in any other manner, payment or security on account of such claim or other rights.  If, notwithstanding the foregoing provisions, any amount shall be paid to Guarantor on account of Guarantor&#8217;s Conditional Rights and either (i) such amount is paid to Guarantor at any time when the Guaranteed Obligations shall not have been paid or performed in full, or (ii) regardless of when such amount is paid to Guarantor, any payment made by Borrower to Lender is subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be repaid by Lender or paid over to a trustee, receiver or any other entity, whether under any bankruptcy act or otherwise (such payment, a </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Preferential Payment&#8221;</font><font style="font-family:inherit;font-size:12pt;">), then such amount paid to Guarantor shall be held in trust for the benefit of Lender and shall forthwith be paid to Lender to be credited and applied upon the Guaranteed Obligations, whether matured or unmatured, in such order as Lender, in its sole and absolute discretion, shall determine.  The foregoing waivers shall be effective until the Guaranteed Obligations have been paid and performed in full.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Impairment of Subrogation Rights; Waivers of Rights Under the Anti-Deficiency Rules</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">Guarantor agrees that upon the occurrence and during the continuance of an Event of Default under the Loan Documents, Lender in its sole discretion, without prior notice to or consent of Guarantor, may elect to (i) foreclose either nonjudicially or judicially against any real or personal property security (including, without limitation, the Mortgaged Property) it holds for the obligations evidenced by the Note or any Guaranteed Obligations, or any part thereof, (ii) accept any transfer or assignment of any such security in lieu of foreclosure, (iii) compromise or adjust any part of such obligations, or (iv) make any other accommodation with Borrower or Guarantor, or exercise any other remedy against Borrower or any collateral or security.  No such action by Lender will release or limit the liability of Guarantor to Lender, who shall remain liable under this Guaranty after the action, even if the effect of that action is to deprive Guarantor of the right to collect reimbursement from Borrower or any other person for any sums paid to Lender or Guarantor&#8217;s rights of subrogation, contribution, or indemnity against Borrower or any other person.  Without limiting the foregoing, it is understood and agreed that on any foreclosure or assignment in lieu of foreclosure of any collateral or security held by Lender, such security will no longer exist and that any right that Guarantor might otherwise have, on full payment of the Guaranteed Obligations by Guarantor to Lender, to participate in any such security or to be subrogated to any rights of Lender with respect to any such security will be nonexistent; nor shall Guarantor be deemed to have any right, title, interest or claim under any circumstances in or to any real or personal property held by Lender or any third party following any foreclosure or assignment in lieu of foreclosure of any such security.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">Guarantor understands and acknowledges that if Lender forecloses judicially or nonjudicially against any real property security for Borrower&#8217;s obligations, such foreclosure could impair or destroy any right or ability that Guarantor may have to seek reimbursement, contribution, or indemnification for any amounts paid by Guarantor under this Guaranty.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:12pt;">Without limiting the foregoing, Guarantor waives, to the fullest extent permitted by applicable law, all rights and defenses arising out of an election of remedies by Lender, even though that election of remedies, such as nonjudicial foreclosure with respect to security for a guaranteed obligation, may adversely affect Guarantor&#8217;s rights of subrogation and reimbursement against Borrower.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:12pt;">Guarantor intentionally, freely, irrevocably and unconditionally waives and relinquishes, to the fullest extent permitted by applicable law, all rights which may be available to it under any provision of applicable law to limit the amount of any deficiency judgment or other judgment which may be obtained against Guarantor under this Guaranty to not more than the amount by which the unpaid </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Guaranteed Obligations plus all other indebtedness due from Borrower under the Loan Documents exceeds the fair market value or fair value of any real or personal property securing said obligations and any other indebtedness due from Borrower under the Loan Documents, including, without limitation, all rights to an appraisement of, judicial or other hearing on, or other determination of the value of said property.  Guarantor acknowledges and agrees that, as a result of the foregoing waiver, Lender may be entitled to recover from Guarantor an amount which, when combined with the value of any real or personal property foreclosed upon by Lender (or the proceeds of the sale of which have been received by Lender) and any sums collected by Lender from Borrower or other Persons, might exceed the amount of the Guaranteed Obligations plus all other indebtedness due from Borrower under the Loan Documents.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:12pt;">Guarantor understands and agrees that Lender may have the ability to pursue Guarantor for a judgment on the Guaranteed Obligations without having first foreclosed on the real property security for such Guaranteed Obligations, that Lender may have the ability to sue Guarantor for a deficiency judgment on the Guaranteed Obligations after a non-judicial foreclosure sale or, regardless of any election of remedies by Lender, if the Guaranteed Obligations or any of the other indebtedness of Borrower to Lender under the Loan Documents is considered to have been provided by a vendor to a buyer and to evidence part of the purchase price for the real property security, and that Lender may be able to recover from Borrower an amount which, when combined with the fair market value of the property acquired by Lender in a foreclosure sale or the proceeds of the foreclosure sale received by Lender, might exceed the amount of the Guaranteed Obligations due and owing by Guarantor and the amounts payable under the Loan Documents.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:96px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:12pt;">Without limiting any of the other waivers and provisions set forth in this Guaranty, Guarantor waives all rights and defenses that Guarantor may have because Borrower&#8217;s debt is secured by real property; this means, among other things:  (a) Lender may collect from Guarantor without first foreclosing on any real or personal property collateral pledged by Borrower; (b) the amount of the Guaranteed Obligations may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the collateral is worth more than the sale price; (c) Lender may collect from Guarantor even if Lender, by foreclosing on the real property collateral, has destroyed any right Guarantor may have to collect from Borrower.  This is an unconditional and irrevocable waiver of any rights and defenses Guarantor may have because the indebtedness evidenced by the Note is secured by real property.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing or any provisions of Section 12(a) hereof, nothing contained in this Guaranty shall in any way be deemed to imply that any other state&#8217;s law other than the law of the State of New York shall govern this Guaranty or any of the Loan Documents in any respect, except as expressly set forth therein, including with respect to the exercise of Lender&#8217;s remedies under the Loan Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision herein to the contrary, upon the indefeasible payment in full of the Note, Guarantor shall have all rights of subrogation available at law or in equity.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit</font><font style="font-family:inherit;font-size:12pt;">.  This Guaranty is for the benefit of Lender, its successors and assigns, and in the event of an assignment by Lender, its successors and assigns, of the obligations evidenced by the Note, or any part or parts thereof, the rights and benefits hereunder, to the extent applicable to the obligations so assigned, shall be transferred with such obligations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Release if Preference, Refund, Etc.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In the event any payment by Borrower to Lender is determined to be a preferential payment under any applicable bankruptcy or insolvency laws, or if for any reason Lender is required to refund part or all of any payment or pay the amount thereof to any other party, such repayment by Lender to Borrower shall not constitute a release of Guarantor from any liability hereunder, and Guarantor agrees to pay such amount to Lender upon demand to the extent such amount constitutes a Guaranteed Obligation.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Right of Set-Off</font><font style="font-family:inherit;font-size:12pt;">.  In addition to any other rights now or hereafter granted under applicable law and not by way of limitation of any such rights, upon Guarantor&#8217;s failure to pay the Guaranteed Obligations, after demand by Lender, Lender is hereby authorized at any time and from time to time, without notice to Guarantor or to any other person, to set off and to appropriate and to apply any and all deposits (general or special) and any other indebtedness at any time held or owing by Lender to or for the credit or the account of Guarantor against or on account of the obligations evidenced by the Note.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consent to Use of Logo</font><font style="font-family:inherit;font-size:12pt;">.  Guarantor hereby consents to the use by Lender of Guarantor&#8217;s logo, solely for the purpose specified, and in accordance with the terms and conditions set forth, in Section 11.12 of the Loan Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">GOVERNING LAW</font><font style="font-family:inherit;font-size:12pt;">.  PURSUANT TO SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, GUARANTOR AGREES THAT THIS GUARANTY AND ALL RIGHTS, OBLIGATIONS AND LIABILITIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise specifically provided herein, any notice or other communication required or permitted to be given shall be in writing addressed to the respective party as set forth below and may be personally served, telecopied (with request for confirmation) or sent by overnight courier service or United States registered mail return receipt requested, postage prepaid.  Any notice so given shall be deemed effective upon delivery or on refusal or failure of delivery during normal business hours.  Notices shall be addressed to the parties at the following addresses or to such other address as the party addressed shall have previously designated by written notice to the serving party, given in accordance with this Section 18.  </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">If to Guarantor:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lexicon Genetics Incorporated</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">8800 Technology Forest Place</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">The Woodlands, Texas  77381-1160</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: General Counsel</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: 281-863-3000</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile: 281-863-8010</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">With a copy to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Andrews Kurth LLP</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">600 Travis, Suite 4200</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Houston, Texas  77002</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Michael A. Boyd, Esq. </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: 713-220-3921</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile: 713-238-7138</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">If to Lender:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iStar Financial Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1114 Avenue of the Americas, 27</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">New York, New York 10036</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Chief Operating Officer</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: 212-930-9400</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile: 212-930-9494</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">With a copy to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iStar Financial Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1114 Avenue of the Americas, 27</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">New York, New York 10036</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Nina B. Matis, Esq./General Counsel</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: 212-930-9406</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile: 212-930-9492</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">With a copy to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iStar Asset Services Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">180 Glastonbury Boulevard, Suite 201</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Glastonbury, Connecticut  06033</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: President</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone:  860-815-5900</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile:   860-815-5901</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">With a copy to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Katten Muchin Zavis Rosenman</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">525 West Monroe Street, Suite 1600</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chicago, Illinois 60661-3693</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Gregory P.L. Pierce, Esq.</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">208972-002289</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: 312-902-5541</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile: 312-902-1061</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consent of Jurisdiction/Service of Process</font><font style="font-family:inherit;font-size:12pt;">.  IN ACCORDANCE WITH SECTION 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, GUARANTOR HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE COUNTY OF NEW YORK, STATE OF NEW YORK AND IRREVOCABLY AGREES THAT, SUBJECT TO LENDER&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS GUARANTY OR THE OTHER LOAN DOCUMENTS SHALL BE LITIGATED IN SUCH COURTS.  GUARANTOR ACCEPTS FOR ITSELF AND IN CONNECTION WITH THIS GUARANTY AND THE OTHER LOAN DOCUMENTS, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS GUARANTY, THE NOTE, SUCH OTHER LOAN DOCUMENTS OR SUCH OBLIGATION.  GUARANTOR ACKNOWLEDGES AND AGREES THAT SERVICE OF PROCESS IN ANY SUCH ACTION, SUIT OR PROCEEDING WILL BE DEEMED EFFECTIVE.  SERVICE OF PROCESS ON GUARANTOR IF PERSONALLY SERVED OR SERVED IN ACCORDANCE WITH SECTION 17 ABOVE OR AT SUCH OTHER ADDRESS AS SUCH GUARANTOR MAY HAVE FURNISHED AS TO ITSELF TO THE SERVING PARTY BY LIKE NOTICE, OR TO THE LAST KNOWN ADDRESS OF SUCH GUARANTOR PROVIDED THEREUNDER.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">WAIVER OF JURY TRIAL</font><font style="font-family:inherit;font-size:12pt;">.  GUARANTOR AND LENDER HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS GUARANTY, ANY OF THE LOAN DOCUMENTS, OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION AND THE RELATIONSHIP THAT IS BEING ESTABLISHED.  GUARANTOR AND LENDER ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF GUARANTOR OR LENDER.  THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL&#8209;ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">OTHER COMMON LAW AND STATUTORY CLAIMS.  GUARANTOR AND LENDER ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS GUARANTY AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS.  GUARANTOR AND LENDER FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.  THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS GUARANTY, THE LOAN DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOAN.  IN THE EVENT OF LITIGATION, THIS GUARANTY MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:48px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">21.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:12pt;">.  Guarantor agrees to fully and punctually pay all costs and expenses, including, without limitation, reasonable attorneys&#8217; fees, court costs and costs of appeal, which Lender may incur in enforcing and collecting the Guaranteed Obligations.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[Remainder of Page Intentionally Left Blank;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page Follows]</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:12pt;">, the undersigned has executed this Guaranty as of the day and year first above written.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">GUARANTOR</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">:</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEXICON GENETICS INCORPORATED</font><font style="font-family:inherit;font-size:12pt;">, a Delaware corporation</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:  </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Julia P. Gregory, Chief Financial Officer and</font></div><div style="line-height:120%;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Executive Vice President</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exh231ernst_youngconsent10.htm
<DESCRIPTION>CONSENT OF ERNST & YOUNG LLP
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC72300BD5DFE82383295BC775BAF1B3D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-8 Nos. 333-41532, 333-168678, 333-183020, 333-210145 and 333-217873) pertaining to the 2017 Equity Incentive Plan and to the 2017 Non-Employee Directors' Equity Incentive Plan of Lexicon Pharmaceuticals, Inc., and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-3 Nos. 333-216825 and 333-220492) of Lexicon Pharmaceuticals, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">, with respect to the consolidated financial statements of Lexicon Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Lexicon Pharmaceuticals, Inc., included in this annual report (Form 10-K) of Lexicon Pharmaceuticals, Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Houston, Texas</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sED194FBED1C648473143BC7760058C96"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Lonnel Coats, certify that:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:5%;"></td><td style="width:6%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:54%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lonnel Coats</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6E19EFB66D84B8A1D0B6BC7760B13B62"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Jeffrey L. Wade, certify that:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:5%;"></td><td style="width:6%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:54%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey L. Wade</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Office</font><font style="font-family:inherit;font-size:10pt;">r</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE AND PRINCIPAL FINANCIAL OFFICERS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s177C929B2FB0C11BD61DBC77615D8951"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.1875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:8%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon's Annual Report on Form 10-K for the year ended December 31, 2017, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1st day of March, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:55%;"></td><td style="width:4%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lonnel Coats</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:55%;"></td><td style="width:4%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey L. Wade</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>lxrx-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:ae5db14f05664e51a6f45a696938c5ed,x:00ab3a343ba04ee697f386b066dad82c-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20171231" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="lxrx-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_invest_InvestmentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_invest_InvestmentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2001Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2001-07-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2004Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2004-04-01</xbrli:startDate>
			<xbrli:endDate>2004-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-01</xbrli:startDate>
			<xbrli:endDate>2014-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4SDDec">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2007Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2007-06-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3SDSept">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-05-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1BegPeriod_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-01</xbrli:startDate>
			<xbrli:endDate>2015-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Oct1toOct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2005Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2005-07-01</xbrli:startDate>
			<xbrli:endDate>2005-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="ratio">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-27CB801ACBF78ADE4250FE7E7F7CDAE3">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-3116C5CB5A356031F2B3FE7E7F7CEB8B">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-6AE42EA52E94B242A508FE7E7F7CE1C0">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-2C9FE70D58BBF04EF06EFE7E7F7C5A50">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-65511D8AEEE625DD7DAAFE7E7F7C94E5">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-40EEAE89A4278BD2C824FE7E7F7CC921">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-912AD543C4B2654CE5A9FE7E7F7CA415">0001062822</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1" decimals="0" id="Fact-BA403914F9DE932D019FFE7E7F7C6E84" unitRef="shares">105591828</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-6034EC732A3D95A6DD97FE7E7F7C8FEB">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-29E1C9599328C4E9FD64FE7E7F7C4F81">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="0" id="Fact-A7264B488F6D6BE6170EFE7E7F7C0081" unitRef="usd">715300000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-26FF6A1D0FF92C4153CCFE7E7F7C9837">LEXICON PHARMACEUTICALS, INC./DE</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-8C9AD7D73BDF0B11CF4FFE7E7F7C4372">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-CC8ED21B583F0B882A9CFE7E7F7CDC72">No</dei:EntityWellKnownSeasonedIssuer>
	<lxrx:AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets contextRef="I2017Q1SD" decimals="-5" id="Fact-93A12AF1E5AFA7E793A58B77A16BDED9" unitRef="usd">6100000</lxrx:AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets>
	<lxrx:AdjustmenttoAccumulatedDeficit contextRef="I2017Q1SD" decimals="-5" id="Fact-AB1623DE8D1AD3D3543C8B77A15CBB61" unitRef="usd">2000000</lxrx:AdjustmenttoAccumulatedDeficit>
	<lxrx:BuildingsCollateral contextRef="FI2017Q4" decimals="-5" id="Fact-826BAA61108D09A9B8E2FE7E7F7CCA84" unitRef="usd">59200000</lxrx:BuildingsCollateral>
	<lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BD0F1F29211246645F82FE7E7F7C5270" unitRef="usd">5927000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
	<lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8C6A72CD5916DCBB73E6FE7E7F7C9BB2" unitRef="usd">-703000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
	<lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CB1987ED9DA00819796AFE7E7F7CF570" unitRef="usd">2101000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
	<lxrx:CoelacanthGoodwill contextRef="I2001Q3SD" decimals="-5" id="Fact-7ADFFABF2641FB12FA43FE7E7F7C1141" unitRef="usd">25800000</lxrx:CoelacanthGoodwill>
	<lxrx:CoelacanthPurchasePrice contextRef="I2001Q3SD" decimals="-5" id="Fact-2DADF1CEDE1869A0535CFE7E7F7C6BC0" unitRef="usd">36000000</lxrx:CoelacanthPurchasePrice>
	<lxrx:CommonStockSharesAuthorizedAfterReverseStockSplit contextRef="I2015Q2SD" decimals="-6" id="Fact-EEB1630C73831D301E0CFE7E7F7CC5D0" unitRef="shares">225000000</lxrx:CommonStockSharesAuthorizedAfterReverseStockSplit>
	<lxrx:CommonStockSharesAuthorizedBeforeReverseStockSplit contextRef="I2015Q2SD" decimals="-6" id="Fact-C7B5911EBCC24DFC37FBFE7E7F7C6D3B" unitRef="shares">900000000</lxrx:CommonStockSharesAuthorizedBeforeReverseStockSplit>
	<lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4" decimals="4" id="Fact-36410915DEAD620B42E9FE7E7F7CE9A5" unitRef="ratio">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
	<lxrx:DeferredTaxAssetremeasured contextRef="FI2017Q4" decimals="-5" id="Fact-C4DAE752E4187C81D7A1BA5DAD9E236E" unitRef="usd">171400000</lxrx:DeferredTaxAssetremeasured>
	<lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug contextRef="FI2016Q4" decimals="-3" id="Fact-6F89E9DEBF6CDE27D11BFE7E7F7C91A5" unitRef="usd">24233000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
	<lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug contextRef="FI2017Q4" decimals="-3" id="Fact-7BFC1509156DD88CFDB9FE7E7F7CF2DA" unitRef="usd">26524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
	<lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon contextRef="FI2016Q4" decimals="-3" id="Fact-11FD55852CDCA0BE44E5FE7E7F7C6EB2" unitRef="usd">18675000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
	<lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon contextRef="FI2017Q4" decimals="-3" id="Fact-E142BA6BE1E991D75E88FE7E7F7C93E6" unitRef="usd">10896000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
	<lxrx:DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible contextRef="FI2017Q4" decimals="-5" id="Fact-2F2F7C5C94D06339361ED8243DE042AD" unitRef="usd">4000000</lxrx:DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible>
	<lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset contextRef="I2017Q1" decimals="-5" id="Fact-54BAB44F0496FD0F7D6996DA29C9101C" unitRef="usd">8700000</lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent contextRef="FD2015Q4YTD" decimals="2" id="Fact-05E7C6BEBE547BE557B5FE7E7F7C3381" unitRef="ratio">0.01</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent contextRef="FD2016Q4YTD" decimals="2" id="Fact-EC19E6550CBE45216AB9FE7E7F7C46F9" unitRef="ratio">0.01</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent contextRef="FD2017Q4YTD" decimals="2" id="Fact-19FCBA14D84947A9FD99FE7E7F7C9C8E" unitRef="ratio">0.18</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance contextRef="FD2015Q4YTD" decimals="2" id="Fact-1ABAEB036815B911B924FE7E7F7CCE48" unitRef="ratio">0.99</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance contextRef="FD2016Q4YTD" decimals="2" id="Fact-260A836CADEB24995BBBFE7E7F7C05CE" unitRef="ratio">0.99</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance contextRef="FD2017Q4YTD" decimals="2" id="Fact-70856A040C98612CC1ADFE7E7F7C64CB" unitRef="ratio">0.82</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance>
	<lxrx:EntityWideRevenueIpsenPercentage contextRef="FD2016Q4YTD" decimals="2" id="Fact-989617EC953ACC77238F96C3558FFF4A" unitRef="ratio">0.09</lxrx:EntityWideRevenueIpsenPercentage>
	<lxrx:EntityWideRevenueIpsenPercentage contextRef="FD2017Q4YTD" decimals="2" id="Fact-E267C56BF1CFCAD3D61AFE7E7F7C0588" unitRef="ratio">0.18</lxrx:EntityWideRevenueIpsenPercentage>
	<lxrx:EntityWideRevenueSanofiPercentage contextRef="FD2015Q4YTD" decimals="2" id="Fact-9ABD2217F31A20FD59E696C3A39278BE" unitRef="ratio">0.98</lxrx:EntityWideRevenueSanofiPercentage>
	<lxrx:EntityWideRevenueSanofiPercentage contextRef="FD2016Q4YTD" decimals="2" id="Fact-107DC09B99F6802DCB23FE7E7F7C9BE3" unitRef="ratio">0.90</lxrx:EntityWideRevenueSanofiPercentage>
	<lxrx:EntityWideRevenueSanofiPercentage contextRef="FD2017Q4YTD" decimals="2" id="Fact-25CB71E1DC67E5BD99AEFE7E7F7C9E42" unitRef="ratio">0.64</lxrx:EntityWideRevenueSanofiPercentage>
	<lxrx:HoldingsContributionToIcon contextRef="I2007Q2SD" decimals="-6" id="Fact-FE3C88475356872799B7FE7E7F7C5163" unitRef="usd">45000000</lxrx:HoldingsContributionToIcon>
	<lxrx:IpsenMaximumRegulatoryAndCommercialMilestones contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-65FB001FC0E841EEB2C1FE7E7F7C1191" unitRef="usd">13100000</lxrx:IpsenMaximumRegulatoryAndCommercialMilestones>
	<lxrx:IpsenMaximumSalesMilestones contextRef="D2014Q4Oct1toOct31" decimals="-6" id="Fact-E385C03889512D15E6D4FE7E7F7C73EA" unitRef="eur">72000000</lxrx:IpsenMaximumSalesMilestones>
	<lxrx:IpsenMilestonePaymentReceived contextRef="D2016Q3SD" decimals="-5" id="Fact-28FBAC79D64ADF629CF1FE7E7F7CFFEA" unitRef="usd">6400000</lxrx:IpsenMilestonePaymentReceived>
	<lxrx:IpsenMilestonePaymentReceived contextRef="D2017Q4Nov" decimals="-4" id="Fact-A3E8789E476A2DBB0C91A03DA4A96B94" unitRef="usd">3840000</lxrx:IpsenMilestonePaymentReceived>
	<lxrx:IpsenMilestonePaymentReceived contextRef="D2017Q4Oct" decimals="-4" id="Fact-AADA22D1C0736C9793D5A039AC728EB2" unitRef="usd">3840000</lxrx:IpsenMilestonePaymentReceived>
	<lxrx:IpsenMilestonePaymentReceived contextRef="FD2017Q3QTD" decimals="-5" id="Fact-B0654E006009D889C062A038E64E3CBB" unitRef="usd">5100000</lxrx:IpsenMilestonePaymentReceived>
	<lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-F3D0BC28EC690F674214FE7E7F7CBC88" unitRef="usd">100000</lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable>
	<lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-1847A40DCE81FDADCC01FE7E7F7C5E22" unitRef="usd">1700000</lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable>
	<lxrx:IpsenRevenueAllocatedtoLicenseDeliverable contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-54A20B8B914361DBD4B9FE7E7F7C02E2" unitRef="usd">21200000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
	<lxrx:IpsenRevenueAllocatedtoLicenseDeliverable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A3382695D820F7214D64FE7E7F7CD22C" unitRef="usd">1400000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
	<lxrx:IpsenRevenueRecognized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3B2FAD36FF65E71B749FFE7E7F7C8DA2" unitRef="usd">2300000</lxrx:IpsenRevenueRecognized>
	<lxrx:IpsenRevenueRecognized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CEC5AFC3353210E776FEFE7E7F7CF2B6" unitRef="usd">7200000</lxrx:IpsenRevenueRecognized>
	<lxrx:IpsenRevenueRecognized contextRef="FD2017Q4YTD" decimals="-5" id="Fact-03A9ED5F065B3625AB0491AE7F9AF713" unitRef="usd">16100000</lxrx:IpsenRevenueRecognized>
	<lxrx:IpsenTotalPaymentsToDate contextRef="FI2017Q4" decimals="-5" id="Fact-D63BC025D1ACBD2EB017FE7E7F7C037E" unitRef="usd">43700000</lxrx:IpsenTotalPaymentsToDate>
	<lxrx:IpsenTotalUpfrontPayments contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-D8E5E5E25AF728482F30FE7E7F7CE5B5" unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
	<lxrx:Ipsenproductsales contextRef="FD2017Q4YTD" decimals="-5" id="Fact-8A68169C59B955CC7DEB91AF32644575" unitRef="usd">800000</lxrx:Ipsenproductsales>
	<lxrx:LandCollateral contextRef="FI2017Q4" decimals="-5" id="Fact-0CF8220EAA6D0DA1642EFE7E7F7CF8EE" unitRef="usd">2700000</lxrx:LandCollateral>
	<lxrx:LexiconPaidHoldingsCash contextRef="I2010Q3SD" decimals="-5" id="Fact-A75CFB02B0097DB08BCDFE7E7F7C7C1E" unitRef="usd">10000000</lxrx:LexiconPaidHoldingsCash>
	<lxrx:LexiconReceivedCashFromHoldings contextRef="I2007Q2SD" decimals="-6" id="Fact-141D5F9E8A8D41E29DBFFE7E7F7CE8D7" unitRef="usd">15000000</lxrx:LexiconReceivedCashFromHoldings>
	<lxrx:LexiconSoldSharesToHoldings contextRef="I2007Q2SD" decimals="0" id="Fact-593BBDBBF61C9E174C85FE7E7F7C41B3" unitRef="shares">1092946</lxrx:LexiconSoldSharesToHoldings>
	<lxrx:Lxrx_AdjustmenttoAccumulatedDeficittoASC606 contextRef="I2018Q1SD" decimals="-5" id="Fact-57320CFA34C4850BDECE96ADBDE97C95" unitRef="usd">14200000</lxrx:Lxrx_AdjustmenttoAccumulatedDeficittoASC606>
	<lxrx:MinimumXERMELOsalestodrawTrancheB contextRef="FI2017Q4" decimals="-6" id="Fact-E92AAE8BDBEDE3715501AE7E3B2CA29C" unitRef="usd">25000000</lxrx:MinimumXERMELOsalestodrawTrancheB>
	<lxrx:OptionsOutstandingEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-04704371145606FA21BDFE7E7F7C7E43" unitRef="shares">4773915</lxrx:OptionsOutstandingEquityIncentivePlan>
	<lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-AD4D81677E273672B47BFE7E7F7CB680" unitRef="shares">187119</lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-D255B6A6DE6E26A950A2FE7E7F7CBD78" unitRef="shares">945723</lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan>
	<lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount contextRef="D2015Q4SD" decimals="-6" id="Fact-15F092315F09D9E6ACF6FE7E7F7C6BCB" unitRef="usd">100000000</lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount>
	<lxrx:SanofiDevelopmentMilestones contextRef="D2015Q4SD" decimals="-6" id="Fact-3BC1C944C943BD074837FE7E7F7C1139" unitRef="usd">110000000</lxrx:SanofiDevelopmentMilestones>
	<lxrx:SanofiOutcomesStudyMilestone contextRef="D2015Q4SD" decimals="-6" id="Fact-3D8940CB6CB79DA3E5D2FE7E7F7CC8F4" unitRef="usd">100000000</lxrx:SanofiOutcomesStudyMilestone>
	<lxrx:SanofiRegulatoryMilestones contextRef="D2015Q4SD" decimals="-6" id="Fact-1CB1F5661193E125DA17FE7E7F7C088A" unitRef="usd">220000000</lxrx:SanofiRegulatoryMilestones>
	<lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable contextRef="D2015Q4SD" decimals="-5" id="Fact-616B35FAF1FA739CF6B0FE7E7F7C6252" unitRef="usd">113800000</lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable>
	<lxrx:SanofiRevenueAllocatedtoFundingDeliverable contextRef="D2015Q4SD" decimals="-5" id="Fact-5D66B925CA808C9BB8BEFE7E7F7CE46C" unitRef="usd">59400000</lxrx:SanofiRevenueAllocatedtoFundingDeliverable>
	<lxrx:SanofiRevenueAllocatedtoLicenseDeliverable contextRef="D2015Q4SD" decimals="-5" id="Fact-53C49E1B31873A9B404FFE7E7F7CD1D0" unitRef="usd">126800000</lxrx:SanofiRevenueAllocatedtoLicenseDeliverable>
	<lxrx:SanofiRevenueRecognized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0FC6A69368EEFDB56F21FE7E7F7C2869" unitRef="usd">126800000</lxrx:SanofiRevenueRecognized>
	<lxrx:SanofiRevenueRecognized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E5AD117630771AF86CE2FE7E7F7C02F0" unitRef="usd">75400000</lxrx:SanofiRevenueRecognized>
	<lxrx:SanofiRevenueRecognized contextRef="FD2017Q4YTD" decimals="-5" id="Fact-744C1B55A8925AEBB713A03807529F0C" unitRef="usd">56300000</lxrx:SanofiRevenueRecognized>
	<lxrx:SanofiSalesMilestonePayments contextRef="D2015Q4SD" decimals="-6" id="Fact-E976C9BFA75E076661B4FE7E7F7CC563" unitRef="usd">990000000</lxrx:SanofiSalesMilestonePayments>
	<lxrx:SanofiSalesofClinicalTrialMaterials contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8D843A5BFAFA0D4DF048FE7E7F7C7B06" unitRef="usd">6300000</lxrx:SanofiSalesofClinicalTrialMaterials>
	<lxrx:SanofiSalesofClinicalTrialMaterials contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3F613C76EA3D0AB0591AA0385FE41790" unitRef="usd">1900000</lxrx:SanofiSalesofClinicalTrialMaterials>
	<lxrx:SanofiUpfrontPayment contextRef="D2015Q4SD" decimals="-6" id="Fact-975B235D99A674BE8B12FE7E7F7C6892" unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-CFD4D3CF40991136EE7DFE7E7F7C3140" unitRef="usdPerShare">11.57</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-58A7DAB00FE76CE530BAFE7E7F7CB5CF" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-79D630AFB16E20C19C4AFE7E7F7C0994" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-F488E9D19548FBEB4D56FE7E7F7C9DFE" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-772E6C21153AB895BBCCFE7E7F7C50AB" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-975254CB1226173A9C03FE7E7F7CBFA3" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-A5C135E9A901043A6085FE7E7F7CB250" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-106474349FB48AA6C582FE7E7F7C2A16">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-FE0F44C0FAA24300D4ABFE7E7F7C1B33">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-92F26D08947135F56682FE7E7F7CDA52">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-107B6CA1BA2EC09A1C71FE7E7F7C77E3">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-9F2B7773415618AF18B8FE7E7F7C572A">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-3AA81B8ECACD7177CC5BFE7E7F7C7856">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-BD125B44EB5C03915983FE7E7F7C279C" unitRef="ratio">0.81</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-6D7A1EAE3990F7124D5DFE7E7F7CB6B7" unitRef="ratio">0.83</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-04D917F13B04344EA61EFE7E7F7C1E53" unitRef="ratio">0.70</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-640609BDC4B336C2EEAFFE7E7F7CDB47" unitRef="ratio">0.64</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-16FB029F2A95B2409789FE7E7F7C8E9F" unitRef="ratio">0.63</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-339A6D8FB03410187764FE7E7F7CA2EB" unitRef="ratio">0.61</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-43C2B3D722BFF94017EFFE7E7F7C6F05" unitRef="ratio">0.012</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-0A8646908A8AE11E757FFE7E7F7C740C" unitRef="ratio">0.011</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-B7E50FDE16E491D09B61FE7E7F7C738D" unitRef="ratio">0.017</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-2E6B4FF914C0DDE342B1FE7E7F7CEF0C" unitRef="ratio">0.018</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-78951D4ECD24E7959B6CFE7E7F7C85EC" unitRef="ratio">0.016</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-A183F9F17C8F7FE11D0BFE7E7F7C423F" unitRef="ratio">0.022</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod contextRef="FD2015Q4YTD" decimals="0" id="Fact-D3897148EC18E884E232FE7E7F7CA2ED" unitRef="shares">21360</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod contextRef="FD2016Q4YTD" decimals="0" id="Fact-F7150465AC6F9B667FC6FE7E7F7C0C3E" unitRef="shares">11456</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod contextRef="FD2017Q4YTD" decimals="0" id="Fact-9D30769E34BB15B3C461FE7E7F7CD317" unitRef="shares">10248</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
	<lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-5062552075AC136977E4FE7E7F7C97AC" unitRef="usdPerShare">7.49</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
	<lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-B045616146928D18C55DFE7E7F7C6D5B" unitRef="usdPerShare">13.96</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
	<lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-FE1BF1E2B1FAC26BB662FE7E7F7C6708" unitRef="usdPerShare">15.61</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
	<lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-2AD5D4A25E6017EB6B11FE7E7F7CD3BD" unitRef="shares">82696</lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-17C00FD9A1F2BE708E67FE7E7F7C867E" unitRef="shares">1118151</lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan>
	<lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-AAA58C447B2A10C27AF7FE7E7F7C6439" unitRef="shares">113940</lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C2B7A1E1B991F2769348FE7E7F7C983B" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6831FDAB0C43A743088CFE7E7F7C753B" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-420B161FCD306136283481B7404B01EA" unitRef="usd">10499000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F12A5DD2822DC1B81D8681B73B6DE4C1" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FEBCD957F7A2EB5C2B8581B37EC5EB89" unitRef="usd">10499000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8B7F949848137426E69081B738F6AD4B" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-06FDCB1221333BB87ED881B73DF89B62" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedtoSymphonyDesigneesShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A8584B69124DFFF6E1CE81B3194A5968" unitRef="shares">660000</lxrx:SharesIssuedtoSymphonyDesigneesShares>
	<lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BCEF7E1C45490A0D0C7EFE7E7F7CA883" unitRef="usd">3150000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AD9994BF687993C627B6FE7E7F7C6B56" unitRef="usd">3514000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9952A1A65EEA29BA2379FE7E7F7C6EFF" unitRef="usd">4567000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CE569FC8112211B16393FE7E7F7C4CB7" unitRef="usd">3693000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AF65C7D6BBCBDC9AFC34FE7E7F7C3582" unitRef="usd">3938000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D697899BCB4D2E1859A8FE7E7F7C0007" unitRef="usd">4905000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
	<lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock contextRef="FD2017Q4YTD" decimals="2" id="Fact-0B5E4EBBF15F0C725FAFFE7E7F7CDF37" unitRef="ratio">1.00</lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock>
	<lxrx:StockOptionsExercisedEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-02BC76100E104C9B8A25FE7E7F7CA776" unitRef="shares">1812584</lxrx:StockOptionsExercisedEquityIncentivePlan>
	<lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2017Q4" decimals="-3" id="Fact-2815B588397AD3709E95FE7E7F7CDC3F" unitRef="shares">0</lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:SymphonFairValueOfBaseAndContingentPayments contextRef="I2010Q3SD" decimals="-5" id="Fact-89715E964D5C84E57713FE7E7F7CAA2A" unitRef="usd">45600000</lxrx:SymphonFairValueOfBaseAndContingentPayments>
	<lxrx:SymphonyAmendmentBuyout contextRef="D2016Q3SDSept" decimals="-5" id="Fact-48CBB1822F56693F80E0FE7E7F7C17C4" unitRef="usd">21000000</lxrx:SymphonyAmendmentBuyout>
	<lxrx:SymphonyBasePaymentDiscountRate contextRef="I2010Q3SD" decimals="2" id="Fact-B0919F2E21B830CA4F01FE7E7F7CFA63" unitRef="ratio">0.14</lxrx:SymphonyBasePaymentDiscountRate>
	<lxrx:SymphonyBasePaymentInShares contextRef="I2012Q3SD" decimals="0" id="Fact-8B2150A3025A4C4E992DFE7E7F7CDF60" unitRef="shares">1891074</lxrx:SymphonyBasePaymentInShares>
	<lxrx:SymphonyBasePaymentObligation contextRef="I2012Q3SD" decimals="-6" id="Fact-B728B122A54FD7FA80D3FE7E7F7C82BF" unitRef="usd">35000000</lxrx:SymphonyBasePaymentObligation>
	<lxrx:SymphonyContingentPaymentDiscountRate contextRef="I2010Q3SD" decimals="2" id="Fact-8BB7F835567049FF45A6FE7E7F7CF238" unitRef="ratio">0.18</lxrx:SymphonyContingentPaymentDiscountRate>
	<lxrx:SymphonyContingentPaymentInCash contextRef="D2014Q4SDDec" decimals="-5" id="Fact-65098E98615577B2BBD0FE7E7F7CAEB0" unitRef="usd">5800000</lxrx:SymphonyContingentPaymentInCash>
	<lxrx:SymphonyContingentPaymentInCash contextRef="D2015Q2SD" decimals="-4" id="Fact-E114FABFAC7DDD0DF253FE7E7F7CE651" unitRef="usd">750000</lxrx:SymphonyContingentPaymentInCash>
	<lxrx:SymphonyContingentPaymentInCash contextRef="D2016Q3SDSept" decimals="-5" id="Fact-004AD1FF964A31AE9559FE7E7F7C6E53" unitRef="usd">3200000</lxrx:SymphonyContingentPaymentInCash>
	<lxrx:SymphonyContingentPaymentInCash contextRef="D2017Q1SD" decimals="-5" id="Fact-AF780053BCB6B8377B79A036495A774C" unitRef="usd">10500000</lxrx:SymphonyContingentPaymentInCash>
	<lxrx:SymphonyContingentPaymentMaximum contextRef="I2010Q3SD" decimals="-6" id="Fact-AF18AA756959782BC0F0FE7E7F7C8DB6" unitRef="usd">45000000</lxrx:SymphonyContingentPaymentMaximum>
	<lxrx:SymphonyContingentPaymentPercentage contextRef="I2010Q3SD" decimals="2" id="Fact-B841F71507903C69C637FE7E7F7C217F" unitRef="ratio">0.50</lxrx:SymphonyContingentPaymentPercentage>
	<lxrx:SymphonyContingentPaymentTotal contextRef="D2014Q4SDDec" decimals="-5" id="Fact-10963419974771BDFFA9FE7E7F7C4D3B" unitRef="usd">11500000</lxrx:SymphonyContingentPaymentTotal>
	<lxrx:SymphonyContingentPaymentinShares contextRef="D2014Q4SDDec" decimals="0" id="Fact-3C807094284529852A31FE7E7F7C39B3" unitRef="shares">666111</lxrx:SymphonyContingentPaymentinShares>
	<lxrx:SymphonyContingentPaymentinShares contextRef="D2017Q1SD" decimals="0" id="Fact-068D60097E596DEB589CA036DB9B367E" unitRef="shares">659905</lxrx:SymphonyContingentPaymentinShares>
	<lxrx:SymphonyIconGoodwill contextRef="I2010Q3SD" decimals="-5" id="Fact-A934969E31BAE6C2F655FE7E7F7C441F" unitRef="usd">18700000</lxrx:SymphonyIconGoodwill>
	<lxrx:SymphonyPaymentInStockLimitation contextRef="I2010Q3SD" decimals="2" id="Fact-E1591090C71CE7BE7006FE7E7F7CE01A" unitRef="ratio">0.50</lxrx:SymphonyPaymentInStockLimitation>
	<lxrx:SymphonyRegulatoryApprovalPayment contextRef="I2010Q3SD" decimals="-6" id="Fact-5827A2CD57758FA6B747FE7E7F7CCDA1" unitRef="usd">15000000</lxrx:SymphonyRegulatoryApprovalPayment>
	<lxrx:SymphonyRegulatoryApprovalPercentageLimit contextRef="I2010Q3SD" decimals="2" id="Fact-BDD32B623FD24038A72FFE7E7F7C116A" unitRef="ratio">0.50</lxrx:SymphonyRegulatoryApprovalPercentageLimit>
	<lxrx:SymphonyRegulatoryApprovalReductionPercentage contextRef="I2010Q3SD" decimals="2" id="Fact-D20389E14CBC9A851F42FE7E7F7C382C" unitRef="ratio">0.50</lxrx:SymphonyRegulatoryApprovalReductionPercentage>
	<lxrx:TigmMaximumExposure contextRef="FI2017Q4" decimals="-5" id="Fact-9B13678EC69D974CF9D0FE7E7F7C074C" unitRef="usd">14200000</lxrx:TigmMaximumExposure>
	<lxrx:TigmPerJobPaymentAmount contextRef="FI2017Q4" decimals="0" id="Fact-72B7F2190690B57D221AFE7E7F7CA2B0" unitRef="usd">2415</lxrx:TigmPerJobPaymentAmount>
	<lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-352EEA8263B4D20EFD20FE7E7F7CF566" unitRef="shares">15000000</lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan>
	<lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2017Q4" decimals="0" id="Fact-BB83E02838639097F263FE7E7F7C018D" unitRef="shares">600000</lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:Totalvalueofsharesbynonemployeeinayear contextRef="FI2017Q4" decimals="0" id="Fact-2C8AFAC12826925F87F6D9295E3B83D5" unitRef="usd">500000</lxrx:Totalvalueofsharesbynonemployeeinayear>
	<lxrx:TrancheBdebt contextRef="FI2017Q4" decimals="-6" id="Fact-5F56933712655E813D1EAE7B1E970856" unitRef="usd">50000000</lxrx:TrancheBdebt>
	<lxrx:TxEnterpriseFundAward contextRef="D2005Q3SD" decimals="-5" id="Fact-83A308FBEAC75B1FF5F6FE7E7F7CD50F" unitRef="usd">35000000</lxrx:TxEnterpriseFundAward>
	<lxrx:TxEnterpriseFundAwardToTexasAmUniversitySystem contextRef="D2005Q3SD" decimals="-5" id="Fact-1E7AC961E65711D330E1FE7E7F7C087E" unitRef="usd">15000000</lxrx:TxEnterpriseFundAwardToTexasAmUniversitySystem>
	<lxrx:WoodlandsCashPaid contextRef="D2004Q2SD" decimals="-5" id="Fact-8D1B3F0447797AE2E4E0FE7E7F7C7EB9" unitRef="usd">20800000</lxrx:WoodlandsCashPaid>
	<lxrx:WoodlandsMortgage contextRef="D2004Q2SD" decimals="-5" id="Fact-F1444D5DFF123B46C426FE7E7F7C834B" unitRef="usd">34000000</lxrx:WoodlandsMortgage>
	<lxrx:WoodlandsMortgageInterestRate contextRef="FI2017Q4" decimals="4" id="Fact-D9CA73B15F7D7C397284FE7E7F7CD195" unitRef="ratio">0.0823</lxrx:WoodlandsMortgageInterestRate>
	<lxrx:XERMELOIntangibleAssetsFiniteLived contextRef="FD2017Q3YTD" decimals="-5" id="Fact-CD30672353183DAB62C38B77A1933C17" unitRef="usd">24700000</lxrx:XERMELOIntangibleAssetsFiniteLived>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9171560EF6BCE9546D75FE7E7F7C8D45" unitRef="usd">52877000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-4C1E4E9A74E05D38149DFE7E7F7C66A4" unitRef="usd">57652000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4B75B732A90901C4F141FE7E7F7CC91E" unitRef="usd">7492000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E000FB6D24B5E76770EAFE7E7F7C2CD5" unitRef="usd">4825000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C9A095F4BDE2EBF9C396FE7E7F7CFC57" unitRef="usd">32114000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D6EFB1F12F865F915C69FE7E7F7C1394" unitRef="usd">12282000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-6506C740ADA083F995D5FE7E7F7CF77E" unitRef="usd">18912000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-51B1889CF14F4CE4E521FE7E7F7CA602" unitRef="usd">0</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-245D7EDB017F9A46E31DFE7E7F7CE99A" unitRef="usd">0</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-3BE987DCC49E64FAB21CFE7E7F7C5FE8" unitRef="usd">18912000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-7C6BC591699E8067DBACFE7E7F7C1929" unitRef="usd">59875000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-61250136E8BCB14F8ECDFE7E7F7C4EBA" unitRef="usd">58623000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-D40085372E74C049C587FE7E7F7CE554" unitRef="usd">-195000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-041207A2A35F93F8A3A0FE7E7F7C7894" unitRef="usd">-222000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-7B0CA62D6FE0F7281F7FFE7E7F7CEE2D" unitRef="usd">1411222000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-3" id="Fact-1FA3B95B949436786C9BFE7E7F7C12D7" unitRef="usd">1435526000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D317F0CDC8B3BF5797E8FE7E7F7C65FD" unitRef="usd">6843000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-02985B516F4C012D6696FE7E7F7C97ED" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B56BFA5D0A4F0447005FFE7E7F7C2D8A" unitRef="usd">6843000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C29323DAF3B4BFC3964FFE7E7F7C7B8F" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-6338DC184ADF9E1C7403FE7E7F7C4C63" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-4A6D8B9B3A919082DF63FE7E7F7C55E6" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-236BC0B02AB0A97C3A53FE7E7F7C2631" unitRef="usd">7452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-A5548AF73A0AEA11E6CCFE7E7F7C56E3" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-265F1BF98470CB066D96FE7E7F7CED60" unitRef="usd">7452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E88CEA0583374ADC13ECFE7E7F7CCB58" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-47825C6F63EB79EB6AABFE7E7F7C6EC8" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-B6962702C482363400F8FE7E7F7C2833" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9D5A6392B6EAEF8C5700FE7E7F7C9FB3" unitRef="usd">9472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-1C5D382737D64A574715FE7E7F7C7629" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4EEF3A33DA920549387EFE7E7F7CDF4E" unitRef="usd">9472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D6F5C7DC1F77D8A6CDE3FE7E7F7CDB90" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-50F4DBB251DA9482B3E7FE7E7F7CBFB1" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-4D753A2F347DA17F881BFE7E7F7C7685" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CBAC2F2FB2CBB2B4B204FE7E7F7C9767" unitRef="usd">4000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AB44479AF197DF2685D5FE7E7F7CEBCB" unitRef="usd">4000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5AC727468CE54A8F0240FE7E7F7CAFC6" unitRef="usd">520000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1ACB53FD3A3440E6754FFE7E7F7C7377" unitRef="usd">527000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-145673A1C71222238F93FE7E7F7C4337" unitRef="usd">599000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-72A902D92D34B1D30BA391A63C39FDD6" unitRef="usd">1500000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8C2520DBA1C69FDC2CEDFE7E7F7C8512" unitRef="usd">3597000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FCF2D76593B0657A6675FE7E7F7CEC78" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2017Q4YTD" decimals="-3" id="Fact-84CB5E72BF642CA0F2AAFE7E7F7C1E40" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-7D42EA2D1426EF7D7965FE7E7F7C98FF" unitRef="usd">475625000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-88173774C9C0F2D38CDBFE7E7F7CB7B6" unitRef="usd">436539000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BAD402E6D61526F1AC6CFE7E7F7CBEDD" unitRef="usd">357874000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D67F93D37889D4958DD2FE7E7F7C5708" unitRef="usd">321995000</us-gaap:AssetsCurrent>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4" decimals="-3" id="Fact-D477811F70B9DB9E93C4FE7E7F7CCF2D" unitRef="usd">299904000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-68715DD06ED6AFCD410AFE7E7F7CB7DF" unitRef="usd">227805000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-40F2F174BA256D899631FE7E7F7C8FB1" unitRef="usd">72099000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-2031EC5CB907C6CAD35BFE7E7F7CB6CD" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-4233B4B0ABA053B0F118FE7E7F7CDC38" unitRef="usd">249127000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-BF670B89CCFCF029680DFE7E7F7C8A36" unitRef="usd">222148000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-424F4257422EC9EAF105FE7E7F7C3BA1" unitRef="usd">26979000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-839CE8652259361FA280FE7E7F7C3ADC" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-AC92E23CF3169450C90AFE7E7F7C79B1" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-0E09C14F1D771A473B1AFE7E7F7C1D79" unitRef="usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-7D79A704FA6971BF27AEFE7E7F7CB0C9" unitRef="usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-5099EB752007B286A3BCFE7E7F7C0D7E" unitRef="usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-63B8C9079D79A227DB0AFE7E7F7CD88D" unitRef="usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-B26AFF136D1DA543F9A5FE7E7F7C5082" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-391129D0ECFD65097997FE7E7F7C835D" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-2790091A7C03CA2FB715FE7E7F7C5C46" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-EFEBE6E1A9BB9E9C4D63FE7E7F7CFAF2" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-4311B04A96036E5CBA01FE7E7F7CF519" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-68B99805AE82E61CB393FE7E7F7C4887" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-A402D1DD74DCDC40FC51FE7E7F7CA10B" unitRef="usd">90000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-3A1EB8E32505D610F39BFE7E7F7CEE46" unitRef="usd">197000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-9D9EE7EF4A3D46322699FE7E7F7C5D88" unitRef="usd">197000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-E05BB913BE7ED74B8531FE7E7F7C45C6" unitRef="usd">107000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-310E07A8EFAC38E7E61AFE7E7F7C01D5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-C176F4B45E2948053441FE7E7F7C7478" unitRef="usd">54000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-7FF0CF9B5905D8F68ABEFE7E7F7C452F" unitRef="usd">222000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-EC32656C926BF6C126A3FE7E7F7C378A" unitRef="usd">222000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-E60213F3929B712C090BFE7E7F7C2EDC" unitRef="usd">168000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-2AECED4E0526466A16A9FE7E7F7C4011" unitRef="usd">46600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-F5F8DB44B81AE8C2C93DFE7E7F7C0F80" unitRef="usd">72188000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-C09EE8B7F8EB42D6B9A5FE7E7F7C0641" unitRef="usd">346699000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-994A1DFA6459C35A1E66FE7E7F7C0138" unitRef="usd">300099000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-DD2CB49D98087F633ADFFE7E7F7C450C" unitRef="usd">227911000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-0170D210216FC3F12CCCFE7E7F7C60A8" unitRef="usd">61661000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-7947943D83CA3BB6D17AFE7E7F7CD0CA" unitRef="usd">27033000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-C1EB98D8FC0E8EE22AEDFE7E7F7C2A4A" unitRef="usd">311010000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-49D79456CFCF4D279179FE7E7F7C8A82" unitRef="usd">249349000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-C5B37930F0D1DCD18EEBFE7E7F7C5F6C" unitRef="usd">222316000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-717501CFCFA746BE3352FE7E7F7CD500" unitRef="usd">46600000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-7C778FDD1126F43524A8FE7E7F7CBEB7" unitRef="usd">72099000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-497453D5C1816A70B694FE7E7F7CC710" unitRef="usd">346504000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-865B6C5EE136F7D36C0BFE7E7F7CE2B6" unitRef="usd">299904000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-A0DEAFA13E403C4A95A9FE7E7F7C6531" unitRef="usd">227805000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-1F3D325A784BB3262560FE7E7F7C6F09" unitRef="usd">61661000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-69FAE00609637DD45ED4FE7E7F7C964D" unitRef="usd">26979000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-661A6FF8FA8379F01FFFFE7E7F7C4673" unitRef="usd">310788000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-D3A4F91F3619B443D1EDFE7E7F7CB25D" unitRef="usd">249127000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-F99F07B7422A9A862944FE7E7F7C534D" unitRef="usd">222148000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-3E2D9315129E5AA1C510FE7E7F7CB3D9" unitRef="usd">137266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-37136C661AF0209D72C1FE7E7F7C2FE0" unitRef="usd">202989000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-9FA8491C365CCFB6D950FE7E7F7CDADF" unitRef="usd">46600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-B3565796B1D6E7F99BA0FE7E7F7C9CD0" unitRef="usd">61661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-F796F7960C578CB6E41AFE7E7F7C65D3" unitRef="usd">46600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-5012384D3393D3A0FF87FE7E7F7CDBEE" unitRef="usd">45093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-D3A6129AD9C5CA3DA5EBFE7E7F7CB34A" unitRef="usd">1507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-DF936BD644FE95B1D541FE7E7F7CF15E" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4" decimals="-3" id="Fact-B9558531BD75C683A811FE7E7F7C5918" unitRef="usd">61661000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-FC4C48B1D33EA48D76A2FE7E7F7CE8D7" unitRef="usd">61661000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-DE419FC27EAD1DBDAF4FFE7E7F7C9705" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-FC849E460C7F068300E4FE7E7F7CB7B2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4CE1CD6A14A589851E17FE7E7F7CC75D" unitRef="usd">65723000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3A5A2B1D5E01FEDF8A13FE7E7F7C8C22" unitRef="usd">-156389000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FE3C74EF001A28240380FE7E7F7C296E" unitRef="usd">15061000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-4A5FC99BAA553CD34C80FE7E7F7C435A" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-69AA4D4829447A038A5CFE7E7F7C76A2" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="3" id="Fact-54CDA91E200438C223A3FE7E7F7C7DFA" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="3" id="Fact-5BA5BBE2C632276F4EDEFE7E7F7C3C5B" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="-3" id="Fact-E8F632129FC6CB4F2B7DFE7E7F7C8280" unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="-3" id="Fact-E0FD27098C1B3BCFD4BCFE7E7F7C7769" unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9DECF9BBFD2E30A418A1FE7E7F7C57A8" unitRef="shares">104582000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C332E42730C790789AA0FE7E7F7CBDE8" unitRef="shares">105711000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-71D550CD299F13737D68FE7E7F7C1581" unitRef="shares">103663000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-36CD95BE31733436B488FE7E7F7C775A" unitRef="shares">103860000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-AC5A36FC1EA6A762FF41FE7E7F7C0BE6" unitRef="shares">104582000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5C2049A4C8C4A4AACA5AFE7E7F7C0C3B" unitRef="shares">105711000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-861135218AB30D631FBCFE7E7F7CA78D" unitRef="usd">105000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-61086E9BBD7934957CDEFE7E7F7C7D62" unitRef="usd">106000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7006DAD7D02AF5BE41A6FE7E7F7C4433" unitRef="usd">-4838000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-22664203347A4A99A7CCFE7E7F7CB2A5" unitRef="usd">-141405000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-61D63DD88CCA1AA6DB85FE7E7F7CD9C1" unitRef="usd">-129077000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C7C89FCD27B8739CC66FFE7E7F7CB65F" unitRef="usd">129728000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E6BFFBA5CA201EF70852FE7E7F7C7DBB" unitRef="usd">83182000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6E8BD65D1748BAA1091AFE7E7F7CAB7A" unitRef="usd">74267000</us-gaap:ContractsRevenue>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CBB615E314AF31B38EC881AE2FEB10DD" unitRef="usd">0</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q4YTD" decimals="-3" id="Fact-33684635C24F5EAFB64E81ADC1271119" unitRef="usd">0</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E99C5F550C452D03B5B781AD44CF8FED" unitRef="usd">1899000</us-gaap:CostOfGoodsSold>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q4" decimals="3" id="Fact-B174CC8C96BF6CEFF4EEFE7E7F7CEB76" unitRef="usdPerShare">8.442</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2014Q4SD" decimals="4" id="Fact-67DD28034CAFA5F2021DFE7E7F7CBFE0" unitRef="ratio">118.4553</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentDescription contextRef="D2017Q4" id="Fact-5378D1068C9CA4CE211B14503E8071B7">200000</us-gaap:DebtInstrumentDescription>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q4SD" decimals="-5" id="Fact-6ADE5052E59E2E28090B145B10E475AA" unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-40AAD6D8637AE938E91AFE7E7F7CDBF2" unitRef="usd">127300000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4" decimals="2" id="Fact-B759884F9BFE2BE3F1E91453DF4ED4FD" unitRef="ratio">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredFinanceCostsGross contextRef="I2017Q4SD" decimals="-5" id="Fact-3165FB8F81C973E14DE1145E5EF6C313" unitRef="usd">4100000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q4" decimals="-3" id="Fact-D71A4922265C560000EE9BA550D6F46C" unitRef="usd">5924000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-668FE5D64A869CDCE66FFE7E7F7C87C3" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F14B943AD591B223BCE2FE7E7F7CA15F" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AC5A7A84CECC5614539AFE7E7F7CD26F" unitRef="usd">-12661000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-B293B1650DE054C6F1E1FE7E7F7CD129" unitRef="usd">18675000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-A1CC01CAC31F76040B4CFE7E7F7C1DA5" unitRef="usd">10897000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BFC560779327666BA15AFE7E7F7C8B6D" unitRef="usd">63372000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-47C5BF43B6F9DD2D3EBAFE7E7F7C0F6E" unitRef="usd">40099000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-51A5D982453A0B1D62BFFE7E7F7C6BD8" unitRef="usd">48934000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D423635DEA5143F96580FE7E7F7C1325" unitRef="usd">22428000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2016Q4" decimals="-3" id="Fact-45961C382FE6BBDF3362FE7E7F7C9AC4" unitRef="usd">39307000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2017Q4" decimals="-3" id="Fact-530F0C9478AC26259081FE7E7F7C1B18" unitRef="usd">12950000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-17BF32F6EE727387F545FE7E7F7C7F52" unitRef="usd">468393000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-1895BC469130338EB1CCFE7E7F7C0F8D" unitRef="usd">352186000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2016Q4" decimals="-3" id="Fact-494F7AA68F20F583C2C5FE7E7F7C8A27" unitRef="usd">86845000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2017Q4" decimals="-3" id="Fact-5A2C224629B0846175F5FE7E7F7C5EBA" unitRef="usd">69561000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-490172BB6CC24FB511A1FE7E7F7C0310" unitRef="usd">258405000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-94AE7FB67829138EED89FE7E7F7C30D9" unitRef="usd">186967000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2017Q4" decimals="-5" id="Fact-E797494358D80131CB78FE7E7F7CCE76" unitRef="usd">382000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-3" id="Fact-3116CBC0D337712E898AFE7E7F7C719F" unitRef="usd">8432000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2017Q4" decimals="-3" id="Fact-F2AB05303123FE0E31ECFE7E7F7C8E2F" unitRef="usd">5579000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4" decimals="-3" id="Fact-678592B98D44F0F28E77FE7E7F7CC22E" unitRef="usd">44111000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4" decimals="-3" id="Fact-32FBB7840A713C267F2CFE7E7F7CE59C" unitRef="usd">46682000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-3" id="Fact-3A62FDE60A6B8ECD652FFE7E7F7C54A6" unitRef="usd">7060000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-3" id="Fact-08FB60BD0E86CF51ED68FE7E7F7C1286" unitRef="usd">3923000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-47F63B4CA53BD69A75AAFE7E7F7C49AD" unitRef="usd">468393000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-10B0196701D2D8C5A1F6FE7E7F7C9D11" unitRef="usd">347303000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-8AF706BD5990371953E6FE7E7F7C1A77" unitRef="usd">18675000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-6546682BD771C5867FB6D82EA8FA417D" unitRef="usd">6014000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-FD1B4C98C21BDBD687CEFE7E7F7C1345" unitRef="usd">18675000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1DE33E71FAA5942C316FFE7E7F7C2E55" unitRef="usd">6014000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesOther contextRef="FI2016Q4" decimals="-3" id="Fact-05A8E5F0830FD86AE05CFE7E7F7CFFF2" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
	<us-gaap:DeferredTaxLiabilitiesOther contextRef="FI2017Q4" decimals="-3" id="Fact-E4A21CEEB3B5B6701B53FE7E7F7C7F43" unitRef="usd">1000</us-gaap:DeferredTaxLiabilitiesOther>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2015Q4YTD" decimals="0" id="Fact-8769CBA461403E60A3B9FE7E7F7C745D" unitRef="usd">332000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2016Q4YTD" decimals="0" id="Fact-8EF78998FABCDA4B19D0FE7E7F7C0DAF" unitRef="usd">733000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD" decimals="0" id="Fact-444CEB72ED1CD6E61327FE7E7F7C7420" unitRef="usd">1033000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B57B73D4EFDFD2F92F8CFE7E7F7CF4D4" unitRef="usd">727000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-860CA2BFABA2AAB60582FE7E7F7C08C3" unitRef="usd">2056000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9C7FC640AAE2E36A80AAFE7E7F7C8240" unitRef="usd">3399000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-2826CFA60E399DF7B3E0FE7E7F7C6354" unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-CA1C6A9CF1EBC34443A3FE7E7F7C3239" unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-B75E8730CFB2A15C21E8FE7E7F7C33F0" unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-89318059670968743213FE7E7F7C3ED5" unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-B0A2AF2CB5B760B5121BFE7E7F7C3D69" unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-EA2E4D9A621831CC15BAFE7E7F7CBD04" unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-7DFB146364A6CBFF0C68FE7E7F7C9EDA" unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-CBDB9AFA836DB80E5606FE7E7F7C9488" unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-F9D2D6FD9005B100D1AAFE7E7F7C3AD9" unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4QTD" decimals="2" id="Fact-EADDFD41C06FBF7A6A2CFE7E7F7CBBA9" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-1CA724839066A4312DC5FE7E7F7C6F8F" unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q4" decimals="-5" id="Fact-64ED08D7FE1B592F3B71FE7E7F7CC4E8" unitRef="usd">18600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q4YTD" id="Fact-FA68DEAF7B288E04FBB0FE7E7F7C6849">P1Y4M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C028F18FE46C351957D8FE7E7F7CE801" unitRef="usd">5927000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FC1E0406741BF0624410FE7E7F7C3E90" unitRef="usd">-703000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q4YTD" decimals="-3" id="Fact-895FBD78FE3108B34A20FE7E7F7CD095" unitRef="usd">2101000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0B73597245145E4B0EACFE7E7F7CBB67" unitRef="usd">-750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q4YTD" decimals="-3" id="Fact-717EED0E3B05E622A0C5FE7E7F7C63F3" unitRef="usd">-3200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E522B65BEDBC03511DE7FE7E7F7C23E7" unitRef="usd">-21013000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2015Q4" decimals="-3" id="Fact-DA9C33A7F1628411E606FE7E7F7C722C" unitRef="usd">22815000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4" decimals="-3" id="Fact-891358FAA9476229155CFE7E7F7C1E2C" unitRef="usd">18912000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4" decimals="-3" id="Fact-5159FFAAE80F8B09B46BFE7E7F7C4B44" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="I2015Q1" decimals="-3" id="Fact-9EC8045C46445664455EFE7E7F7CEE3B" unitRef="usd">17638000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="FI2017Q4" decimals="-3" id="Fact-74FE6D04A05214606910247D1E91412B" unitRef="usd">14417000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2017Q4" decimals="-3" id="Fact-9E1626362CC08A7CB1102478A9EA79C0" unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2017Q4" decimals="-3" id="Fact-8047FCC64D3F1672FC4C247C788EFBA0" unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2017Q4" decimals="-3" id="Fact-7ACB87C4DE2B0BC901E4247BD00FA1DF" unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2017Q4" decimals="-3" id="Fact-40D751195504958F530C247B4EF82CC4" unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2017Q4" decimals="-3" id="Fact-BFFA134CE5AB109C087C247A7EE8E2F3" unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-30FB8ADC8C296AFD28BB2485DC51D098" unitRef="usd">23247000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4E88DE59A56CB821F0E1FE7E7F7C11D8" unitRef="usd">47000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9B70F0CA25C978F8C458FE7E7F7C7230" unitRef="usd">-16000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C1F2024ADAA15243F95EFE7E7F7CC578" unitRef="usd">-3000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-148786D229091EA94B03FE7E7F7C5382" unitRef="usd">23835000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-942122A1169FC713854DFE7E7F7CBE9A" unitRef="usd">43044000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-38A1913EB5FA41B4F9BEFE7E7F7C5491" unitRef="usd">66203000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-3" id="Fact-0E27A41865041AD7DE3AFE7E7F7C3952" unitRef="usd">44543000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-3" id="Fact-9CB399B98BDE2B2A85F0FE7E7F7C22A0" unitRef="usd">44543000</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2015Q4YTD" decimals="0" id="Fact-E6FC1B415229BE60CCEDB083C50DA812" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2016Q4YTD" decimals="0" id="Fact-9BAFE915A5B44CE4217EB083251E1D80" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-DB5FD8DA13F774A1FD2AB082475ADCD6" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2015Q4YTD" decimals="-6" id="Fact-D2C1EA33872078E9D902B07D32E22AAF" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2016Q4YTD" decimals="-6" id="Fact-B829ED4802AD756CE7D7B07C844DBF6B" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2017Q4YTD" decimals="-6" id="Fact-E6E5D2A7A533AB47CD78B078C332B9BB" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6C09D91FF9F8B7F5E9C7FE7E7F7C49A4" unitRef="usd">3597000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2016Q4YTD" decimals="-3" id="Fact-69966D4E9ECFDE55B2DEFE7E7F7CE77A" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AE5A2990904F1D9F584DFE7E7F7C14B4" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3804651250FFE8E3DE97FE7E7F7C5215" unitRef="usd">-4682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-3" id="Fact-867E5E3348FA7253F691FE7E7F7CF004" unitRef="usd">-141429000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-95A12FBBF59DEE485F24FE7E7F7C7D19" unitRef="usd">-141711000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="0" id="Fact-5D98494C14138B342393FE7E7F7C9BC0" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="0" id="Fact-D9D8D7ACF08600102697FE7E7F7CCB11" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9F394B7AEB8BAED853C1FE7E7F7C39BF" unitRef="usd">-6203000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4A0FD197957B96303B56FE7E7F7C9E17" unitRef="usd">-27650000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7C2208558F9D6A411B0EFE7E7F7C587A" unitRef="usd">7172000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-315A0AAF238F6A61CD02FE7E7F7C8D94" unitRef="usd">-124000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D256FC89FF7691CA9AF8FE7E7F7C741F" unitRef="usd">4080000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-046AF4646302DDC4DF14FE7E7F7C494C" unitRef="usd">-166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-47DE3775D4823F169027FE7E7F7C40F9" unitRef="usd">-171353000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9DDCFB86F170089CCEF9FE7E7F7CE456" unitRef="usd">73344000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-577E0FF312A11BA674CCFE7E7F7C4031" unitRef="usd">49779000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A63A9FBAF6BBB878F1B681BB315F07A2" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q4YTD" decimals="-3" id="Fact-16BFC4E72517FDB06A9A81BAEF585A01" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2D4F7B697250D036905B81BA8648D99A" unitRef="usd">1948000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D4008BBD53B5DD764735FE7E7F7CDFE9" unitRef="usd">-416000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8F70A01A5577ADEAD374FE7E7F7CBCEF" unitRef="usd">-32000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3358436D9B77373C3487FE7E7F7C47AF" unitRef="usd">33000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-119937F59E341CCE6329FE7E7F7C87B9" unitRef="usd">-5373000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CFD63AD611D27324CEA3FE7E7F7C0EBB" unitRef="usd">6259000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E1CDC885C2C0305B1999FE7E7F7C5BAB" unitRef="usd">-557000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BC84764DF390D72EE99FFE7E7F7CEAA6" unitRef="usd">6722000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C47969CBE5CBBE7A259AFE7E7F7C436A" unitRef="usd">6567000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2094C3D44017276B20ADFE7E7F7C55A0" unitRef="usd">6984000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F0200273B90DF15B73DEFE7E7F7C2545" unitRef="usd">6270000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8442EA1FDE6C7354BE9BFE7E7F7CF10C" unitRef="usd">6050000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F067193058B4CE90104FFE7E7F7CE59A" unitRef="usd">5870000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryFinishedGoods contextRef="FI2017Q4" decimals="-3" id="Fact-64D55B8A558CB32CAABAC7DE8D028389" unitRef="usd">1183000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="FI2017Q4" decimals="-3" id="Fact-F20D36B91B9531A2F636C7DE8E0D119A" unitRef="usd">1948000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-48D8A5832A775689FC47C7D469B0751E" unitRef="usd">0</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-3" id="Fact-B5D7119C47F99B0F26C4C7D469A5C9C3" unitRef="usd">1948000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterials contextRef="FI2017Q4" decimals="-3" id="Fact-8855A4ECE6C8B207BA64C7DE8B0EE349" unitRef="usd">616000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess contextRef="FI2017Q4" decimals="-3" id="Fact-2428A4C82318987C3CF1C7DE8C0BE50C" unitRef="usd">149000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-A086B19638CCE8C5E617FE7E7F7C25AD" unitRef="usd">346504000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-B17FBA39B7AE454335C1FE7E7F7C8746" unitRef="usd">272898000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-FB896EEA56BEC35F5F32FE7E7F7CFD7E" unitRef="usd">73606000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-750C5DC86BA45D096506FE7E7F7CD35B" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4" decimals="-3" id="Fact-F77C27C476EC6205BCFAFE7E7F7C57F4" unitRef="usd">310788000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-0154769AE018AB24E874FE7E7F7CE5F5" unitRef="usd">283809000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-CDCD1C0501887B9B36DBFE7E7F7C166C" unitRef="usd">26979000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-4CA4514421E610E070EBFE7E7F7C36E6" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7C093FDF26D786A8F90AFE7E7F7C4F83" unitRef="usd">100000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3F9C9652AB0A873E5BFCFE7E7F7C20F9" unitRef="usd">500000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3BE56BF396F64818046FFE7E7F7C0F07" unitRef="usd">600000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-C851188B3A9BB4C78B8CFE7E7F7C12F6" unitRef="usd">318224000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-36EA450E81325CA70E06FE7E7F7C8F5B" unitRef="usd">384437000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-D2952BE00B139E4F474CFE7E7F7CB9FF" unitRef="usd">475625000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-06FFFBD6018A4CE03A72FE7E7F7C3AD2" unitRef="usd">436539000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C92211AF722CEDB87B5BFE7E7F7C3383" unitRef="usd">164643000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-DF95ADD7B56634985B9CFE7E7F7CCEDE" unitRef="usd">124127000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-F7CD9F93703D186520E2FE7E7F7CBC75" unitRef="usd">18912000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-73ACB747504C76DE8D9DFE7E7F7CFC30" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-E46348778DD6B86FF352FE7E7F7CE064" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-AB791B34219415100B6CFE7E7F7C99D9" unitRef="usd">18912000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F4F62B48CE2EC1613CA8FE7E7F7CE129" unitRef="usd">286000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-285E6A750F986ACA9DE2FE7E7F7C6916" unitRef="usd">155000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E7742056BA205E97081DFE7E7F7C0CD1" unitRef="usd">178000</us-gaap:LicensesRevenue>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="-3" id="Fact-8D086D19563C0B4822E8FE7E7F7C3561" unitRef="usd">251594000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7FE9AD95B87D2D4151C6FE7E7F7C1555" unitRef="usd">16280000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-EEE11E3BC01B0EE8DC2CFE7E7F7C3842" unitRef="usd">14094000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="FI2017Q4" decimals="-3" id="Fact-698579AFB1B6A2A6B829FE7E7F7C9CE1" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2017Q4" decimals="-3" id="Fact-0C91DC53003E7E3FE32FFE7E7F7C2AE6" unitRef="usd">14094000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2017Q4" decimals="-3" id="Fact-1E0D9A74EF66267A5717FE7E7F7C7D68" unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2017Q4" decimals="-3" id="Fact-D5401BBC0496F585688BFE7E7F7C5CB5" unitRef="usd">87500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2017Q4" decimals="-3" id="Fact-07663901D239D3B82CE1FE7E7F7C3AB0" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2017Q4" decimals="-3" id="Fact-4479C462EE3F5A4654AFFE7E7F7CDFC1" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BA2BB31C27C5D696C3C4FE7E7F7C7C0A" unitRef="usd">85167000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E824A9FB15BA9C38099EFE7E7F7C4A3E" unitRef="usd">231576000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:MortgageLoansOnRealEstateCarryingAmountOfMortgages contextRef="FI2017Q4" decimals="-5" id="Fact-051FE61ACE940D760ACCFE7E7F7C38C8" unitRef="usd">14100000</us-gaap:MortgageLoansOnRealEstateCarryingAmountOfMortgages>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F41939440F6ABEAB90CAFE7E7F7CC802" unitRef="usd">-2032000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A3E221A7BF76FC6715BCFE7E7F7C955E" unitRef="usd">987000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AA61A95733C9E7D42484FE7E7F7C6D23" unitRef="usd">149933000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3DB770B648788D37D7D7FE7E7F7C27B8" unitRef="usd">-117021000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BD3CDE98905CE5104390FE7E7F7CE1DC" unitRef="usd">18252000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BEB041056769B6FA8204FE7E7F7C930F" unitRef="usd">50522000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-12DD20C8F1D89E4A6DB5FE7E7F7C86D8" unitRef="usd">184776000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-341E0F5F82829F4D8964FE7E7F7CC52E" unitRef="usd">-175628000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-478DB74D3F452288FED4FE7E7F7C9C07" unitRef="usd">-185394000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E83D57EFE7A7AB39A3C0FE7E7F7CFA53" unitRef="usd">-4682000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D0DCF2320F18343A84F6FE7E7F7C7232" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2ACB728BB746E68A967DFE7E7F7CF9BF" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F93788537F5993D82557FE7E7F7C9799" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D84853C1591DB5B6F834FE7E7F7CF47F" unitRef="usd">-4682000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-5849E6B1E76075B8AAE0FE7E7F7C4907" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-71CAD486B71F534E92CEFE7E7F7C1B69" unitRef="usd">-34883000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-929D380264A4BB9CF515FE7E7F7C2F62" unitRef="usd">-38112000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-BDB356805394FB35058CFE7E7F7CFB7E" unitRef="usd">-36015000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-43DC3FD7C1DF275311F0FE7E7F7CF122" unitRef="usd">-32419000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-76E83D050006C0E5C23FFE7E7F7C45C7" unitRef="usd">-141429000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-17CF1EC54895D0C1F441FE7E7F7CC3D9" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A55BA6F5E5CC80BD945DFE7E7F7C3B49" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F03FA6230B0BAE57DC2DFE7E7F7C0BF8" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-0A063FFEC546AFC963BEFE7E7F7C25BF" unitRef="usd">-141429000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-B0DE8CCF5AC5E1CE0B1FFE7E7F7C061B" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-88F44CF4729514D3A48FFE7E7F7C047D" unitRef="usd">-34891000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-7B4A4EFA0A9EF8BEAC3AFE7E7F7C6A12" unitRef="usd">-35059000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-7E575C983F4B04A6B81CFE7E7F7C8A02" unitRef="usd">-30722000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4QTD" decimals="-3" id="Fact-975C4CAED13DC8574DAEFE7E7F7C86C6" unitRef="usd">-28378000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-445CBF698BE52D2AB2C2FE7E7F7C45CA" unitRef="usd">-129050000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-BF66DAB0136A5D809ABDFE7E7F7C9393" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-310A96FE0B454A59A7FDFE7E7F7C8778" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DBCAD19E34D0F1C90348FE7E7F7C735E" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1A8E325C6504FD7AB7D2FE7E7F7C89A5" unitRef="usd">-129050000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-754E6E00729FBC1FC863FE7E7F7C0403" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C1197DB18B9EBB6821FF81B7D44F6A92" unitRef="usd">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B63B642ADEB086EDB89281B7CEA0DC54" unitRef="usd">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-26CDD06EBFBFA6125E1E81B1DAB78E4E" unitRef="usd">1991000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-66D11498F5AFE7051A6481B2781EEF16" unitRef="usd">-1991000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-AA91D3482337ED69A9DB81B7D1E2E8D2" unitRef="usd">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9EAB7273621FB98C4180FE7E7F7CC12C" unitRef="usd">128546000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F5E3E817736EDDDA35CAFE7E7F7CE382" unitRef="usd">220492000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D27F5E419B175FD8C3E0FE7E7F7C47B0" unitRef="usd">227016000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E0E9D8B98253051AA229FE7E7F7C006A" unitRef="usd">1468000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-7641A7F76141E6CE2557FE7E7F7C5D02" unitRef="usd">-33871000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-93415CAE0A28486CCEADFE7E7F7CC683" unitRef="usd">-37021000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-715B2DC4BAB642F6012CFE7E7F7CB3F0" unitRef="usd">-34933000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-DC2FF50D5EBD11258E88FE7E7F7C0740" unitRef="usd">-31330000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7B0A7532DD29EDA1B50BFE7E7F7CC56A" unitRef="usd">-137155000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-21EA7DB2A9B00B4C2AE9FE7E7F7CBE6F" unitRef="usd">-42485000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-D202E0244871446F2F6AFE7E7F7CA1F2" unitRef="usd">-33893000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-A9BB4D6121E97B1EBD20FE7E7F7C8842" unitRef="usd">-29518000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4QTD" decimals="-3" id="Fact-4500A9F34ADEE586761EFE7E7F7C7D09" unitRef="usd">-30785000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-70FD28CDFB6B4C928AB9FE7E7F7C762F" unitRef="usd">-136681000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q4" decimals="-3" id="Fact-0E07834470CB811085D9FE7E7F7C66B8" unitRef="usd">3155000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1400C9E08AA6C1158342FE7E7F7C36BB" unitRef="usd">625000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q4" decimals="-3" id="Fact-2029F4E612548BD640B1FE7E7F7C1730" unitRef="usd">651000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q4" decimals="-3" id="Fact-A0AC865B798F5802CE16FE7E7F7C3DDA" unitRef="usd">639000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q4" decimals="-3" id="Fact-AFC293A2DEBCDFE7F2FFFE7E7F7C0CFD" unitRef="usd">626000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q4" decimals="-3" id="Fact-F352D2C2C16FCEF913E5FE7E7F7CB86F" unitRef="usd">614000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2017Q4" decimals="-3" id="Fact-A4F7C76271331F4FA1EDFE7E7F7CC1B1" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-6CC6FD0F97695CBB75DFFE7E7F7C07D2" unitRef="usd">851400000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0C66056CA6C00A293F8AFE7E7F7CA486" unitRef="usd">3878000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-71527A0922E032C84769FE7E7F7CA8ED" unitRef="usd">4434000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-38FFAD336C711BC745ADFE7E7F7C9AF7" unitRef="usd">461000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-456A235CF0BE06708C37FE7E7F7CA23D" unitRef="usd">429000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-09BCD8B2B7625E14A5F9FE7E7F7C0C2F" unitRef="usd">-156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-AD0A0013D55AB65FDA14FE7E7F7CAD04" unitRef="usd">-156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-47D2D410A37DA90ECCBDFE7E7F7C9135" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5A0BADE1362EB4A3ABF7FE7E7F7C4957" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CAC9F9E99A9E36A32878FE7E7F7CA33A" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-C24E65AA22EB33AE2C65FE7E7F7CC87E" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8D292473468B55604A97FE7E7F7C2C2D" unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D8B7DEE7BBFD695AA6EDFE7E7F7C6A6C" unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-88F95F78BEB686B77943FE7E7F7C37A2" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F8ED50860EDADBE6B2DDFE7E7F7CA8F0" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D10AC546E38806DD4973FE7E7F7C69D4" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-E035525D0AE6B61172CFFE7E7F7CB59E" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-803D24468CA3A9084F74FE7E7F7CBE84" unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-5257F66130A3217C7390FE7E7F7C56EC" unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EED570AC29B5875CFA09FE7E7F7CB0A7" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-567D7241865A816B038CFE7E7F7C7D32" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C37BEBFDCE232803FD5AFE7E7F7CC7EB" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-7D48BB66C697B39FD061FE7E7F7C4EBD" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherIntangibleAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-4A09EA4291C362BC743AFE7E7F7CC70F" unitRef="usd">53357000</us-gaap:OtherIntangibleAssetsNet>
	<us-gaap:OtherIntangibleAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-382CE90479A5436D0D66FE7E7F7C15AC" unitRef="usd">51885000</us-gaap:OtherIntangibleAssetsNet>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-93D2CA65303B10B31E53FE7E7F7C5A20" unitRef="usd">805000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-328FC75B0987749603A4FE7E7F7C2F95" unitRef="usd">292000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-052DBAAA319023D92157FE7E7F7CC234" unitRef="usd">572000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-ACCFFD86DEC948CCD9F2FE7E7F7C1823" unitRef="usd">2293000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-31D661A80636D9775AEEFE7E7F7C05E9" unitRef="usd">1954000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="D2014Q4SD" decimals="-5" id="Fact-414505A38FF94FB65FEEFE7E7F7C23F8" unitRef="usd">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DE5B7E6B9F0E8CBE5CB7FE7E7F7C1056" unitRef="usd">357000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EE84EE39B472B6CF1C3DFE7E7F7CF3FB" unitRef="usd">621000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8217B9B7BC19C80295F0FE7E7F7C4EAA" unitRef="usd">1679000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ED749E41C33F06585439FE7E7F7C4E31" unitRef="usd">326446000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6CEBE4F8A39F530AF0C2FE7E7F7CAD7C" unitRef="usd">425673000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5BA9602E09383F4ABD3FFE7E7F7C9726" unitRef="usd">267873000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CC08CB2592E912305DBBFE7E7F7C0832" unitRef="usd">910000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6FB809B099AC59DF4BA1FE7E7F7CACCA" unitRef="usd">231000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BBED963A231FCCD8F617FE7E7F7CC8AE" unitRef="usd">228000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="2" id="Fact-9607C0F4A38BE81DFA1AFE7E7F7C65AB" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="2" id="Fact-F94D50922AD2A6D81334FE7E7F7C3590" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="-3" id="Fact-2D628DE9BC2E474035F3FE7E7F7C9D77" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="-3" id="Fact-5875D29DBE2EE96A2A3FFE7E7F7C6143" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="-3" id="Fact-08C79684B2B786558FABFE7E7F7CEEA9" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="-3" id="Fact-9627B7FDA446BD43C6FDFE7E7F7CCFA6" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="-3" id="Fact-6E40FDEC29193E243620FE7E7F7C6D4B" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="-3" id="Fact-1E8D4E0FEA3427A16012FE7E7F7C4F42" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-FA8945DD19CAB530F584FE7E7F7C4661" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-61193A9F5FC7A9F54AD4FE7E7F7CF393" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="D2014Q4SD" decimals="-5" id="Fact-EC15628B3130551AFEDCFE7E7F7C5313" unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5F11554FD948A5F34A83FE7E7F7CCD61" unitRef="usd">114000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E48E4131E905A2464CA8FE7E7F7CDD92" unitRef="usd">3624000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0CAEB7F88725BB152B47FE7E7F7C988C" unitRef="usd">7987000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-49A928DBB545392BDB31FE7E7F7C8762" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D3B14881BF51BC0A3F32FE7E7F7C072C" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5E8CD93360C67C8A08BAFE7E7F7C97A3" unitRef="usd">145905000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AC7E05F047B644B47FA5FE7E7F7C3717" unitRef="usd">70000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-46319E91F986DBD366DEFE7E7F7CE9C8" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F1418BDCDEEE7D01DF35FE7E7F7C7256" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FE233CEE1149260B9348FE7E7F7C1428" unitRef="usd">210000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2BBF9C26A882267D85F2FE7E7F7CA9FC" unitRef="usd">444156000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BFD6AD8E4C3DD581001AFE7E7F7CB70B" unitRef="usd">318623000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-323E27068DB0EF8D78C5FE7E7F7C603D" unitRef="usd">335000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-76FF7670771A420FC6A1FE7E7F7CA17F" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-257F997FCE6BD87CF271FE7E7F7CFA31" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4EEA7EE4566FBC2B91DAFE7E7F7CE8CB" unitRef="usd">-4682000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-56ABD66D075CA3EEDF76FE7E7F7CCD8C" unitRef="usd">-141429000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4EC875D29EEB2B72834EFE7E7F7C858A" unitRef="usd">-129050000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-F429A34B1E691CA090ADFE7E7F7CE240" unitRef="usd">79265000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" decimals="-3" id="Fact-CFC65DE711F1CACF3528FE7E7F7C13EA" unitRef="usd">59212000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-2C9CE1E003177DB0B8A4FE7E7F7C82EC" unitRef="usd">7667000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-F127B2F24DF4B8A962ABFE7E7F7CFFFA" unitRef="usd">3423000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-502675B59C8EE85EDA57FE7E7F7C1649" unitRef="usd">6003000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-3" id="Fact-69E90AF078A56804991BFE7E7F7CF97D" unitRef="usd">2664000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" decimals="-3" id="Fact-5ABEEA9729DEB5E7E2FBFE7E7F7C9C01" unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-4055D62EEB18B4D98B56FE7E7F7C7F34" unitRef="usd">76310000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" decimals="-3" id="Fact-10EC46D8BDA9D67569EFFE7E7F7C7046" unitRef="usd">59212000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-DC98850483E1EEE950F7FE7E7F7C42C3" unitRef="usd">4605000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-6386DD62224260E101E6FE7E7F7C0962" unitRef="usd">3423000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-15D298E53F654DF235FFFE7E7F7C9932" unitRef="usd">6006000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-3" id="Fact-E555A268CF79D86E5423FE7E7F7C3BED" unitRef="usd">2664000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" decimals="-3" id="Fact-D1F097D136049D81DE5BFE7E7F7C8AE4" unitRef="usd">400000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-81326D208F41F91BF8BDFE7E7F7C3C9D" unitRef="usd">19390000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-96D99253A5D9259197CDFE7E7F7C5407" unitRef="usd">17687000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-998BC3575EE07152ECB4FE7E7F7CE99D" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-746C9CFFB7A45E6D8EB5FE7E7F7C9AD7" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9498350CC9913FC33D28FE7E7F7C86D4" unitRef="usd">7000</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C2819784ADADB0F436F4FE7E7F7CBE5B" unitRef="usd">1859000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-767E10730383AAEC4156FE7E7F7C7F06" unitRef="usd">2016000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7654A68B7C5D10948987FE7E7F7CCAE3" unitRef="usd">2280000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A8ACEFB2C30B7A47FB92FE7E7F7CC4DE" unitRef="usd">95187000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-70210969CBBBECC0CC40FE7E7F7CC565" unitRef="usd">178151000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C4ECACE815B28B2B30B3FE7E7F7CA467" unitRef="usd">156813000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-44FA00107289B085D402FE7E7F7CAE9F" unitRef="usd">-1250363000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-79251E6E842C4AC653EAFE7E7F7C0838" unitRef="usd">-1381404000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-23901F124EF7FA43938AFE7E7F7C11FD" unitRef="usd">130014000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-08E2F2C0F6D1A8CE27FDFE7E7F7C5BD0" unitRef="usd">83337000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-811466A50BB7B0509ED6FE7E7F7C77B0" unitRef="usd">90335000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7E0D62A11E221E10F739C7F2414C5D14" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-22B76AF114602B7363FBC7F231AB6B38" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-369789185B7950597059C7F201D46C2A" unitRef="usd">15890000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q1QTD" decimals="-3" id="Fact-D4E48D74F6E41538F0CFFE7E7F7C27FD" unitRef="usd">12494000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-D6066C4CF8658B90361DFE7E7F7C98F7" unitRef="usd">20089000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-35320A9F1BF7EFE8C2E5FE7E7F7C3397" unitRef="usd">27717000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q4QTD" decimals="-3" id="Fact-1741289F9E8FF2103C8CFE7E7F7C55FE" unitRef="usd">23037000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q1QTD" decimals="-3" id="Fact-701BE873A9830B6B0B5BFE7E7F7CFAFD" unitRef="usd">18293000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-C705B6145412C37CE336FE7E7F7C5312" unitRef="usd">12053000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-58AF6A3CE4D5F49F8E9DFE7E7F7C92BB" unitRef="usd">26942000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q4QTD" decimals="-3" id="Fact-505691E77ED6B31B47C6FE7E7F7CF7D0" unitRef="usd">33047000</us-gaap:SalesRevenueNet>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E95D06D208CFB9F504D6FE7E7F7CC5E7" unitRef="usd">6843000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-113CC73BF4C5BFE01D36FE7E7F7C0CE5" unitRef="usd">7452000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0CF1E8A956F4F531FB9CFE7E7F7CB718" unitRef="usd">9472000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-C8026E6B5D7B634D8067FE7E7F7CB2F7" unitRef="shares">61000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-CD9D766042946BCDA6FDFE7E7F7C6941" unitRef="shares">418000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-2F35CF77CFABE96322C5FE7E7F7C221D" unitRef="usdPerShare">14.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-458927E95E81854A8388FE7E7F7C7DB2" unitRef="shares">875000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-9654C9753DEB305042EBFE7E7F7C9FCA" unitRef="shares">946000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-A3AF90A7C33204AE2457FE7E7F7C3510" unitRef="usdPerShare">8.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-FEE1DE69A595B674B441FE7E7F7CE81D" unitRef="usdPerShare">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-6097C5D4065F1E2F55DBFE7E7F7CD2F5" unitRef="shares">286000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-9DF30D358633DA76FB17FE7E7F7C62AF" unitRef="usdPerShare">8.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q4" decimals="0" id="Fact-E3CF53B4585E92BA4B90FE7E7F7C922A" unitRef="shares">5906757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4" decimals="0" id="Fact-15D6845B164299FD012AFE7E7F7C3863" unitRef="shares">6565872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-07EAD18009AFAAE32EE3FE7E7F7C45BD" unitRef="shares">2686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-265512DE094AF85A4B1EFE7E7F7CF2E8" unitRef="shares">2727000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-465850A712E44ADA8C15FE7E7F7CE962" unitRef="shares">3077000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-B13EA3DFABF69ECDC7F2FE7E7F7C8B9D" unitRef="usdPerShare">14.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-EC4B26F9F4AF0E57E521FE7E7F7C696A" unitRef="usdPerShare">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-C5EC61FE673F3F3DED8FFE7E7F7C85BB" unitRef="usdPerShare">10.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="0" id="Fact-5F409D68ACD9E9438A38FE7E7F7C3A39" unitRef="usd">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AF63767A3A012E02A698FE7E7F7CA180" unitRef="usd">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4BAE71AC839154B4A17EFE7E7F7CB2B9" unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-37CD7C6CDE62ECF5191EFE7E7F7C309D" unitRef="shares">187000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-B398A1D2F510F390540CFE7E7F7C73FF" unitRef="shares">195000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-964CE712A5FFD9E37473FE7E7F7C4C05" unitRef="shares">157000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-109B0A0E17AEEFEC16ECFE7E7F7C1775" unitRef="shares">155000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-9C5EF70B822D136CD69FFE7E7F7CA785" unitRef="shares">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-26D7D277BDD6EF6DC7C3FE7E7F7C3AD5" unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F9702BF47DA7CA6AC9F8FE7E7F7C61B3" unitRef="shares">197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3A8D44F90C195E9AF0B1FE7E7F7CAB05" unitRef="shares">722000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D93A7B940CDD9C2DBEBDFE7E7F7CCB5C" unitRef="shares">469000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-66B1A5E5951A9480B974FE7E7F7C181A" unitRef="shares">1207000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-E4E972FE921DE1DA2423FE7E7F7CD45C" unitRef="shares">1370000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-87913D1AB20FD2D37651FE7E7F7CD58E" unitRef="shares">892000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-5656CCAA1A44AFC42876FE7E7F7CA081" unitRef="usdPerShare">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-9ED153349479B98762CBFE7E7F7CCF3E" unitRef="usdPerShare">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-4514BAA2313C53E18198FE7E7F7C1DF5" unitRef="usdPerShare">8.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-5" id="Fact-9E71784F44B3A41F3EFAFE7E7F7C9D08" unitRef="usd">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-E333F85455AAF8EC21F3FE7E7F7CF77A" unitRef="shares">4217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-D4C4B923DC02B7EBD156FE7E7F7CA6F7" unitRef="shares">4834000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-71423E385B450A8B8A8CFE7E7F7C01EA" unitRef="shares">4961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2013Q1BegPeriod_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-2EDA521A0CA0C6A60E81FE7E7F7CB356" unitRef="shares">3371000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-AA8A9F705F1831080DA2FE7E7F7C34D2" unitRef="usdPerShare">12.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-55FB76C89A864DC01DF8FE7E7F7C2047" unitRef="usdPerShare">11.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-8F003DDC71E274A226DAFE7E7F7C8C69" unitRef="usdPerShare">11.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2013Q1BegPeriod_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-11BB022493A497B62FA8FE7E7F7C7ED2" unitRef="usdPerShare">14.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-46B23BF5B183738800ADFE7E7F7C577E" unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-440644EBA7854344D6EBFE7E7F7C3353" unitRef="usdPerShare">12.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-0C0B7A89580CEAA80D21FE7E7F7C844A" unitRef="usdPerShare">11.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-45758C2AF4EA61C44AE5FE7E7F7CDE18" unitRef="usdPerShare">27.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-F205FB7E278468A2BB82FE7E7F7C584E" unitRef="usdPerShare">27.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-96BBC8810C92B354E242FE7E7F7C0911" unitRef="usdPerShare">26.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-CEA860EE1F6410438131FE7E7F7C6ECC" unitRef="usdPerShare">8.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-E867B8F04174A15930B4FE7E7F7CE44B" unitRef="usdPerShare">10.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-F196C37AB4F779B7738EFE7E7F7CC160" unitRef="usdPerShare">13.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5DCB128A77E0BDA2D331FE7E7F7CD3F2" unitRef="usdPerShare">6.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-8129CBCFFBDF97229F5DFE7E7F7CBD5D" unitRef="usdPerShare">10.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-CFD4C9F3B9D231429CC7FE7E7F7C706D" unitRef="usdPerShare">14.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q4" decimals="-5" id="Fact-005D285C2BDFA70653B8FE7E7F7CF032" unitRef="usd">2800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q4YTD" id="Fact-4DA4687D9F50AC4BCDF5FE7E7F7CE96D">P5Y2M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD" id="Fact-DC623C37C91BDE60130FFE7E7F7CFABA">P6Y5M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:ShortTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-C778E4912F1ECB9E9E01FE7E7F7C4200" unitRef="usd">299904000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2017Q4" decimals="-3" id="Fact-6A239915CDB2D7BB7FA5FE7E7F7C1544" unitRef="usd">249127000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-03108A62BA1D7443750AFE7E7F7C2315" unitRef="shares">19000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-7AF7C03047AD33ED7607FE7E7F7C6249" unitRef="shares">495000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-DF0A47532D57E485B5EDFE7E7F7CF87F" unitRef="shares">458000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4523F8F71C6790A7923CFE7E7F7C211A" unitRef="usd">114000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-841024710818AD8DD860FE7E7F7C38A9" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FE83B6F23A1B339701EEFE7E7F7CD9AF" unitRef="usd">114000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D66906571541C9D92AD2FE7E7F7C52DB" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-5C2315EB2B8E48D3E8B8FE7E7F7C0023" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-C6E2320A80B7A242F707FE7E7F7C5D43" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F6CD38DD1265A15D400BFE7E7F7CBD2D" unitRef="usd">6125000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-778315736A1CC0462EE7FE7E7F7CF461" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5019D0880BFB0F179C58FE7E7F7C2501" unitRef="usd">6124000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B1F9CF29E2BE037577F8FE7E7F7CEF7B" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-0BEA41B1340E39483D70FE7E7F7C5113" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-78FC5903B49944C12E4AFE7E7F7CB19D" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-37ABBDC742CD901AB600FE7E7F7C8B61" unitRef="usd">5486000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-108E0F0AF779E7B2A805FE7E7F7C9675" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-993204B82AACE76C3572FE7E7F7C36D4" unitRef="usd">5485000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EA22840F17C56DC0BFF9FE7E7F7C00BF" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-82790BBAF1B417E7969CFE7E7F7CCB4F" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-9DE864ED2F8A9EA8F9E4FE7E7F7C81D1" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F720E3E5F630B936E8AD81B5AF7E7C27" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-A0C9BC0B90510249124781B651621734" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A26A1B1F69BF8FA7D6D081B487C48966" unitRef="usd">3143000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D58B888B046E3C6F458881B64E1D359F" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-F8335C64B4F7E053BE2181B522625CCB" unitRef="usd">3143000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-582398D2F828B357F973FE7E7F7CF008" unitRef="usd">284018000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-0E4550DAC0D2A4A0F7C8FE7E7F7C68AE" unitRef="usd">-63000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-640FC279AAFE6E3303D4FE7E7F7CD318" unitRef="usd">1390619000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-982CE077FC502AD6C793FE7E7F7C6380" unitRef="usd">104000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8308A92602DE29A39F9BFE7E7F7CD080" unitRef="usd">-1104252000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-AA5F17964C0CA962E5ECFE7E7F7C1FEA" unitRef="usd">-2390000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-27EA9DDB1948BBDCB4D2FE7E7F7CC472" unitRef="usd">285850000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-AD75096741D6EEDA97F3FE7E7F7C90B9" unitRef="usd">-219000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B559B7E728A7CFAF116FFE7E7F7C7522" unitRef="usd">1397646000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F3C801063F5320B5F7CDFE7E7F7C37EA" unitRef="usd">104000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D2D9FF16093D16BDA29FFE7E7F7C896B" unitRef="usd">-1108934000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-06BBC16BA0FF23844AD9FE7E7F7CCCD6" unitRef="usd">-2747000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-F3103AFD5BFC02F81989FE7E7F7CEAF8" unitRef="usd">157401000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-FAA71033E0EC31FE3F74FE7E7F7C3357" unitRef="usd">-195000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6C8BF9D6BF3635ECEB89FE7E7F7C1FA6" unitRef="usd">1411222000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A2B25654FC0EE46B9B10FE7E7F7C2EE8" unitRef="usd">105000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-4A66D19BD59DB2DDF9B4FE7E7F7C5D9B" unitRef="usd">-1250363000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-242800B077572D416276FE7E7F7C7B43" unitRef="usd">-3368000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-E8B8B30A58DE8D8E792DFE7E7F7C866E" unitRef="usd">52102000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-92C801228F15D1E248A1FE7E7F7C149F" unitRef="usd">-222000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E063697E08AD0670B17DFE7E7F7C3F18" unitRef="usd">1435526000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FE587BA5735460A05786FE7E7F7C12CB" unitRef="usd">106000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D751EE3C2180A69AFD66FE7E7F7CAD68" unitRef="usd">-1381404000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-381FD28534E81C1A56CCFE7E7F7C69A4" unitRef="usd">-1904000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityOther contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-98B0465E75C50B097575A031DE217F9C" unitRef="usd">70000</us-gaap:StockholdersEquityOther>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q4" decimals="-3" id="Fact-820405BE851775DDE3A2FE7E7F7C9FBC" unitRef="shares">306000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2017Q4" decimals="-3" id="Fact-921D259385206101D0F8FE7E7F7C43E6" unitRef="shares">122000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-9A3B2A84DAA08D3737A3FE7E7F7C82A5" unitRef="usd">3368000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-E5DD071D24192080AA83FE7E7F7C4EDD" unitRef="usd">1904000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9FE442666D9C0CB2379BFE7E7F7C2997" unitRef="usd">357000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6EC2A77B52CA503800C6FE7E7F7CFF2F" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2F562D4291498FB9E67DFE7E7F7CD1AF" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3093CCBBBBFED3E40B81FE7E7F7C3E0B" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-38F0794CC4B2FE34D2A4FE7E7F7CE656" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-04C6CF95426C6DD77CEEFE7E7F7C66AB" unitRef="usd">-357000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4B4C666A50FC782D7A29FE7E7F7CF594" unitRef="usd">621000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-5CC9775E8860F1C39985FE7E7F7CDB98" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-672624FCF6C5B2A6D934FE7E7F7C9393" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8EC73B443EB240AEEDFCFE7E7F7CAF04" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-FEA0F26519631AD794BEFE7E7F7CC36E" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-3D17084A2EFAA95D5BECFE7E7F7C1791" unitRef="usd">-621000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2466BB6093CB1EC805A4FE7E7F7C7AF6" unitRef="usd">1679000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6E5EA0CFE1EB9622A8BAFE7E7F7CEAAE" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-138A01C2F9D6CEE5046AFE7E7F7C2B39" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-0B3061A75E92180C6631FE7E7F7CF4EE" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DA50AC988A92798AA3D4FE7E7F7C8263" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-BC7E966A5AFBCAA560A7FE7E7F7C4862" unitRef="usd">1679000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UnamortizedDebtIssuanceExpense contextRef="FI2017Q4" decimals="-5" id="Fact-0C4E6905899E4BED21F6FE7E7F7C3E05" unitRef="usd">1900000</us-gaap:UnamortizedDebtIssuanceExpense>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BF8AC49AF22350D0DEB2FE7E7F7CF861" unitRef="usd">-156000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-92CCD4596E6D77292501FE7E7F7C8224" unitRef="usd">24000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-41C0CDB1B202CB21AE71FE7E7F7C68A3" unitRef="usd">-27000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-1DA494257A9DD87C69AEFE7E7F7C3148" unitRef="usd">121100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6A4B1DB6B7E5AE5B6C33FE7E7F7C9C8B" unitRef="shares">103591000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q1QTD" decimals="-3" id="Fact-209B57BC7BE3C027DDBDFE7E7F7CA835" unitRef="shares">103682000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q2QTD" decimals="-3" id="Fact-EE2FD0F5FFDC71C612FDFE7E7F7C3E21" unitRef="shares">103830000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3QTD" decimals="-3" id="Fact-568A7FD3A8EF5301E3CFFE7E7F7C2D88" unitRef="shares">103885000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4QTD" decimals="-3" id="Fact-A4A49AEC0256FDFBB388FE7E7F7C585E" unitRef="shares">104052000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0A43EF4058D320EFC019FE7E7F7CD9E8" unitRef="shares">103863000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1QTD" decimals="-3" id="Fact-220F3F57B1501CB8EDB5FE7E7F7CC786" unitRef="shares">104461000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q2QTD" decimals="-3" id="Fact-7ABB41345DDCEE3A5A0EFE7E7F7C3853" unitRef="shares">105300000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3QTD" decimals="-3" id="Fact-DF033F4E09A57388AEF4FE7E7F7CE5DD" unitRef="shares">105582000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4QTD" decimals="-3" id="Fact-C0239687A88A4A14BBF5FE7E7F7CEBAC" unitRef="shares">105588000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AE4B68BD242C68ABD162FE7E7F7CD63E" unitRef="shares">105237000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<lxrx:ArrangementsWithSymphonyIconIncTextBlock contextRef="FD2017Q4YTD" id="Fact-A01F1F6EE11DB5EE0C9FFE7E7F7C8FAC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Arrangements with Symphony Icon, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including XERMELO, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &amp;#8220;Programs&amp;#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&amp;#8220;Holdings&amp;#8221;), the Company&amp;#8217;s intellectual property rights related to the Programs. Holdings contributed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$45 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Symphony Icon in order to fund the clinical development of the Programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,092,946&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock on June&amp;#160;15, 2007 in exchange for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and an exclusive purchase option (the &amp;#8220;Purchase Option&amp;#8221;) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.  On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on July&amp;#160;30, 2010 and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,891,074&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to designees of Holdings on July&amp;#160;30, 2012 in satisfaction of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$35 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; base payment obligation.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon also agreed to make up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$45 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in additional contingent payments, which would consist of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of any consideration Lexicon received pursuant to any licensing transaction (a &amp;#8220;Licensing Transaction&amp;#8221;) under which Lexicon grants a third party rights to commercialize XERMELO or other pharmaceutical compositions modulating the same target as XERMELO (the &amp;#8220;LG103 Programs&amp;#8221;), subject to certain exceptions. The contingent payments would be due if and when Lexicon received such consideration from a Licensing Transaction. In the event Lexicon received regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon would pay Holdings the sum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which were attributable to the development of such product, reduced by up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon made any such payment upon United States regulatory approval, Lexicon would have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the payment made as a result of such United States regulatory approval.  The contingent payments were payable in cash or a combination of cash and common stock, in Lexicon&amp;#8217;s discretion, provided that no more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of any contingent payment would be paid in common stock.  In December 2014, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;666,111&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to designees of Holdings in satisfaction of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.5&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contingent payment obligation as a result of receiving an upfront payment pursuant to Lexicon&amp;#8217;s license and collaboration agreement with Ipsen.  In April 2015, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.75 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash to Holdings in satisfaction of its contingent payment obligation as a result of receiving an additional upfront payment from Ipsen in March 2015.  In September 2016, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash to Holdings in satisfaction of its contingent payment obligation as a result of receiving a milestone payment from Ipsen in August 2016 (see Note 15, Collaboration and License Agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2016, Lexicon entered into an amendment (the &amp;#8220;Amendment&amp;#8221;) to the Purchase Option Agreement with Holdings and Symphony Icon pursuant to which Lexicon agreed to pay Holdings &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon Lexicon&amp;#8217;s receipt of regulatory approval in the United States for the marketing and sale of XERMELO, such buyout amount to be in lieu of any remaining payments which may be or become payable to Holdings under the Purchase Option Agreement. In March 2017, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;659,905&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to designees of Holdings in satisfaction of its remaining contingent payment obligation as a result of receiving regulatory approval in the United states for the marketing and sale of XERMELO. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$45.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level&amp;#160;3 inputs. Key assumptions include: (1)&amp;#160;a discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;14%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the base payments; (2)&amp;#160;a discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;18%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the contingent payments; and (3)&amp;#160;a probability adjusted contingency.  No discount rate was used in the valuation of the contingent consideration liability as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as the expected buyout was short-term in nature.  Subsequent changes in the fair value of the Symphony Icon purchase consideration liability were recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, decreased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</lxrx:ArrangementsWithSymphonyIconIncTextBlock>
	<us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-E12603A653EF4ACD4CC2FE7E7F7C481B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cash and Cash Equivalents and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of cash and cash equivalents and investments held at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;222,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;222,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310,788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;300,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;299,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  There were no realized gains or losses for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-13128B1BE334F21855E9FE7E7F7CA367">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&amp;#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&amp;#160;&amp;#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&amp;#160;&amp;#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&amp;#8217; equity.&amp;#160;&amp;#160;Net realized gains and losses, interest and dividends are included in interest income.&amp;#160;&amp;#160;The cost of securities sold is based on the specific identification method.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-3AD1F419E97B2813250EFE7E7F7C82F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaboration and License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Sanofi.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &amp;#8220;Sanofi Agreement&amp;#8221;), with Sanofi for the worldwide development of Lexicon&amp;#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Sanofi Agreement, Lexicon has granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.  Subject to specified exceptions, neither party may (a) perform clinical development activities relating to any other compound which inhibits sodium-glucose cotransporters type 1 or type 2 or (b) commercialize any such compounds in the United States, countries of the European Union and certain other specified countries, in each case during the royalty terms applicable in such countries.  Among the specified exceptions is a right Lexicon retained to pursue the development of its LX2761 drug candidate, with respect to which Lexicon granted Sanofi certain rights of first negotiation specified in the Sanofi Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  In addition, Lexicon is eligible to receive from Sanofi (a) up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$110 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of four development milestones relating to the results of certain Phase 3 clinical trials of sotagliflozin in type 2 diabetes patients, (b) up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$220 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of four regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes, respectively, in each of the United States and Europe, of which two milestones representing the substantial majority of such aggregate amount relate to type 2 diabetes and the remaining two milestones relate to type 1 diabetes, (c) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of a milestone based on the results of either of two outcomes studies in type 2 diabetes patients, the completion of which would likely occur after initial regulatory approval of sotagliflozin in type 2 diabetes, and (d) up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$990 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of six commercial milestones that will be achieved upon reaching specified levels of sales.  The Company believes that each of the development and regulatory milestones under the Sanofi Agreement is substantive.  Due to the uncertainty surrounding the achievement of the future development and regulatory milestones, these payments will not be recognized as revenue unless and until they are earned, as the Company is not able to reasonably predict if and when the milestones will be achieved.  Commercial milestones, which are not encompassed within the definition of milestones under generally accepted accounting principles, will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Lexicon is also entitled to tiered, escalating royalties ranging from low double digit percentages to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;forty&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon will continue to be responsible for all clinical development activities relating to type 1 diabetes and has exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States. Under the terms of its co-promotion option, Lexicon will fund forty percent of the commercialization costs relating to such co-promotion activities. Sanofi will be responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and will be solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States. Lexicon will share in the funding of a portion of the planned type 2 diabetes development costs over the first three years of the collaboration, up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Sanofi will book sales worldwide in all indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The parties are responsible for using commercially reasonable efforts to perform their development and commercialization obligations pursuant to mutually approved development and commercialization plans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The parties&amp;#8217; activities under the Sanofi Agreement are governed by a joint steering committee and certain other governance committees which reflect equal or other appropriate representation from both parties. If the applicable governance committee is not able to make a decision by consensus and the parties are not able to resolve the issue through escalation to specified senior executive officers of the parties, then Sanofi will have final decision-making authority, subject to limitations specified in the Sanofi Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Sanofi Agreement will expire upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country is the period commencing on the effective date of the Sanofi Agreement and ending on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity and 10 years following the first commercial sale in the applicable country. Either party may terminate the Sanofi Agreement in the event of an uncured material breach by the other party. Prior to completion of the core development activities for type 2 diabetes specified in the development plan, Sanofi may terminate the Sanofi Agreement on a country-by-country and licensed product-by-licensed product basis, in the event of (a) notification of a material safety issue relating to the licensed product or the class of sodium-glucose cotransporters type 1 or type 2 inhibitors resulting in a recommendation or requirement that Lexicon or Sanofi cease development, (b) failure to achieve positive results with respect to certain clinical trial results, (c) the occurrence of specified fundamental adverse events or (d) the exploitation of the licensed product infringing third party intellectual property rights in specified major markets and Sanofi is unable to obtain a license to such third party intellectual property rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considered the following deliverables with respect to the revenue recognition of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The exclusive worldwide license granted to Sanofi to develop and commercialize sotagliflozin;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The development services Lexicon is performing for sotagliflozin relating to type 1 diabetes; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The funding Lexicon will provide for development relating to type 2 diabetes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the license had stand-alone value because it is an exclusive license that gives Sanofi the right to develop and commercialize sotagliflozin or to sublicense its rights.  In addition, sotagliflozin is currently in development and it is possible that Sanofi or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Sanofi Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services for type 1 diabetes and the obligation to provide funding for development services for type 2 diabetes over the period of time Lexicon performs services or provides funding, currently expected to be through 2020.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the initial allocable arrangement consideration was the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments or royalty payments.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: exercising the option to co-promote, estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services for type 1 diabetes by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the obligation to provide funding for type 2 diabetes by using internal estimates of the expected cash flows and timing for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in funding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the allocation, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$126.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment for the license in 2015.  The Company is recognizing the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$113.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allocated to the development services deliverable and the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$59.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allocated to the funding deliverable over the estimated period of performance as the development and funding occurs.  Revenue recognized under the Sanofi Agreement was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$56.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$126.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  Revenue for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of sales of clinical trial materials to Sanofi. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Ipsen.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &amp;#8220;Ipsen Agreement&amp;#8221;), with Ipsen&amp;#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &amp;#8220;Licensed Territory&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$43.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in upfront payments, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone upon Ipsen&amp;#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.84 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone upon Ipsen&amp;#8217;s first commercial sale in Germany, and a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.84 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone upon Ipsen&amp;#8217;s first commercial sale in the United Kingdom.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13.1&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8364;72&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified sales milestones.  Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned as the Company is not able to reasonably predict if and when the milestones will be achieved.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon supplies Ipsen&amp;#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considered the following deliverables with respect to the revenue recognition of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Territory;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The development services Lexicon is performing for XERMELO;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The obligation to participate in committees which govern the development of XERMELO&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;until commercialization; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the license had stand-alone value because it is an exclusive license that grants Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, currently expected to be through mid-2018.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company has determined the commercial supply agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the initial allocable arrangement consideration was the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;As a result of the allocation, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;$21.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;of the&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment for the license in 2014, and an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in 2015 upon entering into the amendment.  The Company is recognizing the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allocated to the development services deliverable over the estimated period of performance as development occurs, and is recognizing the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allocated to the committee participation deliverable ratably over the estimated period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  Revenue recognized under the Agreement was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  Revenue for the year ended December 31, 2017 includes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from sales of bulk tablets of XERMELO to Ipsen.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Texas Institute for Genomic Medicine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;&amp;#160;In July 2005, Lexicon received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;350,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cell lines for the Texas Institute for Genomic Medicine (&amp;#8220;TIGM&amp;#8221;) using Lexicon&amp;#8217;s proprietary gene trapping technology, which Lexicon completed in 2007.&amp;#160;&amp;#160;Lexicon also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&amp;#160;&amp;#160;The Texas Enterprise Fund made an additional award of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Texas A&amp;amp;M University System for the creation of facilities and infrastructure to house the library.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the award, Lexicon is responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,616&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new jobs in Texas by December 31, 2016.&amp;#160;&amp;#160;Lexicon will receive credits against those job obligations based on funding received by TIGM and certain related parties from sources other than the State of Texas.  Lexicon will also receive credits against those job obligations for any surplus jobs that Lexicon created.  Subject to these credits, the state may require Lexicon to repay &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2,415&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each job Lexicon falls short beginning in 2013.&amp;#160;&amp;#160;Lexicon&amp;#8217;s maximum aggregate exposure for such payments, if Lexicon fails to create any new jobs, is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$14.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, without giving effect to any credits to which Lexicon may be entitled.&amp;#160;&amp;#160;Lexicon has recorded this obligation as deferred revenue in the accompanying consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-1F09D2E6D41B86869E45FE7E7F7CD7CA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Operating Lease Obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&amp;#160;&amp;#160;A Lexicon subsidiary leases office space in Basking Ridge, New Jersey under a lease agreement, the term of which began in June 2015 and terminates in December 2022.  Rent expense is recognized on a straight-line basis over the lease term.&amp;#160;&amp;#160;Additionally, Lexicon leases certain equipment under operating leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense for all operating leases was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The following table includes non-cancelable, escalating future lease payments for the facility in New Jersey:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;639&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employment Arrangements:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either six or 12 months and, in some cases, payment of a specified portion of the officer&amp;#8217;s bonus target for such year, in the event of a specified termination of the officer&amp;#8217;s employment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Legal Proceedings:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-4FF73EEC2FE11A0DDB3EFE7E7F7CDFD6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon&amp;#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&amp;#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&amp;#160;&amp;#160;The Company has not experienced any significant credit losses to date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6B9E8B5B1D137265F3F1FE7E7F7C1903">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:CostOfSalesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-C1D480E8F0F306FDFCA5B9CCBA930779">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of Sales: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-088A4354B5644BE70351FE7E7F7C244A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Debt Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Notes.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In November 2014, Lexicon completed an offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$87.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Convertible Senior Notes due 2021 (the &amp;#8220;Convertible Notes&amp;#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&amp;#8217;s consolidated balance sheets.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes are governed by an indenture (the &amp;#8220;Indenture&amp;#8221;), dated as of November&amp;#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;per year, payable semiannually in arrears on June&amp;#160;1 and December&amp;#160;1 of each year, beginning on June&amp;#160;1, 2015. The Convertible Notes mature on December&amp;#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118.4553&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.442&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the issuance of the Convertible Notes, the Company incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of debt issuance costs, which offsets long-term debt on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the balance of unamortized debt issuance costs was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.9&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which offsets long-term debt on the consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the Convertible Notes was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$127.3&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and was determined using Level&amp;#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Mortgage Loan. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; third-party mortgage financing and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$20.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash.&amp;#160;&amp;#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;8.23%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&amp;#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  In April 2017, the mortgage was amended to extend the maturity date to April 2018, with the mortgage loan&amp;#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.1&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  This entire balance is recorded as current portion of long-term debt in the accompanying consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as there is a balloon payment due in April 2018.  Lexicon intends to refinance this debt prior to paying the balloon payment.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$59.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, before accumulated depreciation, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The fair value of Lexicon&amp;#8217;s mortgage loan approximates its carrying value.&amp;#160;&amp;#160;The fair value of Lexicon&amp;#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&amp;#8217;s estimated current incremental borrowing rate.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;BioPharma Term Loan.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP that provides up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; borrowing capacity (the &amp;#8220;BioPharma Term Loan&amp;#8221;) available in two tranches, each maturing in December 2022.  The BioPharma Term Loan bears interest at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly.  The first &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranche was funded in December 2017.  The second &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranche is available for draw by March 2019 at Lexicon&amp;#8217;s option if net XERMELO sales are greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the preceding quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the BioPharma Term Loan, the Company incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of debt issuance costs, which offsets long-term debt on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan.  The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&amp;#160;2 inputs using discounted cash flow analysis, based on the Company&amp;#8217;s estimated current incremental borrowing rate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes the aggregate scheduled future principal payments of the Company&amp;#8217;s long-term debt as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,594&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,924&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;231,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q4YTD" id="Fact-38D01E457EDAD266FEB0FE7E7F7C010A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity Incentive Awards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 Equity Incentive Plan:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and restated in February 2000, April 2009, April 2012, April 2015 and April 2017 and renamed the 2017 Equity Incentive Plan (the &amp;#8220;Equity Incentive Plan&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or more of the fair market value of the Company&amp;#8217;s common stock on the date of grant.&amp;#160;&amp;#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&amp;#160;&amp;#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;15,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;15,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock had been reserved for issuance, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;4,773,915&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;945,723&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; restricted stock units were outstanding, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,812,584&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued upon the exercise of stock options, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,118,151&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued pursuant to restricted stock units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;113,940&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 Non-Employee Directors&amp;#8217; Equity Incentive Plan:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&amp;#8217; Stock Option Plan, which was subsequently amended and restated in April 2009, April 2012, April 2015 and April 2017 and renamed the 2017 Non-Employee Directors&amp;#8217; Equity Incentive Plan (the &amp;#8220;Directors&amp;#8217; Plan&amp;#8221;).&amp;#160;&amp;#160;Under the Directors&amp;#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during any calender year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&amp;#8217;s board of directors during such calender year.&amp;#160;Stock options granted under the Directors&amp;#8217; Plan have an exercise price equal to the fair market value of the Company&amp;#8217;s common stock on the date of grant and a term of ten years from the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&amp;#8217; Plan shall not exceed in the aggregate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock had been reserved for issuance, stock options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;187,119&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were outstanding, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;none&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had been issued upon the exercise of stock options and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;82,696&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued pursuant to restricted stock awards granted under the Directors&amp;#8217; Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Option Activity:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;The following is a summary of stock option activity under Lexicon&amp;#8217;s equity incentive plans:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except exercise price data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average estimated grant date fair value of stock options granted during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$8.59&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$6.43&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$4.58&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The total intrinsic value of stock options exercised during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$35,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The weighted average remaining contractual term of stock options outstanding and exercisable was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;6.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;5.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, respectively, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the aggregate intrinsic value of the outstanding stock options and the exercisable stock options was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Bonus and Restricted Stock Unit Activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon granted its non-employee directors &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,248&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,456&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,360&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, respectively, of restricted stock awards.  The restricted stock awards had weighted average grant date fair values of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.61&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.96&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.49&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively, and vested immediately.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&amp;#8217;s stock-based compensation plans for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Aggregate Shares Reserved for Issuance&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;5,906,757&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;6,565,872&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional shares were available for future grants under Lexicon&amp;#8217;s equity incentive plans.&amp;#160;&amp;#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-CFE4E972F8233770EB35FE7E7F7C700F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss per Common Share:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2017Q4YTD" id="Fact-681E5FB75CE2C3FEA053FE7E7F7CE505">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;222,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;283,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310,788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;299,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q4YTD" id="Fact-092A1C1976B666A40229FE7E7F7C676B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&amp;#160;&amp;#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&amp;#160;&amp;#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; significant unobservable inputs (including the Company&amp;#8217;s own assumptions in determining the fair value of the Symphony Icon purchase consideration liability)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&amp;#160;&amp;#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;222,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;283,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310,788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;299,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company did not have any Level 3 assets during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company&amp;#8217;s Level&amp;#160;3 liabilities represented the contingent purchase consideration payable to Symphony Icon, and was estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon (&amp;#8220;Symphony Icon&amp;#8221;) purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, decreased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,927&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of base payment obligation with common stock and cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of contingent payment obligation with cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of contingent payment obligation with common stock and cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&amp;#160;&amp;#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010.&amp;#160;&amp;#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q4YTD" id="Fact-D6BD02FD6E7428023396FE7E7F7CB742">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,927&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of base payment obligation with common stock and cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of contingent payment obligation with cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of contingent payment obligation with common stock and cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="FD2017Q4YTD" id="Fact-F855F2723D2FC52215902487C4684249">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-AD192F285FB1AE7DEE12FE7E7F7C0253">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&amp;#8217;s division responsible for small molecule compound discovery.&amp;#160;&amp;#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&amp;#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$25.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represents the excess of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$36.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 30, 2010, Lexicon exercised its Purchase Option (as defined in Note 10) and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$18.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&amp;#8217;s single operating segment.&amp;#160;&amp;#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&amp;#160;&amp;#160;This test did not result in an impairment of goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-8AB4FB8403EDE8B2917BB9CB2058772F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Indefinite lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&amp;#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill Impairment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&amp;#160;&amp;#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&amp;#160;&amp;#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&amp;#160;&amp;#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&amp;#160;&amp;#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-F9CE0AFEB89D54C38980FE7E7F7C89AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Impairment of Long-Lived Assets:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-E7DB44A1012A89E9B4DFFE7E7F7C5519">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Tax Cuts and Jobs Act (the &amp;#8220;2017 Tax Act&amp;#8221;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including reducing the U.S. corporate income tax rate from 35 percent to 21 percent beginning in 2018.  At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon has not completed the accounting for the tax effects of the 2017 Tax Act; however, an estimate of the effects on the existing deferred tax balances has been made, as further discussed below.     &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Accordingly, Lexicon remeasured certain deferred tax assets and liabilities based on the newly enacted U.S. corporate income tax rate, which resulted in a decrease of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$171.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Lexicon will continue to make and refine calculations and estimates, which could potentially affect the measurement of the deferred tax balances or give rise to new deferred tax amounts.  Where the Company has not yet been able to make reasonable estimates of the impact of certain elements, the Company has not recorded any amounts related to those elements and has continued accounting for them in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the 2017 Tax Act.  Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of Lexicon&amp;#8217;s deferred tax assets (liabilities) at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;186,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;258,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;352,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;468,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability related to acquisition of Symphony Icon&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(347,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(468,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  During 2017, after XERMELO was approved by the FDA, the intangible asset related to XERMELO became finite-lived and as a result &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the related deferred tax liability could be considered as a source of taxable income. Lexicon does not believe it can estimate the reversal of the temporary difference related to the remaining assets acquired with sufficient certainty such that &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the deferred tax liability is not considered as a source of taxable income in assessing the Company&amp;#8217;s need for a valuation allowance in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the 2017 Tax Act.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon had both federal and state NOL carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$851.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$382.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The federal and state NOL carryforwards will begin to expire in 2018.&amp;#160;&amp;#160;The Company&amp;#8217;s R&amp;amp;D tax credit carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$46.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; began to expire in 2018.  The orphan drug credit relates to a credit that is calculated as a percentage of expenditures for development of XERMELO, which has received Orphan Drug designation from the FDA.&amp;#160;&amp;#160;Utilization of the NOL, R&amp;amp;D credit and orphan drug credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&amp;#160;382 of the Internal Revenue Code.&amp;#160;&amp;#160;Based on the federal tax law limits and the Company&amp;#8217;s cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets, excluding the deferred tax liability relating to the XERMELO finite-lived asset, until an appropriate level of profitability is sustained.&amp;#160;&amp;#160;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the valuation allowance decreased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$121.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, primarily due to the effect of the new U.S. federal corporate tax rate.&amp;#160;&amp;#160;Lexicon recorded income tax benefits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tax benefits, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is the release of a valuation allowance as a result of the ability to estimate the reversal of the deferred tax liability related to the intangible associated with XERMELO, as discussed above.  The remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recorded to remeasure the deferred tax liability associated with the remaining indefinite-lived intangible asset associated with Symphony Icon at the newly enacted U.S. corporate income tax rate.  There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; income tax benefits in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company did not have any unrecognized tax benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&amp;#160;&amp;#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&amp;#160;&amp;#160;The Company&amp;#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had no accruals for interest or penalties related to income tax matters.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="FD2017Q4YTD" id="Fact-322BBC697B89E5A3EB31B9B82AC6F7AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Intangible Assets:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  Other intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-14DBF02DD334E3725B22B98CBD6341FD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.  The Company began capitalizing inventory during 2017 after the approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO were recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2017Q4YTD" id="Fact-25FC168EB5556C33B1B6FE7E7F7C2C94">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-09, &amp;#8220;Revenue from Contracts with Customers&amp;#8221;, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or services.  In August 2015, the FASB issued ASU No. 2015-14, &amp;#8220;Revenue from Contracts with Customers: Deferral of Effective Date&amp;#8221;, which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual periods after December 15, 2017 including interim periods within that reporting period. Early application is permitted only for annual periods beginning after December 15, 2016, including interim periods within that reporting period. In 2016, the FASB issued four additional ASUs related to Topic 606: ASU Nos. 2016-08, 2016-10, 2016-12 and 2016-20.  These ASUs clarify various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations and licensing, and they include other improvements and practical expedients.  Two adoption methods are permitted; retrospectively to all prior reporting periods presented, with certain practical expedients; or the modified retrospective method with the cumulative effect of initially adopting the ASU recognized at the date of initial application.  The Company has elected to adopt this new standard effective January 1, 2018, using the modified retrospective transition method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To date, the Company has assessed that ASU 2014-09 will not have a material impact on revenue recognition from product revenue.  The Company&amp;#8217;s only source of product revenue has been sales of XERMELO, which the Company received FDA approval for in February 2017, and subsequently, entered into a limited number of arrangements with specialty pharmacies (&amp;#8220;SPs&amp;#8221;) in the U.S. (collectively, the &amp;#8220;customers&amp;#8221;), under which the Company began shipping to its customers in March 2017.  Under current GAAP, the Company recognizes revenue on its product sales when the customer obtains control of the product, which occurs upon delivery.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&amp;#8217;s net product revenues reflect the Company&amp;#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.  Under ASU 2014-09, the Company expects to be able to utilize a process and controls approach consistent with its historical process and based on the nature of its current contracts with customers, does not anticipate a significant amount of variable consideration subject to constraint.  As a result, the Company does not believe that the adoption of this ASU will have a material impact on the timing or amount of revenues recognized related to its contracts with customers for the sale of product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company expects the accounting for contingent milestone payments to be the most significant change in the accounting for its license and collaboration agreements.  Topic 605 provides guidance specific to the accounting for milestone payments, including the ability to defer the recognition of any milestones until received and, if certain criteria are met, the ability to recognize milestone payments as revenue when received.  Under the Company&amp;#8217;s current accounting policy, Lexicon recognizes contingent or milestone payments as revenue in the period that the payment-triggering event occurs or is achieved.  However, under the new revenue standard, it is possible to recognize contingent or milestone payments before the payment-triggering event is completely achieved, subject to management&amp;#8217;s assessment of the probability of achievement of the milestone and the likelihood of a significant reversal of such milestone revenue at each reporting date.  This assessment may result in recognizing milestone revenue before the milestone event has been achieved. The Company expects to evaluate estimates and timing of milestone achievement and related variable consideration based on the most likely amount method in its application of this ASU to collaborative agreements.  Estimating variable consideration and the related constraint will require the use of significant management judgment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To date, the Company&amp;#8217;s primary sources of collaboration revenue have been license and collaboration agreements with three separate third-party licensees: Texas Institute for Genomic Medicine (&amp;#8220;TIGM&amp;#8221;), Sanofi and Ipsen.  The Company has performed an evaluation of the expected effect of adoption in its accounting for license and collaboration agreements as discussed further below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;With respect to its contract with TIGM, the Company evaluated the variable consideration related to the remaining milestone in the adoption of this ASU and determined based on the most likely amount method that it was not probable that a significant reversal would occur and therefore, no constraint was required.  As a result, under the modified retrospective method, the Company will record a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cumulative-effect adjustment to its accumulated deficit on the date of adoption.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;With respect to its collaboration agreements with Sanofi and Ipsen, the Company evaluated the variable consideration relating to future milestone payments and determined, based on the most likely amount method, that the estimated amounts could be considered as part of the transaction price. The Company then evaluated the variable constraint and determined that the variable consideration amounts are constrained, primarily by future events that are not within the control of the Company. The future events primarily related to receipt of positive results from studies, approval from regulatory agencies, and upon achieving sales in certain locations.  As a result, the Company has determined that there is no cumulative adjustment necessary for these agreements on the date of adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The adoption of the ASU will have no significant impact to the provision for income taxes and will have no impact to the net cash provided by or used in operating, investing or financing activities on the Company&amp;#8217;s consolidated statements of cash flows.  Estimated impacts from adoption of this ASU may differ upon the final adoption and implementation in the first quarter of 2018.  As the Company completes its analysis of the accounting for the collaboration agreements under the new revenue standard, management is assessing the required changes to its accounting policies, systems and internal control over financial reporting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU No. 2016-01, &amp;#8220;Recognition and Measurement of Financial Assets and Financial Liabilities.&amp;#8221; ASU 2016-01 requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is not permitted. The adoption of this ASU on January 1, 2018 is not expected to have a material impact on Lexicon&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;Leases.&amp;#8221; ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement will also require additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. This ASU is required to be adopted using a modified retrospective approach.  Management plans to adopt ASU 2016-02 on January 1, 2019, and anticipates that most of its operating leases will result in the recognition of additional assets and corresponding liabilities on the consolidated balance sheet.  The Company does not expect that the implementation of the ASU will have a material impact on its financial position.  The actual impact will depend on the Company&amp;#8217;s lease portfolio at the time of adoption.  The Company continues to assess all implications of the standard and related financial disclosures. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, &amp;#8220;Stock Compensation,&amp;#8221; which is intended to simplify several aspects of the accounting for share-based payment award transactions. The Company adopted this pronouncement effective January 1, 2017.  Upon adoption, the Company recognized approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance is applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of deferred tax assets, the recognition of this provision of ASU 2016-09 had no impact to the Company&amp;#8217;s accumulated deficit as of January 1, 2017.  Additionally, the Company recorded an adjustment to accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a result of making an entity-wide accounting policy election to account for forfeitures of share-based payment awards as they occur instead of estimating the number of awards that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-D4250ECF172EB00C092CFE7E7F7C73DF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon Pharmaceuticals, Inc. (&amp;#8220;Lexicon&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a Delaware corporation incorporated on July&amp;#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&amp;#8217;s future success is dependent upon many factors, including, but not limited to, its ability to successfully commercialize XERMELO (telotristat ethyl) and any other products which gain regulatory approval, develop and obtain regulatory approval for its other drug candidates, achieve milestones under its collaboration agreements, establish new collaboration and license agreements, obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&amp;#160;&amp;#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&amp;#8217;s future success.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-0D6B0B7FF23263F84474FE7E7F7CD754">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&amp;#160;&amp;#160;The plan covers substantially all full-time employees.&amp;#160;&amp;#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&amp;#160;&amp;#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&amp;#160;&amp;#160;The matching contributions totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1,033,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$733,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$332,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;Company contributions are vested based on the employee&amp;#8217;s years of service, with full vesting after four years of service.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-9BEA416B32BC4B8D5A44FE7E7F7C667D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;In Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7-10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15-40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(59,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-B0752E35D011FC917662FE7E7F7C93F8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and Equipment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&amp;#160;&amp;#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&amp;#160;&amp;#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&amp;#160;&amp;#160;Significant renewals and betterments are capitalized.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2017Q4YTD" id="Fact-B985DAFCBB466ACA16B9FE7E7F7C05AA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;In Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7-10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15-40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(59,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2017Q4YTD" id="Fact-4671C18B4206B122170495CCB8CCB68E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares used in computing consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares used in computing consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Selected Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares used in computing consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares used in computing consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For all periods presented, the weighted average number of shares outstanding are the same for both basic and diluted consolidated net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q4YTD" id="Fact-7BAB5BD9C72662E43CAEFE7E7F7C7D7D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&amp;#160;&amp;#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&amp;#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&amp;#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-EB53C4A09D729FB9E894FE7E7F7C9D73">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized once the Company meets all four revenue recognition criteria described above.  In March 2017, Lexicon began shipping XERMELO to its customers in the United States.  The Company recognizes revenue for product sales of XERMELO at the time the product is received by its specialty pharmacy customers, net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States.  Product shipping and handling costs are included in cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer Credits:  The Company&amp;#8217;s specialty pharmacy customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. The Company expects the specialty pharmacies will earn prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from product sales as they are earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company&amp;#8217;s estimates for expected utilization of rebates are based in part on third party market research data, and data received from the specialty pharmacies. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s activity, plus an accrual balance for known prior quarter&amp;#8217;s unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy, in turn, charges back to Lexicon the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on known sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. The Company&amp;#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Collaborative Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The delivered item or items have value to the customer on a stand-alone basis; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&amp;#8217;s control.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration payable to the Company is commensurate with the Company&amp;#8217;s performance necessary to achieve the milestone or the increase in value to the collaboration resulting from the Company&amp;#8217;s performance;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The milestone relates solely to the Company&amp;#8217;s past performance; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The milestone is reasonable relative to all of the other deliverables and payments within the arrangement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial milestones will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Subscription and license fees are recognized as other revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-BD3731650111D7D496D8FE7E7F7C9F15">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;222,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;222,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310,788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;300,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;299,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;346,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-1E7E126FFAF1B26687DCFE7E7F7CC030">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;186,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;258,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;352,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;468,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability related to acquisition of Symphony Icon&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(347,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(468,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-70904B4578E2D171E104FE7E7F7C820D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;639&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E42AB87FB16896A42A79FE7E7F7C5292">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes the aggregate scheduled future principal payments of the Company&amp;#8217;s long-term debt as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,594&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,924&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;231,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-2C28FC565F81DF5991D5FE7E7F7CF701">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-13196B50EC1E54E5BEE3FE7E7F7CE8F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except exercise price data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E266A4786A7DC6754A29FE7E7F7CE090">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Risk-free Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Dividend&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-EF3ADB199D7A278F5B9DFE7E7F7CB674">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segment Information and Significant Customers:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&amp;#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q4YTD" id="Fact-D9D9CC2AD16257A4DA1FFE7E7F7C4FAB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&amp;#160;&amp;#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, stock-based compensation cost for all outstanding unvested options and restricted stock units was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$18.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&amp;#160;&amp;#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&amp;#160;&amp;#160;Because the Company&amp;#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&amp;#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&amp;#160;&amp;#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&amp;#160;&amp;#160;Expected volatility is based on the historical volatility in the Company&amp;#8217;s stock price.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q4YTD" id="Fact-67631F68F6FA6F04F855FE7E7F7C1EB8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&amp;#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&amp;#160;&amp;#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&amp;#160;&amp;#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&amp;#8217; equity.&amp;#160;&amp;#160;Net realized gains and losses, interest and dividends are included in interest income.&amp;#160;&amp;#160;The cost of securities sold is based on the specific identification method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&amp;#160;&amp;#160;&amp;#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&amp;#160;&amp;#160;Write-offs are evaluated on a case by case basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.  The Company began capitalizing inventory during 2017 after the approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO were recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.   Inventory consisted of the following as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:580px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:434px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:119px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;616&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;149&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon&amp;#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&amp;#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&amp;#160;&amp;#160;The Company has not experienced any significant credit losses to date.&amp;#160;&amp;#160;In 2017, customers in France and the United States represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue, respectively.  In 2016, customers in France and the United States represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  In 2015, customers in France and the United States represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue, respectively.&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, management believes that the Company has no significant concentrations of credit risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segment Information and Significant Customers:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&amp;#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Sanofi&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ipsen Pharma SAS&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;Ipsen&amp;#8221;) represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenues, respectively.  In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sanofi&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and Ipsen represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenues, respectively.  In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Sanofi represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenues. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Intangible Assets:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  Other intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  During &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, intangible assets relating to XERMELO of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the FDA.  The Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in amortization expense related to this asset, which is recorded as cost of sales in the accompanying consolidated statements of comprehensive loss for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and Equipment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&amp;#160;&amp;#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&amp;#160;&amp;#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&amp;#160;&amp;#160;Significant renewals and betterments are capitalized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Impairment of Long-Lived Assets:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During 2015, the Company determined that its buildings were impaired and therefore recorded an impairment loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was recorded in impairment loss on buildings in the accompanying consolidated statements of comprehensive loss.  There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairments of long-lived assets, including finite-lived intangible assets, in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Indefinite lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&amp;#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairments of indefinite lived intangible assets in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill Impairment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&amp;#160;&amp;#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&amp;#160;&amp;#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&amp;#160;&amp;#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&amp;#160;&amp;#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&amp;#160;&amp;#160;There was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment of goodwill in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized once the Company meets all four revenue recognition criteria described above.  In March 2017, Lexicon began shipping XERMELO to its customers in the United States.  The Company recognizes revenue for product sales of XERMELO at the time the product is received by its specialty pharmacy customers, net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States.  Product shipping and handling costs are included in cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer Credits:  The Company&amp;#8217;s specialty pharmacy customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. The Company expects the specialty pharmacies will earn prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from product sales as they are earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company&amp;#8217;s estimates for expected utilization of rebates are based in part on third party market research data, and data received from the specialty pharmacies. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s activity, plus an accrual balance for known prior quarter&amp;#8217;s unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy, in turn, charges back to Lexicon the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on known sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. The Company&amp;#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Collaborative Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The delivered item or items have value to the customer on a stand-alone basis; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&amp;#8217;s control.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration payable to the Company is commensurate with the Company&amp;#8217;s performance necessary to achieve the milestone or the increase in value to the collaboration resulting from the Company&amp;#8217;s performance;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The milestone relates solely to the Company&amp;#8217;s past performance; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The milestone is reasonable relative to all of the other deliverables and payments within the arrangement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial milestones will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Subscription and license fees are recognized as other revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of Sales: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&amp;#160;&amp;#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&amp;#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&amp;#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&amp;#160;&amp;#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, stock-based compensation cost for all outstanding unvested options and restricted stock units was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$18.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&amp;#160;&amp;#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&amp;#160;&amp;#160;Because the Company&amp;#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&amp;#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&amp;#160;&amp;#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&amp;#160;&amp;#160;Expected volatility is based on the historical volatility in the Company&amp;#8217;s stock price.&amp;#160;&amp;#160;The following weighted-average assumptions were used for options granted in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Risk-free Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Dividend&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss per Common Share:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-03B802D25E72EFA6A270FE7E7F7CE0FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Capital Stock Agreements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Reverse Stock Split&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:  Effective May 20, 2015, Lexicon completed a one-for-seven reverse split of its common stock.  All references to shares of common stock and per-share data for all periods presented in this report have been adjusted to give effect to this reverse stock split. Proportional adjustments were also made to all shares of common stock issuable under Lexicon&amp;#8217;s equity incentive plans and upon conversion of Lexicon&amp;#8217;s Notes. Concurrent with the reverse stock split, the authorized shares of common stock were reduced from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;900 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (prior to the reverse stock split) to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;225 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As no change was made to the par value of the common shares, common stock and additional paid-in capital were adjusted on a retroactive basis to give effect to the reverse stock split. No fractional shares were issued in connection with the reverse stock split. Any fractional share of common stock that would otherwise have resulted from the reverse stock split were converted into cash payments equal to such fraction multiplied by the closing sales price of the common stock as last reported on the last trading day immediately preceding the effective date of the reverse stock split.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2017Q4YTD" id="Fact-FDD883439971EAF69BC0FE7E7F7C407C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&amp;#160;&amp;#160;&amp;#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&amp;#160;&amp;#160;Write-offs are evaluated on a case by case basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2017Q4YTD" id="Fact-2D8806DA7AA5C645E192FE7E7F7CEE2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>lxrx-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20171231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="ArrangementsWithSymphonyIconInc" roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc">
        <link:definition>2134100 - Disclosure - Arrangements with Symphony Icon, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ArrangementsWithSymphonyIconIncDetails" roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails">
        <link:definition>2434402 - Disclosure - Arrangements with Symphony Icon, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ArrangementsWithSymphonyIconIncTables" roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables">
        <link:definition>2334301 - Disclosure - Arrangements with Symphony Icon, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetParentheticals" roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals">
        <link:definition>1001500 - Statement - Balance Sheet Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlan" roleURI="http://www.lexpharma.com/role/BenefitPlan">
        <link:definition>2149100 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanDetails" roleURI="http://www.lexpharma.com/role/BenefitPlanDetails">
        <link:definition>2449402 - Disclosure - Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanTables" roleURI="http://www.lexpharma.com/role/BenefitPlanTables">
        <link:definition>2349301 - Disclosure - Benefit Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsAndInvestments" roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments">
        <link:definition>2113100 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsAndInvestmentsDetails" roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails">
        <link:definition>2413402 - Disclosure - Cash and Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsAndInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables">
        <link:definition>2313301 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements">
        <link:definition>2150100 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails">
        <link:definition>2450401 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies">
        <link:definition>2137100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails1" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1">
        <link:definition>2437402 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails2" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2">
        <link:definition>2437403 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2337301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2131100 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables">
        <link:definition>2331301 - Disclosure - Debt Obligations Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails1" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1">
        <link:definition>2431402 - Disclosure - Debt Obligations (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails2" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2">
        <link:definition>2431403 - Disclosure - Debt Obligations (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument">
        <link:definition>0001000 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards">
        <link:definition>2146100 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails1" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1">
        <link:definition>2446402 - Disclosure - Equity Incentive Awards (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails2" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2">
        <link:definition>2446403 - Disclosure - Equity Incentive Awards (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails3" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3">
        <link:definition>2446404 - Disclosure - Equity Incentive Awards (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails4" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4">
        <link:definition>2446405 - Disclosure - Equity Incentive Awards (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables">
        <link:definition>2346301 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2116100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2416402 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2">
        <link:definition>2416403 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2316301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.lexpharma.com/role/Goodwill">
        <link:definition>2128100 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.lexpharma.com/role/GoodwillDetails">
        <link:definition>2428402 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.lexpharma.com/role/GoodwillTables">
        <link:definition>2328301 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lexpharma.com/role/IncomeTaxes">
        <link:definition>2125100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1">
        <link:definition>2425402 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2">
        <link:definition>2425403 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lexpharma.com/role/IncomeTaxesTables">
        <link:definition>2325301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperations" roleURI="http://www.lexpharma.com/role/OrganizationAndOperations">
        <link:definition>2101100 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperationsDetails" roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails">
        <link:definition>2401402 - Disclosure - Organization and Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperationsTables" roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables">
        <link:definition>2301301 - Disclosure - Organization and Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalStockAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements">
        <link:definition>2143100 - Disclosure - Other Capital Stock Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalStockAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails">
        <link:definition>2443402 - Disclosure - Other Capital Stock Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalStockAgreementsTables" roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables">
        <link:definition>2343301 - Disclosure - Other Capital Stock Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.lexpharma.com/role/PropertyAndEquipment">
        <link:definition>2122100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails1" roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1">
        <link:definition>2422402 - Disclosure - Property and Equipment (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables">
        <link:definition>2322301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements">
        <link:definition>2110100 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>2410402 - Disclosure - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsTables" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables">
        <link:definition>2310301 - Disclosure - Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialData" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData">
        <link:definition>2152100 - Disclosure - Selected Quarterly Financial Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataDetails" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails">
        <link:definition>2452402 - Disclosure - Selected Quarterly Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataTables" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables">
        <link:definition>2352301 - Disclosure - Selected Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfComprehensiveLossParentheticalsParentheticals" roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals">
        <link:definition>1003500 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2104100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>2404404 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesGoodwillDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>2404408 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails">
        <link:definition>2404407 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails">
        <link:definition>2404406 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails">
        <link:definition>2404403 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails">
        <link:definition>2404405 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1">
        <link:definition>2404409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2">
        <link:definition>2404410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2304302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets" name="AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_AdjustmenttoAccumulatedDeficit" name="AdjustmenttoAccumulatedDeficit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_ArrangementsWithSymphonyIconIncAbstract" name="ArrangementsWithSymphonyIconIncAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ArrangementsWithSymphonyIconIncTextBlock" name="ArrangementsWithSymphonyIconIncTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_AssetsAndLiabilitiesAtFairValueAbstract" name="AssetsAndLiabilitiesAtFairValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_BalanceSheetParentheticalsAbstract" name="BalanceSheetParentheticalsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_BenefitPlanAbstract" name="BenefitPlanAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_BuildingsCollateral" name="BuildingsCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" name="ChangeInFairValueOfSymphonyIconIncPurchaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_CoelacanthGoodwill" name="CoelacanthGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_CoelacanthPurchasePrice" name="CoelacanthPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit" name="CommonStockSharesAuthorizedAfterReverseStockSplit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit" name="CommonStockSharesAuthorizedBeforeReverseStockSplit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_ConcentrationOfCreditRiskAbstract" name="ConcentrationOfCreditRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedBalanceSheetsAbstract" name="ConsolidatedBalanceSheetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfOperationsAbstract" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" name="ConsolidatedStatementsOfOperationsParentheticalsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" name="ConvertibleDebtInstrumentInterestRateStatedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_DebtObligationsAbstract" name="DebtObligationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_DeferredTaxAssetremeasured" name="DeferredTaxAssetremeasured" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" name="DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" name="DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" name="DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" name="DeferredTaxLiabilityfromReclassifiedIntangibleAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_DeiAbstract" name="DeiAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_EntityWideRevenueIpsenPercentage" name="EntityWideRevenueIpsenPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_EntityWideRevenueSanofiPercentage" name="EntityWideRevenueSanofiPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_EquityIncentiveAwardsAbstract" name="EquityIncentiveAwardsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_FairValueMeasurementsAbstract" name="FairValueMeasurementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_GoodwillAbstract" name="GoodwillAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_HoldingsContributionToIcon" name="HoldingsContributionToIcon" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_IncomeTaxesAbstract" name="IncomeTaxesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_IntangibleAssetsAbstract" name="IntangibleAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_InventoryAbstract" name="InventoryAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenMaximumSalesMilestones" name="IpsenMaximumSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenMilestonePaymentReceived" name="IpsenMilestonePaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueRecognized" name="IpsenRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenTotalPaymentsToDate" name="IpsenTotalPaymentsToDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_IpsenTotalUpfrontPayments" name="IpsenTotalUpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_Ipsenproductsales" name="Ipsenproductsales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_LandCollateral" name="LandCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LexiconPaidHoldingsCash" name="LexiconPaidHoldingsCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LexiconReceivedCashFromHoldings" name="LexiconReceivedCashFromHoldings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LexiconSoldSharesToHoldings" name="LexiconSoldSharesToHoldings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606" name="Lxrx_AdjustmenttoAccumulatedDeficittoASC606" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_MinimumXERMELOsalestodrawTrancheB" name="MinimumXERMELOsalestodrawTrancheB" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_OptionsOutstandingEquityIncentivePlan" name="OptionsOutstandingEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" name="OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_OrganizationAndOperationsAbstract" name="OrganizationAndOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_OtherCapitalStockAgreementsAbstract" name="OtherCapitalStockAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_PropertyAndEquipmentAbstract" name="PropertyAndEquipmentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_RecentAccountingPronouncementsAbstract" name="RecentAccountingPronouncementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" name="RestrictedStockUnitsOutstandingEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" name="SanofiCommercializationCostsFundedbyLexiconMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiDevelopmentMilestones" name="SanofiDevelopmentMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiOutcomesStudyMilestone" name="SanofiOutcomesStudyMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiRegulatoryMilestones" name="SanofiRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" name="SanofiRevenueAllocatedtoDevelopmentDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiRevenueAllocatedtoFundingDeliverable" name="SanofiRevenueAllocatedtoFundingDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" name="SanofiRevenueAllocatedtoLicenseDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiRevenueRecognized" name="SanofiRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiSalesMilestonePayments" name="SanofiSalesMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiSalesofClinicalTrialMaterials" name="SanofiSalesofClinicalTrialMaterials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SanofiUpfrontPayment" name="SanofiUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_SegmentInformationAndSignificantCustomersAbstract" name="SegmentInformationAndSignificantCustomersAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_SelectedQuarterlyFinancialDataAbstract" name="SelectedQuarterlyFinancialDataAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" name="SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" name="SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" name="SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SharesIssuedToSymphonyDesigneesValue" name="SharesIssuedToSymphonyDesigneesValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharesIssuedtoSymphonyDesigneesShares" name="SharesIssuedtoSymphonyDesigneesShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_StockBasedCompensationAbstract" name="StockBasedCompensationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" name="StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" name="StockOptionExercisePriceAsPercentOfValueOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockOptionsExercisedEquityIncentivePlan" name="StockOptionsExercisedEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" name="StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonFairValueOfBaseAndContingentPayments" name="SymphonFairValueOfBaseAndContingentPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyAmendmentBuyout" name="SymphonyAmendmentBuyout" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyBasePaymentDiscountRate" name="SymphonyBasePaymentDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyBasePaymentInShares" name="SymphonyBasePaymentInShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyBasePaymentObligation" name="SymphonyBasePaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentDiscountRate" name="SymphonyContingentPaymentDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentInCash" name="SymphonyContingentPaymentInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyContingentPaymentMaximum" name="SymphonyContingentPaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentPercentage" name="SymphonyContingentPaymentPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentTotal" name="SymphonyContingentPaymentTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyContingentPaymentinShares" name="SymphonyContingentPaymentinShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyIconGoodwill" name="SymphonyIconGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyPaymentInStockLimitation" name="SymphonyPaymentInStockLimitation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyRegulatoryApprovalPayment" name="SymphonyRegulatoryApprovalPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyRegulatoryApprovalPercentageLimit" name="SymphonyRegulatoryApprovalPercentageLimit" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyRegulatoryApprovalReductionPercentage" name="SymphonyRegulatoryApprovalReductionPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TigmMaximumExposure" name="TigmMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TigmPerJobPaymentAmount" name="TigmPerJobPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" name="TotalSharesThatMayBeIssuedEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" name="TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_Totalvalueofsharesbynonemployeeinayear" name="Totalvalueofsharesbynonemployeeinayear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TrancheBdebt" name="TrancheBdebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TxEnterpriseFundAward" name="TxEnterpriseFundAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" name="TxEnterpriseFundAwardToTexasAmUniversitySystem" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_WoodlandsCashPaid" name="WoodlandsCashPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_WoodlandsMortgage" name="WoodlandsMortgage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_WoodlandsMortgageInterestRate" name="WoodlandsMortgageInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_XERMELOIntangibleAssetsFiniteLived" name="XERMELOIntangibleAssetsFiniteLived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>lxrx-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconInc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconIncTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:href="lxrx-20171231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:href="lxrx-20171231.xsd#BenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:href="lxrx-20171231.xsd#BenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:href="lxrx-20171231.xsd#BenefitPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:href="lxrx-20171231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:href="lxrx-20171231.xsd#CollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:href="lxrx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:href="lxrx-20171231.xsd#DebtObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:href="lxrx-20171231.xsd#DebtObligationsDebtObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:href="lxrx-20171231.xsd#DebtObligationsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:href="lxrx-20171231.xsd#DebtObligationsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:href="lxrx-20171231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:href="lxrx-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:href="lxrx-20171231.xsd#Goodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:href="lxrx-20171231.xsd#GoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:href="lxrx-20171231.xsd#GoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:href="lxrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:href="lxrx-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:href="lxrx-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:href="lxrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:href="lxrx-20171231.xsd#OrganizationAndOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:href="lxrx-20171231.xsd#OrganizationAndOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:href="lxrx-20171231.xsd#OrganizationAndOperationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:href="lxrx-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:href="lxrx-20171231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:href="lxrx-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:href="lxrx-20171231.xsd#StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_f61bf97e-c3a5-ba72-7591-eba8e7bb6a44" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_LongTermDebtCurrent_f61bf97e-c3a5-ba72-7591-eba8e7bb6a44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_d971df09-e3c8-ceae-8888-660d288fe07e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_d971df09-e3c8-ceae-8888-660d288fe07e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_32424e4b-3b4f-6262-5789-7226e08c0507" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_32424e4b-3b4f-6262-5789-7226e08c0507" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_865a78b9-3dc2-4444-a8d8-ea3d46665c1b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_865a78b9-3dc2-4444-a8d8-ea3d46665c1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_95be95e4-0ed3-e1e8-0c63-33a490947570" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_95be95e4-0ed3-e1e8-0c63-33a490947570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e9a2cdf1-6f49-806b-7b55-b9320bcfa87f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e9a2cdf1-6f49-806b-7b55-b9320bcfa87f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ac9066b4-6e40-13ed-8628-1a20304926d8" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ac9066b4-6e40-13ed-8628-1a20304926d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7ed6106-862d-edb5-3fd1-677e7651af64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7ed6106-862d-edb5-3fd1-677e7651af64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a3cce359-4901-8e47-7521-d2fa73471a4d" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a3cce359-4901-8e47-7521-d2fa73471a4d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_121f9e9b-9a4d-e32c-aef0-97aedfda4465" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_121f9e9b-9a4d-e32c-aef0-97aedfda4465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e5f1c7a4-b42a-8461-2001-b1f20e51b257" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e5f1c7a4-b42a-8461-2001-b1f20e51b257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_76304021-cc4c-b83e-0c43-ed738e4c3281" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_LicensesRevenue_76304021-cc4c-b83e-0c43-ed738e4c3281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_865a78b9-3dc2-4444-a8d8-ea3d46665c1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_865a78b9-3dc2-4444-a8d8-ea3d46665c1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_922befcd-b5b1-7112-2dca-80fbde69a2fe" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_AssetImpairmentCharges_922befcd-b5b1-7112-2dca-80fbde69a2fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_cc90e9d8-85f5-de51-59c9-fe7e8c451cad" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_cc90e9d8-85f5-de51-59c9-fe7e8c451cad" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9a11eaf9-5f74-f7cc-7851-bef6f9fc11af" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9a11eaf9-5f74-f7cc-7851-bef6f9fc11af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bbf9fd06-b461-3f65-8882-6e322d99a60b" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_da742b63-71db-0112-467b-fe7e8d10a56b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bbf9fd06-b461-3f65-8882-6e322d99a60b" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_da742b63-71db-0112-467b-fe7e8d10a56b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_40c7d4a7-f1a1-0c55-497e-f9a3bb09604c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bbf9fd06-b461-3f65-8882-6e322d99a60b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_40c7d4a7-f1a1-0c55-497e-f9a3bb09604c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>lxrx-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconInc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconIncTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:href="lxrx-20171231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:href="lxrx-20171231.xsd#BenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:href="lxrx-20171231.xsd#BenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:href="lxrx-20171231.xsd#BenefitPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:href="lxrx-20171231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:href="lxrx-20171231.xsd#CollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:href="lxrx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:href="lxrx-20171231.xsd#DebtObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:href="lxrx-20171231.xsd#DebtObligationsDebtObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:href="lxrx-20171231.xsd#DebtObligationsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:href="lxrx-20171231.xsd#DebtObligationsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:href="lxrx-20171231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:href="lxrx-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:href="lxrx-20171231.xsd#Goodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:href="lxrx-20171231.xsd#GoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:href="lxrx-20171231.xsd#GoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:href="lxrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:href="lxrx-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:href="lxrx-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:href="lxrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:href="lxrx-20171231.xsd#OrganizationAndOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:href="lxrx-20171231.xsd#OrganizationAndOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:href="lxrx-20171231.xsd#OrganizationAndOperationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:href="lxrx-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:href="lxrx-20171231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:href="lxrx-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:href="lxrx-20171231.xsd#StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:to="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:to="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:to="loc_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:to="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:to="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:to="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:to="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_273CEF408B6351516B60B4928F3F82E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_273CEF408B6351516B60B4928F3F82E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_273CEF408B6351516B60B4928F3F82E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_273CEF408B6351516B60B4928F3F82E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C85F26F6C504BB6202B1B4928F3F6807_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:to="loc_us-gaap_ClassOfStockDomain_C85F26F6C504BB6202B1B4928F3F6807_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C85F26F6C504BB6202B1B4928F3F6807" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:to="loc_us-gaap_ClassOfStockDomain_C85F26F6C504BB6202B1B4928F3F6807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:to="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_E791B43DA977DB0F8A15B493407EDE7B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_E791B43DA977DB0F8A15B493407EDE7B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_E791B43DA977DB0F8A15B493407EDE7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_E791B43DA977DB0F8A15B493407EDE7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="loc_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_D153785C0EC97FD0DF6BB493407E6396" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_D153785C0EC97FD0DF6BB493407E6396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:to="loc_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:to="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_538B6DC624B1054FB6A5B493408EED16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_538B6DC624B1054FB6A5B493408EED16_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_538B6DC624B1054FB6A5B493408EED16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_538B6DC624B1054FB6A5B493408EED16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_82060EE02BCD138A930DB493408ECE8E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_82060EE02BCD138A930DB493408ECE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_002764AE610955596427B493408EDAC9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_002764AE610955596427B493408EDAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:to="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:to="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_40F5E53A14A56E8A4D2FB493408EAB1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_CommonStockMember_40F5E53A14A56E8A4D2FB493408EAB1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedtoSymphonyDesigneesShares" xlink:label="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_87F1D64B122857877678B493408E961A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_NetIncomeLoss_87F1D64B122857877678B493408E961A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_DD3F4B8CAC2ABE0C9C44B493408E06FD" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_DD3F4B8CAC2ABE0C9C44B493408E06FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:to="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsMortgage" xlink:label="loc_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsCashPaid" xlink:label="loc_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsMortgageInterestRate" xlink:label="loc_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BuildingsCollateral" xlink:label="loc_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LandCollateral" xlink:label="loc_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TrancheBdebt" xlink:label="loc_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_MinimumXERMELOsalestodrawTrancheB" xlink:label="loc_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:to="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:to="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:to="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:to="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:to="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:to="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E3E221286A9FAE5D814EAFFC6F9DF54A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:to="loc_us-gaap_ClassOfStockDomain_E3E221286A9FAE5D814EAFFC6F9DF54A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E3E221286A9FAE5D814EAFFC6F9DF54A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:to="loc_us-gaap_ClassOfStockDomain_E3E221286A9FAE5D814EAFFC6F9DF54A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:to="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:to="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:to="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:to="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E32ED86A5000A0899887FE7EB8DB1F2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:to="loc_us-gaap_RangeMember_E32ED86A5000A0899887FE7EB8DB1F2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E32ED86A5000A0899887FE7EB8DB1F2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:to="loc_us-gaap_RangeMember_E32ED86A5000A0899887FE7EB8DB1F2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:to="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:to="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2659B8FA9920DAA2E759FE7EB8EB4E9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2659B8FA9920DAA2E759FE7EB8EB4E9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2659B8FA9920DAA2E759FE7EB8EB4E9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2659B8FA9920DAA2E759FE7EB8EB4E9A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:to="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388" xlink:to="loc_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>lxrx-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365_label_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365_documentation_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BalanceSheetParentheticalsAbstract" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:to="lab_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3_label_en-US" xlink:label="lab_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="lab_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:to="lab_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:to="lab_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:to="lab_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:to="lab_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:to="lab_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="lab_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:to="lab_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:to="lab_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:to="lab_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:type="arc" />
    <link:label id="lab_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0_label_en-US" xlink:label="lab_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0_documentation_en-US" xlink:label="lab_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_InventoryAbstract" xlink:label="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:to="lab_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:to="lab_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:to="lab_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:to="lab_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978_label_en-US" xlink:label="lab_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:to="lab_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:type="arc" />
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987_terseLabel_en-US" xlink:label="lab_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987_label_en-US" xlink:label="lab_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:to="lab_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20_label_en-US" xlink:label="lab_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:to="lab_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:to="lab_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:type="arc" />
    <link:label id="lab_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="lab_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:to="lab_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:to="lab_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:type="arc" />
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799_label_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799_documentation_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:to="lab_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:to="lab_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:type="arc" />
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:to="lab_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:type="arc" />
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3_terseLabel_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</link:label>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3_label_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of Symphony Icon Inc. purchase liability</link:label>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3_documentation_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:to="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Obligations</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:type="arc" />
    <link:label id="lab_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14_label_en-US" xlink:label="lab_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14_documentation_en-US" xlink:label="lab_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:to="lab_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:to="lab_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:to="lab_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7_verboseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="lab_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:type="arc" />
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:to="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:type="arc" />
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E_negatedTerseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:to="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:to="lab_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:type="arc" />
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF_label_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF_documentation_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:to="lab_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:type="arc" />
    <link:label id="lab_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16_label_en-US" xlink:label="lab_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Capital Stock Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Capital Stock Agreements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OtherCapitalStockAgreementsAbstract" xlink:label="loc_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:to="lab_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:type="arc" />
    <link:label id="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E_terseLabel_en-US" xlink:label="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized Before Reverse Stock Split</link:label>
    <link:label id="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E_label_en-US" xlink:label="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized Before Reverse Stock Split</link:label>
    <link:label id="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E_documentation_en-US" xlink:label="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of common shares permitted to be issued by an entity's charter and bylaws before the effective date of a reverse stock split, without giving effect to the reverse stock split.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit" xlink:label="loc_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E" xlink:to="lab_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_5D5E02BE3F3D7D98FBF095C33E83176E" xlink:type="arc" />
    <link:label id="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763_terseLabel_en-US" xlink:label="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized After Reverse Stock Split</link:label>
    <link:label id="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763_label_en-US" xlink:label="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized After Reverse Stock Split</link:label>
    <link:label id="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763_documentation_en-US" xlink:label="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of common shares permitted to be issued by an entity's charter and bylaws after the effective date of a reverse stock split.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit" xlink:label="loc_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763" xlink:to="lab_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_A75F186732DFA501D41F95C33E8A0763" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:to="lab_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:to="lab_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:to="lab_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9_label_en-US" xlink:label="lab_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:to="lab_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89_label_en-US" xlink:label="lab_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:to="lab_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:type="arc" />
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C_terseLabel_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C_label_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C_documentation_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:to="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:type="arc" />
    <link:label id="lab_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165_label_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165_documentation_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BenefitPlanAbstract" xlink:label="loc_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:to="lab_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:type="arc" />
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A_label_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A_documentation_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="lab_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8CACEBAA0C8AF23FD77895C2D84FD3B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E59DC0C97E0DFD633A8B95C2D85240CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_E3444072E477868FCC5595C2D855B1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_B8808A902D313146ABE095C2D8594DEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5EED0E037AB0F7BC107795C2D85A10A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_10FA5B34AA47A5F5E8E495C2D85CBA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5F5082846CF6D407749795C2D85E9599" xlink:type="arc" />
    <link:label id="lab_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F_label_en-US" xlink:label="lab_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Abstract]</link:label>
    <link:label id="lab_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F_documentation_en-US" xlink:label="lab_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BasisOfPresentationAbstract" xlink:label="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="lab_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Policy</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:to="lab_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:type="arc" />
    <link:label id="lab_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE_label_en-US" xlink:label="lab_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE_documentation_en-US" xlink:label="lab_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_GoodwillAbstract" xlink:label="loc_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:to="lab_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:type="arc" />
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C_label_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon Inc [Abstract]</link:label>
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C_documentation_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon Inc [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ArrangementsWithSymphonyIconIncAbstract" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:type="arc" />
    <link:label id="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381_terseLabel_en-US" xlink:label="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Holdings Contribution To Icon</link:label>
    <link:label id="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381_label_en-US" xlink:label="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holdings Contribution To Icon</link:label>
    <link:label id="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381_documentation_en-US" xlink:label="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On June 15, 2007, Symphony Icon Holdings LLC contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_HoldingsContributionToIcon" xlink:label="loc_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:to="lab_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:type="arc" />
    <link:label id="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88_terseLabel_en-US" xlink:label="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexicon Sold Shares To Holdings</link:label>
    <link:label id="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88_label_en-US" xlink:label="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexicon Sold Shares To Holdings</link:label>
    <link:label id="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88_documentation_en-US" xlink:label="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LexiconSoldSharesToHoldings" xlink:label="loc_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:to="lab_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:type="arc" />
    <link:label id="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0_terseLabel_en-US" xlink:label="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexicon Received Cash From Holdings</link:label>
    <link:label id="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0_label_en-US" xlink:label="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexicon Received Cash From Holdings</link:label>
    <link:label id="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0_documentation_en-US" xlink:label="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LexiconReceivedCashFromHoldings" xlink:label="loc_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:to="lab_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:type="arc" />
    <link:label id="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD_terseLabel_en-US" xlink:label="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexicon Paid Holdings Cash</link:label>
    <link:label id="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD_label_en-US" xlink:label="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexicon Paid Holdings Cash</link:label>
    <link:label id="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD_documentation_en-US" xlink:label="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the cash paid to Holdings.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LexiconPaidHoldingsCash" xlink:label="loc_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:to="lab_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01_terseLabel_en-US" xlink:label="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Fair Value Of Base And Contingent Payments</link:label>
    <link:label id="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01_label_en-US" xlink:label="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphon Fair Value Of Base And Contingent Payments</link:label>
    <link:label id="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01_documentation_en-US" xlink:label="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date fair value.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonFairValueOfBaseAndContingentPayments" xlink:label="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:to="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE_label_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE_documentation_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the base payment.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyBasePaymentDiscountRate" xlink:label="loc_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:to="lab_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the contingent payments.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentDiscountRate" xlink:label="loc_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:to="lab_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Base Payment In Shares</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A_label_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Base Payment In Shares</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A_documentation_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyBasePaymentInShares" xlink:label="loc_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:to="lab_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Obligation</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F_label_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Obligation</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F_documentation_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the $35 million base payment obligation that was paid in common stock.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyBasePaymentObligation" xlink:label="loc_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:to="lab_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Maximum</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Maximum</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the maximum amount for any contingent payment.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentMaximum" xlink:label="loc_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:to="lab_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the percentage of consideration received that will be paid to Holdings.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentPercentage" xlink:label="loc_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:to="lab_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Payment</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE_label_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Payment</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE_documentation_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the payment that will be made upon regulatory approval.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyRegulatoryApprovalPayment" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:to="lab_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Reduction Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E_label_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Reduction Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E_documentation_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the percentage reduction of the regulatory approval payment by previous contingent payments.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyRegulatoryApprovalReductionPercentage" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:to="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Percentage Limit</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6_label_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Percentage Limit</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6_documentation_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.  This represents the percentage by which proceeds of Licensing Transactions must exceed regulatory approval payments in order for Lexicon to have an obligation to make subsequent contingent payments.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyRegulatoryApprovalPercentageLimit" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:to="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Payment In Stock Limitation</link:label>
    <link:label id="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2_label_en-US" xlink:label="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Payment In Stock Limitation</link:label>
    <link:label id="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2_documentation_en-US" xlink:label="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The contingent payments to Holdings may be paid in cash or a combination of cash and common stock, in Lexicon's discretion, provided that no more than 50% of any payment will be paid in common stock.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyPaymentInStockLimitation" xlink:label="loc_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:to="lab_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment In Cash</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment In Cash</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments to Symphony Icon Holdings in the form of cash.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentInCash" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:to="lab_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Amendment Buyout</link:label>
    <link:label id="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104_label_en-US" xlink:label="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Amendment Buyout</link:label>
    <link:label id="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104_documentation_en-US" xlink:label="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In July 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings. In September 2016, Lexicon entered into an amendment to this agreement. This represents the buyout amount that Lexicon will pay Holdings in the event Lexicon receives regulatory approval in the U.S. for the marketing and sale of telotristat ethyl, such buyout amount to be in lieu of any remaining payments which may be or become payable to Holdings under the Purchase Option Agreement.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyAmendmentBuyout" xlink:label="loc_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:to="lab_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment in Shares</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment in Shares</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments to Symphony Icon Holdings in the form of stock.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentinShares" xlink:label="loc_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:to="lab_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Total</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Total</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments to Symphony Icon Holdings, in total.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentTotal" xlink:label="loc_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:to="lab_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:type="arc" />
    <link:label id="lab_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556_label_en-US" xlink:label="lab_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DEI [Abstract]</link:label>
    <link:label id="lab_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556_documentation_en-US" xlink:label="lab_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DEI [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeiAbstract" xlink:label="loc_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:to="lab_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE_label_en-US" xlink:label="lab_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:to="lab_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:to="lab_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B_label_en-US" xlink:label="lab_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:to="lab_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="lab_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905_label_en-US" xlink:label="lab_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:to="lab_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:to="lab_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:to="lab_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7_label_en-US" xlink:label="lab_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:to="lab_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9_terseLabel_en-US" xlink:label="lab_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9_label_en-US" xlink:label="lab_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:to="lab_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:to="lab_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:to="lab_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:to="lab_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300_label_en-US" xlink:label="lab_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:to="lab_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:to="lab_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:to="lab_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A_label_en-US" xlink:label="lab_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:to="lab_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_1C4D8DC90E0837D2A41F909663AB5199" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:type="arc" />
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:type="arc" />
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_RecentAccountingPronouncementsAbstract" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:type="arc" />
    <link:label id="lab_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Abstract]</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationAbstract" xlink:label="loc_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:to="lab_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:to="lab_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:type="arc" />
    <link:label id="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0_label_en-US" xlink:label="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information and Significant Customers [Abstract]</link:label>
    <link:label id="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0_documentation_en-US" xlink:label="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information and Significant Customers [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SegmentInformationAndSignificantCustomersAbstract" xlink:label="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:to="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:type="arc" />
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EntityWideRevenueSanofiPercentage" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5" xlink:to="lab_lxrx_EntityWideRevenueSanofiPercentage_957CBF3EF9D843B6FBB595DCE8FF32C5" xlink:type="arc" />
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Wide Revenue Ipsen Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Revenue Ipsen Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EntityWideRevenueIpsenPercentage" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F" xlink:to="lab_lxrx_EntityWideRevenueIpsenPercentage_8D9BA490657828B2E23395DCE90AA54F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and Software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:to="lab_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:to="lab_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF_label_en-US" xlink:label="lab_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:to="lab_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:type="arc" />
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability from Reclassified Intangible Asset</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability from Reclassified Intangible Asset</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability from Reclassified Intangible Asset - Upon approval by FDA, the indefinite-lived intangible asset was reclassified finite-lived asset and the tax effect was to book to a deferred tax liability with offset to accumulated deferred tax benefit.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:to="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:type="arc" />
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability from Reclassified Indefinite-lived Intangible</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability from Reclassified Indefinite-lived Intangible</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability from Reclassified Indefinite-lived Intangible - remeasured amount calculated using the tax rate of 21 percent from 35 percent and relating to the deferred tax liability associated with the indefinite-lived intangible asset associated with the Symphony Icon acquisition</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:to="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:type="arc" />
    <link:label id="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, remeasured</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, remeasured</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, remeasured - represents the remeasurement of the deferred tax asset and liabilities to the newly enacted US Federal corporate tax rate of 21%</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxAssetremeasured" xlink:label="loc_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:to="lab_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Federal</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:to="lab_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, State</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="lab_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2_label_en-US" xlink:label="lab_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:to="lab_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:to="lab_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3_label_en-US" xlink:label="lab_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:to="lab_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="lab_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:to="lab_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, including stock-based compensation of $4,905, $3,938 and $3,693, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative, including stock-based compensation of $4,567, $3,514 and $3,150, respectively</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on buildings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:to="lab_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:to="lab_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:to="lab_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085_label_en-US" xlink:label="lab_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:to="lab_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:to="lab_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss per common share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing consolidated net loss per common share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:type="arc" />
    <link:label id="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Accumulated Deficit to ASC606</link:label>
    <link:label id="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504_label_en-US" xlink:label="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">lxrx_Adjustment to Accumulated Deficit to ASC606</link:label>
    <link:label id="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504_documentation_en-US" xlink:label="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">lxrx_Adjustment to Accumulated Deficit to ASC606 - Lexicon will adopt ASU 2014-09, "Revenue Recognition" on 1-1-18. This represents the adjustment to accumulated deficit as a result of adopting the new standard.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606" xlink:label="loc_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:to="lab_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:type="arc" />
    <link:label id="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F_terseLabel_en-US" xlink:label="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Excess Tax Benefits Recognized as Deferred Tax Assets</link:label>
    <link:label id="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F_label_en-US" xlink:label="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Excess Tax Benefits Recognized as Deferred Tax Assets</link:label>
    <link:label id="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F_documentation_en-US" xlink:label="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lexicon will adopt ASU 2016-09, "Stock Compensation." This represents the accumulated excess tax benefits that will be recognized as deferred tax assets upon adoption.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets" xlink:label="loc_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:to="lab_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:type="arc" />
    <link:label id="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2_terseLabel_en-US" xlink:label="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Accumulated Deficit</link:label>
    <link:label id="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2_label_en-US" xlink:label="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Accumulated Deficit</link:label>
    <link:label id="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2_documentation_en-US" xlink:label="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lexicon will adopt ASU 2016-09, "Stock Compensation." This represents the adjustment to accumulated deficit as a result of making an entity-wide accounting policy election to account for forfeitures of share-based payment awards as they occur instead of estimating the number of awards that are expected to vest.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_AdjustmenttoAccumulatedDeficit" xlink:label="loc_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:to="lab_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1D5DC06E20502C6E644195E0A71E596B" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:to="lab_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:to="lab_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:to="lab_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8_verboseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued in satisfaction of Symphony Icon base payment obligation</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8_label_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued to Symphony Designees, Value</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the shares issued to designees of Holdings during the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:to="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CB3B68E8B039AFF5E61D95DD5FA3A86E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97641B4924EBB573D57595DD5FB080E8" xlink:type="arc" />
    <link:label id="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA_label_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA_documentation_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the goodwill.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CoelacanthGoodwill" xlink:label="loc_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA" xlink:to="lab_lxrx_CoelacanthGoodwill_7FDC448CA320C6DA0A1C95C25E2213CA" xlink:type="arc" />
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447_label_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447_documentation_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the purchase price.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CoelacanthPurchasePrice" xlink:label="loc_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447" xlink:to="lab_lxrx_CoelacanthPurchasePrice_40AC6A621CAA0106F54A95C25E240447" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C_label_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C_documentation_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyIconGoodwill" xlink:label="loc_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C" xlink:to="lab_lxrx_SymphonyIconGoodwill_3D8A521F2503F6A37DEF95C25E269C9C" xlink:type="arc" />
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9_terseLabel_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9_label_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9_documentation_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the upfront payment under the agreement.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiUpfrontPayment" xlink:label="loc_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:to="lab_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703_label_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703_documentation_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiDevelopmentMilestones" xlink:label="loc_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:to="lab_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608_label_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608_documentation_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRegulatoryMilestones" xlink:label="loc_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:to="lab_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA_terseLabel_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA_label_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA_documentation_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiOutcomesStudyMilestone" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:to="lab_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A_terseLabel_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A_label_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A_documentation_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the potential sales milestones payments under the agreement.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiSalesMilestonePayments" xlink:label="loc_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:to="lab_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0_terseLabel_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Development Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0_label_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Commercialization Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0_documentation_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:to="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueRecognized" xlink:label="loc_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:to="lab_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1_terseLabel_en-US" xlink:label="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Sales of Clinical Trial Materials</link:label>
    <link:label id="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1_label_en-US" xlink:label="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Sales of Clinical Trial Materials</link:label>
    <link:label id="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1_documentation_en-US" xlink:label="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the sales of clinical trial materials recognized in the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiSalesofClinicalTrialMaterials" xlink:label="loc_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:to="lab_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:type="arc" />
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the amount of the upfront payment allocated to the funding deliverable.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B_label_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan.  This represents the total all payments under the agreement to date.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenTotalPaymentsToDate" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:to="lab_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6_label_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the total of the upfront payments under the agreement.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenTotalUpfrontPayments" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:to="lab_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan.  This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenMilestonePaymentReceived" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueRecognized" xlink:label="loc_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:to="lab_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:type="arc" />
    <link:label id="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580_terseLabel_en-US" xlink:label="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580_label_en-US" xlink:label="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580_documentation_en-US" xlink:label="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan.  This represents the amount of product sales to Ipsen.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_Ipsenproductsales" xlink:label="loc_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:to="lab_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenMaximumSalesMilestones" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:type="arc" />
    <link:label id="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B_terseLabel_en-US" xlink:label="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TIGM Maximum Exposure</link:label>
    <link:label id="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B_label_en-US" xlink:label="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TIGM Maximum Exposure</link:label>
    <link:label id="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B_documentation_en-US" xlink:label="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TigmMaximumExposure" xlink:label="loc_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B" xlink:to="lab_lxrx_TigmMaximumExposure_41FA18F4F83908D3781EAFFBFD051C6B" xlink:type="arc" />
    <link:label id="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D_terseLabel_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D_label_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D_documentation_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TxEnterpriseFundAward" xlink:label="loc_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D" xlink:to="lab_lxrx_TxEnterpriseFundAward_1F0041A527ED5071F5D0AFFBFD0C829D" xlink:type="arc" />
    <link:label id="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21_terseLabel_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award to Texas AM University System</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21_label_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award to Texas AM University System</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21_documentation_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" xlink:label="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21" xlink:to="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_48C5228EB580703448ACAFFBFD13AA21" xlink:type="arc" />
    <link:label id="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7_terseLabel_en-US" xlink:label="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TIGM Per Job Payment Amount</link:label>
    <link:label id="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7_label_en-US" xlink:label="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TIGM Per Job Payment Amount</link:label>
    <link:label id="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7_documentation_en-US" xlink:label="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TigmPerJobPaymentAmount" xlink:label="loc_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7" xlink:to="lab_lxrx_TigmPerJobPaymentAmount_0A325FEB8ADD213BBF77AFFBFD1414A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:to="lab_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:type="arc" />
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318_terseLabel_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon, Inc.</link:label>
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318_label_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon Inc [Text Block]</link:label>
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318_documentation_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about a series of related agreements in 2007 providing for the financing of the clinical development of certain of its drug candidates.  These agreements were amended in 2010, when Lexicon exercised is purchase option and reaquired the clinical programs.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ArrangementsWithSymphonyIconIncTextBlock" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:to="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:type="arc" />
    <link:label id="lab_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2_label_en-US" xlink:label="lab_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:label id="lab_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2_documentation_en-US" xlink:label="lab_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IntangibleAssetsAbstract" xlink:label="loc_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:to="lab_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:type="arc" />
    <link:label id="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66_terseLabel_en-US" xlink:label="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">XERMELO Intangible Assets Finite Lived</link:label>
    <link:label id="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66_label_en-US" xlink:label="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">XERMELO Intangible Assets Finite Lived</link:label>
    <link:label id="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66_documentation_en-US" xlink:label="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets relating to XERMELO that were reclassified from indefinite-lived to finite-lived once the FDA approved XERMELO.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:label="loc_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:to="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:type="arc" />
    <link:label id="lab_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF_label_en-US" xlink:label="lab_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Abstract]</link:label>
    <link:label id="lab_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF_documentation_en-US" xlink:label="lab_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConcentrationOfCreditRiskAbstract" xlink:label="loc_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:to="lab_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:type="arc" />
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from external customers attributed to France as a percentage of total revenue.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_5D260A11E46D42159B7295DCB65F5D75" xlink:type="arc" />
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4CE8BA6736F7108127CC95DCB6653271" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:to="lab_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:to="lab_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="lab_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:type="arc" />
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:to="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:to="lab_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:type="arc" />
    <link:label id="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11_terseLabel_en-US" xlink:label="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Woodlands Mortgage</link:label>
    <link:label id="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11_label_en-US" xlink:label="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Woodlands Mortgage</link:label>
    <link:label id="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11_documentation_en-US" xlink:label="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the original $34.0 million mortgage.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsMortgage" xlink:label="loc_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:to="lab_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:type="arc" />
    <link:label id="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC_terseLabel_en-US" xlink:label="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Woodlands Cash Paid</link:label>
    <link:label id="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC_label_en-US" xlink:label="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Woodlands Cash Paid</link:label>
    <link:label id="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC_documentation_en-US" xlink:label="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the $20.8 million cash paid.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsCashPaid" xlink:label="loc_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:to="lab_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:type="arc" />
    <link:label id="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE_terseLabel_en-US" xlink:label="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WoodlandsMortgageInterestRate</link:label>
    <link:label id="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE_label_en-US" xlink:label="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WoodlandsMortgageInterestRate</link:label>
    <link:label id="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE_documentation_en-US" xlink:label="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">WoodlandsMortgageInterestRate interest rate on mortgage loan for Woodlands building and land</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsMortgageInterestRate" xlink:label="loc_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:to="lab_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:type="arc" />
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage Loans on Real Estate, Carrying Amount of Mortgages</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage Loans on Real Estate, Carrying Amount of Mortgages</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:type="arc" />
    <link:label id="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4_terseLabel_en-US" xlink:label="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4_label_en-US" xlink:label="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4_documentation_en-US" xlink:label="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The buildings that serve as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BuildingsCollateral" xlink:label="loc_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:to="lab_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:type="arc" />
    <link:label id="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC_terseLabel_en-US" xlink:label="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC_label_en-US" xlink:label="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC_documentation_en-US" xlink:label="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The land that serves as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LandCollateral" xlink:label="loc_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:to="lab_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:to="lab_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:type="arc" />
    <link:label id="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4_terseLabel_en-US" xlink:label="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B debt</link:label>
    <link:label id="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4_label_en-US" xlink:label="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B debt</link:label>
    <link:label id="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4_documentation_en-US" xlink:label="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B debt - Represents the second tranche of debt available for draw by March 19, 2019 at the Company's option if net XERMELO sales are greater than $25 million in the preceding quarter</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TrancheBdebt" xlink:label="loc_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:to="lab_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:type="arc" />
    <link:label id="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521_terseLabel_en-US" xlink:label="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum XERMELO sales to draw Tranche B</link:label>
    <link:label id="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521_label_en-US" xlink:label="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum XERMELO sales to draw Tranche B</link:label>
    <link:label id="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521_documentation_en-US" xlink:label="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum XERMELO sales to draw Tranche B - represents the minimum sales in a quarter that must be met by the Company before March 19, 2019 in order to draw $50 million on the debt agreement entered into during December 2017</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_MinimumXERMELOsalestodrawTrancheB" xlink:label="loc_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:to="lab_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2" xlink:to="lab_us-gaap_LeaseAndRentalExpense_2CB289780F0D3D6DA4EF95C2E8BE39A2" xlink:type="arc" />
    <link:label id="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357_label_en-US" xlink:label="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data [Abstract]</link:label>
    <link:label id="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357_documentation_en-US" xlink:label="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:to="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:to="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Information by Financial Statement Line Item [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:type="arc" />
    <link:label id="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements, Captions</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:to="lab_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) From Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:to="lab_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:to="lab_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Capital Stock Agreements</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:type="arc" />
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA_label_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA_documentation_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OrganizationAndOperationsAbstract" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:to="lab_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="lab_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:to="lab_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowances of $4</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0_label_en-US" xlink:label="lab_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:to="lab_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:to="lab_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:to="lab_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $58,623 and $59,875, respectively</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481_label_en-US" xlink:label="lab_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:to="lab_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_71B022638D3428909828B4928F3F2F97_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_71B022638D3428909828B4928F3F2F97_label_en-US" xlink:label="lab_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:to="lab_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:to="lab_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:to="lab_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:to="lab_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:to="lab_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA_label_en-US" xlink:label="lab_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:to="lab_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:to="lab_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="lab_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:to="lab_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 105,711 and 104,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:to="lab_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:to="lab_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 122 and 306 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:to="lab_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:to="lab_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:type="arc" />
    <link:label id="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251_label_en-US" xlink:label="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities at Fair Value [Abstract]</link:label>
    <link:label id="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251_documentation_en-US" xlink:label="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities at Fair Value [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_AssetsAndLiabilitiesAtFairValueAbstract" xlink:label="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:to="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:to="lab_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:to="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:to="lab_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:to="lab_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:to="lab_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to designees of Symphony Icon Holdings LLC, shares</link:label>
    <link:label id="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303_label_en-US" xlink:label="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued to Symphony Designees, Shares</link:label>
    <link:label id="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedtoSymphonyDesigneesShares" xlink:label="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:to="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:to="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:to="lab_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131" xlink:to="lab_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131" xlink:type="arc" />
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9_label_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9_documentation_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:to="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:type="arc" />
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:type="arc" />
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase shares outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:to="lab_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:type="arc" />
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:type="arc" />
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued upon the exercise of stock options under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:to="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:to="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:type="arc" />
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749_terseLabel_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749_label_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749_documentation_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:to="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:type="arc" />
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:type="arc" />
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:to="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:type="arc" />
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:to="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:type="arc" />
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:type="arc" />
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense.</link:label>
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>lxrx-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconInc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:href="lxrx-20171231.xsd#ArrangementsWithSymphonyIconIncTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:href="lxrx-20171231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:href="lxrx-20171231.xsd#BenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:href="lxrx-20171231.xsd#BenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:href="lxrx-20171231.xsd#BenefitPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:href="lxrx-20171231.xsd#CashAndCashEquivalentsAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:href="lxrx-20171231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:href="lxrx-20171231.xsd#CollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="lxrx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:href="lxrx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="lxrx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:href="lxrx-20171231.xsd#DebtObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:href="lxrx-20171231.xsd#DebtObligationsDebtObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:href="lxrx-20171231.xsd#DebtObligationsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:href="lxrx-20171231.xsd#DebtObligationsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:href="lxrx-20171231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:href="lxrx-20171231.xsd#EquityIncentiveAwardsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:href="lxrx-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:href="lxrx-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:href="lxrx-20171231.xsd#Goodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:href="lxrx-20171231.xsd#GoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:href="lxrx-20171231.xsd#GoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:href="lxrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:href="lxrx-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:href="lxrx-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:href="lxrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:href="lxrx-20171231.xsd#OrganizationAndOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:href="lxrx-20171231.xsd#OrganizationAndOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:href="lxrx-20171231.xsd#OrganizationAndOperationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:href="lxrx-20171231.xsd#OtherCapitalStockAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:href="lxrx-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:href="lxrx-20171231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:href="lxrx-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:href="lxrx-20171231.xsd#RecentAccountingPronouncementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="lxrx-20171231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:href="lxrx-20171231.xsd#StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lxrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ArrangementsWithSymphonyIconIncAbstract" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_999BCF873A70980C7926FE7EB8FA68C8" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ArrangementsWithSymphonyIconIncTextBlock" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_999BCF873A70980C7926FE7EB8FA68C8" xlink:to="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_C15692243B0F582357AEFE7EB8FAE318" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ArrangementsWithSymphonyIconIncAbstract" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_HoldingsContributionToIcon" xlink:label="loc_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_HoldingsContributionToIcon_36085E21609755F0C7E7A0A57D3B2381" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LexiconSoldSharesToHoldings" xlink:label="loc_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_LexiconSoldSharesToHoldings_1707A83C3D628117A448A0A57D3BEB88" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LexiconReceivedCashFromHoldings" xlink:label="loc_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_LexiconReceivedCashFromHoldings_7F6087B74B48B4F99320A0A57D3B96B0" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LexiconPaidHoldingsCash" xlink:label="loc_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_LexiconPaidHoldingsCash_D254CB08CCA1410AD9A2A0A57D3B78FD" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonFairValueOfBaseAndContingentPayments" xlink:label="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_97C4DB6B0A419CE7667EA0A57D3B2C01" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyBasePaymentDiscountRate" xlink:label="loc_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyBasePaymentDiscountRate_C2F361D15A43125C1A5BA0A57D3B0EEE" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentDiscountRate" xlink:label="loc_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyContingentPaymentDiscountRate_F23F9EB0B1DD69084EBCA0A57D3B6176" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyBasePaymentInShares" xlink:label="loc_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyBasePaymentInShares_E735CC2EA4E2B7E3C19FA0A57D3B6B0A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyBasePaymentObligation" xlink:label="loc_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyBasePaymentObligation_57D047BE1F574D264C7CA0A57D3B9D7F" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentMaximum" xlink:label="loc_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyContingentPaymentMaximum_E3A9E34A97C841A0CBF2A0A57D3B5EB0" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentPercentage" xlink:label="loc_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyContingentPaymentPercentage_C92F4E5018CB3C75C4F3A0A57D3BAC87" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyRegulatoryApprovalPayment" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalPayment_85854406D8D03257C634A0A57D3B66EE" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyRegulatoryApprovalReductionPercentage" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_49429F189D0E846B7204A0A57D3B037E" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyRegulatoryApprovalPercentageLimit" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_754DD9FB12E3E09D3116A0A57D3BA6D6" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyPaymentInStockLimitation" xlink:label="loc_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyPaymentInStockLimitation_72530809E9E1ACB6A9B3A0A57D3BD8E2" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentInCash" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_8828E58ABD703CFFD524A0A57D3B4446" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyAmendmentBuyout" xlink:label="loc_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyAmendmentBuyout_3A27CF29BD29ED2DCFF4A0A57D3B9104" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentinShares" xlink:label="loc_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyContingentPaymentinShares_E82FD5C8738A973AB74FA0A57D3B6747" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyContingentPaymentTotal" xlink:label="loc_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_SymphonyContingentPaymentTotal_BBEBC8A5E11F6BBE79C5A0A57D3BF38A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_05CAC7D3D0F2D54DB138A0A57D3B9EA1" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_EC15F45BE6664943232EA0A57D3B980C" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_05CAC7D3D0F2D54DB138A0A57D3B9EA1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BalanceSheetParentheticalsAbstract" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_A0CC94B423C9479BF3DE91451EBDF365" xlink:to="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8F3417764340491A86591451EBD022B" xlink:to="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_998089A042835F02582D91451EBD36DB" xlink:to="loc_us-gaap_CommonStockMember_C309E0E83B88A1B09FD591451EBD2072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_744FAF65CBE012DEEF5691451EBDDFB9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_FD3B7D6349FB900224CE91451EBDD600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1DB845C7249C4CC8E84891451EBD6CC6" xlink:to="loc_us-gaap_ClassOfStockDomain_4DBF72DF67DF43D33A0891451EBD754B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6FCF1696786A671E6FED91451EBD7FB3" xlink:to="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_DB799F9E90333D46C26391451EBDB10D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2C1E78F1FC654B7DA86391451EBD3AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CCA040A84750E3CFFD8591451EBDFB79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7FC8842EF39ABC4BAC2A91451EBDF229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4057F2C3706903F515BA91451EBDFD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5A8C3850730BEAD87C8991451EBD5D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_177C31209A3DFA0B1D7A91451EBD8068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ADDBBEE5CF5488115EDB91451EBD2198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_CommonStockSharesIssued_B860F035C9ABC1E61FC291451EBD2ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22BDF8A0FC85C1D1852791451EBDDA6F" xlink:to="loc_us-gaap_TreasuryStockShares_D571DA6E5434D37F34E091451EBD2EB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BenefitPlanAbstract" xlink:label="loc_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_23A22D5B81E978309E37FE7EB89CB165" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A8511D88557AC4CA0BDAFE7EB89CE0ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BenefitPlanAbstract" xlink:label="loc_lxrx_BenefitPlanAbstract_6FFEA49B29391E18A198908E807992E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0548C0C0D5C985FCE61F908E80791F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_6FFEA49B29391E18A198908E807992E0" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0548C0C0D5C985FCE61F908E80791F9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_8F803894EA929DE59386FE7EB8ACA434" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_8F803894EA929DE59386FE7EB8ACA434" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BD8ED9BA55A1D636466AFE7EB8AC07C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_FF9071E4E2E0440205AE771D5B221804" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:to="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentAxis_AE1A8AF8E9A3FB812D33771D5B223987" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_CashMember_421A0E9B77699592D6DD771D5B221A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7D66D87B3CCC24E1D599771D5B22E7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2D11D8859D669AD88C52771D5B220A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_812C8972AF51F44FCD89771D5B2204D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_69E7DE6085DDD7DB35FD771D5B22E473" xlink:to="loc_us-gaap_InvestmentsMember_75382938C1343BAF13B2771D5B22B756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_DAFA09871675EA4ACE28771D5B220ABB" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DBC186CCD051CE2D578B771D5B222D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2F842D5186CB57FC8421771D5B22758B" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_C7D5AB0DD4C0F4370DEE771D5B2275BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0EC8011186AD22434097771D5B2296BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAED7EF5486707A4F640771D5B22C718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50110AE9604B101E05EE771D5B220C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_493421A32E18E4674D67771D5B221DCC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_1B90D7FACF7013371439771D5B229257" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1D109D8A15E02BF7ACFDFE7EB9193107" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1D109D8A15E02BF7ACFDFE7EB9193107" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5B7022BDE43BC123E8A0FE7EB9199143" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_58DC314863EB6C855165FE7EB81FD1B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_58DC314863EB6C855165FE7EB81FD1B7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_743D49714351AAF59CFAFE7EB81FFDEE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiUpfrontPayment" xlink:label="loc_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiUpfrontPayment_B55D54EDF1688C308F36AFFA6CB617E9" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiDevelopmentMilestones" xlink:label="loc_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiDevelopmentMilestones_D652098BA60AD886B91FAFFA6CB6C703" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRegulatoryMilestones" xlink:label="loc_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiRegulatoryMilestones_D206843036DB3F7DD90BAFFA6CB7C608" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiOutcomesStudyMilestone" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiOutcomesStudyMilestone_275B26AEE695310EFD73AFFA6CB7C1DA" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiSalesMilestonePayments" xlink:label="loc_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiSalesMilestonePayments_44D7FD24B6526FA857CCAFFA6CB74A1A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_78ED476B1870FC579861AFFA6CB733B0" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_05DB480906312F50958FAFFA6CB78E0B" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_1F8B61B303EACFA6B5B4AFFA6CB7AB19" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueRecognized" xlink:label="loc_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiRevenueRecognized_1C77E01E20064F4A9560AFFA6CB71DFA" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiSalesofClinicalTrialMaterials" xlink:label="loc_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiSalesofClinicalTrialMaterials_6F15CA77997BF4BCF415AFFA6CB74DA1" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_AE39DCD4870C9A26BF16AFFA6CB76A30" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenTotalPaymentsToDate" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenTotalPaymentsToDate_89A4DB74711DD092D106AFFA6CB7482B" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenTotalUpfrontPayments" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenTotalUpfrontPayments_45E620EA30543699FD7CAFFA6CB70BE6" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenMilestonePaymentReceived" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_9C5866C1B5429C5E4EEAAFFA6CB7DF69" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_14788B52EC84257C4EFCAFFA6CB77408" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_64556388D32AF8C8FDB9AFFA6CB7C53D" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_09B801F120534AE4355AAFFA6CB77567" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80E04E7E0DFCFB183EE5AFFA6CB704C2" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenRevenueRecognized" xlink:label="loc_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenRevenueRecognized_508D3937E47624B37B84AFFA6CB87DA1" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_Ipsenproductsales" xlink:label="loc_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_Ipsenproductsales_546386B59513C3B0C99BAFFA6CB87580" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IpsenMaximumSalesMilestones" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_D1CB612F28091A54A794AFFA6CB8AD42" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TigmMaximumExposure" xlink:label="loc_lxrx_TigmMaximumExposure_2496206B32F523B1CC52AFFA6CB86EF2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_TigmMaximumExposure_2496206B32F523B1CC52AFFA6CB86EF2" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TxEnterpriseFundAward" xlink:label="loc_lxrx_TxEnterpriseFundAward_DFC2503BDD5413CE2399AFFA6CB87434" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_TxEnterpriseFundAward_DFC2503BDD5413CE2399AFFA6CB87434" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" xlink:label="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_0C526B1E092C570A7AE8AFFA6CB8F1F6" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_0C526B1E092C570A7AE8AFFA6CB8F1F6" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TigmPerJobPaymentAmount" xlink:label="loc_lxrx_TigmPerJobPaymentAmount_57D872C8640E2AFA076EAFFA6CB8931B" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_070787D9CC6CD41CEADCAFFA6CB2324C" xlink:to="loc_lxrx_TigmPerJobPaymentAmount_57D872C8640E2AFA076EAFFA6CB8931B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_CCB0AF56551E92DABF88FE7EB8EB3517" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_CCB0AF56551E92DABF88FE7EB8EB3517" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D218DADF9B1E40F06356FE7EB8EB320B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_1DFF98AB91AC13F75A5C95BD9AE5DD2A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7F9D0CB6F60BB670F11695BD9AE632B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_1DFF98AB91AC13F75A5C95BD9AE5DD2A" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7F9D0CB6F60BB670F11695BD9AE632B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C68C139A10EEBAFFF12D95BD9AE1F9D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C68C139A10EEBAFFF12D95BD9AE1F9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1735355C8879C2217A3195BD9AE25383" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1735355C8879C2217A3195BD9AE25383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_28E94C40AB9F56B327CD95BD9AE2A733" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_28E94C40AB9F56B327CD95BD9AE2A733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6775124ACD274B8AFA6695BD9AE2FBBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6775124ACD274B8AFA6695BD9AE2FBBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_6031D99EC3543F636F8E95BD9AE25208" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_6031D99EC3543F636F8E95BD9AE25208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_62FEFD4B476E45D270D995BD9AE221D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_62FEFD4B476E45D270D995BD9AE221D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_50D89E4FD106B385472E95BD9AE2173C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_E6A74093B8D2783FD54195BD9AE1569A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_50D89E4FD106B385472E95BD9AE2173C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_23CD3EF80DCA067AE983FE7EB81077FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_23CD3EF80DCA067AE983FE7EB81077FB" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FB718145DBE49E266AA2FE7EB810C596" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_7BEAFA1C3E19D6C60351B4928F3FC919" xlink:to="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:to="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_273CEF408B6351516B60B4928F3F82E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_C4DC287C444EC3ADA48DB4928F3F2A4B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_273CEF408B6351516B60B4928F3F82E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C85F26F6C504BB6202B1B4928F3F6807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F21CD58A3A3CF9932F54B4928F3F90DD" xlink:to="loc_us-gaap_ClassOfStockDomain_C85F26F6C504BB6202B1B4928F3F6807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72349B8038C2C5391EE2B4928F3F964F" xlink:to="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310981FBE26430203AD5B4928F3F8D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_ShortTermInvestments_4C0BC91263491D868298B4928F3FA481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1148D778407F2E1D3FC4B4928F3FB29A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_InventoryNet_4990030F17B6BA859D9BB4928F3F69B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_OtherAssetsCurrent_6B9E356AE986206E92F9B4928F3FB6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_266346A1D3797B2C3251B4928F3F1080" xlink:to="loc_us-gaap_AssetsCurrent_BE9BD233E3081B4E52D7B4928F3F38FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_66DC0D39B2D4DB7545DFB4928F3F080C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_Goodwill_44CAF15086F44B979E63B4928F3F7481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_64E9172CF182C05AA351B4928F3F0B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_29B85621B3858D5B9B1EB4928F3F04A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_Assets_71B022638D3428909828B4928F3F2F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_AccountsPayableCurrent_51044C1D87B69C839C3AB4928F3FA6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6DAA4831921CF5321165B4928F3FFAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2DAE3B2E46DD1FE12295B4928F3FAA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_LongTermDebtCurrent_305CA77709BCDF735004B4928F3FACE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18A72DF7C47B5DF5F08DB4928F3F3A85" xlink:to="loc_us-gaap_LiabilitiesCurrent_824862E984A6A9DFBFEEB4928F3F8BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3EBE7865AC1536A2D7A3B4928F3F5FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_A961BCE90FFA0A10C6A2B4928F3F9909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_DC070D06D4F75C45675BB4928F3FD91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_517FDADB04FDBCF26C3CB4928F3FF7FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_Liabilities_97306654E5D3F34F0582B4928F3FE5EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_CommitmentsAndContingencies_06CE09321FFCD1C4F32BB4928F3FC0F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_PreferredStockValue_840F911F0018E1D1743DB4928F3FDC26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_CommonStockValue_C36D66F3055E42BAC343B4928F3F3A50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_AdditionalPaidInCapital_98A127A13B352FBD8A51B4928F3FFD6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ADAB96CF8F2A3BBFA3D6B4928F3F0EFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62F5DCCCA3BBDADBFDAFB4928F3FA760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_TreasuryStockValue_49B811924279390AABEEB4928F3F8FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4843D219432E14E65C99B4928F3FF042" xlink:to="loc_us-gaap_StockholdersEquity_908B58DEB226ECC0C39EB4928F3FACD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BE9752A2D924E074956BB4928F3F0594" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9FE3247F101F6EA4291FB4928F3F011E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3A33B514851C9B898452B493407E20D2" xlink:to="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:to="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_E791B43DA977DB0F8A15B493407EDE7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_25BC32FE0B1B8C6E811AB493407E8294" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_E791B43DA977DB0F8A15B493407EDE7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_890CD01AF0E5769A48C7B493407E1429" xlink:to="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="loc_us-gaap_ProfitLoss_F90F23AA6C29A5087B73B493407E242F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4EA2E5CE32471094B7A9B493407ED732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_387E8DC2FC1601086CA3B493407E19B6" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_D153785C0EC97FD0DF6BB493407E6396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_D153785C0EC97FD0DF6BB493407E6396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_ShareBasedCompensation_710779EC37680E3BD447B493407EBAE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_334EC992257E5810A40BB493407ED075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_50BDECF30C324C2B6807B493407E1020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DFA37B9292B24CCE0EEBB493407EC984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A848BB79F9529DA92830B493407E7A2B" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09F91CF77D8BE6F0A881B493407E7DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_C6883A7B402BDAC7C12BB493407E1744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9D86782DF1E290773C17B493407E2FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8AC5644BAC87BF1899ECB493407E7D49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6D48BC1C9922EF524A7DB493407E1D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71641AA0BA23BABBCB72B493407E557A" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D04476ED0BCB602FDBE5B493407E8F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9E24B046E00E9382C3D1B493407E5B8E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A8458BC912A37408D2F3B493407E370E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15ACBA6D2D326753200AB493407EF258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8542577E77A487786FF3B493407E6C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_641F1271474D039740C2B493407E92DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_267789B3678552074265B493407E3614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D2B4D80A7D628D3AFA3AB493407EFF8E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_223784A93516BFD3998FB493407EF61C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73311F2D4D99617595B5B493407EECCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_E28CC634A987E928EF1EB493407EF7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6CF0DB6D401B7BD87613B493407EABED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8BC4F57595C385DB7C28B493407EA91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_42CCE4EDEA512A853A39B493407EF04E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FE1B6B2CBFEA2A423590B493407EB26E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_AEDED59F6AF0FDB95E21B493407E8C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EC6F953CE440DCFE0C30B493407E4BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2A0710049D6E8517F737B493407EE0FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76704F0E589A69B985B8B493407EE20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_C24B2661E7F21EC7AC4CB493407E67E7" xlink:to="loc_us-gaap_InterestPaidNet_A4DDE38A933E38AD2850B493407E347E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19F17330E4E49E6784CCB493407E7FE1" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_C9AF4F99BF1481BBD478B493407EC1CB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3643E7CCEF0AC7957299B493407E238D" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_D6160896F8E042FEABDBB493407E02C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_1ACFD12B87152CF50106B493408EE1AA" xlink:to="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:to="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_538B6DC624B1054FB6A5B493408EED16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_7CF6B9EDDBFA6F96D18CB493408E5506" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_538B6DC624B1054FB6A5B493408EED16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B4D2765F82774B2B4856B493408E328B" xlink:to="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_02AD28ECE325AC0644D7B493408EC23F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_ContractsRevenue_82E3E67EF052307365DAB493408E51B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_LicensesRevenue_206229C8C7D8BF487DD0B493408E4F2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_27D486BFE9D262F2AE8CB493408E694D" xlink:to="loc_us-gaap_Revenues_1E773F89F4E66E4B351FB493408E05C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_CostOfGoodsSold_C3B181C6CE4B1B06DFF4B493408E575B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_A977605E10318C5D25BCB493408EAEC0" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_82060EE02BCD138A930DB493408ECE8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_82060EE02BCD138A930DB493408ECE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_D8467D765A6F9BD1484BB493408E1730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_AssetImpairmentCharges_B8B899D05A1B4601CD39B493408E4DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97366601183D81C0837FB493408EEBE2" xlink:to="loc_us-gaap_OperatingExpenses_8477DF40BDE9CAF2EA76B493408E0C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OperatingIncomeLoss_F0A2F42469E59248D937B493408EBDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_InterestExpense_256FEACDDC9331360929B493408ED085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_894112C3D23CC87C6464B493408E680B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D13F209C367BBD3E96A7B493408E28BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_002764AE610955596427B493408EDAC9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_002764AE610955596427B493408EDAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B1ADF5827C6A5BCC38AFB493408ED3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_NetIncomeLoss_65D6CC0146E3C0590F33B493408EDDCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_5DEDCBCEF3827D71295FB493408EDCE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_99ABFDBA9196457822D5B493408E6D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98468105AA13D4A46CFEB493408EB804" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BC1A236A74B35B85BD6DB493408E328C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_C26D1A72234392573679B493408E28D0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_55E5F89B38A4CFF4BB6AB493408E3AA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1533BCC0A010F8B336D1B493408E24E2" xlink:to="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_435AD445D9759B554C1EB493408E26BE" xlink:to="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_40F5E53A14A56E8A4D2FB493408EAB1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_CommonStockMember_40F5E53A14A56E8A4D2FB493408EAB1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_E05D7B2E4F307A89BBBEB493408E3666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_RetainedEarningsMember_89EEAE86E1A80A3D011EB493408E241C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DD90650CE4218EE563D4B493408EC1E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EAB7381655562E0AA335B493408EDB87" xlink:to="loc_us-gaap_TreasuryStockMember_A0B41B0C798B3E7B0E90B493408E65CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_96274BF35C12E04B7F02B493408EFECF" xlink:to="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_E861248DDFB239A4132BB493408EEAFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1DA9FFF0A64FB3654387B493408E1D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockholdersEquity_C046C72EB56DE1ADCDD0B493408EFA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_310D6BFC559BDD879109B493408E87CB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedtoSymphonyDesigneesShares" xlink:label="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_9491F4A4E32040460220B493408E1303" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_1B06D0388925572BD456B493408E711E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C46CE5FB7E825B58ED91B493408EC450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28C4894D4171F158C525B493408E1CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1F7EFA23AD30D8C61240B493408EB8BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6C31613698814379D7E8B493408ECC51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_87F1D64B122857877678B493408E961A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_NetIncomeLoss_87F1D64B122857877678B493408E961A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_DD3F4B8CAC2ABE0C9C44B493408E06FD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_DD3F4B8CAC2ABE0C9C44B493408E06FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A7570FF8110077C7AD1FB493408E387F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockholdersEquityOther_5B5190FFCAB8E0E75DABB493408E181F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4B3366BB1B8FF2E3AC82B493408E320F" xlink:to="loc_us-gaap_StockholdersEquity_F744BB6679F04B269E08B493408EA131" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_8A8C37E755EFBC1B967495BD9B175909" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_8A8C37E755EFBC1B967495BD9B175909" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0552CA24F72713A3B15195BD9B179654" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_C853E0FF8C7009C780C295E0A719AB6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A5E5D874462292A629E595E022A05D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_C853E0FF8C7009C780C295E0A719AB6F" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A5E5D874462292A629E595E022A05D02" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_23CEC0991245589B36EBD48A22D345DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FB18CD4B8741D55C8667D48A22D49278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A40BDF489604593A668ED48A22D4FF2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_DF11B179F689C27B2781D48A22D4276E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_21E26C72FCBD499747B4D48A22D4A84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_D658AAF099F2C76A3781D48A22D44FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebt_3414CB6462F8A5E66948D48A22D4D2EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6C0A47474FADD5A89758D48A22D447C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtCurrent_E360FC79F1E1B16F7CD7D48A22D41DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_DFAA47ABACE7E4792A13D48A22D39210" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_90D92C98F11695A70A55D48A22D4FEC8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_02460B3F7CB809E35574B9DE94141049" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_02460B3F7CB809E35574B9DE94141049" xlink:to="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D1F65C444EE3810309AB9DE9414A620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3B04CF0DCAF5E36CE7C7B9DE9414B384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:to="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0BC73720F80D3D29FEB8B9DE94143432" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E06B4A4B44211CE42502B9DE94146BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C12FD3D68126876DCB78B9DE94144D5C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_E655CF00998C5487CDA1B9DE9414661E" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_2BDAE297A8F437FCAD14B9DE94147561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_791CC42887B4EB8661C3B9DE9414DF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_95BA19B8D350AC884220B9DE9414D111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_91EE0E45A96C3189B43BB9DE941421F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_9D24A753EF7AE1C495C2B9DE9414D820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_A611BC6C4BFCF5979325B9DE9414F7F3" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsMortgage" xlink:label="loc_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_WoodlandsMortgage_537CA66A1D2DF0EB1E31B9DE94147B11" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsCashPaid" xlink:label="loc_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_WoodlandsCashPaid_9C35B8167DC70245DE3AB9DE9414BCEC" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_WoodlandsMortgageInterestRate" xlink:label="loc_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_WoodlandsMortgageInterestRate_D0216FD7AF534D68A270B9DE94145FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A6CD32B3BE10F5C4C11CB9DE9414FF57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_2CB4ADB09BD6A6C46ED7B9DE94149B4A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BuildingsCollateral" xlink:label="loc_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_BuildingsCollateral_613E1B874248AA17A698B9DE941499A4" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_LandCollateral" xlink:label="loc_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_LandCollateral_21DEA8B66C62F5F04E1BB9DE94148BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentDescription_A8EAAA933F0FA5C4E042B9DE9414F615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_AEAEA3C929753C516B80B9DE94145636" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TrancheBdebt" xlink:label="loc_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_TrancheBdebt_0D53C6FA7503A409FC48B9DE941414D4" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_MinimumXERMELOsalestodrawTrancheB" xlink:label="loc_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_lxrx_MinimumXERMELOsalestodrawTrancheB_6A2E4C642E6D81521FFDB9DE94141521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C0DFC0993AD43E60DA5B9DE941494AC" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_5A8F8DD2602BD2BFCFB0B9DE9414CB8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeiAbstract" xlink:label="loc_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DeiAbstract_A1259A65DD061C0F3E64FE7EB81F4556" xlink:to="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:to="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_70E3676CF3F12D7AAE11FE7EB81F55BB" xlink:to="loc_dei_DocumentDomain_38A6BA1D854027E0EF86FE7EB81FDF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_AD8286397C7D76874B1DFE7EB81FD9EE" xlink:to="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityRegistrantName_70D1C65C0BE3FC14B07EFE7EB81F9905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityCentralIndexKey_654E1A16CDAB7903E9AFFE7EB81F8518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_CurrentFiscalYearEndDate_336973A42AD6C8830226FE7EB81FFF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityFilerCategory_E66693F3002730381671FE7EB81FE4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentType_E21DA51F6F7C457D5E3CFE7EB81F32D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentPeriodEndDate_F9BBFB778ACE21AB460DFE7EB81FF7C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentFiscalYearFocus_F12ADAC9384C3A339E75FE7EB81FC7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_DocumentFiscalPeriodFocus_B27D4E334ECDA555BABDFE7EB81FD0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_AmendmentFlag_6743A1A1168C20D2E81CFE7EB81FF300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7B227D0533773F1F5F43FE7EB81FD206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_FEE4459143A2D79CE4C6FE7EB81FAC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityVoluntaryFilers_D448FF86DCF316B4EE88FE7EB81F54E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityCurrentReportingStatus_E836ABE6EAC1598D673DFE7EB81FD2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6F6AC6AC70E61184AC71FE7EB81F6CBE" xlink:to="loc_dei_EntityPublicFloat_2C1B38F03022FE55EBCFFE7EB81F595A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_47973A6D8F62520416FEFE7EB8AC3784" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_47973A6D8F62520416FEFE7EB8AC3784" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_85C14B055173CFB6CB84FE7EB8ACFD63" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_0656A0297F90BF8DF5A2D924657764D9" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_18616813ECADB83CF230D924657775F7" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_CA74D6F75E8419A9972AD92465775F95" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6D0A53CDBE53E75ED449D9246577C47B" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_5F7E1EC64CE78CF09BB0D9246577F8B9" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_F15FC8096145CFD86192D9246577F7FB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_964B6BA3453864C747D4D9246577D263" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_7D18D132503658B90035D9295E2C0749" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_597775593EBC822320EFD92465776849" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_49F32757C0E35985F647D9246577A3E2" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A8BD8075060A35FD1AEED92465778156" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_5B0DA075011B1E271302D9246577F9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_BA4A9D07F781AE442665D924657703EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_E120F620DC59734D7158D9246577C817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14674C3FD121F0D8B518D9246577C31D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_9ECE4281D17A2ED1436E9AAF3601C41E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_9ECE4281D17A2ED1436E9AAF3601C41E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:to="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C22BDDD187EB7EF77DA99AAF360156E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_396AA01716B911780EC39AAF36014EEE" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68AA3BC2170286CD9CBE9AAF360149AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E8CDCE8A6069C4131A19AAF360143A8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BA6D4A29D138E52EBB269AAF36016187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59DF6671C940DB2F11459AAF36014511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6E572EE38AF8E75E844B9AAF3601B502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5DC7E6BED1ECDA29E39D9AAF360129C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1E0D76C5DD6538F5062C9AAF3601047D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_240473709532CC4CF6749AAF36017368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_E1308886F14F7330A90C9AAF3601BD11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19B596BE4E0C666117409AAF360142D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B98F79EB25490B720B39AAF3601F47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF58A247AA1840E2D01D9AAF3601378D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01227367C65BC263379F9AAF3601BD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_DBF8AE012F47E6B78A1B9AAF3601A847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91CFECA6D63C76ACDD3C9AAF36011D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_FDD7E16184D838BA6C869AAF360106A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_977E11569325D105F13D9AAF36011E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DCC03B190E991D4D6E689AAF3601E04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_03FB23C93F7E0B3B7AEC9AAF36015BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A2807C4FE2E3BD5AFFDC9AAF3601C39E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9929CAA80735556F83DB9AAF3601B276" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_4060BC375C0E7BE61E89AFFC6F9D1F2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_4060BC375C0E7BE61E89AFFC6F9D1F2B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5F8C3E87606DE0D69828AFFC6F9D7A40" xlink:to="loc_us-gaap_PlanNameDomain_C8831E31FD28D1608196AFFC6F9DD045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4DACFB27A874C8B265CDAFFC6F9D90E7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3880BAAA0D77D26FA856AFFC6F9D6AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E3E221286A9FAE5D814EAFFC6F9DF54A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12D6C245CBF6DB5D3930AFFC6F9D91EB" xlink:to="loc_us-gaap_ClassOfStockDomain_E3E221286A9FAE5D814EAFFC6F9DF54A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8715588790F8D59BBE9BAFFC6F9DF0E9" xlink:to="loc_us-gaap_RangeMember_C52A963DB52A9C154DF0AFFC6F9DDC89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DA2FACEFCF9FDB0B248EAFFC6F9D64B2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_07CB4A05C1EC4D8D1A0EAFFC6F9DE5AA" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4F9D41B8587BC1E65786AFFC6F9DFD6E" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_729A3D6C86A26051A3A3AFFC6F9DEF8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_B3ADCA542A92F0E544439AAF35E26C30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_B3ADCA542A92F0E544439AAF35E26C30" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:to="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0AFC556D554A71385F2C9AAF35E2EEC2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29F0BE5B76444FC175359AAF35F1DABE" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4014CF4A9D1C56E39C0E9AAF35F18EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B70D402B739C8BFB95F49AAF35E20EBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E1BFE3C03C93B3045B819AAF35F1AEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49184F07364EC18521D99AAF35F1AF6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7F28EB2764517654B83B9AAF35F1CF09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE10388C04A545AE9109AAF35F1AB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24FAC60473542434CBC19AAF35F1F450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_85B57C47EBCBB8F6C99D9AAF35F1A7CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1E9873E97424B1290BFE9AAF35F18F5C" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B6C3225115088BA3FB979AAF35F1E397" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_1CEA847BF399E30E5D839AAF35F107DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D40759C518514F844579FE7EB90ADE1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_32501BB2E69E5D48FAD6FE7EB90A9799" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_C535D44A8DA6C2FEB194FE7EB90A8089" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_B134D95F8961E4249FA0FE7EB8EBB4B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_B134D95F8961E4249FA0FE7EB8EBB4B2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_BAB37DCFCD603E37438EFE7EB8EB1713" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_AssetsAndLiabilitiesAtFairValueAbstract" xlink:label="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_957BCEAC8688824F889AA0ACDC8F4251" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8495DA963CD339D762B0A0ACDC8F89E1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D6B536DC35E8F97AA543A0ACDC8F2793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E9BF0B75D34C0C9CEEE7A0ACDC8F5BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B0D18722AA6695B3895A0ACDC8FEB0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_12EA106716A490C13459A0ACDC8FDF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_CF841CA3E087B1609EEBA0ACDC8FE901" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_C64051E25763CDCDD01BA0ACDC8F7150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_0ECF925398D8F25BE4AEA0ACDC8F9475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_B314285C355AB1BC5212A0ACDC8F70BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_109122F365EE583195E9A0ACDC8FDF16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C5AEB64C91B6E0D53F99A0ACDC8F256E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_033809E27E455B83FCE1A0ACDC8FE1DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_E02824A85171CAF74DC0FE7EB90AB89B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_E02824A85171CAF74DC0FE7EB90AB89B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_A79F151FC9287C278ED2FE7EB90AD394" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CBA699AD7FDA8B756EE0FE7EB90A339A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_BB9C77CFB11BF0308CE6FE7EB90ACC4A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_FA0CD7DF8ED476B9F4C8FE7EB90A05F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E63EEBF04522DA70EB75FE7EB90A8365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BE601B896286E1F00CF3FE7EB90A83ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_15DEE0D38AEAE0933219FE7EB90A6284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EF347AA91A8CBF97A1D9FE7EB90A7E3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19CFF4AF200879B2A1B4FE7EB8AC8F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_283B6D5EE8C993E2ED78FE7EB8AC324D" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50759B2A83763F326A2FFE7EB8ACDEE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_GoodwillAbstract" xlink:label="loc_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_2889457A96ACB831DE82FE7EB8DB70CE" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8AC07B2EE42D63BA4323FE7EB8DB99C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_GoodwillAbstract" xlink:label="loc_lxrx_GoodwillAbstract_B1A21A2CA2429A14EF4995BD9B1B2A1C" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CoelacanthGoodwill" xlink:label="loc_lxrx_CoelacanthGoodwill_FBFE5C495F493CE28F0795BD9B1CF2E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_B1A21A2CA2429A14EF4995BD9B1B2A1C" xlink:to="loc_lxrx_CoelacanthGoodwill_FBFE5C495F493CE28F0795BD9B1CF2E8" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CoelacanthPurchasePrice" xlink:label="loc_lxrx_CoelacanthPurchasePrice_B595654E15976EF2214695BD9B1C364F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_B1A21A2CA2429A14EF4995BD9B1B2A1C" xlink:to="loc_lxrx_CoelacanthPurchasePrice_B595654E15976EF2214695BD9B1C364F" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SymphonyIconGoodwill" xlink:label="loc_lxrx_SymphonyIconGoodwill_A3F018BEFCEF107D985E95BD9B1CE41A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_B1A21A2CA2429A14EF4995BD9B1B2A1C" xlink:to="loc_lxrx_SymphonyIconGoodwill_A3F018BEFCEF107D985E95BD9B1CE41A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_0BBED82A15FB04DE96ADFE7EB8CB03D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_0BBED82A15FB04DE96ADFE7EB8CB03D3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4128B3A06D9B1A7ABD9DFE7EB8CB2548" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_19077563299F8FCF154DB005AD642A14" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_B8DB42B0CFB68AE563C4B005AD6568F6" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5D2B72E9C6A031F7EB8EB005AD658387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_0821CABDE47646B16E7BB005AD65C7A2" xlink:to="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_C568F6DDFCEA188B600CB005AD6506D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7E87CC6727765417BA54B005AD654CB1" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_D09FB56C12ED1185314CB005AD659D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_C03024E3908F9008F924B005AD653F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_F71AF06EDF6AC1B06DC1B005AD653961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DC0822DF076AF16D91B8B005AD651F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3D09A1922B6831882DEEB005AD658500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7D835487AD712C91C7D8B005AD65073B" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_4CF80554D5F14167EE4BB005AD651D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3B082577518BBA5A1E47B005AD654E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_BCDD079CEEC0ADBEAD5CB005AD6504F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2B535B61015897C3DAA3B005AD658231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_C575E20DD20E0BBC2D72B005AD6590A7" xlink:to="loc_us-gaap_DeferredTaxLiabilities_574D9CF4AB8E1BA30FB8B005AD653AF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_175AA818F9AE009A8B04D9CF639C0974" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_35C4D955D512C9D1E89BD9CF639C29E6" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DeferredTaxAssetremeasured" xlink:label="loc_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_lxrx_DeferredTaxAssetremeasured_0C1E17DAD1355E828041D9CF639C6C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5BAE847B54D0B73B7C91D9CF639C7A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_A77631F3BAA62EFC4C7DD9CF639CBD1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6AE627A49D50DDAF5ACED9CF639CEF58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_A7CB54D2095F57A0EA28D9CF639C96B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACC0CD852734196FD072D9CF639CC014" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E210DED8E59811D8280BD9CF639CFD57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_5CE47AAAC564E798EDBEFE7EB8ACB890" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_5CE47AAAC564E798EDBEFE7EB8ACB890" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_DBB6D99527DFBBEE7217FE7EB8ACC9FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OrganizationAndOperationsAbstract" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_23C85A8D4223FCDB0395FE7EB8107AEA" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_78B89451B7AFEA6C9780FE7EB8100218" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OtherCapitalStockAgreementsAbstract" xlink:label="loc_lxrx_OtherCapitalStockAgreementsAbstract_6FF3593B292F0B8F79E2FE7EB82FA633" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_6FF3593B292F0B8F79E2FE7EB82FA633" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0A0DEF2A4DAC49739D7FFE7EB82F0DDD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_OtherCapitalStockAgreementsAbstract" xlink:label="loc_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit" xlink:label="loc_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_9443DE96FB993A83D7D195BD9AD6BB35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:to="loc_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit_9443DE96FB993A83D7D195BD9AD6BB35" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit" xlink:label="loc_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_E51E6954DC2AA8B07B5095BD9AD61A81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_1AD4BFBD4F9EA634F13F95BD9AD67E16" xlink:to="loc_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit_E51E6954DC2AA8B07B5095BD9AD61A81" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_1D83A8C58B67D8E9D31FFE7EB8ACE0E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_1D83A8C58B67D8E9D31FFE7EB8ACE0E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23D6A4E5ECEDBB2DCCC4FE7EB8ACD90E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_46464D5F340D59C8082BFE7EB8DB74A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_46464D5F340D59C8082BFE7EB8DB74A8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74B6BB432CBEADC723E8FE7EB8DBCEEE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_ComputerEquipmentMember_1E70DDD70931374806B8FE7EB8DBD126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_68A105895010C9752987FE7EB8DB8BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_EquipmentMember_D28B56B241BCFA08823EFE7EB8DB3E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_67B57D223E6F1579851FFE7EB8DB10A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_64FB1156D28E67AFBB87FE7EB8DB2769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0CEB8D99B811BA6B714DFE7EB8DB7D0D" xlink:to="loc_us-gaap_LandMember_6FEE0C4077973645CBD7FE7EB8DBEFAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:to="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E32ED86A5000A0899887FE7EB8DB1F2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CF18ACBFA3ACE4A3F8E1FE7EB8DB323A" xlink:to="loc_us-gaap_RangeMember_E32ED86A5000A0899887FE7EB8DB1F2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AB811AB5CABFB200C734FE7EB8DB0165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_84009589E910DBB85D46FE7EB8DBBD18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5B03AE560B71B0C93B1EFE7EB8DB0369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E78220A5725C7B15C9D3FE7EB8DB1D3D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D75CBCACFE9B8C164ACEFE7EB8DB08B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_583E6B7C12A4D0D221E0FE7EB8ACE6CF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1853A6AC947E989B0598FE7EB8ACA93A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_RecentAccountingPronouncementsAbstract" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_A5A1661A57A4E7A47EB7FE7EB8AC2A99" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_F4E428EF764678A30928FE7EB8AC56A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_RecentAccountingPronouncementsAbstract" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_D48F768A111FAD526A5BB9DE4AC59549" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606" xlink:label="loc_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_D48F768A111FAD526A5BB9DE4AC59549" xlink:to="loc_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606_89DAB2BE1EF3C9D4481DB9DE4AC50504" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets" xlink:label="loc_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_D48F768A111FAD526A5BB9DE4AC59549" xlink:to="loc_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets_DD9E0F45946C8871BE69B9DE4AC5C74F" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_AdjustmenttoAccumulatedDeficit" xlink:label="loc_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_D48F768A111FAD526A5BB9DE4AC59549" xlink:to="loc_lxrx_AdjustmenttoAccumulatedDeficit_02A106C3350FFE6C5BC0B9DE4AC542C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_B7DB61C1BD9791C1E2CAFE7EB8AC495A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_B7DB61C1BD9791C1E2CAFE7EB8AC495A" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_5AC50015A3E0857838D8FE7EB8AC6CF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_AC6416BC64BB3479414D90C1AEA12357" xlink:to="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4960A1E09EC9035BFBF090C1AEA137B6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7F2915FBD988D90FE1A890C1AEA12918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_5FD46621EB9CDD3F9B3790C1AEA11BA4" xlink:to="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_SalesRevenueNet_A39EBE199E879E6AEEAD9105D0D69C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_OperatingIncomeLoss_78A466EC6EA10683617790C1AEA192FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_NetIncomeLoss_33C10B3F21B2ABB00430919ACCB08B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_72F648862C57242F9DBE90C1AEA137D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_1EECCE54BEBE418E596E90C1AEA11F4A" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_B55DB1E594D6DF575B9490C1AEA17CA6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_825C16F5FE251B65B3B0B9DE9397D1DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_794D47288FEC37B1CB59B9DE93971E86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_825C16F5FE251B65B3B0B9DE9397D1DD" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_794D47288FEC37B1CB59B9DE93971E86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_68C8D2B27E1AF55B0353FE7EB8EBF098" xlink:to="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:to="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2659B8FA9920DAA2E759FE7EB8EB4E9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_FECC72B39DD6C5EF0A47FE7EB8EB9D98" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2659B8FA9920DAA2E759FE7EB8EB4E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54509BE90F82913D92A8FE7EB8EBDA64" xlink:to="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_6A3FE1124B9D4C1CFE06FE7EB8EBAF06" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_067C48FB425CED22A530FE7EB8EBDC4D" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_BDF6840670D9A65F561DFE7EB8EBB25E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_5C9CD5EC119960E5BFF7FE7EB8FA3C3E" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_022B6BBFF69B603092D4FE7EB8FA450F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ConcentrationOfCreditRiskAbstract" xlink:label="loc_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FA07DB96B796FE45DA0295BD9BE0FBB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FA07DB96B796FE45DA0295BD9BE0FBB2" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4807FE3BA1E7A776976995BD9BE0EF1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConcentrationOfCreditRiskAbstract_06FC8B9CAEA04B5AE92995BD9BDF2FDF" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4807FE3BA1E7A776976995BD9BE0EF1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2D36522EDBFAD3E85684B081A086C382" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_A156FE6EF0267D3A16A2B08246CEFBD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9E41A8FD14180CABAAEAB078C323EACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_079A45E4C42C88879BE2B0676013535E" xlink:to="loc_us-gaap_AssetImpairmentCharges_1EC3D22354E5062EB908B067601361F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_IntangibleAssetsAbstract" xlink:label="loc_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F7D254854CB0B1B210DCD81983F97B35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2E18566E79A5E547A82AD81983F9FDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5D124C31B71FEBED013CD81983F94E05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2776D2BBC34BC837D55CD81983F9AAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D2FAA70339B7E47E47A9D81983F961CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E77DDCED9BB18F24E4BD81983F9165D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_CFB5323199EEC8859CD4D81983F9A1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_577A191825C6E021332DD81983F9B19B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6E3E07C403CC70DA8B95D81983F99B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_25E9878ADA9A8B20BB29D81983F94C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6DB29E8FC439A3392F6BD81983F95443" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CA544F61BAA18B3D6903D81983F9D924" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:label="loc_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IntangibleAssetsAbstract_2DB8A5D74716076AB617D81983E972B2" xlink:to="loc_lxrx_XERMELOIntangibleAssetsFiniteLived_2A0FD423D85A11D00FBED81983F9AA66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_InventoryAbstract" xlink:label="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:to="loc_us-gaap_InventoryRawMaterials_142375C9B9C172929045C7DE8AF47677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:to="loc_us-gaap_InventoryWorkInProcess_BB0CA2DAE03D9C85F237C7DE8BFBC8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:to="loc_us-gaap_InventoryFinishedGoods_8016B85B04383A10C233C7DE8CF305F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_InventoryAbstract_491844A2B17452DA36FCC7DCD65EE6F0" xlink:to="loc_us-gaap_InventoryGross_A3C7C192386960E8292DC7DE8DFCF978" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_BasisOfPresentationAbstract" xlink:label="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_32B426143286743C59BBB989A08A2F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_UseOfEstimates_BE4EDCFF1BB602997789B989A08AA4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2403852CE94B6A49B1DB989A08A8666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C54715C2149C03261CACB989A08A661C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_43376DBEDD07B2FF20A1B98CBD4AC3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_75476658B0E95A39A284B989A08A3F23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_E9C387B1E98CD08EDC96B989A08A0933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5A6FA7CC73D65DDE0777B9B82A97BF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9D4F9F8DEABDD2D6799BB989A08A3D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8CCDFAB26981046ABE37B989A08A50C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_944813CFA0814CF864C7B989A08A6CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6350E5E7537B77C56A35B989A08BDD92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_81B371334BED3FB6B399B9CCBA835993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_76F5700CA5B6DBB54D1AB989A08B6061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_42E8E32754F1DECEC114B989A08BB28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_136AC1C4078E02052E40B989A089C19F" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_EB4417F9F8390B638633B989A08BE1B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_SegmentInformationAndSignificantCustomersAbstract" xlink:label="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:type="locator" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EntityWideRevenueSanofiPercentage" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage_8E1AFF6A5509D2C0C9E495BD9BD60B65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:to="loc_lxrx_EntityWideRevenueSanofiPercentage_8E1AFF6A5509D2C0C9E495BD9BD60B65" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_EntityWideRevenueIpsenPercentage" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage_97AD694748240032802195BD9BD64911" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_F3C44309C4425946858695BD9BD02CE0" xlink:to="loc_lxrx_EntityWideRevenueIpsenPercentage_97AD694748240032802195BD9BD64911" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationAbstract" xlink:label="loc_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_StockBasedCompensationAbstract_06EA46CE5D18BC9CD4AE9B5F90F97487" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:to="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_CCD2283BEA58C301429A9B5F90F9751A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE02DC590863E1B958CE9B5F90F97388" xlink:to="loc_us-gaap_StockOptionMember_6801176E007D8824E2719B5F90F9310D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FC1409E47E75381107639B5F90F9E68D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_19D9BAB80F3535CF36559B5F90F92343" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_93DE8B75DB179EBE2ED69B5F90FAD254" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_0F21044127CDF501A4289B5F90FA7EEB" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_D924679C26882AA568F49B5F90FABE97" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_46A3203A6FD05F6A6C969B5F90FAA789" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0FBB412D07DC1F0E6DD39B5F90FAD188" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_E85CEE09E8CB4EE09BF19B5F90FA872F" xlink:type="arc" />
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B6ED067467977F83BAE9B5F90F90D8A" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_85EBFC5CC58EAF92C7219B5F90FA91B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="extended">
    <link:loc xlink:href="lxrx-20171231.xsd#lxrx_StockBasedCompensationAbstract" xlink:label="loc_lxrx_StockBasedCompensationAbstract_B4A921D051C32375235595BD9BAD8DB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75A18E89B2402560109195BD9BAE3F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_StockBasedCompensationAbstract_B4A921D051C32375235595BD9BAD8DB6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75A18E89B2402560109195BD9BAE3F9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18563B8DA160B9DBF01E95BD9BAEC55A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_StockBasedCompensationAbstract_B4A921D051C32375235595BD9BAD8DB6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18563B8DA160B9DBF01E95BD9BAEC55A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_263461B32A966A00BBDA2487C45BAD5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_3886C62EE79C2FA4FA772476C0F1A1B0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7825EA2398348BDFEB302476C0F22165" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>amendno6tolsagrimage1.gif
<TEXT>
begin 644 amendno6tolsagrimage1.gif
M1TE&.#EA<P27 _<           $! 1P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<
M'!P<'"4E)2HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*C@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X
M.#@X.#@X.#\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_
M/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_/S\_
M/S\_/S\_/S\_/S\_/S\_/S\_/U5555555555555555555555555555555555
M555555555555555555555555555555555555555555555555555555555555
M5555555555M;6W%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q
M<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q
M<7M[>W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_
M?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?W]_?X2$A(V-C8V-C8V-
MC8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-
MC8V-C8V-C8V-C8V-C8V-C8V-C8V-C:JJJJJJJJJJJJJJJJJJJJJJJJJJJJJJ
MJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJ
MJJJJJJJJJK^_O[^_O[^_O[^_O[^_O[^_O[^_O[^_O[^_O[^_O[^_O[^_O[^_
MO[^_O[^_O\;&QL;&QL;&QL;&QL;&QL;&QL;&QL;&QL;&QL;&QL;&QL;&QL;&
MQL;&QLS,S-34U-34U-34U-34U-34U-34U-34U-34U.+BXN+BXN+BXN+BXN+B
MXN+BXN+BXN+BXN+BXO___R'Y! $     +     !S!)<#0 C^ /\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'>IRF#Z!\I#^TR=/W]&E1YTN5?HTZM&D
M4?]A'6B5*\&G2@MN-9A4Z]2O5LW],]<UJ]2W3)W&G0OU*%NH39=B;6I7KSYS
M?/G.;0KX;^'!3N6Q-3>,K6*FYB(K!AQY6./"E)E:'O9XLKS&D $W_BS:\F?.
MC#=S-KTY-6G5L&/+GDV[MNW;N'/KWLV[M^_?P(,+'TZ\N/'8IRTSCEP8]6',
M@9T>YEMW,EZV<:<[QKY7JL"J4_/^$AU/OKQY\CP"3*!8MF?Z !;+MJ^I)0#\
MBL/^7<M_TSZD\R'9=Y]/$]@'X$GU#5B2?P="9)\6#9KT8(0+!O ?A2/9MQZ&
M$Q4HPD3ZU!'  6H)!$D PXB XG<'#%3?,*H$H,HP 4 HHA9:&'7 >BH>M:,J
M$B5HD8@!J"7" ?K4IU8=!]C8I!;ZT BD0"KB^(\6,T*I3P BE!A1@F!)).($
M;-6XY01.<?G7B%I HD^/2!T@ I;#3)!B?EJ(<*%$$W*8T0$&_B2DGQ\-*F&-
MA"9DWX>)>K2H2R=.N58 41;Y3Y.,R2AB?B>NQ&!+-/+W3XI:4?J/F?+ 5Y]
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MJ/JJ]^Z*Q?YSHCSIF6WMR"6_K+9]1&N1ZLGKN7OPPBDG#1_^)! ZO6N^$DY
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MM*ZJ%[VT0#32ZB?#E@IQB3:"8(50R[R\>=*=44),O:U*N[XQ!XVB*ZP<>>A
MKUWN>KYEZ$.7"*C:Q9-BSM7HF]@DTAFYK8$9K%H^%XZZ= ZJ*KI[,O$B)F(D
M#N>E9^N;# IKR2D[#:CUW-3SU'<CBZ84I=>C8!$EFE+='.YM?<+?D:E(+,,M
M3''I-R$"^_IV[$4?.SEBYJ ]\\Q$:?&U1Y8P;2N-VMT.SJ H%3V(E#8XJS(W
M65MW)&[^%2;*37.1NC:G$/]":TJU/4HC>\RP-4-K3,#ZD$W>[2%Y$6HG >_*
MAMJL$8"9:UF$,X?E\A0B>H&E7NA<R(52BCX_:QEH!CTIF4F=;:*XJ)*@%7+3
M>$,UF>2I1"2O*%;WF\,#,"QL&-]*NFO#I47'TS"C-JBB?,41FCE7U?U:]E].
M2VY,BXY 6?T2.C^TEQ[#NR?UULZ/-N)DF3E,/8FC7LY?,[0/69++ 4AYF:>4
M6$L& %-2@3EB?CXA=+[NN!;D":IN74\*C8ZB 4!:L0Z0=FZ?ID!2Z:Z,)D;"
M EEJX:41D$Q=[B!<TW=!&RJ417+W;7!_[/&=3XR\08\8K8_^/BD>-_W(1U_J
MU*.,V,L2EJFNZ4UODJB;(7H42;_IH6K>"-BW]STW(]8L;))H1 "&9C(EIOQ@
MVN:8SX=^]*6/2\"+\(0CC*%T2AC#'I9Q*7G$XB3%/W[RE[\E2B:_DI$V@?7'
M"6DB$ '[XP__ W"XY@<0@40.4//\N_W^;F^)^XN__9._^ZLYM^NR!%3 !61
MB=B=UFLJZOB:Y1&Y5UF+Y3@,IJ ;=G.HD6*=KN$;ONBIM7(/?#N3R&*ZR/(5
MIV$ZZ7D:%JN>QU((RZ"H),$*JDB;X-F-I0*U\Q'!BE(;AGJ=M(D[_EB0R,(5
MGF$]>,H)Y_J4SFB<@:(+A] ;C/#^''N: ,*PC[-2$^+0G_.8K-$YB^]YC\6I
M&P9!'+@)NYA#F:"#$RTTPY6(#]3)#@Y<",X1$')B'*TR")@*B0<\F=-!GRN,
MP>'QF^/XFC7<"HH P:[@*#T<F?_QB.YQ#T44'8C"'XXX"Z%""9E 0F@Q+*2
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ME1OMQ&8.8UXIAPQQ1#M55A<Y8/XP9IP-Y':QYN=H)$"RI&MRQF#.9DXPY?
MHVW>IFZ:'TZUA@3&G03*55O(U7""W$9IW,>-X&.!G'-B',7=D<3-T')97, M
M5\+)C\-M)W=VIW=VIU*$4[^)9_Z(T[WECQ$9#[N1&[#I&K,1FZ9<BDB0$*A\
MQ+C RJJT2JO@RJ]<BW\>RVZV!"1$F6#\!8$,1US:4VLX(T046$=$B3<R1HF9
M66-$4F>\AF"868+&1-!<@Z893-+^H :'<0?E;!B.>$A0Q-$P@$>!U1E3G$R&
M0=B9#<V 1AB%\-)E!("- %E3HEVW (:9D%YNILZ&RDB*D)B.ND:6](V/G08O
M%D>:'$P"$0B$H-J!*DT" 0YY+&EZ1!_MX(S?F45O"L79W*993(;PW4Z-6,9R
M_!>D#0G>7,UJAHA29 :;$8B9+8[2S-V'Y,B KEV- MH]$B:,Q=%P<<R4YJG<
M2$BA51AXY%F7"B3O:4><3MXFB:B;30:532I0>IB&'(B<AFB (HAFV297CJIL
MNF9BCBI2X";;J<4.6H4I^N28=D\@6H4R(L^MJDGUR*->F%QW@6+H5&99B&14
MP$_I""3^0*KBPE499G(&;,;$9=Z%+?K7%E6&,N4&&CF%2/WFB421:&$$7-&/
M_>A'M.:53P".6H758#D6.''B')7$5?4/4E5)NH[62KDH.X%& .6/V*$%0S!K
M!%$&26$E2&T0&%[D=1CDF17$.(I.K58=56#)2RT%&M$5P# $M3HE N:$.93$
M94Y 2BF.#4V'3%*$R++K^QR/]FQ,H5)>=D@5>4!/60;&Z;AJ)@9B?FB/D)W5
MEERA)*U,<1ZB]JR+L;*$_!B&=M:@FL3;RZ&']IQ2N'((#!&)?%&0VPC01CW/
M!A54_:23KW(%20@'T'*6_?002E*$:+'$V%:1;W!*U[W)R=W^A3?!T>=(&BTM
MQZH4YT=,D<(RB&%8%GF 2ME:$$+@T O-5-D2B^( I@9]4K!4EVK.IE*42H$T
MSUBJQKG&!<!1".@9D"U2AW58U$$4BV]<T3C&8G19U@TYZ>9>$E^P%/PDEUS-
MSA_*EH()"TCT4&,-KO<X7H. KAOIZT/-#A^MJW'QH4JIH;"T(4F4ZY%H)8>4
MSRBA%9T2BBH:EYO49EK@YJL(QP,YQ!P5RPPIRFEF1'BP3PHU%.O=$/AT4>F"
MDD=4!JL(!%7,3F/$;^3.+]6NX9C(C[#4R^CX1+.NE",.$<[2A++6UDWDI]E^
MVY]Q!$?(ZTFXB?% KTT 470MWY#^'(@'BBH3R9!()E&]+BWZ!A9%'*U$.BSI
MT-"L&>;!@N%0TH7]TM1*+0;\ 1!F7A'$E$\,007%-BC"MH5<M,7Y_$ZWF@7>
MMD0]ZA5E;>U#Y*K-LBUS5%5@I%2!$<6I&JOBR11.X=8*::F(3"ZK#L6ILFI@
MSF:1]N/?EK%0M+%V); ;/Z-:+'" KNT<<T42Y_%:+#$?*S!+!>B8>6I_62]2
M7$-IA ;#1%)/#41QZ(?C:>B'(:@\%$S5$:^ 9MK;O9FHWLRZR,>%\:]J0(+.
M@2DFZU=PW%DE!X>?.6E'.)B( DZ4 ,>@NL7A=:J:,.5VA%GBL8F0[!>1#)=0
MJEZ+W0C^8EC([UT,Q C?\X$.@_)&(?.'I)7(((OI3/C,*V7=KOH8@]Q9TT0I
M?Y#RNX!:T#%M2)1&T)CSFGB=O%RI;EEJ![\'.B\&\EF.@&YS55P:8:2S?U2(
MR^B31S@.9ZR,PMS19;S+Y$0%ITV'0%.E--?IFUU=A2@%3E :^Q&/=2FK&/^Q
M6?RG1W\T2(>T2(\T29>T29\T2J>T2J\T2[>T2[\T3,<T2K/*L/S*JN#*M^Q)
MKZS*\ZC*\RA*J&S*IL#M>Q:UGU01243$K*';M$W;N:$;O9VGOOD;>7ZG55\U
MQ$BO&X_=@HK=*3??*!.::_Q=P\:(YMF$@JUE@[6%Z>G'5_/^1U>SE2:A]9*%
M1#>#]9/,6-B='E/T5IGXQB.+6))$Z(CZ"VO(!CUO&B2'CHTP7UB+3BVS26)P
MZIQ2F! W!CGWJ)<)-/&0F&6LLM B)I]:=DCHZ/2X"Y7!G5O8L3QWI;[$!X(^
M!%\\"'T@M$<DQBU[1*I1&5PHJVICI( "MHOXLI*--HG@LU!,B7ITBVK 1MQ^
M1^#1#4IDV/2B"=ZTZ>>\->+XS71GJ6$HG@Q7Q&E0=XDL"/*Y1FP+L5PR&D=?
MCQPK3U2BL7:W5YFV=]N$K>O \5<$L@E%=O?B-U?@,0W7JA*2L?(P++M\9NC,
M5$MPHDO01B02XF3D2#Z:Q>M&(L3^J)\/N5.Z/A [<@C$N$=8.N0B2F,Z9I-7
MW*"X1J.(K-)+J/!LNM(I@8KWT9CB7I,LG9%$1.;!B 2^&J12[$E1]-+YRMMM
M+) $$M7L'M"FU-,#V6U/N,G#KN(-[J_#?@00?XJ.DT1#S7=@0/D&R0\C#A 9
MC08SZDJ1DQ$&5XK4"F%]]X4K83#\?/#P<.]+I-#YN!8-7>Y\P-%HJ=#?/JQ^
MR\3YM DO!?D&]T200Y,:#2-, E.MG%^NE,04/0\K;8IW? KMK&H=WZKN;7 *
M329??L3)602?W%4<:86O)1'@8O 2"N\8+W@P&8120TTTE6HS+:'U",?19M-,
MSG5=I&?^,VIMR3DX?F2X^&EB"")[WB)CG9TQ3Z@@ALLCL[-?9;G@&;'6C8S<
M#*(?[<#X;F9(MGH$#P5:8BY(R6867VY09Q0%@D=Q%,D%67VY&^7D&9;6$NG5
M+!G[;7O102F'<]5+6WS1+&7K2?XC#:TE4NSQ9DUN%;W4)@Z'VL*035X52:!D
M;B3$FR\L2PUZ7G!Z3FSF7!1%1D&X34S5*^^$7GF\3BSH/:W?^3KK!Q4$G2\O
MVS8CR%_4<)3MQ9N%G5L%:RNZ4XQ<$./49'SPUQ8W9\7@:1@1FV313N"Q]D"-
M@#-12C'$3D+[%).'"B*7.9TJL;)M>OA<C@BI6^A3:]1E3_C^L(A4Y>DD.E8U
MA".=T+"Q2:GV'FS!)M:9!$:<<>NTU6.K^X!H1J5TRY1GA!_/<7RSZN('Z!K+
M7-#;M]*#5^9*/D_D/,L9>!F#N^4G!7);?KV>47"2'/>QS>@SY\=AW,99',05
M(E:_?L+!\*A2&CC+O!V9*8E0*-BA]\#8]71 !X(^S6S##700*+XKFG%4AYD!
M#GQ0-XR<+K\LA8F1\EST5$,G!=Y4<^6=A(R6:. [A"4G1H;8<]VQRW'$S?2'
M2&XC1;<T]H/C3Y#W1FD\6C9//D^<_];I3JA&B?!AZCU3!4!,@/2/($%Y >05
M5/AOV(0 / I.( A)RT*% 899U+C^D6/'AATY0AJXD,=(@Q@['DRH\)K$A9!<
MLD1(4.!%CQ5!YM39,<# @R8A]=2(DJ!0D0P#G!P)D^.$E1.%;M22=&?5G$P+
M\@B \]_4@EJX+CQH$1)$A5--?NT9=.E +68M'LQHE:73N#.'SB78DBC!80'Z
M*CRJ9>34"0YC_I.K<:H6AVG_=@1+EW)ERY<7_M6+F7/GG)H]AQ:],/!HTY>#
MGE:]>N=8UJKU466M+S3MUW1EWRXX3(3N@N9\5ZT3-KCES<4Y.D9^69\6X,LW
MQCYN6EX=VYQ%7(=N<?+VXB9K_HMYC2AHS!07:GG:]R/2IT[AID;J=R;Z?^A+
M%CR*=+K^QL@$>5CIH&OTT^NMBU8*@$""M!@F+*(@)/"OA.03+ZVB%@QM,84D
M(JP@O.31XAJNY,/*O@GF0K&KI_*[+[?M($F0N!=AI)&R$E_<3SR(Y%GPOZWN
MXRHQQ6R\:J4#AXF/N-T>+"PC\NC;"*;<5,P,+^XN+&I)!)%K3R?U3B)PO)F@
M)'(C+[^":QB3/"1MKL  "VG+Y0ZTJ#2%_HLHLP GRG*F__ZKD[LB3]M/JP1]
M4M#%B89LB3Z?!(J1!YSDB;2_G^[*\J3^<K++*X;X=.BI@N0)2J\)(/IKI  B
M_934":Y1]<.!L*K4Q>DF_(>'F*:4;$[O5&NL08+T$0$LL$3^>,X\XXS-R)PA
M59F@CN<8 JL.@NJ8J[ECNU/,6CP=4P7/%Y?ER!RP5-%''XJX'<:<:\%MT+9M
MM:!M&'CI/5;;8Z^3QUAQ"ZIC.'B+XK0R?5318MI_5*%6%4BL^^JY$+FMUR^%
M-ZL#DNSP)!@J8!DTMHY1S:$H79#S/$]AYP@RYX @*V9H@G\7$F%4!R&9RQQ"
M.U*%51'F<C#F?T1XV:_A]/+W6X)4,99EHE^,EE2PJOQ'GX%MJR.FX42 #&..
M M!.MV&,UFFX=O/5(EF_C 6:(!%D"]%8/ ^8 ."3%-H97K*7ODCL@A(&V>JN
MARMHW:U6.H"H<P,X^9\#VJ;6ZK+^B9RK684CTJ+I4<\:DK6@1!!A@@, =FP8
M5<JNCN#87I8'<F0GN"XW2 XX/?8H_W'9W0,X;].B<G=J;IA[<6K(:2U>7C:V
MNZ>J(V&[O]J,=(;$+78E?:#?F&EQ7;?M+^!\!DY[P'GN5O#SZ3,8L[]U8M\S
MX#N3O"KY1[OS-'WH5T@?SD6K$/W_7\(S (YK@ 7DR7*:9L#@%$Z!#?R*YQP(
M0/A%$(#FHV!G4O:AW=C/*F#:RXP,9!*4Y$PP<.G*2!93GA?E9H([F=1N+B2H
M/'E(1XI)S PA4J=EN>9#&?),6<ZBD1=VA21IB0J4RM25L*Q), )$CGTT*#C_
M6>936MG^")_R\I(W%24A&:1,RH H)[% D ?J^P=*7&5!*'ZH(@=YD/J<6!3
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MY<PY6-C7])&788% !4D$A<?*4FM(.@;J8Z?H_4>$G-7^J+@R338IO  .L#N
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MZV0G.Q/'-GQ5*RT_RU<][7E/?.;K9W?[U]7JYK-\VM.? 25H0>M&3X#>37$
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M,D&9$_,P(!_[P(&PB*@1%8]8"4W\D%";-"OSPXS0BO0HD, 9(T#*"J$XB92
M0XLP0>QR&2IIL<?PL,20D\UPL)XPDS%3KR@K,N_8Q3EB&;_^"( G(0ED; _S
ML,7"XP%YT @6P8REZ\62X,,6TR]/H3X%@S"?L+*(V95>0QV5@!(Z5+$N](S1
MP"V$3$B%7$B&;$B'?$B(+"J(G$B*K$B+7,B>N4B-W$B.1$AGZ4B0#$F1A,B/
M'$F3=$BV.4F5!$DJ,CN$=,F'%)V7G V$S#1S0#W<0KU'.SG"V<G?$)U' TJ=
M%!UZ^TGA^(W!BSS1&3RD1#VF?$JFW+2D;+A-BPAF,37FX#$)FK)2XKH 0I\
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M]<]U:EU^Z_O? !-70 ,>$(&)ZT@"&?@_6#40@A&4(&)X,\'"#:,.(1G+<.H
MEPS6H3>H"4E:/ B7M&#0@QV$Q E5 1?G3,<I,93A#&GH%-+^U1"'.=3A#GG8
MPQV:PQSR &(0@?B;[?0GB/T1XA'[(Q1YM&<\4&S/$T4#%"_=+5)VPV*>P":6
MI4Q+3JSZ5[5R(I*M%2QMU#**MX2R,-549%A@- T/W'2NK %K9W>!XT" Q:2
MR=$HKTHCG'1E-J&EJ29!D@E.%D8N,;E)5^GJE+[BI2A)Q@9/7:O;W- 5M)C0
M$6:+J21*NBA*G\U,7P5CF;'2A:#!3*Q06P,,U,PT2CNI$B7N"D#8=%F4-,JC
M7H!\&'JN,19:&@57_[@&KW!IEIDIZF/VBEG4\$4:26:M(-<8T!N3DY- %<U0
M<_O*(7L6M:$QC%=YE,]7%#F2/*;^#)N+Q%F-QK@461)$5Z2IV6!(H@5>\6!(
MS(FCU-ZVKT3.3(M;?).5($1%4<ZS-/J89D6.P]"(4A1?@*3-%5'"44W-9Z)V
MPE=(WW1)A8+*I)SRZ"('Y4_36/11L5FI8!#5*!/EB:$MJ0U'NTG1XPSCBKR:
M:9LZM9TA&;6GY!'-M]!BT:3PA)E+-4=R?(14J,9(:G:R*D^L.!95 &4N1WW=
M5GN:% F))B1#4DR*'%*1.G1,HR<1CDXD=)B]/40I(A&.=\RDA0SFQ'.0Z!&:
M;*80*0WG(<#LVYHT(A$1G#6#$$WH23.DCQ5Z=(7I@:A)I)13(!UU+ RU$7 @
MP="Y6.G^(FV%2 P%2S'3I/:L!.',0G@V%R-!R">'I9-M%7+:XL10KP6MK$Y$
M.Q7=@FLAQ+6(3MPU%RT<9R=IX6M*(957=P''KYRB;FD4VUJ%I'9*!9D+9%V9
M$V;:LDG*=1%B1R*E\,ID3*NUT6)B"%FULI=E3A%O=IN$WCC=M*,89*A2:^.4
MB3D'54X9, A'H@IW;>>K_7RFHJ8*U(H$,;\<S:F%2W(9V6"5LI3"UTSC&N(M
M\M?$<0H+:5L8@*ZX-D-"R6Q0!L1?/*GG1F99U4P>$H#'A$=F\HQ-'=SE4J)Z
M!9%Y0=IS:T,:WF2%C<<Q#YF$2R-5QG1:*)J+E_""KK*HZ37^>;'2=BGL)B[Y
M5T]D3@EA4QJM$>/8473[B1II RP,BNU,"0E33FX[GCZ+]\\%;29)7.5,EJ$9
MGQF:5$H*O1XGTTFG%1DT6BARGS5B[".8<6K$,/65 U"$;Z#K<P#^4M.]Q/0Z
MBPDUA8J#T*SJZ<XNPHF2X/CG\4R HP_ZB(48E2^NG YYOW)::9Z<D]A>2"[T
M$=Y@I :?BVF$+Y*>&2[/=Q18$<W6*194B;5=&AYW.\;@K@\D4"WN1*GYI-$T
M=Z;4+2@ KUM#DU7H<30RHBFV1Z*766(4IPI$>?SF-Q4&N \1XD.#'QSA"3]X
M"V$X#/VX4"D^=OAT'FY"$X)0NA_^].O>0M+Q#5H0Y"'_-+QCTS6H;4NSM&F8
M49K5SF1>*4TB^5I-R*DV,"X+/=PV";/>!M#!K&TI ?,YPT0R%F\:A3AR-#H^
M$7V2565,.1-HEA/KM4O7^JN5=4PCN@<%3+G!K>F$>G5I$,;9<ZEF6,(J&C#W
MDO.PX[-K[)I)S*Q^Z<[47&*2%EK;MI0QMJ$\1M:Z5R /#:FE_PEJ [N)T.(^
MGXU=3%DB6SD<E36@T52YC)P"7==F%,_%#P?O^U+(Y(5M+]#):)#V.J:?A%7+
MAI 1YI@>?<X!Q8.)-:1;2S';._6^V;JEC&A!1P_9\A6NT2_E5H!JF^T+.TN6
M)CEDW%K^O>=)KN)A5[]&:L+^24R]_9V7V_MUBO:Z+9TG>1P;-OI ?Z7:[:=%
M"^J]G9+W%AN$Q6)KF\"=^G:?E#+4E'06B^(K_.JFWFI.'L(,QEY+/8HL-#9%
M%>3B7"P#640B2[)B599N3/@*Z8J/-G!G2-[J(- #,PIP,,RA+0 %*.AC,XIB
M)C3B+!@,,DKM[4AB)3[")RC$TH!#2@YB50C#QV0K--2#R6*/W#B%R<K$.OX*
M4XH08'#BDEP),V)B.CKCZ2B"U/#I4=K/),+K_NC,(AXM*-*) F.J*T $GUYL
M0\90(6R#)7[PY>#L^11E_EX"K"SD;<A%W3(F='ZN(A"03-#^D.VV8N0^ L4H
M92RXRB5Z;<K(!->\4"(L2D9093,VA")T, &'8O7J!"_\@S,PPT$XPSI>#[ZF
MZG4@0R"FXPK'X[%<SD4F0N^.J05AX['JPDC^#0T5HBOJX%$0HSBL0AX&L1?W
MY@JC JBZ;#PD0P!S BEL8T#R8Z8*<0 _0G7&XK;X(J]2#C9L8^.*PC\L0DE4
MZSH>L"A<2340QAR?Y;%09./D(YKVSU.F8JW$RW181'(>HH4@9'G,L=0$XC7(
M30EQZ[MF\".^T97 ,:]8 \=F8G> 0A>SIB40PTKL9OPJ!3,>R%TD AHC92(W
MZG0:K11E9'UN)4P0HL^@9#!N*%_^9!$9SPHX?"P%&40IXN_\8"4TG,/( $.O
M,F= ^$(B:L(<YL)=2&<K,*C/ZH(:"Z]1YM @.L(<H4Y)2NL@=N*Q (,S',XR
M%L-TFK$NAE!)_L) 7+$N8"78"''"$J7[D(XC:$X[9N*MX*,NJ*.:'$9-FH(C
M'F(S%H=T/(K5!(4O(&<JN"(FRN^FM%$T#*,W2.,7VT3]&G$A0!$J8 03#\WW
MOBO"8DU(6JU*5'!4VF(/"40TAE"V%LD%RP($@:DF&3-!>(5#UB\CH['.KL\U
M.3 V]0Y4_&_<P&\VQVVVQ*W\<I/_!-)3RM(W^6PX!Z4+B_.6M \YN2C;AE-E
MT&5N=*[^1H:E4,R&QN[B50;"Y4A%C"KOC)BC]=*#I)PN;$AO7[1E*?+(/(DO
MR#HC)MYI[M(C#N/-5MYSUV1.(12O\O8"*5II2%Q.D^X&E+().$MJ[%)B[4 '
M8V(F/E])F3RB9MYHW)BC_?)H)I:)\0"ET,A%%*7M2RX3O@B&3RXFH;1PD<QQ
M,F-$.%-FI+)*0G<M95HN/7GF8@(C0 ,O4V[4;I[S^.CL.1LTR;P0,%+O+C(Q
M3R9@D)!T-(!$:*CF(\+35$[F1E/R[J)FC(1M/+//7.;I\*;&X>K.7CH&,8=E
MG%[EF)0&[*:IO);38YK23=\43N-43N>43NO43M%G>8@'883^!W>&QW3V%'QZ
M9WSZIWW )WB@YW#,<7681WWLYW8\1S(6B']:YWTJ]2@>1W,>1R<:QW$F)^02
M!V$^551']8!"E51)57@2AW/X!WXF-8 V!X#F1W]<M555IW[>QW-D57QV]7?J
M)U=GU7NT!R%2]7J$57:&9T_-44_YM$[QU$Z?%5JC55JGE5JKU5JO%5NS55NW
M%4Z%QUL!E7BFAWJX1UB_!U+)M7.$1W-2)W(\%7%.%5X_%39S,Q !HS^_:%[_
M#S'M*3"RAIWH1)7>Z52^T[#B*%\Q1CN#99W0LTC;;C[:TYPB5DC+:6)II+Q&
M-(V^XFL"DYWZ4TQXAO2F-$<S=FG^<O1 46(FFL8DD-0LDFQ+B%1DN8MG3#0I
MEJ);U*9B$ 9GUM3HOL*5="5E")%@3K9.E%(V[#!& %:?QH4T7K0S[M-E&Z/]
MC-90V/-EZH8X/,-JJ?1$K<5MYBGT$@4GDJ:3AC1-)BKT\&CP/B)FD0E,1P_S
M/(9&(:J9)NUI#<OJE&\_3:752F+H"*/1@(]-O>U@!S 6D9-F!Y 7!U<WX0W(
M8*TYFR-R&Z4W6VI%WR320*4U*2LJ;%-LC?3$[N9P^:\9<^E7:A&U.&PQM*8V
M8.,6AY,K9&0IYHHAMJEP1\(_Y@(U1RL2VZ0N&/ I<.<XO&HW5W&V\A%TM&33
M3,)-O\C^N)X2+7;B *P$AF!%>+9)*@>D(4RD(A65:VE$!-XJ?)=R.VA"2:S$
M)QQ'=7CETR2B. 3"QI35#:F6_X85-1FB0&ED(S')?%-Q*75",FZ$@AIC,IA#
MU^+LM20'139#.2'$35?%ZY@)(2!O/5SE*(Z#*?M"293UP=RT+ QDLBI74#8W
MTR*U+S[C=5"3Z3B**<VQ#A$FME[W,U.UR1 FVY(14V(2M3!/&]TP3%SL.,Y/
MAE41="1$.#P'9\*V3QX0FV)R""T+,6@IK]ZK;^IJ;V@0 6]2E#R7HCK.K997
M-(#2(FY+*;SKN_3#2\ZOK,Q$C#\".*+7C/LP10?P_1B"16[^=]=JXO54V $A
ML#_LJ$?*@S[<-V*2$0[=T33@C Q%D#[60C@8L28>>02/<4W8PEI,4C[?Y#YT
M8[[^,)$DY(WW M1PI":F5Q!-93>][&XV196U"S?7K.C*@JGN<2MP[3@6S39Z
MQ"Y:1(0%8R]IK3B\Y"HK9"1$H$<*4$?@L3$T,"OD \.^XZ?4! XS60XOMS,:
MPQQB(BI"8ZJ(&2*\I(-D(Z9> U4RTIAC9'(%15<0<)16Y$>>)2A6:@B?F2W6
M#V<3!9?P2B3.DCTH"I.#TJDLTX&5\:EX0FB<"ICK(Y6GN3.,Q",$[G54URA2
M62'>KY6G,I1^BR<BT4L65QKG>'#^I3,:$=DW$S?\Z)=QV?:5TVVE4[HY6MI2
M[)E-,=JEWT2):QHV]@RG;1JD2<[(2*/FSJRGTZ147 :9KC/V;D(DW 1*:XXF
MIB6:UC9G/*5;7J5"T@@^\@AHE86 @ZY4ZDZ. L.D];5A1,5A1P;TG)!.)J]!
M"^7P/J5>E?IN>O=9K+E/NI0V:$54)DJJ\X631,^<R,EI30-0!JG=@.60NFAK
M@*;QA&U)R*EC1\]8G'HXZ'HQB-920%=K)&_J=*0D6'9?[J5KW(1-G'H@CD*;
M.M0L-/NNQU;&:&[7>G!)AD14)@Q>UCI>;MI/=@1A6L58]DDLH&9&T-14;L/J
ME"->N.[^;(1KE/0V39C#YP94+'CO+IQF1D8C;1ZF**2[:G8Z^P9BIB1J1(@$
MBIXHWY((JA1.O7,H3-;;O=^[A]H;ON>;OF,H=.H;O_-;X3Q0O_L;@^C2OP-<
MP-E;00;<AM[*P-=;B&1HP7G"WP"NB(HHX(0(PZ92WRZ<B.Y-HK:B*-*82!A7
MM[>(GCM%I^^:BW=NJ/L$C[U//V9D5/!X2B&[59 Z8AH4F(8AC204G%JDD1*"
M^0![9+)T],ATQF&O9IEN9:R%3U[4ZL"I:*R%'(&SYE3I17OV61(&$G@%G+X"
ME/;I-JB9NS6/@*W&KNTDS&$#G,)<R7F&26ZL)H:NKC,$M.7^3-)F5BB &VPJ
MR5_7NF\9!JBU15C@"K/A9$U- E_G4V*/UE>HV[F]B,Z%,W I1:"4:6W8A+J3
M@LV-1:-$AC2D#F-8.T/DH5ENUEE*O>Z<]&RI5*K%)*0\?3[BA4=1-FM)NY]B
M!J_O66OP#K0'5,?=Q.'H_*A+8L5/^B+3"AO!@JZ([C&RN:(OBTQ0(S1 >8:B
MUTN$0Z+A0I3 F&76M ;-1,'0 BH7PHIF2,K ,0:]Y"=-"9,<'-S!:C!\!$)R
MCL')!-Y=I-[WXHHH.%*<XHJ,2O[*O+V8"B+P2H8@A-TM M($_G%MXB<%7KXL
M[-\HT.$W8@H-*Y(+IN'5ZN#)I,_^B*QF<4:B98*B1SB=\:GA!%Z-S3@BP+$.
M9BLFF\OA6 .*):3_("0D>&4N6/$E4CQ.8+!F^29KU20MXFNNRLOA0),I-F0:
MK<B+A1W4ZP,S%&>V+A5!MD,GHMF8IZ=/:TQ5),/CFX\CR.W8XC;63Z+EKYB-
M24U'U(-X>A*^AKDPAE!&6((WTM+@UY0KIN/%.B(KD-'(Z.7JQ8;GO9OP"]_P
M#Q_Q$U_Q%Y_Q&]_Q'Q_R(U_R)Y_R*]_R+Q_S,U_S-Y_S.]_S/Q_T0U_T1Y_T
M2]_T3Q_U4U_U5Y_U6]_U7Q_V8U_V9Y_V:]_V;Q_W<U_W=Y_W>]_W?Q_X@U_X
MAS_%NH7^6X\?^9-?^9>?^9O?^9\?^J-?^J>?^JO?^J\?^[-?^[>?^[O?^[^?
M3A=?1D8^-]%G.<T?.7M;\IERW=#_\MW?4$+5N^4_\\<2\]6__FE'_%V,?Q."
MN-T/(";\&TBPH,&"6@($.,BPX3]S ;0X-"?"H46#6NI<=)APX<:) 2 UU#=!
MU4>+JB2>/*A0Y<J7,&/*E*E0X,R;.#OJP\FSI\^8'7^>;"FTJ%&&"BL>7<IT
M9M*F%B$-^P<IP-1A4P\.LWFP*E2'"D5^98CUWS"K_U1E-2C/I4$1;L<25.A1
MKEV<$P(HC7DV;ITZ(NH>T*)250!]9X?I0QNR8..$ QL#58C^L^] PE0]8EZ\
M]A]:LW4'UE&(^//DT#$ABFW<./$_$5S_08Z\]Y^\P%/AW@Q[M[?0FKYY!@U.
M7.APN[R+*_<<<;GSW7J75UT[N[ED>8#1>@U.5+GKR"JM+BZL*N_EN,@#''C.
M?B"/ +&-:N&A19[S]ZC;&Z>L_VCR_OW1!>!%>>4W((#'R:40#P>.!5R#$'8'
MX8'_30C@@Q;:]5Y\&<I4E8$=GI1@B"]52.)=!9XXXHG%K0B5B2Q"QV&,W#5'
MXW(PWM@;ACH*E5=M/4;%7Y <#4DD4I(=N=0!1F;HHI),/<E4CE""%5V5"EZ)
MY5<2;MF40NMY*5-"0!:54%8'K#?^C!939320*G5HL=-14H[I46#FV$98GOJ(
ML":;:^;YUYH:^51G3@NI,N>:D !FGSY:-)KD;S8^-TQ@6N#)'I,@&C1=6B(T
M>D">"6EA4J8B[)2I;!)=.L%4=4SPUVL1=7908)WRQ-\!2L4YP4Z0P$68/G&:
M0^AH)J64':ER'AN 2?\ %B=ZPC7)9:4]-0>IJ0>(=%9$^F#GIUFF#K,>L:9>
M%F=:\!6*4Y='547J0I T*U&C:4%B3IQS*ON06FEAQ>\_^C1:Z'?^:8GH5!"%
M22PD.QEF#L"9#9-G9 ?T.]#$]AEK3L&(#2,/8O(82Q!6<X:<[:0.2J0/8@0/
MI,_%MAG^"R+, \ECZ[5AB@D3O&:B)<^S XEP:JN'Q7Q4BOM=]NQX,0]3AV(R
M!Y#G6:#]=.A-6O2L%&LB8>:96$5125Q%D.H'-$.?COW/ 28M]B;15X=&=[1I
M(;T1KE/>N=!9.^7Y*D(+$960*A!A%8!&\GHFT:IM[7Q0IE:_)*5I!"U&MFI#
ML?RN2I!5)Q)$$HWL.$&Z#>3M0HO9MS*U0C7NV%H3(#U5<[-%MOI47L7ZVNY]
MEVGG58MG1K-AJMX;&DDG5X0MMH:IA#5G!.6NJ^<OQBU;:02#G?5K$B4.M6&J
MB."Z@PK[W#GL5>+GV[>81VEME0NJOW*N V[=5+V1GC_!^2?^PP^#(B,Y'M1N
M?I%Q7;T&8IF"M*TCJ/%(_!Q8(- -\#)M6@U_(&&35PUM+5D)S37H-<$(82M$
M5?E?<7ADOY^,$'LDD@=7>""YA,VHA0WY40OUIR,>WFAM.#P)IU2$0.) Y&,(
M@5O)D%4TC9@K3Q0IGA9F-$6#+ 9QBYL9)-0TJH<PZ54'4,Q6,N:X.67N "6Q
MC6%$,IZ7-2Y=S)D D]8RKBV*S%RP"J-9)E 1U[3%70UZ2A I);Q!RF1H,#1D
M3 2IR(:HAWTW&08DX"25Y_CP) 7[2T9H1IQ+?F1;A*&:<H#(%',0AC#ZLE":
M;KB1?44J)37,G$_X]A5]I,14;&K^""PMY,GKD8TIV)F6HMC#R.+H#"L6ZQ I
M?6(.<^B,DT$R6R-74LQI.B9]/WG@L["&-=EXI%NM,PK3C#*8C5$&,C9J#N"L
MUY->;J2!AKF=XN:F+L_$DB:)9$H\1<,8D:'EB+*13<9^B3Y(7F2-== C 5VS
M'4>) ) K<6=,%A/&P0"K<+8K(UKBZ1IP_6TA@/F*1)URPJ5\IU29L0UCU%)"
M2AE4+B=EC$28!!I(L3)+A13*:*;6&,-X,S)_DPBRU@@1^PPK /:)CFY(]Z)\
MEDT@4R3>V\+CQ%3U5"_D4VGB6&4N].6TD<N<R9]4T:@YF:-;YAH='_=X@#H
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MJE(16H0FU'+@8 "R9<<ZU"A22QVU:[5(U+H5[ 15=2;P_(=S6)VW"<GRE'=
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MFQO3447,.*Y\2M2S"5SA#GFT"VL!OTK$SI[K"MP %KH(RQ];4Q-U(:BYCM>
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MW)%P(T55H(FL)>1-)>#G8)+^$9Q9\V0JE6' B Z&N+*AV&/,9)I+\;%G!!,
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ML5\*5>8-HEZU3XZO$L(5P@$(+?+^$=0RC& =<P07,OPW04O^PW_ZZCR,N##
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MKA( $Y)2D#:2S @MV7"$Z9%7W.#7_,C7L$8?=59:6E.0G%K8^=" '1:1D!Z
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M?R! _!/X3]\!@<,"F#L8X!\D$0.UU!&H;YB6 \,&0C(XD&-'CQQ%R!LH0M]
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M+^H8&BZ  TQ2;:=AO@.*M(:T> Z\H5)TJ$.&>G/(QP@O@TN$I"#9:;Z$M)C
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M4G&*]DNGPCY8M77:DT@,?(+LI/0)OIA9>O5JM'Y1^ UMT6Y?M!EMTS[M^@D
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M# W6ND &BA@/*(Q*"@.W"\&Q1+ (VUGIO+>+6_3&#;(H"92C5W7Z:Y,1.<2
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M]HO#VH6U:D\(%"PU$U0:";OPCH2BC;1!H=3>2_]"3%E$3J)@<6Q?WDT0Q[(
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M1_(0EB#E *H0(,M:<M4[5E:+OP.J0XIGK/R(X$6\*IH$!04<C;1/2V:4[)H
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MYG'B$$98Z:8V1^NTK"->@G[FI'>:C(%6)@8I1EBP,./@!E2PS2>8947BBB:
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MU4?PEK B]H1'&&0[/(M*&.U(O"BV=(I?^[6MF*\^<B-;,&;O$JS$((WU!"(
MJ"0;?V)C"[-(;=5?"W-IE:-MW=1F);-CY>-CG8MA-A%.!@)CO$HB!<\]TBMI
MJ 5"%@2(H)9FZ39,SU10:<.U'.+^&IRDQ#IE.*2D.9[P N&4<Y!V5'EBE>(V
M)YKD_YY60Q:$39"C25XD)2J7*=XR\DCW[P@D-W(#8\Z"(X[B<O>D-"[P:$/7
M)Y.V,#>58FE7,.<690?.+^L64PFW/?960_;D=E.B26*W(-X"68DW.])+\(B"
M_[HB=;>W<?$R2VL#@&)VA'I$FV2$(IFD>N@QHA@R;BK6T![E00R"^![$?E["
MR*;#>^H7>85"H?QIGASB^9Q56+AW,"?6T]X65P=XQ!AX+IU7,?.V/:0G^&H/
MG6H/)((D)!J'5[JV9LM7.6H(/E:F*OCNH6[B(":#N'35?@-36J%C8F#5.^24
M+I77VU+^]C 9U=-X^#"%F#XH6"XM.#$Q&&^-&#&56#"1>-QT>"Y_CH2WS8<-
M$XKW X(EDXB/ WKU,HNQ^(LA\XH7]6X%,Y5R-MNZ6-78^-3">%)GV*/<.'GE
M&#K@6"B=F(S/>(]-N'@?MS#1]"Y'ETWM.(^9^"^--X@->3'I6%:9-X[]F#"!
M>(F%-XG'&##/=SE@:&N#PY&E!H84>"'04H(3C9/);X8<5Y*I0T2 J(JQ0Y%Y
M0GJ23SZVV#C :/@@JWQKJ#UL&98Q&7M@*+SP6"B*#P432('I$2@>ZI5G0X_U
M0Y2A+U(168S5N"XU.0B)(F_<XY-C,D#>$H=UHYM)%5C8UI+^(1:8W>,C8N8^
M'+@GI/<*=0-;E):1;R-7V4A])#& Q8.*97B5,2^="[ H[M&>^=@XD!"?=P4+
M:=DG+#$XGKE^$6RD_N6M@.0BTG6>+G4WROB$!2_!>J)#.*)UW-*@_Q*;_5$,
M/20^%BT\0M63ZUDV]J(.YB5M^\J\&N*V-D*@8QJFLX9$6(2S )8[&'!Y_WDY
MRLK*YB.6>4)Z.<MA8D8ZK 3("*+KO I=:"(-&:BG:<-MS.%8B_ P>.I#D)8[
M,.Q#/D1PX8YV4+</IVJKB_B<@<*C/P)T^Y9"-*+K&@*^/D)?=2JNAU>CF::F
MT];,Z"H\( U9I.5#K@-\SQ732$+^B9PD;&77F=,YJ) C5^\%YH;'=[:%K_;T
M);:#0KJ0HH\E/+QE)M;ZP0C;-N#UKS<Z/A+E7RPB6:A%2B"$)6P,"0.C7L*Y
MB ,[+XDY*) 085:$)C:$\DCYH/?D7TX&05ZX/R"%5J"%-\8YL$[;?45&NY>1
MFOG+LI4UT'I'+"/W$C&[T<AU2=!D:YY62TABL6G2NA=X>B?JRGS$))!6KP$T
M3"6O4TR"LU1[7WS%?;Y;JTTM[#S"/U/)MP7EUU@;8O'/2;P%=Q$D<1]F\(::
ML@$;@Y;KO;A#K#]E82:<( 1W5$0<8PD<R3#;23[6A#HD3<)#<!-*1CH%Q+$/
M>A5$%4S^XCH.#388IY-UI+MU@[ 39<<;NP/1Y<-=IL2JHX;_F$\=+)6>@G 9
M+G)922IO@Y![XRO1HE-X@"-6*5C6XRFFC2B\JE->6UU+F2>N(<IIV\S@E'E;
M-Y4\USC>E-9"!,VA8\Y_0AX$N4F\7%!=&VUSXRS"\NU8 BT2#%ZW4HJ-X^UT
MJ:H&+C$"S2PO<",Z12M9]<PQ_6F30E!7"3+@XBDJ@BP%Y1^<\B$2PZPB@TXU
M R=:MWQ*<E!&_2$XXM'+Z9CU;=5EI4E^*Y4LG2.B_-310J<)]\RULIB^4D<J
M7<A1_)&= W8%Y4?0PG15(]".@GDG=RD'SB.\G'-+N+J)XI7^.(<EQ.9Z.QTW
M"(1G0'TI$JOCI J5;*1R;;W9\UQ6L<Q)AF0LJP1.AR3!,"8WGGR:!3Z2[S*^
MM1$F?CS%U3RDA#NXWUH_?-D[FJK QH3E8A ^Q$1 RN;.%J+38D^,!N95EF9/
MORQ&'/PD@E35+=+,TN3DZZ-)$J(_OO!@&R(*,:<BD,0'^PBB/<JA91BX?SC(
MH<>%)\:HBZ+G"[Y0(;Z-F?Z-AQZ,R3N\)-X^3*V;! ]5;U',8O"XXZQ3,LWP
MG O30F]#Q320_!OC;*Q? >FXW^]6L<Z%64HC!&EZ<9RD'!XP\3Z1H=X_S&%4
M3"@[DIXO]3Z\LGR*G9[4.'HPESK^I!K]/CIJWI'FM\H\Q/6:SO5+5KPJ$2N"
M/=HNC<"K<M922F*\(Z+%=E6>SH.D=?G6:S2#\T>PX9U=Z(_>+RN7[_->ZM%8
M]K?MX)>I]WE^]^.8X/GG]W7#H<U006A$[6>:8('F%"5HYZN$.^1!2ZUE(3!^
M4WTD3*U_33UH.X)42\;.C>0&3V?:)KPQ!DM/^UUD\_"3CCQ*\"^XI,W8WFEX
M_OL2S <9\8_7;NM?8_<?(/X)'$BPH,&#"!%J"1 @H<.'$"-*G$@QXL*&%3,2
M9 A)H\>/(!,RU!*RI,F3%$>B7,F2Y36.+6/*_*ARILV8-5E."##L7YT#\A)J
MZ6GS(D[^$?_T'9B@#Z$\DC.-LAP6@"0DG@F1VH1YL^#"GE^[@F0XX>/"H*H"
MU$E8AVA(J3?-!4":=JU!JF[%:H0K-N=,O/_2YM5KT"_A@H*?'CCLD:'6F2+4
MINW85=]@EEQMZJO#\*>6I@;30F5<T3'ITQ)W/EYYE6ADL)"TV#U0U9RY"2)&
MH^2+4L3B?U21RE4%-'"  V"UB BZFR%HE%2A<C;W3XNJ"5!I:Y&G3P2DU28-
M=Q4L<"%UV9 6/PU@3IZ(8<-$<'[>E39&C6F#1B]?1\L$ZCMI 4EWPQQ WT21
MW7?37,:I\H][5#D(V'?3_1.9*I%1YYX64 EX '5%,728>"W^ 58=5COIHP5R
M#^9&F4SZD,B8B0S9)IN*4$'2'W.HF18B6%A!HLIV@?47V&=M#=.6/'78]4]L
M/>FCBCG#? 9<5<,<>)(\F6E6E4#'"40E43':126(5/Y#)6AG#C2,*EJV)"-J
M=(+Y94NME1?DB0)=!28/D$!R#4L\B-C2!&4]*.(PUW#9D:,G!@H)CR7Q9M)^
M5_8T::%]8E15H)>-%0 /C.5Y8D_#R%,H41,(VM-+ 0Q*&$,*5N3G5:0*E.I.
MFF+DWS60A K13K7.%$!95"4ZS%4D =9H6*T!=N>5DMYDZ58!O/@75B=:Y2E\
MQX**K6ZHF1C6EQ.0NA D.]4YYTG^"PTUD)\+=?J4O50I^N=5'65;'53^R@2K
MMMBRRT-0]'I*$@\D^0OIE['],\&@L7(IJ[''UJFQ0:K%E"=5'<EUI4!I-169
M/I:Q=&U)!V@E E,6-G0 96HU^.1*%\4)TG[RL,@EE0$T56!YBZ6,TKLQ<=83
METOSQ+1 ,=*,,K=BV?=1?FH>UQ1/:3GX-%Y2:I2@7@S*M5AZ_S (=FT!2,@3
M8"F>Z:^3,JTL$]*78A5UIYG&B)0\(-X]+9V R44S29'9S!V=/D9%M7$JWF<>
MR6\W)%=02PD4E @.<@@FP2MQ&7!7&:?-'I<X)E7ST/[&Z""ZOZD.NN"Q;[PQ
MWK:'1&O^[G4;RCMFH_Y.$%@:[RZ\0W8?GWOR<@:OO$VBD_N\\+BW)*NVTA<D
MZS6A,B?/[$>//M/WDKH%K#S?R[-L1\ "U]&RJ0:J:[":!TJIX-E/O^#@^HM:
M;/\581X ']*EWP7.7;X;X-@&R#L!KJ2 # Q)C/@7003F[S#FD!<#(5C!'C&H
M@Q@[#K&.PQ#:F+"$+VM9@HXE@I>UT(4P5,Z*E).;W,BPAOZ1H7*PTT(>XB:'
M+>10#5W((5H)\8<PQ T.<],R&CK1-RE,X@N5J$0:OFR'/60B#7%S !HN)8LP
MO"*M7+B4EGWQBREL&15]HT3[G)&+49R &NUSG#?Z1CEJ9"/^&UMVK -\L8]=
M'.&*Y.A&6@'2D(A,I"+IJ,A&.O*1D(RD)"=)R4I6DHZ,M*0F-UG"1?I1CG$T
MXQK32,(2NE&.<R%D*5>X1_OH,8V$)",70=G&639QA8/\I FY6$<NOG&04!PE
M#X%8Q2#*\(?8X9 RE\G,9CJSF0GJXC.G2<UJ6O.:V,RF-I?)F>/$IIJQ&5*3
MZJ C<:HBG.=413K3^28AJ>)-YWP3?.;YSGG24Y[PM*<^]\G/?OISGR/YIT '
M2M""$G1,5 (<?-1WIH;J W"6T4=[S"%1[EC&-A"ES@3! \('<O*C( VI2$=*
MTI*:]*0H3:E*5\I2DHZPI3"-J4S^9TK3FMKTICC-J4YWRE.0)JJC.#D@4"/"
MHJ%")$;",NKP:J=4F>2K@B)K*F.B2ICX2!4__[OJ@K1ZF"%QM:KL^:KNYC6J
M^TU%?&1+:D3\1!!DT4I;["+8O:["$+=PZ5<#N6NQAO'3IXG533_]:]XZR"7!
M;O4P53+L0]BJV)B\I+%UNR!D=Y;5R2(D: ,975.$^B#Z//0A B*(SK:B5M"F
MA2!U:).>""*;@B!%-S-3W4"P YS?%!9JUEE-VQ0[-,MZY*D1I*IO2Q*C&7'4
MLL =;DENJ]R2&*FY):'*:*$;UL_IB:(UZUE3/&=5"X'E .]L87DH(Y>E&:BV
M3?D)),S^D9NCE18A?!T9;@VR'-8ZR$WW'8A2=!6[6XT&*QFL[4;R^]?>0E<B
MR1U@<0_\$>&*Q<#*/2V#/\+<"6?DN1;.B'0SO!$>!2QB_V!8B,GUN"?]MR.M
MRFQ/IN4Y$#.V)"5>*U& 2ZYK!':\;2T(B($S&G:96,4@CF]FP7?5!'.X($;N
M7Y*/G) */_C&OGTQDR-2V2D;Q'-6C@A5S#KAZJ:-,B#VW-.Z\Z0/J6DM7DW*
M;[R3%*1>"30BH$Z:)1R>]SI$PD+2;X\#9YW9!NY-\Z(.B]S\C_-^!\FZM?-0
M(9QE^0:WRHW.FG$/3.=(.P72D<:PI0]"%<YVF<M--H@\+E;^I>\1)'T/2O7\
M*.4]5<-8T4ZYWD N9I!!>>]BM#;(I JB/OCF-<9<%;*EESP]8@\;TU.!,G*1
MG>7';EHADCTVJ _L99.DF7JP[BBA!7OM2!M;>=]NM(/'$VW#5OK9PV.VE36-
M;C=AELD]C;>\YTWO>MO[WOC.M[[WS6^:HE*5H#Q.&D-)1EF^DHQ/Y%" F)F;
M9&[SX1"/N,27^<VVM.Q-;:F#.LOI3HZK0N-*.J?&R]D6=<HS6/5\IY#@H\YW
M;ER>+3\Y/EUNT)H3E#-6#L"TN0ILK?I5L,+VMKIS%^XL.[DKB86NE-O]#V<S
M?2!8?KJN=-[4SU+DG0=Y-Z<)#)'^/"NOYQ,9C"IVGA2#T.T@<?*TFO0+=I2D
M*2EFA0_4T&Y6E!T$<&YB*IT61Y"WUZGH$5$MISF;*M%FB=>!&_=$)(H0BC:>
M\%I2J]5/K26UBXG+HU6\33"D$9U9WB&?WY;4?SWZ\I2[T1L>ZJ$%4AR?@#94
MU4;,Z?,:>L9EVR"TZ7L=(/2FHEJ&<XB!SU"JU'KNOOL]U3E[%P=27K=/X./:
M0DIOF[01[TJI9FH62)Q-KR;P1"CO&S/'? 9R'>W/WJE#O[30F-H=_6 _SOJ0
M(\E(TF>!D%.TZ=?5?VY#KK1P5KN$1GU* 1K%40=0UEW;YQ-KP5X#48#2PX"%
M!AJ>8P[^>B<F^1<2G$<1\<%U#P)>NF)#!GAVY?$?S(<1+Z,FSQ<?6B<FTK0B
M'1%_#H)S!W%N3'=T-L%7%9@XVF=((MA]]-.![S1HRA1C:6%(#M(=02@L44<1
M^I >QW(@/V,0\:=P^@5>S^=N&.)I_8$V Y$;&!9_=<!F4N@=104</ 1JJ0=4
M"W%?#]4=V6(=NY4>'4).Q^%A;.(=[>434'$;86@E,3)#@4%;"Q&&+-8?Z#$B
MMS=;;Z(@'+6$]3=?!<$B!A8QJY<V(+(<W:4ZB8@0$U2&@;%B3A(P];54VC=C
MBV%@_J$Y#9-?&:@QG39D%KB))P%X#[%\R)<0.U8>1$%]?>;^'G=Q@6WU'/'E
MB6!R7X5%8_3W7P36?,"!%(SE.5&W6QLQ8](G.<I&B[-X7*8E6DA!?4@&9:B#
M=[&H%&8EC0<!@7Y3'>!#@^UF@S91B23S<1A!*2)P(&6B8V$E@!M!,,_ABU<B
M9SWX+V]!8 VC)47%A=5E) :&5K0E8(5&%!)&=3^6;@W8$6GF.IRV@D!U'=BW
M8&ES7UA6?^1AB6 "&A!)$AZ9+_X'''V"DMR"?$G7;7VQB?5%9U@W/&?WB-5Q
M(!J4B?ZE8A8B-(^Q;;WQ4UH1(8L8%.; =7P%&MQ27)E8+VF&?0[IBE33-542
M>X@%C 7!7G)D>=VVE/(G)L-P'A;^B1UFPI7B]T$?QWJ#82)ITX3WX56/.#BO
M*&E<Z!,-T5I@0F(FV1!1^3\>J1<R:1'YY8_>2! 5R);W@8,B&%I"<4#QDA#8
MR&3N.!.YV&=+:'^7X1_O-):JHY' $9!@$C@3E%2;J8$O QHJ4I)(IB#L 5Q6
M%75+2&@Q\E"-63GN5A -R2=UF3UIV%$*XB?,Q2TA211^)9$2.6H_EES<(@_M
MTIS&213^P0/*MB")6)WL<BQ!H1LV")E/ E>Y,G4#(6(^!B8AAAW;.3%@(HL$
M!"9FE6(2PYN4TI,DP5RM IVQ05=0$72$$V,6\W=<.2^)$J#:<T$:!'6995V7
M.1&^(BG^GU(0=W*>DO,^_S48W")DDD,J.U9B$S!C9<%<X$F16L8H1(9@YP=U
ME"$ZHT(6K 5[;N$O(;F<USDO+[)E3P)L2Z=8@ ()!P,23J<7.Q8O=#4!/'(-
MV3,Z'SJ1O9DV.P>>0H8HT!82CV5C$"H_I+>@3I=80THPS^DI[@8N9*5CHZ$%
MZO(B%'0E9-<_QU%/HU@5]"=-?M03/_$FNH4FM'*$RN%^[Q16_J$D97$;W8@5
M7.(@Q*%,NX>(("&#[U8@-G0RFB,?8O)35V%#F6.&53(:0W*7;C*4;4<1=9IF
M]^<FX-D64*,=+_-NX/4=)OFA.@DF3L)HJ,$9=%,E'$@:E8G^$+F1J?8'F)FD
M*(:8%[EH@&F6JS[Q? :H)2]97=:1K%#S'GRIA_%!%,[1@<OR&.Q5)4XB(-/*
M-TGQ'I7(5]K:> .*'RGZK=D3K2U"$!D"A$]A)LC1'>_S0QSR&\NG?Z)%6\X:
M&N5Z8,8*$KD(=;IQFZ0Z=1KR&ZN79M;!<@VA(FX18.3W&[+*?1G1'OQ1&.1'
M&08H$!-@%]YH9H6F'Q)+&;W%E]XHAIZ#D< !(F9&CMD'.1E9>\,EFC*Q&H-)
M.NZI8)^J5!,[9?]*)YJW$B0H03"S,3_K$859%#F[$C(X>CMJ.Y-',MK"6=/E
M)L_A>$BF5JD9$99Q>)S&? E:E@7^81GWHSY7ZW7 ,1A=RVMB:[7,U[9NXK49
M6;7*U38V=[?V%(8=.R9XV[=JT;> &[A^FR2"6[B&VT]A>+B*N[B'JS2,*[C!
M\D^.^[B46[EX*QB6NT_B]QZ9.T\8Q;=\"Q\5];FB^[D3]5"V@;JJ"S@4E27M
M@3(6-1^K2U$0-;NO"[NP2[L:95%KVE$-:D"_L[4KL;1NTKMZ<;1_Q1,3=281
M9;IEB5#P81N=>[A_.[W6ZT_5>[W:.T]UNKV >R:I KX));VV$;JA>U!EV1.G
ME;K1^[SJD[ZFRQV?N[HHTX;VNSB+HU'W*U&H>[K<L65=2[[GV[?2F[[>:[F3
M>[W*<<#^#,Q/K[&X]12Y^11S&U?!%;PL(_=QZ41.T/=QS=H?32(;(#QQU+1P
M)'S"*+Q,-O1$4H1%"*="A(1*I?1O_59O.6>\2K6S1O5S!7:NS86\N-JO/RS$
M%!&P44;$RA6D3R>\SX:CS24EN"&A,NL0?*4%?X:2WT%@&U*T]O<9%S&P#?<<
M!JBNO3J--!$9L*4K*R):0I07 5:$93B%M]A]''(@Q%&"Q(L8N1$XJ>43-40?
M'WH;(R'&-J1?/'09O=FSA_'%.(G$'P'$TNJ!KTD6;&(?1)&MYP4U5/.O3LC%
M#1@J_2&&Z#K'F3J*7O$R3J(4"PQ8RH$0_7&%4'/(\.7($9'^M+A(&Z8\$!C&
M?[E,?LI$'\H46)O1L9P&RWD'EK3<8+43PK>:J6\)'D.2H+P6PF3"(4GUNRLA
M)=9!'QF4J+Y\J\"A3CSROO/$'%TK=_!EJJ@E%#[\MO<CNDZ!SGT'')Y5M4LI
MC'(K)J&'M66G.7'"J<T5L%HY$3TC5&0&=6Y!9UK7C>075D^%.GIH?W3SRF9<
ML<JFSA,)G[#:A1+#FJVCG!(BL;73L:/!C":QKWJ6-FGIRW[W5,_EC<KYL)S!
MBMI(&'SFQLFL8?UZ%4)3*W#;RFNG+]41@_U)+L8:.+E(?)P5DEKQDJARE+$G
MC3!-@$\]=3P)DG8AD<1(GEUU?M[^O&V":HH6*%1W0E7'):D.$6,T6\9&&XT=
M(G9PIBW)E8!D?"0Z!B+F^)IZ(7Z:3!D-^27%>4"MF111?!L@TETJ\K]W-\?,
M%YT'P<0.<7_W6!U-PUFW2,RE*,_6RHF,'8;:ER@I.] YNHN$"VS!J5P"/<4&
M(1?0"K)6_*)=6*9048\%\5PL]CHSAA'WU[1IXY[$4;1\/2^/X9,8<9-5^('S
MLAC1B"IKD8E$"1*B\=L<G387^JU7=E\9ZJM0AQ%+:HZM2">6T:2R994F,4'@
MK,F)%Q9J@ASU2+#R_+,9Q,7U%7LF4EB,9231:I?976;;/=29Y9?D&9@9R1BV
M_!!R 1K^ILJ7T2K>TQ(PRW*O?J.W:I?7KNG*.4T1M_%[>35(EJ<D70F;N7T7
MW]%ZODR9%_X0M]@SAYBC HN+')6 0W(<G-4U_<%GU%%9D'U4X"@]SMD4Q/&$
MKA4JZ4$E^64X\:&4N;G:],>![-;0=&M8J8VT]V$D$(O07?@BK>7AL,VQ9;IB
M(;XD>OD<.NP0#0D>X?H87&CFFMICRGVA5>+C"?C<9F$7]XBV55(E6O':^F7*
M&7J*95H60&$;:G'8%3BK WOB8=>OVE5HA9YTA2%42:=S"X:\MX4<\"$?E,*,
M]CWE]!>*M5I=^5*)J5B79]>HI_@8J?B+$K%#((NT/JSE$D/^G7:QX-*SA3]A
M=FX%(FN<=9>QUL91)Q#KZ+$1?[Y^@KNYYTQ$FB9-V-H(R161@"U2($4[0R-Y
M9=*C(U(HD;&M.5AA)9>9XZ!7%\-C*JS5-M?!5%'8A9<QV;<^7O<ZB3X]ZUP'
M@3'+8 *-PX5!G1TA/6&KG$$16%IP,>R#$<X69@3CHQ5-$P@S&+D8*^WII&[R
M(KOF\+V-GAFMQK^6QV;([? QGN79GR_")=[3$6'&*C13&#=:HZ2!I0M*WB'!
M6(VI.>/Y@RT/=1X&)H."O#96&+?6DM85ZQI]6SC*(R)&V1Q+K;:&$4[,'"7/
ML;)"\;R&Z)R6HCNO*UZQHO/8<];^^=A/3Q3GF>\8*Q12'W90X5=,/ P>GV1%
M+Q*ZEC]/*Q/LN8\"L?8X5FO7F%7\CN6:@C ]!^[#<A<7=!5F122*F'5H>O2K
MQ5RY2#Z!@BC8,VU.W%P(M1%/GA!K^R!Y<<YN/':Z AKD/$_"R/GZ!<]=F1=C
M7OI>VX2HGQ<,I2OFO$_C#+>Z4GAC:_H:/_N'31#!0A]NH?FRK]F8[VEPFXFH
MT;5E.T\N'UUPRWAVIU]D"7E9>^P5$<#PQ29AJ[:RG[;"J$&7_[:0+K?RD%_=
MKSG9CW\$?G[[=""V,3QZ'HAPHB.0+B!"E4&B[Q-DXG('Y'*@5B^V$]Q=;)\
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M_L@8R6!$!/G<3,B(%IA;$DPY3;2+83 R'Y34:(05F55Y^#D8\D 40Q<)V8'
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M8Q7W-544=GA2,C7*67IDA\V \8S$M(SXJJC F*[4')N<((NQR:O84$AP27M
MGV*WR(C^+,M:9).M:*'9SH5B6M--%).I=&!+B ;3/N&VJ;6:$6AN/VT1#08I
M'Y.E+*H,E6R&/>=1-T:-I 3D1)=/0,?6C/& )2-?]W7<HB9@PZ-@CR=B&_;K
M2B^/LFYS=#8U#K:@@G=\>G=XIURH2#8BX_:/ ' &'?')V.^,Y#(UOJ>N3'=?
MUYW5];=_MX75-<;:"#B 0YY"^V1.&B6"+S@"*3B#RR,/ - $ %V$'_C^1'@
M5+A"3+B&3_C\%/*!*_2$:P'?@3CDD7A$H+B* UY$M(5"#WC8G3CD>7-C>#.
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MG CDM]<.MPGR7\<<7X:6F!>:K!K,7_UC],=<Q-?#Q<;/\RC?7H?+=Z/1NZ*
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MLI*5J2PE,8O)RK^D\FDA6>8HBVG,9,I$F#+!RM^.N<IL0K.:W?3F-T]Y@,*
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M*3A$(*?*AB"F;RN8XI6  EV4HR-:X[>T0R?TH=&4XRT@)MD.X@#H(RP.:/J
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MJ2K2C@*3JB*ICW /K*Y3CPJQ-J+/,:NB+, 3D?*R.$-)GDPI,[1@\42 ,";
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MSGA_PUOTY ,G2/2**)[Y!P\X<HT"(H4' N'!0B Q'7E,YX*Z>0X/6K.2E07
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MRDB'JA(1(>$DF%71ZE8%U2LC5:4D$YH4PAC3+D+VQ7DAF5=!0$>V(T))5_\
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M015+ PE;7(K;"20D_!N]&)4LR1IQ"AUU>Q2^2IR(P!$_ZQ/M6#_8(1N^6*Z
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M@9[(NDH'!_=YY)4FO^II?)&-^2P'CQI 29V)35'_2O.[$\ V16S2>*G_B\A
M/\3UK6;^X?!1"%>\+;JJ]2FN 0:*/$WT8($C74\<( $<.:GHW<W#]?G26R>(
M!E%$>-]TW":D<A2C&PJDG=7NQG@VS-$;NU*0PNF=6%G(>K_<-9:[^_",U,AW
MI> !O' A<3U6WVB@@5B(HK@,YP4/SY@*BI#4"4"-+F'DH/@A816+U)@ Z?"/
M5$V/+EH,^/"-K("?2FZ-6\5F-MZ,0+6)_(C[805 Z\@)3476J;_5ZA@,+GGX
M(KF,E/ 9A=95P,<@A6CZVFU@ZS )K+^@2@Z.S? ?58R.P:@,P8\+#V<+>@I
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M8CJQGQ )(C$(TF1T-[K*";6@PXVUCR$^C(L.!Z*0 UA04OJP7P.M*!< _H.
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ME0E\CH)7W8P9O8)5DT/5]&/3CJE';=Y)FM^DGG&\*<[88<^<U M .-,I%'T
M;3>BD\I>F*D1QR'O'R( 3BH-,CS.P4XA,3$<6E1A%H U!3<]H9LC+?(SJN2L
MGG9!'(&R9:>S0-%9YGB(0'34DPD C)\-V:A*-G*4A?ZJ*0K^LTB;A'*J2,X%
MI%R;64X $\E__!!XR2+@X=CF$H> I7%HR1H]RYDZI\!D+76("G6<9\@"R3,E
M"LJ*L@A84HP>Y)U!FXN.5$J6!@$-0P?U%7@PHD^T!?5V!GW+Z.06K(T<0":3
M,TC9[ C/%.H*)K1K*!]75A)1P85L5*$;7.<:PKY:+"L2R0M)5QK"C>HI; RL
MB%Q_4M34/<E?,Z+*3FNR$ ZA"[ EU0)G2:22K/0H7]SLY_0@U9D ].17D,C7
M8\WBUEMIY;5UB<@(%2M2T8VUGZ)ZE=?0.9:\8DLM6JN)8"G"&%;]*FM]18P(
M<&;;FU(%CS<-E:^\!5SOM5,U*H7^T%U,8SJ1A"Q):X&M>=9"7A>IMSIRR]A6
M8/>GS0D&$BN+:,H49!Q0_<RFAGS<9;28G;/L#C]I/,Y'+*B@0:YFP')LEX".
M@KC%^/0HTW),C6Y'([Q$)+/?!1]UW)M/1L7.J:UY+:""^BJD*6ASAC*/A!#,
M&HO)3$(6=AI0+D5>'9UMN$<KC$P4QI20W.<M\]%K(H\I7;E81BM.*XI+C"P4
MZ"GD1VED3UXLH[V-9.61Q<S=5.QB&8 B+: 2M@A!'(<;KC7$,%&^)&6\.^?6
MP>TLB".R5^8<*CV]^*9R:U=)()2=B8*DN$.YXF6BDA.?*&I&)'G*%[\S8/_.
MDSF$I<C^>A?SJVI=JJN]K2QX#Y--ML"U4[,Q[V/H!)-'CVHM?JZ3NA2TK!D9
M!A(T.7.*\5M>HHA:<_,97:&W<LDGY66]6Q%,LB*9Z\F6YL'NL2E?H,V0NT")
M0\I5R'=DJY"$3 HYV1$U8Z/WEDLE^=;12_&^W/8]<EO$;;IJUE89UJY'QBLQ
MEH&BA++I&<C8R]8XD:>G>RN8G?2Z:].Z]")KA\^Q. 0E<3'.1 03)* 5/"[7
MA'A(T,U1BWCW():]E]62-5KIE<PXO<)U:(=+)^3UI2^SEAEK4=8PM_GD+C>!
M])0?XRQNM05$R!EMY@2BX+XE>BR=8XZ$0&.:R6S<;X^.#N+^$DN29"%.TPJ1
MKEFFHM][TYS4>K)>C??;<ST1B*W=?FM" ;4;P5AFTH2+D--)I.I?][<]TU84
M8R-RQ1:EF.\JNXNNSFR:+3]HVF]'RXN,(Q-S9,8LEG%VI/<*9Q#!!NRR(RG0
MO*UND7=M(GKABJTLU,^SN$IAZU;-!(";=<W2O;<E5OR@V"N5H]0HRAI9]\(U
MPN272(WU!G+X4+!B(P']2<^HB4U'U$(A\\Y>:II*KAT%XTS5^2[<Z@)Y=?I4
M:YL"C^->!$K,?\-6OV0^3'?1=V4B IMEO07DU[QID$[;7,P+*VEV)HQ>AZ+C
M;<ME:D)([[;"KE(C^_((5*)CV2[^+R=<C[7$+.Q"PM3,@P=TI.SX2R'6Y$3"
MHURJA$R<@YPHXSZHYD3.Q#_PHRY.PD)8Y=A\;2@\!-=0I-#&9 ((0@L<A0=J
M< .+0S%JL""N8:GP8D78XCYR#\*:ARI*T"NL1%"&0SA.Y$3P(D,@83C6:4 0
MI3=&).2BYQJX#3::HSI8*G:HJ4-<P@?1 U&@<$7*Q3AT9$VV8\U<Y//,@T5P
MPSPJS0K_X0W/D'2H20>A"")Z,#U(@@HW0C'V9 **XP"9BDC\ZL3^R/K0+$K>
MT$*$ RSV)$.$HSC@\$!(8N'>$ C)A)U^Y"=&47;>8TS 4 [E 1+0Q$A4T2)P
M@R$@@B+^TD1%""($40+]<.2YAH$\/JP]Z*/W',5!VN2YON0YHH.X^$\HM+!$
MT +1C"0U^/#PB)!$F.0&\V(K3.T!33$"56S5OM$WQ%$"Q5 <=Y$<5>/=JFD=
MX<6?#(1[P,?WCL?)[B4G[J4>[P@"<\>;D@PB2N:=XNA7<.+@K.@ELFO'YG U
M(,*(G(4A?4)Y\H(ED CN[&5F"JJY2.*=?"]3LFOR#H-8Z@ B%T)9KLPH,J9@
M8"8XED5'3A)M.@(2?()@O.A7?"9).@9AINQH4B82TU$H+O <PS$"H\TG[48A
MBS(H5*^2E#+]$)(L%FV/Y.]XG/)1#-*/]I&02H0J94?_&HG^([;RG)@1'K?O
M*<TO>K 2*5_0769)EVP).(*H1( )*]@R5DBE9V8(+UGH*4 C+U_HASS&A@CF
M+F'R(GJIEWSI+W<I5ER&-'P(.-KM+R.S07 (,WJIA\#,E]ZO,CT%,R(3B"S3
M*2[3,&T",4?SEU1E,SVE*>;2,EG3*70I,7,(,X+IEP"F,T<S,T734X!)EWKI
MENB2EMK24TJ2-VTBEV"I+1%B+DOS-(/(.64)+GNS.&O).*?S,WDS-:5O(2K3
M,9W",VUH,0'SA\#3A[PS58#((VB(, &S+]L3A@[(/?,2(>*3/NLS+QOCH59(
M<H(E/SLB:P(P6( /^$)(A#I(A)+^"RX<JRTVJ(+<YH+&QVT 2$(GE$(KU$+U
M)T(-2&P:8WP8J('$,BU10RB_$2C#CBB1$AU#-"F/LJE85$6%HJN."2S3$BU?
MM$"ZTD:;!.ER=$%J]!M9L0-[I$PL943]ZC$,XAH4I OI1#%.I+^"=".@%#>R
MKT2AM$1:D3 FHP+GXT1\A%6N5$=8,3SF@YNN5$"@Z5&N04(^K$%T1"F 5$$X
MPD%84?Y8\5!2]%ZN%$0>,7:DTCW:E"N<E$OGM$S"5%#B<#6Z$$4$%=&@%$C=
M5$E&(V<@84G10DJ[A$D>4;6.Y_.D%$CS DM+(DE!Q$?F,%FD@T>)0S50)Q=3
M54=!U%7^QR(/0U2Y_L)%J.S^#*3C:(T33^<@]L)?=,+3](/B@.+2-&HQB,X%
M@V(!VZY=AF,ND*;+/B*;3@5@VB7//D*I7*18):VO3M1 2N\RF.TS]H(N:O4X
M="5IJ(,Q%,+\\!12=*Y%YA%WF+(V0D-!8FUSM&8!W]0PO,S>5D->=^)&#*XB
M=*SO8O$@U/4S) 1H2H;3&N(F9"UE!J8]=K3R9&?X0N(=$<J?&L]9.<<L+Z./
M<F(P2LQ&=L)9SJ;ZNJ8GB29;K C*5,%Q[ C!PDU[YL+M;@XD"H]%& 5'42:H
M@.8CXH[,V.(FUA$SLJBJ\BDT"Z-7)A./WN);-[;V5$-YF(+^$-<2F30*+*2&
M113L)E[S ( KYRPBUAH#[C+LL6Y%GR!R/D<K2%HV516+V/BC2'_OSWJUXR8/
M6!X#+.*N_.9.*AB"Y#"#2$84V"Y,(=;/69 '0LPOX(HMBOSD]-QF-\"U0,35
M+&XJ/Y+B9(#B3UR%[+XV;V+2*/=(6$VF>_R4+"(B)SENVN+Q0SAO]EBW-4I%
M(UQOI9:U.F[B3\A/720B5&02M^A$)'M/)<@04?R*+._%:F$T.BXUQ)"-+6"C
M^'CM;Y[",];N]43B9?$Q;*AK,=X&)*PFBX)'(>[C5!+6-:*#5S8U(?E1-B;B
M;-QWYU9K94A,.4'B:">K63/-0'[^"&T:L>XNL4DK0S#&JOCJ;B(^,L%,X]&&
MS^3LPH!%PD6_*5I99#+N-&^Y8G2J]P0OXPOQ@JTB+]UJCW5NAP"/0W'I9%(T
M1=PL(Y*T(R7)$'GX)L+$U6F"1G-;0UQKV((*(S3V9BW4[N/RJ8/-Z%"&K"#:
MD7@B;$;N#<4RN/Q,-KL"+L@R0GLZQY!J[ @A+V*G5  5KNFJHREJ*&4$)#7J
M;S'>[#)LXC2"30*I^,MB5\7RT21:;?B$E_((U\M2#&7]=R(ZS@B'*WQ3QXU_
M)?C<%IZR ZPH3XKU!'L/$6CAM4!2PL#*%CS<PH)"0GWK<+'V]Z+L%B,"F#!&
M=D<: T7^#';FSMC3WHUN%K==D&-:% 5L/==>M$/TR*0>?30"<T(C#^(J<K5
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MA\&XB\8ZBOD>A%(=L_&\)](C9E$5BYA)\7L4-?(0 @PJ6L$IOG&JE[*[G+?
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MMT.YE\Q)"T5D/:\0D **K$"A%,UXK#;)PN2I&S2["Z;8OCI(I#_CFJ= G\'
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ML6?7KE!?WNW?P2/L#C5\>>S!S:>O*R^ /O7OX2ML']_\_/?^JLC7K6..OL8
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MXG8)[B]!><T;Y@"2N?4+Y6PS7-G:0%V6:B;@8.(!,,JB/5B@@ZX9[B3-;IK
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MV=G-*0XN"-)Z!E[]!5>X!EG4K?#8$ LAT4'1G,AON^BTA/W^M2!2S&1--,C
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MD"EZ%M'2["4:^V>> -*:7,M.T80BT^I/7S9%MGA72ZA"#/>\5,1!?E$YDE)
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M'>!50BM@87PT&W-@J2ENR<SUW"*/HOBH#CZZVLZFQJ_L9<4G9EF@0<8GF*;
M!U5WVYGB4(*95TDP.>0QV.VJ-+<<&=$L_@G,[$*#E0R2+4<:Y""_Y*&V9DUJ
MBD[!B3RN\98)73% 79Q4&)E71N7^1!!W5(P5)!JXQC<BIHUPS)T:+>3&,RKE
M@!S4'0=7=J;I],2%F KCGJQ(%CP:Q(5[]")!NCBS@4""!X^T'(P@<1A(>'%F
M\D&4)1O22:3LB&CRL"0I#R,/'H1/(9(*T7U*B<F!\&!/UP@ P2#9E(-,X(H!
M8"1(]A67$.$*EXSDP8XFP*@V9D@V)^,!)#-T$-DP<E2TY.5MJ F:R8!D(=L1
M22WGZ,TL?K-P00PGK'Q)3CXM[YSD3*<Z>SFV,YW00BTZ)_$*J(4!W@N?;]Q8
M.T.BC^V=,Y3]7(X6I_>7JM53C);ZIOH&2L63G"RB$ITH12MJT8MB-*,:W2A'
M.^K1CX+^-*0B'2E)2VK2DZ(TI2I=*4M;ZM*7PC2F,ITI36O*T>=(5 0ZTMBG
M2!6X WP*J&_ZE$X#)X*@ZNBH0TVJ]0Y@O1.) *KLT<)"F&+5JV(UJUK=*E>[
MVE4=>36L8K7J5\CZ*$<)$#9+NQM:B7*WS'6I2^$91ERC1*?J+,U12\/J6J]:
MUK+>\YYZ=2L4';K&)1JV0B=!9&*W6,?&]LN-D%VC'"=K$LE:UIM\M*<>,ULI
M17IVC0(-[1O-25HX=O.T< '@G,"I''U421]C86TCIU.:EMAV.G2M28I !Q?"
M?(\@?0ENR.1'D'\Z<$3(*LAM+:<1C6#NL7&AJWUVZQ- 6J7^-+HU3FG00U=D
M+1<O[^1@BS!5T,+I38QT+2-UF6M<W(+D+@N+2WF-(A+>S+,J#='@S(RC#Q"J
MAC?3 :-JM!N:\_'+CWW2K?3.ZT_FB@ZZB;GG.6'+7(>.5K4%/*B&YXBK#G/3
M*C")C51FN14'AT0+S!047K"$G<U&DB!:@(E[U!49RZSX40:IU2W[D[9GR>>2
MVMF38[#"D 82<S)6V6Q7C'F?%;=R?2 J,D'VX^1_\*"!F;O&@2B"RD%5Q#U2
MR67/!*)C#S<F-Y6=XYJ3HV*!9+D@L434+O'"2*' 9!AY'HAD3>LD,>_)S_Q+
MY,L82>-_S%*7$1FQ0*[!*#)7CBS^4.9!27Z,EH+UL;,RKO'N&KA-.HM('@U<
M<T_4)IOI4)IQA-9@*N$HFRM>,V^D7')/8GV6E/WXU;=9=)U#DN%897F4&8*)
M%\\<8T839):6G,#N($K+84?4A:=LU4FH21;I9G,B.^+RCY?TX3-C>3]QWADQ
M1QU128YKBJ.R9;@+@V(0(W<O-ND)8A&#H2[9T!S$P0X_*U*4\'CD6HJQB+OF
M"['W*6=3<T-=U+X5&S/%1&>Z80BX#-8:/R<GJGXB3*>Z+:BQY<5=_JJ;Y^)T
MR?%2$>!D0?#TV!F7J 0VPC)!4KRS$[G[$1 Y^IY44OY&ERON<"BK"M_?3N9"
M-H6F@>S^.0T061XK"B<FH20SU$60\CRO&)TPYF!10YG[FI.YS%3Z9-Y,)BFJ
M*9F*5) 0G:2(.$$;^0_7H"6:5'3"$ HO$":C09+'SRX3]PVE8I?I^]IDOL4:
MN9W%EEL/U@UUP)+![</-JD-72&ZMG;U;M<*#S%\H_Q-Z2QXN3"DLQXZ+G=.[
MY4M&XP]X_&-.I",\XVTB#^HBY*VM,[<N$<I+AA ;,RDKEJJJ\PM%,+2T=?M%
M2CB*C$H<!*TG:6O>X:23I%S><J>_A3F?DCGLL_*3!C972;^:@%OF^]LN26J<
M( D[VJ=R&M]:R5RC94]!P.WKX\:'] W!?DM@FWE3:9IGL)_^[H3%Q.".H_12
M3,"0_DV%E_@69T@/U+U1W41%1Z1)^X6$<]@'Y=&%X3&)@<"6K;W,W,7*1J#'
MR8S%IS1&A D02(S,O0G&JOC%3K@.X6V%X2&%US!@RBR=BG@%0[@(WOA%J[3(
M 1#'"=5>!GV>J3@$AZ6&_XP7 X)8GXC(N*G:<63(=GQ2F1$:XWB<J$G$BBV6
MH,R-_8VAA]Q2-AW&IM39!% 3I/E=17A1^)#<DXU+DS"95%!;9D@:793$EYD8
MF!D$DGS9.F%%'4X@9B5&,I&+%EB;PS1:(.U'(&Y6<@P#E,$=V$P-#S+*I55$
MJ\P&QNU8,W%A0R@B4CPBO@0@0:3^&J>0!2D1DR,:!=_,BS%9$BV!EOVUA"*U
M&A6!VT3,TD0=T*#9X<Z4T:[(#-O\VKUL(=PA(NN!Q"D!':;H8B6"1@"@TD$4
M(L\%R!!QDW;<ARU2%22HC0W:!";"64^<GC5-!#*1X\^)1.A-8:/0270LS:1(
MCU.L"/IUCUU@!&%,Q$]8!0?ZA#1%E'MTS8S9!*L0AA/&'II(Q@4BRE]T$],A
MG<J)S$291@:I3UDTG)5\B2A62GQTC,N80UGP1ETHDT39A*(<!HF<B-/4R(G,
M451@#))LG0RR&?_U'/E154GDA4&>#$/4"8V,!)+<4RU)'5PX%5/D1M&I0D+
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M7Y451<NDA<Q%A536Q>"^Q\Z$B4.,R4833B97AX$HQD?4KZJ9TZ8XQTJ[7YU
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MK#KU 9IU)HCV:[DW7(L!@@X66 ?^N>=_!W9.D#I,E=_+:QWFC'SZP.'5_T0
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$ @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>amendno6tolsagrimage2.gif
<TEXT>
begin 644 amendno6tolsagrimage2.gif
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MD'5XR(7VV2%"A__HL\,"=BPWET#>#1@1=1/IPU:3_\CE(Y;'[% <.G!EA]U
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M*9ECH*(T,29FAU7QC!@%J/HE4/+4AA6"IDAQMW:SH?Q(-]#W2TE[$".I:H?
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MW_WOAW_\Y3]_^M??_O=WO^[QOW_^]]___^>_VP/  23 ]7N_]0N_]/N/!53
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M<@O[TAID(9,V20F*6*$884VC<;P2:;?"))7J(5:=&I,.8I^#*%%@J1X?A$F
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MF'U\G_LN&8A 'K918SS*.J]V"HPHLN"JE1#RE39^J\?&E87(I&7\T<$!3YF
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M9;%3'V'#-\T3L,#IGBQ02+6$AJK61BU5/ &,U'R4:J4M-@W^F5R<29^@ZXV
M[$-@R=10ADJ5R(,*91U2ELM\IU(YAC;)FTHT#4(M#=."%<!0QZ0E%$+T;3B-
M!G6D:EW*VV\LCM0^"#>N$]. 1]\2STEYE+6J!$K%R.62D\N0;3FVDVYH[L!L
M(YYB+>X61I\PQ-2\[C%Z!>/^ Y(JC4.$DW[*9O?XE(@ 5.(NRH54GXTLFD(
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M-W1'MW0[AW17MW5?]VXS!W9O=VBH9%1PMW&'VXL5!+N,F7#L2N]DLUE]A&T
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ME@@/X3M^IV/LPX@F-C<*DC"H$$LCA46&*A3K+%>JI[1FAR/6!'@B! J5L'"
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M7$>Q.V[2;D*O/2JK=PGS@*SJ**:K?2+Q)J_39J\Z_##U:H^RD8GIH&)($B\
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MN84EC=2'/$XF%PR1Y:):\>)8_(@5J+Y%6&KA)%JDFL=2YF4@=;%#1?N"5;>
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MIJH163B_8KZ7R7PEL*6,U:S-.JM] [I/H_"2PTE9@'K@B-DX(Q*S[W7,;T2
M:AJ)X&CU6[464/UJ6&OWU0'00@2A4^OZQ7K5LK:#%G"R:IS\NF4YV>LF]DIL
M8[?LV,QNMK.?#>UH2WO:T(8.M:^-[6QK^]I5QD9K>>3M8V##L6?J]IG&792J
M!:=FZW[,)K[J%W-:#4Q.$G)CW+PF7\\;*;_>]U'V2AB!D&;^6N,,TEHA-R+^
MIJ]!_R40<J_VH2N=KTG5Q,ZBVPJ5/RME5Q')99R(V1L1C*O.9K,SAAMD7RZ^
M$"Q>%%[)4A;B3O<(4PR*4.KT,2A]$BFW::G<-^5Z%AO3JC2NY57/&FHC8#-I
M<1VSMT MAM$B1XR/753>K#+6.Z$8.LSE(:>):#&HB](8+2"6"J>3/LQ[BA")
M3-J/FQ;=Q3L#-JSX5HL:-1<KH3P24;W3(VE8\V00.XOM0?[RP>CN=$6^KS3R
MHMX_6)1-><?PZPX&Y+\6$*T='API^+7*G[YV=C8!"N5H[_!W,_W"2N$RDM],
MIW;,YBRLEKHQFY\,QBG#X^;,,33^=19,Z-O6E=WW7.ID43G9[U)WO/"<+<FW
M2ZKN,FD^+?_#=_D]8 KYL?GUD_A/:1B&V([<E\F].^G2>;ZJ[*\ >%K.M.B9
M1WJO=US>GBJ\^QH)*<3V3V(3D<G3KMN?6!+K9T@7427WH5R'E'N*M ,3(X#6
MM$FH-7_#M8#.LDV/YVGH@BE"<52[(C#&\R!QH5\747D]=4AP87-8H3!^IR.P
MA2CE=F(- R7?D5?ZA4?6]Q1/AGUD0SF'=D5"%"ORL"LOPQ+99$L[R"+ 4GL,
M5SB^XE5,-7;GXF&45"G"4G+V48*3=%D^(G1FXUAR='+<Y"F*LCK$-1=-^#'R
MDD.FM#W^-O(LPK,I/G=HJV8[!*)Q701O8B%/$5)QA'),2L4H4^@C"9%F=\9>
MJ<)+\U="Q-=Y5.$G&89(X4(0+W0F U9%.)02#8-'9?-(C,4=UZ4>D=AQ Y(F
M]L)9^N%.FN-A-O@78N-3"-%.W.<4F@A9FM)@'((Q8+<Z2 .$CX=.%J4?O4%R
M1%0IQZ0P!6(W4!5A5?2)_:%P 3)09+-^50AVT,@K[/2+*]<5;=02\=1(0B1R
M<K81].1"Q<A%F&A--8)S_S5]9*&-._A0"Y9'=(4J )*&VM,>L8%Y1Z,]%'-8
MYE=%O\%F5J%.MD0V?(<I; ,Z- 0L(9@N11%LMM0OH:5.I[7^7M#Q1N7A(T#8
M?C@E'@1Y,+!8)_+(*/43/O53*9^W2HV"<PNH0D!X3;O33CDD3U271,<"D_H1
M7[.5>%U1-ACR/L:G/KU5@N@R?F,W%$%U+WL%5W5H%JO6+ZN&*5Y%0TD)6R_$
M':M&/RTD*4^S:+AD,;1%,DNQB%.Q %_Y6-L!2J31'AHS/ZR!*#C16SX40][4
M@$C2,V]I2_7!E292@4ZVD_$&DHSQ&T4GF(&I&#!F'.]&&,T'(X;I%?CB&8QY
M(HWB;[U4F9)I%V14'JI")W>6A%/A6)@70T@90_)B+(QVD PE@Z=239JX '93
MC%?1B.6!1X$D1$LB>0]H1M'C6/7^E6#>P7&.&14'>"J+]!N8Q#;:,RZSN5;@
M87/"@H'_MW!)E2<3LX!1B!9"AQ7QP5B3!G##5(+Y0CX7XG!_&98OQ%2Y&3'A
MJ9Z Q$WP!G=)88UF%$J!&1_SLXXQ@IU+<77J\S&2TI[2DX&S 8\DQ!1]B8!2
MAYED<0C]@84)XE9-PBA,YF%-I#V$0CD-<X=,>54ZY2/7)%UPB!1_XB;M21H_
M]T(144[7(BA_F8PF6GB'!F/<]YU,,AM5"$@F@D1%Y%>SIXJ+,9C3MB/1=A+,
MMB-%&F[C)F[D]GCR,&Y.*@]1RB1.:F[B5F56NJ182J56N@G>)@^QX5C;)J9C
M2J;49FW^98JFVT9LPL:F(O!KVM41;@H=KR9L'?&FMH:5]I-J]Y.G'N2G?PJH
M@2JH@TJHA6JHAXJHB:JH__.7-48S @5(VT<K-)0GR")W*O>@?L*1,>I/#L9A
M"Q@>. 9T29%F2\<H'A<B'R)*(I0MZXDV.D(HSU1XBF--IY* 65%3NXA%GF5S
MFE*J-\1,7Q2KO?&IAE9YB.D6&M5U<J&=5P&0T')ZH5IAY49/Q?%[/YIQ-1.;
MEU4E.-<1' *$_@)$T(&C0N0@NG*3G-<>P-)[;O:$9E%V4@%C5E0E@22?X]E.
MGI*;.5@<NE,V%[6@8]&@C@4L^_$G\,9>I %)_E@XD"1+FO/^BJNCDV*%*:)9
M<C06GJ1)4>OI(:;5?DF$1YIRGM^TDX&&3Y(D-HT2=C9T-:?W>UX$-[\78:_T
M>*6$K7QA(GS&2,;%*XWS:=&4E@E5=*UZ-3Z;EC]D%41+-J,J2<.)@L(9%H3I
M%<AZ&\WZ%S>K%2;[5B(Y?$["M<UC%P$;%SB7GV;!H7PA0G8QEF*AM5?19'6!
MM7H!2<_WBFR[+Y"$MVJ#M\]%9&5[:.-"4T8K6+VAM$A2HDP67E#[%/#!+>[T
M>)%E36<"62,*N8QE(JPE3<)7%@11,XR%:36VGR[51E5Y,#FQD%/Y4!.E:3T3
MMV"(HSKXC4J!;);D53VD$R#$6_K^^KH9-9M(T1,ZI4OUZ;5;M&J]VW;-$C;?
M)7[)>!,-F:J4>132X559I'ZA(K9AH2 84I:EJZQ+A"&-1$.PI5\8 F;.@I8Z
M@I76VZAF%S:D"W88<BI_\I*0)!0>4K ^\9_0Z[LX48/$%WU.@2@TFSREA!/[
M%R)PQUC.FQ1[E8P-TH8%K#SB9Z_)D[&/*!@9)5]Q=)Y%=*OKP3HZRB&<%BL*
MC&BHZHMWIG+)X7B(&!7E%'M[9R(19GP^@BPT:,':M'!0UR101VA>\60)Z[N&
MEK9/!"6#6"E^6$2)="4V1[5LH5_Y\B&BQA966Q6-PF)D@R1VDZ[DEURQ"W V
MUKI.EDS^L6E7^@$E)8>%MB0EP**SFZ0\L@JK<4PVJE*/X\=UIJ2XG!*ZT0LE
M)MO 4H0D\;MUG"5/^\=GH<A8ZE%G+&:@VF-:UXN')@7':=A3KMH=-:0BTPA8
M?6E7HB2KPD-S]P3)5_%PYD5+- :#(9*!)[EUROA0-*<B8Z@]BV-?(\MY+CHB
M9U?&!DRSKQNL2((I-E2/;+ASUO1+H$2V.M)"W#=[A2FUSEP9'0PTFNL9-1H8
MUCQO5YP6D-D9HRP:^E:9ENEO,"JW$:<JHLFI>8PD\]%^L:N91%(Q:$B'X%LI
MR3%Q]IRRR8F>;BL4!;@OMCEG,=B-.F2:D\6*948C1.852";^%(LC,D4,0T"L
M:3YR>[5"51>MS]-Y2V&CHWX[.U_[%&&SQ><5O=*9NV<",SW13XGW?0E7P53E
MCG\WHC!&50P"F4'2,/_;P%3[KHX#THP2PW'"(BE!>#$IGPG'=Z$TS#?A>$&T
MOL5B._TA)8KB'00L,AE()KX,K,8LT^K#2][LM@N&+M<4E=^AO[GD)GU9C:V2
M'/O1L/XIEDZG7,="K=$S+OX2FC4"F<F8@YV5=]'RG<(R.GZ]%)CDEY0!II<A
MH9(AS41#S9V!S7]!SEJBSBCXU(4!UJ !SI79;^$\V7DA/ W:QS\8G"@(>QEU
M3@*%T]NDR0WR)V_4T.N\*55(2U7^:$<'UL1-P<+\E<IFM"F1^$2:F$2#8F?J
MT: )$BT5Z&!'V<-9 7L44B5/7$3#S%XB]&E7XH=W=MRF:$UT.&>/#1;1U7E*
MU'9Q0<54$98G""WQ^SFJ<JZ\@7W8',;M9'CV\2%E=SK[J&E>)2E]#5A%5E-R
M][%-H:P2/4].LL<),C!9[3)5DGN)U7FV310<Y8C#9,L4@WB3PB$J=)$.65F$
MTC!F]&(1YRFP^2%^8\MREA9;QV+0&:N)9E^M7!R+=RKH=6CV^I_^:V_18Q2=
MUWN3)ZT6N#DG0;./&(@=\ST%VSB!=$@B.=]))1YGMU?H$L(5#)H<IZ^5=T-Z
MUQU]'&S^@S+)"<%$!_$L\5>!+/QA=W(Q^HIY6NDLGTBX84,_(D5L Y-#..HL
M-S&;C;T>N70U_%O<PGHYQS)#Y/N(AAUB7PDLN6T6*F8Q!M5&T9H6YXU8.'&3
MU;42+<$Q^^01F5B1-SG@E=[IR152'\,=T)5-R*-I)>&XW8&AW15$":6Z70Y>
ME/B 1RNC"#X<+T%P+2%0TY5$+6.Y+>$K))5>R;7%C'5HZCL7RD6JCR5O1)5<
MTDY=5Z,>+X%237.V8R%>O\Z$N,Y8[9%3TO53Y)5<(W41<QLJ:_M/!\%D3V;J
M^=KA.F+CJKQ$-5/)FE:B>?(GGZCJ!X,1A/GD@J'>ML?HB:'^S;KW)8HY&)%M
M-97MK'=X&9G]&9OM;YU=F0X_+^%I7Y_9PJFQ/4,,S_Y%)*G!6UT</2XC@X0;
MB&X$QXM=%6+C<HSR<?7JE@9E?AH%W[X)K27#\EZA1$#X-C]%H$/_;PZ>'"R6
MH-UM2-]=%PE_\&7QXU<1EF<]W(=H7T]LW_RR1*(2,D322,<DFN=)2O%Q3=#1
MU!>*$V'3NP*GL4X&CT8D::-*U2.-6 E^P$HAPS[BWT2R%.NG$QX2AH3"(#K!
M*H%"\5RA]>7MD*44XAA\^%@X]1A33<08]X56+[G\(9L7'_=DZZ/V]]]DJ_R1
M$^T+1.Q.%>_M:#$2+BR;]TNA2<O^,B*NR$I2APY8-?"!01R+RON][_N$VJ>I
MAJ>JIFIN"FMLBOS&I@7(EJ;-MAK-#_UB>J;13_W5;_W0-A_17Z3'=A+BMA)*
M:H7_D*11^J1+^J6.5?Z/^Z1>>AU;ROY>N@GH7V7Q?Z10.AM1"J5.^GCHIO]0
M&C$_!1#_Y/TC:,<.080(!R+$EG!A0H@1)4ZD2'"@O(L6%V)LN-&B1H'_L%T<
M*3(DQHPA&_X3$<!AR(@;.W[LV%'>RI("Y1T;>?&F3FS'!@H=290CT6/'-B55
MFC0HSYT\DVY:BFV3O$U6>5(-2I6J4J]?M8BX&=;L6;1IU:YE&Q;LUIU%NQ:5
MVM9N6(/^%?7NY=LWH;X  >SHF^B2("W#?A/2.DAPTPZ"Z XE#$ +85Z" 2;_
MDPSQV *""S81/!8 '>!CI T?6K!SQ\+2Z!0C9+VS,4'("'>,/IS[7X#4_S99
M=@CZ'^;?F1<>,FS']&.$I6=7!$X0,,( ^M E_BW[GV_=!TL'EY>]NVK5=@X-
MQAY\^ON*Z-A3)@S?/L1-QN_KRV]G4_W"(.J,(!%HB4T?\&B[[;UC-OO-P>HD
M0B<WYA1,:!,'$=INH4VX.T8$B78 $"([W/OG&,8BE(B[^_PZ)L&^]-$/-]Y(
M6P"YB0I,2+K+4MO!Q,QN4S&T$1/"L<46Y2,1R,P@' W!$W/^B\TQ%HWT+J'6
M)CH22;Y>C"Z '39##;LK(9(Q(O^BHV4!$8K\3K0=7K,(L@H+6W Z.[P;#SLW
M2;OS'UI A(B6#*W+3\Y_F*OO,\X$RZ_0?_01 9WM3-2G1(H8XW)33A%"K%-0
M.]TS5%+AVZY45-\;,E56486NU4XU3?40)M\S$-:^S,/UQ!E9O757O;8$5K%?
MA]7R3V/YDJ_/9']#EE-YYFNQV&9W?+9:OC8Q*$_'%@B@S2^9C4@I\"ZU U'2
M)M/G0^(BV]8SRYA3S]H=VCW1#A$<1/!<!T>=;=\?_X),'EIV6/#%<T>DA19)
M P.7-(-%O,S@=N59@+$%ZKN.0>?^'CK.OP0'0R=??$>$;$WG%E2O9(1$*_C+
MA55<U5B#=E!QO<_*-#8_)"N5-$%YZOTL-TD/82ZX?#_M<4<8^4*P014##A@B
M@PWR%M " \WM,:46@%11P"P;DV?:)J5(QMN$]IHB77%EM*\)D[)#OYT"J/$[
MRV1-J&J##//2XLBJ9@W(\@@3P3=)I47S6ES#'&[>?VYLU%[KJFXW\?JV4^^0
MPP7D.\OM9-M!4#1)9_5%%#N/-("!UB/(]; ]^_%%*?G.U[H;(3?3(#>OSI'Q
M3&F=6R$10Y>PP"*WN_O$F?W[3%#.DQ(A8]PLVU BQDQ$V [*/04>6XD U#LZ
M!Q$3=W'^+%,#3+:V,VL7'>-"W[@@/5-3FO."&C,ZM. PFQ(^B]4'1FEJ&6'@
M%RE]F8TSZC(,H5[7F 6HKS(%V<RIX#,_SN2&>X "$OPXU*YCV"$J(DB-ER1%
MG)=])SBC*XAO9@:LI$2*A"UK':2 ]:K[($8V9#O$P'+7-WW0XC\3\A@!!9(=
MS*1P-H>PS(L>L@/98"IR*KL28JH6)N$(QFJCB=/KLC.R?J%+1JG98.18A"_'
ME"B$M5K=L-[6)3;5[#;[2@C.I#@\VECJ1]IR"'@0DQJ+&4@$C1GCBW1VF>^U
M:GU&(J$.CS/! $106QJ;799:!I&U'69!VS'0;HZ%J_Y837W^HKF4@Z(%0L$(
MYX<&(UY"#M>@^=3I,_* 'Y"<P[9$HLE >K,8.C[D'<T\,(,>B]SR(K="T,A'
M;KRQHASSQQG037!D#.-CY&A53>SE$GSPZ= V854:8GI35%429Z=F6$YT4BF=
M>_G0.MT9$=;!T'3O+)6PZ%E..VCAGO34@C;W.2QL_I-JT.--,%5S/OS\J8RX
M@<@$"](NS,!(8K^I$7#\E9B^N<=?%>%1%CW5G#(9$3F>')F =*4[N\UO5.I)
M)7;N4R6EO8XWS&%B2PY#.2:JQCVF24YD,+HF!1[3FR/K%4^QU<T6G1 Q-A3(
M1(U4)245[G91:A$+?].N(5GPD<?^64A>)%4?*6)O2$8\CB\=^E&P5BF"A6'C
M7[;%+?N\T44*-2;@)N(E,^EJHE-#2.R.J#/=D<B?J7+JZ[KWI2M%:#REJ0]2
MK84AX_"'>U9%'[",B"!Y $9,!M':1 (:.(ETE$R' 8[K$D5. @W63*)AWD[%
M-20H+>EL?VIG1*C7T(JF)D+7B\CX!*H8</[V/AL5KHO(F1&.#*0G4+E)<N."
M%*@@Y2M24<I3K+N4JX#E+$U9"S9$<!?PAE>\XPUO/KUBD$WTLT-VTQ:^^OG=
M08XEOO,5@7Q;,DB'C24PWZIO2QS&W_T&0 L!]F^![188YQ38P-\*<(,=_& (
M1UC"$Z;^<(4M?&$,9UC#&^9PASW\81"'6,0C)G&)37QB%*=8Q2T5[B'".9QQ
MM4\O.#R$QJ)&F?<9IE*ZD92GC(,_0!EFJK+"XG=X0]R)Q!0A@X3((:Z$G(UA
MD$X*\5MN#FCD9SJ+@M9!;:ZBXQ[3GF@RBDV,@8[Q9$$9E&Q32Z%S"'.NEK45
MH)L)(7;"N2O'QI6G9(N.D9:7IAU7!S!%4B)\[BBD&#.LKWO3ASX\QJ(1!3/2
MZO,4I!C;Y%ZM"*&@$JU>3#::2W],RUG6T MQ Z!)A54A-SIDI)I&ZFU*+,PX
MC#/5@A/JXQRV/9[)-".391[ C,:!\RO<2[#SI%*'I]6\"F?^@SIM)-5B$CO$
MR7,>Z[S5U#HZV8,RJG6,M$*FK@ZNT[YS=*)=+?DLE#/< Q*N]6)FXC"%*;X$
MDA!I429M!8<6"^&/O.VUGA'I ^"+4<^5D!P1>A\#0/*.5+N9LJ--Z$EC\H[A
MEW56<0TE!4 85$Q4SBP0A0NDT2?:4;L5LG'/'!+C7\:DG&$U<@EML]K_E&NI
M7HVG<LKX=+U&%:W$:4]W8NCG\[SGS8W%9%8973'G)M6UBVO<<K?(Y1.)NM1-
M'5<&E:H\H5H)Q"N2%51=?5<8D0C9CTIT;E+%LTOQ#-L1HG82[0CM?:$*,;]2
MD6@]UB%WIXA2#&,5N.,G %V_$-_^!>(5-L9S5[7M"U:^&Y'T2J1#QCR." A?
MFJLD9,#7 LN"PO));&FWFO(8L)RUX!ZL>.7T.QJ+1%*6$.^>T_7ZQ)4\!GDW
MTML-]B*P?-G-6_C/D\8KY8[6D)Z-D'X"L.Y[!QY6/ .D],IYZ\#7:/*IPZ0.
M$?[M3 ??(EF;97>_)ZP-:FB[PAQ,M\MT;T>NCD.UZM,O39UYGGG8B?Y<HS=6
M1X1U-)'>#//]"O$K5LH,3N,.&#&>[TB(9<$Q]! J7O&,;N.K;6*1M3JJ+O.+
M6_HK-"$/D\*/S> C'L$K/7,,HF$1>D.'@@DYZT"Z!5*(AKHUPP@:C0$4(8DZ
M=3NUPMC^M'%2#$GQCB*J$3X[$C1Z0%>Z$QE9MG3I+38*L]!#ED$+K54)FKZ*
M$#[C,BM<C)L#NE")+<Z@JD9ILOKK*T0IHE;+NY93C=,8"('K-HA@04/CC:FB
M-<Y("GGH(1.1P%I30(W[(S0!ICRT#J'0#LUX,ZQ*,N[;I]+P#_):1$9L1&UQ
M%$>,Q+9X"ZU8"J=PBN<RBL&[1*F(BYW0"9W(B)R@)]E[.E"Z0'=R.E/$%L5S
M&U1<1;H[1%A$DGR:16RQ/EM,%E7\)W-A,6L)%R19I!.QE[-"#J2CEGL)#=Y
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M*0W0: EO"0S\4QDM<H^8VA88D<HVC+8%J!H361DA.9D&$S8P"2S4&=3O %8
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M&*9!=0GIO$[J<%"8BJGL+(J7CBGL3-#N,$]:@";S*(_Q((\ 10]:S"GY9$\
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M!I?Q)Q+F, 0K(.,J(RSD1 \#!D51/-3LC>3%(_%*.M+0)03^<2%Z!GF@[%*
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MAI-:K!,;8H.".+%&4_B"J]$1+B5JR]$YRV<6.+*#>,&!PI.$AC-71S,[>'6
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M#(2]@M\3^D/R</7OKOT<.?'[=3),@!I>_EA!-8,P>W^4")W_H8ZR_RN*+1/
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MK=B,R1C@F%@; DZ%@)@<SB$=7AA$U"$>YJ&%$1E8S2%8V94[ 9>#<8T *LZ
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M \@>*PFC)$626 8$(7> O_!*F/FEI'!,I$>2"),CK9!T;(>/5%QS1K$.2P>
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M:K?&&>(4*M%BUNW(#^XX"?V@UZKGSUJ (OI6XVZUV ZC**VH&AH,N+40HL5
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M0F5Q\($DQ*"K, A!)C:1BA!4H07S-T4I@A"#%Z2@?B#X13!&L#SZ&R$"T7A
M"I:GC&5D(!K#^,;R+*"-82QC!8ER0 CF\8UIW%_2!N@D.@:2D(4T)  1&$A
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MIEIFH!ELN8KHK"10A=V,+**\ONF$R!X%BJ5S#9)F)GM+2V;V518,D]_V.MK
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M4LJ,!FN"\B["5*0098+C+]+$R1+^)F(>#2(@1<AH32%>12+:XMPNIG[4@\I
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M,F(K$B7#W^NEZKHT+?%>6CK)-2+]&$(2S@#:=\")K-;$:+*W3$2[N26)8P*
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M':.5[ OGX\V@H!MHG_'6BXF3'M$Z?K)'Y'4JY_-*L2Q=0'-=]\02'^FEV+&
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M1!1/?C/^H?+F,3LZ3ZF3[>H=IT/'U(<XK6V&M'9R'%YT04%T 5!RU"="-*T
M!LT+I86<H6^&APX9W+&)X>J5QWD;]!U#$VFT6U'NV8?.#@S)<]YX1B%HT#$+
M,B0"?O_<Q]]^.-E!E#ZW,;2@?@8U2!0Z^(GWET&;4+@)B/QI!)V+ UY(G#SH
ML?A>A $41-QL,YWT3X,;;8+>/R,>%>!\+^G%$7CT4<C2DT&*,)QI /ZSP(;'
MQ;BAD/8]R1!1#A&5XT:(A23/ D8.)6&4'AE(6WTKT9)BA,(9M,!.IHG&D);\
MH728DQL=$N8_4#$THT']>81G<G<N-&< -1[:8T,4QDEFG__^- F2'>C]A1*7
M'XW:FI><2LCC/W4>F&B$*Q984)_FA<CF1N99*J9PI])$:4I:#3B<")CZ>HQX
M(_;9'HD#VLIICS(N "!OA=[*FYE98ND1=-&I-B VB_:)G4V;>+G)IA(%F^A\
M\VG$;@!>,I>JI1%BU^"F*JGZCQT(:K$I@2N*MZ^0KP[\;,!:,,BN0ST.N>BW
M/F&C\(;R:'%1Q1+>2RZ)IZU78($/<RK:MLI9%-Z "/M(,$SV-LCN1A%_M/!&
MQVSHWB;SS0F3N1K)0V[.B]*7K[XHS^PRG/?J>Z\\1LM\D,I"TY1K2 %0S>A*
M/YLD'L;_=,PU1 B!K-$F/2.XR4+^%MU[C-$)%R@:U@ W1[/7!XEG]D<-YMKS
MT&(C3>1P"S=(]$8#Y68'R U7R1 V^Z'[D1:\-@3Y/S#S'"%"\AC.$4$@Q0L3
MY7 C!'G/^Q$L@M0F:S0G4(2C3M_:)+[>D-8QSLZM2'9_]&[0??O7)\$4F\[@
MNR)\J_' 55.]8<0W\[RO'99B]"^X,8D@T4*8$YE\PC?+ZCOR-2W-O>(B='X0
M^:?JWA-& UJ*D-;]&H3-1.1N0O32Q*=NMM81XY]N<O.'[2 [2\Z/QK6)PU5$
M-/*0Q\-\YA&D'3!H*_N(\5+G,K1LA&&)XA7F]G,,;$@-A!Y98 ;#)C42CL1J
MJ'D;2R3^!Q*Y?7 F 82)L91S.I'4CCXJN2%+6&<[%ZKL92<<8:YF6)+RX20L
MJ8N4Z#ZRN+2Y;&P>B2!](#@2WM'.=IYQ""VDDA:LW*@L;WG+9LKH$,CTY3O'
MH,4AUGB(3; 1CO>1(QQIL8E"O?$[=[0C'N5XC$+=$9!SM(-P[B,0X1!2((HD
M9$(0N<A'0C*2DIPD)2MI24DN8 &75.1C[/"8'>Q@6* 4I2@]N8!A+2"4.SCE
M*$&IRE"FDGRII)IUJ";+4P9@ ;F\R/=ZZ<M??D^7P!PF,8MIS&,B,YG*7"8S
MF^G,9T(SFM*<)C6K:<UK8C.;VMPF-[OIS4EIT2?B"J=/^$3^3I^DCS79TDB2
M2$/(<T:G@,[)%INZXQD>#B5;Z\3GH9KU'B,A"B1/$<DZ.>7/%091)&+)%@8]
M,M"/@"4D6-)'0SUR4"PZ*CD4I8I%^[;1C7QT9@=EIT8B&I*1M<8J(^1HZD8:
M4($Z5"1@D186P1D3IEATI$X!Z4?:V1*5#H6?).4IJ7((SR?!QR 6>J *<V*@
M:W4H4>*1E'ANXR73< 1!Y@G7J]"$(029QE EP2E'O!35ULWI3_DYE$86 !%)
M>6E"8JJ)/3GE0I@TB542PD\ZW1H@B/"F/IV+TZ)XD\XXO<8Y<!P<%F,C3YB8
M9B%+/>GLGK>HG30IH_1Y44S,@Q[^328-I/D*DD9V8*NSMFUC!Z+%3+4UDLG^
M)0!=F5IC/\-"DJ")3&X:RH(26R O^;6M1-$2.KKXPC<E#:L@T2QPS&,N\:!#
M!/J07LPPA9[0D/:QM7Q2^D@[.*.R!JRG5)!0YM0PSDE-KVJ2[0TSE);23A>\
M2&S)OT(CGVP=@CS,G6Y;\1/<GAK(/*QE:8Q< QZ'7&2D*(7GS(S:M7&V!"@.
MV9+?I*HNCE3.4M)+9].<):]%W;4D+B.8]-0V( ^>"GOT"5A<Z06^'1EQ965#
M4 X;9UG%H4\\JWG5844&WM\$;T"U-55"KX8@M(T0:JEMUXH0A*#;DJ2"3ML8
M#\\;N:G^P6E#0/E1#9<8L]B%-G=#UDB,50)E)VI-7&8;';E$@)$;-NA4<S*Q
MYF(6H<61:U]4K/#_?"S -J>S749L4  O)Y)U;8B%/H3-C>'6$()U.$9&A(RG
MX!0T-M_L73><;TJ.(3B[+FIM.^)5?9CWZ!<&C%ZU W-"NZRM'Y]S@.^!HZT@
MW!)YL%%D,V,+S][;$$NEQ2N;:JV8V,*;D/)'K"FA:$EA6FP/'5NB2%MGLP+M
M&0 U2Z@\63"#?_/8;LN5-;!6R;AIT]31G-DSC58.<QGL6^64JMLJ=@ZG?7(B
MGB#W?^7N=D@0_,U_<S.3N13F*DFY2EAJ,I/D*_@H8YG*5Y;^$I20[.1CAG61
M36(\XQK?N"(SR?&,(W*.>@3D=_+8QEP7RHYZ5.-W5$ZS-:YQ+^9JR\P%LR\S
M8N8O.-^Y8,BH&3&&98Q5.0M4S*F5,*;E*E)I"E:\XI2G1R5)25E5A*;>)F@3
M52@X70K3FP+UKN_4Z4B)>E&,(B2C1*7L6\=IVE=%H:DW)9](*7M1Z@ZLHB!%
M*.B)N]GC7G>OT_WO3,>[UDGD=;8+WNQI)PK;^0[VJ.#T,5U'R5.>7A24'-TJ
M7/=*YK]^],<?OBI%_WQ8)A_&T2/]*5E!O57(<I0O^KPM"S7/I]!2]*<DG2EG
ML3W/)V.6N/Q<+&JQ?5;@(H_.\'O^)4"U]4^;12E;"=^U#2'P>Z@O(2Q5]++9
M6:.MHH0.7J&#TF<2$LP;C#1?Z<..;+)V:01BJ#4*:5>$VD^=/L5.@:3M$&S"
MG/@YXJO?3)?DI4Z&$%"174W%(<V$R%:?'%_G3,B(B,F;A!M+3!<M 9N6_)>8
ML(@G,8PN=4U#:,D._%]L54U@68AHQ%8.[0OR7%?5\(Z#R(D!:HMLG8::U)]'
MB*!#B8 'V@?R@ @7+5B#(,].G%&]8<B^H<:'P%&TG$D.'89MB(9VW!%R38BL
MT0B+M"#5_)__,)H']LEQ0*&$6(A 9,L*!I=Y($]540UG\8P(4E\H3<T6DH2_
M/0GF"(?^='F$!_*@09 @4:Q@#JF'Q &(VNB?V.S 7H"4)[5'% J3'.H+$FJ1
M? 3(>:!%8)U;"OD.>KS)M4R@F=P;.]&8CM6(;BU*"U)>IU#@*;%1:661A+P(
M=/Q1'J)$76T+K:1*%([:MNG8AG1,YWC5;&F$H]A4EFP*8?68_SD'UKP;<'S;
MK652B&6)I:1?E$R(?&@%A=03&[:$) Z%+LDA@F%;>QB)=ACAH3S9 MK!F@R%
MVOS8SSP@;>%&NO44A:A(JN2'4"PCB=""6J7.FS@/01&6GQ14N_U&>W1507";
M:0SC EQ(:)@'8MS<1NRCAK#3#O 0MXE;C2BD[TQ,0'K9F>3^2@4BS0(NXHJ@
MR%V5(TE\2.K(UDA0BZZ<!D6)@+(Y393\A4[L8'E-RH1HX_'D2G&AXJLEG[;T
MR?J@#O/=6DW,#NZ<VJ(LA!7V3U9M#%=IF&C\"/OEQ);8#*](SWD%P+=D3H7D
M#8Q)$$7*CEFBT[,P58]$D?W03?P0C-"P3LFT3G.0&#02V4T(S/3P#+N(4%GR
M1X\P#UW2682!S%/NB ;MC;X\#8R V++0AY?82UD1B0*=BA4R&7K%HPP2"=%L
M3N-\($<HT.D\CJ!]S&,>Q$>22, 8$5,2Q[^@U+\P4),YIECRQW TCA(Q1.,(
MB6?VS:*QAA0)2:3\S:L06J(DB@+^\1A(P(^$*)55?AIUT00D,HAX;$[Z-([4
M*-F*0$[_F26Z- VE>64#U1G0;$20">50M@12JB>^.&)[N@1>PF=ZSJ=C<:86
MU15IM!%.[&=TP&!OW"=/(&)TZ!6_V1&WQ!L\A5]! 4=*VL0:,>A*%&)T8&1]
M,E4;+<9,W=[>.<=662B^R.>'Z@M-BNA/!"BWY&>)XL9_PH8\JNA'%.B+TD:%
MRBAI#&.-,AIU*@<:5LUM^!LMW>*OI".;L @<LJ(^',*PL&05I@XMJ,EQG :+
M3(BE< 6+:DF!AA4-N=4^Y@J%M$>:0<:[_1$[6L=4A6FX[*6?@ 43HB9+R(/.
MQ<A.>!7^'X+%>:@'I2S(??Q17U'%!PH'8865>GRACGK&(:I-E'1$C'K;B8:$
MA\J3FD!%20HJ.H 6I^C?:=C?9L$$M9 C43A(BA[)S-7CD1C;6ZK)"")(XKA)
M2$+@%($(<QR?4! D7P)H2V24AQ(CW;!%J^9)>:BJ7JECE^6@0V5@N.4C'Q*J
M3WB57_7GOD ?$[**=K"%BM@1/K)HGL3'FWP(>-&H3[R3>OP@@@@*J1;%9-$(
M1X!(H5 '>V"H/S'?&<7A3T65N"BI:6SA?WP72(UJ2;D56B2J@91(C##*=J"%
MN(+'.Q65A4KG6P8IOOQ68&*8A;7.;&3?E7$-O$R5T-!536#^)4D\F*K(3Y>X
MSH"4S;U0#E.FZ7F-4RY2CUGMHGFFJ5)ZQ'Q,YG/&"G^ C%(FJXG&R[:DZ6_0
MY4V0SZ<UF 4% -&83?$4!$*,%IBE1%1RRD7@D]R\C-#4#U9&S-$V&5ON!^Z\
MC;$$&LVX&3S&X'IJS46([>R@YQ01C8OA&/O%BZ&=QE?&S,YN&_&PXWG.T&#)
MV:K-T+:L#_ZXFK80+6O@#8-HP=AFU0)=#$BLK5+E3NWD"_D4C+Z@I-U*&8+-
M4'W$&6,V&5>YQL-,V.0DCHIYY\P@;?#\;"O"9Q!!VB72A-B4S5/RBFOBSV3*
M)<.XQV064(?A#NMTKDSD2^U0%X'^((Y&-.?2B&9#N(R544[_=:R(G4KP: S5
M"L_#A"SL8 /-E*:'=6]M5BYO=BMK+$Y!?"_AN.:BWD3GGJQ[\$_BD@_9A 74
M4A>/>*W3A@335HVP=.VZO$K_N4]&< I&_,A>3ECP1DS/L(M +(]43@Y@Z$X
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MB#E4TC9,.!$?NKB297;S3-,PXL@T[5Z<*5%@1#04"<RQ%.=F8G;L1D>&JG"
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MV3\\\M&Q.K>JNHD.>3Q)75P6P#9?J>XX_1H6 E-RB!TL['$NVX%@7,6C!>Q
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M,OZ'XB 2TH0>:['JK[$8V[5=6[]P&R"'Q?3Q7__V_Q]-6_](2W8ZV_\*J[,
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MR!U%5/</$OKO411\X9OHN<6?4>Y_GW+D.PKHKU_]B&3^? RQO/D=JGF&<DY
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MEWZH1&X$'M7\@_043V! #T9$S57.!.9PE59JR&Q8C]\$R^N\5UD4)O<X$TK
M#4I0U./0)6\DGLUDQ6*XU]M)YB^NT%2HY6<E$-Y(#8RT3-TUR'&P1%CN1%&
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M@/WW/TZU3("C$U\!M[(^"M7K(IH9T)D:)2=WH214#AF41J 4I>2L!'\3>N!
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MLY\P#B[=1"NUHR2L";"N8X5VZ-Z\([\V+>J$(J$ #R^<J9P 12Y\[Z. ADZ
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MS+PR/@*1C#@V2W46(4*[2FE ._#Z$((F]$/C8OK*E7BV;*PH@"LYC"HCM.A
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M(3ZSD4F75%##"4$M09S'B9S)J4BVI9R$9$G-"9W_E),N"4$I(EG>8TC>,YU
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MSI%SBB&['%,>(!%<A8I^'SJLCT$0>A>$V[)_3)$O%4=_R1&RM_80F#<4:M3
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M50EWA"MA(*.L2(GKQFGXM%\L1)O2-%N]47% 5"R!>7D?X_2PC>OHB(5&SWC
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MV$H2N-'13W@(G!S8_@8\<F&J3YNK'/MZMIT(@FMA<0,?WBX5NI$P#VL= IA
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M3TZ1QZ?#S%H<:P(,P$REUU%"@R[^:D@Z16W""2!$_!OX3Y\(= ,W[?AW+,#
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M[CI$/UIT>S"UQ# B$*-#2LH-(ZAJ"FJY\$X2<"&A[B(JQ)GT@VD]^+SJ+;0
M A#A113_T<XV_?KC2 3<0OLHK 5_O$J]LYPZ1J]-)FLIR!4Q:ZJATQS24:$%
MU I-GZ84V@$=>=#A[1_5 D,)-J\PA$DEF7"\:Q,S1RKPORS^4QRJ)Z)HD>HW
MUA+RT4NH]&%,H4-$*"ROSP3-;"4[&J+3(?7T.F:R!X^AA;>25)KSK"E'<G#$
MVX#DK-&LBMJ)//8XI<PS^IIJ<)/!("J3.<$NDG11!/]C;-,R-X-HN1TF1,?
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M#(R4NJ8N](@_<0@NY+2.0"[Q6S1]BK[=J2QU^X<U"ZJ/4;27*+.(^AAH$ZK
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MA[HFA$0,A69N!E#,DI9TB5!&#% ,RF'@![[ 1RV1F=@T#66:Q6@L!'YLS)2
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MZ#R/8G>4.>J.U'Y#ID2 H@))Z%L76]>&9O<OY"CH.-<Y%L^"1)4=>$8]#0S
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MH;/28B?AMP"LJ9:F*V.XRHC.Q%&B\VN&=HP6))IT+L<B:QU[J.(_FBIF<+9
MBJ"MJ@*;#-NM_3)[H C.#7NPH9"-G-[)_RQ@G\'V)ADO:0G_\ZIB"=-"YC^(
M$ND0:0;^!QS :!$_UJ=TO"FK+XLO3[UL8]LBJAA%!AD*[94)ZFQ9L&@*JIH^
M^*[:'D^*?9MDU1YR^C-Z&+/\3]'"-1GDT(I5)R"T1CN\XPZE70;D0UR*#;>?
MDRDHSZZ*;9*YG0'\N)H\ IXDI8!:@'<,X/^X'?@_V&2XZ]7GM2U@T4COVOEL
M KTNMH 7M;T8ZRP3.%_( ?!N)7BY6ZGZ\<G)O'EBK!NZ"9$L$KIZ8YJO+JGF
MOUN^R9G0!RZI>.3FEGEB6I2OG19B\S[??)NXWUC(M.6./=O<%RHQ^]J"KC#>
M94XK]+N;5K2DA>$]AG.1^=R*MF<J\%QM5=IB6?A2U#WT= [^&ZI3V&1(]X]-
ML.P8 (Q>?["A.9FE3F&5LXQUT*8__4D,=G;(7&3L4,#N:"X [A/!X[8GP^ Y
M9GZ*02&KL&8= M40APUL(6N^AT(-.9 Q(+Q=_2#8.G5I3H1WNPWR9B@9$ J'
MAR5$FA,M-QG'M48$H]&90#ZV&M<<C&8AE"!XT%4V%/'K9]U#G=[NAIK9J8PU
MWRD(]1@WI9'9 7 V:\Q$R@:>HR6O;0;:8:ERHR\/ <Y:I)F//N"F#WV9:S%3
M ^2.@%@WQJ6G.H2:TB+Y<S[T'>5C$2G0(8!B&53-[2.V YB:5+6JAR"*0W(L
ME((BE:1CH(N.&3I.R6"'HJS-#FG^F<S,3QH(1\M\:'*RL9]JQ+6CHE1G7CNZ
MB P%TI$)=@1[=5H ,QDS,D/1(I.-X5EY;MD0<HX,CS,"ID F,I7XJ'%&Z'*8
M10:JG0YB!U[ON94=,G:[B( E,A ]$#W#"<Q3HJ8JFM26_X)WQLH01&+1BE H
M<>6M\B$LF;I"D2__,T%W6F:9D;&GTMZIK9"B<4;6P5B6!F*?:>8&H1FMXV+
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M4_"9#GWCPSI%UN[U<R':Y;*U<D>)$>K*TIO!0S/GR:^GD="4$20V>*D(NB#
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MA?(#\!^>V-J,(N$&Y"R_ZTHT\3S[2I)G$VPRVO"Z3=8C2$:54OQ'GA9/K"D
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MATP)GKC^"!<SHH@@( ^*LORHD(ZPF^M:-N*1B=R($DPC$"K3M,3AK?$XLXP
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MV6@)!8%7 2H?6FB(R^V%EG#01'V,;_0:>D#%&TE(K#7;VB3<2$P0[ T$-8D
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MV<;26'ONA+A!SJ*5'N5H+'5(3Z7)&84QRU4@2H,-:.1T[-.$A$;E2J LB\X
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M(_9$;ED:X_9T2#\20S7F*F:ZAT2&Y=,&R$S"KB5^+ .9Q"!<I%^>1DEZ)JM
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ALUW;MYW;N]W;OQW<PUW<QYW<R]W<SQW=TUW=E30@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>amendno6tolsagrimage3.gif
<TEXT>
begin 644 amendno6tolsagrimage3.gif
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M)^N1X+%HSHAL!3G'"7%K->:V$[U>FHE]B"DFTF:>IA*X[!2-$5A,N79%\NF
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MCIF@OR*VRF[)*6C1,ZV"M1"1AS/AD- "BJW;K/7!#W]QXJQ!&<J)/!2:Y7^
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M>^Y2I$#9F+D&2GXME,5C61J7[+R-N23-V?8LNWSII=$%3CK^ BQMX YV!5W
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MIY[\=09E1C)"&N&F5>689*1[<;I3D$#NE6F2+@(ZE#P!D+J'DP$P)*)!CL#
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MJ3:5%I/,T%:QR^X2S-OY2@ZM+N@<*H5KGF Z)M,0MFA*J2F=TE&I0(W:J!Z
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M+#$/FYC^.KHX'H=1&LBHG\U1B)$9D5*K'ZWP%Q21B_-IEB%IC Y: *8 M\^
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MPLJ";!A=&#'V8EQZP\3" FB7#(60PF-,V44)(RQ.XR870L?0[)L*(DQX LW
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MQDE%AMK,Z%*^:1::SDVF*_E7L*R%H N=,4,1'(@@)WF04P#1=(.DYC\60 Y
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MH#Q?7;M&_<?/*]B.\DY9O)C5(\6C'OEI;6L4;ERZ=8WZ"H#6[EZ^=AUME!?
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MB(J J2K+N#W"L-.?T2CBD$*7LH_1^,%0<0W=D!#J6)!M8\$L_%&?$8KMJ)(
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MT#'.SUM.P_DP"/L<7+GMFR*:A[X93HS=S\I%Y>?P(V1J#%-VAU[8(V5RATF
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M!]T[BYZ2A7[1&W#924;PM-=9O<V8"(=X&8*GKT64*<(YD++1T4PHS79<#%F
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M7!K5C7*/3M^MTDQ'Q+S0S'OQS5????GMU]]^89 S8#-@6."X@N=<P(."%0[
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M*[W>UB+^N&-LJ\0@U=8H$%A#J@QDL,-)_LEQU 14VN1J'$5/(49J>FTI2 2
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M'H5E=C(JQKV&PPG)N>D6$B5Q$;W^Q;4OD'WTT=BP2MMBRIL5A&BG5LHCV56
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MEC>0/.+!D"-O,14X&CFJ9H0?7::-M&)3I^0ZJ6L8_0J56 :6V2!L7S%X2K;
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M/%R*>]SD+K>YSXWN=*M[W>H63RW+9S[WP>]]ZZNW,/722E6.*I71[K>__;=
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M-$JF:4YC/(ZYFTWGYD+DM.+,R4SE=!Y)(0?#*E0@'+2")DY" GQL?TEP3*?
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M[55(\__\C>Q?UQ<E!_\E9<I<7=K^(1/1$)G2D+,BBIT:*P3\J<H9':2R'>G
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M$-0!1^;0B=;C2W]B4T"9F<%PT:F@G9S*+WK+T@>U5)A8/?%C/TP-/N/L5)N
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M>2YL.U=K6(Y$800(@+7A37*^\-K$&37C3!@A?<G5N8<?XIE1[6)>V!&SH[.
M)R\UN:!R +D9#:=$^=$DUYEF="Y<&90D3;.9;P=-*?<@[7] =<IC2&ZCWX,>
M*KX,6C?^KU;&2T^E99@<M]B4>SQN_DA[ ?$]'AP&5PO4 ]Z'RJTN""^<KM0
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MYY^#'GKH@GF.X"F.G++'54O^1^ >!+X4>T*STVZ&MK7CGKONN_.^NX P"+@
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M*4>W8J;!>%(UHYFM,O]:R+\<@:;^7-WD3+8;6J.$9DN$0"1=B8H63RD6M*5
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M>K=VAF?)=E/M+4+(HIZ4JW.IC92%6=##Z[4T[LY4AKP(V'CU<[0SODZ-*UI
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MGZI_YQ-N@K@SL;"&$A,Z-2)">U=_IU,X2"<LFQ"!%$@$FQQ+N__\CRDC2QP
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M[/(4MD6\;6YWV]O?_K (P3UN<I>;W&\2,;I!Q2YTOVEUD@%5 -S=K2_V*(*
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MH!7:H04.@WLXB9.XFTU:FIVX<7O9F!6Q:V.7#*.(#;-:A4 (#0O+K068A[U
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ML<]K8I1 C#@:2RG7H6,PG3%+IN+4O.;7RV&3[;5, 5>7 HS&:*7(<(_\T<^
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M"SO$IJ7>747[D.=4L?AP"E&C<PWRM)=(D:0XZ*18-,H\$(G^ULFPMMNQUE]
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MX.MAUH0$S:R!MW5JW)G-!FE7%ETO+LO+VO>X@Q*,,6IDRT);7/<:NZ\"MU*
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MS7MX(OW@#:O<2NYPRG\91F(2!G(QQWY@6)_TRNW]:T:4ZF]1Q %S!2^*7XM
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M*DAY7$W*"R!V:568TU*&[8F3K=AI!1W%?1O7$5N<7P\Z\N#+KE>O$OM*=!3
M@]J%'J3*2V(8\4F]'+?2]!# LF6T!Y.,_%<X<@"U."\;/DC6:U6<23@J)JPW
M0-*D"PO[(JLX2>3-*U&:Y;W3S +^@:=\G3KEZ-0>XWN0*Z](T?ESZ-&E3X\.
M X;SZV9@>-#>?;OUW]]A+ APW<-X#^0O!E _NOUH^/'ESZ=?W_Y]_/GU[^??
MWS]_\NBKS++V%KC(P/,07  &]K8ST$'#T%LP/?3&,X.]\!P4CSOPS,N..A!#
M%%&[UT8TT3E']BA.Q117/"XYXX03*+@9:[3Q1AQSU'%''*V39T9R!.*''')^
M+-*7(,GAAQ]YE&RRR"7)0<@A)X?\AY^M'))GR2VUU+(W,/\I*TR>BB1S)9RD
M/+.F%!U:TZ2&N.)GC[=Z0NY-."/#\TVL]A0+)YW\M HB0<TRXY1"$TWI4$5=
M<DK0L)3^O))*)HFLM$@BC>1Q4TYOM*Y34#<-0$8=A8NQ(.)036XX%H]C-<;E
M8C6#N1-K!9%!6T?\\+GKK-MP0@/?^V]88HO]C[STV$N0NXO&RZ[77*,%<8\+
MJ95..1B/*RY4;KNML4F!@LR12"2K9/+*F29K-*A3*$*4HW9A<)/1GN1Q[MV#
M(KK2.(GX<<2,0/_Q12%R9.QW8#<7XH>SA6:$2EV;@N0(!H7K%-B7A \J^"$U
MH0KX(8XD?K@W?#M66$^.,E;8I5G7=9E>EU-Z-&::_^G3+(AK9HJ<,76.&2>5
M?4Z4+*%Y"ZM2+H=\\MN\BIY)Q8X"4-,1>3EJN4R&)1).-H;^>>XH,WD]4/.4
M,<G1=X_,+ER(7K<>RGFFPO#M#-\%OL+2H>,DDA<&@\CA3F.*_^%[(7GV"/R?
M=I=T9 $W"36*'+Z)DV@/(N-T?*+"9;SH("P-(BK(. _B>SAUK\93.5_26\BC
M(0_G4^Z=_EX<).ST%9RBW7R!@>R$18+*]ID@UVX!B_?HV208,DJ=P<$4UHZV
ME(QG2-D%.#.^/)7&8Z]AM56Z62RI:;H<*IG:?2YHD2ART]J/S39I3O5/-ATD
M+,^$?B%Q5>8'=OPQM;*T)05*9#0Q4U/"Y[1&A0Z!B7K; DW2/#$II3*%2<);
MO@<3KUCF,?8B#,.(LIN"<(1H-MO^"%ET4IB4] Q0-J$*"1NFFK5]Y8.(":%$
MIE$5@)7F>*E+B0?PDIF@5*:"-AR)&6!H,\Y$181;,6)B G4\PJ E-HE"2\^:
MB*<I\H0L(YD&%*T&15_ $"6Y$5/ 9@83G<P,8%X\2%RF^,3$H(PP3@E4#BWX
M,3&EI(LQR1IO&L@2*&*EAC;34V :)L.L_:N/![&B4D8X0I"<T8^/D6+6?-<5
M&6Y$B38<T[] XD.W$68WD0R Q;)2RG\TABT>4 U9U&+"?^S1:B/QS$1*I,J]
M7,:4!V'-$O$82S:VA"I)$*)6%OF/ 65&D4>4#1#_09;1?.2&F"'<95!6F-&H
MY4*C2>'^8QRHDH5QJ"%8PDOH=B<4++W+=9WQH$X"H! .0N5PD^G<0J0'$L8U
M[(]HR@C,UIE%F*'DDJNKHIKJU[!U7@F"XT-*X+R&D-<(9 $922@,V#+*^2FP
M81Y(V/S>))+M"<QV]WR=4"YT3(4!CVIU*PUXAC22.3FB<<"SB44?,A*2ZBTL
M,$M,1M@CG.J!A%J(\Z(G-XI2A)#'9+/S'E*MLL^4')27"VA7SLBQ2'X,ASP?
M@]J5&C)0?:ZOB QC*?V"R154@B1OW&,)Y#BW37<R;)_ DU=926FRWM#K0D,B
MGLUZ-E29)=2H/*-32H)*NWJ.Y:PK,=G?'I*^F&S$L4Q%2%_^%BFWG R04$2R
M)Q0+*#"%8&QMOX3J-R5B-K8 AR'SRD@0#<*O#JXNB>%3(#]LNK9W 6UU@8S,
M"F>R,.<LR QSPFL6 7O0?YIL<"*59TA:^Q":&D5?9C"E=@ZRAT 9=2)?4>UJ
MK59<_F&Q;U9<K%F66R8F:E0VS\5?SB271\<Q=";RJ-H_T":0"XEV(<D3R'5T
M8ENVI)-SH[0O=@<&L8=R!+"!)4QT2>)4A#H'* >$B51]J]O]!DTBD%3H1JYZ
MTZ9,]$*((HI=1T:FM#:7?"S)X1<9B:\_8O<A53'QPS3,%>WZM;YD,PA]D9K/
MTT+17^J%")*,ITZ'_)'#$>/H1 S^XMB4B>1=/',GWA %5MKIJ:L2Z:YA(\G>
MD^S2M W#KLK2IY=S[@2X9E 3EM.71NWT,\#<">X/YP>1=T[U.]WUK6\0E9"0
M&*9CU/J70RBGL0!=9E[%<9U(NKO-R^36P3NQR(H<,IP-MPLOK3TI13#"2S9#
M\)D'Y,=%@LO:/=D+2=IEG>[\E&:>")@L5)JN@5-'KHEDS6\)*TM\)\V24L\H
M15JSHLI:W#DFY8UJB.X(7LG&$> EK*O^NO1;Y499DUSPE+]428*1F1'WX?:T
M8#G<H1%2)[!FC,K,]JK,RON4%"-NN.ABJ_? #-%<ZU!F#+-U]?"(8=ZD.TL$
M[LRD6PS^[92\UYX,HQK/?,6>>R^9)FQF2';2<^^)5&4R1.,.?KOLW) T><4K
M$76^="/F,=?DO"EWE'I9WI2$OCS;&)>Y46!=*+S2&[I/>8NK3^LF=7NL=^L<
M($("E56!](LSY"B(F1VV* @SA<(N*=S\KLI3O\ES).DKK,"@ SM 3Z2?YG:>
M1T\,)N.U&$&6.9SN@'-I[(72GM6;G[O$-I'#82GG_ZBQ/O?.%/I^*'#7\>I;
M;/L5B%P:.!+5B<)M)B7MJMT@B=6(NWU3PGFOC3-9!<ER??[ID0L,VB;;0^,F
MW]JDBW[AGPPO0U!>\Y8,J%@>J SMB6E[,[ R]YL!3.]]_WO^X =?^%[)[_"-
M+Y=I"$0>R?<+;:;QH^<[W_GR6/XS7\\3'L+>>]S6/E .7K3L6R7Y0HEGHK3]
M5#"%7U"2K)DAUQ]OG:5>4"C\$S/'<GUYT/^9@?)F2[*+24#JO^YSB94;P(?Y
MN]YP"#?IDB:A%";A$DE1$BKQGR>1$L-!$F_)0 W<0'_;P!L1CE09CN(PE511
M$5890>1X$16QEEAI$6MY#D62END0+AFLP1&A,P[YC=<XCU[9CN$9'A[DP69A
M$ 6AGD0S%B1,0B5<0B:\C".,#]ESP@-1D -Q$ 41#^TP#^G %1OLPFFI"!1L
MD11I%5+Q0$XQ'E"IP'(IEREI0"K^.8KK(Q.)6XI30,"9P#1%@3\#!"3NT[X^
MVT/Y,D"SV\.>*$"?"41"/ J>\J,;2T2Y8SD%5$ H><!,43YQV< C,\,/I!$R
M=)$4\4)0G(YGV;-MRCUDN8PH;$)57,7Y. \]?#F?*RNZPYV%^#@6NCG0NI*T
MTQN9ZJNU"9+L4)>Z&1^<0 L?&S&_\PU=(IR1L!<3HY;$FQS009:.0@Z&\1?K
M.!GV4!=$[ FJH2XR8Z?<"Y0[N9[G2I_,,[H%Z)BK8@^]6,0U,9QT?*9V$11#
MM EKV;MV*3WY,1E-4[#?V8G\H1^4"I>0N9^0T+"W8,>/04BD:+U3:D1'9#]'
M+ J J\C^HZ!(C R*5V2YR:"RC/$ NNE#EM@.DP >H@ LWUH8SM.8,:&79UL;
MM' -39HZF'"\ 4L8NZI'YBH--NN89;.9C.!)$+NNDYBIHSB%F*.8#^J8B&@M
MLI&2F%RRT%$X*(-',LF()<-*,KG'.YP,C;JD4E.*U&.0%RNCELJ8;ER)^C+)
M]O*B@1$=< N?H.2<RJ"?T1$)BH$!F>('U;$91)&'B>J\@A@(T9$1Z\JVJ%L*
MFV0)D!*,#XD(P>RO1:*( ^LC_>N(^I*GXWB-A[@.-+0\,)F3> .ICF&0T5 9
MLQ$)#UL/U[&X1N3)A;$,I$J3!'2.A/$7:"0<:]$P\V''PAS^CH0A%940"?:B
M.)/(3/'1+Q%"P)SC+!:2R&T;0)GX0T=@II+[2K6HI<[(KG9B",YP)D-2E])A
MH_#[0YK@3IOQ)H#ZBMWPHO<LH1URIEA""XV\"<-HC*]( L^Q(LX QQ/#*-=(
MB=N(H409(I*0HS#)SIIHC+;QGLB0*Z78"O?;**!XE+M0SM58FR-JGL H+SV$
M2_I<"/ZD'3'+HM[HR.(,IN]C) 7-(Y^$T<Y0T9,PHQ&]3_33"L*1B!+EI-%2
M/8$I"U@"IK&XC232IUUZ4+$8I.9Y3Z7H'A<B"<U[IJQ!BQ'5(3VABC_24)>X
MBURJHS^2I;VHBMRXH>JKT&:*+7;^8J2PT%"R"(O&$ S 4 G02$3".XF)(<FF
M6ALAQ4P/>I=Z^KY=J\6:U(G<2QE1NTB;4"T\)%1Q8U/!J9,/8X@VVZ&$0M&U
MG#@)11S$.Y3"N+3C=*>O6#DO C"]@4@YG#JN#!-;M(E_P0FDVLRW.AX%K!JJ
MNII,=<R,\$N\"2:)R@B[4I^[D]%L"QB]$Z%?0QQG6JN90S$[- EOJ[?)@<AC
M!<Q18XB^/*P'XA\@(Z4S"=&@\8BNL)T^62[/9*2 D1RB7#T#>M:G6$>[M(YY
MZ9EU53#^.2!'>QN>^<3&.P7*XP@NI8E1X1R*$4DZW;!129V@B:YT@DXQ@;$Z
MF9.5*+_^D^*^TAHS^E(9&>,R/8TJ5/)+@U"OSYFND5C7S/,=GL0**$6<C6#)
M('77]WDKT<&GKW KQ*&8L',RC;' C%".T/.ZU?E,H_ YM%PDVQ0<K4$\^ZH*
MJER-EG437-P3Y,RW5^O8%763M[F3%#(9^MH+?1F37(VJ=#0?PWF-&RNUC*O%
M@GF.UT"925T=_@%0E7"P9!W$2+J7"8/9?F$CB.'5XN0T'(RH!(M*@B0W-'DW
MJ8.3H&&CNC0=^C(9UOP-!>O9V])9T4P_D9.W4MN\WZ"6&..?!>/861JPD1B,
M?Q4EH+BMKD5+Q0J)"]&RC^D>'BNX(B$;MKBJ\4B)=HPNBZ#^4ZO=PXLUBSC<
M49M SY?8I-*P&(%XOM9H&,(IH?&3C<@ #$U*ON5#O"O=B>N4"KE5S^YLH]][
MB\KPIC#ZES;]/2?:DRZR#-RPC-^%M_<U"?W,G;)H#/B846+JH\,0#".2"AP=
MBU2LD^XIC"(B"+[@4>HB.!D]5UX2)=E3"@*V7VTJG8^!*A3UH_>5I%[B)<!0
MFP.>T0[^#-F H5XB(Q_R"T]J(>K;X+,#DSJ5#-K1B?Q+7QE%BVFH4KU07H;[
M"I3Y7T5DB[" )!8VC>2TOQC--HO1+D]B7M/8I8!UB0(MC=XS##DZ'C(B)B+*
MMIYA8 [.LLBB'0%TT8WTW8U4U '^)-I$7-4Q;HE6C;^8RTA4A0F;+12[/26]
M%8KB2!0?!KR8A8J#N48DP1]*W(BFB[*0:3,;\4W$-:E#P4UK0\ZKRYC?H WH
M>"YXW:_JD2E'%1@.,=8M7>0O&HUU&EB_"K#"Z!C!% X(NIO=(F2 (8J%T62$
M.)2!P1<4DK*H6+K%:]$P6V,X48S?HP@CA0TCVCU/,PQ63&9E7F9F;F9G?F;^
M: S:$Q##2";,V(S\S#T"Y@MCUCW%X(YO3@KNX#W8.#YS-N?7/6=U]@J!N(OE
MFS[HHS[K?3YY?B:=X67P\>46CK\P_BA0]I,/+I0G1HI^3L\713%]UHKX-:VC
M)<1ZW4/^KTQH,D8@-%:4);D2*5F2"=P2* &2)-%$'O$OD.84LBG#=JX14C'I
MX5CI&(D*XA!!5$E![&H5%6D.BHC!4.25$LEI4<S"9PF/]$ 0[7E":"[J_#A%
M*]20(%P0:*&(7>'I$4&;48E!Y9#I4Q'!E1YIK0X7($&Z)/&?!U3 9Y).AMA#
MIO/73#N%.@G>XES#.GK>D&@?33*E'QF+E%'>QB2@.L$7LN:<.Z8)I>P-.SP7
MJVACB9YHIPGLP^X)-8:WOC; /5[LA/MGR098RMXP"!SDI=EJSK81&7GI5#D.
M&%Q9V//0EX0A,F+=JW@+]QND4<J^*^*E-P6UHF3A+(IB_1O^:!9#4-EPIPUZ
MR4#YB/WESA9")@%FN IB#/O,7O$!Y@MY#.IJF]2V&7:*BP" (5B*XL[0/ZHX
MC11CT#!1) ;^"33]UH7F""S&8LMF7SZUC&;*3.1=TYJ )M)P,;#@"[W(W\G
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M7!A;NMMG2AZYBTGZ2TR]*9(/0A3>,8F<X@KZ(H[SF%*G$+"Z7!N^' ^H98\
M0?++V#M[:=$8[XK+OI(+,9 *OC>T"7305+!C6AQ2OBFSB]:%.[@7_!ZITCYH
MFF8=TM*WZ'+=$ S)R*3*NV&.N"'7<QM#11E0<IL%CR(L;6 \_5%&"HW>.J*T
MFADL0U>N@;=JRJ6PZ"+)TM%S-W=&XG!\QQ-L\E\ING6CD';O(7$ CJ*9'&<J
MW8O'R#'^F]C?6"HB(]YW9"+XLEZB'40E*,4*[7X@$2)@" V3.73,K#&,"[%/
M;-HE_>1MVBOOXE8)U  -AM]G/TH)AC>#@D:FDU -A^^BNU!1U_Z(V [Q,VFQ
MZWXF'$(DE8AY0TH=E&,ECO_DXJW1WGZ;-]KBCV&,02)>0M*,),H,@G FW_(D
M+YV(M0#XHE'L")H(VQ%XY#'4@!EVGR6J)3D>.1><C<@IK%@8BXE)39W2>103
M"U*>B)!TPI'5R5C7>MU8V9(ZG8@YQTI'?Y$;*4=E+Y)5OEMQIF!4VQ%S/&'[
M0'.(NWR@?Q-9@W"UH$QRJO,@@-$=\#XOGE&2D$H,_B':[JG^Y4^U&IH3,*MI
MO<;>"_.@.9=8]N-MNZJ$3XOQ2^$XUXS-KXE!0*T52G#7=RXW"6;=O[UJ"HA
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M#"2EJ,G^,F+T"KA6[<VU7BVY,]X39YHS(C1[ER$'H9&D6$,.HS '+/73BXP
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M! =J8A=+P-)CD<,I3)'\=09RJ&.]V)99$,8G*L23V 7*C::5T-QVD,..;9R
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MI0RN3"^\M,U+.'ZZ3@XUXWS)*\&J?)%,;+V.TPMNU%"5+^ZBU2K4;D=0H]1
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MDARX@R( %,ZP+VNE,O$<=6IITT6"%[\"S4;@=LE4+.S 5]/J+D:5 E)JAKR
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MGJF+FM&:Q+2\K@-%YR8(]A]=NHAK0OXID3?1QU8]_L7;=V]&PEEK^O*0^%^
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M)$5RXAC&$A6?Q'D; 5<4HS%PT2P"@64?8Q2I"#"B^"IX@H<^V35=^1*59#H
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M8JEJS\IIRT[D)_>PM28V?!'AI/O\KW4FI\3F>\1-*_$7(R> 4S14S'K:75S
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M9=\>UI,^ *072>@[0A)]K20E;-Q\\"T_^5@O?BV+3_SB P^9=3+&U'T12I[
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MU3IXF]3-R\U_WNR2QT7@="0/7+3EEA@"ENAR43IYGD*:UOB*;"5D^D'V-..
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M7'Y4W=\.;==@C%#<C%>K9$;8"1=]O-BAF=!!6(YP989"M) */: )_=YUS$3
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M!6;:(X"1<$SJ,/-@:(K%Q9 *P-, :@+ITTD3BJTPUI@T-+U_2,T,(7+6ZHS
M4]**CZK/V+-)14(9BDZN54%<Z)3^Y&)Z:@&KAF*)G 6$%0[!A>[K:T24HH*O
MJ*9X.HC6C5;E5:-<!8)AJVS16HB?)"OSD*LK_S%MRCAKRVDCS+S%J,.^6(JH
MI0<I8Q>J'[D*L:7<]DCMI$!36L"1)$N5C!\V;0+8(#H;PLDD1TP::4%3,\(,
MK=H(ZQ:A>]4RK4;TP*U7Y0 -7=EE;@5^66:U-IS9YAQ;OEEG3G/>^25':O8V
M"?[4L\OGC):S.>5Z_SH:9:=S]!>BY^1Q) DR@5-2+4>(#FMJ>7SA^J D)*XM
M9EX]X'JM )H2=:* D[C2T]M&?4M'B#[]R2**U@*:79'WXS2)40.8YA\/"'\H
M@+VF\<#^<4^3L_J?X P_**W!K9U\PXCD&=KR\@J2)VVNDX@<I^HPL@CJU5NB
M:Z3788]=]MEIK[UV#UA\'?>18C0#=[H:97$!1X</8($%8EQ@\5&5)]SYYZ&/
M7OKIJ:_>^NNQSU[[[;%7'O'COT_^4>(;3;Y$1QOMK?SUR\_=?=OAEWU!U^.O
MW_[[$RUXQ&$76)/ /?8WHH+9Z12KJ=,I$&C U_CD30UTX ,A&$$)3M"!8/L2
MV+BTDU,4B1Q,.=>4A&0N,_GJ90QS&N!8EQ&(I? R9V.A0>B5PIN\[#.6&50*
M4?A"F?5,ASNZ3P]YI2\@\HF'0]092,IF1-09D8EI2]U"I#3^#7G(0XI3E*(O
MIO$:1U3-$5E4VQ<) D8QCI&,933C&;]XDYM\,0DW:2/N@&:&TG7G<8/CWAWQ
MF$<][I&/=T2<[V[BN#F^48YN[!L:$6E&#PSMC%G$H@6GX0LJ3G%R3/26$"W)
M$1"UA6@/FY'EDHB1L"'$+2HR3=,.XY8)0<P7"+S2PS#VJA^U\DK5DDR7Y/,6
M<C@)8*VTSI?^P[ )@4U$-93+D,[%$'E YEWH":5U'%;$3+X,B=,4B0NM>30"
MZ8Q!V>13#KUYM!B&DW6^XY&YIK1+>:BS@Q9L#@7A&4]YMI*>/EF@ >^S-&_Z
MHH9):QH 02F7&1HD.B;1UD]@P)_^90FD8#D2UX%PQU"V9(LLK)EA3-["S\@,
MBRNF:1?.'(.4KZ1&+_Q05S7A8IUN_@-$&3V+PM1B3(\TAS!(88EY+!<H[M2L
M)C()&Z0J=!$3;8<P!!I*5E[DM&+1BC^8 >@)I=D1A2VK:S&A2ZO,\BAIC>@N
M2[218OBYH+?X3GD ZY"G+)403/V(5D/JBO&<1!=D]68D0ZV-\B@JT;<A#4<O
M(^%+ *2M4@(G3T3Z$U5.=J)G#@4R[SR2JW26)!.R5&K &=)DS?14<I8S:)L]
M&B8]ZY=<#51$#7FFB*X&'K*D-B&!@T]H=,0V,K$E+3\DB\1"UEF/!( _ WV-
MY9[#6X'^J.XK-L$)2H%V$*]*9&RZG0IAL"K;A!ANKZP*#2JYDIR]HE2T]KI+
M5&4F-KQ)Y+0JX^XM2<.>*R4V(=BY2.&*BY V]DDW?K%<Y8"#W_2D!Y-$R95^
MWX(X)?%G&KLAFG"#0Q'2BJAK?JVL1I*;(];&]Q\6^1M;(C)*T2Y$O+9E2'5]
MP=JD/8V;.%L(<0>BSU+]R%/ B1RXQ-:XS(&DP:H-+V\)PEHG1IARA^M:YW"W
M.(D03BV?DEKG%((>YR9DPG)!G) -8L<:3\Y6# ;.I K98%'QIW-8!<X7J4,T
MNRRRLJ#UK$9%)+ ]>!2\K\4+6=XK*_Y0]&/MM?+ ()LY)6?^!<V*H0P, ,@@
MDS:D+Q::W$56:) ]0 8D?>GO79C$5++(]"4AV=.^6/J44YP$-6GYC$CQS-+*
M2(J4)=)EF\VKO- D;<1'1#61/(79/@-%JU")46)0,[E3S*;5BTEKP#:R:)"M
MM$[=%65I^B(I._7F57]MC6&VE6<1[4IEP7DLA.,2M@4U&-0(69!FR>(O,UPV
M-@#TUYH^HF)>U7EDJ8%!@7QQI ZQZB<(9!5&\IKG;2)6A=@TDV,,G2*_&"8M
M2:V02&9RI4S!!TT9L:M2*&U./R^E($Q2=,H6#!^*WL6C>G[2'O"5%HIQY&0)
M#C69U#U-#Z\V(S5#-6E7!=\0D1;^=6/1\$"Z5J,1LY>@9BN:<%O;$,MAF'%=
MG;#)SS0V@:UJOM 9>L\/EY_*29?"7Z$(2)YCYJ_PY]75=DF$[7RT\_9)NRES
M;F )NI#XR%$@38^,Y$24Q. \Q[8!N-I((MF=*1M[H,&YBP?PRQ#QCC>[2-N[
M2#YU^-T^F#HQ<SM$FBR12 *]R+,<[45H/+:]HUUF=_NR;(5H=Q%-G2*R1?%M
M!3_6NXA..?Y&6^ 1U]OD!&?*,B;3CT4OHK=%U"]76SEJ S1XL@1>)!,6&\\]
M9UJ"!G[N7XZ]<AX$$K93)^661,U-'$.<JP?O/"OMB%NJBZ"1L,27B&VX7WP'
MF:RX)7;^BB[LI&LTOP6/<RJP$E=%#^*:V#QG1 E5:5]$Y5,VY-W\3TP>1<$4
M!MQZ[252Y4'VQP.LHKK\ BS@HRGT@JZZPUQXHBO6RU?X"25.QN!\1I6,XCF$
M#=QV9NP68Z%&8R!J J.HQ2LZ2,^X(C4$8SEXS\^\XDNX V,"92_"AB7LPD7L
M34$RHS.B[3*<Y"G03$)@R#]FT"^> D$B\"GN#]^H366<K2,<0:8@$-BX(LTR
M@\70A2%([3'^Y3".Y$ENAMVFS=C4*I=6@U9X@OT"+<F2SEY"HD8<A$9<STS0
M+CV2D"9B9N%&IN,(ZD?RBK>Z8C5*))9LX@\Q D2"1%T,KZ+^X@W0:BEF "@J
M[H+S:*)L$HM _HSZ0FN$,.L4VT(20RL'57$C#.T5S:OK&! 6CR1)'L05IX)*
MH&EB*B19XDU99J-*)$LLC@).O&372HLJBN)-GH-.XDTC\NUE/*\CB ,R3.K]
MQ ]V6&+3* )1DHPR<,=-0.635(HB.H1%H,5XR.<C$'%EEJFV8N,^6&,HK@\^
MJ.X<1P;SD$=C]@(MV$*CEF/-7H=9,&(!O44O&*@ZK$VEE,2NBNU,WBDN*J,Y
MW&QR0,XO,*3C9DT,#X4SV&*OB*F9+C+NA&Y>PJ/A=LG;'NMD8DYBM$X6Y0++
MWJ@F#2F1<#(G=?*,?&<G$2ELI*C^B\ FBX82):ZHBAYIDI02.RJLDCSB\612
MF6@Q*CU"!2T)*@FEBWBDP'2(YU;F]%SF]Z &%)G(#(C/:1!RB.*&A9Q(.I@O
M#">'B@;" YH"S)Q)N1ZDC1ZB)_?CBR@B]F"//]X(OT3'[LJL^JBR5U(Q*ND/
M:C#+12H),HM$"$-(2*RJ2+X$)3K(.>:I,SUSGB2%33[3@5XC;.J)GEI)@1)H
MT>I$?P"(J_ G-NM'_F2S-N5'8W2'=U@$?8!G0=0G1L@G>8BG>="JCXSS.)$3
MCX@S>H@3>;S'>)"'?81S-WMG=W#3-K$S=KJP?RC%3@YHT>X)@5JI@!#()QAH
M--$3@C#^*)V8HIT^2#(G\]K>;)J2Z84*L%ZHD$?,D75B,C$YPOO\4UM8T;/2
M,BJM,D MXT"-R,L0M%[V;6:JL4';XAT70T@. X0X*#[7*3.9Q(+2\T-MPY[&
M<PY)=--XXC6S,T5O,WB,(SB7,SEA-$;1RCF'TW5X<W?H1T7QYU%><3=%A-D8
MHG]P9C&!0]GD8T%F*>$DY4%.PJ;XPG64!U^.I0LGAB!80R]8A-C\3?^TXT^\
M+UMNXSL(1.((BDZNRF[ZYSX1Q!5]Q\MT<2J&XM?B],,R\75$A"DVQC\ "-#Z
M@S!, JXF9BK-!$]P9"CZRM7*2Y/68E>6*;%@:1CMA&">+C+^WLF99&T-?1$X
MA F8J&*RK@T7&6\:PQ(Q_;,C)910"O14 ^0^534K2=6(3+75%.)!644^C:LU
M]",N#)*AF'"L?$*YI&+C!F17[,3]7N)DR-17-HF@'(/W-H6A%F8V_"^I.(;A
M,A4TYG,]X@H]2(*BJB).4,D($P(R!(,L-F2=M@-D$I5I- 72!+5'%!2P#.,,
MPRW%NI$B**H@6+"%&F) PT4(3<3>$H)"O[4P,&0#CVH?E<4PLF59-D0\L<L
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MDO-.1T3'<F#;3* F!)KE&";50%W-K3P=QC'.YW#E^5IKDI":Q#1(2'&ZCFC
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M6#UT)A,5$2IX(SS'-(RDHA#/AR>A<GZ,1QR1EXF.P6P0&2L1\A*UJ$H5@CV
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MB?O"2 I3-4*EL(M?G$-:^:K71,K^8' C&"R@6YZ8+#;5K6F#>F%&XF<V?L'
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27,S'G,S+W,S/',W3/"<" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>amendno6tolsagrimage4.gif
<TEXT>
begin 644 amendno6tolsagrimage4.gif
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M=YIK6#M>TYKD&2EG]KC@1'(&2?\1*BJ=VJZ%S?1V=C0(_QYB0L:@\(-G(^%
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M$R_C"(GPB9UHK"'AE)F@*HK+-ZL)1A^+NMV;BJJ #--@GUW)$H;KCBH4I[D
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M7J5;"$U3]9T3]JV)T'7?&Y%0 )5<L3 32VDVA\%2%5S0^C676?NIQS JZ<M
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M(@=UK60E0HG?5"8;."]OIMA!CX0134<8\ZAKE=E-23 $FT ;1$D[<MK_Q#M
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MAS)WN?OJO&K2QH@B"*-U=EZ,'@5!/3S')0^S^?-UD;6X0!H/S<#C8_'"O=M
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M\1,(VVO<"YR3H:I&<5^AMJYW@1BPBA#B8'7;ZC:, 692]$]_]:ZF:Q$>9K+
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M#+JSRR\F+%==BH+-S\D@W^*V6Y1Z?&O"/-\)UL0Y\T1.LVM+^ *WC5;)3KD
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M:*CFE, /KTQ&CS7P?E)7\X6&;I<D],RXXIB6]H[4PMO)SE)"=1#%&M4AA.A
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M-LU?S_S^]^&5'T[?#T9SXY3- \0_@0,)%C1XL. =2 @9-G0H;J%#B1,IZ@M
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MZKRB3?'>IN=48AC]!E^L"\[6"/28*P$7YVJ^A$R*D?,@APQA9AGOX&L,8S*
M4".F\3)*X_P0ADE"IDO>9%JN*-2<+"@,Q<$<PC4X#(QP IY\XQVC0H#L43J"
M@CN$(BQ2;"]\0AVU(AO;*\]*T"DH++I49?3>PV9:PQ^'(ABWPHH\D!JOSC>L
ML0?AYB,&Y%JFIU=FXQT[XCJT UW^"J(A1T(<1V- N(=VX$*I<*4\=.@MM&+2
M^B0V8&4XWK$W!(B]%(8CP2-L7L<GKT4D7&I)8$-9N*\EEJO5YJ(EU*PQHN(_
M#&(98<;!5A*E<I(]S,M>\J8N)*=<GH-V'LJU!FTE>".B? P]]@,ND&)B;LPD
M4(),+&,L\DG:#@305%),#,)6&*( )Z)<BE+'1(8O^69AK(0GW (HL&Q#%B8P
MMP/$0.0D!F5.X*9<#B^DUH@6)>+^TB(7^Z0V!D-N=%%DXB,H$^PY)DID#"(J
MJZ3T"N*@B"[!_.M&:L,V'T5.,(2@-B2? @A-Q$\E\RD^C(0^B"(H_ )#J 0Y
M!^I-9G+^./)IOM0*(SL$.?/,%0_'+5;S;&;",):'GV("(J1S-+Y%8X+F.IDF
M. L"P.82K=[S5)[CG&(C3$K%P3BH*R#%/?!$(Z.&3J+M&%UB/4/#560(6% E
M"%)B.6AB.3[$,*!"/DT&6!IR5-Q#0(+-98@M)XS$5L+S*P[33!8481HS/9Q$
M9[[B+IXC1NI"*P[$JJYB)PSH&<'#+3IIR/ZA 6CB&P<R*!Q&SR34)X#F)^($
M7>PS0?BC3?@+@09S(B++Q6K$8W S,2KC68Y3'-^EHA[%)XH&,D,R*.S+-\R&
M0Q!"(/W&2 ZBOP),V=B*0PD"OJ9S22!B-^/"/&7C4?R"3$'^["?F:Y^(1N+:
MM$^6$BP,XDXE@R:0363DQJ!>,Z(:->5( FWZ0FYF(D\%U20Z CD-=4G2M$]>
M$XP&%$ \]3:3L2.]DR)^<]GJHSXJ<CB,1E0_]2!0-6/R)39UI2@]SR.R4E>[
M2RU[%4"<%%CSY4S[IK*PATE-*R/B2BRF9WH:[^:*KRO*QSV\+V]V9(<PTOE(
M"'[HZJ;2Y#0H+E-BY-^H<"[<XR E8J_*$8W QHD":'I$AZ[@3BI.XPD9)V$(
M,%9KXE[USV,P1MY$YCLHB(E *K?.XGFF" EQL'2\2$,.<K%0*F_RKX:8$ +7
M;(+*Q AERME20RM4XW2XZB=5(Z[^O&^,+&0M#E:H*N=-<R(:*<IDH;0L=DU^
M3&AW!G!CVR]X*!:-]I4DY V"^.]:TN]HRD>-#'5')%8RN*])F[ AKNC\UHKY
MHD);?FHHRF0&GRKYW*4ZIG#D#(CA=(1[@B[R0G-8J>ILR8@X74+T,B7!XF),
M*BJB*JIMYS:]2J_TED-H'G47\99O=7%,).I1Q6)N(TIP16\V#=>A4H)O'Q5P
M%S<7(Q=R"0JA!HIR<;$5'RH6Y4MO:?&@7O$5 :HT4R\5 6H32Q=U4U=U)X,C
MYL,28V\29V*/$I$-[\GVV*D/M\4.YY!W<V^70BF5M(25P(F51*161&27?.F9
MEI=YF]?^>9]WF:+)E89$EJJW 6Z)>$\)D1RK=QN)D-I0#2F&$=_HGB:H$E5O
MGMXI#=\HGMP)$ 61,SKO;HX(6=Y*A?[.IEHV0#0$W"3&^Y1HJC0(/4(N!4^'
M?R4.8^[U.S!(96,$22X'@ZK-7.=BLM96(O!*./SJ8.''<@X.ILI.6UBG7PDG
M8,>..YVO<5[$(="._)YGC+0OXO9&L[YH6Y<FA2ZR(P1(:$%G+4!*8F](*I_V
M.XQ6,'UV)%"X>TXJB$W&X"IV4A "8$6C! W';%%CK#00V^3NB6*'9]NU(:@0
MAIM8>S"H=Y0H"2_N9</6L=S- @VBB-8J,'(V53$F;/?"_D#^11^W,#*X+0!Q
MRGDR"'R,\%N/AFP=+T?35AZ-&/'. Y$OQE0;>21D]KFZV,J<=B+*Y)'M9CU7
MHO%TI2P?IXH91T @)]28T8+?IF.A"[V<8A41HI5I$T.'U#V>LSB3$VI& U--
M8C7]3JIZI5^:9#"L0G]A,R;&0CQ\HDRUIDO*8D&BA#F6A9$[,R0'N/T:A\0*
MQB@XY$M/8DYJ$HUD!FXJKZFLJEC5!"TJHTB$)2RD;2NX>64B B2WPCU29T>1
MSR/UAC<>A1Y;0Y%78CE68CVRZ&K 12_>"8P8ERSPA8\*)U:-A*[>Z1WT=G4B
M@L(2 S).1$9NY)3J*6% 1&,>)-'^HBU+V.I8.'.35:*3K=FA!V/(H!2=)W-X
MM84\G<5B0DQ(J'B82P+4]E-)EN9 HMDWU$4O\D*BXZ*MY%>!:$A:+NZD1X),
M=LEGN,DPA@6[-&8Q@3!28B9 U=2[+!6*4YDA%$QD^#39MO,G.)5[-C797%E5
MX=261\-RL2.G:^*G"*Z$W.5_NO9:YYJMU*4S--2.Q4>X(*Z'>^DG/P0+1P.%
MIM5=RJB:/6+ZWK7H8.Y7>.HRU(6!NLBO5([<S ?G>+G;>FEE5:XK-N.7XKB0
MIPBU[F[Y3ODSJK:0*5ELH*@D5DN /D> <JR7A(QV4MMY%FN$E[7=)$-B5!CZ
MS(ZXV:K^>40PAXS*[/:X>J*Q=SACW.(#VT ;/<!ZJ%S["\?U8_=8.#0T7N<Y
MAX6#79<H@:C8DE][238;@ V2B^(#<PJ9*.PS=HJH+,"DN/H9XR0$CU4N@0:%
MA>_'==ZJ<@XN7G6.NY?XJ1H<:WY.FN=MLVSJ?FPHL5:9C/C:>C3<\IHZ\H :
MDC,DQ/]FP:W-PT<\<D:HQ'NU1E$\)T[<Q0ULQ2$G;A.W<#\CK/2&?S8;I$[N
M+3C\,-9/8.O']](JOIW8A"-5*IHG:W4K^BIE>NXJ1@KK.UCXBOXM;WK(N/,W
M6+T(M>;CM6"NC=&[->)CK$AEA]/5;B*P,3X(R%6"MG^6!A_^*&?W2B"*JHN
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M=^[YYZ"'+OKHI)=N^NFHIZ[ZZJRW[OKKL,<N^^RTUV[[[;CGKOONO/?N^^_
M!R_\\,07;_SQR">O_/+,-^_\\]!'+_U0AU=O_?789Z_]]MQW[_WWX(<O_OCD
MEV_^^>BGK_[W+ITTG_M?5!6_://%7T*T)=R?/_[VSW^G_!C^\5, W;0? =[G
M3FU)X'TVA9%V.?"!$(R@!"=(P0HZT%;$B :,-)C!=VSP'9?2S;%$.#WIF61D
MI6M?Z:AD,='AC5:X>Z'D7"*NWXF&9#)DW0EAZ+L3UM!W.1P>WJ3EN!,243 F
M&4E-C,0D?21.,'FK3UFV=9<4/7$P96DA<RBS+XDTR$=,5!4*=3=$R=$-0<&[
M8<?*J$.\79%W6?QAJI &)(K0Z%?9"F+*$A+&Q;%1<B>D(A+'6)C>'$4JNM#-
MDHC2JYFL!&M"68M!&B+'HD0Q/DELB",KLR6S&(1&\G+.AWZ2&4?%)X[U>1M:
MO,)(\S@'0&X9F7/P8I6]/$2+P!K^8^[^^+@S%D^-'--CZD[XQMVA,F6H4DAP
MRE(S>)ED()SDX:N$63)FZL4NSQ2';Q32 '&4JE='3!4O(6=$)Q5&+2N[V\MF
MU)Q3XJV2*8I1'7G"D/74+#[4O-TX&T<W>.JN)@9CTCY/YT/B'?-DNN@+8H;C
M%,_ [4!2J<O.3G*R?'),.XC1BGY2XQM07N4ESKD.#K<$2+R%;'1X$V3G6.A/
MS'5)ES&$*>,LVCM@YA%DK=LA\0I*/)KR;J"-TZGI+CDZGJ)4IK5[J305]\Y?
MXFVD)T6=4(7'TN+Y='= 95PYFU06W6@SG.)\*I'$FDRCM!0^!ST2E80"-'@R
M\DA<7&K^18$6T)'*E2?;' I8#P;/IB8IDV5!XT2<*)F!S#-* +7K6,.IS12)
M%)-^99))2/D2%Y7@L M)RV"0FJ*ZX/(\SG&(+CHS$;I%!(U5*4R/F+.4L-Z5
M2*OQ#8 X:Y\ZP>UE65W<5B4KK[H)!#"C^6:3$CO6RDCTK7MJ0%G&\JA2"==$
M:2622822%^IBTR[.>5%=149;DGWU#BKI8\ERBU>_I*65/\FNHL9BDO=89)O(
MC==G4Y1);>Y$)\WIC#@:H)O18DPM9KE;37[27@#3Q2ZK@1I_B_(LYA#7BT\<
M3M[(LUF8'D92;C$/JIPIE9)43%%Y@8E6'A7?>;G129-55F;^*[L6\]3E+K&<
M"5$*4YL8-\FS9RW8I+RBDY"<93Z_/0M)'?1.DQ3$*K-4C95T 1.G_)8]>=')
M< 3+G*NJ52K.0K!M95R9EBBGD6 N:Y3(*[/=DHZHV7HF>QB3*M'DN')Q[1V9
M<=MAA+Z'Q!%K4]T@4:/F5.6W;K%(>D]R3PI5=DG=N6S%\K(2O)XD)+JABE>T
MV2*:^ 9J]23MGAQ"EP4'D<5YJ0U;5=)IH:S&+Y752C%91LS*:?IDGA4OQX $
MH_P<5IZJX<XY4V1E(0F-:(J$D= Z%)9W%+*M-0H+@//V9GP.F9R]UAR:0U?5
MT2E5SMV%6;0Y)JKI;J9.T:K8B.[^Q)Z B6I4)<%4N%?!G?9UT<.]$E>>A647
M424G8GFSRG.P8C&BM%"$W.&3XHR:QL@*;]NVFS/,IGIFWY).-++67)QW-W'(
MG9AX-IWFLZ5Z<>'AV*K9WN7&BXAPR2R7WMP<2&IJ,K3</ 9)>+,-D9)<,0+K
MN\DG\0A3NGFD6"=)K. L"5, 8Y(&G*4@BX%YR'LNKZC A" H&G'.'F.8%U^T
MY(IRRQ(%-EK=1.7"!%GP>3H>)<"2>#&Y^8J7NJ+(^RQX((T6&,*2E''7OLK;
M_U@BW.F"D#4CI^QD1]F6ZN+UD>AB+OKI>\I\CMC*BM6#-&//5RAT%))X$"+&
MYLFKDU3^\2AID\M$%.7C\/;8QS&<2%%AC'428I+8)F2T-5I*4YH=F&D'R;[L
M,3HW?U)GF]!U)+0ORL>5+I"^Y.0I6SI,0D;39R%U/EM1T2YS8539WR;'(=H,
M/G=?JR^M=]CW'*ZN5 8BJ3K/$5[:1(F7;ZM>TJ*_3O!R^N0[W+/&;_=("J^/
MMVEN'0,;F3V8I7^!5U%:YQ?F,6/P$H!1 G&I4A,:<EDCHTV<9F <\6&?MU[Q
MIG9X5%S<1U_O9Q?O@!<R43&($@1E,1/:E!>C41/7M($_-W)!A7658WN?$UV?
M<WHO4W\J(X."!R7"\V WU8$W:'# PX#IM%J/\WS DW\N<T+^Z_.$4!B%4CB%
M5%B%5GB%6)B%6KB%7-B%7OB%8!B&5KA7BA,<3+)J$Q%QD*5]=H0>"B@R0E@?
M$>>"*3)ONC-)@%1ZP%-B<Z2'J&.&/46&NF.'P5,@*$.(%?-Z$PACL+$Q:L$A
M(I5G>59G!Z(N7C<7V;=B$($<>$B"@I%GPA4QSD$2>=98P@(FI?<HFI6!<?(:
ME?@O<0@1ALB(L_%63J9,0](L!#:!\T9AY<&*?/<ROZ$:,H<RG8A/7@$7$$$2
M\:5-"8$E6$(5>H)HS,&,G/9G'Q81TK&*X!4O<F08\:(FIB*+ST$>)&$1U%,R
MX,@<&R,6IJ$@$H&-^\5-H3(I=83^%W@U(NLX$2.(0ZY2-8OXB+&R'*M5%SG"
M:?&U:V3Q$]%A2O%"94RB>,YQ2-*G%H$6D,K&33,!"6""-3P!D5D1D EB,(@8
M&->!*O.XD!12'+.HD?F!C=I8&2B"%HIV&G,A9IFB3&AD6A/1DB4S;P,Q)B-2
M?24Y$?VWB>_AD?P"'GC%:!,B*OBH=HSR',<!7N'EB8&A&,VR;RC1%)MH&J9H
MD63!*?C2B2WT''7!$B[!<V!F8O)A&HY(&3!1B31AC;>Q'-_AA'<S%\>X,OA"
MC8LGB$6A7EI!90 R$3")%L7!2:Q7C+ A<)%!,<+"%7-S!Q"562(U7R7AA[Y(
M%4 "9,+^@B!*J3'WIQ9R\X9#X9B!L8J^P9'@)5A:9'Z<-H%$875BN8PPLHJ;
M613]N$;<P11A(14>5$L2%4;X,8ENT4U4H9K"PD29^!<@V20"!R#Z #</X108
M$3 682/A\A>N@D*/XA>2^97UT8F^^%G0M".]B8>OY"(&\2AR26\D@1DB>12<
M,1>_,9$+4IHQ4Y1#R(:1LW28TY>Y0Z!!Q9Q'(IA928?>Q9]*XH?2&7PK\A Z
MR!SGEBH?(1%,I)!+@FMOT7QZ46L\H6L@6D@@"IT<(S478BD;(B99 Q$<X4$<
M:35\UAS+H0\^84_=J2LBL2(AZ#$*:J-A\Q!7<9C<-" FL1C^:-0UZW$5*X$3
M-<&2*H$?/C$798$1"*)[+H&E%6$PMCDY_GE1[ %"8QH-'J1!9WJF8<%!9IJF
M[\!N&00C45$N7V)!=GJG>)JG[0(R>MJG?OJG#I0_@#JHA%JH%B2HAIJH[2(2
M^^$F@-*H#901 A0M!X1 =Q*I56$3]U,_)]&I+N$2[[(WH:HW^=,^[B:&J)JJ
MJKJJK)H]GZH_[Q- ^^,U)\% E'JIN/HUD.HN"=2K#\2HBAJL%:1!Y1*"#GHD
M7[(<BF&"F36D.BD97T(IGI5V-IH@R^&D:.2172.:!#$A3D1%!7%-:OBM%&*D
MV,$3NLEWE280R2@A^6$0'(*C0)+^F;'(,.]*'1"1&DR:'PX!=XG$$"'Q19D5
M1@-2'D':)!6R(])AF2L3IECD'S="$#LB%O4T+*()H48A-"MB-?>R,S=20P=2
M0Q>B,8@1-!V+1R?Z;>J(L6V8'Q[[&2F[&7I2&!,:L[FV(A'7F[.6AA4Q4]')
M.PY[A\>*?T_4EV%YFX-QE,)!'UYI)N]X9V[!9O::$F.A7FA!*1P;E16CAD@;
M)Q#R(0^C%R<I&U6#>:DQB6"BGS%1&+#H3H1A&S]J34)W&HG#8FBY'+[8*35B
M,4&;+>8Z,GAW,GW+8$8W=W>YB6+"8T<'0_L('UIIM>-Y%RO2FY0Q2C_2%PEU
M2T&AM>7^,4]4 ; S@83",;30=; J>5I002=']*,P"A7[)BTJ 1I,E+<T4:]/
M$B.-,BF*\AJA&"G7,6(B0IK&1JT8B*(F4QE)9DTD);JO<:$,:Y$VZQR"A:.]
M J2@]1K&M2SF-B'^!1%>%B]W!F\NN2,["K 0 C2W86ZD*R1#]G=0QB+D*1E*
MJQ:>(1V=8B0PF9(%HK9T4;4SH5E:J8FGM5#U*1&@6;QJL2+SQI:/<JUP^15^
MD9()$Y.*8KM76T^(X4BN\IQ26WP4VDPXP9;T^!?<,;BOPK%T(1LF3'>F.[IC
M<6&;6+]&TD+TPDFGP;(4P9&J<9O=J"_>2RK7H;.W213:A!/^@,E-1K$3'G0A
M1H>RZWM*IFN@U9NO<H7"-.$JF]<?AZ2+26S!^&0I4!=8N%M]$G&+*LLC\E$<
M+)@@!8.&R'JMG'9RB7%$BK<9@D2\FK003%%CL8I'*SRUPE*UV\O%W4%*II'%
M1]$IB"&-$5M[@&S 3ZPR?VPY#58Z GHYD[PZF8PRPY$JFQ(DA/(R?!@E I<J
MW>(RZ1(Y+=PDFBDSJQR1KRP97\"@@Z%!:[)%F/<6M S)EF.XH%/)9^;%JAS+
MJ+/))]/)Q3/**$;,F)/*J5,FND&F;5JF,))!JW I[1*<X2*LW.RGC-I ;1$M
MX1Q LIJI^=.I*>5NH]JJ57@R;/O^'B;8%"-CD(JLQP!:&+2+:>^<7[JALP@A
M(?>I>;HA=D*W*FIS30'(&9H2%#6V&7Q):K=Q= AB-0PU'3$A%+YH'<'2PWF,
M>C[X%6>1=#/9'Q91-=;9)E[A+-'W&1<!D\8<)%6G$R1A'3C\*B_=*2G]<L!A
M'6+G&,O2360\FG-['MCY-B-B@HKQ(P$-H^$RG^XZNE;#:9(V8'%"JC;R,3!A
M&%991\I\8P>+G08<:'#C<)AG@K6Q$7<S*+(W$0VT6JO!-OHBS-4(>Q4AP@*A
M&.NZF7FEB_-QG5N!LF&#$W#'N8KRLT=R((0-K_?Z1(7QHB%*-,VQHO?2P=WA
M,8;=L2[^8K.G820THHV:74_ME!4?2G>1_"2)4YVD,4:B"Q^Y,HP-\1Y(F'Q
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M2L8=*+P:D/$95NH7C;N=<3U>>/0<$-U_-$LA@7:=,$0</+$CYLJO=61^=_?
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M_?O_/P #*, !$K" !H3?^^;7E 7:2'P&@Q[N'N2HJJS),#8:UH^(L:>0821
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M%!)3#,=PN$R98 T7=RS53@=F6D1(TNITZNS.,/ C M%]\&PS+ 1#B&LISR1
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MRR:4PV4NA%[VI"@(AW@56;YF))$9DK2&E$G.DG $A"2PT"#@+)G <CYRII"
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M!4O0%-G2(\Z=/'OZ)$@LP,^>*G4.#'+'9%)B"__=:3KQH$A]05:)A*D/XL0
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M,O82I[4KE6EAGJ0,E2_J/?!'MSE(O.PB$8B8;#<QD2;[-O6J4-(FG5Q!$*+
M,I'IW0V(0ZE. ,CC3^<,<Z $+:A!#XK0A"ITH0QMJ$,?"M&(2G2B%*VH12^*
MT8QJ=*,<[:A'/PK2D#ZT.MCQYS"Q4Q$ <6>E=X%)>;SSTO-DIZ4$JJE-U6.A
M?V*H01L:48@TI"(+,21%#.%GFTYIU#HQL9%5 Z1M9&(4;"[^QXP7O"2V<&+&
MXXEC-'B\X^^FN$9'*J:K+XEE:Y[D5$L=AR=$/([)N DEM%[F=Z]YQ^_2F,3C
MH$27;.+B(KO$5R!>L8U)71/DP(2SPAKIAXKE$\(:BR=70;9/2P43Q!CSM83\
M,3F/'>M@X)2<ONWS8*DJ'MU>\KC3(*XQ$]0B&YE3':79)CGJ:XA'5ENX%$I$
M=_NS&KD(U=7>R@@W6RH9G#A7/][0CCC^&]P[S)B7#:))'R7X%&&K%-CEP"TK
MU?4)/N$R&DB\1;QEJQ\659.0'P4%B7 2V';7^[F?S"]A!/PE:[OBS,0F[;HZ
MTF_ZU&441.FR <ECK<=6=TAU$9C^:;W:20)[PM@L83,(]A(;88H#K,RDMV7V
M?4EF=%+ V"!U1YOKB[?ZLF"& ' 5VY(()/#5E:']I+*8++"U6B1$&O=F)%\"
MH*6JLS#&G<9[#<X<6V%T29_H.$MNRLH;<2,XIPRFL\O)U""=0AD9'K9UE;H*
M5UNWVE)^;9]BU1)ND%)* G(6):J2<6.B_-I8B2ICAMFQ4SH,I;YL=2<4X5IR
MPCRXV[7K-:/-G73Q%JTX/=AY?;E-Q:A2-2S3ES3Z@*68<-RV% =EBM\E[> J
M-B;JFH^6.(&A[$0"*_CN5RU[2W*H#OT3[C6F=7^B\K$JUD>0\9 AR5FT#T<,
M)/:U4#;^_')T$FV[D18+68 TQAQJ(FTD2-LF+'.9W4,TZ*='UX^1L4')3([F
M81%BFB]=.6]ER)*V1 \N.+$>4P-N<MKP-<MH9=FU4:4ZV?/Q-]\SY/>48.UO
M(_FZL.8^TK:74V0Z'?9-!U]LGB)LU,-".WQ8C?7$1W+Q_H9$'$)MS!F_YUJ/
M:^2-;P0QX*3)F==@)N% L;&G0Z4;@R&GD!S;BUWT0A.?C>5)H7R*79%"880\
MI9#(@PMN=$Y*985LD4M.:C@#[EFH*Z9O4A]*P:L.I._D*1JKX;ID %34$96D
M0F+/D$3T""(0K<)"JX#0@BB$H&@4B$(WK;M_.&)W^\@G[WS^O\L7U//W]*"G
MI3.5J5Y*\-+P_#VE)BUI140*^<A+?O*4GZA I0.@Z6S'.^#1SGCT M!1^AT]
M>N%[>Y 5)D%VMB$H@<C,!_C?T\S%F%/Y#"2:%CEUIF1H&:G(H4(&X'15;)6M
MWW=>*%P"@T%FCJU3VM/]IBR%2&9M"B,DOL7[XI?@.6#*VF$)[#7RM\5LY!BY
M$G4911E]F*MBK=PKP+GTLSL1S=Y8RJYR,#.V HOM^R"SB$>4!GXZ<77=5'UP
M@11T-18&XS-0DWP\H4F?8A9_%!5' TEV<SP( DE5M'!<XE]&=#%1 A<8^"0^
M<T'B$#.ND59L954D-T405R5XA1#^0/%_(9<T#G(C&8<:P(9U5@)7.Z@D35<E
M@=)E4R85W6=G:D$1?/$]?2&!@D(9^X,8XG-#=N9LHQ44/J)!U+0<?38R>S%(
M8;8]MG=R.B,Y:\9"!M%<<*8<_N4OWG)"+*$M]B)MM',:DK45!=(T'F%_9/)Z
M<M8^<M)PB4%=Z;88,D='E*8HH907QF=TPR(V8=$]S[%$!H,HMN84-($@<),\
MLE9JHN(:"N%7C"@C'=A-%6,L@@0=@7@'24)U02$V5?0HWM0N/N&"4N)C(P,X
M+/<2&<80<$-EM=AL#6>)MLA:5A%E=7A*[X95@W$1J42*I:1)XL8<BX9L$ 8U
M'3,8R++^@6T17H,A.'"68L"DC.!S9_6V)LT"(^EB%,/(9Z?11W-A9%?Q)4##
M+XC$1H8B$X_Q&8PU6N5T%%U19JS67;&#$X"6:Z71.JNX(J.AC/&6$\G2%PXI
M7&-%'!6(,@6A59#H%.KU&@5RD<_3$F?A*[?A?GFB*S+$+VL"A)?C)OX#1T[A
M,>-7''@!',PS@&9V*'N1A$7EATX16@)DAV7S:SM1@!?9+S9D%S$DBC'RC$,!
M:).A@C-V*\:".7>B$S,1.3^!;T&X7U4$<*@W6Z4V8\DC33^Q0%+"<JM%CK81
ME)%#5ZED(U^S:="1-M%Q:.SX$P^F:N=E+%4!%GMC'0<Q;(O^9#U,(4>81'$G
M@SAT\TLK"41XZ8,!Z8,OT8,[.'"3J2-@J5@W.2.8\5>)X69U(IE#@C5<<F5L
M ID*=YKGB(-UPC%X I)*XA@W0G]#U"(3V5BIB74?@YD\@7B]R1,> IP\DAWY
MQIG#>2.C"22\B9S-H8/-62-<AR9>-U0E0G8@\@YK1W=T9WKWP3=U1WKJ05,S
MA1[<P7DN)5#I^7B5AU NAR5()A$P&&7]\YR[B!K%8X^CDF5]89&9\QG4]1GN
M18GVLE3*&6Z-T8!THQ.+@V;)\BJF]D?ON#6Q D( 5HW7@THM4IJV46=YE!20
MZ(^@,31+0Q&^D10.)&0&(UO1%2?^@E.B]K.4)%:;0Z$H&[9-UR05!8,<33$_
M&=.$O\(<6^5CNL%%M'$QMX$7U'40_%<<#W$1#D-I?IA=<U$207 F5W-P!KHC
M31D^O),<JI<M"F$1C^46"%(:M,$V15,@+IA#+NDC:YF#7<(Q[,,LTQ$2CJ&9
M?A0=1:EB-^$8/O([NM& ? $WD7:61B(V'5H9WY=DYU%@F#$6A\(K% @4EN1=
M=V$43\F6];D3/C,;?](:YH,<CV,@2.0Z?L%QGOB2QP$X431CE:DDS5*/@[&3
M+X>$<5D] ?:$KX$83SE:_N)L^S,YL2(57+I#@G(F^T1DF:$[J^4]TF9"HO.0
M/ :D1P'^JSW!B3YI$BQAI3*!;1A9' "I+E@4E)FR:2\1B%R2%<2#:C&J(XXY
M% "ZE2M"')C1 %"!'"%1@7I!-I>69SKA/U8*+H7B3(TC:5;SA"783"VA-D\Q
M$J_2H-\#B0EA<W##0UK:7^_G@*988(<H$H1XH1VR%PG!$GL"D?@E%1LJ8F%R
MB\IS%1=KI1XQA![1-&@8,YRC7SYCB8<J,[.3$:GU([;6:<F2+;<WD"8!=)#
M$I5"=;K5(J":$>]28&592!0!24H[.&=109B3A'9AL9\B2#S!) A#=+EQK4 B
M-I?$-XKHDXREFY@QJ%U(*GN6$DB!B4A1& ?V-EGH8?N3%??^^B.> 1-GH9Q_
MNS%X>W;L A$90Q7F$D\L-!W%:A9/9X(.\7_/82X_0F^AHBRKRA3YTF6@H8Y"
MMDLGQ3C)US?J9QV0$A,=>IE=<AL4IJB5RZE#DJ>!TT[5QQ6T81V,(A1Q,32,
M54",6AO'Z1-8F:)@41(4"QHK89B&0QG?1UVCX; <,S2 YAF $Q?D="6Z1Z_I
M=&@8FYSINK$^=(+G,EJE]&'?AR 6MB)$9RYI)#AN<46!J)LWXF.::BR.L;R[
M=#%C5AOSY1HCDZ-W"DK]TIHT4F3JI[Z24FJ4\42O(2H>:RH70RIB!KU*6;O2
MLZGQ@U5$5#?:>H2:\CO%DCSU,\#^V*I#EU@69^M8X=F=,=P?+C4@VZD>!A(B
M%Q(A/K7#/65VE5$9::<B#F*=0&6#OVF#1"S$.DQV%\+$#L+$96=VUVDA4\P0
M34S%3HS%8J?#[Z!U0\4A)5)49)<B95R=8[RTJ.9OH+J9V@2=6^JN,/?&9KG!
M96*#>1+'_Y+ 57*N,K/'/I&=)CFC?7*_4L><S?E\R%F<<RPCBPQ9PLG(093'
MYS/(P%G(D:PGF"S)=:S)2N:>7/FQS,8N]]M>L/<2DOH]\ (5'",.@($I*1M:
M4[E!6CJ1UI.0M_(U/P02/[)A#EE!LL>D5^'";:$N(?=#/H(Y.Q.+-(%F"]="
MXH2L#D;^OGS\A[JBJ6 "KW0\.)Y(&:N56N&6*4^YA]W$/E[[$TKCLZ(20B-Q
M/"E)7I:BN*:S$REI:6H+5I.L&"JK%NE[%$DZD/R,0>@J*,^F*05I<VEXM&++
MR41RN93T7% A7E4$/[=!%J*F.J\Q%@B2))YA*#NS8-O(EEVB&S(!.\H[*M1[
M0O@9$:TT$7C+KF63-KBI-)^"I"I<Q^IG$?-<MLW+-E^1?*[W$FG#MZ4V'=5%
M-!CQ(QD=PDP3'<4L':FDABR+K:$URIQ:JPBJ7NS2-[IB,Z/"(@5$7,0AK&=B
MKM>5DK.($ 3*K+Q(MX*2U))3/:;\<K783<GU)0"V1W;H/7_^PCV+5JZ\NAN5
M7"69@AO.1B;93(L2@1$:R*?.M1IRP15&.,XX&1DC4T%1MD_&DM,BZS7'TX:/
MU992MC 6 1W'$W0K(RZM]IDX,LT&;;X.!C5N833*U(DBC+ 0)AE?HV.7/%Q?
M53EKX<;B8"[>$V*Q\JCF A7G-Z\'0R8H^F.$:#75A2WA<IHV0M'W"=,G)!!-
M2VY/Z[,=8[6TB!("^S^ 8VI\5E7)9(G"Q!G?RA.XJ5B\?<YJ,7UJ8:I)TQ8:
M:QLL\G\, ;9"V19Y=)AY%()^85=MQ3B 0]=#<>!+*T<" 45WW!B2P=]?C49V
MM1JKVB&MK21Z]%4+_:Z"S59V]#W^E<:"WK9'!1E(95FM]X>!.H&*9>2PID).
MR#$WZU(\8O,51.I"D>JA9C%]"HD9I+0KH[1(XDLCUQQK(YT23#YS>T.]3:$;
MMT(;8R,JYT=HP-5J7"U>42W76*)Z6+L65PYT*5LM&&'DI#$=<M$TC+(M"\$L
M#%. ,.$:TP/2T39TN@$TXV(7=05GKJ@I>[.YO4@KCS)-(],4G$*E&;PR"PVJ
MM4)=B7NG*]V'Y26 E*Z,@T1TD8Z!C]$4W^69I502%ET97--P\%U8[*GJJ\[J
MK>[JKP[KL2[KLZY0)N51WX%XT0$=Z8E2,+&G+V4=SZ%XNK%YVS%3A5=XYF%X
M,"7#ZF'^'<V>=]FY=F_GPU2\PQ02=A]2(YW<7_*M%A5"(QQBDI\L)=&3QJ(;
MI[B"&GDDG7F4/.FQ*T\"@@&.(_SUG*?1FB)N=:L"XHFAD$JF)&S,[6GAR(T%
MR0//E/B<& */R=Z.\''V\)C6[P_/W5UR&G7:V >3V_>M%FT9N@<KP@NWTPE$
M7 DY0MQCK,)\&&4TE83KC:.16VP9$@^&3>RC+)7&(@M>9?<#7%"A.W;=/+8-
MS<=ZH J7T)/-)<W5(ND6T0'#+G0[)W-"%0ZFWRI\E2LLMB"$.VJ#UEX"X'86
M="&;W>:]TVVA\$@HXI7%6$8#;8($6AODET>9WVCA\,LQ2X?^=$SKTAIV6!KF
MVA3  B.@-1JX<99(CCJ2\QFK=3<BWSN9U1>MXR^Z"#9$+BCA:/:.KM6[)HND
MNTNVQRY=W=4ML3X.;"L?E[WMVYC;%ZO8>A9EC_6JX2BLV,WP(A>TQ2X3D[YE
M+[Q5']47/#*3F$?>>! )AT['-ZW<=H3^HO.!DRT7U/0IK/=*>&-_:!(W@=C8
MU6L<'JOZ/OK_<T'0.I0M0T]1BO3M]G^?M<+TNS V/V+G_9KM$A(-@50^!H^H
MC1;H[&K* =!H ="*^K&& Q!![MQI$.".N#L!_BV$=&?A0WT*'_XC%H#8PHK_
M5DG\!RG(Q(D608XD6=+DR #Z1I;^N @RXLB(%TNDC+GP)49=X@22U*7KG<A_
M#5;]"]*@9,:32962U!?D'<2/%5LBO*/+8,E5#D$2TPHRZU:."3NV##*4I-2E
M6+M:5?GOZDBD$_49G5BU1(.V=0U""F!V(<>%NB#=%7>R!"20+$T&:9G6\6/(
M#P,4CES9\F6X'S%OYIR6<6?0H4$.%%W:M.6WIT^OHJOZWSO$G36[?AR7]D1=
M76\OG+U;*5#?)ALO%"?N*41=?L41._YP.41BPQ>^*_R.&.6MT84#IJTO^O?&
M5%OJRXW]'\*/=XCI6@\IK_J)7*O&C]WQ#B3I8X\"ARQ_N,<[S-JHOL%Z>Z>H
M^OZY0Z#^@UX+X"/O[@/I':L:7&C!53[K:+*@#((/JJ0T#"XT_D8T<:&O3E2Q
M1!5#:PZD $HPZ9WCFGOJJ6A,RO&=':>[\9]H:'R-QB")"9)'YI $TKIHB%G%
M2">?7&7*Z**1<DHLLZ12RRPK*H%+,,,4<TPRRUSEB[[,5'---MO,*LL [_@B
MP*SB'.C-.>W,4\X[2LASE9G.+"&AF6(LP<\^ XA1448+;?101B-5%,U%);7T
M4DPSU7133COU]%-00Q5U5%)+-?545#D]=$Y%!_UB4$1CS7,F.M]T\U9<HW33
M2>::1)))8(VT[IU5@.5QR'\44Y$8OEQ:5"MB"L(K)/,BXRO^@&E!I%"H^!@$
M"9+E9N+VH8%*T 6B#.L3!UN!&HA-E]X>LZZ!%RER*,($]2DW+]XZNBO?( 3*
M:[EL_\EMH($H:R"_RW022#JCT/OPH:B"&!0[?0=ZD1ASG4-XH'.3U:U%B@1Z
M<;EX6TSMLHSOJ#>P@?Z3T*:L0B9W(M8:'IFX /E]:+V1<IJ(PI[/NL]G[>)3
MS^>'K(NN+?"N.ZNUX$B#3)]JSWN9(J8I(L;GY[([*6GH&);,;->Z%DUMT6PC
M^6W,T()[[LM$//&F^.[*R\F"?V+[,<$>6L5FHOP24:1U5PJ90XH FT_QAW+#
M+( 7P:W+Y@S)U<IED'21T:VN[$[^::1U\V*QLVR3:UQPB8"6BUZ#N\I<,L(?
M@OVOG5O4J=[9X5[9LHIV.NGQZ69K**B++*PK9<<JRJN!PX)($,;:B1J.M<&8
M9EQN!0FO*+?\,O[]0K.C/='JQV8.J?*+N$.)<'U]UI>D=QJXKP2H^Y*\I--I
M<_]"R@1!4=.[T.>L%YAS<8<8S!L:7>;BE_VT*&<&HQQ1SA47OPTM)' Q8  L
MQQ.J14XG$(Q/_Y:2(HP$(6L7JD\%R1?"OY#D+2(A7&L:4#URC:YW"B(A2.QF
M(KQYIRU!: O4$L0XRUB(8T0928 @(A%(((8]/[M#6Z88N*"8AW@VB1>\)C>1
ME$TLBP[^4DEOG#(=Q&1P@I+Q&19MA[;(<,4FB*DB2,1QNQ)@AUDT*TP%(V*>
M$M4/1KDC6<<$QT 3C:\_K?$@<<@%M7J%\$,9L0J*8-@\P(RK63*LWL)R*)D5
M*FADQ/O)&X5CP/.,+H(F0I]CU">9XWCG.E*IESZ4I3VX$/ M8G$+60B)Q."X
M+W$D.:->0)D;2.3&(,W97TF<R)#0]7!U)G)/7;0B/.><SDE,4][0XA679GF(
M4+ESWF5:&1*&741RNA!*;NPGG1\&92A6J9Q?@%*3B32K(KIY9DGB2;>EJ!*@
MM%G@0/T'1X-.CI )G9LB&8HS1':&*W]S)0Y)YK;=G),V/3'^*# ?"A'. 12C
M'YW.0D_$/=7H(S8458INF":.E[[(.Q,ICDM:BE"2NI"DH9'C3D%C0I\^QJ%!
M3:1)'SHGHGYTI+31:%([\S^GFHAW"B%257NE)2OA2JM;#=,7;'6G@>3I56$=
ME*$\U*A4I56M:\T43E7CMF0^K82-*:7.7B,]W(P'.#<) N&(>,:*O$LK#<#.
M@1H3L^BH$&:5*<MY[E*7IZ",</,IJ."8Y9,[&G!:ZG,21YKR)+Z=+32,X5AO
M]@B[BF"'/5R)#D$H-D_\$8<OAPV08!@W5-^(PUS,"D#(*GM#WQEU*9[D"[]L
MB9^$!) ][KJ00W2J+!0)MR3L5*#^_8HY$4\VDSA]P8BY!,BT:+VC)A$I@4 >
MY!RA9.V!33'@ @6:F?-)%SJ-/"3'0L::/A7,.>9JI54419D^10N'$1D@1J#G
M46J-B+>C"5"V&F"QHG '(8K2S8(C]['8;J6QT!$C6$QTL(V!C,.0V)HX&M(8
M67X'.\LA&^F.AYNM-2Z42Z$.Z;@&$XB\[&5A.PI"C1,9BO[3-W@#"7#GU[VF
M0;4VT6HAO\:EH,94$!(D?'%=*4*U#J<2-_(MB6[S$B_B+4AS_9)+,7MK2C:.
M9,KH;!M?0F>3=WIN<S[#3W,/^<3\("0D7+Z-YW!S%XN.B+Z8B8C)9M0;9:XT
M9@8[5[K^CM/4M%0R:##\R46:@IB> @<V,>J:?YFFH8T4)M0R/',)V68^5O+Y
M0C;KTYBQBS2.6)DBY7VB"><B4*X0UB3OW<TP?Z8HIG'4)*^4M!T7JE-0;J=%
M,]-7>5L2EZ6>!X8:>L>"N#L2=V6%KLXM'Z_3Q\^"$/!;SU94P<J[G!6F]VLV
M*7>4HQSC9+5$E2\>B9!OL^E5%&9=]LMC$^LC:VO9SVJNBUR,&M.0V1$1(Y)R
M8%\/ YUWXJ9V]';,K2.UG.DM,*3VXMA%]G@A@T0X9%'T7'A0>D V2_2&)2<S
M<3+4%MT*K@'0$^#G.M[/QE637-/#[6XX)G""J.2.T='UVP;^;9D';D@EJ;4E
MT".F'M;2)YLCM+-EV +GUI+;9NMB&%#@X[DA:L4CO($@=SX3+:%7\(Y/*?8T
MCQ+1TT!Z>"CNV 0S]!W8?8@T7*>(@&*SKJ>@6G+Z6,728UMC>^V:I:+QM8(T
MT]-__!$Z-LDPV3:93^\!4H8SCO9IZAQYE3R.XDG/)42PBY7I^;K5QM%'3+J6
MVLL,BG]=*QU/AK(NRJ#Z9[/1:+PR2!*=;'#5_'/K0RFG*] 6J4@\JNJ27G,D
MBARKJLS_E?2/="3J7Y]&@;\1\X$TI" Y/T<HC&ID@%K^7:L:_4]5/]R0NGZZ
M+3'5P;%.0I7,T"R_3?Y$K0B\3XK^[+CSO^:1ID(JOH2*AON#/Y,@/P7\#0-4
MP)YK0!)IO[=Y/PELD?VK&@J\0+<00 X\C0S\P.#H/Q$\D?-S#;>!(8+[-<YP
M$KM1N+]HCA=KIJRHJ:KS)"0CE_&H(5>##.PHM9:#LB1+MK]0J8)3B0G2/0>)
MG,: O!-\#)62O8?((]U+C8_(,+>X/;K@N^TZ+!;$';@AO.TR#P94&7&KC=;A
MC\\C"H<(F_WAK@W3+I&YC+8CLL0X+,I80YEC&XOIG)&9G9^HEFRIO=F1P]V+
MK\C(LA)I.Z_0+U%RB8?SI^]8.JA;(+/Q-A1DIR=:K;&S1**3IE9"-<5"GL@#
MP(XX%S'^,Q@&X8NMZ;S2&!3W>C9ZF8L JJ+BV@J! PK_PI92(["C0Y<?PB>X
MP$2E:+:1V46&*8CSVI"+NRLY [Y!@4&&6)2' )"%BD)=$+J"P$*4>$#&NZ13
M1(GC<,4062WI\;B1 0P-&:80@CPK@SR4RR<(DKNT2,45%,*%D$(%P;3:41X@
MU+3_N9V_\$:3.(S66Y#".++SN(_9"D*-Z KT01\NQ+P]&ZB(2) R7)$SK#AZ
M61=4HBEOPZ@#2:7/RL<-9$0TDZ&S&)UK*Z<O5! ) PI(<)?DFJ[8X!YM@CN:
MB0X"="7U4\1Z0<DKDXSTZ"!4U JA9+?:&465-!$E%)R=<<3^H("6E( ]+0L*
MEH@6[HC(D0''H3PI+/0ORH@(L^ E8JJ6N6@BCUH7GZ"G4E0)4PP,8@PH JJ0
MDM 77M.S5/*MK81( YHP>=.K>HD1CP .A.!&&"%(T( I\9H.J:$IYO"PSH I
MT-L*UHN/)H2(O&A,FXC,LODQY_ 9>C0)%LN+PI,+\(#,XSC-R(N:X9@BR)2K
M:NQ&TY :LC&QX?#,%/N.YF 6\T@Q+?*9".P.D*F6U/2=C70,JO")DNJ[[Q":
MC,FW;]D*XM%''QP( DF8"S.>W,1.?I$/OW M:/H\G=!.C(@B?KFC!.N6+?+#
M\TE.DD 8+1(8*J*O0B..0>DGC8/^KL$8B"%2B'U[)8/Y2&>1JH8\O<YQ'#^"
M14-"GM[Q#A&)"&A1CP9-/.'PRM+0EQN:LFD9.PMJFHGQG,*(EN\@GE6H#WWQ
MN Q+)MXXEZ88S!B[O,HPS)9X)M@@CK:HH\BI'JNTCK: '?74FN&+'18BCI:P
M'Q3Y)D1Z0N-C*R=]4BB-4BF=4BJM4BN]4BS-TD]QE$N9"2YME4CQJK**D5?Q
M$U@9*T.9D[(**S8-D#^IE2FA$Z_2DD/A*C>I4SO-TUT1$Y[\#BGQE2"A'.6;
M/NI[C>\KP<N 1Y_R0!/9B-OX D95BBFQ/\5LD>9 0-=0OQ83C=&,#&*IC$H-
MJ%"MC:3^&-6D&$Y$-;\-;!$+3-7;R$BF6M4&!#A7?:L$K-7.<%1<O0TFK<W>
M2(@-6P@CPYE;38J9ZZ:1A"4=-+ IK)84F3?=P$&OJ(].+8EJZZ6?F:S&6",<
M5-1R2@V!HM5\M)E>58J9)#&:DA'TD<*FH$TGK(^3NQ![DM70B+F_ #!Z91D@
MM S \Q>;ZD&<B$%YBKR40562D%&KR$9G$B,]4HB(J!%>4Z568T,RG(VU-"$E
M,\3;:,^E()[+8QS@XA^M&+2<  XD98J?^9RNL,,G.JG>6$;2^$NH4J;"0-<6
MO<K"V8H<=8AK#0P&JJS=4)U2W)S-08P@=8M\65&>A<':ZPC^E=B:C"&FC"W6
M75O*[V@B4>.(QIJ+)KRND6"-+_L:JX!7 6(*TC)+[XA+T<) !N(HH+4:77VJ
M"X%1<O$M"-&-9$VS?<2N_.C+R"A/:P,N'5W6)#6EP4W1BHRAEW2.>$&PSF@0
MV,RGSQD<I<F+9AHTW,,V?OE%N#&DL,C7R]A74-6,FJRW&.,.6ZI9=?T<ZX2,
MI,P_O64('&I=*Y/1@9Q#896.[2D1V-788624S1#0CFT,;"(MH, H;N&+;+2(
MZ#"(PL#!?EU)ND,;EKT->,R<4:.\/#,*K $FCAF8F+FV^ 0SM'G*W7A1QE60
M;'$SOCC#,G0CB&A=303#D)K:R6'^&+-$S=+MD^52"*NHQ6_1C.@-C(^<V+.8
M26Y4V]M%O[C=U:ISX+D40<YU8" K5[HQ6,NXT<<U*-_-5/A,"ZPAG>'02XQX
MO0D9X7%\S.F0B[ND6M X3B.5FMU,&H2 (,);NJA)R*(!J>I8M.E8K>BP*/-5
MC8-!F)#1EQ/]NP#YCT%I&81)N<A+B%?"*X+UX?4I"=NMN K)0P]I(0YYD,$P
M.::\*R>IHXT(F0";CSL*N9F "B0JVVAY$H85W\U;/TP=B>S;OD$5%N9XDE\Y
MDHN8OB'IOAW!/F0A5/"KO_I+$D"MJD-Y#5[A%3V=9*XR"$J^9#V-$4S>9$XV
M$T*A9*_^BI.OPI,X>5-1#F4YR8H\T60^,=, .10_611(\5(TB65)H10MS65=
MWF5>[F5?OE(NY=)7F90^45,U;>4Y.1-;F9(Y[>2MJC;*(1;K*!9J9I)>862K
MRI$5IN %/A'KB)>6:8F&^!@4<>&3@(U^:M>%[,X..XB6J9R&, ^N6+&/T;L-
ME _=V!_8D Z$FY"/.)C?U)@)J;#!<9(6FC&DXPH>)#P!#;Z,J9V:<0GE$0<@
M?I*_^.!>XU@*F1MA9)D3+1_VX!?V($.=FTW)V$ QS [/S([?C(X56@^U\8[3
ME"7P,@E9.HOA =V*JHR7@@D!7#P0-&=N=@PO&NK2R%^C_BG^A"8HT^**\1$V
MC1!J.[)D(-PBG8)>B;!7-HL+[9+6B8"N:H4)9H&>]^ 7$=''Q]DXAOB<00..
MD6H\Q[4,FHS$CA@*#WU$BJB=M,1KT/FUK@&,"6Z1,-)II+-@8F()N&MGBFF?
MI^@F,$PB5%(FJ:P+BB%7ATBNY& :=_'-892+!-S4I(2F\PFTQ:"MQ9:;QKL<
M<?PU@P OQB&-N/TG<BP-H(5)?:@?4;,A::IM\7Q);*(8 GH)):MMVM"BS=$,
MXH)(E^I-H^!,^YB.R68(YG$/)4-JR. /RJ6?PTH0[<+M<^8+[* U,$+CX-[7
MP5W2I49!!I)&;&4=S#A:3RK8+9/^78,)C\HKHR,%).D(/FO:C(]+&1%!BKKJ
MC35SI%3<(8R"ZB($C=^;C\&%L^/ M:ZXB"#-W(5#FA *;)49CK ^J."EROSX
M$+24I!J];+;>0$B+*/[.I@AOCO=J<)M#S%)L*0@*;2*EL6TV)XSVH</J(//X
MO2;JVZ/(N-MRB+CUZFQRV9"(C9U (3K^F=9PR8S0O7.*R.:U+FPA)YT\ZN'H
MJ[ULFE1Z:0(EBA4Z)WH3F(59C[XH<ZD."1QJVJT@T&8R2XH+"D/%01>:<HYP
M&RJGFA"$$:!.J 9VX X'C4!G\ C^0 U/ZI/H:*+"X+]U;*LC;41DI1V7*$I7
ML#8G&<+^WHP.#D/Z@<_PL3'HZ!JVL6X05K'.7+>?P0^GF<2?N5KG"&DT.L;-
MC**3V>'ZIB*;#0R$2O2/&O1=+70(C-0&?')&IS'##JYD!PUBYPR<^\#P\Y%$
M?@I'O3Z>=)H_=69NURHW5>4[ 90 *%-R!]-?/G=T3_=2N:B "6#S]/+YC6I"
M$R?@F")H+K/;[IN_>I+OP@@CGPVGQH[^'(C7OF<DYQRGYO JJE#U@)>L,-GF
M%?@VMIWR$B!&2F_'F#G[ <+3RK?^8@X&82YY)='=$ZB$*+?1<705R9"$4(Z%
MB:(P7/;7>9(GHSSS4NZ9:(N&N.L<?.S(8*>/K A%J9=HR2_^RRU=J+#HA0W@
MQUR@[+'6$PL]25EZ$_%RY;1$;_)/R8SS7RQBG2\OBZ(*,4+GE]YTN]JR+/L@
MZE3KOC.:W=9#PM-#]QP1(7*)3?51TBP-T#0]9S+[9@=T=B>)C?BRUG9OV3"=
MS4TYI)![/Y-WT4[)) ?8C*\CLXP7:4V-QRG8IQ!&X-BA:BR[0T\+Z'J\V]DE
M.D-CRUY<CUERNM&):XO;3[\-E?_;_SIG M<; L:K/:*0'T3QG;FCY&11X?L+
M<QE;K,7'F:3YV!HT)'^PP4%VKWSVS;#ZQS@<PPGDC_#\IBEJC(C%W%TXN' O
MLP@L[%DE!<-;?CNXY^U;=R,7Y>C^BQ-;B= A"_Y2FSH/II"QBO4@VCL[BITI
M)H"X$R  I'\&#_[3UT#<.V((W]W1%P A18$4+V)$&,"A07$!&D#2A[$!1V)!
M*.K21;'!*HP*2^@2>? =)&(3#T(2M^H.1H$A#][A:3"(2HP!9&9,JG0I0I,'
MB94@IK/H/Y+_B#4XN.HF4Z50#XHK2#' NX,*_[T+(O*DP9=![V2]>G(5VX,!
MQ*&D:O".V*X(/3K<>;7OP2 <ASKD._BI86)0Q3;0)_'POU5Q$:H=B]=O5WUU
M_WU&:[ACB9DD'4,J7;5LT*9<@>K]%R VY]I*]1$3F?J@KH+B+ML.GM$F9>&Z
MV.HZ6EG^:%#'3L5MAJ27F-!_D'C>:2F[>O#6;8L2$TM=9%J&XE)JQ"S4J?7-
M.(O^[G@7[<T[;/6)E6Y0E^J]VC-Z)YR H]E&X#_)&805170]=1%_%X5745\,
M4:1/"2(I:-!"&-DDH(?4F;717MS)YMY%J2'U3W9@718$B1F^HYQW'6*D"XD>
M^E639D,15M6-_XCS8UH %F<C4*L$&10D =Q1W%[]"2?B11Y=1"![Z6'V7U(G
M+?E1 Q])]&40 [UVT1VQV9=1C#BRB>-6;<(9YU)GREFGG<K9F2>;4NK9IY_#
M\?FGG 3]26&;#0EJ6X"):NADG_@QZA>-D>+8)*5,77<ICA;^IJAI15#V&1&<
MNICHZ4-XFNKAFZEJNBBK?T93YJM^!CJKK1S6>JM2 6BIJZ]*N9IH5+]2.BFQ
MQR[X([+$WO'%4F6595!9T;SS#K7_4 MMM=$X%LTJQ*P2KKCCDENNN>>BFZZZ
MZGXA:[&AA<:>1-&NZN%-QG[V6J8J4K5*;YM)5)15LJ6(ZF>7*=8=E@GEZ]Z:
M5UTFD6>%J<;@/R40)MA^_?:%:IL#SV=0">>M%S)H$N]W4WP'0CGIE5\!F>NE
M01JTY%BT:4H<F^S9C! DVL7H$'J@%4661+R!2JB BUKH6*EH178@6W?@1:7/
MRH+F7$5E*N1NUHY%.UNC &+=Y\#^?HEC$U(2X06366=7R&10:WV;G%AOV1>:
M."6\A;&*35J&,\24ZF,9=Y;I$R->= 5E<F$?!5$"JA8*)1&93%[4@"XZ6^=B
M YGU5+:=6WWYGTG459<:) ::-E#J#900Q)@R*220X";=$:U\207+&76. M?4
M=3TNAE-03^NS.6K14@>)[D]!0OQ3"3NG]44/FWKE2AQ!PM*86GG-F70VB4?B
M:R'3&-I9!ED&%'<>UZQE[^)71TQL9V..V%6QZ1CS829;;"6GZA2.J).<RE4N
M<M>1THOJ8B"E7<5=_?/?K?0A$!.Y[56<J]1.X(:0IGT0=S,ASTD <QD(=J=7
M"0J>; [^,S#<)(<R(/+*37)B$+*(S"%J2XI".%*"TP2!A2/2E >[<K[_.49*
M09#>7LJTMTY%*"E"C!J'A/BG&?(F !?*' &?TI^1+<=,3X.+3 +EF2[^S5-0
M0<J8ZK*Z@_!M2Z42QV>2QRL(S08NE3N*]C[E(<"8!8Q>D]VP]H.=P[RC <=3
M2A#P,J\$W00DP[N(1%:Q.A72"5>I"D]V1&+!YH E>A>IEX"HLQ.\D.HA-D(2
M]*BV%]XH"90UZZ19E/0\5R(D8<)I)!Q-I),S'<:"/Q,)+C^)-YG@3DNZV,ET
M@H<]."53)9D$TB+W$BW*X8UY2OK+\)#BD11-1H,?T67-8O?^M$MMT$,NDB5<
M5!2[R&G..DSRFVG6QK>ZH+ V6,F@1[;91/"X"'0!6*<,X9*;&Y[$)F\A8*TX
MUTZ)!&$GB#S.\\PDNCRQKBM!0PC&.(<5QV3&)BK1!4DHFA"!O(6*%Z/,'=M2
ME\+)#2[GS!"EC 1'L8S&,LX9C2AQXBB-'00X07(/'75W.L<TH*)#C)0EI<66
M#67M:F !6NK<,TW<D.8I&#KA\_J8RXLF!9!Q^^!>BN(J2T50)AF5EA C:A>9
M](8B*TMC4)5"RF5A9"L"N1R9)/>%$DA.BR7X:[/NP#?"(A:PS>+;Y0+;+KY"
M-K*2G2R9]OK7P0;6L)B5'&"_8-C^Q2YVLZ!%;% (.]CL>'857PA7=G92KM:R
M=ERMS<YLP]6NVL+6MN+*[;IZZ]O?H@NEP!TN<8MK7. *][C*-2Z3E,LM<CF'
M6\1X[K=6\5QP=:LAU,KN=+5;+6AUM[N(FA9YT9*G%5VJD'CM$\S6*ZU?S>]8
M=XB&K]#;IW>L%DY M56LW)N1N_K70_$-<%?Z2V !;?3 :I097O.GX%O9-U(,
M?G!PVDOA5PWXPI%JEH9G9>#L<:>=3<$GO<+7E0!):4AV0<C ]G4QZ&BD(-A#
MZPW7II7JD),SR<%+FC:F$?<$$$_+E Q.;J*T]FFE+B9"GXEM$\"!?66:2K-@
MXL!20Z'^>,0]DWH'4M J5EM96#:"*]:$_4+2)J($,P[ILDJ.)AN77B2?M7&5
M_=:Z0YHVC2N1$QF)1*6ALLJ'(T0):U(1H@O=#<U,8^Y3F3/R&N\@&31;RJ)(
MBA).?P7528DT48;F2A&:1LK%8AY;1RQ2):'0LXE"2271(!2U_<;(BG1-U)!5
M%+)XHHP]R4G1WO"BLT0ZQ["%V=PJNC@W,X7FJP(*DN-J9D7/%/LA.8X@;0X8
M1!Q&<"!FM8^<I<67:*4%+EO4Y"9QS)5,N;BED6;3OG(W%A:7A"<6I CH*L.5
M:1(L<[=<=%)V8Z&X^-DNAXGC#1.3HOV*+8(("2!8/O-,.&W^=3\RM$[%]/+$
MPG DG) TBFL<92J-WY#?B4JG<>0-.P I52X7&59K"-1MOP1(<R"EL;24([O*
M-":&>-D-^=3TF;2%9R)B3?#&:S:Y9N>2B13I4DOMY?%=:41WM5KK7IQ$N8?4
M&RBJD0A/("@S4#-*U+_[2$+P)"MC':5_!#?+$N-,%1&QQ=,5 :N=@J [:$O)
M(]]:$A/W6S,G[7KN*1M*6;!HT0^9[&<Q,XI*$JD2FQ1>1#!+N$M8*!"DD#17
M'Y5GQI<T[E$V>5GK[G!7!DUZIABK39UZ'I$%55&2GSY/L!=0I\X)EBX^+9B4
MMPUY7#+5"1UT2I\N*%BZZG''?-#^/;@I#E:!)?([/1TC0)?*3*1S38GJ+BP\
MJ9YC=,.7P]C/.:RFL8T(@Q]\?UK6><+-=1!Y)O2?;"B789P*Z>GY"=ID,]2)
M:.W#EV$Y[169B 5)A<=]-(]&W(5-?,0/10RJV(V-2!U' !/-J5Q&N)6 [)BK
MM47^&$DBR<2*R%T+[<5G %60E,6^()\%4855*$1+9%EE.,0W_5?H(<M6[(1G
MT=9F4=8.0M9C:=$/=M9A\8UJ&18.$E9A9<=AE=9G)=9I#80/\F 42N$44F$5
M6N$58F$6:N$6<F$7>N$7@F$8BN$8DF$9FN$9HF$5[A5@_:!I>=9F'>$;[L1I
M+:%JN=;^<N&AN0!6<6&7N$P7,;S#*C2$M0"B=%W%MHR7M(";?T58[%$*@%%*
M(&)$-"S*%SP/)'H%?2V<('Y:=?0*1' B1U6+N'Q:"6"249%+M#0B9WB+=57$
M?X2B5JB08(#++*I093Q$MG +^]!@4B!*4[@B0D1#Q<1B@FA'N(S2+6K))4)2
M]$5*(%84-,[*[ 4',JJ)4ED+15S+IVD$W66$)E)$M2S%3UT$.#+++?Y)HSDB
MAX#*.B;*_[ECG9AB/#YB+^J)3<6,=-#<#B69;; $4'2,!%*%FQ5<@L0=J+"-
MO<&&1G01GYB>;?")$KV;751'R"1;:VB<L3#<4W %)L+<803^$(%8RD-R8''0
M$:!1D-%EQ&50HZ>X6V4@C#->$=+9AMXI1,IA7$644=GM1:D$C(!IR1/9V5&\
M@WN\D3BDR,@,&,UDVT]T(D9D2A<U%8 H':/)9)PA14NM">>(6D(H4DSDE7@H
MDNUQY)0H"]B](V$0BN*DU8'<2 8"Q;T5A"XU'2014U84Y7N03:0,I)3X)3%9
M6J  (D!6AGM82=ETI2$E6V&@8U?P(V-@#4K5C&&"6Q'M!UOT%,IHA5E=Y,!E
M'%3-(*O@(S_V5 29R.@QQ056H)NQT*-)8$%L3B!E7(W=T)+57FC 7VT$GJ2-
M19>QQ<, !SZ&W @NW(WH!_A4"E7^3,I\))O&34YH]%3^91&$<$=+>LI\8(\Z
M^HEUGEA1+ D!4>#T+)UVN)5;@5QPJ";>?$ZO4)Z(,)G]I!23=%$&?9JLY)C5
MM*6:6>#S =VA[<E53N0-:4>'D";6)&1=]83''2='C9EP,DJ A)-T9LC-N09R
M=D3BH$ING%GZ2<9 T1M93IN@T-QHB!@U!=U,?=Z*45*M),QD,*57,2;BL5VI
MC9)8^%U5Q*B&Q(:4$.0&4L;>R-KZ;$?-G9-'KA=JTB-A)NG"V:.&<>>2ZI-V
MZLIYKE^*?LCS;1B6#@J PLEYZ(J#KM=BS@0E=5%%$9 SPF.77I,,(5^"^&=3
M-,GT==_^4V@)#!6'4YZ?DWBI!3;F4B2)4X92J04/ODWE3! %+OW09O!')G7-
M-&V%BV@)G_@=[@3<@C2IK]PHE(8G/1JI(SXIE$J*E-Y*C/2IAIFC.**JME@+
M(JZJ>(&+=A4BW]1B'O96<]'JK1+7;-$6$A(AKPZ$:@5A /S5#Z9AL1KKL2)K
MLEZA#G+691FA8I&6*08%KA;7:I%+NZ2*X9Q(5(@$'1F62F6JFL"%EIA$L\4F
M=;R&9RP3B:C%.C7=Z:@7NAHF7VW&0R:%O 827Z2HW;FEX]@(?Z1(DRB4@ZG(
M=50'?OP0 I))7'1J6,$%83!;16&:BW3/\^1$6@R$2JD.=QS^QZ/Q53-.XY<4
M6D?P1U4RRJ<NQ3KQZX)\B7IE7NK$#F44ZJ@)AREA!-4%E?[AS549+"4%5, N
M5,VX2,K9"-XH'UTP48BF(Y=*"Z"BQ77H#DTT"1HU!+C(A-0^CTXXK:'9D%E<
M!UG"Z)_HPQRUJ5P-YG $W_))'QI)2_"=F,F"ZIZ4:MRZR:76R6@2!+C #R\M
M%6?\HVL43,',!%?0R 3MAVKT6,$R)![IIQ'1SA$-16_:Q=NM&8G<I&G6W,(M
MIN+Q8J4P7YE,347BU(F(!8_R2<]\6E^@;*$<A]M-(TTJRD"P+=3\1<QQTE5@
M68@P+;UIR6C(#%O #XZ6'4S 3J?^.)BPX8:V_L7(9L1)Q@Q1#!0:X2RM[&Z^
ME9W4&2\E+5!%(E&)7*8?W5#7!62->&.<X-L/&1#[1(;]C$1$E.T/?9(75863
M$"BB#43628BI2,GGN"6IR8;235NA_=O6;N#30(3AK<3<WJO'''"R40;(Q&!<
M_&U5C-EE+,EIXA@39538=FZJX.-/5H4C-8;-SII?U&5^AD6<<:V&$%.6[-1:
M!$;PR,J"#@66OL:#6$A!8%J 0@TQ%03[&B206%!@G 0(L\^-9%W#,M+GS@02
M@T=UI 4R;5_H^HRLJ!?FWLJ#:$3UVHET)J=*7L5F3"6DK#!85,<_C@:5UL8$
MPUM'*%7^F0#5(X715=2<)[&0X28$&"5$4E+%"QZ(!G,QCL NU.6HQ4 $,H45
MJ%R>_K2:]&';4Z@42I0OG$R3%UO%E#WR]78NYY#$.R@/^12'UY5*;/8$W-9)
M%&5NV96*BTC?8H8MB_X/36C1M='D"4<I3B@2MX7GQ(2(T=T=3"[QX!!G@F"H
M%!4'!RLDA:5I[%EF/"HQZ:TNW0+*[!++E^F)\\ )3?S*]#(:-<L)*ML*F"Y+
M:=I*;B(+E>F*+9]7G(!E;9 EFR"I?WF6-%<=W3YSAT4S/=<G3B(+T>ESG%PQ
MHV3R/X?K/R]-('M(>>GB=VV7M]0BN+0BM3*7M:;+:NWJKC[^ZV -!&<IJ[&V
M(Z5TY:+H"-$M<T'V)-1P1UT82UR%\%/T!D?$T% L#G#$B$S0D53@1HL */PX
M*"_39ATK[@;&G]ZI;]E1QMK]CF,DS#V/Q,"I1#\QI$WM1F& 4%J(A?,:B&?T
M![#-',B*YH743DXZ[R8-<HZPQ9[Y3+$!:8)0#>=,Q,M B1IWADVH$,D%#+C$
MD]0,A5!8A1<S1A*9R+$1IQKC!L%"3)\V,ZV\<U?P1]HPD%JPY2O^QC5A#%P>
MB&%#DGTP[U5@C.TEII]84%ZSCV'P2<<:6\9JA^54UHZ$XU[]AV<$!?XN)%/9
MA_E%%/D%!<Y(;;35S,]$3W6<AXW^V!Y-8#-8C)DZ^T7A$! 93TG9)@CU_85S
M#U\X0O>G=1%2<-E3O/-&7@H^FAH%@\7F]:T)<TAU"&>/X@E[J,_(KAV^N4N$
M);;DPJFA[>CC4N[^Y 4DZ=^C_<C*)O.  %Y_I' $?<N8. 1$I)_ >;6M]826
MB>IVDI1J'*^6REY9P]S#\I!Z)<\%M86_K,78QLY5/W@"0\]/5]'5)!S7X4;L
MA,[^%L7L7$QD,%M&K-V1*$5\ZXF%,X4BV:7166E4A>^;V060B<[*?@1(B>EG
M_PF-?2>/3"<-=0JC N\YY?0MR2[O4#@[]X=".:5HOUS\S7="A$<#;+;0&NSC
M;GA2(+?^8Z;KR" P,._%7)YQ2_P;5#B)E"C(E5@,S9195RY34G W4Y$Y(JV3
M62G2%9?T >%%(ET.EYB(+//VWPP+@H]@WF00; <<NO9()(N@GVY%<<L%2W0H
MK]F.4=E'1%C(9GA$8WW@<9 K^HZ8I=*>0L5@8)&)BAS&>:C7RBK@Y41+1+4N
M8VP$4J2>7YO*F/3L])R.."TVZ@$11V".0!"2V,@.ZM ;4J1&AN2SE?W(K1T%
MD*;4"B$5^/&MO<5$1]$%[33&V00)94 HBW\0*V\)0@N(CG>%J!'<:&"%';,&
MEAV%A>@%A/(K<2CU#T>-.)?P@]*&:@X>3FP&>B42BSF:30/^30&CY/PHK9X
ME4K4B^.X&';[V5'CS-Z<R!XM'=:L.>IQ!=#AAV$8KUI1AD(\_$U$=D[VKWHD
MQ+?8#Y-X7+D7YW^I'U[]U7#-JLY;5]%+=![::M*/RZQ"='5!--@(XA^^:K<
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M'%*@\@3"DZBI*ZJ9JZML@PG1X3"T+0@:-=K4*. N@PCI&*/.J"&=I6)-G_'
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M,,<Y=*5*0YP&HM8$UJD2*0'@$-H;HY3F'<H*;!HMBQF/0%: X$+K0694 I9
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M R=_<71FOQ6=\=/4EV;7419Y7\=)U_[G.[).\QG[0ORRRX#I-\2*D3OP7[\
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M4,!HW[S+(U<RW7N"WJ.,S Q6540ZM;U-(%$3M>2.[W[A[9, (JF.YOJ8C.L
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M0=WQCH8@<OC/5,J5J")!5QD4XH4K$K.80%_HI9)I:PE%T$LGHKC86W@9YZ-
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MALETM)3X"('9B6*$$7MD,H"\ _O1B"TK1=-.Q&=!B&2QRT)/S5#@44I4,9.
M#752& /:K5Z8L0'^CY@T[9PFM!"&GG<*-=N0]8A)] UM"R1\QEMH,RW7C[]&
MZ4=GSD)_+Y3N9U'X<5:]Z^"!ZG[6A@X*1=A"F+.R\W*A,485<O$U,V-!(ZL
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MG0_+#>-[9F8[S\IFVK,H^I.J7$C?]44NG)UF?!QEY79J$ (R\^:2&DI+NER
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M%S,F6"%YUY:X#"1'Q<U]9T)8C2[N3/0%8&V;XQ+S;K-[/,N:3P@FW(6%%V&
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M-$.+]D6),930 34P05Q <YC+89+@Q$U\\S<8 36-@34=42OU1D0.^5RS!#C
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MS80G[=6_DRC=,M)DN"=W\A@/K=!IS2:H0R;S(Q&MTG;ZXZ</,]>'.S#GA->
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M7@6A+(J,490F!""\K$*%N(K2>S8$%P!9D"IL=$AR)DF4,8&$,:[LTEE4Q)O
M0# S\>/,T$[4)0:.9G3I2<LN U "%7U&'QI3BYEHHH\Q+68B[\G,;!9R)?BA
M)'.:T]'^<PKWFFWNL3<M8M\VOT(6FYB$,]C\5*(.8JCT+)-%\:,=0H29/=[(
MR23C/%(6/P7-O.RSE9GZU%<@$4Z$F&Y6?(0(7R!SFFV^Y8\V^4Q/?A8173E$
M'!4E$3$02I17]HJ?-NE-S]1$(H2:]"$CI18B#4FZ0K[TC)LB71H;4R.4!,6F
M,BG.._0C2*(D95]/&5)5G&6=H#RE8H0:4$-8V<IX%7):$6F+QGH2)W!E]!]?
MT,F@BEJ5X^ D6G%*SU*KDD[K_(,C_#K<282ZE"$-;)HD6IBG6L<2N?(+)>D*
M71T#M)1"PHI,9A%)B=C"DB\ B*%;X:I!!/(2MM0*7&3*S$_^WO15?FGEL8YM
MRZ#>6*Z@-!:L^]G<'CFG'IL0BT (J>M.CB-8=2'D6:2,RH[4RKG/]LJJ$_G"
M3UD"PX:0RZXM2==&(.*OL;8461/[%TNLPCC-2B:O2"5*:?R%DW\QQ5]^Q4BG
M*,*YF'9E7L<AR1?(*I:0M,M3JR"6<06"N)S 4%G_2DC#MOLLH<@P*:[9"'X9
M=SJXU/)#J;F->BT%'"35*C^7(=%31B7(V"WD0[]T4)'&.N"6^/=4E4+3;Y!4
M),Y$11SGO2WCV#1)P71I3,OQTJORU)P8/:=0-9%2G]C**:9(*5''+-)'+0:7
MOE#8QJ?#$:A$6;F'*(E$RW&)B K^--'%RF2U$9G/Y1;<R2+));)2Z1(5"]H6
M>+:DG6WISJA:W!#SF!8]6#Z(<@H"R13G)0"9&M1!6,:OFD1J(GP2T)$FVI,:
MS^I);P[?2)W<I5'69"@!1I(N>*:X,O-SF"-Q::OB#!MQ? FH0H[6'RNCE#J7
MYX]<XF-X@1/JO8#THU1*L%BH]!Y^\7-#"K&301HT3LP>Y!U4&O13_5)I5P68
M(1^6TVG&U!=%?J?52Q[0.,U,5)Y,9R&#9M60;]SIG*HI7L(NB)ZP V*FVC9*
M%NX)BA7:$C8%&D8 F@YG[NP7C>UF*;HI28CU4V2QJ'O*^+Z=CP;=Y]JQ]#N1
M@>:<6QG^Z$5&BS']&4V4CSL<C2&)Q)K4*U"4PJ9X^80M9"7V:A#CI5>.2B#+
M='!($<*B5B)*X.M>\S;[/*KZ6"=.TG3L;=ABDM8LZS9"/HUGEJ3N6%'[*3Z?
MRY\O,QA(>HDGQRZ0P:VC$[CHAZ8= 3;L?D.1 4<&Z4:G>(,!Q6:0OF1,<GD'
M7I8-*).?&I2^GDJJJ]L7'^&FA3)!\CLSQR6OC+W<E\'OU#47WBLM2U]5Q[-C
MJ:*=J4+%.C59"EG!Q92*MV0AKQ,NVZ^9\:<<5==5U8E5$__>B'S$J^3]<YQR
MZR*^VO8=T0A\28@UG#L8K"I7,2Z\'"+8>FI.J4PE\FF[LE;^R5\3JUVJ:VDD
M\R:'4^RM+&$HFEK/KZ!@=E3JK6Y#IELD9>VV-+GFD>_CF/O;=^E7#D834+]:
MQ]H?9+JD1&M#JETL@$^WSZ W%J]J/Y3=FF650B7QF2P6L<F+KF]YG8=QJB7Y
M%8"[F1K"+U/K"E3[B.QZ")(X++& *\CR' !<EM8J0)[2C\)ZG9WJE;L!&IMH
MDX=RO[1S"+U)G(6XN[5YJ-$8FA)\&>^@BW'B&J*)B,] ',MS+)6K$HA*C6LZ
MC57H#6C*$L.8"Y=!E*+SJ"-YF=70&&D!.IG P2)$CIC!C38+-23$0IB!.X)Z
M*'?JMF>:O)7KE7<X$;NH)933O3/^[(KY604V"8O*\)@="8S*,!. LC.3F3$G
M$:B(H!_G2C/K,!,:(9&0J(ES:HR-H:B0$)-/L[,XF9_CX*6'J+MBX;>N6+&/
MN#D'*J44(0Z=*#N3. \,2:<NY!?+^ MU0HCY:$- LQC\6!0Y 8Q?*CL:>@EZ
M69H6VHWF>(L2&"=1"HPX*8[*$(\V SO_0\,#H@\'N9LO\22;<)2PRY1H'"W3
M6":J.$5#*9/@*+44Y(I0H\:6D LW(XIQR[=?&PVBJQQH^HCI$!NKVK6UV1%Z
M"YI@)!+DH+*2,+J.DZFK L@TZ4&!%)W^*\BM\"N$[!SP.R3O2Y/T:Y*(:4AD
MX;[.><C^4BD!OE*=T\NCN+L=H#(DK6J=B'255=A(]M \RWG(CP1(MG@.#2JA
M%2JAUA BF[Q)G,Q)G=Q)GNQ)G_Q)H Q*H1S*G:Q)#8HA&#HA(S*B$$JB1<(@
M#XI*$-(@#WJ.#=H@)F(@"H*B!+(BK[P?KXPB*@I+LBS+UYB?_CD9!$F4D*"S
M3%%#DW&?CA&,CZG+D2$9]!$?[ADC,NK+FOF+[L@:20$;O9&+O1F<O"%!OR@+
M>%Q(KA"E7/$QX  =-?([EZ1"Q[P]#<M,8.+,KE!&SU05T.RCY M-50DU8'E#
MTVR( [,8P_&+Q8R-V. ;P7P:O_R=Q.C+Z,D>[1@9EI'+N'3^R_R)'[,T2Q@R
MRZB,2@52(*E$# AR3N>,2:+<2=5!2>1 ',3IR% 1JX*P3O=;H\U,#]9##Y\R
MR8-,E?)\B-5;(XI<3?8H336"3_<,%?;+1(R<SX#$SUX)2?V,E9+LSU9I28L!
M.'A11"H)$ELS.N#(/P8CCA7QBTE*%).Y&XJXD)>@-FZ3QB()3Z+@-I_(D0H]
M$C*)I2/Y$$S4I/\0AS$9C&0K.\))"Q4QCP@#$5-1T7C!"P2UMBDA#+OP$ITH
MD^EHCL"0DK)3+-6<%<#PB>7@F3 CLB.%"*:;,D"#D!^EB:A;QQQ%#BF1SR-9
ML0$Y":9#Q+3@D\U DM$0I:TA1YO^P(PQB3[!6"1\21'%<#F<2PJ3H"6'P$1@
MN<] Q+(#FM/&2)0:@XL9ZA"!$*:]:,VG6R0CA"$(6I)P5!7;X!5"+3)65)3+
M01)ZT8DQ:2%)4PM96R2G\PL%.K>J(+PTT1%0[:<36:?X82E+; SWR2>_,!G4
M/!)?# Y:1;LF&4G<8)F/:L.O>"B'6JE!&1HGK!0Y5!S$&9J/"L']K"N>\*I5
M4C0%A4->$;=G,PO5 @G(:AB(J:J?^!2"I"J8L-/-6SQS+;RY:HD\@[UUHA>-
M1,1422-F097B$"XNP]>)("OD.I7VM!7N-(W;4<@%C8H>-"L>D0H*'%@<>T_N
M<"LS*D;^@5F*"*S/+@.0_V10XJM IB@]/B45@Z48QZ)7_#.CSA*SS/+8<P4M
M8SE/5_FJQ),MI>B4\^*.[,L=_EO9ZKJ<Y](MSJ"MI!*)H4!-.SV)Q'L\Y%!0
M"A0^G455UR*WZVO7!MLOQJN5B3$(#LR_GWT(X N^]_,ZTCD+F[",0:D[I^,T
M]IB0B3@/,[L-01J1 :D)(3O%7YN+XH@/Z-.VD5@.>A-1<+M;W/@5"C,S%&M#
M!$G0>L4R5EG1FX@1%6U!5B,SSF!;+D.259+,7LFE3 I95]%$]DB+'GPWA-"@
MMMH1BFM$=BTK%L$DC1(E*O&[XB#4,]13,[VFM,NEI' [ J7^',\%E=%$K888
M,+<CT88@I='I)!F3NX8X'KF="Z*+%LP\S3_RT=)%B8D:,0RK1:4 C-98N4%I
M@#KQ'/XLE@&;C@;JB^O #:-#S=LM$-$UG<A@IJ00#8*#B>FEEN/P$A$1.,BD
M'!U9B^RX5;9XRX_XDZ6 L],J*B$37_>#VE(1I #&.1FCL#D9-'*ZC1'K,G(C
M#)'(&'I=TX<5W*;;$J7B4!+6IY)HP<[*,RKYC2LQDT[BM#ACB*[#X%#QQC<;
M-F3:83][K=WUCOP[L_Q"B2?ME>W5T[XZXHXXB>DP.9\(IPQ=VK(P.+?CTB)I
MCNH8D]/*E&L;N98XB5U3J.>S-93^N]53^44W$3@E#BX9,M7/9&)^R9P^/$&%
M?!(1D9XY2QB/8BB;4K)*N59)_;-#I L.,2,,CL13Q5[%R<<H?-/7(5N+B6*;
MX(D&8HKG^*[2JC<T Y!(1!+&R$<=YM46P<3 6%'\K62:C1+K+8^?V+("?@_:
M@+F#+"J LUNQ#1T8DIRB8J^-*"Y!9BSK @E8 4"2>#Z*F*'.$XFO;<FHR-H,
MXXJX$PC7^!>>Z)9T'1 W$;W#@2&-B4  Q B+0XB5:-JI6%RFT-C#XXQ\2:^7
M>*_-^MB)4 CZ<]?J-)=A0<#?%<V A8FH,"^<.@J<>"YFR<!R 69[3NBRH@J!
M^$ (_(G^W56\:-ZJKA()T(L8UKL)MR((]W@)JV*]>66OZ^R)NOK/N=VCLE(_
MJH!F<8Z(S##HR?N4C]37K5H7EJ!I>1[0X6BK<49'D$B8I.#HXNBI<CF<RM*P
MKMU/*"&NV.(L_(J]B CAGZXE1H8*VC%IX&"_H?"<(6:]B$DL=L78KF6CZ2*_
MCA"J5;).: 4D' ;0B7;KMM9/T'7K%@E>/,)B\' TV8'CR6E28/D<]TN*N]F*
M6M&/<-H:F8AK6Y$Z$ZR23GOGD40;H#D.GAFGL,#!'TR-*Z06F#45CB%"/=%&
M6C4V,_DD/'R-\^"56.T,110,<=,G@8.UM54+$DD@&G,PQ3C^8ZK CVPZU:"8
MD/=(F-WX)\Q(0)MK#?Z@B4.,%@B^'46Z396+&<$L3-BTE7+US+#M3[NF:Q@I
M2+SN"F<-E:6!HS;N',TE%;U6(\6>H]EIH_+-HTDCR4@%%1W9E7Z6E;7NHV13
MG<&!&[W!FQP!<,',F_^NFP/.CJ%)S-[1F06';N)Y#P>/\.1I'@FO< OW'@J_
M\.)!F42A");)GC'B\+SL& D]F=]$F2T*SO;1HK8L3A?W'PAZ\?^)<1DOS@7Z
MGQL_( =:SJ/LH!"BH)C4(!^_H!%B(0N2H2*2U^E<<B:?3A>R(2(R<JB<RN0$
M<BM'C ARC:Z<HAJO<3K[G_=9<9#^,7$.01GQ$9XIEBFU=>OKYLSU=L^YYF[P
M$-!!^FXYEPF_MN[SUL\WOW/VZ%T_-[+\I>O!+O01/'3!M),T+Y:-2)VB(H9_
M(;U>U:\5)@K@<FIH1HC\HA?]:.B;39U_V5T4;H@KB1>PKKX&8R6/L)=Y11W;
M 9<_&A92XM@T<0J-]6AZ04"ML'7URW5="R_7C3S5\>:%R*K6F=JU)7:LN*[-
M$S>,L+_7VF>Q^)7YH192AY5L\3U(3PJ<L$Z-L4ZNN2:<#EQD&=DE$7>L<%B8
M"*MHT3"N0<G-I/7%;J7[/IVD#G0CZVQ\QQU[YQ6-9A$T6?/)] Z &T-4G^/5
MS9+S,!3^FOK'?YP2E&OSD3@O$(Y%L[ ,:NL8[U O>*IA;'2US.GS[U@.(0L\
M>(J[V&D.83O%_U5'O&41,#X=J4$O3N;OYGXZE]>F;]/"-_O H5F*=IL\:6\)
M+9:,+7,7Z56JKC*=H^_YO2/#F>@0)%-3"1OZ]]QSP#6,+J2Y2'1@ALCS?1$D
MKW^GJ_40K7<(D4\5CX>3PCG0_LLTQ$G2X]B-PXZ1_2Z4]M5W4BE2GQ@PVHZ,
M _?HD#I&O9N2^GF*2=U578M>$QG-E@</NE@/>Y$A:;'2:$R+0Q8F6S2Y3UHP
M+0UVW\!#'BZBXU@FP+B<_)85 E6-M6<S0']/_?@-#X5;B#;^G0\!N+&7W<4
MU+W]\TR2ZH0F-LL,^E&Y^X^'BQ0958$'E8[1>7RMB9"B,,$28JK W#%)Q>TN
ME@TN#ZL/%3H'#_2U2#D)N<$P$"<;UE.18W+/K\"@G8^,1\,EF4MI,DA@OMT5
M.\ X&0EDL:=0;#M_3X 0]V\@P8(&"08X.!"2KH&Z KS3=>>@N #$+NHK2"Q
M1H<!(!&;>!!2 WUW1)Y$^$ZA1(4N7\)4>*<AP2 -B1&\ VE@19P%5S48V/'?
MG0!W?/[3]S&I0J4-(>T<2 RD2)E58V+%NC*GSP8E_HEKL#+E0+($A[8<2C2J
MK@9(#P:YRC6A2Z!97P9!BO1=D(/^'#T.+-'WW])_#6@&$%@0$MV- K<2YDF7
MZ.2%!=TN'/QRX]W.GLE6U'4Q[M[*1.5Z)KBJJKX2B@%+U9Q2W->"=U;EK-H
MMV2"&WUR'F@QM>VK=]2&+3@<+%W-4JL&_T?,^<S<-6FV) Y3W)W7=[;J"QER
M,*37_]X=1ZC\]2K-NF0'%:Y6.WV%[TSGK:^_X/W]TCDR1M-!JRD4UT@XG521
M8LMI%X" _ZQ27@"U'=2?5%%%-UUK?Q4GU%(F-0!)"70M%YU!D%2URF33N90?
M5E.)MU]BQ)D6F( F$=. <V51R*")K;T7GT'B!,$82@(&P)M!V?G7F4ZJ33:<
MBX1=]5O^9D/2591D415$I& =!;$2BR[=06&3=T5H6P,E2>7@>08V)21!NI@Y
MD(KS01(F93B%]-]\JNV8&F8&*?7G81XIMM&.C 5*F)*%F03IC/\\]&=L;8($
MYT$FGNEDG66]%5F']7&GFCB0*-GF90(IM9)S?4J5%%W)$521<AAJEF1]9?KV
M(%AR0K703L3<F!Y8&0UJDVT"/E233TPVV1U/[YQZ4)D9H;<8;]3^ V=[/[$V
MV;?"==JD:4>5JYV%^ND*88W5QEH0G06UMB!.;A(6JF<^_M63?9.)0PRU#^&D
ME$]F.515"5Q2.JF+MLKT((?**L1@NB]-VIE2!L&*D$^:\IC^DX F[C90$'6N
MBQF*O;&$VL4&52>5D$\^^=];_OYG[5@4EB#7F,U*=%(0$_I:ELLO"R77<#C[
M)N=/^AI&9J@Q4[F1T$85#6&CG0UJ&]1@X33HP@W3A-E#YG7+F\$&38F1Q5[G
MQ&6['->(M&?O0/9/-.>-VJF^*^7]SBK 0;9*-.\0$\TJD!$S>$&*K^+X0((O
MKERJGC4>>5D&02[Y>;=M16'FD7M.3 FI4NXYA)JK=C1QG4>.8$$E?/'69+"S
M;K1!I*>ZVN40V9U5-*<;SA_I7P=O4-W$J7BZ:HM_P7OQ*AJ5=^,&C?@H\C&-
MR.#P$^Y-6(D!3)AWS@3U;%2;(MW^5T()X3?^Z2JT4ZCE>?,[C_[\R+^=/&'F
M8Z4HO*$>^28TN23QREV\&9Z*E(0>]1WP-K6YCTCFMXHO4.B"\]N,ZY#6,XV\
MSRRG6Q?Y0O>.X:VD@?.## 8A] 4[+0=X!-*(Z^SGOW_T+')DH9UP'/@^@F P
MA<2;7_B(@I1HB 2)^CM/ /:V$>LM#T*?\DP)0M4QZ;PE&L 3CDB^()+E5/%^
M;4KA"[&7-RT^;BNYFP@)7<*I&T:K@W"$X]SF:$=*R?&.2..0'ONHKBCZ$2O]
M*U>:_*,/2%C*CX,,'A^39Q( ^A%:@<Q*:Q*I1X1-,BNBR:1JG.8?M'4K7DV9
M3WB&H@_^)H6'/\0P3RDW)1#%9,0\%P%ETSBIG:(4,)>ZW"4O>^G+7P(SF,)L
M@#![V;T">F5- 5B38)(9!*\\LYG-')J.2L!,'24SF]:,9C2ON29<WF%HVR3F
M,P/ 36="TYGCE&8WS\E.9;;3FM<\637G"<T),?.90S/G-LWIS7?2DY[I#.@V
MMWFR(!P4FG%!:)GBTK.3A?.@0BO322IJT8MB-*,:M>B(-NK1CX(TI!XUBDA+
M:E*=5'0U*+WH*G3!D).@"D41<NE,(X0JE^JBI3>]*4UU(1J&$"NG/OVI:'PZ
MN(]<Y"*B22I3F^K4IT*56!:)*E6K:M6K8C6K3\V35J^*.*;^!DP<XJ!6P(BA
MC['J0Q_4.NM:UVK6M*Y5*)/$I"V;8M:Z0BB/^]&%)3VSR;J^$:\PH:M@RU7'
MPIY)DHCUS[H66U= +C9CCG7L(NW6R,E>3+&8G1Q3TJI6<7SVLV,5:UF[2M6A
MF3:U3ETJ:T73TL81JZ5&98AL;7H2FD)%)Z@ZJ4G)Q]O?9K1G%HU+.",J&(06
M])S43&8QFQO,24(RK3$A+''^M$K?W&5[,KH<8_OJ$NF^;&7^ ^]W(=FDQF[6
MC^A-KV33B]?*[M&[[M6.>.>+UP3:MZ[CRJ\M PO'VPPHAH";&W7O4H(4G@M*
M<#.=1AKW!;Q]83('7MU/4)8_A'#^]T6U>T>$(6.AU53F';69,/IPN+BB;*5/
MPR.(X"XLE3H5F'G?B3#,7-C#V9W&766\#]X8=,%/60R-D]1BXPS(1#OIU6Y"
MUH^*>GPY!JI()*8#L<?N4,; *,^\,7F@DC:2RU")^'!;?.)]!GA@+0+0RCB$
M7Y("<&73G7"++*:?FW='XHII]V)RSLK\3$.]"OMN4[G,6P'-5, B(B27 XQ>
M%*_H/]-=Y9@0C/+1YA<]C7CQ<>Z;XG\@J)$HJGF.%MQ=F?(V:H5DCG'2^TGD
MM)PY@SS8)2VL#]Y2HSC['"0:VX,DHNWFWQL"^"Q]0=>))A/CSHCC0<8Z'[.#
MH*1 Y:?^8PR"F)WBHY;#$H=JKY*3BW*$/K21A4,(([:LBE;?<LFII?]#B&*D
M]>D;,SNO!0'9 07; (&8I61^_+63.-(:AO%-)3 34T(VDA%4^866=V'04!BL
M/.!DZ2]C(\Q@NI8P#X5J4ARB-D]NM1!/^B7/Y2I4:C96; 7K[BROB<Z]L:3P
M5+%)O-ZVRAVIMNSXR/RR^((6OBCC(5_5S$2Y?0E^D^>Y0;5K."(B2,M9S*4B
M@65D5=E:F_1%I"CNMT$=:0U2:D06D%$M7\)!6T4.;B:$_44?%J?4*M+ZP6[A
MY!TA<B-D@Q?LSX%J2-1)\DNXLR;?,"Q#LJ&+:V 6E7PKB5;^S*&)IO9,G#%)
MYT$SEX^'''*Y>;FKEES)R5^*TI%S&[(H;)*.2$Z&K1F9A%!ZXGC&]FNEC=!D
MO8$,.O"4DF$XRO[Q)80)0\YRAP9\QT[/=%5&7 H9^,:DYY<I4%2H?1_3/*1N
M5(-@1/1M&)IPG&,E.#U(&)-(Y.M9OGX1M&\XQ!BB!WY$:FE+!TO >"1E&/3^
M([>\HC*EPE2=9<(1D W?'C<,RTIX4%W1S5$0),I'$!M^%5COT<ND2,2$_$E%
M((XN0 90799UU$=[E07 ,<<J.4W8/1,>68M(, U^3=[Y2<VF; V_)0]H6)2.
M2-FRI9Q_ !AM+,EDF)QAX 9(R(O^Y%7%M F)8ZB*<(B<0L!+3=#-90!'4*0>
MBP7!M6%@WI6%DL2,_#6)2VT.H12&G'"=<D <N,Q)BM!%[MV1H_U?()%A9SA;
M4@@&JFT?2Y@&7\C*O?@$^&&,N6D7Q1B(4@R&F\@=T/T@P"%,1E",0:#'4*A(
M%#X<GQ50UNR+PL%$C31+EYB5XR6-&Z'&W2U)59";)?Z#%=K=WPB)BZQ-^1V@
M<CS(.S $8X"21(1$4$Q%4D">M7":K[WA0DS$WPF?LRV2N\T;U#3=&3H%R1D<
MF?!=Q?P)YA'*4>@(S-S,;> ? .Z?(O[>5'B%$=+)CLC=9M2=W=!;WH%(14W*
ML6W'3(3^!..-!!^UQ).42IL0%]0114.$G8GD""%V71'22\_L5E#(H'1P85#(
M7488BSZ01DZQ24M,GA26&X3,S#'&1'E(!WE8D6R,3%X0B_LQ1UI9S R9S$3@
M3!K>T!]>1'W)'3XB#0MF10*%TT(T!%\LU=+=E=KE32?R50R9I/+X"D'^!,/(
MW6O R>_)RN'MA$EDA$Q22FWXA%+($H/DE!3*H6%\S-?8H6&)7P,>Q"3RQ^BE
M$ALF"I]T!+'!4A":DIP0B4-P("[6G+XP)7G4QFM,7,U,(\>(Q5G 3*#,(LS4
MXL68!"S)"M.EBE/(A-K0$)G@22"&QT@ZB*608R163(L<3&7^T%^43(V490QA
MM47R^9Z6Q9M]+29_N403>69J<&1H"D\WDN:9+-E\365]7,1Y.20D:69GK.:9
MF";S*$3NX)HA'L[N, X W=I+C.:C10ZB7<_N5(Z=U,[DX.;J2(X&'41MK,;7
MF&%.7%GR1-A)1)A//%^)K)!R6 0!^99R8 _YI$J[-- /_80GRAM]J,C4V,X8
M)HF*()K_21%1U$91A(\7.1SZQ!J4>)CZT$Z1J9$NT5UHAM-A6E7 (,YHL958
MO<-9K1);22A:8<L=S69H:M9I?J:&WA!*%I8&=LI6?A(D]M&%[D<.^H\ND&C-
M.:0?/=)]M>B^Q2C2=&9]Z&2TQ.;^''DH8E6C:OGH10Q.4>74*DZ%1* (3-W&
MD4J$2ND6BASIDS[$2@'7E%+I23U3E6)IEGY41VEIEWIIEG+IEX+4.RY4F4:4
M5X33<8T(\,F3/"V3.RG3,A&3,A&3I,6I<^%IGNKIGO)IG_KIGP)JH JJH!)3
MH2V3-9&/<K%30DG41($4,8EIE1XI2CEID=;4*M86;6EJ3^44L01549E6./WH
MJ%:5:*G5A*X5A3XH6K%J+!7EF>QH8=4HAX(FA\9$<-IJKM5FKFI'(N:7>O*J
M9=VD?^QJL.:8L?[7[2'KQ>#JLG+62AP.XAQ.XER$K@U.[%RK]#1KAQ+6E##*
M6\QJWSG^S1,F!58F!:J0J[!]SFV8$DQQ3*.$A-P,*R[V(T:"A5QPAR^:C%BM
M!@7*RTG,AT\=A#ZL1KO-Z'2I1>^%1/#!C9&:ARHR+."U#(84*]*XXE6NZ*-5
MK'VX%-0@*+T,SE!$A!69!XC>!>(T6%F!TF&"4J@<9B)AQ*802FNZ!.+,1\#T
ME8GJ!XHBV\#VW==494PD4E^%J[/>TL$:+9H@;=*^",@EJW$26]?U37U$3Y5T
M665$21%-A*'Q"5)6QGX&!G?5*N:$3VH6IW2<'6_<'>1L19D%AD^$T>81!)K!
MS-(."(W9AHG!$(L9#A5FR0!=Q6BZ[>-L+"&ID=+DJ-$5[NS^\$:F*4>*90D
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M'?%P=57^D5<D$E^H141,FT#T27O@%R[W#PXO27LTL:/%131N($) !P*[Q72
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M!' 3\WPY]IS[$K]]%$EIA*='D(^^T$F>@ <^TSZ*C!X(_5Z7"0W_O/X_ T2
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MEENJA*@$,S1"AH*H+*IW&@A*'S#Q*L&K518=2)?'\%R.K ;_@41"73:SE"!
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M!<#4FI[6QE4+96H^NKR#SWINV4)GQE XD(+,CO4X(\"W:2(EYK4*2R_/HZJ
M9F\6Y0^;Y"QV2J)AB*6]AA^#QU0X$V?WHHFI!D*"P"NP\BES,!P3XB8DJY5!
MNX<RAR<"6B9T>P2CPJD[&ZM#3E64&",N92#%68QS69QKFR82\5-FCXCS3Y)/
M(BK\#V-2DN\N>KCW(FG7R684QK,XEX6BF%4ZA6V^.Q&G\+8+V;9'Z3=W0RT\
MQB=$@I$)(V5M=*Q- F/(PE]R1&8R0@A#EXS<^Y./UYU,XK)J[K-3THE'9"F+
M^25.EE_^!ASJVH4B:TJ9+=.>)IT'V<^T.6.M@TM3!BM:R?A[=N9:JWP$(ZLS
MOO58-/5 \C1<MJDVTU"%D$5OU(,L&@=#3IB2E]SX^*V&4E>I&U7,D\3==J/4
MDCN'Z?C<&"))4*:,:M4X^,(IMB3=6T17H@T^, *!:9B-5,><@'PX=C3:7EAF
MWS<;A5&%44W>WRA[U6,]*X:S131 @42'*N- 7^+6$\2;#@G@\),[I^-%20-"
M"!I(OL-ZS[,W3G@15V=#0[@$#*-5(AYW;T2MYJ@@Q*1&)$4]IDU'(GY-6\\]
M3DU9Y(<TVD1_Y\-W5'Q/#*E.V50WH&.<U-3<PW?RS)B>K)O^= _S<WM<<^/\
M<Z_XSP1=<HU=3U"=4R>W=<7]*J2%MJR^N$Z"O7UKXD.+ESVKD2?&C&_\CFCV
MSP0K;L6KQFH,>P0+<5<,Q2Q&.H[EO.2%\%ELP+[);Q^B<!O?\1\?\B-?\B>?
M\BO?\B^_.S/?\!D_\-7JL/JV\!,W\5GLO/R>P$[?]/_+[V&LV/^+]1,,]D\?
M;_V^;! ?P60%L;)KQC:B;/)^N_K>]]]K^J0KU*C++]357#OMR)8_NIRK8 =:
M;)%+8J.VT;",@KX,8[.,)K%?[/FES?EED_/"MAK[S0:<=*%\9[M=T+#^ZLE>
MAKB>AY^D^T?:_>T-[>/?/=8^[;7^C/^Y?\L>%B#$$=-'C)C @@@3*EQ(+, =
MAA C2IQ(,>$J8KHP9L0(:94N71Y!?@S94=>=57=20DK)LJ7+ERR#W/E'LZ;-
MFSASZMQ9,"<D<30))M1',PBQG4AMBDL)U&80HO^6WB1VIVE-<9#^O2OX;NHJ
MJ#7UZ<KY[B/-ADEYBM/WCJ#-$E:M!NUY4Q?1K6#G=KVI3V[-LE#O9$U+N&9!
MO[J ;CUZ\TY7H3@-XGSG=^[8?ZL"%-[,62GCFVL[BTZ[JL'HG'UWYD6J;W5K
MPYI/!Q6]6K;MVS0#U,:-%"WOW\ )W[D<O+CQWP%6'5_.?'2 P<VC2]=I<KK.
M$I._!.C^^F[FV2\U']I.2;.$\K/G_]T!7S,V,>SA_\''[!X^2IOO&Z<_&[OS
M*O;_$)/>*@-Z1]-)N>V%&8&,9<98"8SU5]YG_T13@H('&HA;?NII.%,)T=#T
MA8%416-@<@>>AV)[&OXSXDV96;?3%RJV**&,,-XXFGFYV?B@=Q<&Z)YFZ]5$
MHTW1Z+A90Y^50".!2KIH(X&K8!A B)/%YB1-,;X30(/>;3>5>02^:&&%*^8D
MIHR^;882B5^^H]U>W7VI4Y+K[?=/ /,5V29^=TAXWYX8VH2@C(%2J%6:@0;@
MZ)KM/>H0FIFM6>FCBM:TRGQH.HHE3FE*URBDF3EH9 F!%KK^J*.?2>JHIICJ
MU-!%-L6H4ZB=G1F9=CD%RBE]&G;W1:9<$E@KE<862VR%R?[%X$Z#XM@>A9 <
MI1NH3BU;F#X-H$1A$(8:6%UNYWETDY<'#J8/I%2%Y9!)Q/UYFFE!:4@,N#1Y
M"=6]-(GSZ[I'E18>=/\859,N7PH(%GF_<?M0 V#IUB:Z1>%$GCC]V9JANUOI
MHJ#&TN*D3PFK18GC*OC:!DD XNA"\D[BT'O58)!@A_ _^J3\E\EI =SKLM'^
MTT  #60*J:&7^;RF;]?^,VY.&./TTTXLXR@O8?S^;).=D040!'$TC91R$!++
M/)7.50NITW#2&EQ3$ 3C')ZB>3W^Q19LLX7=8K\=B0MA4K@RM]^U#75%#+U<
M[RF79#05[318?SL--DXR]<JPFI-S1G%X>_<K<[="'L6D>H$IFE%-H%=;D^H#
MT01)W/H8> >]A^M-7>?6K3DR5$VO3J'CLN5\>,IPA<MY>\JUB]_+0K?ZV=,K
MHS[8U9TE_A2@L!I&K\Z-[W5'RI<7_!GH0@86]VTK.128]R5\5$)LJMOT^EDI
M@XSJ\5$%<!G((1NV<MP\LX[ <(,JX.GD>OU"F<RH<A2IH,QMU"L,QC(E%9T$
M+3QIRPVQ$O><B6E&8Q$LF(+T4;/$@6HWS*E=9Y0'(QME#C_ZFQ!F=)89[N''
M;)5SFMG^#'6^Z+@-,PW(R/?.AI15G \2F=LAWV8(F@;@;D]ZFD[6A 0W%KWM
MA8W#R=,P0K9,S0XE0: 3N*)W*RP29G/R^5I*5J-"]<0F,[H(X[EZF"V<*/&)
M9_G<0Q H-3Q&AVMYR6" 6O3#T0 O4/^(7WC2$[.@; \_D( *459"/^SQ!RKC
M"J%PTG,Z2S:.,8)QVF=&1J$V&;!Y;S-0 YH2RM\P+(X!.N*UNB._]!!E34.T
MHNW*XQW^]6]K-PG@= 88O#5-BB]R[-5^1@84C*W%3FCLC,]NHL1:V9!+8(L2
MVX0$E(PA#BJ4] D63=:[WA3D*[;1I*RXAQ4U:0MU!2N!3!S^)4<[33 G;;0)
MMRIS(#,NYX?WTZ!-JFF87U&E-E6QF!/O4 (G%NI0H(JB#T<HIB"D[##$;*'(
MKKFGDC&&22MI34J6%</3;&YT](E,2A &RDCRR6)TS)EKRGD@CJK'ED_)##\3
MZ4?FQ/$.M>D=QE932-K())2Q.YNY^I62Z\6/6_(,0D/W=53\!*%;4'F'3$H
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M[[X.7.O1H59]Q.S>'2ANE:Z1^B"M.OM/WQV<J^[:??N/F$RX&,F*@S20&,;
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M?1QQ(U9L"22 B!PT*J]CXJ"C9/RG1B<U!50RLYD8B;.N)<[^Z9%)' EITO5
MH=5Q1BD<#/=FET0[FH297Y/97H2F-C!E*86/%.!(LDC & )K1PUXR^P\0DF(
M_$2&?#D(.>T6PXS\<2'/#" H0Y*88:('3$!BR021([/Y-25P3H&,18;(1J'
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M*/6A7BQR#5!TC<IQC.N,B%5Y+?9BMOB^SEO"JIA&8DT=;#@%B[1@%%]=;[4
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MEQ%^[$! EK)N!U.P)LI\3'>HGMR5H+^JXOL9Q&AA8$F@A9U%&<<:ZZ2:S'#
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M(1\%^1W$*CI&?YK5"W+KU4S&U\TK>(:<$0;&7-C%+%N$=S'^\+L617OHY](
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MSL(2T35H@=4CK]' U+BV >XJ-_F,>..F4\PT"$7:M1S?#->8HP3N>0OY0D7
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M[&HVCNZWA&>H2B]M2LNW6.2^+ *1M$L290]=+I%B3E%$] &3.F,XZ =\1*1
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MB=?:&*<$"2R]ZF<M4<KM_N5\?(,5689/D>=^@L-T4!=U;_,4;',5FS(3VZ-
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M%VXM6$#^+/4M'G(DG==DFS@14C(1]/1S0: 14G(\6M1?\0)K,J$@=\(2N")
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M((V0O3 Q#YD[(,$8"EIB&<"I'^]#ILP*2IAX/3Z2#[@P2WFY.1RSO4'2(/K
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M61&2C_3S0*DQLH!!8X^;GU%H%:V*K'@N::I.,.FOB9C N#2;A0V/ LV)TPQ
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M8A*8&EIA+E4<1&&K-K="3<V.467^8<N.+D*YB?R(-L>!A*M.9"+1+"X(F F
M/FRHN9<$(2F!6042%=* I>3J<G%)UC_*=)'W"(:)&Z'<B-A2D/88QHC>V5)*
M;#@DBL!'<,U946!8M+@DF0AC3N'B/QI0$Y==9$8IJ4FG[O<FS.11<<R:5!_-
MLT=:X7!(-HR)+E#"2 5E$2R/,X\50\(42)*1?K'2"[/.=$*]A"J+58R0O2PX
MQ-714#CBH*$^QGA#"Z9(,JQ44"O%J$EBA'(5W*%(K(+(*&B9$DD2X:(XKD3,
M2]:02MO1"RH30C6FK(B1W-%)5V"V04E29T0G2F8#E',C)'VF ;TA1MAL11&M
M4>D=0JO^#(]TP:PZ"JF%5-&1:"!1LP8(<IGSF\C/$+F;<&I$'S&KR9F61#,;
MZJ.>L$0FT#2T"C2],S%\^X\,:X23ZZ%J(Q*%"T)6LZ' F(H@89DC<5:!%'V2
M[RL7^<)%92(<Q'!%-"G=IU=BXCSFB24L/DF)E,ZG4HV61DZL>6)GJ$2<LF3*
M56!2GF@(Z:G\N,I^\81+2[P'%9EVKR8@&4L%,Z-"Y&@$A R$'JUR11'HL2HA
ML]K-5F[R0"!IDBM;"6#X-@@IRACGKG@A2L].8Q+)W$Z/3P'I6YE"T3<A[Z3D
MD:"N.,*_?0Y%GSG!309[5D*O J:$W1D23!KRE8Z");/UF\C^4H!70JBJQ3.Q
M.NUU/,G5R_P#(FQAT-_"<B0!UM:37#D@078:44T%*2$-F$T#;&B3XL)PJMS\
MI1TSDY6_E*U:.$22?0* 0Y1"DHM)4N0UJW+&9DXFB]X-J5@FDY4WBN6'F#G3
MKHSD&^;H CQ$+*I"B$@3)VZD0N"Y3UA$V4P:E<69.-4;S>AW.*E6)4@Z*J%A
MFYB?[RBGCN)@8IGP.<F,G FNO0R)#:&[$>EBQ)&9:A.#)_.C@(9$DU'LB\CP
MRLS@["1#U<V,BZW(X9,D*;V"?=21+ G7Z@ S3%OR## E5+.,])".LWD'U?3[
M#R9-A,;(]% 0K@GD-YWI(JPD7P/^?I2D"@/W(O?LZJ*JBQ_%G-C)JCVP7&BT
M(#%?6!?"U0B0WQ%G CI4MAA!I9K$1,L+TWB<%9:Q_3!S7CK:![[2^^E48S*W
MYH89/F)F)HM8,I BJ0625RUJ5E3,&,UQA\%7]=%"-$11$9F(/6>N'_E,M<N,
M?D\MQ14+Y7:(Q_ 82,-R[J+B0H*6-;_)D8$D55.I DQ =F0I]2'L*"LI2RI:
M>3'.SDBMGW+%D. PV("1=0TI!\Q$*T3#1WY,@;Y5YL14V#H>#,X=,Q)EED2Y
M1_P1K? NB62W;+L\G6;EAYU,H'22*$XH.6]:EC2BG6F2HMD^=Z/L31 F5C/+
M$,6(B C^6 )\0W6RCB1N09S8VE\7MK7N7HAHE")(5N9GB7EV$.5</=-G/A7?
MU[Z41YZZ"K2>$+F,F15Y.V(4IUB(+G0R44>$1RL+">@BLR)K9F]CE W1RB@T
M<EYG!!AUFYL(A!?$H-93LNC2V/0=FW'L6; >=<Q<<#).5Z#U6A5 H_M<5!^_
M#8RSRANK^WKL:I%ZG"PR0.!$9"<6V4VNE(<HW]'*>/I<JD)6.I"5ZA.G]1O?
M;!03)Z 19H-,ITY>BU/2_Z8)3[L)+-;7F:7_=:1Z(04:WTB<;Y3/AK-AOTK+
M>YW$ANBTP.9SN0%7HYM87?9["=-@7CE/D*VLJBY>J<UFKF[^$P;6I"VC:OT^
MBS,JKESE3AF9*TN<RZJ6$+!3N/-I)372P+0Z][4N?+7Z@P-M]E,EC>]'L-SE
M;YP>N7"US1&1C^%RU5/1_SC4K3HP9,#X[U8@Y%;<+W&^(RK0;>*,(_^6!5K:
M8T .Q#9^I3T$1#[PX]:*A;Y 2AS"Z@X\!*%TP2G$X:!R*4*$1=!B3G*@!@9C
M4 9GD 9KT 9O$ =S4 =WD =[T =_$ B#L =SIV?VXB0&[V>@)'=\PGAZ)'MN
M(GOV @IOPGB@,$HLJBCN3@NWD N[T N_$ R-(H(*@@PEZR \HB#VQ'D"A4X
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M]&8"]R-9E&T^E460SA$28_C]9KB/Q8*/ 4=ZU^-7&_ 9;^6%TRUGH^-/;\5
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..LB-;LB>;LBL[<0(" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image27.jpg
<TEXT>
begin 644 image27.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B JH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#^7E;E% &'Y/B7_H(:'_X)[_\ ^7E5;Z+Q']BO-U_HFW[)<Y"Z1?@D>2_
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MZ<()RG.<I*,8Q3E*322;:(O)\2_]!#0__!/?_P#R\H\GQ+_T$-#_ /!/?_\
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MJ<GO0QF7\'\&8C(IY7B')WGA,YXRXSRZ2@HU*-6G*=-_GLWP"_:$^)4K3?M
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MS$J$9 D(/((BEP1Z_<H\U?23_OU+_P#$5^5(_P"",'[#6.=/_::)[G_ANO\
M;6&?_,\UH:3_ ,$=/V)-$U73-9L-/_:2%[I.HV&J69N_VW_VR]1M1=Z==PWU
MJ;BPO_CE<V5Y"MQ;QF6UNX)K:XC#0SQ21.Z-^+3R'P(4)NGXF^*4YJ+<(S\&
M.%X0E*WNQE->.-24(MM*4E3FXJ[4)-6?HJKFE]<%@;=;9E7;MZ?V8K^EUZGZ
ME5^/WPYTWXV_ O\ ;J_X*4?&2[_9K^,GCCP1\<HOV5#\'M8\$+\-[F#QK>_!
M[X':[X.\86BIK_Q%\/7?AU8/%-Y9Z797_B>TTFPOHY6U.TFGTR&6[3]@  .!
MZD]2>223U]R>.@Z# K\\?B)_P4L^ /PH\??'WP=\1/#_ ,4/#&@_LQ>)?@3X
M;^-_Q5NO#'A_4?AMX&/[1ZV9^%FOZE=Z+XPU+QB?"FHR:A8Q^(O$D7@M]-\$
M)<?;?&$FCZ9!=7T'X^>@?,WA+X'_ !FO_P!KOXHZ]\?OAA^T'XNB\-_&+XA?
M&;X3_$+PAXC^ ]S\ O%WP(\;?!2U\&P_ /Q3%=_9OC9KE_H,][KO@:_^!GB2
MV7X7^)O%6D^&?C'9:K8QW;W6A>6:S^RY\;?!7[,?[<'[.WAGX#>-_&4GQ*_8
M6^('A?\ 8U\=)K?A>3Q9\+M%\:^'/'\?@W]@WQ;XBUCQI8ZVVN?!3XA>([3Q
M#X1^+EQ<3Z'XK\(ZW::5XV\9MKWPNTK4?$G[&_ ?XZ^&/V@?"WB?Q9X8T7Q'
MH%OX3^+WQN^"NJZ=XJ@TB'51XH^ OQ6\5_"'QC=0C0]7UW3Y=%O?$WA#4KO0
M+I-0:>[T:XL+F]M=/O)IK"W]H26"4,8WCD".T+E,.$="5>)BN=KQL"KH<%&^
M5@#Q0!^1'@+X<?&/4_V@?'=G\2/@#\1&\50^.[7XO_LL_M61ZWX0M_ WPD\$
M:Q^R_P"%OA4OPO\ &VG:7\1[#QY/J7@#QK-\0(=:^#%]X.\3_#/XD:CK.B_$
MZ2]EU=K[4_"OR+\6_P!E+]IKQW^R9K6F^$/@YX_\)_'@?\$Z?C-^SO\ M >&
M+/Q'H5O)^T'^U!JQ^$$/PK\9:3XN/C6RTKQM>Z%XS\._%3XD:/\ &W7-0TO5
MM.\+^/Y/#NL7MKJ^N^(/#GAW^C/?'E>1E@0N <L  QVD#E<8.1D8P::\MO&@
MDD>)(Y&10[%51WD8)&NXX#-([*D8R3(S*J;BP! /S\_9<^%GC+X;?M7?MM:A
M:_#W5?A]\!_B.?V<?&?PNA$>DV'AO7O'<7PZU[1OC=KMKH>G:G=WNG>*;O5(
M/!5OXRU76M.TVY\5ZG8#58;S7Y;>^U(_H341DA218RZ++(&*(2 [A N\JOWF
M$89=Y P@9=V RY59HG+JDBLT;!) IW%'*APC@9*N497V'#;&5\;6!(!)17.Z
M[XM\->&;GPY9Z_K>GZ3=^+_$,/A/PO;WUPD$VO>))]+U;7(]%TJ-OGO=1.CZ
M#K6J-;0!W2PTK4+N39!:3R)9TO5+J\M9[C5-(N_#\D>K:MI\%MJ%UI=S)=V=
MEJ]UI^EZO%)I5]?VZ6OB*SAM=7TVSN)8M5MK;4+>SU6QL-5CN;&$ V:*B,\*
MR+"TBB5EWK$3^\*;E0R!/O>6'=$9\;%=U5F#, ?#/V;OV@_"'[3OP;\'?&SP
M7I7B/P]X=\:S^*K?3-&\8P:39^)+6;PCXR\2>"=4@U"VT36->TH3#4_"^H3Q
MBPU?4(C9-!,9LF14 />**KW<\EM:W%Q%:SWTL,,DL5E:M;)<WDJ(6CM;=[VX
MM+-)[APL,37=W;6RNZF>XAB#R+\__LL?M+^!/VN?@3X&_:&^&^E^*]&\!_$.
MVU>]\-P^-M.TK2/$$MCHNO:IX;N;N]T[2-<\0VME')J>C:@EO%+J1N6@A6XE
M@A26/< ?1%%1M+&KI&SJKR9\M"<.^T9;:I^9M@(9\ [%(+8!S4E !1110 44
M44 %%%% !1110 4'^H_GS110!^6/BKX4?MZ_M3ZIK.B^.]8^"'[&_P (M$\8
M>,])\->(?AEH,?QW_:O\7>%-.\7:_H^@>-/#GB[XCZ#I7PE_9BU;Q9X3ATGQ
M%!9Z9X0^/WBG0KB^22#Q)X>U:$P6?Z*_#/P./AIX \(^ 5\6>./'2^$M"L=#
M'C'XE>))_&'C[Q(+&+RO[7\6^*+F"UGUW7;S_67^I2V\#7$I+>4@PH^9/VF?
MVE?&GP0\>_#SP;\._AWJWQV\<_$CPAX\N?"_P/\ ".EZGIOB;4;[PQJW@R*?
MXC^(?BC>6USX ^''PC\#6VO_ &3X@77B6*Y\5ZM/XB\/VGPK\/\ CSQRFG_#
MWQ7[%^S?KWCKQ-\'/"VM_$SQO\._B'X[O;OQ;_PDOB3X3Z1K&A_#Y=1MO&GB
M*T;PWX<T[Q#?:AX@B@\$0P0^";V?7;D:U?:KX=O[_5;:PO[JXT^T /7==U0Z
M)HFL:R+&\U0Z3I>H:F-,T]K)+_4386<UV+&R?4KO3].2[N_)^SVS7]_962S2
M(;J[MH!),GPSXP_X* _#;PQ^Q-\(?VS9-.L-'TCX]>!_A-XI^%?@?XF_$;X?
M?"-]5UWXQ^%[/QAX7\%>(OB1XRUB#X:^$M6@T.74+C4]1U/77T?SM(NK/2[G
M5+RYTV"]^WO%,-[<>&O$,&G6OV[4)M#U:&QLO/AM?M=Y+I]Q';6WVFX9;>W\
M^=DB,\[+%$&,DAVJ:^%/V?OAG\;_ (&_L+?LC_L\:M\&OA[\4O%/@/X!_"[X
M%?&3PUK?Q,L=)\(PKX,^&NF^#=9OK2[N_ 7BJR\:^$];U#27AO;"?3--U'^P
M-1$YTC4+I+G1P =O>?M;:IH>BV,?B7X.^(;/X@^'_@5:_M%?&GP!H/BKPSXL
M?X5_#R[O==T^SAMO%6E^7X?^(/BG6KGPIXP/AC1?#,D5GK\'@[Q%+'K5HT>C
M1ZW];^'/$6B>+_#^A^*_#6I6^L>'?$NCZ7X@T'5K-F:TU31=:L;?4]*U&V9U
M1VM[ZPNK>Z@+(K&*9"RJ20/RV\#_ +#'Q%^ ?A#5?"OPFNO"/B"/XA_LB:/^
MRGJL.L:GK.DZ)\*D\'>-OCKXO^&=_P"%H;E-6U#7/A?\/M*_:&\7>!=*\)%[
M+Q+!X5\#_#O2K*Y2WFU*?0_T@^$?PXT?X/?"OX:_"7P]-<7&@?##P!X,^'>A
MSW>W[5-H_@CPUI?A?3);G:2OVB6QTJ"2?:2HE9P"1@D ]#K\-/VRS_QO&_X(
MM_\ 9%O^"HO8C_FF7P/]:_:GQ7X0\*>.]"O?"_C;PUH/B_PUJ1MCJ'A_Q-I-
MAKFBWQL[J&]M#=Z9J4%S9W!MKRW@NK<S0OY-Q#%-'MDC5A^"7[3/PA^%/PY_
MX+?_ /!&^U^'_P -/ 7@>VUOX*_\%.AK5OX1\(Z!X=AU?[!\,O@V+'^U(](L
M+1;\V8U"^6U-V)3;K=W"Q%%F<$ _H/HK$_X1KP[_ - +2/\ P76G_P :H_X1
MKP[_ - +2/\ P76G_P :H VZ*PSX<\.#KH>D9P3C^SK0D@=< 0Y./85\Q?%C
M]J+]E/X-Z^G@GQ3XH\.:O\3+@.+'X0_#KPSJ7Q6^,-^XA6:(6_PM^&^C^)_&
ML,$X>-$U#4='L-*1I%,]_#'N=>7%XW!X"E[?'8O#8.CS1A[7%5Z="GSRTC!3
MJRC%SD](Q3YI/9,]SA_ACB3BS'K*N%\@SGB/,W1J8CZAD>68S-<8L/12=?$2
MP^"HUZL,/034JU>452HQ]ZI.,=3ZYICRQQJS.ZJJ L[$@*B@%BSL>$4*"2SD
M* "2<"OSR'C3]K;XR;5^$7[,WP__ &<?"5U]E:+XB_M7W%EK_CQK*Y7$UYHW
M[.GPBU6[99XE.^VM_B#\9? ^H13;%U'PZNR2!ID_8(\#^*ECUS]K'XK_ ! _
M:7ELP;F3PQXQU&Q^&?P!TN0."WV'X'?#7_A&O!>I6(B7RB/B7>_$6]>,L;G4
M9G<O7E2SJOB(R>699B:]-1<GC<R<LER^"BN:3G/%T9YE*+A[U.MA\KKX:HM5
M74;R7W$_#W(N'8RK>(7B#P[D+I+FK9%PE4PWB+Q2J;BVJJADF8X;@?".C-2A
MCL#G7'V3YS@N2;GE52<52EW7BS]O3]G_ $O7KWP3\-=2\3_M)?$JP>**\^'7
M[,_AJZ^,.LZ7<23FV^S^+/$VA2Q?#/X=/%*&\Z3XD>//"442*[LV%-?'?[8>
MK_\ !5;XR_ +QSHOP+^!/PK^$(\<6-]X(E\,>(OBIHWBWX[0^$]?L-0L]?\
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M$+=7[MV]6VTK?DQ^WK^S/^T'\0M/^'E[H.MZQ\8K7PQ%XSNM7DO['X<>#_\
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M#P]^PR_QI_;;_P""BNM?M'?#/QE=?LY?&;Q-^P_XF\":==>*;;3OA]\:+O\
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M(_%GB'Q5XM^-&DV]@)-7\4R36.G0_P!+F!Z#@Y' X/K]:-J_W1^0]<_SY^M
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M+W_P7Z-_\@5S'2;]%8']E:K_ -#)>_\ @OT;_P"0*/[*U7_H9+W_ ,%^C?\
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M3;[OB:[;_=L-%/\ *P-._LK5?^ADO?\ P7Z-_P#(%<91OT5@?V5JO_0R7O\
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MEEYQOXS:B<6]V8@#^AFBL#^U=5_Z%N]_\&&C?_)]']JZK_T+=[_X,-&_^3Z
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MX7BO(?&EM\-/BM<>)VL6NCXAUCPCXX\$Z7/;SV&D+I6J3:#:>(;K]2G\<?\
M!4GX9+<R>)O@;^R9^U)I44JQQ:A\&/BWX]_9M\>7$"F7,T/PX^,WAOXI>!)K
MB1%A_P!'D^.^EPK,[@3F(!Q]R^%M3U-/#/AU4\/WDJKH6C!9!?:0@<#3;7#!
M7OE<!NH# -@C(!R!O?VKJO\ T+=[_P"##1O_ )/KU.._I%\8^*G%V?<:>*'#
MGAUQQFW$6.^OYC+&\&8#AVO.K&%&AAZ?]O<"U.%.+J]#!X3#X;!86EC>(\6H
M83#TJ4W4Y6Y1A<HP^!P]+#X*MB\-3HQY(<N)G65KMR?LL5[?#IRDW*3C1C>3
M;5KGP"W_  4>\/>"7FA_:-_99_;0_9L6QB4ZCX@\5? '5_C+\.K63]TKR2?$
MW]E34_CWX1LM/#R_+J.OW.@PB-'>X6V*,B^^_!O]M?\ 9&_:#GAL/@M^TG\$
M_B3K4JDR>&/"_P 2/"U[XQL6 8M!JO@J74K?Q?I-TFUO-L]3T.TNHBK+)"K*
MP'OW]I:ESCPU>*6ZE=0T96/U9;\-^M>!?&+]F;]GG]H6/R_CI^RU\)_B\RPF
M""Z^(O@7X;>+=3LEV.BOIVL:S;7>KZ9/$LC^3<Z??6UQ S%X94?YJ^2_M7PC
MS=6S'A+B[A'%UE^\QW"O$F#S_),')123PG"7$V6T<YQ$7)N3CB_$A2222JZM
MF_)CZ?P5\/B(K:->C*E4E_BQ%&;IJW>.#^1].>8G4G;DX&\%,GT <*3^&:?7
MYAQ_\$X?AYX-:U;]GCXE_MD?LKK:2F>#2O@[^T_KWB'P'#*9$E A^#WQ[U+X
MT?!^VM@4\LV6G^"-/MFA9X]J[@RS)\./^"HWPXBF;P'^TA^S]^T7I\<FZ+1/
MVGO@?)\)?&=U#&C;(&^*_P"S5XTE\*1W$[!!)=2_L]M&K,\ODX"PU+X,X'S+
MW^'?%3**7,^2AEW'7#O$/"F<5ZKDXQBJF28?C;A+"4VE=U\QXPP5**:]HZ:N
MT?6,3#2M@:C[SPM:E7II=[5'AJ[?E##R?:Y^FU%?FR/VN_VQ_AY#<3?'+_@F
M]\4-6L;-%6;Q'^R+\:?A!^T9I+OYA0SKX5\=ZA^SQ\5WB9 )_(TKP'KUTBDQ
ME9' +V-*_P""J_[&K7]KH7Q#\?ZK^SCXMNA$J^#?VM?!7C7]EG73<RI&RVMM
M>?'#P]X,\):K*6D6.-M$\4ZG!.P8VTTR .<ZO@_XC.$JN5<-U.+:%.#J5\3X
M?YCD_B+AL'!14W+,:_ N8<0TLLM&2E)9C+"RBG[T8O0:S#![5*RP[>RQ<*F#
ME)_W%BH47/\ [<YO(^\[?_D=M3_[%;1/_3QXBKJZ_ SPW_P</?\ !-'7OVN]
M7_9XA^)>O:9??;9OAY:_&+7]-\/Z+^SW?^*/#=]K<]VEM\4;WQ2D<.@WMU++
MI>D^,-2T33_"&H7EN;J+71HUYINJWOV+/_P55_9L\03RV'P"\/\ QP_;"U2&
M<02I^R/\'/&/QA\*0/DJ1>?%XV7ASX&6:[AL$L_Q/6(L<ARO)]K.?H[>._#E
M;+Z/$'A#XAY)_:>4X//<-B,VX4SC+\#'*,>YQPN88W,<5A:6 RS#2E3J1J3S
M+$X3ZO.$HXA4I*QG3S;+*RFZ6/PE3DG*G)0KTY3]I&S<(PC)SG*S32A&5T]+
MGZ74A95QN8+DX&2!D^@SWK\T[GXX?\%*/B@YM_A)^Q=\+?@!H]RZR6WC#]L'
M]H'2]8\36EHRADFD^"G[,MA\1;6[N&4AO[.U#X[^')T<-#<R6[@E<^;]E/\
M;$^)8N3^T#^W=\9+:PNGCFE\"_L>> _A/^R[X04DYELQXYU^_P#C;\?Y;8*3
M$EWI7Q2\*WD@Q-MMY/E7REX;8/+9+_6WQ$\/^'96C46"R_.:W'N8XBA>//\
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M\'WOB>(V6F>*]+U[1_$-M<WN@W&LZF_A_7K""'4;9-0>SU1-7TVVL+6Q_6_
M['?1&Q/B-DT?''AKQ5RCP_\ JN:2S;$91QI@,_4L<\#6664ZN7Y1P+P]GM+
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M ,XV@#]IZ*_%C_B(<_X(_?\ 1VUS_P"([?M5_P#SC:/^(AS_ ((_?]';7/\
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M^S3HO@'P?\1_%D_A3]O3]C3XJ^+1\*]-O[SQ7X8^&OPH^,>D>,?B!XOT^>P
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M?V8/V./@#XN^%'[5GA3X.V/P'^/GP)^)>C?L[>#O!6J_$[X7?M47WQ,\-_\
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MST[4NU<@[1D# .!D ]0#V'L* /P2^)&A_%[POX/UGXL?"OP_\?\ X->&==^
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M\-O&-MX\L?B'JBZ?XE\;-XYUG5_$.DZ$FKV6H7&D:3=:';ZOHLEI)%K7GZ<
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M@WQ)X&TNXU?7_#^HZ3<ZS#K7B?P_K>@W6DS 'Z39!R 1D=1Z=^?3CFF"2,G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827679376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information Document - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 26, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LEXICON PHARMACEUTICALS, INC./DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,591,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828142928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,661<span></span>
</td>
<td class="nump">$ 46,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">249,127<span></span>
</td>
<td class="nump">299,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $4</a></td>
<td class="nump">4,825<span></span>
</td>
<td class="nump">7,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,948<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">321,995<span></span>
</td>
<td class="nump">357,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $58,623 and $59,875, respectively</a></td>
<td class="nump">17,687<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets</a></td>
<td class="nump">51,885<span></span>
</td>
<td class="nump">53,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">436,539<span></span>
</td>
<td class="nump">475,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">57,652<span></span>
</td>
<td class="nump">52,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">12,282<span></span>
</td>
<td class="nump">32,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">40,099<span></span>
</td>
<td class="nump">63,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of deferred issuance costs</a></td>
<td class="nump">14,094<span></span>
</td>
<td class="nump">16,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">124,127<span></span>
</td>
<td class="nump">164,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">22,428<span></span>
</td>
<td class="nump">48,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="nump">231,576<span></span>
</td>
<td class="nump">85,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liabilities</a></td>
<td class="nump">6,014<span></span>
</td>
<td class="nump">18,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">384,437<span></span>
</td>
<td class="nump">318,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 225,000 shares authorized; 105,711 and 104,582 shares issued, respectively</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,435,526<span></span>
</td>
<td class="nump">1,411,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,381,404)<span></span>
</td>
<td class="num">(1,250,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 122 and 306 shares, respectively</a></td>
<td class="num">(1,904)<span></span>
</td>
<td class="num">(3,368)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total equity</a></td>
<td class="nump">52,102<span></span>
</td>
<td class="nump">157,401<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 436,539<span></span>
</td>
<td class="nump">$ 475,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814037360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 58,623<span></span>
</td>
<td class="nump">$ 59,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">105,711<span></span>
</td>
<td class="nump">104,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827894080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenue</a></td>
<td class="nump">$ 15,890,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborative agreements</a></td>
<td class="nump">74,267,000<span></span>
</td>
<td class="nump">83,182,000<span></span>
</td>
<td class="nump">129,728,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Royalties and other revenue</a></td>
<td class="nump">178,000<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">90,335,000<span></span>
</td>
<td class="nump">83,337,000<span></span>
</td>
<td class="nump">130,014,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of Goods Sold</a></td>
<td class="nump">1,899,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $4,905, $3,938 and $3,693, respectively</a></td>
<td class="nump">156,813,000<span></span>
</td>
<td class="nump">178,151,000<span></span>
</td>
<td class="nump">95,187,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
<td class="nump">2,101,000<span></span>
</td>
<td class="num">(703,000)<span></span>
</td>
<td class="nump">5,927,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative, including stock-based compensation of $4,567, $3,514 and $3,150, respectively</a></td>
<td class="nump">66,203,000<span></span>
</td>
<td class="nump">43,044,000<span></span>
</td>
<td class="nump">23,835,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss on buildings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,597,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">227,016,000<span></span>
</td>
<td class="nump">220,492,000<span></span>
</td>
<td class="nump">128,546,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(136,681,000)<span></span>
</td>
<td class="num">(137,155,000)<span></span>
</td>
<td class="nump">1,468,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,984,000)<span></span>
</td>
<td class="num">(6,567,000)<span></span>
</td>
<td class="num">(6,722,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">1,954,000<span></span>
</td>
<td class="nump">2,293,000<span></span>
</td>
<td class="nump">572,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Consolidated net loss before taxes</a></td>
<td class="num">(141,711,000)<span></span>
</td>
<td class="num">(141,429,000)<span></span>
</td>
<td class="num">(4,682,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="num">(12,661,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (129,050,000)<span></span>
</td>
<td class="num">$ (141,429,000)<span></span>
</td>
<td class="num">$ (4,682,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Consolidated net loss per common share, basic and diluted</a></td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing consolidated net loss per common share, basic and diluted</a></td>
<td class="nump">105,237<span></span>
</td>
<td class="nump">103,863<span></span>
</td>
<td class="nump">103,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">$ (27,000)<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="num">$ (156,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (129,077,000)<span></span>
</td>
<td class="num">$ (141,405,000)<span></span>
</td>
<td class="num">$ (4,838,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811343152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss Parentheticals (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 4,905<span></span>
</td>
<td class="nump">$ 3,938<span></span>
</td>
<td class="nump">$ 3,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense', window );">Stock-based compensation expense associated with general and administrative expense</a></td>
<td class="nump">$ 4,567<span></span>
</td>
<td class="nump">$ 3,514<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828391568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2014</a></td>
<td class="nump">$ 284,018<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 1,390,619<span></span>
</td>
<td class="num">$ (1,104,252)<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (2,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(357)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(4,682)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,682)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(156)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2015</a></td>
<td class="nump">285,850<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">1,397,646<span></span>
</td>
<td class="num">(1,108,934)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,452<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">6,125<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,124<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(141,429)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(141,429)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2016</a></td>
<td class="nump">157,401<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">1,411,222<span></span>
</td>
<td class="num">(1,250,363)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(3,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedtoSymphonyDesigneesShares', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
<td class="nump">10,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,499<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">5,486<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of Treasury Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,679)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(129,050)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(129,050)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2017</a></td>
<td class="nump">$ 52,102<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 1,435,526<span></span>
</td>
<td class="num">$ (1,381,404)<span></span>
</td>
<td class="num">$ (222)<span></span>
</td>
<td class="num">$ (1,904)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedToSymphonyDesigneesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the shares issued to designees of Holdings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedToSymphonyDesigneesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedtoSymphonyDesigneesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedtoSymphonyDesigneesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814114848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (129,050)<span></span>
</td>
<td class="num">$ (141,429)<span></span>
</td>
<td class="num">$ (4,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,399<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="num">(703)<span></span>
</td>
<td class="nump">5,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">7,452<span></span>
</td>
<td class="nump">6,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">(12,661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="nump">166<span></span>
</td>
<td class="num">(4,080)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,948)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(557)<span></span>
</td>
<td class="nump">6,259<span></span>
</td>
<td class="num">(5,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase) decrease in other assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and other liabilities</a></td>
<td class="num">(7,172)<span></span>
</td>
<td class="nump">27,650<span></span>
</td>
<td class="nump">6,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenue</a></td>
<td class="num">(49,779)<span></span>
</td>
<td class="num">(73,344)<span></span>
</td>
<td class="nump">171,353<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(185,394)<span></span>
</td>
<td class="num">(175,628)<span></span>
</td>
<td class="nump">184,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(267,873)<span></span>
</td>
<td class="num">(425,673)<span></span>
</td>
<td class="num">(326,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">318,623<span></span>
</td>
<td class="nump">444,156<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">50,522<span></span>
</td>
<td class="nump">18,252<span></span>
</td>
<td class="num">(117,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of fees</a></td>
<td class="nump">7,987<span></span>
</td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(1,679)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt borrowings, net of fees</a></td>
<td class="nump">145,905<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings</a></td>
<td class="num">(2,280)<span></span>
</td>
<td class="num">(2,016)<span></span>
</td>
<td class="num">(1,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">149,933<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="num">(2,032)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">15,061<span></span>
</td>
<td class="num">(156,389)<span></span>
</td>
<td class="nump">65,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">202,989<span></span>
</td>
<td class="nump">137,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">61,661<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">202,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">6,050<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Common stock issued in satisfaction of Symphony Icon base payment obligation</a></td>
<td class="nump">$ 10,499<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedToSymphonyDesigneesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the shares issued to designees of Holdings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedToSymphonyDesigneesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84241808&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818663824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OrganizationAndOperationsAbstract', window );"><strong>Organization and Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, its ability to successfully commercialize XERMELO (telotristat ethyl) and any other products which gain regulatory approval, develop and obtain regulatory approval for its other drug candidates, achieve milestones under its collaboration agreements, establish new collaboration and license agreements, obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OrganizationAndOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OrganizationAndOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631771056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation:</font><font style="font-family:inherit;font-size:10pt;"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash, Cash Equivalents and Short-Term Investments:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory: </font><font style="font-family:inherit;font-size:10pt;"> Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.  The Company began capitalizing inventory during 2017 after the approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO were recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.   Inventory consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:580px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:434px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;In 2017, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">82%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;"> of revenue, respectively.  In 2016, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2015, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of revenue, respectively.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, management believes that the Company has no significant concentrations of credit risk.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information and Significant Customers:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2017, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Sanofi</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">Ipsen Pharma SAS</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Ipsen&#8221;) represented </font><font style="font-family:inherit;font-size:10pt;">64%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;"> of revenues, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">Sanofi</font><font style="font-family:inherit;font-size:10pt;"> and Ipsen represented </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;"> of revenues, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Sanofi represented </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of revenues. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangible Assets:</font><font style="font-family:inherit;font-size:10pt;">  Other intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, intangible assets relating to XERMELO of </font><font style="font-family:inherit;font-size:10pt;">$24.7 million</font><font style="font-family:inherit;font-size:10pt;"> were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the FDA.  The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> in amortization expense related to this asset, which is recorded as cost of sales in the accompanying consolidated statements of comprehensive loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,247</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment:</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During 2015, the Company determined that its buildings were impaired and therefore recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in impairment loss on buildings in the accompanying consolidated statements of comprehensive loss.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairments of long-lived assets, including finite-lived intangible assets, in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairments of indefinite lived intangible assets in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">  or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment of goodwill in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;"> Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Product Revenues</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized once the Company meets all four revenue recognition criteria described above.  In March 2017, Lexicon began shipping XERMELO to its customers in the United States.  The Company recognizes revenue for product sales of XERMELO at the time the product is received by its specialty pharmacy customers, net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States.  Product shipping and handling costs are included in cost of sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer Credits:  The Company&#8217;s specialty pharmacy customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. The Company expects the specialty pharmacies will earn prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from product sales as they are earned.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company&#8217;s estimates for expected utilization of rebates are based in part on third party market research data, and data received from the specialty pharmacies. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarter&#8217;s unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy, in turn, charges back to Lexicon the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on known sales to contracted customers.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. The Company&#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Collaborative Agreements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration payable to the Company is commensurate with the Company&#8217;s performance necessary to achieve the milestone or the increase in value to the collaboration resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone relates solely to the Company&#8217;s past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone is reasonable relative to all of the other deliverables and payments within the arrangement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial milestones will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Subscription and license fees are recognized as other revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Sales: </font><font style="font-family:inherit;font-size:10pt;"> Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> following approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:10pt;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016:</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Common Share:</font><font style="font-family:inherit;font-size:10pt;"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818595136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221;, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or services.  In August 2015, the FASB issued ASU No. 2015-14, &#8220;Revenue from Contracts with Customers: Deferral of Effective Date&#8221;, which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual periods after December 15, 2017 including interim periods within that reporting period. Early application is permitted only for annual periods beginning after December 15, 2016, including interim periods within that reporting period. In 2016, the FASB issued four additional ASUs related to Topic 606: ASU Nos. 2016-08, 2016-10, 2016-12 and 2016-20.  These ASUs clarify various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations and licensing, and they include other improvements and practical expedients.  Two adoption methods are permitted; retrospectively to all prior reporting periods presented, with certain practical expedients; or the modified retrospective method with the cumulative effect of initially adopting the ASU recognized at the date of initial application.  The Company has elected to adopt this new standard effective January 1, 2018, using the modified retrospective transition method.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company has assessed that ASU 2014-09 will not have a material impact on revenue recognition from product revenue.  The Company&#8217;s only source of product revenue has been sales of XERMELO, which the Company received FDA approval for in February 2017, and subsequently, entered into a limited number of arrangements with specialty pharmacies (&#8220;SPs&#8221;) in the U.S. (collectively, the &#8220;customers&#8221;), under which the Company began shipping to its customers in March 2017.  Under current GAAP, the Company recognizes revenue on its product sales when the customer obtains control of the product, which occurs upon delivery.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.  Under ASU 2014-09, the Company expects to be able to utilize a process and controls approach consistent with its historical process and based on the nature of its current contracts with customers, does not anticipate a significant amount of variable consideration subject to constraint.  As a result, the Company does not believe that the adoption of this ASU will have a material impact on the timing or amount of revenues recognized related to its contracts with customers for the sale of product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects the accounting for contingent milestone payments to be the most significant change in the accounting for its license and collaboration agreements.  Topic 605 provides guidance specific to the accounting for milestone payments, including the ability to defer the recognition of any milestones until received and, if certain criteria are met, the ability to recognize milestone payments as revenue when received.  Under the Company&#8217;s current accounting policy, Lexicon recognizes contingent or milestone payments as revenue in the period that the payment-triggering event occurs or is achieved.  However, under the new revenue standard, it is possible to recognize contingent or milestone payments before the payment-triggering event is completely achieved, subject to management&#8217;s assessment of the probability of achievement of the milestone and the likelihood of a significant reversal of such milestone revenue at each reporting date.  This assessment may result in recognizing milestone revenue before the milestone event has been achieved. The Company expects to evaluate estimates and timing of milestone achievement and related variable consideration based on the most likely amount method in its application of this ASU to collaborative agreements.  Estimating variable consideration and the related constraint will require the use of significant management judgment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company&#8217;s primary sources of collaboration revenue have been license and collaboration agreements with three separate third-party licensees: Texas Institute for Genomic Medicine (&#8220;TIGM&#8221;), Sanofi and Ipsen.  The Company has performed an evaluation of the expected effect of adoption in its accounting for license and collaboration agreements as discussed further below.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to its contract with TIGM, the Company evaluated the variable consideration related to the remaining milestone in the adoption of this ASU and determined based on the most likely amount method that it was not probable that a significant reversal would occur and therefore, no constraint was required.  As a result, under the modified retrospective method, the Company will record a </font><font style="font-family:inherit;font-size:10pt;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;"> cumulative-effect adjustment to its accumulated deficit on the date of adoption.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to its collaboration agreements with Sanofi and Ipsen, the Company evaluated the variable consideration relating to future milestone payments and determined, based on the most likely amount method, that the estimated amounts could be considered as part of the transaction price. The Company then evaluated the variable constraint and determined that the variable consideration amounts are constrained, primarily by future events that are not within the control of the Company. The future events primarily related to receipt of positive results from studies, approval from regulatory agencies, and upon achieving sales in certain locations.  As a result, the Company has determined that there is no cumulative adjustment necessary for these agreements on the date of adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption of the ASU will have no significant impact to the provision for income taxes and will have no impact to the net cash provided by or used in operating, investing or financing activities on the Company&#8217;s consolidated statements of cash flows.  Estimated impacts from adoption of this ASU may differ upon the final adoption and implementation in the first quarter of 2018.  As the Company completes its analysis of the accounting for the collaboration agreements under the new revenue standard, management is assessing the required changes to its accounting policies, systems and internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, &#8220;Recognition and Measurement of Financial Assets and Financial Liabilities.&#8221; ASU 2016-01 requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is not permitted. The adoption of this ASU on January 1, 2018 is not expected to have a material impact on Lexicon&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases.&#8221; ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement will also require additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. This ASU is required to be adopted using a modified retrospective approach.  Management plans to adopt ASU 2016-02 on January 1, 2019, and anticipates that most of its operating leases will result in the recognition of additional assets and corresponding liabilities on the consolidated balance sheet.  The Company does not expect that the implementation of the ASU will have a material impact on its financial position.  The actual impact will depend on the Company&#8217;s lease portfolio at the time of adoption.  The Company continues to assess all implications of the standard and related financial disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, &#8220;Stock Compensation,&#8221; which is intended to simplify several aspects of the accounting for share-based payment award transactions. The Company adopted this pronouncement effective January 1, 2017.  Upon adoption, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance is applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> of deferred tax assets, the recognition of this provision of ASU 2016-09 had no impact to the Company&#8217;s accumulated deficit as of January 1, 2017.  Additionally, the Company recorded an adjustment to accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> as a result of making an entity-wide accounting policy election to account for forfeitures of share-based payment awards as they occur instead of estimating the number of awards that are expected to vest.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632639376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents and Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of cash and cash equivalents and investments held at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,805</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,699</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,504</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">$7,000</font><font style="font-family:inherit;font-size:10pt;"> in realized losses for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  There were no realized gains or losses for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818644048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; significant unobservable inputs (including the Company&#8217;s own assumptions in determining the fair value of the Symphony Icon purchase consideration liability)</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,809</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,788</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,898</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,606</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,504</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  In </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s Level&#160;3 liabilities represented the contingent purchase consideration payable to Symphony Icon, and was estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon (&#8220;Symphony Icon&#8221;) purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.  The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,927</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of base payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,815</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636016752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Lives</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">In Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5-7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7-10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15-40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,687</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,390</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633307824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including reducing the U.S. corporate income tax rate from 35 percent to 21 percent beginning in 2018.  At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, Lexicon has not completed the accounting for the tax effects of the 2017 Tax Act; however, an estimate of the effects on the existing deferred tax balances has been made, as further discussed below.     </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Accordingly, Lexicon remeasured certain deferred tax assets and liabilities based on the newly enacted U.S. corporate income tax rate, which resulted in a decrease of </font><font style="font-family:inherit;font-size:10pt;">$171.4 million</font><font style="font-family:inherit;font-size:10pt;">.  Lexicon will continue to make and refine calculations and estimates, which could potentially affect the measurement of the deferred tax balances or give rise to new deferred tax amounts.  Where the Company has not yet been able to make reasonable estimates of the impact of certain elements, the Company has not recorded any amounts related to those elements and has continued accounting for them in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the 2017 Tax Act.  Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of Lexicon&#8217;s deferred tax assets (liabilities) at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,307</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability related to acquisition of Symphony Icon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,896</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(347,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(468,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,014</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;"> deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  During 2017, after XERMELO was approved by the FDA, the intangible asset related to XERMELO became finite-lived and as a result </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the related deferred tax liability could be considered as a source of taxable income. Lexicon does not believe it can estimate the reversal of the temporary difference related to the remaining assets acquired with sufficient certainty such that </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the deferred tax liability is not considered as a source of taxable income in assessing the Company&#8217;s need for a valuation allowance in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the 2017 Tax Act.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, Lexicon had both federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$851.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$382.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The federal and state NOL carryforwards will begin to expire in 2018.&#160;&#160;The Company&#8217;s R&amp;D tax credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$46.7 million</font><font style="font-family:inherit;font-size:10pt;"> began to expire in 2018.  The orphan drug credit relates to a credit that is calculated as a percentage of expenditures for development of XERMELO, which has received Orphan Drug designation from the FDA.&#160;&#160;Utilization of the NOL, R&amp;D credit and orphan drug credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets, excluding the deferred tax liability relating to the XERMELO finite-lived asset, until an appropriate level of profitability is sustained.&#160;&#160;During the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the valuation allowance decreased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$121.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to the effect of the new U.S. federal corporate tax rate.&#160;&#160;Lexicon recorded income tax benefits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;"> in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  Of the </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;"> tax benefits, </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;"> is the release of a valuation allowance as a result of the ability to estimate the reversal of the deferred tax liability related to the intangible associated with XERMELO, as discussed above.  The remaining </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded to remeasure the deferred tax liability associated with the remaining indefinite-lived intangible asset associated with Symphony Icon at the newly enacted U.S. corporate income tax rate.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> income tax benefits in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company did not have any unrecognized tax benefits.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had no accruals for interest or penalties related to income tax matters.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635906512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$25.8 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the excess of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;"> purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 30, 2010, Lexicon exercised its Purchase Option (as defined in Note 10) and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632081184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Obligations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Notes.</font><font style="font-family:inherit;font-size:10pt;"> In November 2014, Lexicon completed an offering of </font><font style="font-family:inherit;font-size:10pt;">$87.5 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially </font><font style="font-family:inherit;font-size:10pt;">118.4553</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$8.442</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of the Convertible Notes, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> of debt issuance costs, which offsets long-term debt on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the balance of unamortized debt issuance costs was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">, which offsets long-term debt on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Convertible Notes was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$127.3&#160;million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mortgage Loan. </font><font style="font-family:inherit;font-size:10pt;">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;"> third-party mortgage financing and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash.&#160;&#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.23%</font><font style="font-family:inherit;font-size:10pt;">.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  In April 2017, the mortgage was amended to extend the maturity date to April 2018, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance of </font><font style="font-family:inherit;font-size:10pt;">$14.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#160;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  This entire balance is recorded as current portion of long-term debt in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> as there is a balloon payment due in April 2018.  Lexicon intends to refinance this debt prior to paying the balloon payment.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at </font><font style="font-family:inherit;font-size:10pt;">$59.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, before accumulated depreciation, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BioPharma Term Loan.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP that provides up to </font><font style="font-family:inherit;font-size:10pt;">$200 million</font><font style="font-family:inherit;font-size:10pt;"> borrowing capacity (the &#8220;BioPharma Term Loan&#8221;) available in two tranches, each maturing in December 2022.  The BioPharma Term Loan bears interest at </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;"> per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly.  The first </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;"> tranche was funded in December 2017.  The second </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> tranche is available for draw by March 2019 at Lexicon&#8217;s option if net XERMELO sales are greater than </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;"> in the preceding quarter.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the BioPharma Term Loan, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> of debt issuance costs, which offsets long-term debt on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan.  The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes the aggregate scheduled future principal payments of the Company&#8217;s long-term debt as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,094</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,576</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818760528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Arrangements with Symphony Icon, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ArrangementsWithSymphonyIconIncAbstract', window );"><strong>Arrangements with Symphony Icon Inc [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ArrangementsWithSymphonyIconIncTextBlock', window );">Arrangements with Symphony Icon, Inc.</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arrangements with Symphony Icon, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including XERMELO, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &#8220;Programs&#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&#8220;Holdings&#8221;), the Company&#8217;s intellectual property rights related to the Programs. Holdings contributed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;"> to Symphony Icon in order to fund the clinical development of the Programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,092,946</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock on June&#160;15, 2007 in exchange for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;"> and an exclusive purchase option (the &#8220;Purchase Option&#8221;) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.  On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> on July&#160;30, 2010 and issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,891,074</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to designees of Holdings on July&#160;30, 2012 in satisfaction of an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35 million</font><font style="font-family:inherit;font-size:10pt;"> base payment obligation.   </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon also agreed to make up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;"> in additional contingent payments, which would consist of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of any consideration Lexicon received pursuant to any licensing transaction (a &#8220;Licensing Transaction&#8221;) under which Lexicon grants a third party rights to commercialize XERMELO or other pharmaceutical compositions modulating the same target as XERMELO (the &#8220;LG103 Programs&#8221;), subject to certain exceptions. The contingent payments would be due if and when Lexicon received such consideration from a Licensing Transaction. In the event Lexicon received regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon would pay Holdings the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;"> and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which were attributable to the development of such product, reduced by up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon made any such payment upon United States regulatory approval, Lexicon would have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the payment made as a result of such United States regulatory approval.  The contingent payments were payable in cash or a combination of cash and common stock, in Lexicon&#8217;s discretion, provided that no more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of any contingent payment would be paid in common stock.  In December 2014, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and issued </font><font style="font-family:inherit;font-size:10pt;">666,111</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to designees of Holdings in satisfaction of a </font><font style="font-family:inherit;font-size:10pt;">$11.5&#160;million</font><font style="font-family:inherit;font-size:10pt;"> contingent payment obligation as a result of receiving an upfront payment pursuant to Lexicon&#8217;s license and collaboration agreement with Ipsen.  In April 2015, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$0.75 million</font><font style="font-family:inherit;font-size:10pt;"> in cash to Holdings in satisfaction of its contingent payment obligation as a result of receiving an additional upfront payment from Ipsen in March 2015.  In September 2016, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash to Holdings in satisfaction of its contingent payment obligation as a result of receiving a milestone payment from Ipsen in August 2016 (see Note 15, Collaboration and License Agreements).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, Lexicon entered into an amendment (the &#8220;Amendment&#8221;) to the Purchase Option Agreement with Holdings and Symphony Icon pursuant to which Lexicon agreed to pay Holdings </font><font style="font-family:inherit;font-size:10pt;">$21.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon Lexicon&#8217;s receipt of regulatory approval in the United States for the marketing and sale of XERMELO, such buyout amount to be in lieu of any remaining payments which may be or become payable to Holdings under the Purchase Option Agreement. In March 2017, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and issued </font><font style="font-family:inherit;font-size:10pt;">659,905</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to designees of Holdings in satisfaction of its remaining contingent payment obligation as a result of receiving regulatory approval in the United states for the marketing and sale of XERMELO. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45.6 million</font><font style="font-family:inherit;font-size:10pt;"> and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Key assumptions include: (1)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14%</font><font style="font-family:inherit;font-size:10pt;"> for the base payments; (2)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">18%</font><font style="font-family:inherit;font-size:10pt;"> for the contingent payments; and (3)&#160;a probability adjusted contingency.  No discount rate was used in the valuation of the contingent consideration liability as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> as the expected buyout was short-term in nature.  Subsequent changes in the fair value of the Symphony Icon purchase consideration liability were recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ArrangementsWithSymphonyIconIncAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Arrangements with Symphony Icon Inc [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ArrangementsWithSymphonyIconIncAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ArrangementsWithSymphonyIconIncTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about a series of related agreements in 2007 providing for the financing of the clinical development of certain of its drug candidates.  These agreements were amended in 2010, when Lexicon exercised is purchase option and reaquired the clinical programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ArrangementsWithSymphonyIconIncTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809446304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Lease Obligations</font><font style="font-family:inherit;font-size:10pt;">:&#160;&#160;A Lexicon subsidiary leases office space in Basking Ridge, New Jersey under a lease agreement, the term of which began in June 2015 and terminates in December 2022.  Rent expense is recognized on a straight-line basis over the lease term.&#160;&#160;Additionally, Lexicon leases certain equipment under operating leases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for all operating leases was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The following table includes non-cancelable, escalating future lease payments for the facility in New Jersey:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">614</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">639</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Arrangements:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either six or 12 months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818600576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Stock Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalStockAgreementsAbstract', window );"><strong>Other Capital Stock Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Other Capital Stock Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Capital Stock Agreements </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse Stock Split</font><font style="font-family:inherit;font-size:10pt;">:  Effective May 20, 2015, Lexicon completed a one-for-seven reverse split of its common stock.  All references to shares of common stock and per-share data for all periods presented in this report have been adjusted to give effect to this reverse stock split. Proportional adjustments were also made to all shares of common stock issuable under Lexicon&#8217;s equity incentive plans and upon conversion of Lexicon&#8217;s Notes. Concurrent with the reverse stock split, the authorized shares of common stock were reduced from </font><font style="font-family:inherit;font-size:10pt;">900 million</font><font style="font-family:inherit;font-size:10pt;"> (prior to the reverse stock split) to </font><font style="font-family:inherit;font-size:10pt;">225 million</font><font style="font-family:inherit;font-size:10pt;">. As no change was made to the par value of the common shares, common stock and additional paid-in capital were adjusted on a retroactive basis to give effect to the reverse stock split. No fractional shares were issued in connection with the reverse stock split. Any fractional share of common stock that would otherwise have resulted from the reverse stock split were converted into cash payments equal to such fraction multiplied by the closing sales price of the common stock as last reported on the last trading day immediately preceding the effective date of the reverse stock split.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalStockAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Stock Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalStockAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818557840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Incentive Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Plans</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and restated in February 2000, April 2009, April 2012, April 2015 and April 2017 and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock had been reserved for issuance, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4,773,915</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">945,723</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,812,584</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued upon the exercise of stock options, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,118,151</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued pursuant to restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">113,940</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and restated in April 2009, April 2012, April 2015 and April 2017 and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of more than </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> during any calender year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calender year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">600,000</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">600,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock had been reserved for issuance, stock options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">187,119</font><font style="font-family:inherit;font-size:10pt;"> shares were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">none</font><font style="font-family:inherit;font-size:10pt;"> had been issued upon the exercise of stock options and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">82,696</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued pursuant to restricted stock awards granted under the Directors&#8217; Plan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Activity:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except exercise price data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(157</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,961</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,834</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at end of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,077</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,727</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,686</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average estimated grant date fair value of stock options granted during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.59</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.43</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.58</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.7</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The weighted average remaining contractual term of stock options outstanding and exercisable was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.4</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.2</font><font style="font-family:inherit;font-size:10pt;"> years, respectively, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of the outstanding stock options and the exercisable stock options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Bonus and Restricted Stock Unit Activity:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Lexicon granted its non-employee directors </font><font style="font-family:inherit;font-size:10pt;">10,248</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">11,456</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">21,360</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, of restricted stock awards.  The restricted stock awards had weighted average grant date fair values of </font><font style="font-family:inherit;font-size:10pt;">$15.61</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.96</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.49</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively, and vested immediately.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aggregate Shares Reserved for Issuance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,906,757</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6,565,872</font><font style="font-family:inherit;font-size:10pt;"> additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818612512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Benefit Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,033,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$733,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$332,000</font><font style="font-family:inherit;font-size:10pt;"> in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after four years of service.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818607824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sanofi.</font><font style="font-family:inherit;font-size:10pt;">  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Sanofi Agreement, Lexicon has granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.  Subject to specified exceptions, neither party may (a) perform clinical development activities relating to any other compound which inhibits sodium-glucose cotransporters type 1 or type 2 or (b) commercialize any such compounds in the United States, countries of the European Union and certain other specified countries, in each case during the royalty terms applicable in such countries.  Among the specified exceptions is a right Lexicon retained to pursue the development of its LX2761 drug candidate, with respect to which Lexicon granted Sanofi certain rights of first negotiation specified in the Sanofi Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;">.  In addition, Lexicon is eligible to receive from Sanofi (a) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$110 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of four development milestones relating to the results of certain Phase 3 clinical trials of sotagliflozin in type 2 diabetes patients, (b) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$220 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of four regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes, respectively, in each of the United States and Europe, of which two milestones representing the substantial majority of such aggregate amount relate to type 2 diabetes and the remaining two milestones relate to type 1 diabetes, (c) </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of a milestone based on the results of either of two outcomes studies in type 2 diabetes patients, the completion of which would likely occur after initial regulatory approval of sotagliflozin in type 2 diabetes, and (d) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$990 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of six commercial milestones that will be achieved upon reaching specified levels of sales.  The Company believes that each of the development and regulatory milestones under the Sanofi Agreement is substantive.  Due to the uncertainty surrounding the achievement of the future development and regulatory milestones, these payments will not be recognized as revenue unless and until they are earned, as the Company is not able to reasonably predict if and when the milestones will be achieved.  Commercial milestones, which are not encompassed within the definition of milestones under generally accepted accounting principles, will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Lexicon is also entitled to tiered, escalating royalties ranging from low double digit percentages to </font><font style="font-family:inherit;font-size:10pt;">forty</font><font style="font-family:inherit;font-size:10pt;"> percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon will continue to be responsible for all clinical development activities relating to type 1 diabetes and has exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States. Under the terms of its co-promotion option, Lexicon will fund forty percent of the commercialization costs relating to such co-promotion activities. Sanofi will be responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and will be solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States. Lexicon will share in the funding of a portion of the planned type 2 diabetes development costs over the first three years of the collaboration, up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">. Sanofi will book sales worldwide in all indications.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The parties are responsible for using commercially reasonable efforts to perform their development and commercialization obligations pursuant to mutually approved development and commercialization plans.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The parties&#8217; activities under the Sanofi Agreement are governed by a joint steering committee and certain other governance committees which reflect equal or other appropriate representation from both parties. If the applicable governance committee is not able to make a decision by consensus and the parties are not able to resolve the issue through escalation to specified senior executive officers of the parties, then Sanofi will have final decision-making authority, subject to limitations specified in the Sanofi Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Sanofi Agreement will expire upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country is the period commencing on the effective date of the Sanofi Agreement and ending on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity and 10 years following the first commercial sale in the applicable country. Either party may terminate the Sanofi Agreement in the event of an uncured material breach by the other party. Prior to completion of the core development activities for type 2 diabetes specified in the development plan, Sanofi may terminate the Sanofi Agreement on a country-by-country and licensed product-by-licensed product basis, in the event of (a) notification of a material safety issue relating to the licensed product or the class of sodium-glucose cotransporters type 1 or type 2 inhibitors resulting in a recommendation or requirement that Lexicon or Sanofi cease development, (b) failure to achieve positive results with respect to certain clinical trial results, (c) the occurrence of specified fundamental adverse events or (d) the exploitation of the licensed product infringing third party intellectual property rights in specified major markets and Sanofi is unable to obtain a license to such third party intellectual property rights.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considered the following deliverables with respect to the revenue recognition of the </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The exclusive worldwide license granted to Sanofi to develop and commercialize sotagliflozin;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The development services Lexicon is performing for sotagliflozin relating to type 1 diabetes; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The funding Lexicon will provide for development relating to type 2 diabetes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the license had stand-alone value because it is an exclusive license that gives Sanofi the right to develop and commercialize sotagliflozin or to sublicense its rights.  In addition, sotagliflozin is currently in development and it is possible that Sanofi or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Sanofi Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services for type 1 diabetes and the obligation to provide funding for development services for type 2 diabetes over the period of time Lexicon performs services or provides funding, currently expected to be through 2020.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the initial allocable arrangement consideration was the </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments or royalty payments.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: exercising the option to co-promote, estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services for type 1 diabetes by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the obligation to provide funding for type 2 diabetes by using internal estimates of the expected cash flows and timing for </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;"> in funding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the allocation, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$126.8 million</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment for the license in 2015.  The Company is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$113.8 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the development services deliverable and the </font><font style="font-family:inherit;font-size:10pt;">$59.4 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the funding deliverable over the estimated period of performance as the development and funding occurs.  Revenue recognized under the Sanofi Agreement was </font><font style="font-family:inherit;font-size:10pt;">$56.3 million</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;">$75.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$126.8 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  Revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> includes </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of sales of clinical trial materials to Sanofi. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ipsen.</font><font style="font-family:inherit;font-size:10pt;">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$43.7 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> in upfront payments, a </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;"> milestone upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a </font><font style="font-family:inherit;font-size:10pt;">$3.84 million</font><font style="font-family:inherit;font-size:10pt;"> milestone upon Ipsen&#8217;s first commercial sale in Germany, and a </font><font style="font-family:inherit;font-size:10pt;">$3.84 million</font><font style="font-family:inherit;font-size:10pt;"> milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13.1&#160;million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8364;72&#160;million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified sales milestones.  Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned as the Company is not able to reasonably predict if and when the milestones will be achieved.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon supplies Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considered the following deliverables with respect to the revenue recognition of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Territory;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The development services Lexicon is performing for XERMELO;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to participate in committees which govern the development of XERMELO</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">until commercialization; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the license had stand-alone value because it is an exclusive license that grants Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, currently expected to be through mid-2018.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company has determined the commercial supply agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the initial allocable arrangement consideration was the </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As a result of the allocation, the Company recognized </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$21.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">of the</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment for the license in 2014, and an additional </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> in 2015 upon entering into the amendment.  The Company is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the development services deliverable over the estimated period of performance as development occurs, and is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the committee participation deliverable ratably over the estimated period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  Revenue recognized under the Agreement was </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  Revenue for the year ended December 31, 2017 includes </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> from sales of bulk tablets of XERMELO to Ipsen.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Texas Institute for Genomic Medicine</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;In July 2005, Lexicon received a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing </font><font style="font-family:inherit;font-size:10pt;">350,000</font><font style="font-family:inherit;font-size:10pt;"> cell lines for the Texas Institute for Genomic Medicine (&#8220;TIGM&#8221;) using Lexicon&#8217;s proprietary gene trapping technology, which Lexicon completed in 2007.&#160;&#160;Lexicon also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&#160;&#160;The Texas Enterprise Fund made an additional award of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the award, Lexicon is responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,616</font><font style="font-family:inherit;font-size:10pt;"> new jobs in Texas by December 31, 2016.&#160;&#160;Lexicon will receive credits against those job obligations based on funding received by TIGM and certain related parties from sources other than the State of Texas.  Lexicon will also receive credits against those job obligations for any surplus jobs that Lexicon created.  Subject to these credits, the state may require Lexicon to repay </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,415</font><font style="font-family:inherit;font-size:10pt;"> for each job Lexicon falls short beginning in 2013.&#160;&#160;Lexicon&#8217;s maximum aggregate exposure for such payments, if Lexicon fails to create any new jobs, is approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">, without giving effect to any credits to which Lexicon may be entitled.&#160;&#160;Lexicon has recorded this obligation as deferred revenue in the accompanying consolidated balance sheets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643625872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SelectedQuarterlyFinancialDataAbstract', window );"><strong>Selected Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,518</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,785</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,871</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,518</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,785</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,871</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all periods presented, the weighted average number of shares outstanding are the same for both basic and diluted consolidated net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SelectedQuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected Quarterly Financial Data [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SelectedQuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814178272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation:</font><font style="font-family:inherit;font-size:10pt;"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash, Cash Equivalents and Short-Term Investments:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Accounts Receivable, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory: </font><font style="font-family:inherit;font-size:10pt;"> Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.  The Company began capitalizing inventory during 2017 after the approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO were recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information and Significant Customers:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangible Assets:</font><font style="font-family:inherit;font-size:10pt;">  Other intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment:</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  </font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;"> Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Product Revenues</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized once the Company meets all four revenue recognition criteria described above.  In March 2017, Lexicon began shipping XERMELO to its customers in the United States.  The Company recognizes revenue for product sales of XERMELO at the time the product is received by its specialty pharmacy customers, net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States.  Product shipping and handling costs are included in cost of sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer Credits:  The Company&#8217;s specialty pharmacy customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. The Company expects the specialty pharmacies will earn prompt payment discounts and, therefore, the Company deducts the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from product sales as they are earned.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company&#8217;s estimates for expected utilization of rebates are based in part on third party market research data, and data received from the specialty pharmacies. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarter&#8217;s unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy, in turn, charges back to Lexicon the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on known sales to contracted customers.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. The Company&#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Collaborative Agreements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration payable to the Company is commensurate with the Company&#8217;s performance necessary to achieve the milestone or the increase in value to the collaboration resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone relates solely to the Company&#8217;s past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The milestone is reasonable relative to all of the other deliverables and payments within the arrangement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial milestones will be accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Subscription and license fees are recognized as other revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Sales: </font><font style="font-family:inherit;font-size:10pt;"> Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> following approval of XERMELO by the FDA, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive loss.  As a result, cost of sales for approximately the next two years will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:10pt;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Common Share:</font><font style="font-family:inherit;font-size:10pt;"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of Presentation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814215648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated future amortization expense for intangible assets as of December 31, 2017 is as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,247</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016:</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809481872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.10344827586206%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,805</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,699</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,504</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653221712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,809</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,979</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,788</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,904</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,898</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,606</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346,504</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,927</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of base payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,815</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13467-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75026489&amp;loc=d3e13220-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14172-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6629870800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Lives</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">In Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5-7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7-10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15-40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,687</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,390</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635906512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,307</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability related to acquisition of Symphony Icon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,896</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(347,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(468,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,014</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809888336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations Debt Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes the aggregate scheduled future principal payments of the Company&#8217;s long-term debt as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,094</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,576</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653025584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">614</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">639</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811068848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except exercise price data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(157</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,961</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,834</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at end of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,077</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,727</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,686</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818726416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SelectedQuarterlyFinancialDataAbstract', window );"><strong>Selected Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,518</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,785</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,871</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,518</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,785</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,871</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all periods presented, the weighted average number of shares outstanding are the same for both basic and diluted consolidated net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SelectedQuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected Quarterly Financial Data [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SelectedQuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809307392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Inventory (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="nump">$ 616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross</a></td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 1,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818600576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConcentrationOfCreditRiskAbstract', window );"><strong>Concentration of Credit Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance', window );">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent', window );">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConcentrationOfCreditRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of Credit Risk [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConcentrationOfCreditRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from external customers attributed to France as a percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659799216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SegmentInformationAndSignificantCustomersAbstract', window );"><strong>Segment Information and Significant Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueSanofiPercentage', window );">Entity Wide Revenue Sanofi Percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueIpsenPercentage', window );">Entity Wide Revenue Ipsen Percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueIpsenPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EntityWideRevenueIpsenPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueSanofiPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EntityWideRevenueSanofiPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SegmentInformationAndSignificantCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Information and Significant Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SegmentInformationAndSignificantCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828387808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Intangible asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_XERMELOIntangibleAssetsFiniteLived', window );">XERMELO Intangible Assets Finite Lived</a></td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_XERMELOIntangibleAssetsFiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets relating to XERMELO that were reclassified from indefinite-lived to finite-lived once the FDA approved XERMELO.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_XERMELOIntangibleAssetsFiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819402512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815906000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814177936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655929808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 18.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 4 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-Based Compensation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809513760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606', window );">Adjustment to Accumulated Deficit to ASC606</a></td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets', window );">Accumulated Excess Tax Benefits Recognized as Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AdjustmenttoAccumulatedDeficit', window );">Adjustment to Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lexicon will adopt ASU 2016-09, "Stock Compensation." This represents the accumulated excess tax benefits that will be recognized as deferred tax assets upon adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AdjustmenttoAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lexicon will adopt ASU 2016-09, "Stock Compensation." This represents the adjustment to accumulated deficit as a result of making an entity-wide accounting policy election to account for forfeitures of share-based payment awards as they occur instead of estimating the number of awards that are expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AdjustmenttoAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_Adjustment to Accumulated Deficit to ASC606 - Lexicon will adopt ASU 2014-09, "Revenue Recognition" on 1-1-18. This represents the adjustment to accumulated deficit as a result of adopting the new standard.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_AdjustmenttoAccumulatedDeficittoASC606</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828664112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">61,661<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">61,661<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">222,316<span></span>
</td>
<td class="nump">227,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">222,148<span></span>
</td>
<td class="nump">227,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">27,033<span></span>
</td>
<td class="nump">72,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">26,979<span></span>
</td>
<td class="nump">72,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">249,349<span></span>
</td>
<td class="nump">300,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">249,127<span></span>
</td>
<td class="nump">299,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_InvestmentsMember', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">311,010<span></span>
</td>
<td class="nump">346,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">$ 310,788<span></span>
</td>
<td class="nump">$ 346,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 325<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75031664&amp;loc=d3e22529-158502<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828027856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">$ 61,661<span></span>
</td>
<td class="nump">$ 46,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">249,127<span></span>
</td>
<td class="nump">299,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">310,788<span></span>
</td>
<td class="nump">346,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Accrued Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">61,661<span></span>
</td>
<td class="nump">45,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">222,148<span></span>
</td>
<td class="nump">227,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">283,809<span></span>
</td>
<td class="nump">272,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Accrued Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">26,979<span></span>
</td>
<td class="nump">72,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">26,979<span></span>
</td>
<td class="nump">73,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Accrued Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Accrued Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811346112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
<td class="nump">$ 2,101<span></span>
</td>
<td class="num">$ (703)<span></span>
</td>
<td class="nump">$ 5,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="num">(703)<span></span>
</td>
<td class="nump">5,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</a></td>
<td class="num">(21,013)<span></span>
</td>
<td class="num">(3,200)<span></span>
</td>
<td class="num">(750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,912<span></span>
</td>
<td class="nump">$ 22,815<span></span>
</td>
<td class="nump">$ 17,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817079104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 76,310<span></span>
</td>
<td class="nump">$ 79,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="num">(58,623)<span></span>
</td>
<td class="num">(59,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">17,687<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">4,605<span></span>
</td>
<td class="nump">7,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">6,006<span></span>
</td>
<td class="nump">6,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="nump">3,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">59,212<span></span>
</td>
<td class="nump">59,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 2,664<span></span>
</td>
<td class="nump">$ 2,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828988096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Deferred Tax Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 186,967<span></span>
</td>
<td class="nump">$ 258,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">46,682<span></span>
</td>
<td class="nump">44,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug', window );">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</a></td>
<td class="nump">26,524<span></span>
</td>
<td class="nump">24,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, In Process Research and Development</a></td>
<td class="nump">69,561<span></span>
</td>
<td class="nump">86,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Tax Assets, Deferred Income</a></td>
<td class="nump">12,950<span></span>
</td>
<td class="nump">39,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Other</a></td>
<td class="nump">5,579<span></span>
</td>
<td class="nump">8,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">352,186<span></span>
</td>
<td class="nump">468,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon', window );">Deferred Tax Liability Related to Acquisition of Symphony Icon</a></td>
<td class="num">(10,896)<span></span>
</td>
<td class="num">(18,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="num">(10,897)<span></span>
</td>
<td class="num">(18,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="num">(347,303)<span></span>
</td>
<td class="num">(468,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="num">$ (6,014)<span></span>
</td>
<td class="num">$ (18,675)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828338960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 27, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset', window );">Deferred Tax Liability from Reclassified Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible', window );">Deferred Tax Liability from Reclassified Indefinite-lived Intangible</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxAssetremeasured', window );">Deferred Tax Asset, remeasured</a></td>
<td class="nump">171,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="num">(12,661,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Change in Amount</a></td>
<td class="nump">121,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
<td class="nump">851,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating Loss Carryforwards, State</a></td>
<td class="nump">$ 382,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetremeasured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, remeasured - represents the remeasurement of the deferred tax asset and liabilities to the newly enacted US Federal corporate tax rate of 21%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetremeasured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability from Reclassified Indefinite-lived Intangible - remeasured amount calculated using the tax rate of 21 percent from 35 percent and relating to the deferred tax liability associated with the indefinite-lived intangible asset associated with the Symphony Icon acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability from Reclassified Intangible Asset - Upon approval by FDA, the indefinite-lived intangible asset was reclassified finite-lived asset and the tax effect was to book to a deferred tax liability with offset to accumulated deferred tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814215648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 30, 2010</div></th>
<th class="th"><div>Jul. 12, 2001</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthGoodwill', window );">Coelacanth Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthPurchasePrice', window );">Coelacanth Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyIconGoodwill', window );">Symphony Icon Goodwill</a></td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyIconGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyIconGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816756720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</a></td>
<td class="nump">$ 14,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-term Debt, Maturities, Repayments of Principal in Year Two</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-term Debt, Maturities, Repayments of Principal in Year Three</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-term Debt, Maturities, Repayments of Principal in Year Four</a></td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-term Debt, Maturities, Repayments of Principal in Year Five</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Long-term Debt, Maturities, Repayments of Principal after Year Five</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Gross</a></td>
<td class="nump">251,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Debt Issuance Expense</a></td>
<td class="num">(5,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term Debt, Current Maturities</a></td>
<td class="num">(14,094)<span></span>
</td>
<td class="num">$ (16,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities</a></td>
<td class="nump">$ 231,576<span></span>
</td>
<td class="nump">$ 85,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816187248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details 2)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage', window );">Convertible Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.4553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="nump">$ 8.442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 127.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_WoodlandsMortgage', window );">Woodlands Mortgage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_WoodlandsCashPaid', window );">Woodlands Cash Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_WoodlandsMortgageInterestRate', window );">WoodlandsMortgageInterestRate</a></td>
<td class="nump">8.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages', window );">Mortgage Loans on Real Estate, Carrying Amount of Mortgages</a></td>
<td class="nump">$ 14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BuildingsCollateral', window );">Buildings Collateral</a></td>
<td class="nump">59.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LandCollateral', window );">Land Collateral</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">200000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TrancheBdebt', window );">Tranche B debt</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MinimumXERMELOsalestodrawTrancheB', window );">Minimum XERMELO sales to draw Tranche B</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BuildingsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The buildings that serve as collateral for Lexicon's mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BuildingsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LandCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The land that serves as collateral for Lexicon's mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LandCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MinimumXERMELOsalestodrawTrancheB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum XERMELO sales to draw Tranche B - represents the minimum sales in a quarter that must be met by the Company before March 19, 2019 in order to draw $50 million on the debt agreement entered into during December 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MinimumXERMELOsalestodrawTrancheB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TrancheBdebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tranche B debt - Represents the second tranche of debt available for draw by March 19, 2019 at the Company's option if net XERMELO sales are greater than $25 million in the preceding quarter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TrancheBdebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WoodlandsCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the $20.8 million cash paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_WoodlandsCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WoodlandsMortgage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the original $34.0 million mortgage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_WoodlandsMortgage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WoodlandsMortgageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>WoodlandsMortgageInterestRate interest rate on mortgage loan for Woodlands building and land</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_WoodlandsMortgageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the outstanding balance due under the mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04.(c) Schedule IV)<br> -URI http://asc.fasb.org/extlink&amp;oid=27047687&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 310<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6589523&amp;loc=d3e617274-123014<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829087984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Arrangements with Symphony Icon, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 30, 2012</div></th>
<th class="th"><div>Jul. 30, 2010</div></th>
<th class="th"><div>Jun. 15, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ArrangementsWithSymphonyIconIncAbstract', window );"><strong>Arrangements with Symphony Icon Inc [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_HoldingsContributionToIcon', window );">Holdings Contribution To Icon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconSoldSharesToHoldings', window );">Lexicon Sold Shares To Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconReceivedCashFromHoldings', window );">Lexicon Received Cash From Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconPaidHoldingsCash', window );">Lexicon Paid Holdings Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonFairValueOfBaseAndContingentPayments', window );">Symphony Fair Value Of Base And Contingent Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyBasePaymentDiscountRate', window );">Symphony Base Payment Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentDiscountRate', window );">Symphony Contingent Payment Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyBasePaymentInShares', window );">Symphony Base Payment In Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyBasePaymentObligation', window );">Symphony Base Payment Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentMaximum', window );">Symphony Contingent Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentPercentage', window );">Symphony Contingent Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyRegulatoryApprovalPayment', window );">Symphony Regulatory Approval Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyRegulatoryApprovalReductionPercentage', window );">Symphony Regulatory Approval Reduction Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyRegulatoryApprovalPercentageLimit', window );">Symphony Regulatory Approval Percentage Limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyPaymentInStockLimitation', window );">Symphony Payment In Stock Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentInCash', window );">Symphony Contingent Payment In Cash</a></td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyAmendmentBuyout', window );">Symphony Amendment Buyout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentinShares', window );">Symphony Contingent Payment in Shares</a></td>
<td class="nump">659,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentTotal', window );">Symphony Contingent Payment Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,101<span></span>
</td>
<td class="num">$ (703)<span></span>
</td>
<td class="nump">$ 5,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ArrangementsWithSymphonyIconIncAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Arrangements with Symphony Icon Inc [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ArrangementsWithSymphonyIconIncAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_HoldingsContributionToIcon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On June 15, 2007, Symphony Icon Holdings LLC contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_HoldingsContributionToIcon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconPaidHoldingsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the cash paid to Holdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LexiconPaidHoldingsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconReceivedCashFromHoldings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LexiconReceivedCashFromHoldings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconSoldSharesToHoldings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LexiconSoldSharesToHoldings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonFairValueOfBaseAndContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonFairValueOfBaseAndContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyAmendmentBuyout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In July 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings. In September 2016, Lexicon entered into an amendment to this agreement. This represents the buyout amount that Lexicon will pay Holdings in the event Lexicon receives regulatory approval in the U.S. for the marketing and sale of telotristat ethyl, such buyout amount to be in lieu of any remaining payments which may be or become payable to Holdings under the Purchase Option Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyAmendmentBuyout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyBasePaymentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the base payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyBasePaymentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyBasePaymentInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyBasePaymentInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyBasePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the $35 million base payment obligation that was paid in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyBasePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the contingent payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments to Symphony Icon Holdings in the form of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the maximum amount for any contingent payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the percentage of consideration received that will be paid to Holdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments to Symphony Icon Holdings, in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments to Symphony Icon Holdings in the form of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyPaymentInStockLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contingent payments to Holdings may be paid in cash or a combination of cash and common stock, in Lexicon's discretion, provided that no more than 50% of any payment will be paid in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyPaymentInStockLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyRegulatoryApprovalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the payment that will be made upon regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyRegulatoryApprovalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyRegulatoryApprovalPercentageLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.  This represents the percentage by which proceeds of Licensing Transactions must exceed regulatory approval payments in order for Lexicon to have an obligation to make subsequent contingent payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyRegulatoryApprovalPercentageLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyRegulatoryApprovalReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the percentage reduction of the regulatory approval payment by previous contingent payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyRegulatoryApprovalReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818668208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637659584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases, Future Minimum Payments, Due in Four Years</a></td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Operating Leases, Future Minimum Payments, Due in Five Years</a></td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Operating Leases, Future Minimum Payments, Due Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">$ 3,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633307440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Capital Stock Agreements (Details)<br> shares in Millions</strong></div></th>
<th class="th">
<div>May 20, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalStockAgreementsAbstract', window );"><strong>Other Capital Stock Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit', window );">Common Stock, Shares Authorized Before Reverse Stock Split</a></td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit', window );">Common Stock, Shares Authorized After Reverse Stock Split</a></td>
<td class="nump">225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws after the effective date of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommonStockSharesAuthorizedAfterReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws before the effective date of a reverse stock split, without giving effect to the reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommonStockSharesAuthorizedBeforeReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalStockAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Stock Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalStockAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827539760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock', window );">Stock Option Exercise Price as Percent of Value of Common Stock</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan', window );">Total Shares That May be Issued, Equity Incentive Plan</a></td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingEquityIncentivePlan', window );">Options Outstanding, Equity Incentive Plan</a></td>
<td class="nump">4,773,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Equity Incentive Plan</a></td>
<td class="nump">945,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedEquityIncentivePlan', window );">Stock Options Exercised, Equity Incentive Plan</a></td>
<td class="nump">1,812,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</a></td>
<td class="nump">1,118,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan', window );">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</a></td>
<td class="nump">113,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Totalvalueofsharesbynonemployeeinayear', window );">Total value of shares by nonemployee in a year | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan', window );">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Options Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">187,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan', window );">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">82,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">5,906,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">6,565,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Totalvalueofsharesbynonemployeeinayear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Totalvalueofsharesbynonemployeeinayear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828504304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 2) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 01, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 8.59<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="nump">$ 4.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,834<span></span>
</td>
<td class="nump">4,217<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 11.17<span></span>
</td>
<td class="nump">$ 11.24<span></span>
</td>
<td class="nump">$ 12.35<span></span>
</td>
<td class="nump">$ 14.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 14.31<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="num">(458)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="nump">$ 12.17<span></span>
</td>
<td class="nump">$ 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 26.42<span></span>
</td>
<td class="nump">$ 27.33<span></span>
</td>
<td class="nump">$ 27.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 13.84<span></span>
</td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="nump">2,727<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.95<span></span>
</td>
<td class="nump">$ 12.55<span></span>
</td>
<td class="nump">$ 14.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6660902704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</a></td>
<td class="nump">10,248<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="nump">21,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 15.61<span></span>
</td>
<td class="nump">$ 13.96<span></span>
</td>
<td class="nump">$ 7.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810653328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 4) - Restricted Stock Units (RSUs) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 8.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 14.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 8.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630481792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 1,033,000<span></span>
</td>
<td class="nump">$ 733,000<span></span>
</td>
<td class="nump">$ 332,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829502304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2005 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiUpfrontPayment', window );">Sanofi Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiDevelopmentMilestones', window );">Sanofi Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRegulatoryMilestones', window );">Sanofi Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiOutcomesStudyMilestone', window );">Sanofi Outcomes Study Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiSalesMilestonePayments', window );">Sanofi Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount', window );">Sanofi Development Costs Funded by Lexicon Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable', window );">Sanofi Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable', window );">Sanofi Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueRecognized', window );">Sanofi Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="nump">$ 126,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiSalesofClinicalTrialMaterials', window );">Sanofi Sales of Clinical Trial Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoFundingDeliverable', window );">Sanofi Revenue Allocated to Funding Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalPaymentsToDate', window );">Ipsen Total Payments To Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalUpfrontPayments', window );">Ipsen Total Upfront Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMilestonePaymentReceived', window );">Ipsen Milestone Payment Received</a></td>
<td class="nump">$ 3,840,000<span></span>
</td>
<td class="nump">$ 3,840,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable', window );">Ipsen Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones', window );">Ipsen Maximum Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable', window );">Ipsen Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable', window );">Ipsen Revenue Allocated to Committee Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Ipsenproductsales', window );">Ipsen product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumSalesMilestones', window );">Ipsen Maximum Sales Milestones | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TigmMaximumExposure', window );">TIGM Maximum Exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TxEnterpriseFundAward', window );">TX Enterprise Fund Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem', window );">TX Enterprise Fund Award to Texas AM University System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TigmPerJobPaymentAmount', window );">TIGM Per Job Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the maximum regulatory and commercial launch milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the maximum sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan.  This represents the amount of milestone payments earned during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This is the amount of the upfront payment allocated to the committee participation deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalPaymentsToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan.  This represents the total all payments under the agreement to date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalPaymentsToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan.  This represents the total of the upfront payments under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Ipsenproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan.  This represents the amount of product sales to Ipsen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Ipsenproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiOutcomesStudyMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiOutcomesStudyMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoFundingDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the amount of the upfront payment allocated to the funding deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoFundingDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the potential sales milestones payments under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiSalesofClinicalTrialMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin.  This represents the sales of clinical trial materials recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiSalesofClinicalTrialMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin.  This represents the upfront payment under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TigmMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TigmMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TigmPerJobPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TigmPerJobPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TxEnterpriseFundAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TxEnterpriseFundAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816986208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue, Net</a></td>
<td class="nump">$ 33,047<span></span>
</td>
<td class="nump">$ 26,942<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
<td class="nump">$ 18,293<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
<td class="nump">$ 27,717<span></span>
</td>
<td class="nump">$ 20,089<span></span>
</td>
<td class="nump">$ 12,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) From Operations</a></td>
<td class="num">(30,785)<span></span>
</td>
<td class="num">(29,518)<span></span>
</td>
<td class="num">(33,893)<span></span>
</td>
<td class="num">(42,485)<span></span>
</td>
<td class="num">(31,330)<span></span>
</td>
<td class="num">(34,933)<span></span>
</td>
<td class="num">(37,021)<span></span>
</td>
<td class="num">(33,871)<span></span>
</td>
<td class="num">$ (136,681)<span></span>
</td>
<td class="num">$ (137,155)<span></span>
</td>
<td class="nump">$ 1,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (28,378)<span></span>
</td>
<td class="num">$ (30,722)<span></span>
</td>
<td class="num">$ (35,059)<span></span>
</td>
<td class="num">$ (34,891)<span></span>
</td>
<td class="num">$ (32,419)<span></span>
</td>
<td class="num">$ (36,015)<span></span>
</td>
<td class="num">$ (38,112)<span></span>
</td>
<td class="num">$ (34,883)<span></span>
</td>
<td class="num">$ (129,050)<span></span>
</td>
<td class="num">$ (141,429)<span></span>
</td>
<td class="num">$ (4,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Earnings Per Share, Basic and Diluted</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted Average Number of Shares Outstanding, Basic and Diluted</a></td>
<td class="nump">105,588<span></span>
</td>
<td class="nump">105,582<span></span>
</td>
<td class="nump">105,300<span></span>
</td>
<td class="nump">104,461<span></span>
</td>
<td class="nump">104,052<span></span>
</td>
<td class="nump">103,885<span></span>
</td>
<td class="nump">103,830<span></span>
</td>
<td class="nump">103,682<span></span>
</td>
<td class="nump">105,237<span></span>
</td>
<td class="nump">103,863<span></span>
</td>
<td class="nump">103,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MA]]-V'EC#_8?&U\%NQ9^W47W!5!+ P04    " #LI%Q,F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( .RD7$SP\@ONG0(  *,)   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL?5;;CML@$/T5RQ^P-OB:51(I%U6MU$K15MT^$X?$UMK&!9)L
M_[Z O:X#X\U#S.6<.0S,P"SOC+^)DE+IO3=U*U9^*67W' 2B*&E#Q!/K:*MF
MSHPW1*HNOP2BXY2<#*FI QR&:="0JO772S-VX.LEN\JZ:NF!>^+:-(3_W=*:
MW5<^\C\&7JI+*?5 L%YVY$)_4OFK.W#5"T8KIZJAK:A8ZW%Z7OD;]+Q'F288
MQ&M%[V+2]K0K1\;>=.?;:>6'>D6TIH74)HCZW.B.UK6VI-;Q9S#JCYJ:.&U_
M6/]BG%?.'(F@.U;_KDZR7/FY[YWHF5QK^<+N7^G@4.)[@_??Z8W6"JY7HC0*
M5@OS[Q57(5DS6%%+:<A[_ZU:\[WW,PD::# !#P0\$J+H4T(T$**1@.)/"?%
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M007>Y0F&H4Q5Y%2E:%DCIR46]'T71%ZEO,@\1;ZEM71+BWRSJGW<-M'9+.G
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M[S]K_Z5-/B3SEE9^763_''?UX7ENY[.=?T\O6?VMN/[J^X34?-9G_[O_\%G
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M:*+'*91)1]@!@0*W2HXOK4";&6 W<[&; 3:?!Q ZO+1$#B1K2&\@6)!ZW-*
M]C3 IN9B4P/L0P_:63R9UR2I"._>D*3A?%P_;6^ _<W%_@:$'3E%R<<@YXY:
M<S"HS(1VVM[ 8NTRUFZ)*2'! #5]:%9R[&<;B@W39R('VF(!>ZR+/1:P-3X
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MM0 A#Y/%]GK)J,3L. 8=.05T)&>&4/OLSK6#SJ1$$5"Q^6H'G5&):0T&'0E
MARWZDH..-_050&+4D0AU*%!)L$_BZ#"D!D^214#&'+9*DE&)V7,,7Q+!%X4\
MR3E&>^% '4PR$I$,7; EYP)7!ZPU@17R<"*7#H$=9NR29%1B6H-11G*4$9)N
MX$L[H@#)G1)LW].>*;9+$FLQ<^,<0XH"D,+P5J$-!\^G# =DU""[)+)+8KLD
ML3;9- >CBN*HP@A7<5)I%O+08?L%0,C<L4JBJ>5B>ZYD5&+Z@_E* ;YBA*L
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MJR)I,%JECH1XR1ECE-AS "XLL\._B'3L6@1<B]>_G*33V,22V Y+3*4D%LD
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MS%()!=H)HXF%.J>WV\,Q#?$QX+> P2W.)%1R-N8I&-^KG&Z"()!0^L# <;O
M'4@9B%#&GXF3SBD#<'E^9?\::\=:SMS!G9&/HO)M3F\HJ:#FO?0/9O@&4SW7
ME$S%_X +2 P/2C!'::2+*RE[YXV:6%"*XL_C+G3<A_%F]WF"K0.2"9#,@)N8
MAXV)HO(OW/,BLV8@=NQ]Q\,3;P\)]J8,SMB*>(?B'7HOQ7:?9NP2B*:8XQB3
M+&/F"(;L<XID+<4Q^0!/UN&[586["-^]47B]3I"N$J21(/UOB6LQ^W=)V**G
M"FP3I\F1TO0Z3O+".P_L;1+?Y%_X..WWW#9".W(V'E\V]K\VQ@-*V5SA"+7X
MP69#0NW#\1.>[3AFH^%--_T@-G_CXB]02P,$%     @ [*1<3 <J0&"U 0
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MNW"\]6<SCMEH..RF'\3F;US\ E!+ P04    " #LI%Q,P-A@;K(!  #2 P
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M@SUH?].@4=QYT[3,]@9X'4%*LC1);IGB0M,RC[ZS*7,<G!0:SH;802EN?IQ
MXEC0'7US/(FV<\'!RKSG+7P!][4_&V^QA:46"K05J(F!IJ!WN^,I"_$QX)N
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MV7A\U]C]RA@/F,KF!@>HP>\U&PHJ'XYW>+;CD(V&-]WT?]C\B?,_4$L#!!0
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MQ?:,YYPY,Q[GH['/K@/PY%5)[0K:>=\?&'-5!XJ[*].#QIO&6,4]FK9EKK?
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MQT]XMM.8388W_?R#V/*-B]]02P,$%     @ [*1<3)C".)&U 0  T@,  !D
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MOI>!NM0UDW]WO!*W34C"^\)K>2ZT78BR=<O._ ?7/]N]-+-H8#F6-6]4*9I
M\M,FW)+G'5E9 X?X5?*;>A@'=BL'(=[LY.MQ$\8V(E[Q7%L*9EY7_L*KRC*9
M./[TI.'@TQH^CN_LG]WFS68.3/$74?TNC[K8A,LP./(3NU3Z5=R^\'Y#LS#H
M=_^-7WEEX#82XR,7E7+/(+\H+>J>Q812L_?N73;N?>N^S.]FV(#V!G0P6#J#
MJ'/D(O_$-,O64MP"V?W\EMD<DV=J_DUN%]VO<-],\,JL7C-*Z#JZ6J(>L^LP
M] %#!D1DV <7%+G8T8DYQ>8)C#!QYLF'"!-,D$*"U!&D'PC2T1819H:=S*"3
M&2"8CYP@S ([F4,G<T"P'#E!F!5VLH!.%E,"&H^<((Q'$TOH9 D(QK)#&$_B
M5]#)"A",$X\PGL23&%=0#"C&J8<@3^Z)IU()H!AG'X(\Z2>P7+>$3BF2L0 @
MR*, @NN:)(!B<O0@D$<$!)<_ ;6=C&4 03X=X!. @/).)CI ()\.\"% 0(4G
M$QT@D$\'^!P@H,C3B0X0R*<#?!004.?I1 <(Y-,!/@T(*/5TH@,$&NL@>KA<
M:R[/KJU002XNC>MI'E:'UF5+W>7\'][U/=^9/)>-"@Y"FRO>7<0G(30WL<1/
M1BN%:;6&2<5/V@X79BR[?J.;:-'VO50T-'39/U!+ P04    " #LI%Q,DTD+
MU,8!   W!   &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QM5-MNXR 0
M_17$!Q2'Q$DVLBTUK:JNM"M%76W[3.SQ107C HZ[?[^ 7==->3',<.;,F8%Q
M,DCUJFL @]X%;W6*:V.Z R$ZKT$P?2,[:.U)*95@QIJJ(KI3P H?)#BA4;0E
M@C4MSA+O.ZDLD;WA30LGA70O!%/_CL#ED.(5_G \-55MG(-D2<<J^ /F;W=2
MUB(S2]$(:'4C6Z2@3/'MZG",'=X#GAL8]&*/7"5G*5^=\;-(<>0$ 8?<. 9F
MEPO< >>.R,IXFSCQG-(%+O<?[ ^^=EO+F6FXD_RE*4R=XCU&!92LY^9)#H\P
MU1-C-!7_"R[ +=PIL3ERR;7_HKS71HJ)Q4H1['U<F]:OPWBRVTYAX0 Z!= Y
M8._SD#&15W[/#,L2)0>DQMYWS%WQZD!M;W+G]*WP9U:\MMY+1C?;A%P<T80Y
MCABZP*QF!+'L<PH:2G&DW\)I.'P=5+CVX>LO"G=A@DV08.,)-E\(]E<EAC _
MPDGB8)+X.T$<724)8:X[2187)T!5_LEJE,N^]>.R\,Y3<4O]Q7_"QY'ZS535
MM!J=I;'/QU]R*:4!*R6ZL5IJ.\6SP:$T;KNS>S6^Y=$PLIO&E,S_BNP_4$L#
M!!0    ( .RD7$RKI2-LMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;&U3VT[<,!#]%<L?@'>]64"K)!(+0JU4I!6H[;,WF5R$+ZGM;.#O
M&3LA36E>;,_XG#,7C]/!V%?7 'CRIJ1V&6V\[PZ,N:(!)=R5Z4#C366L$AY-
M6S/761!E)"G)^&9SS91H-<W3Z#O9/#6]EZV&DR6N5TK8]R-(,V1T2S\=SVW=
M^.!@>=J)&E[ _^Q.%BTVJY2M NU:HXF%*J-WV\,Q"?@(^-7"X!9G$BHY&_,:
MC.]E1C<A(9!0^* @<+O /4@9A#"-/Y,FG4,&XO+\J?X8:\=:SL+!O9&_V](W
M&;VEI(1*]-(_F^$;3/7L*9F*_P$7D @/F6",PD@75U+TSALUJ6 J2KR->ZOC
M/HPWUWRBK1/X1. SX3;&86.@F/F#\")/K1F('7O?B?#$VP/'WA3!&5L1[S!Y
MA]Y+SO<\99<@-&&.(X8O,-L9P5!]#L'70ASY?W2^3M^M9KB+]-TR^LU^72!9
M%4BB0/)/B;LO):YADB]!V**G"FP=I\F1PO0Z3O+".P_L77Q$]A<^3ON3L'6K
M'3D;CR\;^U\9XP%3V5SA"#7XP69#0N7#\0;/=ARST?"FFWX0F[]Q_@%02P,$
M%     @ [*1<3. #-S7" 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL;53M;ML@%'T5Q .4A,1-%MF6FDY3)VU2U&GM;V)??ZA\N(#C[NT'
MV'&]C#^!>WWN.><"-^F@])MI "SZ$%R:##?6=@="3-& 8.9.=2#=ETIIP:P+
M=4U,IX&5H4AP0E>K>R)8*W&>AMQ)YZGJ+6\EG#0RO1!,_SD"5T.&U_B:>&[K
MQOH$R=..U? +[._NI%U$9I:R%2!-JR324&7X87TX)AX? "\M#&:Q1[Z3LU)O
M/OA>9GCE#0&'PGH&YI8+/ +GGLC9>)\X\2SI"Y?[*_NWT+OKY<P,/"K^VI:V
MR? >HQ(JUG/[K(8GF/I),)J:_P$7X [NG3B-0G$3?E'1&ZO$Q.*L"/8QKJT,
MZS#Q7\OB!70JH#<%9!0*SK\RR_)4JP'I\>P[YJ]X?:#N; J?#$<1OCGSQF4O
M.4V2E%P\T80YCABZP*QG!''LLP2-21SI?^4T7KZ).MR$\LU2?;>/$VRC!-M
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MKO25M!>GY5R!-@P?=,6=_C(L 856F>E>SX5['RY0?)R?/EZ^/]4_4$L#!!0
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M7)GI6L]%UQNZA>)-W_;PT'N3_U!+ P04    " #LI%Q,&[SEN_D!  !C!0
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M)M5%,,>U9$R"LN@]*(^UZGCSA$ I]7"KQGR\]^-$LFYJ:6CNJ]D_4$L#!!0
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M;:%)I>HH,-EQ%@BHM^%3O#ED!F\!/SL8Y6P?F$I.G+\8XTNU#2.3$! HE5'
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M&X%F(V 1US +,6;)/\!D]YF)V25H=@D(&+660HQ1*AN(,4HE@Y@;.[L"S:X
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M]->&G91*:)?D3M,^Z)ODN"C$3G6OB7YOANO4L%"R-E?%8+ROKOX!4$L#!!0
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MS9L&'[E<0K&FX_0?-YSTT\$&YM,U_P=02P,$%     @ [*1<3&^C\I.] @
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MM3?CF7-%M<O@4=>AU(_EN&#TK,PTT7/1OQC]0O%V> W!^"07_P!02P,$%
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M!_' 008[2$ 'B7&0#!S,G6A;S-Q@:H/)TH# + 1D(6.6)'(N#L(@F&0&DLP
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M?=69,4G5'J- I<]5-?/=I*1GJ8>I&O.VHVTGDC6V6P^[OPSKOU!+ P04
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M()=&@-0DJG:E72GJ:G>?'1@NJHVI;4+W[]<VE!*"^H(]XW/.7/ XZH1\526
M1N^<U2K&I=;-GA"5EL"I>A -U.8D%Y)3;4Q9$-5(H)DC<49\S]L03JL:)Y'S
MG642B5:SJH:S1*KEG,I_!V"BB_$*?SA>JJ+4UD&2J*$%_ +]NSE+8Y%1):LX
MU*H2-9*0Q_AIM3^%%N\ ?RKHU&2/;"47(5ZM\3V+L6<3 @:IM@K4+%<X F-6
MR*3Q-FCB,:0E3O<?ZL^N=E/+A2HX"O:WRG09XQU&&>2T9?I%=-]@J&>-T5#\
M#[@",W";B8F1"J;<%Z6MTH(/*B853M_[M:K=VO4GF\U 6R;X \$?":NO"<%
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M?P]GKD9H<:G:#GK1LM[A4!_=+_[AE&F]$;RT,(I5W]&57!A[U8/OU='U=$)
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MZCJR^@U_Y[F0=S,1'MLJ;_K_SO;<M%4ALXBI%.G/X3,K^\_+\$U$9!@> #(
MK@%@#PAD0# U()0!X=0 *@/HU(!(!D13 V(9$$\-8#* 30U(9$ R-8#X'SOG
M3PZY;C:9'/*QW43=;V]HK+Y3'](V7<[KZN+4P\5V2KMKFLQ$E$C>C?:]WW\I
MNK41H^]+2J.Y]]YEDIK5H($;31@$8\VSKJ$T'FM>= VY*CPQS>M< 9WK"A /
M-O:XQS3)6/. :")_K%EC&C+6/&(:&&L^8QIE[9XP3:BL+Z:AROKJ&HB5VK]@
M>93]WF":&-^I .^JH,\0W,[$-V0(\0QAGR$<S4'9Z_6@B7I-V6L"7_[A7A3W
MHHB7LF[K04-OO BQ>D6X5Z1[Q6KO19H7@-4KQKUBQ$OIX76LUV5?0X9[,<1+
MN1;63/-*$JM7@GLEB)=R3:V3_UM7QVL4D#[BIER=:RD:MT? ;'8F'A/$CJIV
M1+>#R&J'(_6. &(7J=P&[4(3$!N[#71!E#$-$>4&4?ZI! -K2("4H-UZ GW%
M$K0"7:B6.IZ5@5\$ 5BL HSH!*-):',S$(P@"%/1_T)TAH5!;',S,(P@$&/*
M0CY*T6UM$%*;FX%B!,$84S"VDJ+1O8"%^O[>3Q4^(,((Z^1G1$B)K4X#00F"
M4 ;JJNH,!0)H(^M*8FTM VP)0EL6J--"<!O8%@$,M 6$MDRA[2,@M+7U,1A8
M"PAK&57-B XJFY<!M(" EJF@E:)181'!=A<0T&)ML$&$8.,9&"@+"&692EG0
MX6DC.AC8"0@[F<+.SU)$8+0$!B,#-@'!)E.Q"<A/OQ!L91FP"0@V$V6_GD#'
M9D!MOUO @$U L)D0U4UG%[&[&> %"+P24%>2(;<$0A4G[^;9M>#UH7]+TSC;
MZERVW3/%S>CU3= ==,^^ROB*S)X(,OY"9IOA6?F_],-KIZ]I?<C*QGFK6O',
MW3\6[ZNJY6+R_B?1 $>>[JXG.=^WW6$LCNOA=<]PTE8G^2K+N[Y/6_X&4$L#
M!!0    ( .RD7$Q7ZHGWOP,  #D0   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8R+GAM;(V8V9*;.A"&7X7B/H,D)"&F;%?%^W:JIG(JR35CRS85%@?P.'G[
MB,6,:3H3WQB0O[\7=<M('ES3[$=^TKJP?L51D@_M4U&<GQTGWYUT'.1/Z5DG
MYIM#FL5!81ZSHY.?,QWL*U$<.8P0Z<1!F-BC037VDHT&Z:6(PD2_9%9^B>,@
M^SW647H=VM2^#7P)CZ>B''!&@W-PU/_KXNOY)3-/3FME'\8ZR<,TL3)]&-J?
MZ?-6E7P%? OU-;^[M\I,7M/T1_FPV@]M4@:D([TK2@N!N;SIB8ZBTI )XV=C
MTVY=EL+[^YOU>96[R>4UR/4DC;Z'^^(TM)5M[?4AN$3%E_2ZU$T^PK::Y+?Z
M34<&+R,Q/G9IE%>?UNZ2%VG<6#&AQ,&O^AHFU?7:V+_)< %K!*P5&-\?"=Q&
MX+X+^(<"W@CXHP+1",2C MD(Y*,"KQ%XCPI4(U"/"OQ&X#\JH.16.?(ND1]+
MVF+3A[W<RDT9D#AU8U6=.@V*8#3(TJN5U6OM')1+FCX;E3%>CE:]7WUINC4W
MHV\CX;L#YZVTU##CFF'WC/"ZS+K/T)9P3 AM' R-8\QZ>M;U,.D3+@&13OL,
M[Q(SA)"DR\PQ3UUD@9FA76;99X0/PEEAC !3^\^IV?P[X&T?\11>(!=O%+<R
MX'8BE;@%CEO@E07>L0#::%PSLF*2.A.7<$!-^A23/@>S,NU3E!$!6F:&4(K!
M)3!'/)KN W$M$,KS**"6"$6(\D%G8-'SN_[IS+C 9UP@,Z[ C->,N//SR26>
M DTX03#F"PJL33%KKH+3.4,PSCAT.L>L4;>W&#&,^RYPNL0PCS"P;%=X"A[
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MU3V*CZ-O@B:0'90?12_V&R%]:WKB5CYVB*+_$JP>&[0:C&ZA-%OFM\5VBY.
ME1_ AGC2VSE>XO[W/NQWH"?@G@(Y UVO@)/O:SY0I0]8AHN9]P?EB&VAH[,0
M"_P)G]F"W,,Q#,G"=!]%C-;AILYWV'+4G)L;?(]%2JBHH(Z=.#I:EL5MK_#[
MI;[-MBJ7<$:_#+HECCR:_-_K)5I@J_;_>\I;;_,O!<[U'6@_FVR5[]DR%1?1
MZ3_\OY?3Z?A[>8I^FGR/VB#0?")_1+,GVQ[DCT"*0 F@%)79/2A4<%GK7<5?
M(Q<)_X2N_&WRQWUY2"[29')U-1^YJ=QGP))XRBAY*SK%ZG/.'[T!G92GCBO9
M!=-.X#_HQ\*C0/N4GX'[!6]6\/_X.S> &[9@X8V#ZZ\.';,9^6_X+?%A-D2-
M^'(+5['5A^_VFXP^@=?3KPTXLQ <$A#J@?XH1*RL<E*>8?QBD]4%[%![5U?[
MVSN@MI*YM3! VH#8O8UQ*Z0"^NL&U#SX_=:1(:EW12O&$5GL<-]7\);SN.K6
MJCMUP(\0OI&"AE3? F\"7H *)6G_\-^,[D"S7S:KNM@Y FSSU=VV*JO; PC[
M%?L7G)<W=>YA6G":W.*1;.FKMY@LXP-TN- FNL6\-.+9I'X1I\SJ&K4T&G\$
M^G6>&*J=7'P/N[]OD4TT^]4J;]"9CB$18&?XU?T.Y@WG>4CPKE=U8]R?:;+<
MM\!:,(RZ*5JBV)2.5IRJN.,RZLV^A./$T\MK4(W1'Y7\VZOW/[UZ^TMRVL+6
MMG71M,A&V[M#^8S59O@J'X4CN/N[ @Z$_%AU?HLNB HI=H=2)2M3/28^Q64[
M\!QS421!&GU=[V^!$6_79 _ "K/570$#>1IJ9&OQG>#T@[.#9T&=*X#-;L&@
MC)XC=;A[WC))TFM0 *R07EL7BG7+ARN14VI*7=S>M71K<3+F(J?DTH!-)A_5
M3;YV/BK<UUSW@4F6;DB&^03(RO<WZ.8ATF:?$!X<, N^IUXVC))K9'!P,?8E
M776\^QFZ<G$U!>7<")DPK=_A9]E/A/9TC9]K::ZXKAPW':0N!G=!@=[7JN6T
M#Q+IJ"O[-AO<'I1$8#V3X0WKL?8ZV'L] >TGO'E$SCQAD!^RIB!6]@X9#)P
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MHD<UZEJZ(MXB<(H"B2TF/I!"-"9<JSW9>L#2T.BL>J=&7^8+P0SAH5BPWHU
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M#\_^NNVYP*FU9I9@D,&[(@7;SLF$!W'\=GS(;^.Z+5;SS1 O=+%>]6"%3P*
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M5*,7JAK]F.V>=_Z*;BM7P4*Q;^6\(O$HQWJ/+BBX<.R$HMJ!^?@[Y1/QF$!
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M/6G 50EJZ<W!%29DS4Z1:=@[?N\NR^V^6#,D@5^KW%%4G;"H"=Z_[<3.T37
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M=12:+DE=A<A_XC+9O"L#?VT;L8%*LBH4QL7DUE/^CZ+=JG9(A3,<K!XT*0;
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M7D+]<:5 T%>$1UOXP6?^>1[M:[739"NJA,#G@C@ZS9YIC+,?'D.T9=?22J6
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MK-Z:=WR?[VOJ$_H1;S58@R0;.D +KZL (_MS50O*#$,>N.V3LD1&%J(-B Y
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MN*OT<?9J$"FMN+21:U5,T,\T@W!%NM*OHB:G@/"@LA+VID37PR9N4"[Q??(
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M:WKE_H7@X )TJGVA\>#W;8>LG_3IR?@\/4>$<%" , T2_SN_G,I_+YD$[(G
MOEXAF/H4-)/+*_S'17I!@.I3.)'9\(G@*5SH7EZDV/7TF>SQE:X8!,IL-G[H
M1"[UZ<MT,I%3F"U25#WYW\@[K[[!B9R[$[EP_YJ[?TW^5B<R2Q=T K!ALS'_
M%\@43VH\GR8/<QE[H_[.5_[.5_[.5_[.5Q[F*Z^'>JFRSMK!C>_VHK'HW1(T
M:+(-:YF$O-"=U..6,]*&VXVZ11#S5 "DFZ;"-GFY-'*3?I=D'JWS91LWBV%,
MI7Z<;0%K4.^P:I"/6'J$%&ZW(HBF4)=I4&UI_0C2U=$A/5K\!^/YOO884N\0
MC!M-GU/]U[,.-G4F5O([BX!Q#)]73X&\F33N(7HH^;(IGS>[;)7_T^]V H+^
MN_XO<9N:8;W;]T8V L<'4%R8K(GCD=3$[:XJR\-9=8]1,/2PP5YF# =!J-3R
MT0 BG)V]K.WS,><(=2$0KELS.PK*Q-OS*T.ZOU(W\\ .=9[C?=C5G$&@OH'^
MQ>,<*$NF/3 =_PI&Y.C1<&+.T_/C]?4[Y^D1Z[*QCA1%,/%.<W*M(%R8P@>3
MDU.L-0HR22]7311#)T/3:'U[67"P1[T=&-0HV;RD:^$<I4/O= -\O7OD<1&[
MTW%PT)0,(0$8BY?*7&.$K3WV'EI JHVY]Z/Z]=#R=YO31<_&4B6JR,!_8!NX
MS]B!K!TD"GPN[3S-R !HP9]]Q+3?-UN$\J:%/C?N-<UC0;Z,4&8E0D]@!W&@
M&/<"TTM5%[<$];+!Q&W>6MI.A$"23O+8@!QS)#F>3E57N9_3</\NG&RWYT/*
M+@C.6[;SD71M'.O7$1"QZP( 9UXJ&G6]JRBM!GDT:*4KF7,0G_ M,/H_1)YX
MA,-@;Q<&^+4+ O<@QP1?/S93.KZ3U36]T)J6)P9F[B_["@E,6@]0E,HYY :F
MFGPN\ON&.-0#<VBB5@U[CO)HUVZCW*"WIE[3B>G'N<NA'/$AN#3R#7(EPH:7
M% :XY68$>.5 L.(J!!_8SJBVEXI:EFC.$Z$<;S4?&$4;<%^D2(6!XGX+H^3G
M'-,B!CZ:<A@.0]3,(+!X$*&3&?_+"UOW&$=.?7T#1[3=C#'XBOZG(!8N7L]5
M@H,;R)5-#G=ZW;G('^M,H-%^(:_AM<J<]^03Q.,9NM(]CSZWP8,*>^VT/+X^
M6KM'5:O8H@.<X(QJEAM+=,SC84?Y)41!&)Q2("3?,%%H$ -B]YPAAT7RU7[9
MWNQ+_W'LV]AP,#!,)N"VWYET06Z Q\ AUY2%=X_(D&?5S8WX+&%9'%Q8E9QD
M0)"*M'4Z  D.9JDB/K3>C+,!1LF?W* LA?'B<?B< '@0469YD/^B9M$Y->23
M6TYGYK-)_J_\]V/^I4U^*(%$8_6F7W-Q(SU/])]Z&4R:C69K5O>L[S$Q1HT@
M1>]L6ONF#\ =)TS:1W1Z&JY99_>^@I @WC]Q]Y-JI2GN+D>%TA%BB-E;[!"2
M[8HVDSR+0E>K0I'Y.D'O2O:8P]K5:)I4'[U^>>WP6)4R.5Y.Z3]1^AV2O\_@
MXE2\,$G*% E*J@:GU[R@,8LM,4)$Y!&HJ+ZI22<>BXS:Y.09B'L_B#+@L2B-
M'OJ0NR/*?'.,R*&$AOYONM1(A0B7S!%3"8<P5ETF9*16!%HYE)"C [LC[ZJ@
MH*%CZK]<V_=%\REYZ?2LXP_#P"\XV1]?>]X)#\1J0!J*V.VZEXDY=+UD5V&=
M9,%=7_QW>4_YPS5\.,IU:K'*K94:ARTHXW_-CXZ$0Y"8C&8K 38_8>PC5&8K
M)7K]-;R*"M09X@6BY/0J)@9\ZKU 3?0I'WW+1S:QWY)(DN0WR0J0:;,\VX%U
MN &^ Z8>LE2R0HK*=/!@8P7YCF8TP%M<2^7TW0A",TYIY/ZLJ-\B,-:: U3&
M<I0C$/&/F5*8:]0-7=S2=7E/>@!NWC!YZ;-O-(8KUIFU5U\0^BTH"EXPLF+#
M.*X$.Z[BKN'Q-+@,%Q^X:U%B==QJ+SH+60C:X"5]7 ERM/M.?/:"F-[MP4;"
M3R"L&<7ONHUGVA[B<):'SW[7YC6]K6G^*[>B^8K6,D_M7Z.GU=>*IBOK6RR-
MPNMV3:9CBHYN5"#>XO[^9@V ];[.5YZ+0ECX/V3R>710&3%=;,]4) _*']??
M#+;;43QLP!*]#UQ?[6''O18>&B9<V+9:[;&WE9B^<$O_*OZ*-_%,I4,4;592
M$CH8.9[X+51.'.X*>H30NW6&V26JDFB.%&8EN2PIN(JH5-)P70'U3O#I4FJ(
MQK<2[5V!!NQ7I/6E\.GG2?#[7'_/^B70^5U>2L<Y<H\VUIXC6<J' "<MCL%'
M+K=OL3<^ZUBVEO%G,8?9=>Q&$QMNQKF <HZ2GS!W.=]RLVKT_Q22? BRCN 5
M443EQHB]0V9 .I0J+)G7A3 &#I?MCJR>#56R^U?]H;IED+4LG1N&5U6+1J==
M)DH"=$3]=12P<K!*\_M,[/9EWN(3?N*J9.9="^O-!M?-#+9&>;*K&E;CWF*Y
M,UUB=[/["<0.T?/:<_Y5R<E:WKVDD2U5N,7LBF\):ZPA-?$U1&->\I */P4J
M!/7 DG!H1 2HE10U7$ZN4FH4!SKW2?I(H)P=S64T6B<I$T'UW]2VBOZ,B7/R
M@ROJ.#)SN <;\K-PY@RI%J UF0JD[B0PZ0=')$1^SG\F'N?Q>"+UGOV1!IN
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M3WU1Q[Y4=1@J>,LQ3)B<S5V^CH+D^)\L:VE#>7]?KS?__%]02P,$%     @
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M8E.6=W'=Q#UXW7USUYYC_[G@S5=02P,$%     @ [*1<3 [LKP$> @  ?R4
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M^'H[T-OY>CO0V_EZ.]#;^7H[T-OY>CO0VV_PKA*]K.3K[4!OY^OM0&_GZ^U
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M<U!+ 0(4 Q0    ( .RD7$QF\PM@@@   +$    0              "  >D
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ [*1<3'K9 6#N    *P(
M !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ [*1<3)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #LI%Q,\/(+[IT"  "C"0  &
M        @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ [*1<3$ 5^<I(!   @!0  !@              ( !R@L  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .RD7$RS(8Q+;@(  *P(   8
M              "  4@0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #LI%Q,.W>)2#L$  #;$P  &               @ 'L$@  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ [*1<3 ^X']T$ @
M3 4  !@              ( !71<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( .RD7$Q%[A=AB@4  .X@   8              "  9<9
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #LI%Q,M.RE
MDW@%  !*'   &               @ %7'P  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ [*1<3,_V:/ZU 0  T@,  !@
M ( !!24  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .RD
M7$P'*D!@M0$  -(#   8              "  ? F  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #LI%Q,P-A@;K(!  #2 P  &0
M        @ ';*   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( .RD7$SOY(F>M $  -(#   9              "  <0J  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ [*1<3 4@S/RU 0  T@,
M !D              ( !KRP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #LI%Q,:+S2^;,!  #2 P  &0              @ &;+@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .RD7$P<O=\0
MM $  -(#   9              "  84P  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ [*1<3,8KA;*U 0  T ,  !D
M ( !<#(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #L
MI%Q,01#PA+4!  #2 P  &0              @ %<-   >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .RD7$S(B-P.M $  -(#   9
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M970R,2YX;6Q02P$"% ,4    " #LI%Q,F,(XD;4!  #2 P  &0
M    @ '@/P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M .RD7$Q@>U8OM $  -(#   9              "  <Q!  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ [*1<3#4:,_A^ @  W D  !D
M             ( !MT,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #LI%Q,DTD+U,8!   W!   &0              @ %L1@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .RD7$RKI2-LMP$
M -(#   9              "  6E(  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ [*1<3. #-S7" 0  -P0  !D              ( !
M5TH  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #LI%Q,
M%G77;K<!  #2 P  &0              @ %03   >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( .RD7$S!@:J*MP$  -(#   9
M      "  3Y.  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ [*1<3-E\T=6W 0  T@,  !D              ( !+%   'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #LI%Q,\072*;<!  #2 P
M&0              @ $:4@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( .RD7$Q/)F,?Q $  #<$   9              "  0A4  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ [*1<3,(&S[*W
M 0  T@,  !D              ( ! U8  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #LI%Q,G5<)N=(!  "+!   &0
M@ 'Q5P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .RD
M7$Q-#O(Z_@$  (<%   9              "  ?I9  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ [*1<3!N\Y;OY 0  8P4  !D
M         ( !+UP  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " #LI%Q,Q=#KD4<"  "*!P  &0              @ %?7@  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .RD7$Q86?UP_P$  'X%
M   9              "  =U@  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ [*1<3)+/LN7H 0  U 0  !D              ( !$V,
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #LI%Q,Y.\J
MLW\"  "@"0  &0              @ $R90  >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( .RD7$PH,-8QS $  #H$   9
M  "  >AG  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M[*1<3,WKO1;. 0  > 0  !D              ( !ZVD  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #LI%Q,]Y9\4. #  ")$@  &0
M            @ 'P:P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( .RD7$SFK>G=.0,  +L.   9              "  0=P  !X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ [*1<3(;8VZ5< @
M:0<  !D              ( !=W,  'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #LI%Q,;Z/RD[T"  !E"P  &0              @ $*
M=@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .RD7$Q*
M"<G,T0(  (L*   9              "  ?YX  !X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ [*1<3-SV1\-\ @  .P@  !D
M     ( !!GP  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .RD7$Q5U;Y;[0$  -H$   9              "
M 6V*  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ [*1<
M3))220CY 0  MP4  !D              ( !D8P  'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #LI%Q,7"Z"^; !  "_ P  &0
M        @ '!C@  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( .RD7$S5Z>YTH0(  #8)   9              "  :B0  !X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ [*1<3"3![571 P  X1
M !D              ( !@),  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #LI%Q,0#:#?Q,"  "2!0  &0              @ &(EP
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .RD7$SDN41R
M5@(  %H'   9              "  =*9  !X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ [*1<3 )O9S'T 0  Y 0  !D
M ( !7YP  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #L
MI%Q,*#8" @($  !;$P  &0              @ &*G@  >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .RD7$Q7ZHGWOP,  #D0   9
M          "  <.B  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#
M%     @ [*1<3#/[!_L?CP  9DP" !0              ( !N:8  'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ [*1<3!IW@IIY @  F@T   T
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8;6Q02P4&     $< 1P!C$P  T$$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentAndEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001500 - Statement - Balance Sheet Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BalanceSheetParentheticals</Role>
      <ShortName>Balance Sheet Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003500 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals</Role>
      <ShortName>Statements of Comprehensive Loss Parentheticals (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Arrangements with Symphony Icon, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc</Role>
      <ShortName>Arrangements with Symphony Icon, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143100 - Disclosure - Other Capital Stock Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalStockAgreements</Role>
      <ShortName>Other Capital Stock Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2146100 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149100 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2150100 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2152100 - Disclosure - Selected Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2304302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Debt Obligations Debt Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables</Role>
      <ShortName>Debt Obligations Debt Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2337301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2346301 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwards</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2352301 - Disclosure - Selected Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>Selected Quarterly Financial Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Intangible asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2404407 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2404408 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2404409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails</Role>
      <ShortName>Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Cash and Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Property and Equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipmentDetails1</Role>
      <ShortName>Property and Equipment (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/Goodwill</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Debt Obligations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails1</Role>
      <ShortName>Debt Obligations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Debt Obligations (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails2</Role>
      <ShortName>Debt Obligations (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Arrangements with Symphony Icon, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails</Role>
      <ShortName>Arrangements with Symphony Icon, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437402 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437403 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2443402 - Disclosure - Other Capital Stock Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails</Role>
      <ShortName>Other Capital Stock Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/OtherCapitalStockAgreements</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446402 - Disclosure - Equity Incentive Awards (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1</Role>
      <ShortName>Equity Incentive Awards (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446403 - Disclosure - Equity Incentive Awards (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2</Role>
      <ShortName>Equity Incentive Awards (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446404 - Disclosure - Equity Incentive Awards (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3</Role>
      <ShortName>Equity Incentive Awards (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446405 - Disclosure - Equity Incentive Awards (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4</Role>
      <ShortName>Equity Incentive Awards (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2449402 - Disclosure - Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlanDetails</Role>
      <ShortName>Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/BenefitPlan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450401 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationAndLicenseAgreements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lxrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2452402 - Disclosure - Selected Quarterly Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>lxrx-20171231.xml</File>
    <File>lxrx-20171231.xsd</File>
    <File>lxrx-20171231_cal.xml</File>
    <File>lxrx-20171231_def.xml</File>
    <File>lxrx-20171231_lab.xml</File>
    <File>lxrx-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001062822-18-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-18-000008-xbrl.zip
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M9=63D"K13ZK$74@5J/6GP*K^:OU.ID8]!5:)?JPZ^5G3;<WF4V!5_VF#1UO
MZ\EHR:?K^?DZ?R[+ONC%SZ/YE!$L?_KC@U_]QNJC^E?3CS3\Y/S+8%;,FW[U
MEK[R\]X_"TC?%;,/Z<OKOWT^^@JKL,ZJ](W?KB^+V6 Q7>9T>E'W/S: ;/[0
MVAM\,9E>CB8[W]%.Z^9+MGYK]5%%6@=G -]HNIO?5_#'WMPNKF=M<A'^>-_]
MD^?%Z"=S"?*9$FEQ//C\ZE8.WQ<7&^='KY=;=C!<G!'IK$+8.!NE,CXPPE$,
M,L@HG3>!OO[Y8C"> SW9CZ_>Z*YGL_17H_EP,/YG,9B%Y0;9X^448^&XL]Q0
M+A#%D5BZ>GFPRK[^^6REIMK>M$+BI\/KR^J!92HVPM_-]X B#) >#"=!,TL8
M,1RI"@IVZ/7/\9]+%#O?T@PCX=P7!'$:WHD\5]9&Q$)$(JQ <$#TNE1'33"J
MMVR#6.+;?TD$YQA[94((@G#OI3=F!4&SP%]OV-F=;]J&D9+%>[R=H1!,4-HP
M(I7UQ"G"5F]WFN#7/X.1^X_-]Z:?7KTNE); P=_.!N,WD_/BVW\4-WN\5V-B
M/&?4P=H+SES@1J_>:QCFF[9HYYNV8-2CPTLM.G][O4@YZ723>0/3[<R^UZ_.
MB^'H$K;;7U^C-7#6,$0U9E'[H"GQ".NX B>"8J]?)050_M+*%&#$N<:*J VP
M+7BVD"\WVOOB:CI;P*<?%H/%?KL(41:<I,10K[D1WFNY@@K;"3;T/Y-V[GK3
M)IHX&A<S!T+U>3K;9S&)A@VKN09>*<>"CEY40L2B B$RPV$Q3F:F.']5_OHZ
MI(W7;2)Y=_UI/!K&\72PV,2Q/,PCNU;02"*894I%X84- DM4[6N$ %&]@J5_
M(#&G*/W/.JZUEV^B>E]\'LU!#">+WP:7^^PR(F(4!GL4HR8.Q)LZ5^UQ1>7K
MGW\)__7&O?WMU;N_F_>_&A?^^/C&F5\^_.]7;WYS/_SHPSJNS==O0OO/Z?AZ
M N[5DJG[2)!RVH#2D=3ZB"S&+K)*V!F5Y/7/OTW7W[[UALW7_Z,8C_]C,OUS
M\@%LYG12G+^9SZ_!\>R&X9P*GF#+%0482A&C*Q9YE\/8\:8$9_QM]FU]HGSX
M-BSF\X^#;[:8%!>IRK 83C]/1O]=G _FOK@H8$><P\=F/B\6\TQ1+.]%K0G:
M&5]79-2 *HL8%%@T !?^&XR)E 8+ZX/7VY(F\*V<'8>RIO/\_UXOQU$LIFN_
M!E](QWX]B3$6"T)]4!X;3SU-"GI)#/@,5F3;AJ -8EJA5(A7O27F;CI.#X Z
M;]K;;"=*180U1F",E$?::*L"J6R6V5#/)4JNR3K,AO=7V-R7P>1S\692M;E]
M>_'AYO+JRW1R\P8POID,WUW/AE\&\^*7T>#3: R"F,LVOY7M-?ATW;J &@#'
M"XPK)DP(QJ.JX',B40-\6:,_ .%IJ1/MU"DG0/DZ#]90>! :28.H5)VU9)NZ
M,XGH(Z).ME/G+-9*PK;V)ID1+;6HG+7(\[4C&.$343<MQH,AZ/PO?YM.S_\<
MC<?;>_NV0\"N72.-C]'8"(811XM)-*QR_3%F^=[F:GW7Y.]O@+:"_VXV&A8]
M\1$/ +$+/F EM$&<\LH ".LRUE*!FO%M@%@#N>6+F>O%E^DLJ5=S 4K@??$5
MK-FRDN+#U;A!=2XO(:W#%VOP0P#=21&X8HIB3Q$.J(+ON$<-/B.!R&^3A)X0
M]R'.%A?367$L=4Y:V- X6.<(\]%1&6VU.)[:!NHT0OM2MP/C&GD3^&@Q^C0N
MQY^]F8#W4T8B;X &^*7%>U#CR9$M4@)E"!\,/A>=-H6MQ\6P*9#&W ?C!4$6
M(M,J' G:\#7Z;G,1Z ?$":]H.P!@1=ZV<9\5MQF'\WYVT3%O@H2 FF$%WC_V
M8+>MX;"O="!4A.T=A"5FZRNT&\=.J,E?<?#?HX4;S&8WL(RI4&G^=G8%JL[/
MKC_G%(@M"M;5JXA*!PBZ;!3.!R(]QI68:;RQ#$L=Q0BENPGH1'=*NK979ITN
M::/#/ D8!&A*N>AM)5X1%%]&E^"$G9BNRJ2\+TJW["/X:/_O>C0?I:JQ34/4
M;]$PCIYSQ<'H.X-L8"SP.EK.+3ZH=\D;B>L!\>04MBU?P(Q8 W$D#EK#MN)!
M5:DJ#?Y-1B%26MPIA1>SZ27$!^/!?)Z2\^<I'W(Q A#%>/0U_><"/(VDCOII
M$!))<D*=9AX)2C45.'A%&(0$B!'CMPEE:(?^Z ^T)[FKKY7[H2G*V4DC9]98
MQB)B6D1PQ:476@MOB 85@[#;IE')_C1NH*LI&\V'XVE2J&\G?RNFGV>#JR^C
MH4F36I/MFUP7$7XI? .3,1F,'<12TTNPB&:QF(T^79?2LHQ](7*!$'QV\_;"
M3R\AMAH7MU9EGUB$K/$"\9"<JV #9Q+^P<',KP2;THTT26WV\(H5=T[.@W(N
MCW/6.1<<UD%PCAPH/$ZP,+5&9R+J[YES>0RUSCFLH[,&,Z^89M+HZ'7%.>U4
M:.)<:C'UY#BWF,;98#)LR ^V;TILK D64:$PM^!T6[V6D@],-3%(ZU,Q:(7Z
M/OC0OL6(0$91X0SX@X1IS:VMG$'$7:.@/$T^M&\8B107!C'DM!*8.(<A4%[Y
M5\S9)CXH<F=\N$V_CLZ+VQ]X<S4O)KOBKNYEUN K81F<YM0X)R6A*FKA*+B4
M,49F&C7I:IF[P!R!NGU1 A'@* D;L8LNY4H%-K5PJL9-6FFQPU%_&$RF%Z,V
MV.VZ11OK"<$R4FP( K\=C%ABMJ$ZG?\U[ZF=L+?1'(.[74@PDMXA;<%4"(6(
M=Y;0.JL8:"-N=!^XV\6$<&<E#M@[(0.W8.I,=0ZE R--N 7KC?OOTU5&>[+<
MMQ!-?)QF@4[=D&M7GB<&ZI1BDE,NE"12:UL=)W(L:!8 ;&:P=N.HH):B_NO@
MV^CR&ISFS^F(8#J[,9/SE!\"RD:#\:]@C4$/38K-LYB&6R^[?'S!HT4(1X>"
M8CB _7"XSG7J+->)Z<:I3"^,C91]&,#'A]&QD52DBCM$E=(<$X]Y$+YR!20-
MZ[JQ+&>1FP<R+8BV4*_^_MW@YK(\'1X6*3S+<(OV%*Z*UCBIO6!@H@1$5+%B
M>XPA2W,(EJ/=@>1 O+=W?M8!KZ?]# U**MB(4ACBK44IRX2H-\QH875VDD05
MNWO J?I_)V #@2I(@D,2/",M-?4< &O@.E$-N9:[!;Q^LV.73%@D. L("82T
M!T%V2!! K()@H&NLS4Z[&G;B7HAO=:09CZ?#0>FXI-TZ6BR*PI?)AME@.Q_2
M0Z-$ZI%UP&,G-(I",H*KG6C=AKV_30%M4[$?OBZ:?!JX.2V[>)^ *@RJWC#D
M75 X>N.=0]6&Y8'DJ3NY!UG-$+L(^V4$1FU^BJ7B#%P;JR!T8E1@;SVK0W-$
M0D84P60/JG)\1U*TZS!UXSR>4D6$YEZ!LR9!Y-8*:\"/RW)5.%>H!U-2EQ_L
M=<*]#IM:$L$G3D4O/$AL):OKIQ0HL&P%Z"[8-8C>&#M8ZX+C)CI*.248!2E%
M#'5*WF8Y7;E32([ V'#:O(X14:.#YQ%4J*6"<&,1 P,%&+6)$F?>&!8[U<XN
MD!^GB\'X5J_./T[SFL6NE+$7U,*VXCY5M'H2+#Q>[38JLT,G1G,=T@"B >4?
M5Q<S0+9Z[E#UX%7@\+_ 3=A1BBD2:55_"RYZPQD3;P:\A6<3\=5L>GX]7,R3
MU]5[W941"@OM. 0\G$-0[ -H,Q,I$8QQF4%4&<#UUU? TKC'0VMND(N*$!2,
M$1YY@P4C]791(5MFLK'*FV^N 17?1H#BW6!T7D4.@_F7+)V/6KU.([D#=Y^
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M-\AAU!%+O23$QJ@9K&RH&^9&U-P^"Y.[X'T;&QX#XX_7..N,1T8))C121IF
M<9!<5HR7##7ZM0C?B= _=L8?KVPVFGC*P%'T 8O -/9@<T6=SZ#*-S/^Z&/Y
MQ\OX!PCPUM>#!&$9Z![,'/(^4$9LM1XA[MH(ZK[6XT%\T9,LTVGUE4PWV3T+
MSA,6I.:P;:KC2\7#CF42+\MT]Z'=^C(9K&C4$:<>\C*"8?&HREXQ0AL=643N
MS9[?^3*5C++3R75ZQ5;QUM]2X_7YJNIIG_+9C=L55&F)F0H.JZ 4"X22-2=U
MW6Y4;6(Q%4>'S?M3]+#<RTLY-TI1).:("6[ JP35(61T52D*<C0T<*^\??2]
M<"\O)=TH3/ 42:'!.%J+N:6.U3Z+IU@V<0\1=K21/)1[GUK>]>FF?J3Y78/L
M7:GCPF1^/4Y3JN?+%X^:BQ?+#],UY);"S_9&2QP)PCE!$F05]J^6,E3!J);&
M[2K>E#\PO<[OQ\2#I[0Z[>VD+ *E@ 6&T(DHCY7C=9)9>&YWEM;2'[1X69[C
MEZ>]:Q9X'#;BD%QXXXBPH.GK*G*)U,[EX5L)G<?$A,WEF9?C2L[?7<_FU_#D
MQ^G6FTHH\[NXP)KF+GEF" \BY6FLL'C-"M@F#R3U(-D0^Y.B[\>8LG;^6![@
M- 4H>FW2 +0 $A5$/35)R&8_ BO,<1\N[(+:0?":N2S9>/2-96.X<HQ)2PQ&
MCD@3*V(%V[@C6A-+-4.MM.Z!LI%.^.9MDVM?S$>?)T4QW]O ;H[B(#:=%&*K
M-:PB^#6TOM6C%<UN\3:1LPO,D<@[1J0(15.W)8L<HT8RBE)'^%7NB#\H\H[Q
M)XP@"V8S@J)  MP:HH#IJ;\/8A;AO,$;1JR\!7;?!*Q%O*""DVI?BF<R!=-)
MNLZR$1>O=74HK[FDQV;%%S :(,D@TM/+(H^7-Q@3,3'<^S2MSCML%?9*),90
M*WQ@+FLX^.@Y<GY>MJ1/;7E&YV\F;G U6@S&75P(UGG-08[3>0N'':HX<('*
MX'BP*K\:^C3$XWVQ&(PFQ7D8S":I;TD'%Y2543.M8&=0R8@(*3^?9$%%83Q[
M^.W=D_R/LW(*R$VI\3MH1R+ZLO(=4TJM3:.25$F[CPH"]NS^W]&T+_*'EQ^?
MB/BUJ34=I!N0=6:%3B4K,481<.JJ9RG6S' MFOIF"(&:I7\G534/2O.[[=ZF
M@\?)/*7/IL-14F?_&"V^_*V8I*Y+$'N;\\O1I!P=F$ST[</]YY>Y$"50QSC3
MR""/G*SJ/HQ2V3U@NNQAM"+S9,#OA1<=IMQXK36S42BI-76"2+O62H1G5XLI
MQ^S)\J+#.=":@X-I! _!$&T-H;*J?A AQFU>0 @N'PLOP',O!K/A%_C-M>X6
MA^X0%[C0T2F<%"%.<\%T56W(G,V:?%%P7@_B1"OL>^!#U^Z(@COI(8!WUCN=
MVBU623#*57X;7)<-2)X>'SIVAA>I$D@#%Y@G 2NN316J +V9/(!>Y7?-A^4Q
M4/B66AC=SLHS\]O6XF\O;J<3KEF_OCD<9'E@P=J8VBPY25(?FBK-$&E#)1K^
M89/DO@B;Z)NOOGY^=#,S8IU,_34#>*U.6V5(=67,2"F:HFB%"?@$.4VMJ-K)
M.%5&:$,^29HTPL%T:VD\E4@'7='FW<9QWXJVAI7J#;*F=.GLK(W%3.)>]EN?
MI!G5Q8ZNG]V](=-A&P]:,,^=8H%+B2M-; S) M;4J6[=6=D?V#8Q-P;^^KP\
M%KF^F5[GC33*5NH?BJO%3O!,.6LQA)3I0A)8$(5"U;\)@R5I&#;: 'X;2 8T
MD71+19H6DCJ5O=]N ]O(Z<V,NL8ZDD @^*7(&1;K3M+1B,9B8,RVD.Y TH;X
MS:3!W4]HR39:M!&B$7!*#46$&Y8FEFOB:^4DFIOX:8QD"^(5DC:T;S^-1Y]+
M]=V-=Z.OBI4DM5(AAK/H930*^4J.%;&9;T5YHR@T0LD 9\)]N%@H"\&PHCRY
M>JD)-..F\H\CH>UC4O;"TXT^92^VFLK>M@O^X'TQ;!DB@;0*:>8.![UAB4V#
MFU>Z(]A\3K-J8OD.. ?#SN>TKL\'"!BS-.37@-OE/?*1\$I.@N#YW'M^#Y"[
M-1U"S'@<(RAJ0[$!\\/70@>>AY3D/EC=,2L]2EAP3FVZEJ(H2(C4!E'!- =_
M@.6]V1$_*>C;UI)[&$2Q@1HK8R3$)QQ\4O!I4*R$6OF\[3EK5B2[T'3#WC%+
MI]O *(;+\@^I$03:VHFZTV4::-2D27@G[(99.CN?+9M^]U<C&&E!&=9:,O ^
M;!K"74\*]'FV'^/]Y*2$TXUZU&0@=P%?MY'4*02N(".*<:(5Q/:TLNA4-W9^
M3CWAZN+B+D1'8,]VYH:G+I1/TT9DX%KX (ZM=FEC>@NHFP_W!-<0<AT,/ TX
MVC65O:MYN:9,IYH<;$UJ[ (1<]U?&R0^'YXKFZ1C'4$&KW90DK/^R^ARM&CV
M05HW8, </" -L1QV0:934U29\H!PXYRV; /N@I)A7AN[='4UFWZMY@/TU'=<
M$6F(\V#!N0)'U,(NK)H6>I-/@FK6=SOA[ .\TC$EO3W5GO>46$$HA-P,464D
MJ<)HC,5^7._$M <5[XLT4 "6ZE %#ON6*ATP<]9IHSB.K"KJH(HTEO[N04D#
MKHJ:CZ//E[>&*7R[*J<@]IMZH"T&C5$._?&@OUW4M0N(FFS\9OOXAO=O8 /(
M_]_TTZKX)&]EW963D 2\:X(U$AI9+M-DOZHAFB&YATI8U5I]Q^MK>,FZ+-7=
MQR\#,.\WMEB>31R;2*$\W4I41-"4#4,AY9*JD  "W:;8:W-3]L*V!T5W465C
MP24,B"BJ!-5@BR+06TD.5DU5-F(_&OLF5\I?^IJR%].+Y:L^W4RFD^+V-T:3
MP4TQF/4K(7+*0(B!22H,(CPJ&8771/- @6R?357@&66=>&KXMW,*SHM/W9MC
M4_6#-&E*)29@4X/"U*=[Y=+BH,N1JLTH:YQK+Z[1? NI#OUJ-IH7J6]T6?NR
M[9X@WIZ3HH:BU$D/@C1N(>KA=?MYSU%7+-\(H1W@Q^G'XMM@;B[_F*2VT'.0
ME0\W\T5QV1,Y#M(X+3!$DA)C3RD*E4N(5#[K9WO?]L)6D?0/\&M H,_+L2RI
M'"%#S;*8>+/]+[8T(@;NMY8FD,#J-)H,-JM*(&@CD,]>GP/[=3I;?-XVB-W
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MY+ [XB2!042]5\HY@XT1WJJJ*-=KEQWEGX'7A[:FJN\->[*8P3OG[XNOQ>2
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MXV7H&<#Y-J"VO8@LK_7FFK!.J("B">C2ZP*'*WQ+@P$*6TR*B]&BMQ46*7_
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M==$L0GD+',R$:D;8[&OMA;'K3$ P#-&'%)CA(%Q8/U?BOBD<ITKB.T#9?CY
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MN%R'R_L8IZ&+R,K18\. )_JV1BWBJCK%T)-:(:>.!DBJRCK$4P<<I\&Z<Y(
M-FFT%,VP;(:C4Q5/KW2PM5N"E!&SF4UT**R5[L^GQO0L4+U<6V>JHCI$<53B
ML\(:8#9MF5ZFT@%K)QRG0KL3M]0,7(,YBF4:AF;IBFH7FB(%6[WE"&FF,!\.
M+?R4U-.E3IWIJ3#J.;9MJ\12J.I9E)0)N2Y56^HM,SJ W@K.<P#?U\//!7O%
M,W7/=RW-=+%]?Y'J1,QVRSM*FRF&9X-\W]AB H>.V&#?XNQBPV"V7Z3T81_N
M=A4-ZW"9'02YS+/X95:V\9-S*3YFV0:^B=PD:PRSQ15H_]!^VSZ[12,:4YB-
M$7?L4H*NZ;+L7VUW,U";*14'@M6QDBQ(TE^CU2:=/(19],NLHF$=3?J>SQP#
MC%\K4'Q33(XM2!_[V;66T>#:^T%Z[@+V' $?S$_?5RU',R@VYP?Y4[:=4H..
M;#]RX07LLZW!EG,LQW!<8F$K48N5/64TWVY7+.B-.5BGK>!+8D] PTFCR@BI
MXZLM/.#QO@8X5P-%9R:(4ZN$76UE1JE4UQI5-;O@.1WN/42CN[[C:X%I [@@
M6.U *8O[;<]H:0 :!=M$O0#<>V@%NP/KF%=NJ=C,P7:\LLN/9=#V4$C=,/N"
M^W.*K';]]'D>+M? JE _7BU:"L(!5..Z"K :RBSJ6X2J"O.<HLY ,=MV'J_H
MV[6$K:#UM:!]Y!0XIF*!SF/9+K.\0'/L0L,'$=TZPE3MYD&76]"^=J:.[UFZ
M:@.@ 6@59E 9Q.J:=KL==:-'YHD+2N40=\ZT/H?I+RFWQJ9\: I8,+\]A ?,
M-*)5Y5E7<)2:!G+:\7&RATW*GBRL.7 ^?P788+<*J2SG(,#Z6(JQ?2F@9G@,
MDP]MC]JZ9Q*U;-NG,DNYS%+XSYF]63\D*=J?Q]DRU-.IZ?F6XU)?,S1%94%A
MRUB>4?6D9?Q%^6@^9=L*FO \!_)==@TZ_CQJ>8Y/?=_">1PEY]6)IIX?<M0*
MC\4W\%G#TDT-<Q!-G3$SL M.Z_NVU0'U'G@%%*?"N@O#EDX-T#T]&S0$Q]-4
MS%DN>$Y@Z^>"]9?-.@-#'KTHQR%7]S4E ,N+6L12?:JI>ED[I7N:<SS %5">
M!?7NZ2.FIV'=KJUJU+ )5DP6*EM0J_CJ$VK.7HX<1V>;V/3. [78=D!+"UC9
MSUW3VT.0MH+)WWTT:#M'\Q#8<AMTQ\ U\#^:7;9<#G9W2MH+6C*)HFD6I,G"
M34 U2]?H86J-D-IOH/HNP=[5CDI PV(H]KS"F\[@R_WS5W; L@WDW'1]GE'*
M D(8TP+/TDR;8=V?68@)UVOO/&D4D^R%Z)G@[S-)-1-L(I7XEL)LJNE:91";
MY[4[X0#CN"S\>[0_Q;5]X,2F:5#F.(11L*T+*6V:+>O(:(Z&Z '^[;/3#J ?
MS;(MT#,<AVE,M2CVDRWT<=-HM[;="_JV86JGP+Z'>#S5(9II$B=@Q'$54#/*
M6?>*T6Y4<5'8]YFGONEZEJKJBJOSSH*F8Y?FJ=TQ@8-9#6_UZ6NHN$&X;["/
ML2^V:_@*"Q3-<'1-PV-@%RFHJD%:D5]C.P,] +Q>5[:'S#1=)1:8WSB0T7,\
M5=>]PGWI6^U9/5>RJCT$&!"-F([G>K[O&YX"]IY:[!<PLUV3U'M:U6_A/)+#
MKI[ SG63^3R:8,I!]LOL.9ZVP*>JZN)@0\VBNN)8E5Y_1*.M_:*D-33N!#![
M7^6^.:&.$U@NU6W3I%0W/).5\0S0L]I^.4UK5NM<PRKW>5<"3[<]T!&PK)EA
M!X#2*>$82GN2.3&Q;?(95XFCV/KR[JD4C"%#T4'^*GY@>H;I%F=05]KU?:JZ
M70+L@:VW)>UMKAX$AFXHAD%L#8P\;.=;]O)H3TQXX=7L(3],([,L(W!]L+--
M,%BH4:PFL-M.^UY6,XO7)_5STGS?-GQ?8[H>."YU+.*57;%,MW56VL,JRI<?
M"M(>:F"Z[7@@+Q6#N;;J^QX.4"NLD[9ZW-7P^WB@]K4K]EWAH?)]=/904]7*
M1LK,/*A=\5:@NG?X[VD+T+TF/>#!5C6'^+I%7%NQE+(^V:?M/D@&R+H6=]@!
MS3/A+M)[MM[K/'UY6D6U5"!G$_,4'+@L__/C8I4FWW@6T=XT+& FS/,-0@)
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M'*= ND>T$:*ZKJ$Z 4A:.!T@,4HZ5%R_91D8&J-G@G1O1G1 ?-.V&-K@<$0
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ME<FJ?0K[9VS(W7Y7W-UN6Q8K$NM!<')<-%]1F$=-YE(@:QO0QE2G\"P&2GM
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MAARD<,08[5/6/[<\?G7'ZJO4LX* Z(JE>D3'1/6RQS$H]2V=#+FE:34[Z[S
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M7!K=(P82,.'"%9K8@*)8W/'[,D8]@:==9(71O0C3KQ''&%<#PGF4TPO</=W
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MFX'=#.QF8#>#'77]G.;M1E">C]MAB/$5C%M\1;1X=3+RM5#<U2'N:I U4-S
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MXB\Q!_;%>48_C+,7GG$)YC;>DL,N2");XY[4^R3=Q?.Y(,W)MNID(39&;K(
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M!ICZX\U#\HA4(4EW#/KW<C,#K@UZ6<Z"%U$ZB;E6VR+3WS9W_Y1T)=5,6 ?
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M:(+LD,%4Z+=QIAYE;M#KL%.JO#^'/%EBXI+\7227P2^S^#N/V$\+# E$''K
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MW6<#6MESH 08).MJSI.*:U_#K0^PTS?_@I.(J=[EZ<'*YW0C960%QAJ2NE"
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M$D4+N;?-IQ:VA6@8B[8A6(I3X8-?3L48O^57T2Y"#'J0,;&RSVQ;9@[#-\_
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MJGE+ YFR2R&Q+%9VD FG"9^PAMG0^,OH-SX,Y1=1T8Y@Y?5_6$F&I;O1OS8
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MSV=VJ/EV\'7+"92J!9\L^ZX#1Z2OV,,=%4L>@-+R'H"+-EEOF8FWX&C8:N7
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M$7\2?]:2/\79]I:Y1'6U.Y]UB!KO\+R5>U%1 !YX\)*=R);Y.:]"PJ="')7
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M]$)4UW= :<(ZR/U3SMU,\[5#7?>#+*L-^RAK5:4B\;L/!MC*"YCS^QR[\8B
M^DOMJ[O)]:UQ>7=[-9[<#/K7O?%D;,2A[_'D\KHU]M4.2/^0,Y9%<R-!3TT2
MM#IX%Z^21EYLV6$T0?5NS,69M@T,V1%PP1TIKA$"*P*)SQ]L_HCXEM<  B?W
M$)^<S.P"UB "[TD-!"4:E=.4"W0 6Q-'#-;"I_B3=-OAMB>&CD:7.IVO3=<*
M%NU AD!VC (D6-HN6&1+GB/' !U6]M%P*SL0)\FM,.F?> ^VL"]<_>DZ-98Z
M:%!E9X1DC*MY;?5>U#?U@/PY&\W(3T6\1X[Y*9)F(B-9X-[6)+')>YDEYDS
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M*^YC,T]V+]05O(&[<#G8BX%00=GF)/"[LJ]B0V\!C_ !1(1]I:K,W^! 9CP
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M5<L4)S&DT#W'W2I@%-SQ40].5OTE\%.,*%G4 ;F_M"P/-QC<^X^^Y\*?EB3
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M&!MQ.?R<?:CK^4OFY.R-+EZ3/%C"@,4=1UWSXQOCC?@,JMB*/Q^NGA[M6;B
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M@G+B-N2''!_<.S.F<0DPY2O3&G##43+)"*E)+$@L2"Q(+$@L2"Q(+$@LVAT
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MD.R3,EUPVON9X]O9L]YQ4NCO\VL6+/#?[5^1#:8N@LRE._N\\/SP"TSZ@_O
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M#_7)L+Q]T[JO/MY'*1XM,0AJSVV$-;E,L\%8[Y=7_[#VJ_]:K*$J&^'[3SP
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MNJ/N;=?HQSU6QZ9Q0SU63]ACM5]*C]7QB9N<#JG-: N:EKVVEU[%)&Y.XU$
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MLB473RVL\+U5RRD<S?B0\G6 (I<G6G5BFZ\++#[+1:#T%'2,Y8&GU%939RV
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MJ>3FPUC[*N52&R;GG8"NK'\%L<TEPP2F&Y>]V:*2/^.R..V2S(508EHE5G"
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MMVY1IT%,%$#0V-5)%%:'.%ZV<AV=:,<!UJ'GFV;@)Y\4L<+917P+8OAA2T9
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M:U.^2?MW_17EP[VFD_E"\-?5R[3RJPV-B!>W,N_%WQVZ&5Z_^_M>P,H7(\T
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MX+FT6--2K#DRA=#J?8=DK&[]=G?8S.UN.Z&W!3Z-[VU<W,5Z  [) V#1KQ6
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M-MX6V'=;@-PCH>Y%^3B;Y$&YLDQ\DZK+.:P_]0%5N4,YTZ>@JP(D,J,M^"-
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MYE2L%+D _!EBE 5B%I]E8SM%OY.'U=:7LVWJBWAV5S[<R3^]I?/^.R#,?./
M3AY65SOZ6PPY);5CK*D=K=J@8$:8[6R C5+MK$!O<**8S['(,'[JZ8'?CPJ?
M"DXNK'U06'Y.&/KQ@+N@7'QT]5_<65$@;(7>]<*%C+.Q2#YMQ1Z@2[A;_PT]
MP%OX":04>OQVW 'OR(\EGW>V48#$1RG$QUU#&L&.PZ(Q"U$8"8L_4Q+-SSOB
M4Z_H(PIAT''"I?B(:WPE()B_I70YXG>$'SI.?'T<GS]]WO'@&(7IU3FDB'A/
M4AYAQGN18?[#RV6G>/\?Q5^A"4D.'X? :U.8(:\KU3!X@#^> C=,[5G!U7\Y
M<YC(9;B-BV_N *Z"O[]%^'F@7A0/&.N)K/DF*%R$%SYO!PRAY<MO@@T3C*/@
M8YBJV11?-9/RS9*?C@%CY"/QR>5AF!U)4&+2N/B^F*Q$6OWET")(HY(-Q,<0
MNYO<YYJ@,C!=D>8A6GUTL81$>6OOT>,B0K['%3'Y]:004N!G%BMO'4K -_G
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M@P]0'&+ S:B.[Z9">\;XA*9!TL!>+^;R*,<4B?I68VNB,)=[]O_(.)U'6]M
M5GV[N8A$,YKL\Y\!G@<M+V \U*T9$+$5VG>?I=I>RY&@72AJA#.>Q>@&F<0:
MQTO,*UEB/<)@"0%=0VQ2NJF-?7KJ 5>R>D_7KS7WY5Q<BT4G<XH8%)N]Y/QA
M!J+B9G,38J7%3^0)+@ ;!E^QV,S%^!OSN&32-@U.G51S'?"-Y\9<DR?/P1'G
MXJ0853<. ,870L-I+B]1W3@@&/D57I60"H7VG%HEI[P4CR.]D<?GW^8/5C0J
MN?=IN?@[T(P'YP!\^N4_4$L#!!0    ( .RD7$STIEPL"1@  -D# 0 5
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MTO?)B&&O]F<FPIG7 #,;+;97*NNN Z_K!&BU(-1P1*0AQ@@GB-B.D1G#&A,
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M' /ME!7<"+D=+[6@N7W!+I0'S<$YPVE6 YNA1NT .3<8(B 5MEX!#2VO)H$
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M^ENVK''@=:!:@#!NC3@7!'"/7$3/FVK1U$BJX9W5=RO^#L%)&4*_?HLY]O2
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M# 9K&,?!3*0QU(!9[TFUUG ZP"./#F3S9@%N@TDZ);W(XK?*Z!$;%=$L7U^
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M<S02W&-J08=J$NX.:*]1*T1,,>/,>.PALEPI!RML*6WQ<GQ/]YBZD>UAHK0
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M])9NY#2P!YUN9'M?]TBVD>?% O7"8"<X \PZ8)D42&R'SQ5IGG/U8I*-U"9
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MSD.LYS?.KJY?#^0 CPY7#.73F19I;3#11F!N*:U05:K%S:W>G$&]FEN=HC4
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M=-JK6R?GB)X[F@?X$;[R/U_B,/[UG_X_4$L#!!0    ( .RD7$R#X)2B#M$
M .B^"@ 5    ;'AR>"TR,#$W,3(S,5]L86(N>&UL[+UK<]PXEB;\?7\%WIZ>
MZ.X(N8KWR\3,;(  6>M=5]MANZ9GHF(C@\J$)&YEDFJ2:5O]ZU^ MTQ)F2D
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MMK31=IOT9P?! .K+#AJ"-GEV8#Z\KNSPB'7%V4$NHJ\W.TCZJR [C&%Z?'9
M^[*DI>S*C$(#^PE$B6^8MNV;CCTL[@PM5VC9]WAK\W8#.I2J])N;XK'ZK(-=
MI?K[$K$3*VL'1THY1;E>NC(*^\.M?'),<9V?R7;,O+_>9K?-N8:'H^EP J'C
MPPBBV(\=/[2@:6,G@):%[=!ZL1(:]6Q]+U>S$>P(DMSAE]*<"9QS.05W<D=:
MRG#(=W+E&9]/B(L2BA9P'N5H%PJ%34:L'GI7Y+=LDPNS^G-:=TKUD=RG#\W
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M><(0B^:")457/CM,$%C-&6-D'+ARR%2Q7EI6F<SOLWEF6N:Y%Q/1]^FOZ8[
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M,V3+T&&]+CXM6/7SR:O//Q7%YFNVW=+,\+2,?I8@'"<P;910@Z:#DL!ST #
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M0F,K%-"V_U5L-ZS#B8J\+K/K/6N3GPMF>&5[1N#&END9H>^ZB8'\V.^M67;
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M %>AZZ,HL>,DQ(%C1UX216[H8A0'26);R.7N:(\WI;E'W ($#"'H(((6(SB
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M] S?BZ!G^C@PPX!6NRQHL3"V\,/U,?1>)-#*!/[HI>)A8W'8.-AW%/A$V58
M1C;^>4GKE_A&&J49\(N\#H7*><.Y)KU\R%:[=79SEQ!75&?O\R\T[C^6X3-M
M8;UPL6DYR#:A;R8QC+%AVJ@5( F=V. [(*AN6-T5X$Y2&B>TLKYKA 5GWJ)&
M8$8FTF$ QG77:;#GK':J@UW/6B<SB)>6*M5;8B8KC1H4.UTHU(4=<[/]EX>%
M3[^F_UV4:)U65?0MKQ:)CRW7"5P'00.:T#(-/$C@0YN+.E6.JYD[7WEQ;Y]
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MN/^/+RP5Q(PMMM0/%Q][M_)<@1XQ?CI1$]Z=Q>5"C":'XSP"+4D="I4SB_-
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M#R9?<JZI0ZXC,J"/0[)"C3*G+1B)73\?F$: (+']S';#,'(@#)PD\Z _C!L
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MII85SX&7]E)CG=0[Q<I<5<FRD3. @/7H^6+ULAK+RJMHI@EHYC5X8F<QEA*
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M'$JAS'MT]K:%=/OV\8?9KA.D/=6"$$@X*I2V'&#CO:6H5I:$D"35\BY=O.T
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M]['!1>L]-0.1N-P98^2@<(1Q8AFOM\76I+!M@);]*=3?L5CWIP-'T_*<_M$
M^#7:$8N/Q6*Q,P1Q9[U@N*5* VN) 9Y@#JQSCQCJ=Z'%CI#\*U76'L:]7;O^
M/LJGY3SRQ?Q+!.+10GVXB%L&C"QVWJINUD( S@@ 89RGRB)49HZ3-:J2G9OI
MUA7'ND%[ &Q[O!G^ZSQ.F#]F\X?95,XAG5T6\^SKZ,=Q/&S6=G#*6>[*BPF,
M ZZ(9P14F!D.S\QO=@*&=B*'(7.W5/U=<?=9VX'&R0Z4DPP0#0%T@#ZN+L#
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M9W.Z);A;7XU*\RN?726L1J];",IA:2-,T6HS4B&F/:R<DYPIG'2)_5TZ?SM
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MGH,=;@:$%CF2AF=O2J2\[OY[,2N>,WH_7797#$(2",MD[ @;([AAA-4.""9
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MC^=WV5,W^F'4:U0_0" A0AXSZAP5&$KJGIC*,&7+.\#+4:?3>!T(HR\B'LW
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MW"@/4FN/L!;+T?2-<^885-O8=M8W6CYGT]5;T84:_]==OLC+<3Z_U-Q@[WE
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M3*D32  "RSXS(YI8Y09TJ=\92YK!>;'3[>:6;',M=LX!]W7+0+5R(A[@*;%
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M+,95:A\8\1I"RJ+@.<:5U_IY:4:<R7%$+O1!MR[P[FV!F\RGIY>P[4.!>>>
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M>"TR,#$W,3(S,2YX;6Q02P$"% ,4    " #LI%Q,6_2[Q_43  #*_@  $0
M            @ &(7 $ ;'AR>"TR,#$W,3(S,2YX<V102P$"% ,4    " #L
MI%Q,]*9<+ D8  #9 P$ %0              @ &L< $ ;'AR>"TR,#$W,3(S
M,5]C86PN>&UL4$L! A0#%     @ [*1<3!5W$T5(2   QHH# !4
M     ( !Z(@! &QX<G@M,C Q-S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( .RD
M7$R#X)2B#M$  .B^"@ 5              "  6/1 0!L>')X+3(P,3<Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " #LI%Q,H;[))&UL  "64 4 %0
M    @ &DH@( ;'AR>"TR,#$W,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$
' $0/ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
